<SEC-DOCUMENT>0001558370-23-002698.txt : 20230302
<SEC-HEADER>0001558370-23-002698.hdr.sgml : 20230302
<ACCEPTANCE-DATETIME>20230302164131
ACCESSION NUMBER:		0001558370-23-002698
CONFORMED SUBMISSION TYPE:	10-K
PUBLIC DOCUMENT COUNT:		79
CONFORMED PERIOD OF REPORT:	20221231
FILED AS OF DATE:		20230302
DATE AS OF CHANGE:		20230302

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			NextCure, Inc.
		CENTRAL INDEX KEY:			0001661059
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				475231247
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		10-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38905
		FILM NUMBER:		23699747

	BUSINESS ADDRESS:	
		STREET 1:		9000 VIRGINIA MANOR ROAD, SUITE 200
		CITY:			BELTSVILLE
		STATE:			MD
		ZIP:			20705
		BUSINESS PHONE:		240-399-4900

	MAIL ADDRESS:	
		STREET 1:		9000 VIRGINIA MANOR ROAD, SUITE 200
		CITY:			BELTSVILLE
		STATE:			MD
		ZIP:			20705
</SEC-HEADER>
<DOCUMENT>
<TYPE>10-K
<SEQUENCE>1
<FILENAME>nxtc-20221231x10k.htm
<DESCRIPTION>10-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='UTF-8'?>

      <!-- iXBRL document created with: Toppan Merrill Bridge iXBRL 10.2.0.4 -->
      <!-- Based on: iXBRL 1.1 -->
      <!-- Created on: 3/2/2023 8:38:11 PM -->
      <!-- iXBRL Library version: 1.0.8405.27969 -->
      <!-- iXBRL Service Job ID: 7ed7deab-bb7e-407f-9963-e4a2bfd20126 -->

  <html xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:nxtc="http://www.nextcure.com/20221231" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:srt="http://fasb.org/srt/2022" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:iso4217="http://www.xbrl.org/2003/iso4217" xmlns="http://www.w3.org/1999/xhtml" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xs="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2015-02-26" xmlns:xbrldi="http://xbrl.org/2006/xbrldi"><head><meta content="text/html" http-equiv="content-type" /><title></title></head><body><div style="margin-top:30pt;"></div><div style="display:none;"><ix:header><ix:hidden><ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" sign="-" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_RXcXID7xNk6EeeFbPOwNnw">2.69</ix:nonFraction><ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" sign="-" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="2" name="us-gaap:EarningsPerShareDiluted" id="Hidden_KIFVcKMshUCILTfOaw4l-Q">2.51</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_b0KSGAix2UKsmGKHFGsxaQ">27744209</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="0" name="us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding" id="Hidden_rS5K0gsUw0ydwct3CpK7vg">27615977</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" xs:nil="true" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" name="us-gaap:PreferredStockValue" id="Hidden_ckQuX0NUl067JlGreg9o-Q"></ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" xs:nil="true" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" name="us-gaap:PreferredStockValue" id="Hidden_AVNy09DaIUuRzQxF2MJKCA"></ix:nonFraction><ix:nonNumeric contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_Y-cqdjMky0anGfcN4D8zww">http://www.nextcure.com/20221231#AccruedAndOtherLiabilitiesCurrent</ix:nonNumeric><ix:nonNumeric contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" name="us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" id="Hidden_TUuyXS3SSEeIh0Y1lSNfqQ">http://www.nextcure.com/20221231#AccruedAndOtherLiabilitiesCurrent</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_0ZTpWsbJLEqaeEw3VSWmxw">27774536</ix:nonFraction><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityCentralIndexKey" id="Narr_sA3mG-8AnU2jzNb4yHAB8g">0001661059</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:CurrentFiscalYearEndDate" id="Narr_oJCjLWonE0G9wSZtRd3Hng">--12-31</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:DocumentFiscalYearFocus" id="Narr_TdMgNGir9UuSJB50aMCnJQ">2022</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:DocumentFiscalPeriodFocus" id="Narr_GFPpG8BcmUqeqIz-SA1fkQ">FY</ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:AmendmentFlag" id="Narr_rNyQUEv2X0qaR4DX94rVJQ">false</ix:nonNumeric><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_VHnfYaVN4EiAQyRH9rcAqA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" name="us-gaap:PreferredStockSharesOutstanding" id="Hidden_IK3tc8XvT0W_mIMyRwi_tw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="INF" name="us-gaap:CommonStockSharesIssued" id="Hidden_EjCt_RanekGTBb6zLZI6cg">27680997</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="0" name="nxtc:FairValuesAssetsLevel1ToLevel2TransfersAmount" id="Hidden_ALFYw5z460y6TXowa2XL9Q">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="0" name="nxtc:FairValuesAssetsLevel1ToLevel2TransfersAmount" id="Hidden_xz6FFA6uT0mQ6fRBaD7AoQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="0" name="nxtc:FairValuesAssetsLevel2ToLevel1TransfersAmount" id="Hidden_FFzONT6OAUCKHJSioasszQ">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="0" name="nxtc:FairValuesAssetsLevel2ToLevel1TransfersAmount" id="Hidden_sF1qYAy1vUqAHu_dZdjC0w">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="0" name="us-gaap:CommonStockSharesOutstanding" id="Hidden_BEloqN_kIUiSEA3CJtNPlQ">27774536</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_5_3_2019_To_5_3_2019_ffq9d8PSt0mdc28BJxL5QQ" decimals="4" name="us-gaap:StockholdersEquityNoteStockSplitConversionRatio1" id="Hidden_GEsLDUz530Gxz5k36Ixidg">0.1245</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" id="Hidden_ZrMEVCBOgkqTt6a3SIdRRA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" id="Hidden_HRbFi8ke60aH_3jsKm7FlA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" id="Hidden_KHCh8U0vHE-yYnQcworSUA">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="0" name="us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" id="Hidden_HIlaRUEnF0qbB1XconopJw">0</ix:nonFraction><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" name="us-gaap:PreferredStockSharesIssued" id="Hidden_pC0KVSDrpUCOl6qY3Bjkag">0</ix:nonFraction></ix:hidden><ix:references><link:schemaRef xlink:type="simple" xlink:href="nxtc-20221231.xsd"></link:schemaRef></ix:references><ix:resources><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rOjqenRZREyd1NyoeFubKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_11_19_2019_To_11_19_2019_k_sFpRsB_0WOgCeVqnif5g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-11-19</xbrli:startDate><xbrli:endDate>2019-11-19</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tPHNqpHq2kuQFJEI1p3JZQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_3_2019_To_5_3_2019_ffq9d8PSt0mdc28BJxL5QQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-03</xbrli:startDate><xbrli:endDate>2019-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pA4TDj6OTk643-r859LTcQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WRaiII9KkkuLfyaPn6l8EA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_x6LhcuNomEuLDIBzS5kclw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dCZjOHvncEGYV4kEJYoMcA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AMSNidZSTkiUmUQgTX6WXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51jEFO9m-Eapl6pE0wPajA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3YsHqMa8U06STQUHwqaIeg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3vwRuWC6SU2eMxTt8KjrSg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9M-kF4_ysEuVCqAg9WPuNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_2_2019_o6OFQ40YgEyzamR4P8fk6Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-12-02</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_11_19_2019_Zz1QYveV3kqsEGkewxdtfA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-11-19</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MInUrgAThkee5MzGS2_rNw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_S3g67ITO1UG2PaPwVbTH0Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_vASUCe3mXEShFcN7roPOFw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2020-01-01</xbrli:startDate><xbrli:endDate>2020-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_I1bCpdmof0eokGR4x8FVCA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_4xX7epy4hkGSbwwR_hzucA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_gdOPWWwYIk-1_fM2ZbqmhA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1v3p_PfN6ku6GNiQC6D3Xg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_YBa26s9G0UemyPzMQSEebA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_6T-mMXX7Tk2kXUXSd6hCrA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-AdmtV4Y4E2el33p-R4o7Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_JFjr3X-iS0q7yBVBU-uoTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_itU9-PmAeki7z14co80kbg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_2k8diS0Dt0SajXRwD2H9pw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_s8Q9roYBs0mJ-WQs8x7lXQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nxtc:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vSYHseosFUeoXezPK_DwZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5wQASsCk1kGj8FiA4J8kUA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jWIXUY1zdUKLE6_2RdA-vg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_B8DlzbFCLUSo9Q5ArS1Eqw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_nHuF1bXQ4UWlM6L_pFhCDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nxtc:ResearchEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5RSY3CZwm0S1VjPnBbQ2qQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_1bxFiSQkekaQznzCFGTEyg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_9gGAYZTy_U-F2bBDboUuHg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_8_1_2021_To_8_31_2021_QUjo54fwz0S0O0oyBr9gCg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-08-01</xbrli:startDate><xbrli:endDate>2021-08-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CQRdBMZPLEKTJoEaubbMvw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gI-VD-V8dkWDjrK8eQOPfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_oikFh3LVykC7K0InhoySfQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3eszyap510GTal9lTSf5TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_dIyXP5BpbkGbErryI05k3w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5-Bu-eXe006BJ3_wB91BDA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NJQoeyaVbkORdIFR-hPZZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_C3fDpqg0Z0q1RzbPm02j9g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_1_31_2019_mPEpuuDRUUKsmnCtaVs9OA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-01-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_4_30_2016_fg7QH1JCMUKlmj0t5s8Cog"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2016-04-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TgHp4cCUE06VUtY2h3ln1w"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x59fHK3h6US54LesHKMlWw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaUNhIOQzE-uaj0TJAxBUg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2019-05-13</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_D46SFEZZN0aTWX1Xr95ZPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_tlc5w1VAtUGsrUcZTfo1pg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_v5woPB-Gu0eGhZbi1jiBTQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_KMR2V40rz0WEvFMh7SGH2A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2019-05-03</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2020_QgZGOIBcMEe2uMPs4IJ4-A"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2020-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_RJ-xwh_wV0-uMLJTUoRWww"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember__yYHlcWVlkCe8veQpXoODg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8mxuMVEvVECi33rG7hy8TQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4yfMi2VPkWj9z09O5KR2g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_BevS1rj6TkCrU3_9XVnY4Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Pd5kHKPoGUawJuu7EPVYpQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_8exjrnhK4U25OrK5dhgHWg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_03bv1J6VnEK7iPOZioYxuQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eGfbitKLGk6VtkSOTwNSZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_4Bc0BKCyvkywArPzGa-ufg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_zu6x2W08xUuSowvqAgpX-g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_n1J87RqwcE-D74ie7jOgeA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ip93Wfm4iEeGxOE28jx6nw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f-KycTXTtEGUeina0uYgfw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DQ6MmhQyV069Qs7Ih1PO6g"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_0wxdrOUI5Uq9n6FoN-ND_Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-03</xbrli:startDate><xbrli:endDate>2019-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_SRji9FsHhkW2MxxpNEJcRQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-03</xbrli:startDate><xbrli:endDate>2019-05-03</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_QFG6gM-uuk2TLGjd7TLz8Q"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2019-12-02</xbrli:startDate><xbrli:endDate>2019-12-02</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_DrWQ9sKhMUyebJfoMay_Jw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2019-05-13</xbrli:startDate><xbrli:endDate>2019-05-13</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QjIgQ3Cie0eiBOwS3XozJA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JLiZDuh8TkiEItJlU1AcwA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ZBgPDtK_ukm2DSu8kFg3MA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NKtrp11L7UqjNJ0bCbPyIg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Ym0BL0i97UaomE43uV-bYQ"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Wm2A56lBgkCPpaUm6E_ypw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_PfvSQBm2r0egI8U0wsBykg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_tC3N1hSTQ06SevgSev4lPA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier><xbrli:segment><xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember></xbrli:segment></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2021-01-01</xbrli:startDate><xbrli:endDate>2021-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2021-12-31</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_6_30_2022_VAIVvh0mOE-2MiNUaNezsg"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2022-06-30</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="As_Of_2_24_2023_1fR9h1Abg0u8OQ_Y5NgKhw"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:instant>2023-02-24</xbrli:instant></xbrli:period></xbrli:context><xbrli:context id="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001661059</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2022-01-01</xbrli:startDate><xbrli:endDate>2022-12-31</xbrli:endDate></xbrli:period></xbrli:context><xbrli:unit id="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww"><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg"><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_Vote_NTyCJtIjU0i5jZ9cnBFqVg"><xbrli:measure>nxtc:Vote</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ"><xbrli:measure>xbrli:pure</xbrli:measure></xbrli:unit><xbrli:unit id="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw"><xbrli:divide><xbrli:unitNumerator><xbrli:measure>iso4217:USD</xbrli:measure></xbrli:unitNumerator><xbrli:unitDenominator><xbrli:measure>xbrli:shares</xbrli:measure></xbrli:unitDenominator></xbrli:divide></xbrli:unit><xbrli:unit id="Unit_Standard_segment_SvUt3NvuT0moPQCiN6jnXA"><xbrli:measure>nxtc:segment</xbrli:measure></xbrli:unit></ix:resources></ix:header></div><div style="max-width:100%;padding-left:4.47%;padding-right:4.47%;position:relative;"><div style="margin-top:7.2pt;min-height:20.15pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:9.2pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;text-align:center;border-bottom:1.0pt solid #000000;border-top:3.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;font-weight:bold;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><a id="_3c684170_f4cd_4853_b6f4_e1c61343f164"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">UNITED STATES</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:13pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">Washington, D.C. 20549</b></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:13pt;text-align:center;margin:0pt 0pt 4pt 0pt;"><b style="font-weight:bold;">FORM&#160;</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:DocumentType" id="Narr_agu6uoZHqUe6Iu1IFuSE8Q"><b style="font-weight:bold;">10-K</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:7.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:5pt;margin:0pt;"><b style="font-weight:bold;">(Mark One)</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_5d2f0701_b0ce_4bad_a053_4d67aaabd2b1"></a><a id="Tc_0aDQdhXJwkmE-E0iIPt6jQ_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:6.45%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:93.54%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:DocumentAnnualReport" id="Tc_Xm9sqddsMUycUw2CEvJ_4g_1_0"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9746;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">ANNUAL Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:7pt;font-weight:bold;">For the fiscal year ended </b><ix:nonNumeric format="ixt:datemonthdayyearen" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:DocumentPeriodEndDate" id="Narr_lZCjPJvjTU6bPjKh02GAZw"><b style="font-size:7pt;font-weight:bold;">December 31, 2022</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">or</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_d5e1ee58_c4e0_4444_b6c4_4b35f78c6975"></a><a id="Tc_4pYteKuo9Uy3o7K_zG7xCQ_1_1"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:6.45%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:93.54%;margin:0pt;padding:0pt;"></td></tr><tr><td style="vertical-align:top;width:6.45%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:DocumentTransitionReport" id="Tc_V1Gz5zv0J0OnYRYiXoBf-g_1_0"><b style="font-family:'Segoe UI Symbol';font-size:7pt;font-weight:bold;">&#9744;</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:93.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.27;margin:0pt;"><b style="font-weight:bold;text-transform:uppercase;">Transition Report Pursuant to Section&#160;13 or 15(d) of the Securities Exchange Act of 1934</b></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:6pt;text-align:center;margin:0pt;"><b style="font-weight:bold;white-space:pre-wrap;">For the transition period from          to         &#160;.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:6pt;font-weight:bold;">Commission File Number: </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityFileNumber" id="Narr_prXysED14UKc3BoHQJenSQ"><b style="font-size:6pt;font-weight:bold;">001-38905</b></ix:nonNumeric></p><div style="font-family:'Times New Roman','Times','serif';font-size:6.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:15pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityRegistrantName" id="Narr_GtWmpXwiyk-3IUGUGGefMQ"><b style="font-weight:bold;">NextCure, Inc.</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">(Exact name of registrant as specified in its charter)</p><div style="font-family:'Times New Roman','Times','serif';font-size:8.0pt;margin-bottom:4pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1px;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto;"><a id="_1da0343e_05ab_4528_811c_63ef7c2883ee"></a><a id="Tc_R88Z9YORzU6MNps2SvM9fw_1_0"></a><a id="Tc_nXozytJvJU6K9pQbGvffnw_1_1"></a><a id="Tc_y7iA0IOdYEW1kaMPuRK_IA_3_0"></a><a id="Tc_czp1zgBpbEakvRwwcNH75Q_4_0"></a><a id="Tc_921d1nJ880uJuXaIuuzVCg_4_1"></a></div></div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityIncorporationStateCountryCode" id="Tc_Hr0SdvmK30eTOcM9vRPLhQ_0_0"><b style="font-size:7pt;font-weight:bold;">Delaware</b></ix:nonNumeric></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityTaxIdentificationNumber" id="Tc_lfCuz-mTDkC_tvFZS6UZHg_0_1"><b style="font-size:7pt;font-weight:bold;">47-5231247</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.26;text-align:center;margin:0pt;">(State or other jurisdiction of</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.26;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> incorporation or organization)</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.26;text-align:center;margin:0pt;">(I.R.S. Employer</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.26;text-align:center;margin:0pt;"><span style="white-space:pre-wrap;"> Identification No.)</span></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><span style="font-size:3pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityAddressAddressLine1" id="Narr_tjDEmH33XESh5BAyXYL3EQ"><b style="font-size:7pt;font-weight:bold;">9000 Virginia Manor Road, Suite 200</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;"><br /></b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityAddressCityOrTown" id="Narr_yq2RI-VOL0GZwOmTIdij9g"><b style="font-size:7pt;font-weight:bold;">Beltsville</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">, </b><ix:nonNumeric format="ixt-sec:stateprovnameen" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityAddressStateOrProvince" id="Narr_ka8zp53ZwEWBzf1eSNzQ_w"><b style="font-size:7pt;font-weight:bold;">Maryland</b></ix:nonNumeric></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityAddressPostalZipCode" id="Tc_RjN37S0WO02qUJ2XOl9yKQ_3_1"><b style="font-size:7pt;font-weight:bold;">20705</b></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.26;text-align:center;margin:0pt;">(Address of principal executive offices)</p></td><td style="vertical-align:top;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.26;text-align:center;margin:0pt;">(Zip Code)</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;">Registrant&#8217;s telephone number, including area code:</span><b style="font-size:7pt;font-weight:bold;"> (</b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:CityAreaCode" id="Narr_dolGVVS7VUW8nQEkML6ufQ"><b style="font-size:7pt;font-weight:bold;">240</b></ix:nonNumeric><b style="font-size:7pt;font-weight:bold;">) </b><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:LocalPhoneNumber" id="Narr__uDLDP79GE6c579vxfGZ9w"><b style="font-size:7pt;font-weight:bold;">399-4900</b></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-indent:36pt;margin:0pt;">Securities registered pursuant to Section 12(b) of the Act:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:3pt;visibility:hidden;">&#8203;</span></p><a id="_ab712d9a_5858_47a8_9bdc_27523d042820"></a><a id="Tc_ofnFDRXSW0C6GvhcGU-y0Q_0_0"></a><a id="Tc_5oX7vwskLUm0kTjjGoTkug_0_1"></a><a id="Tc_GWs7QQH_bEmnphmZDKIREA_0_2"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:-0.044857025%;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:34.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;">Title&#160;of&#160;each&#160;class</p></td><td style="vertical-align:top;width:31.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Trading Symbol(s)</p></td><td style="vertical-align:bottom;width:34.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;">Name&#160;of&#160;each&#160;exchange&#160;on&#160;which&#160;registered:</p></td></tr><tr><td style="vertical-align:top;width:34.38%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-align:center;text-indent:-7.2pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:Security12bTitle" id="Tc_JqmDCjjyz0CWI6rt4MMiVg_1_0"><span style="font-size:7pt;">Common Stock, $0.001 par value per share</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:31.25%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:TradingSymbol" id="Tc_v5XmRrDa1EyuSL4CVaLM3Q_1_1"><span style="font-size:7pt;">NXTC</span></ix:nonNumeric></p></td><td style="vertical-align:top;width:34.35%;border-bottom:1px solid #000000;border-left:1px solid #000000;border-right:1px solid #000000;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><ix:nonNumeric format="ixt-sec:exchnameen" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:SecurityExchangeName" id="Tc__WmsMax4_UeLWxBsjuuk-Q_1_2"><span style="font-size:7pt;">Nasdaq Global Select Market</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;text-indent:36pt;margin:0pt;">Securities registered pursuant to Section 12(g) of the Act: None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is a well-known seasoned issuer, as defined in Rule&#160;405 of the Securities Act.</span><span style="font-size:7pt;"><br /></span><span style="font-size:7pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityWellKnownSeasonedIssuer" id="Narr_WdV1u0lY6EaJnYM2zrfslw"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark if the registrant is not required to file reports pursuant to Section&#160;13 or Section&#160;15(d)&#160;of the Act.</span><span style="font-size:7pt;"><br /></span><span style="font-size:7pt;">Yes </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span><span style="font-size:7pt;"> </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityVoluntaryFilers" id="Narr_281UFUIN70WrbRFvZCApXA"><span style="font-size:7pt;">No</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant: (1)&#160;has filed all reports required to be filed by Section&#160;13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports) and (2)&#160;has been subject to such filing requirements for the past 90 days. </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityCurrentReportingStatus" id="Narr_nicgsjoT8ECThx6p0g49dQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule&#160;405 of Regulation S-T (&#167;232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). </span><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityInteractiveDataCurrent" id="Narr_Qr1OuKL2xUif4gtPA5raqQ"><span style="font-size:7pt;">Yes</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span><span style="font-size:7pt;">&#160;No </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;text-indent:36pt;margin:0pt;">Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company or an emerging growth company. See the definitions of &#8220;large accelerated filer,&#8221; &#8220;accelerated filer,&#8221; &#8220;smaller reporting company&#8221; and &#8220;emerging growth company&#8221; in Rule&#160;12b-2 of the Exchange Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:51.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.26;margin:0pt;">Large accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;line-height:1.26;text-align:right;margin:0pt;">Accelerated filer <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p></td></tr><tr><td style="vertical-align:top;width:51.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;margin:0pt;"><ix:nonNumeric format="ixt-sec:entityfilercategoryen" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityFilerCategory" id="Narr_jnGSe3jI1Umog9HMOdgqdw"><span style="font-size:7pt;">Non-accelerated filer</span></ix:nonNumeric><span style="font-size:7pt;"> </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:right;margin:0pt;"><span style="font-size:7pt;">Smaller reporting company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntitySmallBusiness" id="Narr_fzNCCLNxtUyRRpTIGZFnhA"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr><tr><td style="vertical-align:top;width:51.07%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:48.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.26;text-align:right;margin:0pt;"><span style="font-size:7pt;">Emerging&#160;growth&#160;company </span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityEmergingGrowthCompany" id="Narr_irNh-FKHx0Crg9ktGKwjfw"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></ix:nonNumeric></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityExTransitionPeriod" id="Narr_KbAV9gSypUy31jNXNLFijQ"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 5pt 0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant has filed a report on and attestation to its management&#8217;s assessment of the effectiveness of its internal control over financial reporting under Section 404(b) of the Sarbanes Oxley Act (15 U.S.C. 7262(b)) by the registered public accounting firm that prepared or issued its audit report. Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:IcfrAuditorAttestationFlag" id="Narr_jFxun91o60GIH8rkTH6Cxg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;"> No </span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;text-indent:36pt;margin:0pt;">If securities are registered pursuant to Section 12(b) of the Act, indicate by check mark whether the financial statements of the registrant included in the filing reflect the correction of an error to previously issued financial statements. <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;text-indent:36pt;margin:3pt 0pt 0pt 0pt;">Indicate by check mark whether any of those error corrections are restatements that required a recovery analysis of incentive-based compensation received by any of the registrant&#8217;s executive o&#64259;cers during the relevant recovery period pursuant to &#167;240.10D-1(b). <span style="font-family:'Segoe UI Symbol';">&#9744;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:7pt;">Indicate by check mark whether the registrant is a shell company (as defined in Rule&#160;12b-2 of the Exchange Act). Yes&#160;</span><ix:nonNumeric format="ixt-sec:boolballotbox" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:EntityShellCompany" id="Narr_jjEQLX6g3kuzf2MHqZbSOg"><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9744;</span></ix:nonNumeric><span style="font-size:7pt;">&#160;No&#160;</span><span style="font-family:'Segoe UI Symbol';font-size:7pt;">&#9746;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">The aggregate market value of the registrant&#8217;s common stock held by non-affiliates as of June 30, 2022 the last business day of the registrant&#8217;s most recently completed second fiscal quarter, was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" format="ixt:numdotdecimal" scale="6" contextRef="As_Of_6_30_2022_VAIVvh0mOE-2MiNUaNezsg" decimals="-5" name="dei:EntityPublicFloat" id="Narr__XWlirJAx0uQvvSe5CjcTQ">115.5</ix:nonFraction> million, as computed by reference to the closing price of the common stock on the Nasdaq Global Select Market on that date.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;background:#ffff00;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 5pt 0pt;">As of February 24, 2023, the registrant had <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" format="ixt:numdotdecimal" scale="0" contextRef="As_Of_2_24_2023_1fR9h1Abg0u8OQ_Y5NgKhw" decimals="INF" name="dei:EntityCommonStockSharesOutstanding" id="Narr_cPkwgvhk30KzNWFN0k23zw">27,774,536</ix:nonFraction> shares of common stock, par value $0.001 per share, issued and outstanding.</p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">DOCUMENTS INCORPORATED BY REFERENCE</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="font-size:5pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:justify;margin:0pt;">Portions of the registrant&#8217;s definitive Proxy Statement for its 2023 Annual Meeting of Stockholders, which will be filed with the Commission within 120 days after December 31, 2022, are incorporated by reference into Part III of this Report. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="font-size:4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-bottom:1pt;padding-top:1pt;border-bottom:3.0pt solid #000000;border-top:1.0pt solid #000000;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:91.06%;border:0;margin:30pt 4.47% 30pt 4.47%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3e78b64c_dc66_4c39_a85f_58fa16056e01"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">NextCure, Inc.</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Form 10-K</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">For the Year Ended December 31, 2022</b></p><a id="TOC"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">TABLE OF CONTENTS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTI_73467"><b style="font-style:normal;font-weight:bold;">PART&#160;I</b></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ItemIBusiness_368398"><span style="font-style:normal;font-weight:normal;">Item&#160;1</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#ItemIBusiness_368398"><span style="font-style:normal;font-weight:normal;">Business</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">6</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_446956"><span style="font-style:normal;font-weight:normal;">Item&#160;1A</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1ARiskFactors_446956"><span style="font-style:normal;font-weight:normal;">Risk Factors</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">30</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_216361"><span style="font-style:normal;font-weight:normal;">Item&#160;1B</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item1BUnresolvedStaffComments_216361"><span style="font-style:normal;font-weight:normal;">Unresolved Staff Comments</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_180608"><span style="font-style:normal;font-weight:normal;">Item&#160;2</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item2Properties_180608"><span style="font-style:normal;font-weight:normal;">Properties</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_9287"><span style="font-style:normal;font-weight:normal;">Item&#160;3</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item3LegalProceedings_9287"><span style="font-style:normal;font-weight:normal;">Legal Proceedings</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">75</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_549389"><span style="font-style:normal;font-weight:normal;">Item&#160;4</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item4MineSafetyDisclosures_549389"><span style="font-style:normal;font-weight:normal;">Mine Safety Disclosures</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTII_356648"><b style="font-style:normal;font-weight:bold;">PART&#160;II</b></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketForRegistrantsCommonEquity"><span style="font-style:normal;font-weight:normal;">Item&#160;5</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item5MarketForRegistrantsCommonEquity"><span style="font-style:normal;font-weight:normal;">Market for Registrant&#8217;s Common Equity, Related Stockholder Matters, and Issuer Purchases of Equity Securities</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_699531"><span style="font-style:normal;font-weight:normal;">Item&#160;6</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item6SelectedFinancialData_699531"><span style="font-style:normal;font-weight:normal;">Selected Financial Data</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussion_693637"><span style="font-style:normal;font-weight:normal;">Item&#160;7</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7ManagementsDiscussion_693637"><span style="font-style:normal;font-weight:normal;">Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">76</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitative_728376"><span style="font-style:normal;font-weight:normal;">Item&#160;7A</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item7AQuantitativeandQualitative_728376"><span style="font-style:normal;font-weight:normal;">Quantitative and Qualitative Disclosures About Market Risk</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">84</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatements_538537"><span style="font-style:normal;font-weight:normal;">Item&#160;8</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item8FinancialStatements_538537"><span style="font-style:normal;font-weight:normal;">Financial Statements and Supplementary Data</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">85</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreements_266846"><span style="font-style:normal;font-weight:normal;">Item&#160;9</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9ChangesinandDisagreements_266846"><span style="font-style:normal;font-weight:normal;">Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_609124"><span style="font-style:normal;font-weight:normal;">Item&#160;9A</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9AControlsandProcedures_609124"><span style="font-style:normal;font-weight:normal;">Controls and Procedures</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_9B._Other"><span style="font-style:normal;font-weight:normal;">Item&#160;9B</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_9B._Other"><span style="font-style:normal;font-weight:normal;">Other Information</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Item&#160;9C</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item9CDisclosureRegardingForeignJurisdic"><span style="font-style:normal;font-weight:normal;">Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIII_212520"><b style="font-style:normal;font-weight:bold;">PART&#160;III</b></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficers_124962"><span style="font-style:normal;font-weight:normal;">Item&#160;10</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item10DirectorsExecutiveOfficers_124962"><span style="font-style:normal;font-weight:normal;">Directors, Executive Officers, and Corporate Governance</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">107</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_11._Executive"><span style="font-style:normal;font-weight:normal;">Item&#160;11</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_11._Executive"><span style="font-style:normal;font-weight:normal;">Executive Compensation</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_12._Security"><span style="font-style:normal;font-weight:normal;">Item&#160;12</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item12SecurityOwnershipofCertainBenefici"><span style="font-style:normal;font-weight:normal;">Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_13._Certain"><span style="font-style:normal;font-weight:normal;">Item&#160;13</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_13._Certain"><span style="font-style:normal;font-weight:normal;">Certain Relationships and Related Transactions and Director Independence</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_14._Principal"><span style="font-style:normal;font-weight:normal;">Item&#160;14</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_14._Principal"><span style="font-style:normal;font-weight:normal;">Principal Accounting Fees and Services</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#PARTIV_681968"><b style="font-style:normal;font-weight:bold;">PART&#160;IV</b></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatement_2226"><span style="font-style:normal;font-weight:normal;">Item&#160;15</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#Item15ExhibitsandFinancialStatement_2226"><span style="font-style:normal;font-weight:normal;">Exhibits, Financial Statement Schedules</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">108</p></td></tr><tr><td style="vertical-align:top;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_16._Form"><span style="font-style:normal;font-weight:normal;">Item&#160;16</span></a></p></td><td style="vertical-align:top;width:85.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#_Item_16._Form"><span style="font-style:normal;font-weight:normal;">Form&#160;10-K Summary</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">111</p></td></tr><tr><td colspan="2" style="vertical-align:top;width:94.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#SIGNATURES"><span style="font-style:normal;font-weight:normal;">SIGNATURES</span></a></p></td><td style="vertical-align:top;width:5.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">112</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">2</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_1ceec26d_503c_4b3d_9b1d_29ccf0beba97"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SPECIAL NOTE REGARDING FORWARD-LOOKING STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This Annual Report contains forward-looking statements, including with respect to our plans, objectives and expectations for our business, operations and financial performance and condition. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking statements. The forward-looking statements are contained principally in the sections entitled &#8220;Business,&#8221; &#8220;Risk Factors&#8221; and &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; but are also contained elsewhere in this Annual Report. In some cases, you can identify forward-looking statements by terminology such as &#8220;aim,&#8221; &#8220;anticipate,&#8221; &#8220;assume,&#8221; &#8220;believe,&#8221; &#8220;continue,&#8221; &#8220;could,&#8221; &#8220;due,&#8221; &#8220;estimate,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;objective,&#8221; &#8220;plan,&#8221; &#8220;predict,&#8221; &#8220;potential,&#8221; &#8220;positioned,&#8221; &#8220;seek,&#8221; &#8220;should,&#8221; &#8220;target,&#8221; &#8220;will,&#8221; &#8220;would&#8221; and other similar expressions that are predictions of or indicate future events and future trends, or the negative of these terms or similar language.&#160;Forward-looking&#160;statements include, but are not limited to, statements about:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the timing, progress and results of preclinical studies and clinical trials for NC410, NC762, NC525 and any other product candidates we develop, including statements regarding the timing of initiation and completion of studies or trials and related preparatory work, the period during which the results of the trials will become available and our research and development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing or likelihood of regulatory filings for NC410, NC762, NC525 and any other product candidates we develop and our ability to obtain and maintain regulatory approvals for such product candidates for any indication;</span></td></tr></table><a id="_cp_blt_2_2"></a><a id="_cp_text_2_3"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the identification, analysis and use of biomarkers and biomarker data;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the continued impact of the COVID-19 pandemic on the initiation, progress or expected timing of our clinical trials and the timing of related data, our efforts to adjust trial-related activities to address the impact of the COVID-19 pandemic, and other future impacts of the COVID-19 pandemic on the economy, our industry and our financial condition and results of operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the development of patient selection assays and companion or complimentary diagnostics for NC410, NC762 or any other product candidates we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our manufacturing capabilities and strategy, including the scalability of our manufacturing methods and processes;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the potential benefits, activity, effectiveness and safety of NC410, NC762, NC525 and any other product candidates we develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intentions and ability to successfully commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations regarding the nature of the biological pathways we are targeting;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our expectations for our FIND-IO platform, including our ability to discover and advance product candidates using our FIND-IO platform;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the potential benefits of and our ability to maintain our relationship with Yale University;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our estimates regarding our expenses, future revenues, capital requirements, needs for or ability to obtain additional financing and the period over which we expect our current cash, cash equivalents and marketable securities to be sufficient to fund our operations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our intended reliance on and the performance of third parties, including collaborators, contract research organizations and third-party manufacturers;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to protect and enforce our intellectual property protection and the scope and duration of such protection;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments and projections relating to our competitors and our industry, including competing therapies; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of current and future laws and regulations.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These statements, and other forward-looking statements, are based on management&#8217;s current expectations, estimates, forecasts and projections about our business and industry, are not guarantees of future performance and involve known and unknown risks, uncertainties and other factors that are in some cases beyond our control, and that may cause our actual results, levels of activity, performance or achievements to be materially different from those anticipated by the forward-looking statements. Forward-looking statements contained in this Annual Report should be considered in light of these factors and the factors set forth under &#8220;Risk Factor Summary&#8221; below and the&#160;factors described elsewhere in this Annual Report, including in the sections entitled &#8220;Risk Factors&#8221; and&#160;&#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations.&#8221; These&#160;factors, and the other cautionary statements made in this Annual Report, are applicable to all related forward-looking&#160;statements wherever they appear in this Annual Report. If one or more of these factors materialize, or if any&#160;underlying assumptions prove incorrect, our actual results, levels of activity, performance, or achievements may vary materially from any&#160;future results, activity, performance, or achievements expressed or implied by these forward-looking statements.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">3</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We caution readers not to place undue reliance on any forward-looking statements made by us, which speak only as of the date of this Annual Report. We undertake no obligation to publicly update any forward-looking statements after the date of this Annual Report, whether as a result of new information, future events or otherwise, except as required by&#160;law.&#160;We qualify all of our forward-looking statements by the foregoing cautionary statements. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">RISK FACTOR SUMMARY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following is a summary of the principal risk factors that make an investment in our common stock speculative or risky. Before you invest in our securities, you should read the following summary together with the more detailed description of material risks described under &quot;Risk Factors&quot; in Item 1A of this Annual Report and the other information contained in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have a limited operating history and no products approved for commercial sale. We have a history of significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability. We have never generated revenue from product sales and may never be profitable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at all.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to the Discovery and Development of Our Product Candidates</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The impacts of the COVID-19 pandemic could continue to adversely affect our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our business is dependent on our ability to advance our current and future product candidates through preclinical studies and clinical trials, marketing approval and ultimately commercialization, each of which is uncertain.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Regulatory approval processes are lengthy and inherently unpredictable.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Clinical development involves a lengthy and expensive process with uncertain outcomes, and as an organization we have limited experience designing and implementing clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could result in delays in product development and in additional costs, delays or the inability to develop, obtain regulatory approval for or commercialize our products.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Initial positive trial results and positive results from preclinical studies and early-stage clinical trials may not be predictive or indicative of results obtained when the trial is completed or in later stage trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We, or our collaborators, could continue to encounter difficulties enrolling patients in our clinical trials due to the COVID-19 pandemic or otherwise.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Because the numbers of subjects in our Phase 1/2 and Phase 1 clinical trials are small, the results from each of these trials, once completed, may be less reliable than results achieved in larger clinical trials.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our current or future product candidates may cause undesirable side effects or have other properties that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to the Regulatory Approval and Commercialization of Product Candidates and Other Legal Compliance Matters</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be unable to obtain regulatory approval of our product candidates. The denial or delay of any such approval would prevent or delay commercialization of our product candidates and harm our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, and the market opportunities for any such product candidate may be limited.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Development of product candidates, in combination with other therapies, exposes us to additional regulatory risks.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on data and our information technology systems, and any failure of these systems or any related security breaches, loss of data, or other disruptions could harm our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Manufacturing</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Given our limited operating history, our manufacturing experience, as an organization and with our manufacturing facility, is limited. We are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">4</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing and, if approved, commercializing our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The loss of our third-party manufacturing partners or our or our partners&#39; failure to comply with applicable regulatory requirements or ability to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We depend on third-party suppliers for key materials used in our manufacturing process, and the loss of these third-party suppliers or their inability to supply us with adequate materials could harm our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Intellectual Property</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We have filed patent applications for our product candidates, but we have to-date obtained only a small number of patents from these applications. If we are unable to obtain and maintain patent protection, or if the scope of the patent protection obtained is not sufficiently robust, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are party to a license agreement with Yale University under which we acquired rights to intellectual property related to certain of our product candidates. If we breach our obligations under this agreement, the agreement could be terminated, which would adversely affect our business and prospects.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may not be able to protect our intellectual property rights throughout the world.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may be subject to claims, or we may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful; our intellectual property could be found invalid or unenforceable.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Reliance on Third Parties</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We rely on third parties to help conduct our ongoing and planned preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for our product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may depend on other third-party collaborators for the discovery, development and commercialization of certain of our current and future product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We may seek to establish additional collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Our Business</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If we are unable to establish marketing, sales and distribution capabilities for any product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt;">Risks Related to Our Common Stock</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The price of our common stock has been and may in the future be volatile and fluctuate substantially.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">We are now and may in the future be subject to securities litigation, which can be expensive and could divert management&#39;s attention.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">If securities analysts do not publish research or reports about our business or if they publish inaccurate or unfavorable research about our business, the price of our stock could decline.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall, even if our business is doing well.</span></td></tr></table><div style="margin-top:12pt;"></div></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">5</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="PARTI_73467"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART I </p><a id="ItemIBusiness_368398"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 1. Business</p><a id="_Toc18318196"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or &#8220;FIND-IO&#8221;, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidate NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1. &#160;In June 2020, we initiated a Phase 1/2 clinical trial of NC410 in patients with advanced or metastatic solid tumors. The Phase 1 dose-escalation portion of this open-label trial was designed to evaluate the safety and tolerability of NC410 and determine its pharmacologically active and/or maximum tolerated dose. In October 2022, we announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA&#174; (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, in immune checkpoint refractory patients (colorectal, esophageal, endometrial and head and neck cancers) or immune checkpoint na&#239;ve solid tumor patients (colorectal and ovarian cancers). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidate NC762 is a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or &#8220;B7-H4&#8221;, a protein expressed on multiple tumor types. In July 2021, we initiated a Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial was designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. In November 2022, we announced initial data from the Phase 1 portion of this trial which indicate that NC762 appears to be well tolerated. Safety expansion studies are ongoing with the intent of selecting a recommended Phase 2 dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidate NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or &#8220;AML&#8221;, blast cells and leukemic stem cells, or &#8220;LSCs&#8221;. Preclinical data show that NC525 kills AML blast cells and LSCs while sparing hematopoietic stem and progenitor cells, or &#8220;HSPCs&#8221;. In February 2023 we initiated a Phase 1 trial for NC525 to evaluate the safety and preliminary efficacy of NC525 in AML, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia (CMML). &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, we announced that based on the current efficacy data, we decided to discontinue our clinical development of our product candidate NC318 (S15 mAb). &#160;We will, however, continue to provide Yale University with drug product for its ongoing investigator-initiated trial of NC318 in combination with pembrolizumab in lung cancer patients.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our approach to identifying targets for new immunomedicines is based on our FIND-IO platform. FIND-IO embodies a rational approach to the discovery of novel cell surface and secretory molecules that drive functional immune responses. We use our immunology knowledge, experience and capabilities and tools we have developed, including our FIND-IO platform, to support our discovery efforts. We are working to discover novel targets that play a key role in mediating immune dysfunctions that allow tumors to evade the immune system. We seek to identify and develop immunomedicines that counteract these outcomes and to further validate and advance our product candidates. We have identified multiple novel targets using our FIND-IO platform, including those for which certain of our research programs are being designed to target.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">6</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:273pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Our Pipeline</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We leverage our understanding of biological pathways and our FIND-IO platform to discover, validate and build a proprietary pipeline of immunomedicine candidates. The figure below details our pipeline of product candidates and principal discovery and research programs.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;text-align:center;margin:0pt;"><img src="nxtc-20221231x10k005.jpg" alt="Graphic" style="display:inline-block;height:273pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:485.3pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Our Strategy</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our strategy is to use our fully integrated discovery and product development infrastructure to build a sustainable pipeline of product candidates to treat cancer patients who are not adequately served by currently available therapies. The key elements of our strategy include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Advancing the clinical development of our product candidates, NC410, NC762, and NC525. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">For NC410, we initiated the Phase 1 portion of a Phase 1/2 clinical trial in June 2020 and reported that NC410 was shown to be well tolerated. In October 2022, we announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA&#174; (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, in immune checkpoint refractory patients (colorectal, esophageal, endometrial and head and neck cancers) or immune checkpoint na&#239;ve solid tumor patients (colorectal and ovarian cancers). For NC762, we initiated a Phase 1/2 clinical trial in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types in July 2021, and previously announced that NC762 was well tolerated. In October 2022, we initiated NC762 into a Phase 1b expansion cohort study dosing at 10 mg and 20 mg using a CLIA-validated assay to select patients with B7-H4 expression in tumor types including NSCLC, ovarian, endometrial, hepatocellular and breast. For NC525, an IND was submitted with the FDA, we have received clearance to proceed, and we initiated a Phase 1 trial in February 2023 to evaluate the safety and preliminary efficacy of NC525. &#160;Additionally, while we announced in November 2022 that we would not be moving forward in our amended Phase 2 monotherapy clinical trial for NC318, we believe scientific evidence supports a combination of NC318 with anti-PD-1 therapy and continue to provide NC318 drug product to Yale in support of the Yale investigator initiated Phase 2 clinical trial of NC318 in combination with pembrolizumab in patients with NSCLC.</span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Building an oncology pipeline of novel targets for new immunomedicines focused on non-responders</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We continue to leverage our immunological expertise and our FIND-IO platform to identify novel targets relevant to overcoming immune suppression.</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">7</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Leveraging our fully integrated development, quality systems and cGMP manufacturing capabilities. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Our </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approach is to integrate key aspects of product development within our organization. We have assembled a team with extensive experience in identifying, characterizing and developing novel immunomedicines. We seek to couple discovery of important targets with the capability to rapidly streamline target validation and conduct key IND-enabling studies, leading to clinical development of product candidates. Our purpose-built, dedicated, state-of-the-art cGMP manufacturing facility utilizes single-use technology to support development of our pipeline and advancement of our product candidates into and through clinical development. The facility has production capacity of 2,000 liters and is designed to operate as a multi-product facility. Compared to working with third-party manufacturers, we believe our facility provides better quality assurance, greater control in scheduling and prioritizing manufacturing activities and enhanced capital efficiency.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Expanding our current focus and creating new opportunities outside of the oncology field</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. While our primary focus is oncology, the functional screening approach and proprietary technology of our FIND-IO platform are broadly applicable to the identification of positive and negative immune modulators, and therefore can be used and expanded to discover novel targets in other inflammatory diseases. Our goal is to enable next-generation immunomedicines for other serious inflammatory diseases with significant unmet medical needs in fields beyond oncology.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;">Extending the reach of our product candidates through strategic partnerships and collaborations</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">. We have exclusive worldwide rights to our current product candidates and our FIND-IO platform. We expect to explore a variety of market opportunities for our current and future product candidates and our platforms, including through the pursuit of strategic partnerships or other collaborations with regard to selected indications or geographical areas, such as Asia. We intend for our product candidates to be developed and commercialized globally, by us in key markets and in collaboration with other companies for other geographies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Immuno-Oncology Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The immune system has powerful biological mechanisms to defend and protect the body from pathogens, such as viruses, parasites and bacteria. It also provides surveillance against cancers by recognizing and responding to antigens that are uniquely or highly expressed on cancer cells. In cancer, complex interactions between immune cells and growing tumor cells can prevent an immune response by blocking cellular interactions, resulting in immunosuppression in the TME. This phenomenon, referred to as immune evasion, is a hallmark of cancer where the tumor can prevent tumor-specific immune cells called T-cells from functioning within the TME or gaining access to the tumor site, which allows the tumor to continue to grow, leading to disease progression. Tumors in advanced cancer have multiple mechanisms of evasion in the TME that can differ from tumor to tumor.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Remodeling the TME and overcoming its immunosuppressive properties is a major focus of cancer research and drug development. Checkpoint inhibitors are a drug class designed to counteract certain tumor defenses against the immune system. Currently approved checkpoint inhibitors were developed based on the belief that an immune system inactivated by co-inhibitory proteins, known as checkpoints, could be reactivated to recognize and attack the tumor. Therapies against checkpoints, such as PD-L1, PD-1 and Cytotoxic T-Lymphocyte Antigen, or &#8220;CTLA&#8221;-4, have produced impressive results in the clinic across an array of cancers and have been approved for several malignancies. However, despite the recent success of these checkpoint inhibitors, it is estimated that up to 60% to 70% of cancer patients do not respond to single-agent therapy with checkpoint inhibitors. This limited efficacy highlights the importance of our effort to identify novel targets and molecular pathways responsible for tumor immune evasion mechanisms that we believe will work independently from current targets for cancer immunotherapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Our Approach to Developing Immunomedicines for Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our approach to identifying targets for new immunomedicines in cancer is based on the combination of our FIND-IO platform, our immunological expertise and our belief in the importance of understanding biological pathways and the normal function of the immune system in the TME. Rather than focusing on a specific type of immune cell, we are targeting molecules that modulate the immune system in ways that we believe may provide new treatment opportunities for patients that are differentiated from currently marketed targeted therapies as well as those in development. Our primary goal is to develop immunomedicines that increase response rates, efficacy and durable overall survival among patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types that are not </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">8</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:198.75pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">adequately addressed by currently available therapies. We design our product candidates either to restore the normal effects of the immune system to promote elimination of the tumors or to counteract tumor immune evasion mechanisms.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our FIND-IO platform applies a function-based screening approach to identify human proteins and to determine whether those proteins alter or stop an immune response resulting in immune evasion. The platform is designed to identify novel cell surface molecular interactions that drive functional immune responses. Our FIND-IO platform broadly and quantitatively evaluates interactions between relevant protein components and different T-cellular types over time in order to identify novel targets that either increase or decrease immune-related functional responses associated with desired immune responses against tumors. By identifying novel immune modulators through the FIND-IO platform, we aim to develop next-generation immunomedicines that restore normal immune function in the TME.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To create our FIND-IO platform, we industrialized, expanded and optimized the T-cell Activity Array, or &#8220;TCAA&#8221;, a predecessor of the FIND-IO platform that Dr.&#160;Chen used to discover the immunosuppressive properties of multiple checkpoint molecules, including PD-L1 and S15. Our work in developing the FIND-IO platform beyond the TCAA includes using different and expanded gene libraries, adding biological pathways and reporters, expanding immune cell types and, most importantly, increasing the repertoire of functional assay readouts. We also broadened the platform to look at signaling within both the immune cell and the cell expressing the library gene. By transfecting cells with library genes, which encode membrane-bound or soluble proteins, FIND-IO is designed to determine whether the genes have signaling functions when interacting with an immune cell.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our FIND-IO technology includes proprietary approaches to functionally assess immune pathways in both primary immune cells and established cell lines from immune lineages, including T-cell subsets, monocytes, macrophage subpopulations, dendritic cells, cancer cell lines and cells isolated from diseased patients. This platform allows us to identify proteins that can be targeted with novel immunomedicines to repair and maintain anti-tumor immunity. By focusing on understanding the TME in oncology, we believe we can identify multiple new positive and negative modulators of immune cells, including T-cells, NK cells, macrophages and myeloid-derived suppressor cells.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Our product candidates target or are affected by a variety of cell types in the immune system. For example, NC410 targets the negative signaling from dendritic cells, macrophages and T-cells mediated by the binding of LAIR-1 to its ligands collagen and C1q. NC762, on the other hand, is enhanced by NK cells. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;"><img src="nxtc-20221231x10k006.jpg" alt="Graphic" style="display:inline-block;height:198.75pt;width:363.85pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 10pt 0pt;">Our Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NC410</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1. Multiple preclinical studies support our understanding that eliminating or blocking the binding of LAIR-1 restores normal immune function in multiple immune cells. Our translational work has shown that NC410 blocks the interaction of LAIR-1 with its binding partners, thereby promoting </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">9</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">T-cell function and dendritic cell activity to contribute to restoring anti-tumor immune activity. Consistent with our strategy, we believe NC410 has the potential to address the needs of patients who are not adequately addressed by currently available therapies. We have exclusive worldwide rights to NC410. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Background of LAIR Pathway in Solid Tumor Cancer</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">LAIR-1 is a co-inhibitory receptor expressed on T-cells and several other immune cell subsets, including monocytes, macrophages and dendritic cells. Its binding partners include certain types of collagen and complement component 1q, or C1q.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under normal conditions, collagen forms a scaffold to provide strength and structure to tissues. C1q is part of the innate immune system to protect the host from infection and other foreign agents. Both collagen and C1q are highly upregulated and expressed under pathologic conditions, such as in the TME and in the immune organelles close to the tumor site known as lymph nodes, which are important sites for mounting immune responses to the tumor. However, binding of LAIR-1 to collagen or C1q leads to immune suppression. Our preclinical studies have shown that LAIR-1 and LAIR-2 bind to similar ligands, including collagen and C1q. LAIR-2, which is a secreted protein as opposed to a membrane-bound protein like LAIR-1, binds to the same regions of these ligands with stronger affinity than LAIR-1. However, because LAIR-2 does not induce immune suppression when binding to these ligands, LAIR-2 functions as an efficient decoy for LAIR-1.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the harsh conditions of the TME, collagen and C1q are overexpressed as a membrane protein on many types of tumor cells and in the ECM surrounding the tumor. This increased expression of collagen and C1q, combined with insufficient levels of natural LAIR-2, leads to increased binding of LAIR-1, resulting in immune suppression, tumor immune evasion and tumor growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NC410 is a novel immunotherapeutic protein that was developed to block LAIR-1-mediated immune suppression by mimicking the natural decoy effects of LAIR-2. Our approach of using NC410 as a therapeutic is intended to take advantage of the natural LAIR-2 regulatory system in humans, which maintains human immune function under normal non-pathologic conditions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The mechanism of action of NC410 prevents immune suppression caused by LAIR-1 binding to collagen or C1q and promotes anti-tumor immune activity. As the figure below shows, when LAIR-2 and NC410 are present in the TME, they bind to collagen or C1q preferentially compared to LAIR-1 given their higher binding affinity. This has the effect of blocking the collagen or C1q from binding to LAIR-1, which otherwise would have resulted in an immunosuppressive effect. By blocking this interaction with LAIR-1 and its binding partners, T-cell function and dendritic cell activity is promoted in order to restore anti-tumor immune activity.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">10</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:228.02pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NC410 is Designed to Prevent Immune Suppression Caused by LAIR-1</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><img src="nxtc-20221231x10k007.jpg" alt="Graphic" style="display:inline-block;height:227.52pt;left:0%;padding-bottom:0.5pt;position:relative;top:0pt;width:468pt;" /></p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Our Clinical Development Plan for NC410</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and others have analyzed genomic and protein databases and observed that LAIR-1 expression levels negatively correlate with survival rates for several cancers, including brain, renal, colorectal, glioma, lung, urothelial and ovarian cancers. These analyses support possible targeting of these tumor types as primary indications for therapeutic treatment with NC410. We have conducted expansive screening efforts on tumor samples from different solid tumor types to identify tumors that express LAIR-1 on immune cells and varying levels of collagen in the TME, to guide our ultimate selection of patients for the Phase 2 portion of the Phase 1/2 clinical trial. We plan to develop a CLIA-certified assay to select patients for the Phase 2 study.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In June 2020, we initiated a Phase 1/2 clinical trial of NC410 in patients with advanced or metastatic solid tumors. The Phase 1 clinical trial enrolled a total of 40 patients across 7 cohorts ranging from 3 mg up to 200 mg. NC410 has been shown to be well-tolerated up to 200 mg once every 2 weeks (Q2W). Notable treatment-related adverse events included infusion reactions, anemia and a worsening of a baseline lymphopenia. The best response achieved was stable disease greater than 12 weeks in 8 patients across different doses and indications. Based on the preclinical and clinical data to date, we determined that a combination strategy was more likely to achieve clinical response in a Phase 1b/2 instead of a monotherapy approach.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2022, we announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA&#174; (pembrolizumab), Merck &amp; Co., Inc.&#8217;s (Merck) anti-PD-1 therapeutic, in immune checkpoint refractory patients (colorectal, esophageal, endometrial and head and neck cancers) or immune checkpoint na&#239;ve solid tumor patients (colorectal and ovarian cancers). The rationale for moving directly into a combination trial for NC410 is based on NC410&#8217;s mechanism of action, as seen in preclinical modeling and also during the NC410 Phase 1 dose escalation study readouts. It has been shown that elevated collagen levels in the extracellular matrix (ECM), the tissue matrix surrounding the tumor, are associated with resistance to PD-1 and PD-L1 therapies. In non-clinical colorectal models and early-stage monotherapy clinical studies conducted by NextCure, we have demonstrated that NC410 can remodel collagen in the ECM, which enhances T cell infiltration into the tumor. This results in immune activation, enhanced immune function in the TME and significantly enhances anti-PD-1 activity in multiple preclinical tumors models. We believe that this may translate to improved responses in patients with immune checkpoint refractory or immune checkpoint na&#239;ve solid tumors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company entered into a supply agreement for KEYTRUDA with Merck &amp; Co., Inc. (known as MSD outside the United States and Canada) for the Phase 1b/2 clinical combination trial.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">11</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:153pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NC762</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NC762 is a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or &#8220;B7-H4&#8221;, a protein expressed on multiple tumor types. We believe NC762 acts by inhibiting tumor cell growth. While the inhibitory effect on tumor growth does not appear to be dependent upon T-cells, we believe NK cells may contribute to enhanced anti-tumor activity mediated by NC762. We have observed in preclinical studies that NC762 inhibits the growth of human melanoma tumors in mice, and we believe that NC762 has the potential to treat multiple tumor types. In July 2021, we initiated a Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer, or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial is being designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. After a recommended dose for the Phase 2 portion of the trial is determined, the efficacy of NC762 will be evaluated in select tumor types. We have exclusive worldwide rights to NC762.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">B7-H4 Background</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">B7-H4 is a cell surface protein expressed on multiple tumor types, including non-small cell lung cancer, ovarian cancer, breast cancer and hepatocellular carcinoma, and on tumor-associated macrophages, and shows limited expression in most normal tissues. B7-H4 was initially discovered in 2003 in the Mayo Clinic lab of our scientific co-founder Dr. Lieping Chen. It is a member of the same family of co-inhibitory checkpoint proteins as B7-H1, known as PD-L1, which was also discovered by Dr. Chen&#39;s laboratory (see &quot;Immuno-Oncology Background&quot;). B7-H4 has been shown in published articles to negatively regulate T-cell immune response, inhibit cytokine production, suppress antigen-presenting cells, promote immune escape and play a role in tumorigenesis and tumor development. Expression of B7-H4 in tumor cells has been shown in preclinical research and published articles to be correlated with reduced overall survival, and B7-H4 has generally non-overlapping expression with both PD-L1 and S15. Given the low expression of B7-H4 on healthy cells and the results of our preclinical cross-tissue reactivity studies, we believe that anti-B7-H4 treatment is unlikely to inadvertently cause adverse effects of tissues and pathways outside of B7-H4 positive tumors and tumor-associated macrophages.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NC762 is a novel immunotherapeutic protein that binds to B7-H4 on the cell surface of tumors. We believe NC762 acts by inhibiting tumor cell growth and killing tumor cells, including by enhancing immune response. Preclinical research indicates that the primary mechanism of action of NC762 inhibits tumor cell growth independently of immune cell infiltration into the TME. NC762 was also designed to enhance immune response by allowing for enhanced binding to CD16a/Fc&#947;RIIIa, a receptor found on the surface of natural killer, or NK cells, in order to increase antibody-dependent T-cell-mediated cytotoxicity, or &#8220;ADCC&#8221;, activity. ADCC is a process by which effector cells such as NK cells interact with and kill antibody-coated target T-cells such as tumor cells. Extensive in vivo modeling data using human melanoma in mouse models expressing B7-H4 indicate that NC762&#39;s anti-tumor effect may be enhanced in the presence of NK cells, but that it has an anti-tumor impact even in the absence of peripheral blood mononuclear cells (comprising several types of white blood cells including NK cells), and that the primary mechanism by which NC762 inhibits tumor growth is therefore ADCC-independent. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><img src="nxtc-20221231x10k008.jpg" alt="Graphic" style="display:inline-block;height:153pt;left:0%;padding-bottom:0pt;position:relative;top:0pt;width:320.4pt;" /></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Preclinical studies did not raise any significant safety concerns with NC762. Specifically, dosage of cynomolgus monkeys at doses up to 100 mg/kg did not result in any observed adverse effects. A tissue cross-reactivity study of 37 tissues from three individuals found no signals that NC762 binds to tissues other than tumor tissue, which indicates that </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">12</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">NC762 is not expected to bind off target and harm cells, tissues and pathways outside of B7-H4 positive tumors and tumor-associated macrophages. In addition, an analysis of changes in serum cytokines <i style="font-style:italic;">in vitro</i> leads us to believe that treatment with NC762 is unlikely to trigger overactive immune responses known as cytokine storms that can have harmful effects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have developed an IHC assay using a commercially purchased antibody to test tumors for B7-H4 positivity and have performed screening of multiple tumor types. We intend to use this assay to select patients for treatment through patient biopsies, including in the Phase 1 dose expansion portion of our planned Phase 1/2 clinical trial, and have validated the assay for use in clinical trials. We also intend to retroactively use immunophenotyping and serum analysis as part of our clinical trials to determine the types of cells present after treatment in order to identify biomarkers, to look for signs of clinical activity, and to help determine the likelihood of responsiveness to treatment with NC762.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Our Clinical Development Plan for NC762</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We and others have observed that B7-H4 is widely expressed on a number of cancers, including non-small cell lung cancer, ovarian cancer, breast cancer and hepatocellular carcinoma. These analyses support possible targeting of these tumor types as primary indications for therapeutic treatment with NC762. Using a B7-H4-specific antibody that we identified and optimized for IHC analyses, we are currently staining various cancer tissues to gain a more comprehensive and definitive understanding of B7-H4 prevalence in both primary and metastatic lesions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">In July 2021, we initiated a Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial was designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. The Phase 1 clinical trial enrolled a total of 18 patients across 5 cohorts ranging from 0.5 mg up to 20 mg. NC762 was well-tolerated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.27;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">In October 2022, we initiated NC762 into a Phase 1b expansion cohort study dosing at 10 mg and 20 mg using a CLIA-validated assay to select patients with B7-H4 expression in tumor types including NSCLC, ovarian, endometrial, hepatocellular and breast.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.4pt;margin:0pt;"><span style="font-size:9.4pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NC525</p><a id="_Hlk126832639"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NC525 is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia (AML), blast cells and leukemic stem cells (LSCs). Preclinical data show that NC525 kills AML blast cells and LSCs while sparing hematopoietic stem and progenitor cells (HSPCs). Preclinical data were presented at the ASH Meeting in December 2021. The data showed that NC525 (i) inhibits colony formation of AML LSCs <i style="font-style:italic;">in vitro</i>, (ii) inhibits AML growth in the MV4-11 derived xenographs (CDX) animal model <i style="font-style:italic;">in vivo</i> and (iii) restricts AML progression in patient-derived xenografts (PDX) <i style="font-style:italic;">in</i> <i style="font-style:italic;">vivo</i>. We have exclusive worldwide rights to NC525.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 3pt;"><i style="font-style:italic;">Background of LAIR-1 and AML </i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:9.9pt;margin:0pt;"><span style="font-size:9.9pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A significant unmet need exists for patients with AML whose disease relapses after, or is primarily refractory to, standard of care treatments. &#160;In such patients, relapse is mediated by the persistence of chemotherapy-resistant LSCs. NC525 is a humanized immunoglobulin gamma 1, kappa (IgG1&#954;) monoclonal antibody specific for Leukocyte Associated Immunoglobulin Like Receptor 1 (LAIR-1) protein. While LAIR-1 is exclusively expressed on immune cells, its expression is elevated on AML cells. LAIR-1 is highly expressed on leukemic stem cells from AML patients but its relatively low expression on normal hematopoietic stem cells (HSCs) makes it a unique and attractive target for a novel AML therapy. Based on the non-clinical studies performed with NC525 and its parent molecule 11B3.IgG1 to date, NC525 binds human LAIR-1 with an affinity of approximately 3 nM. NC525 induces anti-leukemic activity primarily by modulating LAIR-1 signaling in the AML cells, and to some extent, inducing IgG1 antibody-dependent cellular cytotoxicity (ADCC). In multiple humanized cell lines (CDX) and patient derived (PDX) mouse models, NC525 exhibited potent anti-leukemic activity. NC525 potently restricted leukemic tumor growth of MV4-11 and THP-1 cells in the humanized murine CDX models. In PDX models, the disease progression and tumor burden of the patient-derived AML bone marrow transplanted in NSG-SGM3 mice was significantly abolished by NC525 treatment. This anti-tumor activity was observed in at least four independent experiments utilizing bone marrows derived from different AML patients. NC525 also inhibited colony formation of patient-derived leukemic stem cells in an in vitro assay but did not affect colony formation of normal HSCs. Likewise, NC525 did not affect normal immune cells from CD34+ cord blood cells reconstituted in an NSG-SGM3 murine model. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">13</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><i style="font-style:italic;">Our Clinical Development Plan for NC525</i></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We initiated a Phase 1 trial in February 2023 to evaluate the safety and preliminary efficacy of NC525 in patients with AML, high-risk myelodyplastic syndrome, and chronic myelomonocytic leukemia (CMML). &#160;This open-label trial is being designed to evaluate the safety and tolerability of NC525 and determine its pharmacologically active and/or maximum tolerated dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">NC318</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NC318 is a monoclonal antibody that binds specifically to human S15 with high affinity. S15 is a member of the sialic acid-binding immunoglobulin lectins, or Siglec, family, a distinct subgroup of the immunoglobulin superfamily of proteins. Siglecs are expressed on most white blood cells of the immune system, except for T-cells. &#160;We have exclusive worldwide rights to NC318.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In October 2018, we initiated the Phase 1 portion of a Phase 1/2 clinical trial to evaluate NC318 as a monotherapy in patients with advanced or metastatic solid tumors. This open-label Phase 1/2 clinical trial was designed to assess the safety and tolerability of NC318, to define the maximum tolerable dose and/or pharmacologically active dose and to assess preliminary efficacy. Based on the results of the Phase 1 portion of that Phase 1/2 clinical trial, we began enrolling patients in the Phase 2 portion of the trial in October 2019. &#160;In April 2021, Yale University commenced a Phase 2 investigator-initiated clinical trial of NC318 in combination with pembrolizumab in patients with non-small cell lung cancer (NSCLC). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2022, we announced that we would not continue to move NC318 forward in the Phase 2 monotherapy clinical trial. Although NC318 has been shown to be well-tolerated in patients, based on the totality of the NC318 monotherapy efficacy data we decided to wind down that clinical study. &#160;Patient dosing has been completed in our Phase 2 monotherapy clinical trial for NC318, and we expect patient follow up to be completed in first quarter of 2023. &#160;The Company will continue to support Yale University&#8217;s ongoing Phase 2 investigator initiated trial (IIT) of NC318 in combination with pembrolizumab in NSCLC patients by providing NC318 drug product to Yale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our Research Programs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to advancing our clinical trials for NC410, NC762 and NC525, we are also pursuing preclinical evaluation of other potential novel immunomodulatory molecules.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Our FIND-IO Platform </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our FIND-IO platform uses proprietary approaches to functionally assess immune pathways in both primary immune cells and established cell lines from immune lineages, including T-cell subsets, monocytes, macrophage subpopulations, dendritic cells, cancer cell lines, and cells isolated from diseased patients. This platform allows us to identify proteins that can be targeted with novel immunomedicines to repair and maintain anti-tumor immunity. We have identified multiple novel targets using our FIND-IO platform, including those for which certain of our research programs are being designed to target.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">The goal of our FIND-IO platform is to sustain a pipeline of novel immunomedicines that restore normal immune function to treat cancer and other immune-related diseases. While we are primarily focused on cancer treatment, we believe that our proprietary technology, our approach, our understanding of biological pathways and the convergence of immunology and inflammation provide us with opportunity to explore novel immunomedicines for other significant unmet medical needs. To maximize the full potential of our platform and expertise, we are expanding the functional screening approach of our FIND-IO platform to the identification of novel targets in autoimmunity and inflammation, as well as in neuro-inflammatory diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;"><span style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Our Collaboration Agreements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Agreements with Yale University</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">License Agreement with Yale</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We entered into a license agreement with Yale, or the Yale Agreement, in December 2015 pursuant to which we obtained an exclusive, royalty-bearing, sublicensable worldwide license to products that either incorporate certain licensed </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">14</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">patents used in the discovery of targets or arise out of research and development of Dr.&#160;Chen&#8217;s laboratory at Yale, including S15, and subsequently amended the Yale Agreement in January 2020 and October 2021. We are obligated to pay Yale low single-digit royalties on sales of products, including NC318, that are either covered by the patents licensed to us under the Yale Agreement or arise out of Dr.&#160;Chen&#8217;s laboratory as a result of research under the corporate sponsored research agreement described below, subject to minimum annual royalty payments in the low to mid hundreds of thousands of dollars. Until we are required to pay royalties under the Yale Agreement, we must pay an annual license maintenance fee to Yale in the mid to high tens of thousands of dollars. In addition, with respect to each product covered by licenses under the Yale Agreement, we are obligated to pay Yale milestone payments upon (i)&#160;the initiation of each of a Phase&#160;1 clinical trial, Phase&#160;2 clinical trial and Phase&#160;3 clinical trial or a pivotal trial, (ii)&#160;first commercial sale in the United States and (iii)&#160;first commercial sale in China, Japan or a major European country, in an aggregate amount of up to $2,975,000. The term of the license agreement with Yale runs, on a country-by-country basis, until the later of the expiration of all licensed patents or 10&#160;years from the first commercial sale in such country, unless Yale has cause to terminate earlier for our material breach of the license, bankruptcy or if we or any sublicensee bring a challenge against Yale in relation to the licensed patents. We have the right to terminate the Yale Agreement for Yale&#8217;s material breach or at any time during the term with six months&#8217; prior written notice to Yale.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Sponsored Research Agreement with Yale</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In connection with the Yale Agreement, we also entered into a corporate sponsored research agreement, or &#8220;SRA&#8221;, with Yale, pursuant to which we had agreed to provide an aggregate of up to $15 million to fund a research program aimed at discovering new targets for immunomedicines. The SRA was subsequently amended in January 2020, October 2021 and September 2022 and will expire on March 31, 2023. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Manufacturing</p><a id="_cp_text_1_134"></a><a id="_cp_text_1_136"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have a purpose-built, dedicated, state-of-the-art cGMP manufacturing facility that utilizes single-use technology to support our pipeline and advance our product candidates into and through clinical development. The facility has a production capacity of 2,000 liters in order to support multiple product candidates. The investment in our manufacturing facility is a critical element of our ability to quickly identify whether a candidate is likely to be successful and to facilitate an efficient development path. While other companies may need to work with third parties for antibody production, we can do so in our own facility. Compared to working with third-party manufacturers, we believe our facility provides better quality assurance, greater control in scheduling and prioritizing manufacturing activities and enhanced capital efficiency. We are currently manufacturing all of the drug supply for our ongoing preclinical studies and our Phase 1/2 clinical trials of NC410 and NC762, and Phase 1 clinical trial of NC525, and intend to provide the drug supply for our future clinical trials of NC410, NC762 and NC525 and for the Yale IIT combination trial for NC318. As we advance the development of our growing pipeline of product candidates, we will continue to evaluate the merits of further expanding our internal manufacturing capabilities, including for the production of commercial drug supply, as compared to collaborating with third-party manufacturers. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Competition</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries, and the immuno-oncology subsector, are characterized by rapid evolution of technologies, fierce competition and strong defense of intellectual property. We believe that our programs, platforms, technology, knowledge, experience and scientific resources provide us with competitive advantages, but we also face competition from pharmaceutical and biotechnology companies, academic institutions, governmental agencies and public and private research institutions, among others. Our competitors include larger and better funded biopharmaceutical, biotechnology and therapeutics companies, including companies focused on cancer immunotherapies. Moreover, we may also compete with smaller or earlier-stage companies, universities and other research institutions that have developed, are developing or may be developing current and future cancer therapeutics.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Product candidates that we successfully develop and commercialize will compete with a range of therapies that are currently approved and any new therapies that may become available in the future. Key product features that would affect our ability to effectively compete with other therapeutics include the efficacy, safety and convenience of our products. Currently marketed oncology drugs and therapeutics range from traditional cancer therapies, including chemotherapy, to antibody-drug conjugates, such as Genentech&#160;Inc.&#8217;s Kadcyla, to immune checkpoint inhibitors targeting CTLA-4, such as BMS&#8217; Yervoy, and PD-1/PD-L1, such as BMS&#8217; Opdivo, Merck&#160;&amp;&#160;Co.&#8217;s Keytruda and Genentech&#8217;s Tecentriq, to T-cell-engager immunotherapies, such as Amgen&#8217;s Blincyto. In addition to these marketed therapies, numerous compounds are in clinical development for the potential treatment of cancer.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">15</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The availability of reimbursement from government and other third-party payors will also significantly affect the pricing and competitiveness of our products. Our competitors may also obtain FDA or other regulatory approval for their products more rapidly than we may obtain approval for ours, which could result in our competitors establishing a strong market position before we are able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends in part on our ability to obtain and maintain proprietary protection for our products, methods and manufacturing processes, to operate without infringing on the proprietary rights of others and to prevent others from infringing on our proprietary rights. We rely on a combination of patents, patent applications and trade secrets, as well as contractual protections, to establish and protect our intellectual property rights. We seek to protect our proprietary position by, among other things, filing patent applications in the United States and internationally. Our patent estate includes patents and patent applications with claims relating to our product candidates, methods of use and manufacturing processes, and claims for potential future products and developments. As of December 31, 2022, our intellectual property portfolio includes, on a worldwide basis, 20 pending foreign patent applications relating to NC318, NC410, NC762 and NC525, two pending U.S. patent application relating to NC318, one pending U.S. patent application relating to NC410, two pending U.S. patent applications relating to NC762, one U.S. patent application relating to NC525 and additional pending patent applications for other discovery and research programs. Patents resulting from our patent applications for NC318, NC410 and NC525, if issued, are expected to expire beginning in 2037 absent any patent term adjustments or extensions and for NC762, if issued, are expected to expire beginning in 2039 absent any patent term adjustments or extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, as described above, under the Yale Agreement, we have an exclusive, royalty-bearing, sublicensable worldwide license from Yale for an intellectual property portfolio, including among other things a patent relating to methods of use for S15 that covers the use of NC318 and a patent relating to FIND-IO. These and any other patents that might issue from these licensed patent applications are expected to expire no earlier than 2036 absent any patent term adjustments or extensions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For all patent applications, we determine strategy for claim scope on a case-by-case basis, taking into account advice of counsel and our business model and needs. We file patents containing claims for protection of all useful applications of our proprietary technologies and any products, as well as all new applications and/or uses we discover for existing technologies and products, based on our assessment of their strategic value. We continuously reassess the number and type of patent applications, as well as the pending and issued patent claims to ensure that maximum coverage and value are obtained for our processes and compositions, given existing patent office rules and regulations. Further, claims may be modified during patent prosecution to meet our intellectual property and business needs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.25;text-align:justify;text-indent:32.4pt;margin:0pt 2.95pt 0pt 3pt;">We also rely upon trade secrets, know-how and continuing technological innovation to develop and maintain our competitive position, including with respect to our FIND-IO platform. We seek to protect our proprietary technology and processes, in part, by confidentiality and invention assignment agreements with our employees, consultants, scientific advisors and other contractors. In addition, in the ordinary course of our business, we enter into agreements with other third parties for non-exclusive rights to intellectual property directed to other technologies that are ancillary to our business, including laboratory information management software and research and development tools. In addition, we have trademark registrations with the U.S. Patent and Trademark Office, or the USPTO, for &#8220;NextCure&#8221; and our logo.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Government Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Government Regulation and Product Approval</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities at federal, state and local levels, as well as in foreign countries, extensively regulate, among other things, the research, development, testing, manufacture, quality control, import, export, safety, effectiveness, labeling, packaging, storage, distribution, recordkeeping, approval, advertising, promotion, marketing, post-approval monitoring and post-approval reporting of biological products. Along with third-party contractors, we will be required to navigate the various preclinical, clinical and commercial approval requirements of the governing regulatory agencies of the countries in which we intend to conduct studies or seek approval or licensure of our product candidates. The processes for obtaining regulatory approvals in the United States and in foreign jurisdictions, along with subsequent compliance with applicable laws and regulations and other regulatory authorities, require the expenditure of substantial time and financial resources.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">16</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Government policies may change, and additional government regulations may be enacted, that may prevent or delay further development or regulatory approval of any product candidates, product or manufacturing changes, additional disease indications or label changes. We cannot predict the likelihood, nature or extent of government regulation that might arise from future legislative or administrative action.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Review and Approval for Licensing Biologics in the United States</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, the FDA regulates our current product candidates as biological products, or biologics, under the Federal Food, Drug, and Cosmetic Act, or &#8220;FDCA&#8221;, the Public Health Service Act and associated implementing regulations. Biologics, like other drugs, are used for the treatment, prevention or cure of disease in humans. In contrast to small molecular weight drugs, which have a well-defined structure and can be thoroughly characterized, biologics are generally derived from living material (human, animal or microorganism) are complex in structure, and thus are usually not fully characterized. Biologics include immunomedicines for cancer and other diseases.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Biologics are also subject to other federal, state and local statutes and regulations. The failure to comply with applicable statutory and regulatory requirements at any time during the product development process, approval process or after approval may subject a sponsor or applicant to administrative or judicial enforcement actions. These actions could include the suspension or termination of clinical trials by the FDA, the FDA&#8217;s refusal to approve pending applications or supplemental applications, withdrawal of an approval, Warning Letters or Untitled Letters, product recalls, product seizures, total or partial suspension of production or distribution, import detention, injunctions, fines, refusals of government contracts, restitution, disgorgement of profits, or civil or criminal investigations and penalties brought by the FDA, the Department of Justice, or the DOJ, or other governmental entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An applicant seeking approval to market and distribute a biologic in the United States must typically undertake the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completion of non-clinical laboratory tests and animal studies performed in accordance with the FDA&#8217;s good laboratory practice, or &#8220;GLP&#8221;, regulations; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacture, labeling and distribution of investigational drug in compliance with cGMP; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">submission to the FDA of an IND application, which must become effective before clinical trials may begin and must be updated annually or when significant changes are made; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">approval by an independent institutional review board, or &#8220;IRB&#8221;, or ethics committee at each clinical site before each clinical trial may be initiated; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">performance of adequate and well-controlled human clinical trials in accordance with the FDA&#8217;s current Good Clinical Practices requirements, or &#8220;cGCP&#8221;, to establish the safety, purity and potency of the proposed biological product candidate for its intended purpose; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">preparation of and submission to the FDA of a biologics license application, or &#8220;BLA&#8221;, after completion of all pivotal clinical trials requesting marketing approval for one or more proposed indications; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain satisfactory completion of an FDA Advisory Committee review, where appropriate, as may be requested by the FDA to assist with its review; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of one or more FDA inspections of the manufacturing facility or facilities at which the proposed product, or certain components thereof, are produced to assess compliance with cGMP and data integrity requirements to assure that the facilities, methods and controls are adequate to preserve the biologic&#8217;s identity, safety, quality, purity and potency; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">satisfactory completion of FDA audits of selected clinical investigation sites to assure compliance with cGCP requirements and the integrity of the clinical data; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">payment of user fees under the Prescription Drug User Fee Act for the relevant year; </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">17</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtain FDA review and approval of the BLA to permit commercial marketing of the licensed biologic for particular indications for use in the United States; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">compliance with post-approval requirements, including the potential requirements to implement a Risk Evaluation and Mitigation Strategy, or &#8220;REMS&#8221;, adverse event and biological product deviation reporting and to complete any post-approval studies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">From time to time, legislation is drafted, introduced and passed in Congress that could significantly change the statutory provisions governing the testing, approval, manufacturing and marketing of products regulated by the FDA. In addition to new legislation, FDA regulations and policies are often revised or interpreted by the agency in ways that may significantly affect our business and our products. It is impossible to predict whether further legislative changes will be enacted or whether FDA regulations, guidance, policies or interpretations will be changed or what the effect of such changes, if any, may be.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical and Clinical Development</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before an applicant can begin testing the potential candidate in human subjects, the applicant must first conduct preclinical studies. Preclinical studies include laboratory evaluations of product chemistry, toxicity and formulation, as well as <i style="font-style:italic;">in vitro</i> and animal studies to assess the potential safety and activity of the drug for initial testing in humans and to establish a rationale for therapeutic use. Preclinical studies are subject to federal regulations and requirements, including GLP regulations. The results of an applicant&#8217;s preclinical studies are submitted to the FDA as part of an IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">An IND is a request for authorization from the FDA to administer an investigational new drug product to humans. An IND is an exemption from the FDCA that allows an unapproved drug to be shipped in interstate commerce for use in an investigational clinical trial. Such authorization must be secured prior to interstate shipment and administration of a biologic that is not the subject of an approved BLA. In support of a request for an IND, applicants must submit a protocol for each clinical trial. Any subsequent protocol amendments must be submitted to the FDA as part of the IND.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Human clinical trials cannot begin until an IND is effective. The IND automatically becomes effective 30&#160;days after receipt by the FDA, unless the FDA raises safety concerns or questions about the proposed clinical trial within the 30-day time period. In such a case, the IND may be placed on clinical hold and the IND sponsor and the FDA must resolve any outstanding concerns or questions before the clinical trial can begin. Submission of an IND therefore may or may not result in FDA authorization to begin a clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may also place a clinical hold or partial clinical hold on such trial following commencement of a clinical trial under an IND. A clinical hold is an order issued by the FDA to the sponsor to delay a proposed clinical investigation or to suspend an ongoing investigation. A partial clinical hold is a delay or suspension of only part of the clinical work requested under the IND. For example, a specific protocol or part of a protocol is not allowed to proceed, while other protocols may do so. No more than 30&#160;days after imposition of a clinical hold or partial clinical hold, the FDA will provide the sponsor a written explanation of the basis for the hold. Following issuance of a clinical hold or partial clinical hold, an investigation may only resume after the FDA has notified the sponsor that the investigation may proceed. The FDA will base that determination on information provided by the sponsor correcting the deficiencies previously cited or otherwise satisfying the FDA that the investigation can proceed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials involve the administration of the investigational product to human subjects under the supervision of qualified investigators in accordance with cGCP regulations, which include the requirement that all research subjects provide their informed consent for their participation in any clinical trial. Clinical trials are conducted under protocols detailing, among other things, the objectives of the trial, the parameters to be used in monitoring safety and the effectiveness criteria to be evaluated. A separate submission to the existing IND must be made for each successive clinical trial conducted during product development and for any subsequent protocol amendments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A sponsor may choose, but is not required, to conduct a foreign clinical study under an IND. When a foreign clinical study is conducted under an IND, all FDA IND requirements must be met unless waived. When the foreign clinical study is not conducted under an IND, the sponsor must ensure that the study complies with cGCP regulations in order to use the study as support for an IND or application for marketing approval, including cGCP regulations, including review and approval by an independent ethics committee and informed consent from subjects.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">18</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Furthermore, an independent IRB for each site proposing to conduct the clinical trial must review and approve the plan for any clinical trial and its informed consent form before the clinical trial begins at that site and must monitor the trial until completed. Regulatory authorities, the IRB or the sponsor may suspend a clinical trial at any time on various grounds, including a finding that the subjects are being exposed to an unacceptable health risk or that the trial is unlikely to meet its stated objectives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Some trials also include oversight by an independent group of qualified experts organized by the clinical trial sponsor, known as a data safety monitoring board, or &#8220;DSMB&#8221;. DSMBs provide recommendations for whether or not a trial may move forward at designated check points based on access to certain data from the trial and may recommend halting the clinical trial if it determines that there is an unacceptable safety risk for subjects or other grounds, such as no demonstration of efficacy. Other grounds for suspension or termination may be made based on evolving business objectives and/or competitive climate. There are also requirements governing the reporting of ongoing clinical trials and clinical trial results to public registries.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical Trials</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For purposes of BLA approval, clinical trials are typically conducted in the following sequential phases:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;1: The investigational product is initially introduced into healthy human subjects or patients with the target disease or condition. These trials are designed to test the safety, dosage tolerance, absorption, metabolism and distribution of the investigational product in humans and the side effects associated with increasing doses. These trials may also yield early evidence of effectiveness. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;2: The investigational product is administered to a limited patient population with a specified disease or condition to evaluate the preliminary efficacy, optimal dosages and dosing schedule and to identify possible adverse side effects and safety risks. Multiple Phase&#160;2 clinical trials may be conducted to obtain information prior to beginning larger and more expensive Phase&#160;3 clinical trials. </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Phase&#160;3: The investigational product is administered to an expanded patient population to further evaluate dosage, to provide statistically significant evidence of clinical efficacy and to further test for safety, generally at multiple geographically dispersed clinical trial sites. These clinical trials are intended to generate sufficient data to statistically evaluate the efficacy and safety of the product for approval, to establish the overall risk/benefit ratio of the investigational product and to provide an adequate basis for product approval by the FDA.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These phases may overlap or be combined. In some cases, the FDA may require, or companies may voluntarily pursue, additional clinical trials, after a product is approved, to gain more information about the product, referred to as Phase&#160;4 trials. Such post-approval trials, when applicable, are conducted following initial approval, typically to develop additional data and information relating to the biological characteristics of the product and treatment of patients in the intended therapeutic indication.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Progress reports detailing the results of the clinical trials must be submitted at least annually to the FDA and more frequently if serious adverse events occur. In addition, IND safety reports must be submitted to the FDA for any of the following: suspected serious and unexpected adverse reactions; findings from epidemiological studies, pooled analysis of multiple studies, animal or <i style="font-style:italic;">in vitro</i> testing, or other clinical studies, whether or not conducted under an IND, and whether or not conducted by the sponsor, that suggest a significant risk in humans exposed to the drug; and any clinically important increase in the rate of a serious suspected adverse reaction over such rate listed in the protocol or investigator brochure.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our planned clinical trials may not be completed successfully within any specified period, or at all. Furthermore, the FDA or the sponsor may suspend or terminate a clinical trial at any time on various grounds, including a finding that the research subjects are being exposed to an unacceptable health risk. Similarly, an IRB can suspend or terminate approval of a clinical trial at its institution, or an institution it represents, if the clinical trial is not being conducted in accordance with the IRB&#8217;s requirements or if the drug has been associated with unexpected serious harm to patients. The FDA will typically inspect one or more clinical sites to assure compliance with cGCP and the integrity of the clinical data submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">During clinical development, the sponsor often refines the indication and endpoints on which the BLA will be based. For endpoints based on patient-reported outcomes, or &#8220;PROs&#8221;, and outcome reported outcomes, or &#8220;OROs&#8221;, the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">19</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">process typically is an iterative one. The FDA has issued guidance on the framework it uses to evaluate PRO instruments. Although the agency may offer advice on optimizing PRO and ORO instruments during the clinical development process, the FDA usually reserves final judgment until it reviews the BLA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Concurrent with clinical trials, companies often complete additional animal studies, and develop additional information about the chemistry and physical characteristics of the drug and finalize a process for manufacturing the product in commercial quantities in accordance with cGMP. The manufacturing process must be capable of consistently producing quality batches of the drug candidate and, among other things, must develop methods for testing the identity, strength, quality, purity and potency of the final drug. Additionally, appropriate packaging must be selected and tested, and stability studies must be conducted to demonstrate that the drug candidate does not undergo unacceptable deterioration over its shelf life.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">BLA Submission and Review</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;">If an applicant successfully completes all required clinical testing in accordance with all applicable regulatory requirements, an applicant may submit a BLA requesting licensing to market the biologic for one or more indications in the United States. The BLA must include the results of product development, nonclinical studies and clinical trials; detailed information on the product&#8217;s chemistry, manufacture, controls and proposed labeling. Under the Prescription Drug User Fee Amendments, a BLA submission is subject to an application user fee, unless a waiver or exemption applies. The cost of preparing and submitting a BLA is substantial. </span><span style="font-size:10pt;">The submission of most BLAs is additionally subject to a substantial application user fee, currently for 2023 exceeding $3.2 million, and the manufacturer and sponsor under an approved BLA are also subject to annual program fees, currently $393,933 for each prescription product.</span><span style="font-family:'Arial','Helvetica','sans-serif';"> </span><span style="font-size:10pt;">These fees are typically increased annually.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA will initially review the BLA for completeness before accepting it for filing. Under the FDA&#8217;s procedures, the agency has 60 days from its receipt of a BLA to determine whether the application will be accepted for filing and substantive review. If the agency determines that the application does not meet this initial threshold standard, the FDA may refuse to file the application and request additional information, in which case the application must be resubmitted with the requested information and review of the application delayed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With certain exceptions, BLAs must include a pediatric assessment, generally based on clinical trial data, of the safety and effectiveness of the biologic in relevant pediatric populations. Under certain circumstances, the FDA may waive or defer the requirement for a pediatric assessment, either at the sponsor&#8217;s request or by the agency&#8217;s initiative.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After the BLA is accepted for filing, the FDA reviews the BLA to determine, among other things, whether a product is safe, pure and potent and if the facility in which it is manufactured, processed, packed or held meets standards designed to assure the product&#8217;s continued identity, strength, quality, safety, purity and potency. The FDA may convene an advisory committee to provide clinical insight on application review questions. Before approving a BLA, the FDA will typically inspect the facility or facilities where the product is manufactured. The FDA will not approve an application unless it determines that the manufacturing processes and facilities comply with cGMP and are adequate to assure consistent production of the product within required specifications. In addition, the FDA expects that all data be reliable and accurate and requires sponsors to implement meaningful and effective strategies to manage data integrity risks. Data integrity is an important component of the sponsor&#8217;s responsibility to ensure the safety, efficacy and quality of its product or products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA will typically inspect one or more clinical sites to assure compliance with cGCP regulations before approving a BLA. If the FDA determines that the application, manufacturing process or manufacturing facilities are not acceptable, it will outline the deficiencies in the submission and often will request additional testing or information. Notwithstanding the submission of any requested additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">FDA performance goals generally provide for action on a BLA within 10 months of filing, which (as discussed above) typically occurs within 60 days of submission, but that deadline is extended in certain circumstances. Furthermore, the review process is often significantly extended by the FDA&#8217;s requests for additional information or clarification.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The FDA may refer applications for novel products or products that present difficult questions of safety or efficacy to an advisory committee. Typically, an advisory committee consists of a panel that includes clinicians and other </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">20</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">experts who will review, evaluate and provide a recommendation as to whether the application should be approved and, if so, under what conditions. The FDA is not bound by the recommendations of an advisory committee, but it considers such recommendations carefully when making decisions and usually has followed such recommendations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After the FDA evaluates a BLA and conducts inspections of manufacturing facilities where the investigational product and/or its components will be produced, the FDA may issue an approval letter or a Complete Response Letter, or &#8220;CRL&#8221;. An approval letter authorizes commercial marketing of the biologic with specific prescribing information for specific indications. A CRL will describe all of the deficiencies that the FDA has identified in the BLA, except that where the FDA determines that the data supporting the application are inadequate to support approval, the FDA may issue the CRL without first conducting required inspections, testing submitted product lots and/or reviewing proposed labeling. If the deficiencies have been addressed to the FDA&#8217;s satisfaction in a resubmission of the BLA, the FDA will issue an approval letter. In issuing the CRL, the FDA may recommend actions that the applicant might take to place the BLA in condition for approval, including requests for additional data, information or clarification. The FDA may delay or refuse approval of a BLA if applicable regulatory criteria are not satisfied and may require additional testing or information and/or require post-marketing studies and clinical trials. Even with submission of this additional information, the FDA ultimately may decide that the application does not satisfy the regulatory criteria for approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">During the approval process, the FDA will determine whether a REMS is necessary to assure the safe use of the biologic. A REMS is a safety strategy to manage a known or potential serious risk associated with a product and to enable patients to have continued access to such medicines by managing their safe use, and could include medication guides, physician communication plans or elements to assure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. If the FDA concludes that a REMS is needed, the BLA sponsor must submit a proposed REMS and the FDA will not approve the BLA without a REMS that the agency has determined is acceptable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA approves a product, it may limit the approved indications for use for the product, or require that contraindications, warnings or precautions be included in the product labeling. The FDA may also require that post-approval studies, including Phase 4 clinical trials, be conducted to further assess the drug&#8217;s safety after approval. The FDA may prevent or limit further marketing of a product based on the results of post-market studies or surveillance programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may also require testing and surveillance programs to monitor the product after commercialization. For biologics, such testing may include official lot release, which requires the manufacturer to perform certain tests on each lot of the product before it is released for distribution. The manufacturer then typically must submit samples of each lot of product to the FDA, together with a release protocol showing a summary of the history of manufacture of the lot and the results of all of the manufacturer&#8217;s tests performed on the lot. The FDA may also perform certain confirmatory tests on lots of some products itself, before releasing the lots for distribution by the manufacturer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After approval, many types of changes to the approved product, such as adding new indications, manufacturing changes and additional labeling claims, are often subject to further testing requirements and FDA review and approval, depending on the nature of the post-approval change. The FDA may withdraw the product approval if compliance with pre- and post-marketing requirements is not maintained or if problems occur after the product reaches the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Post-Approval Requirements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any products manufactured or distributed pursuant to FDA approvals are subject to pervasive and continuing regulation by the FDA, including, among other things, requirements relating to recordkeeping, periodic reporting, reporting of certain deviations and adverse experiences, product sampling and distribution and advertising and promotion of the product. After approval, most changes to the approved product, such as adding new indications or other labeling claims, are subject to FDA review and approval. Biologic manufacturers and their third-party contractors are required to register their facilities with the FDA and certain state agencies. These facilities are subject to routine and periodic unannounced inspections by the FDA and certain state agencies for compliance with cGMP, post-marketing safety reporting and data integrity requirements, which impose certain procedural and documentation requirements to assure quality of manufacturing and product. FDA has increasingly observed cGMP violations involving data integrity during site inspections and is a significant focus of its oversight. Requirements with respect to data integrity include, among other things, controls to ensure data are complete and secure; activities documented at the time of performance; audit trail functionality; authorized access and limitations; validated computer systems; and review of records for accuracy, completeness and compliance with established standards.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">21</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Post-approval changes to the manufacturing process are strictly regulated, and, depending on the significance of the change, may require FDA approval before being implemented. FDA regulations also require investigation and correction of any deviations from cGMP and impose reporting requirements upon us and any third-party manufacturers that we may decide to use. Accordingly, manufacturers must continue to expend time, money and effort in the area of production and quality control to maintain compliance with cGMP, data integrity, pharmacovigilance and other aspects of regulatory compliance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA may withdraw the approval if compliance with regulatory requirements and standards is not maintained or if problems occur after the product reaches the market. Later discovery of previously unknown problems with a product, including adverse events of unanticipated severity or frequency, or with manufacturing processes, or failure to comply with regulatory requirements, may result in revisions to the approved labeling to add new safety information; imposition of post-approval studies or clinical trials to assess new safety risks; or imposition of distribution or other restrictions under a REMS. Other potential consequences include, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">restrictions on the marketing or manufacturing of a product, complete withdrawal of the product from the market or product recalls; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fines, Warning Letters, Untitled Letters or holds on post-approval clinical studies; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal of the FDA to approve pending applications or supplements to approved applications, or suspension or revocation of existing product approvals; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, or refusal of the FDA to permit the import or export of products or Import Alert; or </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permanent injunctions and consent decrees, including the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA strictly regulates the marketing, labeling, advertising and promotion of prescription drug and biological products placed on the market. A company can make only those claims relating to safety and efficacy, purity and potency that are approved by the FDA and in accordance with the provisions of the approved label. The FDA&#8217;s regulation includes, among other things, standards and regulations for direct-to-consumer advertising, communications regarding unapproved uses, industry-sponsored scientific and educational activities and promotional activities involving the Internet and social media. Promotional claims relating to a product&#8217;s safety or effectiveness are prohibited before the drug is approved. After approval, a product generally may not be promoted for uses that are not approved by the FDA, as reflected in the product&#8217;s prescribing information. In the United States, healthcare professionals are generally permitted to prescribe drugs for such uses not described in the drug&#8217;s labeling, known as off-label uses, because the FDA does not regulate the practice of medicine. However, FDA regulations impose rigorous restrictions on manufacturers&#8217; communications, prohibiting the promotion of off-label uses. It may be permissible, under very specific, narrow conditions, for a manufacturer to engage in non-promotional, non-misleading communication regarding off-label information, such as distributing scientific or medical journal information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a company is found to have promoted off-label uses, it may become subject to adverse public relations and administrative and judicial enforcement by the FDA, the DOJ or the Office of the Inspector General of the Department of Health and Human Services, or &#8220;HHS&#8221;, as well as other federal and state authorities. This could subject a company to a range of penalties that could have a significant commercial impact, including civil, administrative, and criminal fines, penalties, and agreements that materially restrict the manner in which a company promotes or distributes products. The federal government has levied large civil, administrative, and criminal fines and penalties against companies for alleged improper promotion and has also requested that companies enter into consent decrees and permanent injunctions under which specified promotional conduct is changed or curtailed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The distribution of prescription drug and biological products are subject to the Drug Supply Chain Security Act, or &#8220;DSCSA&#8221;, which requires manufacturers and other stakeholders to comply with product identification, tracing, verification, detection and response, notification and licensing requirements. In addition, the Prescription Drug Marketing Act and its implementing regulations and state laws limit the distribution of prescription pharmaceutical product samples, and the DSCSA imposes requirements to ensure accountability in distribution and to identify and remove prescription drug and biological products that may be counterfeit, stolen, contaminated, or otherwise harmful from the market.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">22</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Term Restoration </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">After approval, owners of relevant drug or biological product patents may apply for up to a five-year patent extension to restore a portion of patent term lost during product development and FDA review of a BLA under the Drug Price Competition and Patent Term Restoration Act of 1984, referred to as the Hatch-Waxman Act. The allowable patent term extension is calculated as one-half of the product&#8217;s testing phase, which is the time between IND and BLA submission, and all of the review phase, which is the time between BLA submission and approval, up to a maximum of five years. The time can be shortened if the FDA determines that the applicant did not pursue approval with due diligence. The total patent term after the extension may not exceed more than 14&#160;years from the date of FDA approval of the product. Only one patent claiming each approved product is eligible for restoration and the patent holder must apply for restoration within 60&#160;days of approval. The USPTO, in consultation with the FDA, reviews and approves the application for patent term restoration.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For patents that might expire during the application phase, the patent owner may request an interim patent extension. An interim patent extension increases the patent term by one year and may be renewed up to four times. For each interim patent extension granted, the post-approval patent extension is reduced by one year. The director of the USPTO must determine that approval of the product candidate covered by the patent for which a patent extension is being sought is likely. Interim patent extensions are not available for a product candidate for which a BLA has not been submitted.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Biosimilars and Marketing Exclusivities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Biologics Price Competition and Innovation Act, or &#8220;BPCIA,&#8221; created an abbreviated approval pathway for biological product candidates shown to be highly similar to or interchangeable with an FDA licensed biological product. A biological product on which another biological product candidate&#8217;s BLA relies to establish biosimilarity is known as a reference product. Biosimilarity sufficient to reference a prior FDA-approved product requires that the biological product candidate be highly similar to the reference product not withstanding minor differences in clinically inactive components, and there be no clinically meaningful differences between the biological product candidate and the reference product in terms of safety, purity and potency. Biosimilarity must be shown through analytical trials, animal trials and at least one clinical trial, unless the FDA waives a required element. A biosimilar product candidate may be deemed interchangeable with a prior approved product if it meets the higher hurdle of demonstrating that it can be expected to produce the same clinical results as the reference product and, for products administered multiple times, the biologic and the reference biologic may be switched after one has been previously administered without increasing safety risks or risks of diminished efficacy relative to exclusive use of the reference biologic. Complexities associated with the larger, and often more complex, structures of biologics, as well as the process by which such products are manufactured, pose significant hurdles to implementation of the abbreviated approval pathway that are still being worked out by the FDA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A reference biologic is granted 12&#160;years of exclusivity from the time of first licensure of the reference product, and no application for a biosimilar can be submitted for four years from the date of licensure of the reference product. The first interchangeable biosimilar biological product has exclusivity against a finding of interchangeability for other biologics for the lesser of (i)&#160;one year after first commercial marketing of the first interchangeable biosimilar, (ii)&#160;18&#160;months after the first interchangeable biosimilar is approved if there is no patent challenge, (iii)&#160;18&#160;months after resolution of a lawsuit over the patents of the reference biologic in favor of the first interchangeable biosimilar applicant, or (iv)&#160;42&#160;months after the first interchangeable biosimilar&#8217;s application has been approved if a patent lawsuit is ongoing within the 42&#160;month period. State pharmacy laws and regulations govern whether products deemed &#8220;interchangeable&#8221; by the FDA will, in fact, be readily substituted by pharmacies, and may impose additional requirements such as notification of prescriber and/or patient, documentation and recordkeeping.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If a biologic is designated and approved for an orphan indication, it will be granted seven years of orphan drug exclusivity. An orphan indication is granted to biological products and drugs designated and approved to treat diseases or conditions affecting fewer than 200,000 individuals in the United States, or if there is no reasonable expectation that the sponsor will be able to recover the costs of developing and marketing the drug or biological product in the United States. During the seven-year exclusivity period, the FDA may not approve any other applications to market the same drug or biological product for the same disease, except in limited circumstances, such as a showing of clinical superiority to the product with orphan drug exclusivity. A biosimilar may not be licensed by FDA for the protected orphan indication until after the expiration of the seven-year orphan drug exclusivity period or the 12-year reference product exclusivity, whichever is later.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">23</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pediatric exclusivity adds an additional six-month exclusivity period to any marketing exclusivities and patents that a biological product has obtained. In order to obtain pediatric exclusivity, a BLA sponsor must conduct pediatric studies as requested by the FDA in a Written Request. The data do not need to show the product to be effective in the pediatric population studied; rather, if the clinical trial is deemed to fairly respond to the FDA&#8217;s request, the additional protection is granted. If reports of requested pediatric studies are submitted to and accepted by the FDA within the statutory time limits, whatever statutory or regulatory periods of exclusivity or patent protection cover the product are extended by six months. While pediatric exclusivity is not an actual extension on a patent term, it effectively extends the preclusive effect of the patent on FDA&#8217;s authority to approve another application that relies on the product with pediatric exclusivity.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The BPCIA is complex and continues to be interpreted and implemented by the FDA. On December 20, 2019, President Trump signed into law H.R. 1865, the Further Consolidated Appropriations Act of 2020. The law includes significant provisions concerning the FDA&#8217;s implementation of the BPCIA, such as clarifying that &#8220;chemically synthesized polypeptides&#8221; are no longer excluded from being regulated as biologics, while &#8220;peptides&#8221; (polymers composed of 40 or fewer amino acids) will continue to be regulated as drugs unless they otherwise meet the statutory definition of biological products. In addition, the Further Consolidated Appropriations Act of 2020 clarifies exclusivity and procedural issues related to certain biologics approved as drugs pursuant to new drug applications, or &#8220;NDAs&#8221;, to be the subject of an approved BLA, or transition biological products. The law also incorporates provisions intended to reduce price and increase competitiveness in the pharmaceutical industry. The law amends the FDCA to create a private right of action against NDA or BLA holders that refuse to provide sufficient quantities of samples of an approved reference product to generic and biosimilar developers. In July 2018, the FDA released its Biosimilars Action Plan to improve the efficiency of the biosimilar and interchangeable product development and approval process. The Further Consolidated Appropriations Act of 2020 is consistent with FDA guidance documents issued in December 2018 that were intended to advance the agency&#8217;s biosimilars policy framework. The implementation of the Further Consolidated Appropriations Act of 2020 and the ultimate impact of the agency&#8217;s Biosimilars Action Plan are uncertain and may evolve over time through future laws and regulations and guidance provided by regulatory and governing bodies. In addition, there has been discussion of whether Congress should reduce the 12-year reference product exclusivity period. Other aspects of the BPCIA, some of which may impact the BPCIA exclusivity provisions, have been the subject of recent litigation. As a result, the ultimate implementation of the BPCIA is subject to significant uncertainty.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Regulation of Companion Diagnostics and Laboratory Developed Tests</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A companion diagnostic is an <i style="font-style:italic;">in vitro</i> diagnostic that can: identify the patients most likely to benefit from a particular therapeutic product; identify those likely to be at an increased risk for serious side effects; or monitor responses to treatment with a particular therapeutic product for the purpose of adjusting treatment to achieve improved safety or effectiveness. Under the FDCA, <i style="font-style:italic;">in vitro</i> companion diagnostics are generally regulated as medical devices. The FDA has generally classified <i style="font-style:italic;">in vitro</i> companion diagnostics as high-risk, Class&#160;III devices, which require FDA approval of a premarket approval application, or &#8220;PMA&#8221;, but recognizes the possibility of a moderate-risk IVD companion diagnostic (<i style="font-style:italic;">i.e</i>., Class&#160;II device), which would require clearance of a 510(k) premarket notification or grant of a <i style="font-style:italic;">de novo</i> request. Approval or clearance of the <i style="font-style:italic;">in vitro</i> companion diagnostic device will ensure that the device has been adequately evaluated and has adequate performance characteristics in the intended population.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For those <i style="font-style:italic;">in vitro</i> companion diagnostics that require PMA approval, the process involves gathering and submitting clinical and preclinical data on the device for review by the FDA. It involves a rigorous premarket review, during which the applicant must provide the FDA with reasonable assurance of the device&#8217;s safety and effectiveness, as well as information regarding the device&#8217;s design, manufacturing and labeling. In addition, the FDA will typically inspect the device manufacturer&#8217;s facilities for compliance with the Quality System Regulation, which imposes testing, control, documentation and other quality assurance requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has issued guidance on the approval of therapeutic products and <i style="font-style:italic;">in vitro</i> companion diagnostic devices. According to the FDA&#8217;s guidance, for novel therapeutic products including biologics, an <i style="font-style:italic;">in vitro</i> companion diagnostic device and its corresponding therapeutic should be approved or cleared contemporaneously by the FDA for the use indicated in the therapeutic product&#8217;s labeling.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In some cases, information from a diagnostic test may be useful to a prescriber, but not necessary for the safe and effective administration of the therapeutic product. In those cases, health care providers may employ information derived from a complementary diagnostic test such as a laboratory developed test, or &#8220;LDT&#8221;, when administering a therapeutic product. An LDT is a type of <i style="font-style:italic;">in vitro</i> diagnostic test that is designed, manufactured and used within a single laboratory. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">24</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">LDTs can be used to measure or detect a wide variety of analytes (substances such as proteins, chemical compounds like glucose or cholesterol, or DNA), in a sample taken from a human body.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Centers for Medicare and Medicaid Services, or &#8220;CMS&#8221;, regulates LDTs and the laboratories that develop them, and enforces the Clinical Laboratories Improvement Amendments, or &#8220;CLIA&#8221;. CMS evaluates whether there is clinical utility for each specific test, and also performs post-market oversight of laboratory operational processes. CMS&#8217;s oversight through the CLIA program is designed to confirm that a lab assesses analytical validity but does not confirm whether it had results from an analytical validity assessment that were sufficient to support the claimed intended use of the test.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Historically, the FDA has generally not enforced premarket review and other FDA requirements on LDTs because LDTs were relatively simple lab tests and generally available on a limited basis. Due to advances in technology, however, some LDTs are now much more complex, have a nationwide reach and present higher risks, such as detection of risk for breast cancer and Alzheimer&#8217;s disease, which are similar to those of other IV <i style="font-style:italic;">in vitro</i> diagnostics that have undergone premarket review.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA has announced that in the future it intends to assert jurisdiction over LDTs and proposed increasing regulatory requirements for LDTs through a risk-based framework. The FDA received considerable resistance to its proposal, and to date generally exercises enforcement discretion with respect to LDTs, leaving responsibility to CMS.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">New laws, regulations or changes to existing laws, regulations and policies may result in changes to the requirements for LDTs or <i style="font-style:italic;">in vitro</i> diagnostic devices and to the FDA&#8217;s compliance and enforcement policies.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Healthcare Regulation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Pharmaceutical Coverage and Reimbursement</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to successfully commercialize any of our product candidates for which we may receive regulatory approval will depend in significant part on the availability of coverage and reimbursement from third-party payors, including governmental healthcare programs, such as the Medicare and Medicaid programs in the U.S., private health insurers, managed care organizations, and other entities. Third-party payors may limit coverage to specific products on an approved list, or formulary, which might not include one or more of our product candidates. Third-party payors, together with regulators and others, are increasingly challenging the prices charged for pharmaceutical products and related services, in addition to their cost-effectiveness, safety and efficacy.</p><a id="_cp_change_19"></a><a id="_cp_change_21"></a><a id="_cp_change_23"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No uniform policy for coverage and reimbursement exists in the United States. Though we expect our initial product offering to be covered under Medicare Part B, and third-party payors often rely upon Medicare coverage policy and payment limitations in setting their own coverage and reimbursement policies, payors have their own methods and approval processes apart from Medicare determinations. Therefore, the availability and scope of coverage, as well as reimbursement rates can vary significantly from payor to payor. &#160;The marketability of any products for which we may receive regulatory approval for commercial sale depends on these payors&#8217; coverage policies and reimbursement rates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, obtaining coverage and adequate reimbursement is a time-consuming and costly process. We may be required to provide scientific and clinical support for the use of any product to each third-party payor separately with no assurance that approval will be obtained, and we may need to conduct expensive pharmacoeconomic studies in order to demonstrate the cost-effectiveness of our products. We cannot be certain that our product candidates will be considered cost-effective by third-party payors. This process could delay the market acceptance of any product candidates for which we may receive approval and could have a negative effect on our future revenues and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Other U.S. Healthcare Laws and Compliance Requirements</p><a id="_Hlk59959673"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, our business is subject to healthcare fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business, particularly once third-party reimbursement becomes available for one or more of our products. The healthcare fraud and abuse laws and regulations that may affect our ability to operate include but are not limited to:</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">25</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal Anti-Kickback Statute, which prohibits any person or entity from, among other things, knowingly and willfully soliciting, receiving, offering or paying any remuneration (including any kickback or bribe), directly or indirectly, overtly or covertly, in cash or in kind, to induce, or in return for, either the referral of an individual, or the purchase, lease, order, arranging for or recommending the purchase, lease, or order of any item or service for which payment may be made, in whole or in part, under federal healthcare programs, like Medicare or Medicaid. A person or entity can be found guilty of violating the statute without actual knowledge of the statute or specific intent to violate it. The federal Anti-Kickback Statute has been interpreted to apply, for example, to arrangements between pharmaceutical manufacturers on the one hand and prescribers, purchasers, and formulary managers on the other, including, for example, consulting/speaking arrangements, discount and rebate offers, grants, charitable contributions, and patient support offerings, among others. A conviction for violation of the federal Anti-Kickback Statute can result in criminal fines and/or imprisonment and requires mandatory exclusion from participation in federal health care programs. Exclusion may also be imposed if the government determines that an entity has committed acts that are prohibited by the federal Anti-Kickback Statute. Although there are a number of statutory exceptions and regulatory safe harbors to the federal Anti-Kickback Statute protecting certain common business arrangements and activities from prosecution or regulatory sanctions, the exceptions and safe harbors are drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical and biological products, may be subject to scrutiny if such arrangements are not designed to fit squarely within an exception or safe harbor. Our practices may not in all cases meet all of the criteria for safe harbor protection from Anti-Kickback Statute liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal civil and criminal false claims laws and civil monetary penalty laws, including the civil False Claims Act, or &#8220;FCA&#8221;, which prohibits anyone from, among other things: (i) knowingly presenting, or causing to be presented, claims for payment of government funds that are false or fraudulent; (ii) knowingly making, or using or causing to be made or used, a false record or statement material to a false or fraudulent claim; (iii) knowingly making, using or causing to made or used a false record or statement material to an obligation to pay money to the government; or (iv) knowingly concealing or knowingly and improperly avoiding, decreasing, or concealing an obligation to pay money to the federal government. Private individuals, commonly known as &#8220;whistleblowers,&#8221; can bring FCA qui tam actions, on behalf of the government and may share in amounts paid by the defendant to the government in recovery or settlement. Pharmaceutical companies have been investigated and/or subject to government enforcement actions asserting liability under the FCA in connection with their alleged off-label promotion of drugs, purportedly concealing price concessions in the pricing information submitted to the government for government price reporting purposes, and allegedly providing free product to customers with the expectation that the customers would bill federal healthcare programs for the product, among other things. In addition, a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the FCA. Moreover, manufacturers can be held liable under the FCA even though they, in most cases, do not submit claims directly to government payors if they are deemed to &#8220;cause&#8221; the submission of false or fraudulent claims. FCA liability is potentially significant in the healthcare industry because the statute provides for treble damages and significant mandatory penalties per false or fraudulent claim or statement for violations. Such per-claim penalties are currently set at $13,508 to $27,018 per false claim or statement for penalties assessed after January 30, 2023, with respect to violations occurring after November 2, 2015. Criminal penalties, including imprisonment and criminal fines, are also possible for making or presenting a false, fictitious or fraudulent claim to the federal government;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal Health Insurance Portability and Accountability Act of 1996, or &#8220;HIPAA&#8221;, which, among other things, prohibits knowingly and willfully executing, or attempting to execute, a scheme to defraud any healthcare benefit program, including private third-party payors, and prohibits (i)&#160;knowingly and willfully falsifying, concealing or covering up a material fact or making any materially false, fictitious or fraudulent statement or representation and (ii)&#160;making or using any false writing or document knowing the same to contain any materially false, fictitious or fraudulent statement or entry in connection with the delivery of or payment for healthcare benefits, items or services. Similar to the federal Anti-Kickback Statute, a person or entity can be found guilty of violating the HIPAA fraud provisions without actual knowledge of the statute or specific intent to violate it; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">HIPAA, the Health Information Technology for Economic and Clinical Health Act, or &#8220;HITECH Act&#8221;, and HIPPAA&#8217;s implementing regulations, and certain state and local laws impose requirements relating to the </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">26</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">privacy, security and transmission of individually identifiable health information held by covered entities, including health plans, healthcare clearinghouses and certain healthcare providers, and their business associates, individuals or entities that perform certain services on behalf of a covered entity that involve the use or disclosure of individually identifiable health information. HIPAA includes several tiers of civil monetary penalties as well as criminal penalties. In addition, state attorneys general have authority to file civil actions for damages or injunctions in federal courts to enforce HIPAA and seek attorneys&#8217; fees and costs associated with pursuing federal civil actions. Research institutions that we collaborate with and healthcare providers who may prescribe our products, once commercialized, are subject to privacy and security requirements under HIPAA. The Department of Health and Human Services Office for Civil Rights (OCR) has recently increased its enforcement efforts on compliance with HIPAA, including the security regulations (Security Rule), bringing actions against entities which have failed to implement security measures sufficient to reduce risks to electronic protected health information or to conduct an accurate and thorough risk analysis, among other violations. Although we are not directly subject to HIPAA other than with respect to providing certain employee benefits, we could potentially be subject to criminal penalties if we, our affiliates or our agents knowingly obtain or disclose individually identifiable health information maintained by a HIPAA-covered entity in a manner that is not authorized or permitted by HIPAA; </span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Numerous other federal and state laws and regulations that also govern the privacy and security of individually identifiable health information, including state data breach notification laws, state health information or genetic privacy laws, and federal and state consumer protection laws such as Section 5 of the Federal Trade Commission, or &#8220;FTC&#8221;, Act and the California Consumer Privacy Act, or &#8220;CCPA&#8221;. The CCPA gives California residents expanded rights to access and delete their personal information, opt out of certain personal information sharing and receive detailed information about how their personal information is used by requiring covered companies to provide new disclosures to California consumers (as that term is broadly defined) and provide such consumers new ways to opt-out of certain sales of personal information. The CCPA provides for civil penalties for violations, as well as a private right of action for data breaches that is expected to increase data breach litigation. Although there are certain exemptions for personal information subject to HIPAA and personal data collected in a clinical trial context, the CCPA&#8217;s implementation standards and enforcement practices may increase our compliance costs and potential liability. Additionally, a California ballot initiative, the California Privacy Rights Act, or &#8220;CPRA&#8221;, passed in November 2020, and went into effect on January 1, 2023. The CPRA will impose additional data protection obligations on companies doing business in California, including additional consumer rights processes, limitations on data uses, new audit requirements for higher risk data, and opt outs for certain uses of sensitive data. It also created a new California data protection agency authorized to issue substantive regulations and could result in increased privacy and information security enforcement. Additional compliance investment and potential business process changes may be required. Laws similar to the California laws have passed in states such as Virginia and Colorado, and comparable laws have been proposed in other states and at the federal level that may ultimately have conflicting requirements that would further complicate compliance and adversely affect our business. For example, on March 2, 2021, the Virginia Consumer Data Protection Act was signed into law, which went into effect on January 1, 2023, and on July 8, 2021, the Colorado Privacy Act was signed into law, which will take effect on July 1, 2023, was signed into law. </span></td></tr></table><div style="margin-top:12pt;"></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The FTC and many state attorneys general are interpreting existing federal and state consumer protection laws to impose evolving standards for the collection, use, dissemination and security of health-related and other personal information. For instance, the FTC has promulgated standards for fair information practices, which concern consumer notice, choice, security and access, and also require notice of certain health information breaches outside the HIPAA context. Consumer protection laws require us to publish statements that describe how we handle personal information and choices individuals may have about the way we handle their personal information. Violating consumers&#8217; privacy rights, publishing untrue information about security practices, or failing to take appropriate steps to keep consumers&#8217; personal information secure may constitute unfair or deceptive acts or practices in violation of Section 5 of the FTC Act. Additionally, the FTC recently published an advance notice of proposed rulemaking on commercial surveillance and data security and is seeking comment on whether it should implement new trade regulation rules or other regulatory alternatives concerning the ways in which companies (1) collect, aggregate, protect, use, analyze, and retain consumer data, as well as (2) transfer, share, sell, or otherwise monetize that data in ways that are unfair or deceptive. Federal regulators, state attorneys general and plaintiffs&#8217; attorneys have been and will likely continue to be </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">27</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk59952987"></a><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"></td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">active in this space, and if we do not comply with existing or new laws and regulations related to patient health information, we could be subject to criminal or civil sanctions.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">In addition, some countries are considering or have passed legislation implementing data protection requirements or requiring local storage and processing of data or similar requirements that could increase the cost and complexity of research activities. </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">These laws and regulations, as well as any associated claims, inquiries, investigations or any other government actions may lead to unfavorable outcomes including increased compliance costs, delays or impediments in the development of new products, negative publicity, increased operating costs, diversion of management time and attention and remedies that harm our business, including fines or demands or orders that we modify or cease existing business practices.</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The federal Physician Payments Sunshine Act, implemented as the Open Payments Program, which requires manufacturers of drugs, devices, biologics and medical supplies for which payment is available under Medicare, Medicaid or the Children&#8217;s Health Insurance Program (with certain exceptions), among others, to report annually to CMS information related to direct or indirect payments and other transfers of value they make to U.S.-licensed physicians, physician assistants, nurse practitioners, clinical nurse specialists, certified nurse anesthetists and certified nurse-midwives and U.S. teaching hospitals, as well as ownership and investment interests held in a company by physicians and their immediate family members; and </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Analogous U.S. state and local laws and regulations, such as state anti-kickback and false claims laws, which may apply to sales or marketing arrangements and claims involving healthcare items or services reimbursed by non-governmental third-party payors, including private insurers; state laws that require pharmaceutical companies to comply with the pharmaceutical industry&#8217;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government or otherwise restrict payments that may be made to healthcare providers; state laws that restrict the ability of manufacturers to offer co-pay support to patients for certain prescription drugs; state laws that require drug manufacturers to report information related to clinical trials, or information related to payments and other transfers of value to physicians and other healthcare providers or marketing expenditures; state laws that require drug manufacturers to report information on the pricing of certain drugs; state laws and local ordinances that require identification or licensing of sales representatives; and state laws governing the privacy and security of health information in certain circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will be required to spend substantial time and money to ensure that our business arrangements with third parties comply with applicable healthcare laws and regulations. Even then, governmental authorities may conclude that our business practices do not comply with current or future statutes, regulations or case law involving applicable fraud and abuse or other healthcare laws and regulations. If governmental authorities find that our operations violate any of these laws or any other governmental regulations that may apply to us, we may be subject to significant civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, exclusion from government funded healthcare programs, such as Medicare and Medicaid, and additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws, and we may be required to curtail or restructure our operations. Moreover, we expect that there will continue to be federal and state laws and regulations, proposed and implemented, that could impact our operations and business. In addition, the approval and commercialization of any product candidate we develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. The extent to which future legislation or regulations, if any, relating to health care fraud and abuse laws or enforcement, may be enacted or what effect such legislation or regulation would have on our business remains uncertain.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Healthcare Reform</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">There have been and continue to be a number of healthcare-related legislative and regulatory initiatives and reforms in the United States that significantly affect the pharmaceutical industry. For example, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or collectively, the &#8220;ACA,&#8221; was passed in March 2010, and substantially changed the way healthcare is financed by both governmental and private insurers and significantly impacted the U.S. pharmaceutical industry. Among other things, the ACA: subjects biologics to potential competition by lower-cost biosimilars; addresses a methodology through which rebates owed by manufacturers under the Medicaid Drug Rebate Program, or &#8220;MDRP,&#8221; are calculated for covered outpatient drugs that are </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">28</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">inhaled, infused, instilled, implanted or injected; increases the minimum Medicaid rebates owed by manufacturers under the MDRP and extends the rebate program to individuals enrolled in Medicaid managed care organizations; establishes annual fees and taxes on manufacturers of certain branded prescription drugs; and creates a Medicare Part D coverage gap discount program in which, as a condition of coverage of its products under Medicare Part D, manufacturers must agree to offer point-of-sale discounts off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ACA and certain of its provisions have been subject to judicial challenges as well as legislative and regulatory efforts to repeal or replace them or to alter their interpretation or implementation. For example, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Cuts and Jobs Act of 2017, or the &#8220;Tax Act,&#8221; includes a provision that repealed the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year, commonly referred to as the &#8220;individual mandate.&#8221; The Bipartisan Budget Act of 2018, among other things, amended the ACA to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. CMS rules issued in 2018 permit further collections and payments to and from certain ACA-qualified health plans and health insurance issuers under the ACA risk adjustment program. The Further Consolidated Appropriations Act of 2020 fully repealed the ACA&#8217;s &#8220;Cadillac Tax&#8221; on certain high-cost employer-sponsored insurance plans and, effective in 2021, the annual fee imposed on certain health insurance providers based on market share. On January 28, 2021, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, policies that create barriers to obtaining access to health insurance coverage through the ACA marketplaces. Most recently, on March 11, 2021, Congress enacted the American Rescue Plan Act of 2021, which included among its provisions a sunset of the ACA&#8217;s cap on pharmaceutical manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program. Under the ACA, manufacturers&#8217; rebate liability was capped at 100% of the average manufacturer price for a covered outpatient drug. Effective January 1, 2024, manufacturers&#8217; MDRP rebate liability will no longer be capped, potentially resulting in a manufacturer paying more in MDRP rebates than it receives on the sale of certain covered outpatient drugs. The American Rescue Plan Act also temporarily increased premium tax credit assistance for individuals eligible for subsidies under the ACA for 2021 and 2022 and removed the 400% federal poverty level limit that otherwise applies for purposes of eligibility to receive premium tax credits. In the future, there may be additional challenges and/or amendments to the ACA.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018, the United States District Court for the Northern District of Texas ruled that the individual mandate is (i) unconstitutional as a result of the associated tax penalty being repealed by Congress as part of the Tax Act and (ii) not severable from the rest of the ACA, and that as a result the entire ACA is invalid. On December 18, 2019, the U.S. Court of Appeals for the Fifth Circuit affirmed the district court&#8217;s decision that the individual mandate is unconstitutional but remanded the case to the district court to reconsider the severability question. The Supreme Court of the United States granted certiorari on March 2, 2020 and heard oral argument on November 10, 2020. On June 17, 2021, the Supreme Court dismissed the lawsuit without ruling on the merits of the states&#8217; constitutionality arguments.</p><a id="_Hlk127370991"></a><a id="_Hlk127371053"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Additionally, there has been increasing legislative and enforcement interest in the United States with respect to specialty drug pricing practices. Specifically, several U.S. Congressional inquiries and proposed and enacted pieces of federal and state legislation have been designed to, among other things: bring more transparency to drug pricing; reduce the cost of prescription drugs under government payor programs; review the relationship between pricing and manufacturer patient programs; and reform government program reimbursement methodologies for drugs. Policymakers have also indicated that they will continue to seek legislative and administrative measures to control drug costs. For example, in August 2022, President Biden signed into law the Inflation Reduction Act of 2022 (&#8220;IRA&#8221;), which implements substantial changes to the Medicare program, including drug pricing reforms and the creation of new Medicare inflation rebates. &#160;Namely, the IRA imposes inflation rebates on drug manufacturers for products reimbursed under Medicare Parts B and D if the prices of those products increase faster than inflation; implements changes to the Medicare Part D benefit that, beginning in 2025, will cap &#160;beneficiary annual out-of-pocket spending at $2,000, while imposing new discount obligations for pharmaceutical manufacturers; and, beginning in 2026, establishes a &#8220;maximum fair price&#8221; for a fixed number of high expenditure pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with the Centers for Medicare and Medicaid Services. On October 14, 2022, President Biden issued an Executive </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">29</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">Order on Lowering Prescription Drug Costs for Americans, which instructed the Secretary of the Department of Health and Human Services to consider whether to select for testing by the CMS Innovation Center new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs. On February 14, 2023, the Department of Health and Human Services issued a report in response to the October 14, 2022, Executive Order, which, among other things, selects three potential drug affordability and accessibility models to be tested by the CMS Innovation Center. &#160;Specifically, the report addresses: (1) a model that would allow Part D Sponsors to establish a &#8220;high-value drug list&#8221; setting the maximum co-payment amount for certain common generic drugs at $2; (2) a Medicaid-focused model that would establish a partnership between CMS, manufacturers, and state Medicaid agencies that would result in multi-state outcomes-based agreements for certain cell and gene therapy drugs; and (3) a model that would adjust Medicare Part B payment amounts for Accelerated Approval Program drugs to advance the developments of novel treatments. &#160;It remains to be seen how these drug pricing initiatives will affect the broader pharmaceutical industry.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement limitations, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in their prescription drug and other healthcare programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, in May 2018, the Trickett Wendler, Frank Mongiello, Jordan McLinn and Matthew Bellina Right to Try Act of 2017, or the Right to Try Act, was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Human Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends upon our ability to retain and attract highly qualified management and technical personnel. As of December 31, 2022, we had 99 full-time employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We consider the intellectual capital of our employees to be an essential driver of our business and key to our future prospects. Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, is critical to our success, and competition for skilled personnel is intense and the turnover rate can be high in our industry. We have historically addressed the turnover we have encountered and grown our headcount in support of our expanding pipeline of research programs and product candidates, but we continue to monitor our turnover rate and the overall supply of skilled labor in the market. We also monitor our compensation programs closely and provide what we consider to be a competitive mix of compensation and benefits for our employees, as well as participation in our equity programs. None of our employees are subject to a collective bargaining agreement or represented by a trade or labor union.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Corporate Information and Access to SEC Reports</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We were incorporated in Delaware in September 2015. Our primary executive offices are located at 9000 Virginia Manor Road, Suite 200, Beltsville, Maryland 20705 and our telephone number is (240) 399-4900. We make available, free of charge, on our website at <i style="font-style:italic;">www.nextcure.com</i>, our annual reports on Form 10-K, quarterly reports on Form 10-Q, current reports on Form 8-K and any amendments to such reports as soon as reasonably practicable after such reports are electronically filed with, or furnished to, the SEC. The contents of our website are not incorporated into this Annual Report.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_a6ffe5c8_53a7_4af4_9650_6904c6936d7a"></a><a id="Item1ARiskFactors_446956"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 1A. Risk Factors</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt;">Investing in our common stock involves a high degree of risk. You should carefully consider the risks described below together with all of the other information in this Annual Report, including our financial statements and the related notes and the information described in the section entitled &#8220;Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations,&#8221; before deciding whether to invest in our common stock. If any of the events described below </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">30</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;margin:0pt 0pt 12pt 0pt;">actually occurs, our business, results of operations, financial conditions, cash flows or prospects could be harmed. If that were to happen, the trading price of our common stock could decline, and you could lose all or part of your investment. Additional risks and uncertainties not presently known to us or that we currently deem immaterial may also impair our business operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Risks Related to Our Financial Position and Need for Additional Capital</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have a limited operating history and no products approved for commercial sale. We have a history of significant losses, expect to continue to incur significant losses for the foreseeable future and may never achieve or maintain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company with a limited operating history. Since our founding in 2015, we have incurred significant net losses. Our net losses were $74.9 million and $69.4 million for the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, we had an accumulated deficit of $261.8 million. We have funded our operations to date primarily with proceeds from public offerings of our common stock, private placements of our preferred stock and upfront fees received under the Lilly Agreement, which was terminated effective March 2020. Since commencing operations, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, identifying business development opportunities, raising capital, securing intellectual property rights related to our product candidates, building and optimizing our manufacturing capabilities and conducting discovery, research and development activities for our product candidates, our discovery programs and our FIND-IO platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect that it will be several years, if ever, before we have a commercialized product. We expect to continue to incur significant expenses and operating losses for the foreseeable future. The net losses we incur may fluctuate significantly from year to year. We anticipate that our expenses will increase substantially if, and as, we:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">continue to advance the preclinical and clinical development of our existing product candidates and our research programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">leverage our FIND-IO platform to advance additional product candidates into preclinical and clinical development;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seek regulatory approvals for any product candidates that successfully complete clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our cGMP manufacturing capacity, </span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">including to provide drug supply for future clinical trials</span><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">hire additional clinical, quality control, regulatory, scientific and administrative personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expand our operational, financial and management systems and increase personnel, including to support our clinical development, manufacturing and commercialization efforts and our operations as a public company;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintain, expand and protect our intellectual property portfolio;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">establish a marketing, sales, distribution and medical affairs infrastructure to commercialize any products for which we may obtain marketing approval and commercialize, whether on our own or jointly with a partner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acquire or in-license other technologies or engage in strategic partnerships; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">incur additional legal, accounting or other expenses in operating our business.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">To become and remain profitable, we, whether on our own or jointly with any potential future collaborator, must develop and eventually commercialize products with significant market potential. We will need to be successful in a range of challenging activities, including completing preclinical studies and clinical trials, obtaining marketing approval for product candidates, manufacturing, marketing and selling products and satisfying any post-marketing requirements. We may never succeed in any or all of these activities and, even if we do, we may never generate revenue that is significant or large enough to achieve profitability. If we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our failure to become and remain profitable would decrease the value of our company and </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">31</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">could impair our ability to raise capital, maintain our research and development efforts, expand our business or continue our operations. A decline in the value of our company could also cause you to lose all or part of your investment.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have never generated revenue from product sales and may never be profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our ability to generate revenue from product sales and achieve profitability depends on our ability, alone or with collaboration partners, to successfully complete the development of, and obtain the regulatory approvals necessary to commercialize, our product candidates. We do not anticipate generating revenue from product sales for the next several years, if ever. Our ability to generate future revenue from product sales depends heavily on our, or our potential future collaborators&#8217;, success in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">completing preclinical studies and clinical trials of our product candidates, including our ongoing Phase 1/2 clinical trials for NC410 and NC762 and Phase 1 clinical trial for NC525;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">seeking and obtaining marketing approvals for any product candidates that we or our collaborators develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receiving acceptance of INDs for future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying and developing new product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">launching and commercializing product candidates for which we obtain marketing approval by establishing a marketing, sales, distribution and medical affairs infrastructure or, alternatively, collaborating with a commercialization partner;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">achieving coverage and adequate reimbursement by hospitals and third-party payors, including governmental authorities, such as Medicare and Medicaid, private insurers and managed care organizations, for product candidates, if approved, that we or our collaborators develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">manufacturing cGMP supply of our product candidates for clinical trials and, if approved, commercial sales;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining market acceptance of product candidates, if approved, that we develop as viable treatment options;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">addressing any competing technological and market developments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">negotiating favorable terms in any collaboration, licensing or other arrangements into which we may enter and performing our obligations under such arrangements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining, protecting and expanding our portfolio of intellectual property rights, including patents, trade secrets and know-how;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">defending against third-party interference or infringement claims, if any; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">attracting, hiring and retaining qualified personnel.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate incurring significant costs associated with commercializing any product candidate that is approved for commercial sale. Our expenses could increase beyond expectations if we are required by the FDA or other regulatory agencies to perform clinical trials or studies in addition to those that we currently anticipate. Even if we are able to generate revenue from the sale of any approved products, we may not become profitable and may need to obtain additional funding to continue operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will require substantial additional financing to pursue our business objectives, which may not be available on acceptable terms, or at all. A failure to obtain this necessary capital when needed could force us to delay, limit, reduce or terminate our product development, commercialization efforts or other operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our operations have consumed substantial amounts of cash since inception. We expect to continue to spend substantial amounts to continue the preclinical and clinical development of our current and future programs. If we receive </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">32</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">marketing approval for any product candidates, including NC410, NC762 or NC525, we will require significant additional amounts of cash in order to launch and commercialize such product candidates. In addition, other unanticipated costs may arise. Because the designs and outcomes of our planned and anticipated clinical trials are highly uncertain, we cannot reasonably estimate the actual amounts necessary to successfully complete the development of and commercialize any product candidate we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future capital requirements depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, timing, results and costs of researching and developing NC410, NC762, NC525 and our other product candidates, including targets identified through our FIND-IO platform, and of conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining marketing approval for NC410, NC762, NC525 and any future product candidates we develop, if clinical trials are successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing NC410, NC762, NC525 and any future product candidates for preclinical studies and clinical trials and in preparation for marketing approval and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities, including marketing, sales and distribution costs, for NC410, NC762, NC525 and any future product candidates we develop, whether alone or with a collaborator, if any of these product candidates are approved for sale;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain additional strategic collaborations, licensing or other arrangements on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of any such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our current collaboration and license agreements remaining in effect and our achievement of milestones and the timing and amount of milestone payments we are required to make, or that we may be eligible to receive, under those agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or royalties on, our future products, if any; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing therapies and other developments in the oncology market.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Unless and until we generate sufficient product and royalty revenue to finance our cash requirements, we expect to finance our future cash needs through a combination of public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances and licensing arrangements. As of December 31, 2022, we had $159.9 million in cash, cash equivalents and marketable securities. Based on our research and development plans, we expect that our existing cash, cash equivalents and marketable securities will enable us to fund our operating expenses and capital expenditure requirements into mid-2025. This estimate is based on assumptions that may prove to be wrong, and we could use our available capital resources sooner than we expect. Changes may occur within or beyond our control that would cause us to consume our available capital before that time, including changes in and progress of our development activities, acquisitions of additional product candidates and changes in regulation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we raise additional capital through marketing, sales and distribution arrangements or other collaborations, strategic alliances or licensing arrangements with third parties, we may have to relinquish certain valuable rights to our product candidates, future revenue streams, research programs or technologies or grant licenses on terms that may not be favorable to us. If we raise additional capital through public or private equity offerings, the terms of these securities may include liquidation or other preferences that adversely affect our stockholders&#8217; rights. Further, to the extent that we raise additional capital through the sale of common stock or securities convertible or exchangeable into common stock, your ownership interest will be diluted. If we raise additional capital through debt financing, we would be subject to fixed payment obligations and may be subject to covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures or declaring dividends.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">33</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adequate additional financing may not be available to us on acceptable terms, or at all. If we are unable to obtain additional financing on favorable terms when needed, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Risks Related to the Discovery and Development of Our Product Candidates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">As an organization, we have limited experience designing and implementing clinical trials, and we have never conducted pivotal clinical trials. Failure to adequately design a trial, or incorrect assumptions about the design of the trial, could adversely affect the ability to initiate the trial, enroll patients, complete the trial, or obtain regulatory approval on the basis of the trial results, as well as lead to increased or unexpected costs and in delayed timelines.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The design and implementation of clinical trials is a complex process. We have limited experience designing and implementing clinical trials, and we may not successfully or cost-effectively design and implement clinical trials that achieve our desired clinical endpoints efficiently, or at all. A clinical trial that is not well designed may delay or prevent initiation or completion of the trial, can lead to increased difficulty in enrolling patients, may make it more difficult to obtain regulatory approval for the product candidate on the basis of the study results, or, even if a product candidate is approved, could make it more difficult to commercialize the product successfully or obtain reimbursement from third-party payors. Additionally, a trial that is not well-designed could be inefficient or more expensive than it otherwise would have been, or we may incorrectly estimate the costs to implement the clinical trial, which could lead to a shortfall in funding. If we select an incorrect dose or dose administration schedule, that could negatively impact the results of the trial, including if we select doses that are too low to be effective or administer doses too infrequently based on the half-life of the active ingredient. We also expect to continue to rely on third parties to conduct our pivotal clinical trials (see &#8220;Risks Related to Reliance on Third Parties&#8221;). We rely, or will rely, on third parties to help conduct our ongoing and planned preclinical studies and clinical trials for NC410, NC762, NC525 and any future product candidates we develop. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize NC410, NC762, NC525 and any future product candidates we develop, and our business could be materially harmed. Consequently, we may be unable to successfully and efficiently execute and complete clinical trials that are required for BLA submission and FDA approval of NC410, NC762, NC525 or future product candidates. We may require more time and incur greater costs than our competitors and may not succeed in obtaining regulatory approvals of product candidates that we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The impacts of the COVID-19 pandemic could continue to adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic has led to changes in the operations of many healthcare facilities, including clinical trial sites. The impacts of COVID-19 continue to place a significant strain on our clinical trial sites, raise concerns around monitoring patient safety, slow patient enrollment and cause delays in our clinical trials and issuance of results. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect our clinical trial going forward. We are continuing to work closely with our clinical partners and have taken steps as necessary to adjust our protocols and timelines due to the impact of the COVID-19 pandemic. The impacts of the COVID-19 pandemic could adversely affect our clinical trials and operations in other ways as well. For example, challenges may arise as a result of patients, members of the clinical team, or our employees becoming infected with COVID-19 or otherwise unable or unwilling to participate in trials or come to work, as applicable, as a result of COVID-19, interruptions to the supply chain or manufacturing, site closures, or difficulties in meeting protocol-specified procedures, including difficulties adhering to protocol-mandated visits and testing. The COVID-19 pandemic may also increase the likelihood and severity of other risks discussed in the &#8220;Risk Factors&#8221; section of this Annual Report, including but not limited to risks related to the conduct, progress and outcomes of clinical trials, risks related to reliance on third parties, risks related to our operations and dependence on key personnel, and risks related to our need to obtain additional capital.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The COVID-19 pandemic and its impacts continue to evolve, including the emergence of variant strains of the COVID-19 virus. Although vaccines are now available are being distributed globally, we cannot predict the full scope, duration and severity of disruptions resulting from COVID-19 or their impacts on us. Business disruptions for us or the third parties with whom we engage, including the collaborators, contract organizations, third-party manufacturers, suppliers, clinical trial sites, regulators and other third parties with whom we conduct business could materially and negatively impact our ability to conduct our business in the manner and on the timelines presently planned. The extent to which the COVID-19 pandemic may impact our business and financial performance will depend on future developments, which are highly uncertain and cannot be predicted with confidence, including the scope and duration of the pandemic and the extent and effectiveness of government restrictions, relief measures and other actions implemented to address the impact of the pandemic, and resulting economic impacts.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">34</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our business is dependent on our ability to advance our current and future product candidates through clinical trials, obtain marketing approval and ultimately commercialize them.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are early in our development efforts. We initiated our first clinical trial for NC410 in June 2020, our first clinical trial for NC762 in July 2021, and our first clinical trial for NC525 in February 2023. Our ability to generate product revenues, which we do not expect will occur for several years, if ever, will depend heavily on the successful development and eventual commercialization of NC410, NC762, NC525 and any future product candidates we develop, which may never occur. Our current product candidates and any future product candidates we develop will require additional preclinical or clinical development, management of clinical, preclinical and manufacturing activities, marketing approval in the United States and other jurisdictions, demonstration of effectiveness to pricing and reimbursement authorities, sufficient cGMP manufacturing supply for both preclinical and clinical development and commercial production, building of a commercial organization and substantial investment and significant marketing efforts before we generate any revenues from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The clinical and commercial success of our current and future product candidates will depend on several factors, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">timely and successful completion of preclinical studies and our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sufficiency of our financial and other resources to complete the necessary preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of INDs for any future product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful enrollment in and completion of clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successful data from our clinical program that supports an acceptable risk-benefit profile of our product candidates in the intended patient populations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to consistently manufacture our product candidates on a timely basis or to establish agreements with third-party manufacturers, if needed;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">whether we are required by the FDA or comparable foreign regulatory authorities to conduct additional clinical trials or other studies beyond those planned or anticipated to support approval of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of our proposed indications and the primary endpoint assessments evaluated in the clinical trials of our product candidates by the FDA and comparable foreign regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">receipt and maintenance of timely marketing approvals from applicable regulatory authorities;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">successfully launching commercial sales of our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence, duration and severity of potential side effects or other safety issues experienced with our product candidates, if approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">entry into collaborations to further the development of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining patent and trade secret protection or regulatory exclusivity for our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">acceptance of the benefits and uses of our product candidates, if approved, by patients, the medical community and third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">maintaining a continued acceptable safety, tolerability and efficacy profile of the product candidates following approval;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">35</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our compliance with any post-approval requirements imposed on our products, such as post-marketing studies, a REMS or additional requirements that might limit the promotion, advertising, distribution or sales of our products or make the products cost-prohibitive;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">competing effectively with other therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">obtaining and maintaining healthcare coverage and adequate reimbursement from third-party payors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to identify targets and immunomedicines, whether through our FIND-IO platform, through our relationship with Yale or otherwise; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">enforcing and defending intellectual property rights and claims.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These factors, many of which are beyond our control, could cause us to experience significant delays or an inability to obtain regulatory approvals or commercialize our current or future product candidates, and could otherwise materially harm our business. Successful completion of preclinical studies and clinical trials does not mean that NC410, NC762, NC525 or any future product candidates we develop will receive regulatory approval. Even if regulatory approvals are obtained, we could experience significant delays or an inability to successfully commercialize our current and any future product candidates we develop, which would materially harm our business. If we are not able to generate sufficient revenue through the sale of any current or future product candidate, we may not be able to continue our business operations or achieve profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The time required to obtain approval by the FDA and comparable foreign authorities is unpredictable but typically takes many years following the commencement of clinical trials and depends upon numerous factors, including the substantial discretion of the regulatory authorities. In addition, approval policies, regulations or the type and amount of clinical data necessary to gain approval may change during the course of a product candidate&#8217;s clinical development and may vary among jurisdictions. We have not obtained regulatory approval for any product candidate. Neither we nor any future collaborator is permitted to market any biological product in the United States until we or the future collaborator receives regulatory approval of a BLA from the FDA. It is possible that none of our current or future product candidates will ever obtain regulatory approval from the FDA or comparable foreign regulatory authorities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our current and future product candidates could fail to receive regulatory approval for many reasons, including the following:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with the design or implementation of our clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate to the satisfaction of the FDA or comparable foreign regulatory authorities that a product candidate is safe, pure and potent for its proposed indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of clinical trials may not meet the level of statistical significance required by the FDA or comparable foreign regulatory authorities for approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be unable to demonstrate that a product candidate&#8217;s clinical and other benefits outweigh its safety risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may disagree with our interpretation of data from clinical trials or preclinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the data collected from clinical trials of our product candidates may not be sufficient to support the submission of a BLA to the FDA or regulatory submissions to comparable regulatory authorities to obtain regulatory approval in such jurisdiction; and </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">36</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or comparable foreign regulatory authorities may find deficiencies with or fail to approve our manufacturing processes or facility or the manufacturing processes or facilities of third-party manufacturers with which we contract for clinical and commercial supplies.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">This lengthy approval process as well as the unpredictability of clinical trial results may result in our failing to obtain regulatory approval to market any product candidate we develop, which would significantly harm our business, results of operations and prospects. The FDA and other comparable foreign authorities have substantial discretion in the approval process and in determining when or whether regulatory approval will be granted for any product candidate that we develop. Even if we believe the data collected from current or future clinical trials of our product candidates are promising, such data may not be sufficient to support approval by the FDA or any other regulatory authority.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, even if we were to obtain approval, the FDA may approve any of our product candidates for fewer or more limited indications, or a more limited patient population, than we request, may grant approval contingent on the performance of costly clinical trials, development of an <i style="font-style:italic;">in vitro</i> companion diagnostic, or other post-marketing requirements, or may approve a product candidate with a label that does not include the labeling claims we believe are necessary or desirable for the successful commercialization of such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA or comparable foreign regulatory authorities may change their policies, promulgate additional regulations, revise existing regulations or take other actions that may prevent or delay approval of our future products under development on a timely basis. Such policy or regulatory changes could impose additional requirements upon us that could delay our ability to obtain approvals, increase the costs of compliance or restrict our ability to maintain any marketing authorizations we may have obtained. Any of the foregoing scenarios could materially harm the commercial prospects for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Clinical development involves a lengthy and expensive process with uncertain outcomes. We may incur additional costs and experience delays in developing and commercializing or be unable to develop or commercialize our current and future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To obtain the requisite regulatory approvals to commercialize any of our product candidates, we must demonstrate through extensive preclinical studies and clinical trials that our product candidates are safe, pure and potent in humans. Clinical testing is expensive and can take many years to complete, and its outcome is highly uncertain. Failure can occur at any time during the clinical trial process, and our future clinical trial results may not be successful. We may experience delays in completing our clinical trials or preclinical studies and initiating or completing our planned clinical trials and development efforts. Additionally, we cannot be certain the ongoing and planned preclinical studies or clinical trials for NC410, NC762, NC525 or any future product candidates will begin on time, not require redesign, enroll an adequate number of subjects on time or be completed on schedule, if at all. For example, we announced in November 2022 that based on current efficacy data, we had decided to discontinue our monotherapy Phase 2 clinical trial for NC318. We may also experience numerous unforeseen events during our clinical trials that could delay or prevent our ability to receive marketing approval or commercialize the product candidates we develop, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">results from preclinical studies or clinical trials may not be predictive of results from later clinical trials of any product candidate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other regulatory authorities, IRBs or independent ethics committees may not authorize us or our investigators to commence a clinical trial or conduct a clinical trial at a prospective trial site;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or other regulatory authorities may require us to submit additional data such as long-term toxicology studies, or impose other requirements on us, before permitting us to initiate a clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may experience delays in reaching, or fail to reach, agreement on acceptable terms with prospective trial sites and prospective contract research organizations, or &#8220;CROs&#8221;, as the terms of these agreements can be subject to extensive negotiation and vary significantly among different CROs and trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinical trials of any product candidate may fail to show safety, purity or potency, or may produce negative or inconclusive results, which may cause us to decide, or regulators to require us, to conduct additional nonclinical studies or clinical trials or which may cause us to decide to abandon product candidate development programs;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">37</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number of patients required for clinical trials may be larger than we anticipate or we may have difficulty in recruiting and enrolling patients to participate in clinical trials, including as a result of the size and nature of the patient population, the proximity of patients to clinical trial sites, eligibility criteria for the clinical trial, the nature of the clinical trial protocol, the availability of approved effective treatments for the relevant disease, competition from other clinical trial programs for similar indications and clinical trial subjects and the impact of public health emergencies, such as the COVID-19 pandemic;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it may be difficult to enroll a sufficient number of patients, enrollment in these clinical trials may be slower than we anticipate, or participants may drop out of these clinical trials or may fail to return for post-treatment follow-up at a higher rate than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our CROs and other third-party contractors may fail to comply with regulatory requirements or meet their contractual obligations to us in a timely manner, or at all, or may deviate from the clinical trial protocol or drop out of the trial, which may require that we add new clinical trial sites or investigators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may elect to, or regulators, IRBs or ethics committees may require that we or our investigators, suspend or terminate clinical research or trials for various reasons, including noncompliance with regulatory requirements or a finding that participants are being exposed to unacceptable health risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any of our product candidates could cause undesirable side effects that could result in significant negative consequences, including the inability to enter clinical development or receive regulatory approval;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the cost of preclinical or nonclinical testing and studies and clinical trials of any product candidates may be greater than we anticipate;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may face hurdles in addressing subject safety concerns that arise during the course of a trial, causing us or our investigators, regulators, IRBs or ethics committees to suspend or terminate trials, or reports may arise from nonclinical or clinical testing of other cancer therapies that raise safety or efficacy concerns about our product candidates; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the supply, quality or timeliness of delivery of materials for product candidates we develop or other materials necessary to conduct clinical trials may be insufficient or inadequate; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or third parties on whom we are dependent, may suffer business interruptions resulting from geo-political actions, including war and terrorism, or natural disasters and public health emergencies, such as the COVID-19 pandemic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may encounter delays if a clinical trial is suspended or terminated by us, the IRBs of the institutions in which such trials are being conducted or ethics committees, or the DSMB recommends suspension or termination for such trial or by the FDA or other regulatory authorities. Such authorities may impose such a suspension or termination due to a number of factors, including failure to conduct the clinical trial in accordance with regulatory requirements or our clinical protocols, inspection of the clinical trial operations or trial site by the FDA or other regulatory authorities resulting in the imposition of a clinical hold, unforeseen safety issues or adverse side effects, failure to demonstrate a benefit from using a product candidate, changes in governmental regulations or administrative actions or lack of adequate funding to continue the clinical trial. Many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of marketing approval of our product candidates. The FDA or other regulatory authorities may disagree with our clinical trial design and our interpretation of data from clinical trials or may change the requirements for approval even after they have reviewed and commented on the design for our clinical trials. In addition, factors outside our control, such as government shutdowns, natural disasters and public health emergencies such as the COVID-19 pandemic, could disrupt business at the FDA or other regulatory authorities, which could result in delays of reviews, approvals and communications with regulatory authorities related to our clinical trials and product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Principal investigators for our clinical trials may serve as scientific advisors or consultants to us from time to time and may receive cash or equity compensation in connection with such services. If these relationships and any related compensation result in perceived or actual conflicts of interest, or a regulatory authority concludes that the financial relationship may have affected the interpretation of the trial, the integrity of the data generated at the applicable clinical </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">38</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">trial site may be questioned and the utility of the clinical trial itself may be jeopardized, which could result in the delay or rejection of the marketing application we submit. Any such delay or rejection could prevent or delay us from commercializing our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we experience delays in the completion, or termination, of any clinical trial of our product candidates, the commercial prospects of our product candidates will be harmed and our ability to generate product revenues from any of these product candidates will be delayed. In addition, any delays in completing our clinical trials will increase our costs, slow down the development and approval process for our product candidates and jeopardize our ability to commence product sales and generate revenues. Significant clinical trial delays could also allow our competitors to bring products to market before we do or shorten any periods during which we have the exclusive right to commercialize our product candidates. Any such events would impair our ability to successfully commercialize our product candidates and may harm our business and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of these occurrences may significantly harm our business, financial condition and prospects. In addition, many of the factors that cause, or lead to, a delay in the commencement or completion of clinical trials may also ultimately lead to the denial of regulatory approval of our product candidates or result in the development of our product candidates stopping early.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Preclinical development is uncertain. Our preclinical programs may experience delays or may never advance to clinical trials, which would adversely affect our ability to obtain regulatory approvals or commercialize these programs on a timely basis or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">With the exception of NC410, NC762, NC525 and NC318, all of our product candidates are still in the preclinical stage, and the risk of failure for such product candidates is high. In order to obtain FDA approval to market a new biologic we must demonstrate proof of safety, purity and potency, including efficacy, in humans. To meet these requirements, we will have to conduct adequate and well-controlled clinical trials. Before we can commence clinical trials for a product candidate, we must complete extensive preclinical testing and studies that support our planned clinical trials in humans. We cannot be certain of the timely completion or outcome of our preclinical testing and studies and cannot predict if the FDA will accept our proposed clinical programs or if the outcome of our preclinical testing and studies will ultimately support the further development of our current or future product candidates. As a result, we cannot be sure that we will be able to submit INDs or similar applications for our preclinical programs on the timelines we expect, if at all, and we cannot be sure that submission of INDs or similar applications will result in the FDA or other regulatory authorities allowing clinical trials to begin.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Conducting preclinical testing is a lengthy, time-consuming and expensive process. The length of time of such testing may vary substantially according to the type, complexity and novelty of the program, and often can be several years or more per program. Delays associated with programs for which we are conducting preclinical testing and studies may cause us to incur additional operating expenses. Moreover, we may be affected by delays associated with the preclinical testing and studies of certain programs that are the responsibility of our potential future collaborators over which we have no control. The commencement and rate of completion of preclinical studies and clinical trials for a product candidate may be delayed by many factors, including but not limited to:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">an inability to generate sufficient preclinical or other </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vivo</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> or </span><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">in vitro</i><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"> data to support the initiation of clinical studies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delays in reaching a consensus with regulatory agencies on study design; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA not permitting the reliance on preclinical or other data from published scientific literature.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Interim and preliminary results from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit, validation and verification procedures that could result in material changes in the final data.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">From time to time, we may publish interim data, including interim top-line results or preliminary results from our clinical trials. Interim data and results from our clinical trials are subject to the risk that one or more of the clinical outcomes may materially change as patient enrollment continues and more patient data become available. For example, notwithstanding the durable responses initially observed in our ongoing Phase 1/2 clinical trial of NC318 in NSCLC, we </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">39</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">announced in November 2022 that based upon then-current efficacy data we decided to discontinue our Phase 2 clinical trial for NC318 monotherapy. Preliminary or top-line results also remain subject to audit, validation and verification procedures that may result in the final data being materially different from the interim and preliminary data we previously published. As a result, interim and preliminary data may not be predictive of final results and should be viewed with caution until the final data are available. Differences between preliminary or interim data and final data could significantly harm our business prospects and may cause the trading price of our common stock to fluctuate significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Initial positive trial results and results from preclinical studies and early-stage clinical trials may not be predictive or indicative of results when the trial is completed or in later stage trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The results of preclinical studies may not be predictive of the results of clinical trials. Preclinical studies and early-stage clinical trials are primarily designed to test safety, to study pharmacokinetics and pharmacodynamics and to understand the side effects of product candidates at various doses and schedules, and the results of any early-stage clinical trials may not be predictive of the results of later-stage, large-scale efficacy clinical trials. In addition, initial success in clinical trials may not be indicative of results obtained when such trials are completed. There can be no assurance that any of our current or future clinical trials will ultimately be successful or support further clinical development of any of our product candidates. There is a high failure rate for drugs and biologics proceeding through clinical trials. A number of companies in the pharmaceutical and biotechnology industries have suffered significant setbacks in clinical development even after achieving promising results in earlier studies, and any such setbacks in our clinical development could have a material adverse effect on our business and operating results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if our clinical trials are completed, the results may not be sufficient to obtain regulatory approval for our product candidates. Data obtained from preclinical and clinical activities are subject to varying interpretations, which may delay, limit or prevent regulatory approval. In addition, the results of our preclinical studies may not be predictive of the results of outcomes in human clinical trials. For example, our current or future product candidates may demonstrate different chemical, biological and pharmacological properties in patients than they do in laboratory studies or may interact with human biological systems in unforeseen or harmful ways. Product candidates in later stages of clinical trials may fail to show desired pharmacological properties or produce the necessary safety and efficacy results despite having progressed through preclinical studies and initial clinical trials. Even if we are able to initiate and complete clinical trials, the results may not be sufficient to obtain regulatory approval for our product candidates. In addition, we may experience regulatory delays or rejections as a result of many factors, including changes in regulatory policy during the period of our product candidate development. Any such delays could negatively impact our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Because the numbers of subjects in our Phase 1/2 and Phase 1 clinical trials are small, the results from each of these trials, once completed, may be less reliable than results achieved in larger clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:18pt;margin:0pt;">A study design that is considered appropriate includes a sufficiently large sample size with appropriate statistical power, as well as proper control of bias, to allow a meaningful interpretation of the results. The preliminary results of studies with smaller sample sizes, such as our Phase 1/2 clinical trials of NC318, NC410 and NC762, and Phase 1 clinical trial for NC525, can be disproportionately influenced by the impact the treatment had on a few individuals, which limits the ability to generalize the results across a broader community, thus making the study results less reliable than studies with a larger number of subjects and making it difficult to predict final results from preliminary results. As a result, there may be less certainty that the respective investigational drug product would achieve a statistically significant effect in any future clinical trials. If we conduct any future clinical trials of NC410, NC762, or NC525, we may not achieve a statistically significant result or the same level of statistical significance seen, if any, in our Phase 1/2 and Phase 1 clinical trials. Similarly, if we conduct a clinical trial of any other product candidate we develop with a small sample size, the results of any such trial may be less reliable than results achieved in larger clinical trials and may provide less certainty of achieving statistically significant effects in any future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our approach to the discovery and development of product candidates using our FIND-IO platform is unproven and may not result in marketable products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The success of our business depends in part upon our ability to identify targets based on our proprietary FIND-IO platform and to develop and commercialize immunomedicines. Our approach to the discovery of targets using the FIND-IO platform is novel. We have not yet initiated or completed a clinical trial of any product candidate developed for a target identified from the FIND-IO platform. The platform may fail to accurately identify targets that modulate the </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">40</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">immune system and are appropriate for immunomedicines. Even if we are able to identify targets from the FIND-IO platform and to develop corresponding product candidates, we cannot assure that such product candidates will achieve marketing approval to safely and effectively treat cancer or other disease states.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we uncover any previously unknown risks related to our FIND-IO platform, or if we experience unanticipated problems or delays in developing our FIND-IO product candidates, we may be unable to achieve our strategy of building an oncology pipeline of novel targets for new immunomedicines focused on non-responders. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our current or future product candidates may cause undesirable side effects or have other properties when used alone or in combination with other approved products or investigational new drugs that could halt their clinical development, delay or prevent their regulatory approval, limit their commercial potential or result in significant negative consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Before obtaining regulatory approvals for the commercial sale of our product candidates, we must demonstrate through lengthy, complex and expensive preclinical testing and clinical trials that our product candidates are safe, pure and potent for use in each target indication, and failures can occur at any stage of testing. As with most biologics, use of our current or future product candidates could be associated with side effects or adverse events which can vary in severity from minor reactions to death and in frequency from infrequent to prevalent. There have been serious adverse side effects reported in response to immunotherapies in oncology. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Possible adverse side effects that could occur with treatment with immunomedicines include an immunologic reaction early after administration that, while not necessarily adverse to the patient&#8217;s health, could substantially limit the effectiveness of the treatment. In addition to any potential side effects caused by the product or product candidate, the administration process or related procedures also can cause adverse side effects. If unacceptable adverse events occur, our clinical trials or any future marketing authorization could be suspended or terminated.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If unacceptable side effects arise in the development of our product candidates, the DSMB may recommend or, we, the FDA, or the IRBs at the institutions in which our studies are conducted could suspend or terminate our clinical trials or the FDA or comparable foreign regulatory authorities could order us to cease clinical trials or deny approval of our product candidates for any or all targeted indications. Treatment-related side effects could also affect patient recruitment or the ability of enrolled patients to complete any of our clinical trials or result in potential product liability claims. In addition, these side effects may not be appropriately recognized or managed by the treating medical staff. We expect to have to train medical personnel using our product candidates to understand the side effect profiles for our clinical trials and upon any commercialization of any of our product candidates. Inadequate training in recognizing or managing the potential side effects of our product candidates could result in patient injury or death. Any of these occurrences may significantly harm our business, financial condition and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although our current and future product candidates have undergone and will undergo safety testing to the extent possible and, where applicable, under such conditions discussed with regulatory authorities, not all adverse effects of drugs can be predicted or anticipated. Immunomedicines and their method of action of harnessing the body&#8217;s immune system are powerful and could lead to serious side effects that we only discover in clinical trials or during commercial marketing. Unforeseen side effects could arise either during clinical development or after our product candidates have been approved by regulatory authorities and the approved product has been marketed, resulting in the exposure of additional patients. So far, we have not demonstrated that NC410, NC762, NC525 or any other product candidate is safe in humans, and we cannot predict if ongoing or future clinical trials will do so. If any of our current or future product candidates fail to demonstrate safety and efficacy in clinical trials or do not gain marketing approval, we will not be able to generate revenue and our business will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">In addition, we are ourself studying NC410 in combination with other therapies, supporting Yale&#8217;s study of NC318 in combination with other therapies, and may develop NC762, NC525 and future product candidates in combination with other therapies, which exposes us to additional risks relating to undesirable side effects or other properties. For example, the other therapies may lead to toxicities that are improperly attributed to our product candidates or the combination of our product candidates with other therapies may result in toxicities that the product candidate or other therapy does not produce when used alone. The other therapies we are using in combination may be removed from the market, or we may not be able to secure adequate quantities of such materials for which we have no guaranteed supply contract, and thus be unavailable for testing or commercial use with any of our approved products. The other therapies we </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">41</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">may use in combination with our product candidates may also be supplanted in the market by newer, safer or more efficacious products or combinations of products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we successfully advance one of our product candidates through clinical trials, such trials will likely only include a limited number of subjects and limited duration of exposure to our product candidates. As a result, we cannot be assured that adverse effects of our product candidates will not be uncovered when a significantly larger number of patients are exposed to the product candidate. Further, any clinical trial may not be sufficient to determine the effect and safety consequences of taking our product candidates over a multi-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of our product candidates receives marketing approval, and we or others later identify undesirable side effects caused by such products, a number of potentially significant negative consequences could result, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may withdraw their approval of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to recall a product or change the way such product is administered to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">additional restrictions may be imposed on the marketing of the particular product or the manufacturing processes for the product or any component thereof;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory authorities may require the addition of labeling statements, such as a &#8220;black box&#8221; warning or a contraindication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to implement a REMS or create a Medication Guide outlining the risks of such side effects for distribution to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we could be sued and held liable for harm caused to patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to fines, warning letters, or other regulatory enforcement action;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to injunctions or the imposition of civil or criminal penalties;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be required to conduct additional post-market clinical trials to assess the safety of the product;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may be subject to product seizure or detention, or refusal to permit the import or export of products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">FDA may refuse to approve pending applications or supplements to approved applications filed by us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product may become less competitive; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our reputation may suffer.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any of the foregoing events could prevent us from achieving or maintaining market acceptance of the particular product candidate, if approved, and result in the loss of significant revenues, which would materially harm our business. In addition, if one or more of our product candidates or our immunotherapeutic development approach generally prove to be unsafe, our entire technology platform and pipeline could be affected, which would also materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If there are continued difficulties enrolling patients in our clinical trials, our clinical development activities could be delayed or otherwise be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The successful and timely completion of clinical trials in accordance with their protocols depends on, among other things, our ability to enroll a sufficient number of patients who remain in the trial until the trial&#8217;s conclusion, including any follow-up period. We may experience difficulties in patient enrollment in our clinical trials for a variety of reasons. For example, we experienced a slowdown of enrollment in our ongoing clinical trials as a result of the COVID-19 pandemic. The enrollment of patients depends on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patient eligibility criteria defined in the protocol;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">42</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the nature and size of the patient population required for analysis of the trial&#8217;s primary endpoints and the process for identifying patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the number and location of participating clinical sites or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the design of the trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to recruit clinical trial investigators with the appropriate competencies and experience;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">clinicians&#8217; and patients&#8217; perceptions as to the potential advantages and risks of the product candidate being studied in relation to other available therapies, including any new products that may be approved for the indications we are investigating;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the availability of competing commercially available therapies and other competing drug candidates&#8217; clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to obtain and maintain patient informed consents for participation in our clinical trials; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the risk that patients enrolled in clinical trials will drop out of the trials before completion or, because they may be late-stage cancer patients, will not survive the full terms of the clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">factors outside of our control, including as a result of business interruptions resulting from natural disasters and public health emergencies, such as the COVID-19 pandemic.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, our clinical trials will compete with other clinical trials for product candidates that are in the same therapeutic areas as our current and potential future product candidates. This competition will reduce the number and types of patients available to us, because some patients who might have opted to enroll in our trials may instead opt to enroll in a trial conducted by one of our competitors. Because the number of qualified clinical investigators is limited, we expect to conduct some of our clinical trials at the same clinical trial sites that some of our competitors use, which will reduce the number of patients who are available for our clinical trials at such sites. Moreover, because our current and potential future product candidates may represent a departure from more commonly used methods for cancer treatment, potential patients and their doctors may be inclined to use conventional therapies, such as chemotherapy, rather than enroll patients in our ongoing or any future clinical trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Delays from difficulties in patient enrollment in a clinical trial may result in increased costs or affect the timing, outcome or completion of the trial, which could delay or prevent our receipt of regulatory approval of the applicable product candidate or to abandon the trial altogether.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be required to suspend, repeat or terminate our clinical trials if they are not conducted in accordance with regulatory requirements, the results are negative or inconclusive or the trials are not well designed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Clinical trials must be conducted in accordance with the FDA&#8217;s current cGCP or analogous requirements of applicable foreign regulatory authorities. Clinical trials are subject to oversight by the FDA, other foreign governmental agencies and IRBs or ethical committees at the study sites where the clinical trials are conducted. In addition, clinical trials must be conducted with product candidates manufactured in accordance with applicable cGMP. Clinical trials may be suspended by the FDA, other foreign regulatory authorities, us, or by an IRB or ethics committee with respect to a particular clinical trial site, for various reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deficiencies in the conduct of the clinical trials, including failure to conduct the clinical trial in accordance with regulatory requirements or study protocols;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deficiencies in the clinical trial operations or trial sites;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen adverse side effects or the emergence of undue risks to study subjects;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">deficiencies in the trial design necessary to demonstrate efficacy;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">43</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the product candidate may not appear to offer benefits over current therapies; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the quality or stability of the product candidate may fall below acceptable standards.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have chosen to prioritize development of NC410, NC762 and NC525. We may expend our limited resources on product candidates or indications that do not yield a successful product and fail to capitalize on other candidates or indications for which there may be a greater likelihood of success or may be more profitable.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because we have limited resources, we have strategically determined to prioritize development of NC410, NC762 and NC525 rather than other product candidates based, in part, on the significant resources required for developing and manufacturing immunomedicines. To date, no regulatory authority has granted approval for an immunomedicine targeting the LAIR pathway or B7-H4. As a result, we may be foregoing other potentially more profitable immunomedicines or therapies or those with a greater likelihood of success. Our decisions concerning the allocation of research, development, collaboration, management and financial resources toward particular product candidates or therapeutic areas may not lead to the development of any viable commercial product and may divert resources away from better opportunities. Similarly, our potential decisions to delay, terminate or collaborate with third parties with respect to, certain programs may subsequently also prove to be suboptimal and could cause us to miss valuable opportunities. If we make incorrect determinations regarding the viability or market potential of any of our current or future product candidates or misread trends in the oncology or biopharmaceutical industry, our business, financial condition and results of operations could be materially adversely affected. As a result, we may fail to capitalize on viable commercial products or profitable market opportunities, be required to forego or delay pursuit of opportunities with other product candidates or other diseases and disease pathways that may later prove to have greater commercial potential than those we choose to pursue, or relinquish valuable rights to such product candidates through collaboration, licensing or other royalty arrangements in cases in which it would have been advantageous for us to invest additional resources to retain development and commercialization rights.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may need to develop, or enter into a collaboration or partnership to develop, complementary or companion diagnostics for our current or future product candidates. If we, or our future collaborators, are unable to successfully develop complementary or companion diagnostics, or experience significant delays in doing so, we may not realize the full commercial potential of our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">One of the key elements of our product development strategy is to identify cancer patient populations that may derive meaningful benefit from our current or future product candidates. Because predictive biomarkers are being and may be used to identify the right patients for current or future product candidates, we believe that our success may depend, in part, on our ability to develop complementary or companion diagnostics in collaboration with partners. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have limited experience in the development of diagnostics and, as such, we may rely in part on future collaborators in developing appropriate diagnostics to pair with our current or future product candidates. We have not yet begun substantial discussions with any potential partners with respect to the development of complementary or companion diagnostics and may be unsuccessful in entering into collaborations for the development of any such diagnostics for our current or future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Companion diagnostics are subject to regulation by the FDA and similar comparable foreign regulatory authorities as medical devices and require separate regulatory approval or clearance prior to commercialization. Complementary diagnostics may be subject to regulation by CMS or the FDA and similar comparable foreign regulatory authorities and may require separate regulatory approval or clearance prior to commercialization. Gaining regulatory approval could be time consuming and costly and could delay regulatory approval of the related product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We and our collaborators may encounter difficulties in developing such tests, including issues relating to the selectivity or specificity of the diagnostic, analytical validation, reproducibility or clinical validation. If we, our </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">44</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">collaborators, or any third parties that we engage to assist us, are unable to successfully develop complementary or companion diagnostics for our current or future product candidates or experience delays in doing so: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">development of our current or future product candidates may be adversely affected if we are unable to appropriately select patients for enrollment in our clinical trials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not realize the commercial potential of our current or future product candidates if, among other reasons, we are unable to appropriately identify, or it takes us longer to identify, patients who are likely to benefit from therapy with our products, if approved.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any of these events were to occur, our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Risks Related to the Regulatory Approval and Commercialization of Product Candidates and Other Legal Compliance Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to obtain FDA approval of our product candidates under applicable regulatory requirements. The denial or delay of any such approval would prevent or delay commercialization of our product candidates and adversely impact our potential to generate revenue, our business and our results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To gain approval to market our product candidates in the United States, we must provide the FDA with clinical data that adequately demonstrate the safety, purity and potency, including efficacy, of the product candidate for the proposed indication or indications in a BLA submission. Product development is a long, expensive and uncertain process, and delay or failure can occur at any stage of any of our clinical development programs. A number of companies in the biotechnology and pharmaceutical industries have suffered significant setbacks in clinical trials, even after promising results in earlier preclinical studies or clinical trials. These setbacks have been caused by, among other things, preclinical findings made while clinical trials were underway and safety or efficacy observations made in clinical trials, including previously unreported adverse events. Success in preclinical testing and early clinical trials does not ensure that later clinical trials will be successful, and the results of clinical trials by other parties may not be indicative of the results in trials we may conduct.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not previously submitted a BLA or any other marketing application to the FDA or similar filings to comparable foreign regulatory authorities. A BLA or other similar regulatory filing requesting approval to market a product candidate must include extensive preclinical and clinical data and supporting information to establish that the product candidate is safe, pure and potent for each desired indication. The BLA or other similar regulatory filing must also include significant information regarding the chemistry, manufacturing and controls for the product.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The research, testing, manufacturing, labeling, approval, marketing, sale and distribution of biological products are subject to extensive regulation by the FDA and other regulatory authorities in the United States and other countries, and such regulations differ from country to country. We are not permitted to market our product candidates in the United States or in any foreign countries until they receive the requisite approval from the applicable regulatory authorities of such jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA or comparable foreign regulatory authorities can delay, limit or deny approval of our product candidates for many reasons, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to demonstrate to the satisfaction of the FDA or a comparable foreign regulatory authority that our product candidates are safe and effective for the requested indication;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or a comparable foreign regulatory authority&#8217;s disagreement with our trial protocol or the interpretation of data from preclinical studies or clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to demonstrate that the clinical and other benefits of our product candidates outweigh any safety or other perceived risks;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or a comparable foreign regulatory authority&#8217;s requirement for additional preclinical studies or clinical trials;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">45</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or a comparable foreign regulatory authority&#8217;s non-approval of the formulation, labeling, or specifications of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the FDA or a comparable regulatory authority&#8217;s failure to approve our manufacturing processes and facilities or the manufacturing processes and facilities of third-party manufacturers upon which we rely; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">potential for approval policies or regulations of the FDA or a comparable foreign regulatory authority to significantly change in a manner rendering our clinical data insufficient for approval.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if we eventually complete clinical testing and receive approval from the FDA or comparable foreign regulatory authorities for any of our product candidates, the FDA or comparable foreign regulatory authorities may grant approval contingent on the performance of costly additional clinical trials which may be required after approval. The FDA or comparable foreign regulatory authorities also may approve any of our product candidates for a more limited indication or a narrower patient population than we originally requested, and the FDA or comparable foreign regulatory authorities may not approve any of our product candidates with the labeling that we believe is necessary or desirable for the successful commercialization of any such product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Of the large number of biopharmaceutical products in development, only a small percentage successfully complete the FDA or other regulatory bodies&#8217; approval processes and are commercialized. Any delay in obtaining, or inability to obtain, applicable regulatory approval would delay or prevent commercialization of our product candidates and would materially harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if a current or future product candidate receives marketing approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If any current or future product candidate we develop receives marketing approval, whether as a single agent or in combination with other therapies, it may nonetheless fail to gain sufficient market acceptance by physicians, patients, third-party payors, and others in the medical community. For example, current approved immunotherapies, and other cancer treatments like chemotherapy and radiation therapy, are well established in the medical community, and doctors may continue to rely on these therapies. Our approach to targeting different components of the TME is novel and unproven. In addition, adverse events in clinical trials testing our product candidates or in clinical trials of others developing similar product candidates and the resulting publicity, as well as any other adverse events in the field of immuno-oncology that may occur in the future, could result in a decrease in demand for our current or future product candidates. If public perception is influenced by claims that the use of cancer immunotherapies is unsafe, whether related to our immunomedicines or our competitors&#8217; products, our products may not be accepted by the general public or the medical community. Future adverse events in immuno-oncology or the biopharmaceutical industry could also result in greater governmental regulation, stricter labeling requirements and potential regulatory delays in the testing or approvals of our products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our current and any future product candidates we develop do not achieve an adequate level of acceptance, we may not generate significant product revenues and we may not become profitable. The degree of market acceptance of our current and any future product candidates, if approved for commercial sale, will depend on a number of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">efficacy and potential advantages compared to alternative treatments, including those that are not yet approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to offer our products, if approved, for sale at competitive prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">convenience and ease of administration compared to alternative treatments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the willingness of the target patient population to try new therapies and of physicians to prescribe these therapies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the strength of marketing, sales and distribution support;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">46</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the ability to obtain sufficient third-party coverage and adequate reimbursement, including with respect to the use of the approved product as a combination therapy;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the regulatory approval and adoption of a companion or complementary diagnostic, if needed or advisable; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the prevalence and severity of any side effects.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The market opportunities for any current or future product candidate we develop, if approved, may be limited to those patients who are ineligible for established therapies or for whom prior therapies have failed, and may be small.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any revenue we are able to generate in the future from product sales will be dependent, in part, upon the size of the market in the United States and any other jurisdiction for which we gain regulatory approval and have commercial rights. If the markets or patient subsets that we are targeting are not as significant as we estimate, we may not generate significant revenues from sales of such products, even if approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cancer therapies are sometimes characterized as first-line, second-line or third-line, and the FDA often approves new therapies initially only for third-line use. When cancer is detected early enough, first-line therapy, usually chemotherapy, hormone therapy, surgery, radiation therapy or a combination of these, is sometimes adequate to cure the cancer or prolong life without a cure. Second- and third-line therapies are administered to patients when prior therapy is not effective. We may initially seek approval for NC410, NC762, NC525 and any other product candidates we develop as second- or third-line therapies. If we do so, for those products that prove to be sufficiently beneficial, if any, we would expect potentially to seek approval as a first-line therapy, but there is no guarantee that any product candidate we develop, even if approved, would be approved for first-line therapy, and, prior to any such approvals, we may have to conduct additional clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The number of patients who have the types of cancer we are targeting may turn out to be lower than expected. Additionally, the potentially addressable patient population for our current or future product candidates may be limited, if and when approved. Even if we obtain significant market share for any product candidate, if and when approved, if the potential target populations are small, we may never achieve profitability without obtaining marketing approval for additional indications, including to be used as first- or second-line therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are studying NC410 in combination with other therapies and may develop NC762, NC525 and future product candidates in combination with other therapies, which exposes us to additional regulatory risks.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are studying NC410 in combination with pembrolizumab and may develop NC762, NC525 and future product candidates in combination with one or more currently approved cancer therapies. In addition, we are supplying NC318 drug product to Yale in support of Yale&#8217;s IIT study of NC318 in combination with pembrolizumab. These combinations have not been tested before and may, among other things, fail to demonstrate synergistic activity, may fail to achieve superior outcomes relative to the use of single agents or other combination therapies, or may fail to demonstrate sufficient safety or efficacy traits in clinical trials to enable us to complete those clinical trials or obtain marketing approval for the combination therapy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, we did not develop or obtain regulatory approval for, and we do not manufacture or sell, any of these approved therapeutics. Therefore, even if any product candidate we develop were to receive marketing approval or be commercialized for use in combination with other existing therapies, we would continue to be subject to the risk that the FDA or comparable foreign regulatory authorities could revoke approval of the therapy used in combination with our product candidate or that safety, efficacy, manufacturing or supply issues could arise with these existing therapies. This could result in our own products being removed from the market or being less successful commercially. Combination therapies are commonly used for the treatment of cancer, and we would be subject to similar risks if we develop any of our product candidates for use in combination with other drugs or for indications other than cancer.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also evaluate NC410, NC762, NC525 or any future product candidate in combination with one or more other cancer therapies that have not yet been approved for marketing by the FDA or comparable foreign regulatory authorities. We will not be able to market and sell NC410, NC762, NC525 or any product candidate we develop in combination with any such unapproved cancer therapies that do not ultimately obtain marketing approval.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">47</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If the FDA or comparable foreign regulatory authorities do not approve these other biological products or revoke their approval of, or if safety, efficacy, manufacturing or supply issues arise with, the biologics we choose to evaluate in combination with NC410, NC762, NC525 or any product candidate we develop, we may be unable to obtain approval of or market any such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Even if we receive marketing approval of a product candidate, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense. If we fail to comply or experience unanticipated problems with our products, we may be subject to administrative and judicial enforcement, including monetary penalties, for non-compliance and our approved products, if any, could be deemed misbranded or adulterated and prohibited from continued distribution.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any marketing approvals that we receive for any current or future product candidate may be subject to limitations on the approved indicated uses for which the product may be marketed or the conditions of approval or contain requirements for potentially costly post-market testing and surveillance to monitor the safety and efficacy of the product candidate. The FDA may also require implementation of a REMS as a condition of approval of any product candidate, which could include requirements for a medication guide, physician communication plans or additional elements to ensure safe use, such as restricted distribution methods, patient registries and other risk minimization tools. In addition, if the FDA or a comparable foreign regulatory authority approves a product candidate, the manufacturing processes, labeling, packaging, distribution, adverse event and deviation reporting, storage, advertising, promotion, import and export and record keeping for the product candidate will be subject to extensive and ongoing regulatory requirements. These requirements include submissions of safety and other post-marketing information and reports, registration, as well as continued compliance with cGMP and cGCP, for any clinical trials that we may conduct post-approval. Later discovery of previously unknown problems with any approved candidate, including adverse events of unanticipated severity or frequency, or with our or our third-party manufacturers&#8217; manufacturing processes or facilities, or failure to comply with regulatory requirements, may result in, among other things:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">suspension of, or imposition of restrictions on, the marketing or manufacturing of the product, withdrawal of the product from the market, or product recalls;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Warning Letters or Untitled Letters, or holds on clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">refusal by the FDA to approve pending applications or supplements to approved applications we file, or suspension or revocation of approved biologics licenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product seizure or detention, monetary penalties, refusal to permit the import or export of the product, or placement on Import Alert; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">permanent injunctions and consent decrees including the imposition of civil or criminal penalties.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Given the nature of biologics manufacturing, there is a risk of contamination. Any contamination could materially adversely affect our ability to produce product candidates on schedule and could, therefore, harm our results of operations and cause reputational damage. Some of the raw materials and other components required in our manufacturing process are derived from biologic sources. Such raw materials are difficult to procure and may be subject to contamination or recall. A material shortage, contamination, recall or restriction on the use of biologically derived substances in manufacturing our product or product candidates could adversely impact or disrupt the commercial manufacturing or the production of clinical material, which could materially and adversely affect our development and commercialization timelines and our business, financial condition, results of operations and prospects and could adversely affect our ability to meet our supply obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, the FDA strictly regulates the promotional claims that may be made about drug and biological products. An approved product may not be promoted for uses that are not approved by the FDA as reflected in the product&#8217;s approved labeling, or off-label uses. The FDA and other agencies actively enforce the laws and regulations prohibiting the promotion of off-label uses. The FDA has issued guidance on the factors that it will consider in determining whether a firm&#8217;s product communication is consistent with the FDA-required labeling for that product, and those factors contain complexity and potential for overlap and misinterpretation. A company that is found to have improperly promoted off-label uses of their products may be subject to significant civil, criminal and administrative penalties.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">48</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The FDA and other regulatory authorities&#8217; policies may change, and additional government regulations may be enacted, that could prevent, limit or delay marketing approval of a product. We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action, either in the United States or abroad. If we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any government investigation of alleged violations of law could require us to expend significant time and resources in response and could generate negative publicity. Any failure to comply with ongoing regulatory requirements may significantly and adversely affect our ability to commercialize and generate revenue from our products. If regulatory sanctions are applied or if regulatory approval is withdrawn, the value of our company and our operating results will be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, if we are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we are not able to maintain regulatory compliance, we may lose any marketing approval that we may have obtained, and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not mean that we will be successful in obtaining and maintaining marketing approval of our current and future product candidates in other jurisdictions.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining marketing approval of our current and future product candidates in one jurisdiction does not guarantee that we will be able to obtain or maintain marketing approval in any other jurisdiction, while a failure or delay in obtaining marketing approval in one jurisdiction may have a negative effect on the marketing approval process in others. For example, even if the FDA grants marketing approval of a product candidate, comparable regulatory authorities in foreign jurisdictions must also approve the manufacturing, marketing and promotion of the product candidate in those countries. Approval procedures vary among jurisdictions and can involve requirements and administrative review periods different from, and greater than, those in the United States, including additional preclinical studies or clinical trials conducted in one jurisdiction may not be accepted by regulatory authorities in other jurisdictions. In many jurisdictions outside the United States, a product candidate must be approved for reimbursement before it can be approved for sale in that jurisdiction. In some cases, the price that we intend to charge for our products is also subject to approval.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also submit marketing applications in other countries. Regulatory authorities in jurisdictions outside of the United States have requirements for approval of product candidates with which we must comply prior to marketing in those jurisdictions. Obtaining foreign marketing approvals and compliance with foreign regulatory requirements could result in significant delays, difficulties and costs for us and could delay or prevent the introduction of our products in certain countries. If we fail to comply with the regulatory requirements in international markets or fail to receive applicable marketing approvals, our target market will be reduced and our ability to realize the full market potential of our product candidates will be harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend on data and our information technology systems, and any failure of these systems could harm our business. Security breaches, loss of data, and other disruptions could compromise sensitive information related to our business or prevent us from accessing critical information and expose us to liability, which could adversely affect our business, results of operations and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We collect and maintain information in digital form that is necessary to conduct our business, and we are dependent on our information technology systems and those of third parties to operate our business. In the ordinary course of our business, we collect, store and transmit large amounts of confidential information, including intellectual property, proprietary business information, personal information, protected health information and data to comply with cGMP and data integrity requirements. It is critical that we do so in a secure manner to maintain data security and data integrity of such information. We have established physical, electronic and organizational measures to safeguard and secure our systems to prevent a data compromise. We have also outsourced elements of our information technology infrastructure, and as a result a number of third-party vendors may or could have access to our confidential information. If we or our vendors fail to comply with applicable data privacy laws, or if the legal mechanisms we or our vendors rely upon for the transfer of personal data are ever deemed inadequate, or if we or our vendors experience a data breach resulting in exposure of personal data subject to the applicable laws, we could be subject to government enforcement actions and significant penalties against us, criminal and civil liability for us and our officers and directors, private litigation or adverse publicity. </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">49</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">The OCR, pursuant to legislation passed in 2021, recently issued guidance on recognized security practices for covered entities and business associates, the OCR indicated that recognized security practices will not be an aggravating factor in OCR investigations, but that implementation of recognized security practices strengthen an organization&#8217;s cybersecurity and regulatory posture, as well as possibly lessening enforcement penalties in a potential regulatory enforcement. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our internal information technology systems and infrastructure, and those of our current and any future collaborators, contractors and consultants and other third parties on which we rely, are vulnerable to damage from computer viruses, malware, natural disasters, terrorism, war, telecommunication and electrical failures, cyber-attacks or cyber-intrusions, phishing, persons inside our organization or persons with access to systems inside our organization. We and our third party service providers regularly defend against, respond to and mitigate risks from data security incidents. The risk of a security breach or disruption or data loss, including by computer hackers, foreign governments and cyber terrorists, has generally increased as the number, intensity and sophistication of attempted attacks and intrusions from around the world have increased. In addition, the prevalent use of mobile devices that access confidential information increases the risk of data security breaches, which could lead to the loss of confidential information or other intellectual property. The costs to us to mitigate network security problems, bugs, viruses, worms, malicious software programs, ransomware and security vulnerabilities could be significant, and while we have implemented security measures to protect our data security and information technology systems, our efforts to address these problems may not be successful, and these problems could result in unexpected interruptions, delays, cessation of service and other harm to our business and our competitive position. If such an event were to occur and cause interruptions in our operations, it could result in a material disruption of our product development programs. For example, the loss of clinical trial data from completed or ongoing or planned clinical trials could result in delays in our regulatory approval efforts and significantly increase our costs to recover or reproduce the data. Likewise, we rely on third parties to conduct clinical trials, and similar events relating to their computer systems could also have a material adverse effect on our business. Moreover, if a computer security breach affects our systems or results in the unauthorized release of personally identifiable information, our reputation could be materially damaged. In addition, such a breach may require notification to governmental agencies, the media or individuals pursuant to various federal and state privacy and security laws, if applicable, including HIPAA and its implementing regulations, as well as regulations promulgated by the Federal Trade Commission and state breach notification laws. We would also be exposed to a risk of loss or litigation and potential liability, which could materially adversely affect our business, results of operations and financial condition. We may need to expend significant resources and make significant capital investment to protect against security breaches or to mitigate the impact of any such breaches.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The successful commercialization of our product candidates will depend in part on the extent to which third-party payors, including governmental authorities and private health insurers, provide coverage and adequate reimbursement levels, as well as implement pricing policies favorable for our product candidates. Failure to obtain or maintain coverage and adequate reimbursement for our product candidates, if approved, could limit our ability to market those products and decrease our ability to generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The availability of coverage and adequacy of reimbursement by third-party payors, including managed care plans, governmental healthcare programs, such as Medicare and Medicaid and private health insurers is essential for most patients to be able to afford medical services and pharmaceutical products such as our product candidates that receive FDA approval. Our ability to achieve acceptable levels of coverage and reimbursement for our products or procedures using our products by third-party payors will have an effect on our ability to successfully commercialize our product candidates. Obtaining coverage and adequate reimbursement for our products may be particularly difficult because of the higher prices often associated with drugs administered under the supervision of a physician. Separate reimbursement for the product itself or the treatment or procedure in which our product is used may not be available. A decision by a third-party payor not to cover or not to separately reimburse for our products or procedures using our products could reduce physician utilization of our products once approved. Assuming there is coverage for our product candidates, or procedures using our product candidates by a third-party payor, the resulting reimbursement payment rates may not be adequate or may require co-payments that patients find unacceptably high. We cannot be sure that coverage and reimbursement in the United States, the European Union or elsewhere will be available for our current or future product candidates, or for any procedures using such product candidates, and any reimbursement that may become available may not be adequate or may be decreased or eliminated in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our ability to successfully commercialize any product candidate, whether as a single agent or combination therapy, will also depend in part on the extent to which coverage and reimbursement for these product candidates and related treatments will be available from third-party payors. Third-party payors decide which medications they will pay </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">50</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">for and establish reimbursement levels. It is difficult to predict at this time what government authorities and third-party payors will decide with respect to coverage and reimbursement for our current and future product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, third-party payors are increasingly challenging prices charged for pharmaceutical and biological products and services, and many third-party payors may refuse to provide coverage and reimbursement for particular drugs or biologics when an equivalent generic drug, biosimilar or a less expensive therapy is available. It is possible that a third-party payor may consider our product candidates as substitutable and only offer to reimburse patients for the less expensive product. Even if we show improved efficacy or improved convenience of administration with our product candidates, pricing of existing third-party therapeutics may limit the amount we will be able to charge for our product candidates. These third-party payors may deny or revoke the reimbursement status of our product candidates, if approved, or establish prices for our product candidates at levels that are too low to enable us to realize an appropriate return on our investment. If reimbursement is not available or is available only at limited levels, we may not be able to successfully commercialize our product candidates and may not be able to obtain a satisfactory financial return on our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is significant uncertainty related to the insurance coverage and reimbursement of newly-approved products, especially novel products like our immunomedicines. To date, no regulatory authority has granted approval for an immunomedicine targeting the LAIR pathway or B7-H4. The Medicare and Medicaid programs are increasingly used as models in the United States for how private third-party payors and other governmental payors develop their coverage and reimbursement policies for drugs and biologics. Some third-party payors may require pre-approval of coverage for new or innovative devices or drug therapies before they will reimburse healthcare providers who use such therapies. Moreover, eligibility for reimbursement does not imply that any drug will be reimbursed in all cases or at a rate that covers our costs, including research, development, manufacture, sale and distribution. Interim reimbursement levels for new drugs, if applicable, may also not be sufficient to cover our costs and may not be made permanent. We cannot predict at this time what third-party payors will decide with respect to the coverage and reimbursement for our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">No uniform policy for coverage and reimbursement for products exist among third-party payors in the United States. Therefore, coverage and reimbursement for products can differ significantly from payor to payor. As a result, the coverage determination process is often a time-consuming and costly process that may require us to provide scientific and clinical support for the use of our product candidates to each payor separately, with no assurance that coverage and adequate reimbursement will be applied consistently or obtained in the first instance. Furthermore, rules and regulations regarding reimbursement can change, in some cases on short notice, and we believe that changes in these rules and regulations are likely.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, if we or our collaborators develop companion diagnostic tests for use with our product candidates, we, or our collaborators, will be required to obtain coverage and reimbursement for these tests separate and apart from the coverage and reimbursement we seek for our product candidates, once approved. While we and our collaborators have not yet developed any companion diagnostic test for our product candidates, if we or our collaborators do, there is significant uncertainty regarding the ability to obtain coverage and adequate reimbursement for the same reasons applicable to our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, a primary trend in the healthcare industry in the United States and elsewhere is cost containment. Government authorities and third-party payors have attempted to control costs by limiting coverage and the amount of reimbursement for particular medications. Increasingly, the third-party payors who reimburse patients or healthcare providers, such as government and private insurance plans, are requiring that drug companies provide them with predetermined discounts from list prices and are seeking to reduce the prices charged or the amounts reimbursed for medical products. We cannot be sure that coverage and reimbursement will be available for any drug that we commercialize and, if coverage and reimbursement are available, we cannot be sure as to the level of reimbursement. Reimbursement may impact the demand for, or the price of, any product candidate for which we obtain marketing approval. If reimbursement is not available or is available only to limited levels, we may not be able to successfully commercialize any product candidate for which we obtain marketing approval. We expect to experience pricing pressures in connection with the sale of our product candidates due to the trend toward managed health care, the increasing influence of health maintenance organizations and additional legislative changes. The downward pressure on healthcare costs in general, particularly prescription drugs and biologics and surgical procedures and other treatments, has become intense. As a result, increasingly high barriers are being erected to the entry of new products.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">51</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Enacted healthcare legislation, changes in healthcare law and implementation of regulations, as well as changes in healthcare policy, may increase the difficulty and cost for us to commercialize our product candidates, may impact our business in ways that we cannot currently predict, could affect the prices we may set, and could have a material adverse effect on our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the United States, there have been and continue to be a number of legislative initiatives to contain healthcare costs. In particular, there have been and continue to be a number of initiatives at the U.S. federal and state levels that seek to reduce healthcare costs and improve the quality of healthcare. For example, the ACA substantially changed the way healthcare is financed by both governmental and private insurers, and significantly impacted the U.S. pharmaceutical industry. The ACA, among other things, subjects biologics to potential competition by lower-cost biosimilars, addresses a methodology by which rebates owed by manufacturers under the MDRP are calculated for drugs that are inhaled, infused, instilled, implanted or injected, increases the minimum Medicaid rebates owed by manufacturers under the MDRP and extends the rebate program to individuals enrolled in Medicaid managed care organizations, and establishes annual fees and taxes on manufacturers of certain branded prescription drugs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The ACA and certain of its provisions have been subject to judicial challenges as well as legislative and regulatory efforts to repeal or replace them or to alter their interpretation or implementation. For example, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed comprehensive repeal legislation, bills affecting the implementation of certain taxes under the ACA have been signed into law. The Tax Act included a provision that repealed the tax-based shared responsibility payment imposed by the ACA on certain individuals who fail to maintain qualifying health coverage for all or part of a year that is commonly referred to as the &#8220;individual mandate.&#8221; The Bipartisan Budget Act of 2018, among other things, amended the ACA to increase the point-of-sale discounts that manufacturers must agree to offer under the Medicare Part D coverage discount program from 50% to 70% off negotiated prices of applicable brand drugs to eligible beneficiaries during their coverage gap period, as a condition for the manufacturer&#8217;s outpatient drugs to be covered under Medicare Part D. Also, in 2018, CMS issued final rules permitting further collections and payments to and from certain ACA qualified health plans and health insurance issuers under the ACA risk adjustment program in response to the outcome of federal district court litigation regarding the method CMS uses to determine this risk adjustment. The Further Consolidated Appropriations Act of 2020 fully repealed the ACA&#8217;s &#8220;Cadillac Tax&#8221; on certain high cost employer-sponsored insurance plans and, effective in 2021, the annual fee imposed on certain health insurance providers based on market share. On January 28, 2021, President Biden issued an Executive Order to initiate a special enrollment period from February 15, 2021 through August 15, 2021 for purposes of obtaining health insurance coverage through the ACA marketplace. The Executive Order also instructed certain governmental agencies to review and reconsider their existing policies and rules that limit access to healthcare, including among others, policies that create barriers to obtaining access to health insurance coverage through the ACA marketplaces. Most recently, on March 11, 2021, Congress enacted the American Rescue Plan Act of 2021, which included among its provisions a sunset of the ACA&#8217;s cap on pharmaceutical manufacturers&#8217; rebate liability under the Medicaid Drug Rebate Program. Under the ACA, manufacturers&#8217; rebate liability was capped at 100% of the average manufacturer price for a covered outpatient drug. Effective January 1, 2024, manufacturers&#8217; MDRP rebate liability will no longer be capped, potentially resulting in a manufacturer paying more in MDRP rebates than it receives on the sale of certain covered outpatient drugs. The American Rescue Plan Act also temporarily increased premium tax credit assistance for individuals eligible for subsidies under the ACA for 2021 and 2022 and removed the 400% federal poverty level limit that otherwise applies for purposes of eligibility to receive premium tax credits. In the future, there may be additional challenges and/or amendments to the ACA. It remains to be seen precisely what any new legislation will provide, when or if it will be enacted, and what impact it will have on the availability and cost of healthcare items and services, including drug products.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In December 2018, the United States District Court for the Northern District of Texas ruled that the individual mandate is (i) unconstitutional as a result of the associated tax penalty being repealed by Congress as part of the Tax Act and (ii) not severable from the rest of the ACA, and that as a result the entire ACA is invalid. In December 2019, the U.S. Court of Appeals for the Fifth Circuit affirmed the district court&#8217;s decision that the individual mandate is unconstitutional but remanded the case to the district court to reconsider the severability question. The Supreme Court of the United States granted certiorari on March 2, 2020 and heard oral argument on November 10, 2020. On June 17, 2021, the Supreme Court dismissed the lawsuit without ruling on the merits of the states&#8217; constitutionality arguments.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Other healthcare-related legislative and regulatory initiatives and reforms have been proposed and adopted in the United States since the ACA was enacted. In August 2011, the Budget Control Act of 2011, among other things, created measures for automatic spending reductions under certain circumstances. A Joint Select Committee on Deficit Reduction tasked with recommending a targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021 was unable </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">52</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">to reach required goals, thereby triggering the legislation&#8217;s automatic reductions. In conjunction with the operation of subsequently enacted law, this has resulted in aggregate reductions of Medicare payments to providers of, on average, 2% per fiscal year into 2031, with the exception of a temporary suspension from May 1, 2020 through March 31, 2022 and a subsequent reduction to 1% from April 1, 2022 until June 30, 2022, unless Congress takes additional action. The American Taxpayer Relief Act of 2012, which was signed into law in January 2013, among other things, further reduced Medicare payments to several types of providers and increased the statute of limitations period for the government to recover overpayments to providers from three to five years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Moreover, payment methodologies may be subject to changes in healthcare legislation and regulatory initiatives. For example, beginning in 2018, CMS has maintained a reduced rate of payment under the Medicare outpatient prospective payment system and ambulatory surgical center payment system for certain separately payable drugs or biologics acquired under the 340B Drug Pricing Program, and a CMS indicated in a recent rule that it will continue to consider setting an even lower payment rate based on collected hospital survey data. We expect that additional state and federal healthcare reform measures will be adopted in the future, any of which could limit the amounts that federal and state governments will pay for healthcare products and services, which could result in reduced demand for any product candidate we develop or complementary or companion diagnostics or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">CMS may develop new payment and delivery models, such as bundled payment models. In addition, there has been heightened governmental scrutiny over the manner in which manufacturers set prices for their marketed products, which has resulted in several U.S. Congressional inquiries and proposed and enacted federal and state legislation designed to, among other things, bring more transparency to drug pricing, reduce the cost of prescription drugs under government payor programs, and review the relationship between pricing and manufacturer patient programs; and reform government program reimbursement methodologies for drugs. . For example, included in the Consolidated Appropriations Act, 2021 were several drug price reporting and transparency measures, such as a new requirement for certain Medicare plans to develop tools to display Medicare Part D prescription drug benefit information in real time and for group and health insurance issuers to report information on pharmacy benefit and drug costs to the Secretaries of the Departments of Health and Human Services, Labor and the Treasury. Additionally, in August 2022, President Biden signed into law the Inflation Reduction Act of 2022, which implements substantial changes to the Medicare program, including drug pricing reforms and the creation of new Medicare inflation rebates. &#160;Namely, the IRA imposes inflation rebates on drug manufacturers for products reimbursed under Medicare Parts B and D if the prices of those products increase faster than inflation; implements changes to the Medicare Part D benefit that, beginning in 2025, will cap beneficiary annual out-of-pocket spending at $2,000, while imposing new discount obligations for pharmaceutical manufacturers; and, beginning in 2026, establishes a &#8220;maximum fair price&#8221; for a fixed number of high expenditure pharmaceutical and biological products covered under Medicare Parts B and D following a price negotiation process with CMS. On October 14, 2022 President Biden issued an Executive Order on Lowering Prescription Drug Costs for Americans, which instructed the Secretary of the Department of Health and Human Services to consider whether to select for testing by the CMS Innovation Center new health care payment and delivery models that would lower drug costs and promote access to innovative drug therapies for beneficiaries enrolled in the Medicare and Medicaid programs. Most recently, on February 14, 2023, the Department of Health and Human Services issued a report in response to the October 14, 2022 Executive Order, which, among other things, selects three potential drug affordability and accessibility models to be tested by the CMS Innovation Center. &#160;Specifically, the report addresses: (1) a model that would allow Part D Sponsors to establish a &#8220;high-value drug list&#8221; setting the maximum co-payment amount for certain common generic drugs at $2; (2) a Medicaid-focused model that would establish a partnership between CMS, manufacturers, and state Medicaid agencies that would result in multi-state outcomes-based agreements or certain cell and gene therapy drugs; and (3) a model that would adjust Medicare Part B payment amounts for Accelerated Approval Program drugs to advance the developments of novel treatments. We expect that additional U.S. federal healthcare reform measures will be adopted in the future, any of which could limit the extent to which the U.S. federal government covers particular healthcare products and services and could limit the amounts that the U.S. federal government will pay for healthcare products and services. This could result in reduced demand for our product candidates or additional pricing pressures.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Individual states in the United States have also increasingly passed legislation and implemented regulations designed to control pharmaceutical and biological product pricing, including price or patient reimbursement limitations, discounts, restrictions on certain product access and marketing cost disclosure and transparency measures, and, in some cases, designed to encourage importation from other countries and bulk purchasing. Legally mandated price controls on payment amounts by third-party payors or other restrictions on coverage or access could harm our business, results of operations, financial condition and prospects. In addition, regional healthcare authorities and individual hospitals are increasingly using bidding procedures to determine what pharmaceutical products and which suppliers will be included in </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">53</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">their prescription drug and other healthcare programs. This could reduce the ultimate demand for our product candidates that we successfully commercialize or put pressure on our product pricing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Additionally, in May 2018, the Right to Try Act was signed into law. The law, among other things, provides a federal framework for certain patients to access certain investigational new drug products that have completed a Phase 1 clinical trial and that are undergoing investigation for FDA approval. Under certain circumstances, eligible patients can seek treatment without enrolling in clinical trials and without obtaining FDA permission under the FDA expanded access program. There is no obligation for a pharmaceutical manufacturer to make its drug products available to eligible patients as a result of the Right to Try Act.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot predict the likelihood, nature or extent of government regulation that may arise from future legislation or administrative action in the United States. If we or any third parties we may engage are slow or unable to adapt to changes in existing requirements or the adoption of new requirements or policies, or if we or such third parties are not able to maintain regulatory compliance, our product candidates may lose any regulatory approval that may have been obtained and we may not achieve or sustain profitability.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our relationships with customers, third-party payors and others may be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm, administrative burdens and diminished profits and future earnings.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Healthcare providers, physicians and third-party payors in the United States and elsewhere will play a primary role in the recommendation and prescription of any product candidates for which we obtain marketing approval. Our current and future arrangements with healthcare providers, third-party payors, customers, and others may expose us to broadly applicable fraud and abuse and other healthcare laws and regulations, which may constrain the business or financial arrangements and relationships through which we research, as well as sell, market and distribute any products for which we obtain marketing approval. The applicable federal and state healthcare laws and regulations that may affect our ability to operate include, but are not limited to, those described in &#8220;Business&#8212;Government Regulation&#8212;Healthcare Regulation.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Because of the breadth of these laws and the narrowness of the statutory exceptions and regulatory safe harbors available under such laws, it is possible that some of our business activities could be subject to challenge under one or more of such laws. The scope and enforcement of each of these laws is uncertain and subject to rapid change in the current environment of healthcare reform. Federal and state enforcement bodies have recently increased their scrutiny of interactions between healthcare companies and healthcare providers, which has led to a number of investigations, prosecutions, convictions and settlements in the healthcare industry. Ensuring that our business arrangements with third parties comply with applicable healthcare laws, as well as responding to investigations by government authorities, can be time and resource consuming and can divert management&#8217;s attention from the business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our operations are found to be in violation of any of the laws described above or any other government regulations that apply to us, we may be subject to penalties, including civil, criminal and administrative penalties, damages, fines, disgorgement, individual imprisonment, possible exclusion from participation in federal and state funded healthcare programs, contractual damages and the curtailment or restricting of our operations, as well as additional reporting obligations and oversight if we become subject to a corporate integrity agreement or other agreement to resolve allegations of non-compliance with these laws. Further, if the physicians or other providers or entities with whom we expect to do business are found not to be in compliance with applicable laws, they may be subject to criminal, civil and administrative sanctions, including exclusion from government funded healthcare programs. In addition, the approval and commercialization of any product candidate we develop outside the United States will also likely subject us to foreign equivalents of the healthcare laws mentioned above, among other foreign laws. All of these could harm our ability to operate our business and our financial results.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to certain U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations. We can face serious consequences for violations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Among other matters, U.S. and foreign anti-corruption, anti-money laundering, export control, sanctions and other trade laws and regulations, which are collectively referred to as Trade Laws, prohibit companies and their employees, agents, clinical research organizations, legal counsel, accountants, consultants, contractors and other partners from authorizing, promising, offering, providing, soliciting, or receiving directly or indirectly, corrupt or improper payments or </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">54</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">anything else of value to or from recipients in the public or private sector. Violations of Trade Laws can result in substantial criminal fines and civil penalties, imprisonment, the loss of trade privileges, debarment, tax reassessments, breach of contract and fraud litigation, reputational harm and other consequences.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our business is heavily regulated and therefore involves significant interaction with public officials. We have direct or indirect interactions with officials and employees of government agencies or government-affiliated hospitals, universities and other organizations. We also expect our non-U.S. activities to increase in time. Additionally, in many other countries, the health care providers who prescribe pharmaceuticals are employed by their government, and the purchasers of pharmaceuticals are government entities; therefore, our dealings with these prescribers and purchasers are subject to regulation under the U.S. Foreign Corrupt Practices Act of 1977, as amended, or &#8220;FCPA&#8221;. We plan to engage third parties for clinical trials or to obtain necessary permits, licenses, patent registrations, and other regulatory approvals and we can be held liable for the corrupt or other illegal activities of our personnel, agents, or partners, even if we do not explicitly authorize or have prior knowledge of such activities. In particular, our operations will be subject to FCPA, which prohibits, among other things, U.S. companies and their employees and agents from authorizing, promising, offering, or providing, directly or indirectly, corrupt or improper payments or anything else of value to foreign government officials, employees of public international organizations and foreign government-owned or affiliated entities, candidates for foreign political office, and foreign political parties or officials thereof. Recently, the SEC and Department of Justice have increased their FCPA enforcement activities with respect to biotechnology and pharmaceutical companies. There is no certainty that all of our employees, agents, suppliers, manufacturers, contractors, or collaborators, or those of our affiliates, will comply with all applicable laws and regulations, particularly given the high level of complexity of these laws. Violations of these laws and regulations could result in fines, criminal sanctions against us, our officers, or our employees, the closing down of facilities, including those of our suppliers and manufacturers, requirements to obtain export licenses, cessation of business activities in sanctioned countries, implementation of compliance programs and prohibitions on the conduct of our business. Any such violations could also result in prohibitions on our ability to offer our products in one or more countries as well as difficulties in manufacturing or continuing to develop our products, and could materially damage our reputation, our brand, our international expansion efforts, our ability to attract and retain employees and our business, prospects, operating results and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to comply with environmental, health and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to numerous environmental, health and safety laws and regulations, including those governing laboratory procedures and the handling, use, storage, treatment and disposal of hazardous materials and wastes. Our operations involve the use of hazardous and flammable materials, including chemicals and biological materials. Our operations also produce hazardous waste products. We generally contract with third parties for the disposal of these materials and wastes. We cannot eliminate the risk of contamination or injury from these materials. In the event of contamination or injury resulting from our use of hazardous materials, we could be held liable for any resulting damages, and any liability could exceed our resources. We also could incur significant costs associated with civil or criminal fines and penalties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we maintain workers&#8217; compensation insurance to cover us for costs and expenses, we may incur due to injuries to our employees resulting from the use of hazardous materials, this insurance may not provide adequate coverage against potential liabilities. We do not maintain insurance for environmental liability or toxic tort claims that may be asserted against us in connection with our storage or disposal of biological or hazardous materials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Risks Related to Manufacturing</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Given our limited operating history, our manufacturing experience as an organization and with our manufacturing facility is limited.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Manufacturing is a critical component of our approach to developing immunomedicines and we have invested significantly in our manufacturing facility. We currently manufacture our product candidates for preclinical and clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Manufacturing drugs for clinical trials and for commercial sale is subject to oversight by the FDA to ensure compliance with cGMP and by other regulatory authorities under other laws, regulations and standards. We cannot assure you that we can successfully manufacture our products in compliance with cGMP and with any other applicable laws, </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">55</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">regulations and standards in sufficient quantities for clinical trials or for commercial sale, or in a timely or economical manner.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our manufacturing facility requires specialized personnel and is expensive to operate and maintain. Validation is an ongoing process that must be maintained to allow us to manufacture under cGMP guidelines. We cannot guarantee that our facility will remain in compliance with cGMP.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Manufacturing pharmaceutical products is a highly complex process in which a variety of difficulties may arise from time to time. We are currently the sole manufacturer of NC410, NC762 and NC525 and if anything were to interfere with our continuing manufacturing operations in our facility, it could materially adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we fail to develop sufficient manufacturing capacity and experience, whether internally or with a third party, or fail to manufacture our product candidates economically or on reasonable scale or volumes, or in accordance with cGMP, our development programs and commercialization of any approved products will be materially adversely affected. This may result in delays in commencing or continuing our clinical trials for NC410, NC762 or NC525. Any such delays could materially adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be unable to successfully scale-up manufacturing of our product candidates in sufficient quality and quantity, which would delay or prevent us from developing and, if approved, commercializing our product candidates<span style="font-style:normal;font-weight:normal;">.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In order to conduct clinical trials of our product candidates, we will need to manufacture them in large quantities. Currently, our product candidates are manufactured in small quantities for use in various preclinical studies and our ongoing Phase 1/2 clinical trials of NC410 and NC762 and Phase 1 clinical trial of NC525. We intend to expand our manufacturing capacity, which will require us to incur significant expenses. If one or more of our product candidates progress to late-stage development, we may incur additional significant expenses in the further expansion or construction of manufacturing facilities and increases in personnel in order to manufacture product candidates in sufficient quantities. We cannot assure you that we will be able to successfully manufacture product candidates at a larger scale in a timely or economical manner, or at all. If we are unable to successfully increase our manufacturing scale or capacity, the development, testing and clinical trials of our current or future product candidates may be delayed or infeasible, and regulatory approval or commercial launch of any resulting product may be delayed or not obtained, which could significantly harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The loss of our third-party manufacturing partners or our, or our partners&#8217;, failure to comply with applicable regulatory requirements or to supply sufficient quantities at acceptable quality levels or prices, or at all, would materially and adversely affect our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Although we currently manufacture our product candidates for preclinical and clinical trials, certain elements of manufacturing, including Master Cell Bank manufacturing and fill-finish services, take place at qualified third-party contract manufacturing organizations, or CMOs. If approved, commercial supply of NC410, NC762, NC525 and any future product candidates may be manufactured at a CMO or CMOs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The facilities used by our CMOs to manufacture our product candidates are subject to various regulatory requirements and may be subject to the inspection of the FDA or other regulatory authorities. We do not control the manufacturing process at our CMOs and are completely dependent on them for compliance with current regulatory requirements. If we or our CMOs cannot successfully manufacture material that conforms to our specifications and the strict regulatory requirements of the FDA or comparable regulatory authorities in foreign jurisdictions, we may not be able to rely on their manufacturing facilities for manufacturing elements of our product candidates. In addition, we have limited control over the ability of our CMOs to maintain adequate quality control, quality assurance and qualified personnel. If the FDA or a comparable foreign regulatory authority finds our facilities or those of our CMOs inadequate for manufacturing our product candidates or if such facilities are subject to enforcement action in the future or are otherwise inadequate, we may need to find alternative manufacturing facilities, which would significantly impact our ability to develop, obtain regulatory approval for or market our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Additionally, our CMOs may experience manufacturing difficulties due to resource constraints or as a result of labor disputes or unstable political environments. If our CMOs were to encounter any of these difficulties, our ability to </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">56</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">provide our product candidate to patients in clinical trials, or to provide product for the treatment of patients once approved, would be jeopardized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are subject to multiple manufacturing risks, any of which could substantially increase our costs and limit supply of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The process of manufacturing immunomedicines, including our product candidates, is complex, time-consuming, highly regulated and subject to several risks, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">product loss during the manufacturing process, including loss caused by contamination, equipment failure or improper installation or operation of equipment, or operator error. Even minor deviations from normal manufacturing processes could result in reduced production yields, product defects and other supply disruptions. If microbial, viral or other contaminations are discovered in our products or in the manufacturing facilities in which our products are made, such manufacturing facilities may need to be closed for an extended period of time to investigate and remedy the contamination;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor and raw material shortages, including due to restrictions on the movement of people or goods, natural disasters, public health emergencies, power failures, other business disruptions and numerous other factors; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any adverse developments affecting manufacturing operations for our products may result in shipment delays, inventory shortages, lot failures, product withdrawals or recalls, or other interruptions in the supply of our products. We may also have to take inventory write-offs and incur other charges and expenses for products that fail to meet specifications, undertake costly remediation efforts or seek more costly manufacturing alternatives.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also make changes to our manufacturing processes at various points during development, for a number of reasons, such as controlling costs, achieving scale, decreasing processing time, increasing manufacturing success rate or other reasons. Such changes carry the risk that they will not achieve their intended objectives, and any of these changes could cause our product candidates to perform differently and affect the results of our ongoing or future clinical trials. In some circumstances, changes in the manufacturing process may require us to perform ex vivo comparability studies and to collect additional data from patients prior to undertaking more advanced clinical trials. For instance, changes in our process during the course of clinical development may require us to show the comparability of the product used in earlier clinical phases or at earlier portions of a trial to the product used in later clinical phases or later portions of the trial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We depend on third-party suppliers for key materials used in our manufacturing processes, and the loss of these third-party suppliers or their inability to supply us with adequate materials, or rising prices due to inflation, could harm our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We rely on third-party suppliers for certain materials and components required for the production of our product candidates. Our dependence on these third-party suppliers and the challenges we may face in obtaining adequate supplies of materials involve several risks, including limited control over pricing, availability, and quality and delivery schedules. As a small company, our negotiation leverage is limited, and we are likely to get lower priority than our competitors that are larger than we are<span style="white-space:pre-wrap;">. In addition, COVID-19, the war in Russia and Ukraine, and resulting economic conditions have disrupted global supply chains, including pharmaceutical and medical supply chains. We cannot be certain that our suppliers will continue to provide us with the quantities of the raw materials that we require or satisfy our anticipated specifications and quality requirements whether due to our size, COVID-19, or otherwise.  </span>Any supply interruption in limited or sole sourced raw materials could materially harm our ability to manufacture our product candidates until a new source of supply, if any, could be identified and qualified. We may be unable to find a sufficient alternative supply channel in a reasonable time or on commercially reasonable terms. Any performance failure on the part of our suppliers could delay the development and potential commercialization of our product candidates, including limiting supplies necessary for clinical trials and regulatory approvals, which would have a material adverse effect on our business. In addition, the current inflationary period may result in higher prices from our suppliers, which could materially increase our costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">57</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As product candidates proceed through preclinical studies to late-stage clinical trials towards potential approval and commercialization, it is common that various aspects of the development program, such as manufacturing methods and formulation, are altered along the way in an effort to optimize processes and results. Such changes carry the risk that they will not achieve these intended objectives. Any of these changes could cause our product candidates to perform differently and affect the results of planned clinical trials or other future clinical trials conducted with the materials manufactured using altered processes. Such changes may also require additional testing, FDA notification or FDA approval. This could delay completion of clinical trials, require the conduct of bridging clinical trials or the repetition of one or more clinical trials, increase clinical trial costs, delay approval of our product candidates and jeopardize our ability to commence sales and generate revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Risks Related to Intellectual Property</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have filed patent applications for our product candidates, but no patent has yet issued from these applications. If we are unable to obtain and maintain patent protection for our product candidates, or if the scope of the patent protection obtained is not sufficiently broad or robust, our competitors could develop and commercialize products similar or identical to ours, and our ability to successfully commercialize our product candidates may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our success depends, in large part, on our ability to obtain and maintain patent protection in the United States and other countries with respect to our product candidates. We and our licensors have sought, and intend to seek, to protect our proprietary position by filing patent applications in the United States and abroad related to our product candidates and technology that are important to our business. To date, only a limited number of patents have issued from our patent applications. The patent position of biotechnology and pharmaceutical companies generally is highly uncertain, involves complex legal and factual questions and has, in recent years, been the subject of much litigation. As a result, the issuance, scope, validity, enforceability and commercial value of our patent rights are highly uncertain. Our pending and future patent applications may not result in patents being issued that protect our technology or product candidates or that effectively prevent others from commercializing competitive technologies and product candidates. Because patent applications in the United States and most other countries are confidential for a period of time after filing, and some remain so until issued, we cannot be certain that we or our licensors were the first to file&#160;a patent application relating to any particular aspect of a product candidate. Furthermore, if third parties have filed such patent applications, we may challenge their ownership, for example in a derivation proceeding before the USPTO, to determine who has the right to the claimed subject matter in the applications. Similarly, if our patent applications are challenged in a derivation proceeding, the USPTO may hold that a third-party is entitled to certain patent ownership rights instead of us. We may then be forced to seek a license from the third party that may not be available on commercially favorable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The patent prosecution process is expensive, time-consuming and complex, and we may not be able to file, prosecute, maintain, enforce or license all necessary or desirable patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Even if the patent applications we license or own do issue as patents, they may not issue in a form that will provide us with any meaningful protection, prevent competitors or other third parties from competing with us or otherwise provide us with any competitive advantage. Our competitors or other third parties may be able to circumvent our patents by developing similar or alternative technologies or products that do not infringe our patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are party to a license agreement with Yale University under which we acquired rights to intellectual property related to certain of our product candidates. If we breach our obligations under this agreement, the agreement could be terminated, which would adversely affect our business and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a party to a license agreement with Yale pursuant to which we in-license patents and technology for certain of our product candidates. This license imposes various diligence, milestone payment, royalty, insurance and other obligations on us. If we fail to comply with these and other obligations or otherwise materially breach this license agreement, Yale may have the right to terminate the license. If this agreement is terminated, we may not be able to develop, manufacture, market or sell the product candidates or products covered by the agreement, or we would have to negotiate a new or reinstated agreement, which may not be available to us on equally favorable terms, or at all.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">58</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our intellectual property agreements with third parties may be subject to disagreements over contract interpretation, which could narrow the scope of our rights to the relevant intellectual property or technology or increase our financial or other obligations to our licensors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Certain provisions in our intellectual property agreements may be susceptible to multiple interpretations. The resolution of any contract interpretation disagreement that may arise could affect the scope of our rights to the relevant intellectual property or technology or affect financial or other obligations under the relevant agreement, either of which could have a material adverse effect on our business, financial condition, results of operations and prospects. Moreover, if disputes over intellectual property that we have licensed prevent or impair our ability to maintain our current licensing arrangements on commercially acceptable terms, we may be unable to successfully develop and commercialize the affected product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by government patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Periodic maintenance fees, renewal fees, annuity fees and various other government fees on patents or applications will be due to be paid to the USPTO and various government patent agencies outside of the United States over the lifetime of our licensed patents or applications and any patent rights we own or may own in the future. We rely, in part, on our outside counsel or our licensing partners to pay these fees due to the USPTO and to non-U.S. patent agencies. The USPTO and various non-U.S. government patent agencies require compliance with several procedural, documentary, fee payment and other similar provisions during the patent application process. In many cases, an inadvertent lapse can be cured by payment of a late fee or by other means in accordance with the applicable rules. There are situations, however, in which non-compliance can result in abandonment or lapse of the patent or patent application, resulting in partial or complete loss of patent rights in the relevant jurisdiction. In such an event, potential competitors might be able to enter the market and this circumstance could have a material adverse effect on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may not be able to protect our intellectual property rights throughout the world.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Filing, prosecuting and enforcing patents on product candidates in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States are and could remain less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may be less likely to be able to prevent third parties from infringing our patents in all countries outside the United States, or from selling or importing products that infringe our patents in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and, further, may export otherwise infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many countries have compulsory licensing laws under which a patent owner may be compelled to grant licenses to third parties. In addition, many countries limit the enforceability of patents against government agencies or government contractors. In these countries, the patent owner may have limited remedies, which could materially diminish the value of such patent. If we or any of our licensors is forced to grant a license to third parties with respect to any patents relevant to our business, our competitive position may be impaired and our business, financial condition, results of operations and prospects may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Changes in patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Changes in either the patent laws or interpretation of the patent laws in the United States could increase the uncertainties and costs surrounding the prosecution of patent applications and the enforcement or defense of issued patents. Assuming that other requirements for patentability were met, prior to March 2013, in the United States, the first to invent the claimed invention was entitled to the patent, while outside the United States, the first to file&#160;a patent application was entitled to the patent. After March 2013, under the Leahy-Smith America Invents Act, or the &#8220;America Invents Act&#8221;, the United States transitioned to a first inventor to file system in which, assuming that other requirements for patentability are met, the first inventor to file&#160;a patent application will be entitled to the patent on an invention regardless of whether a third </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">59</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">party was the first to invent the claimed invention. The America Invents Act also included a number of significant changes that affected the way patent applications are prosecuted and also may affect patent litigation. These include allowing third-party submission of prior art to the USPTO during patent prosecution and additional procedures to attack the validity or ownership of a patent by USPTO administered post-grant proceedings, including post-grant review, <i style="font-style:italic;">inter partes</i> review and derivation proceedings. Additional changes in patent law could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the patent positions of companies in the development and commercialization of biologics and pharmaceuticals are particularly uncertain. Recent rulings from the U.S. Court of Appeals for the Federal Circuit and the U.S. Supreme Court have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. This combination of events has created uncertainty with respect to the validity and enforceability of patents. Depending on future actions by the U.S. Congress, the federal courts and the USPTO, the laws and regulations governing patents could change in unpredictable ways that could have a material adverse effect on our existing patent portfolio and our ability to protect and enforce our intellectual property in the future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may become involved in lawsuits to protect or enforce our intellectual property, which could be expensive, time-consuming and unsuccessful.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Competitors may infringe our patents or the patents of our licensors, or we may be required to defend against claims of infringement. Countering infringement or unauthorized use claims or defending against claims of infringement can be expensive and time-consuming. Even if resolved in our favor, litigation or other legal proceedings relating to intellectual property claims may cause us to incur significant expenses and could distract our technical and management personnel from their normal responsibilities. In addition, there could be public announcements of the results of hearings, motions or other interim proceedings or developments, and if securities analysts or investors perceive these results to be negative, it could have a substantial adverse effect on the price of our common stock. Such litigation or proceedings could substantially increase our operating losses and reduce the resources available for development activities or any future marketing, sales or distribution activities. We may not have sufficient financial or other resources to adequately conduct such litigation or proceedings. Some of our competitors may be able to sustain the costs of such litigation or proceedings more effectively than we can because of their greater financial resources and more mature and developed intellectual property portfolios. Uncertainties resulting from the initiation and continuation of patent litigation or other proceedings could have a material adverse effect on our ability to compete in the marketplace.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets and other intellectual property, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we own, develop or license.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Issued patents covering our product candidates could be found invalid or unenforceable if challenged in court. We may not be able to protect our trade secrets in court.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">If we or one of our licensing partners initiate legal proceedings against a third party to enforce any patent that is issued covering one of our product candidates, the defendant could counterclaim that the patent covering our product candidate is invalid or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, written description or non-enablement. In addition, patent validity challenges may, under certain circumstances, be based upon non-statutory obviousness-type double patenting, which, if successful, could result in a finding that the claims are invalid for obviousness-type double patenting or the loss of patent term, including a patent term adjustment granted by the USPTO, if a terminal disclaimer is filed to obviate a finding of obviousness-type double patenting. Grounds for an unenforceability assertion could be an allegation that </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">60</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">someone connected with prosecution of the patent withheld information material to patentability from the USPTO, or made a misleading statement, during prosecution. Third parties also may raise similar claims before administrative bodies in the United States or abroad, even outside the context of litigation. Such mechanisms include re-examination, post grant review, <i style="font-style:italic;">inter partes</i> review and equivalent proceedings in foreign jurisdictions. Such proceedings could result in the revocation or cancellation of or amendment to our patents in such a way that they no longer cover our product candidates. The outcome following legal assertions of invalidity and unenforceability is unpredictable. We cannot be certain that there is no invalidating prior art of which the patent examiner and we or our licensing partners were unaware during prosecution. If a defendant were to prevail on a legal assertion of invalidity or unenforceability, we could lose part, and perhaps all, of the patent protection on one or more of our product candidates. Such a loss of patent protection could have a material adverse impact on our business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our product candidate discovery and development processes that involve proprietary know-how, information or technology that is not covered by patents, including portions of our FIND-IO platform. However, trade secrets can be difficult to protect, and some courts inside and outside the United States are less willing or unwilling to protect trade secrets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Third parties may initiate legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial success depends upon our ability and the ability of any collaborators to develop, manufacture, market and sell our product candidates and use our proprietary technologies without infringing the proprietary rights and intellectual property of third parties. We cannot provide any assurances that third-party patents do not exist which might be enforced against our current manufacturing methods, product candidates or future methods or products, resulting in either an injunction prohibiting our manufacture or sales, or, with respect to our sales, an obligation on our part to pay royalties or other forms of compensation to third parties.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology and pharmaceutical industries are characterized by extensive and complex litigation regarding patents and other intellectual property rights. We may in the future become party to, or be threatened with, adversarial proceedings or litigation regarding intellectual property rights with respect to our product candidates and technology, including post grant review and <i style="font-style:italic;">inter partes</i> review before the USPTO. The risks of being involved in such litigation and proceedings may also increase as our product candidates approach commercialization and as we gain greater visibility as a public company. Third parties may assert infringement claims against us based on existing patents or patents that may be granted in the future, regardless of their merit. There is a risk that third parties may choose to engage in litigation with us to enforce or to otherwise assert their patent rights against us. Even if we believe such claims are without merit, a court of competent jurisdiction could hold that these third-party patents are valid, enforceable and infringed, which could materially and adversely affect our ability to commercialize any of our product candidates or technologies covered by the asserted third-party patents.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are found to infringe a third party&#8217;s valid and enforceable intellectual property rights, we could be required to obtain a license from such third party to continue developing, manufacturing and marketing our product candidates and technology. However, we may not be able to obtain any required license on commercially reasonable terms or at all. Even if we were able to obtain a license, it could be non-exclusive, thereby giving our competitors and other third parties access to the same technologies licensed to us, and it could require us to make substantial licensing and royalty payments. We could be forced, including by court order, to cease developing, manufacturing and commercializing the infringing technology or product candidates. In addition, we could be found liable for monetary damages, including treble damages and attorneys&#8217; fees, if we are found to have willfully infringed a patent or other intellectual property right. A finding of infringement could prevent us from manufacturing and commercializing our product candidates or force us to cease some of our business operations, which could materially harm our business. Claims that we have misappropriated the confidential information or trade secrets of third parties could have a similar negative impact on our business, financial condition, results of operations and prospects.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">61</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Others may claim an ownership interest in our intellectual property and our product candidates, which could expose us to litigation and have a significant adverse effect on our prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we are presently unaware of any claims or assertions by third parties with respect to our patents or other intellectual property, we cannot guarantee that a third party will not assert a claim or an interest in any of such patents or intellectual property. For example, a third party may claim an ownership interest in one or more of our, or our licensors&#8217;, patents or other proprietary or intellectual property rights. A third party could bring legal actions against us to seek monetary damages or enjoin clinical testing, manufacturing or marketing of the affected product candidate or product. If we become involved in any litigation, it could consume a substantial portion of our resources and cause a significant diversion of effort by our technical and management personnel. If any such action is successful, in addition to any potential liability for damages, we could be required to obtain a license to continue to manufacture or market the affected product candidate or product, in which case we could be required to pay substantial royalties or grant cross-licenses to patents. We cannot, however, assure you that any such license would be available on acceptable terms, if at all. Ultimately, we could be prevented from commercializing a product, or forced to cease some aspect of our business operations as a result of claims of patent infringement or violation of other intellectual property rights. Further, the outcome of intellectual property litigation is subject to uncertainties that cannot be adequately quantified in advance, including the demeanor and credibility of witnesses and the identity of any adverse party. This is especially true in intellectual property cases, which may turn on the testimony of experts as to technical facts upon which experts may reasonably disagree. Any of the foregoing could have a material adverse effect on our business, financial condition, results of operations or prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to protect the confidentiality of our proprietary information, the value of our technology and products could be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Trade secrets and know-how can be difficult to protect. To maintain the confidentiality of trade secrets and proprietary information, we enter into confidentiality agreements with our employees, consultants, collaborators and others upon the commencement of their relationships with us. These agreements require that all confidential information developed by the individual or made known to the individual by us during the course of the individual&#8217;s relationship with us be kept confidential and not disclosed to third parties. Our agreements with employees and our personnel policies also provide that any inventions conceived by the individual in the course of rendering services to us shall be our exclusive property. However, we cannot guarantee that we have entered into such agreements with each party that may have or have had access to our trade secrets or proprietary technology and processes, and individuals with whom we have these agreements may not comply with their terms. Thus, despite such agreement, there can be no assurance that such inventions will not be assigned to third parties. In the event of unauthorized use or disclosure of our trade secrets or proprietary information, these agreements, even if obtained, may not provide meaningful protection, particularly for our trade secrets or other confidential information. To the extent that our employees, consultants or contractors use technology or know-how owned by third parties in their work for us, disputes may arise between us and those third parties as to the rights in related inventions. To the extent that an individual who is not obligated to assign rights in intellectual property to us is rightfully an inventor of intellectual property, we may need to obtain an assignment or a license to that intellectual property from that individual, or a third party or from that individual&#8217;s assignee. Such assignment or license may not be available on commercially reasonable terms or at all. We also seek to preserve the integrity and confidentiality of our trade secrets by other means, including maintaining physical security of our premises and physical and electronic security of our information technology systems. However, these security measures may be breached, and we may be forced to bring claims against third parties, or defend claims that they may bring against us, to determine the ownership of what we regard as our intellectual property.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adequate remedies may not exist in the event of unauthorized use or disclosure of our proprietary information. The disclosure of our trade secrets would impair our competitive position and may materially harm our business, financial condition and results of operations. Costly and time-consuming litigation could be necessary to enforce and determine the scope of our proprietary rights, and failure to maintain trade secret protection could adversely affect our competitive business position. In addition, others may independently discover or develop our trade secrets and proprietary information, and the existence of our own trade secrets affords no protection against such independent discovery. For example, a public presentation in the scientific or popular press on the properties of our product candidates could motivate a third party, despite any perceived difficulty, to assemble a team of scientists having backgrounds similar to those of our employees to attempt to independently reverse engineer or otherwise duplicate our antibody technologies to replicate our success.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">62</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may be subject to claims asserting that our employees, consultants or advisors have wrongfully used or disclosed alleged trade secrets of their current or former employers.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of our employees, consultants or advisors are currently, or were previously, employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants and advisors do not use the proprietary information or know-how of others in their work for us, we may be subject to claims that these individuals, or we, have used or disclosed intellectual property, including trade secrets or other proprietary information, of any such individual&#8217;s current or former employer, or that patents and applications we have filed to protect inventions of these employees, even those related to one or more of our product candidates, are rightfully owned by their former or current employer. Litigation may be necessary to defend against these claims. For example, in 2021, a third party filed a lawsuit in Federal court against the Company, and in 2022 claims were added to that lawsuit to add our Chief Executive Officer as a co-defendant with Company. &#160;This lawsuit alleges that our Chief Executive Officer breached contractual and fiduciary duties he owed to the plaintiff by, among other things, improperly utilizing plaintiff&#8217;s purported confidential information to benefit the Company&#8217;s business, including with respect to our discovery efforts. For more information regarding these proceedings, please refer to Note 8 to the Company&#8217;s Financial Statements. If we fail in defending claims of misappropriation and similar claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Any registered trademarks or trade names may be challenged, circumvented or declared generic or determined to be infringing on other marks. We may not be able to protect our rights to these trademarks and trade names, which we need to build name recognition among potential partners or customers in our markets of interest. At times, competitors may adopt trade names or trademarks similar to ours, thereby impeding our ability to build brand identity and possibly leading to market confusion. In addition, there could be potential trade name or trademark infringement claims brought by owners of other registered trademarks or trademarks that incorporate variations of our registered or unregistered trademarks or trade names. Over the long term, if we are unable to establish name recognition based on our trademarks and trade names, then we may not be able to compete effectively, and our business may be adversely affected. Our efforts to enforce or protect our proprietary rights related to trademarks, trade secrets, domain names, copyrights or other intellectual property may be ineffective and could result in substantial costs and diversion of resources and could adversely impact our financial condition or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Intellectual property rights do not necessarily address all potential threats.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The degree of future protection afforded by our intellectual property rights is uncertain because intellectual property rights have limitations and may not adequately protect our business or permit us to maintain our competitive advantage. For example:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may be able to make products that are similar to our product candidates but that are not covered by the claims of the patents that we own or license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any partners or collaborators, might not have been the first to make the inventions covered by the issued patent or pending patent application that we license or may own in the future;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we, or any partners or collaborators, might not have been the first to file patent applications covering certain of our or their inventions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">others may independently develop similar or alternative technologies or duplicate any of our technologies without infringing our owned or licensed intellectual property rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">it is possible that our pending licensed patent applications or those that we may own in the future will not lead to issued patents;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued patents that we hold rights to may be held invalid or unenforceable, including as a result of legal challenges by our competitors;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">63</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our competitors might conduct research and development activities in countries where we do not have patent rights and then use the information learned from such activities to develop competitive products for sale in our major commercial markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may not develop additional proprietary technologies that are patentable;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the patents of others may have an adverse effect on our business; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">we may choose not to file&#160;a patent for certain trade secrets or know-how, and a third party may subsequently file&#160;a patent covering such intellectual property.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Should any of these events occur, they could significantly harm our business, financial condition, results of operations and prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Risks Related to Reliance on Third Parties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We rely or will rely on third parties to help conduct our ongoing and planned preclinical studies and clinical trials for NC410, NC762, NC525 and any future product candidates we develop. If these third parties do not successfully carry out their contractual duties, comply with regulatory requirements or meet expected deadlines, we may not be able to obtain marketing approval for or commercialize NC410, NC762, NC525 and any future product candidates we develop, and our business could be materially harmed.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently do not have the ability to independently conduct preclinical studies that comply with GLP requirements. We also do not currently have the ability to independently conduct any clinical trials. The FDA and regulatory authorities in other jurisdictions require us to comply with regulations and standards, including cGCP, or requirements for conducting, monitoring, recording and reporting the results of clinical trials, in order to ensure that the data and results are scientifically credible and accurate and that the trial subjects are adequately informed of the potential risks of participating in clinical trials. We rely on medical institutions, clinical investigators, contract laboratories and other third parties, such as CROs, to conduct GLP-compliant preclinical studies and cGCP-compliant clinical trials on our product candidates properly and on time. While we have agreements governing their activities, we control only certain aspects of their activities and have limited influence over their actual performance. The third parties with whom we contract for execution of our GLP-compliant preclinical studies and our cGCP-compliant clinical trials play a significant role in the conduct of these studies and trials and the subsequent collection and analysis of data. These third parties are not our employees and, except for restrictions imposed by our contracts with such third parties, we have limited ability to control the amount or timing of resources that they devote to our current or future product candidates. Although we rely on these third parties to conduct our GLP-compliant preclinical studies and cGCP-compliant clinical trials, we remain responsible for ensuring that each of our preclinical studies and clinical trials is conducted in accordance with its investigational plan and protocol and applicable laws and regulations, and our reliance on the CROs does not relieve us of our regulatory responsibilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Many of the third parties with whom we contract may also have relationships with other commercial entities, including our competitors, for whom they may also be conducting clinical trials or other drug development activities that could harm our competitive position. Further, under certain circumstances, these third parties may terminate their agreements with us upon as little as 10&#160;days&#8217; prior written notice. Some of these agreements may also be terminated by such third parties under certain other circumstances. If the third parties conducting our preclinical studies or our clinical trials do not adequately perform their contractual duties or obligations, experience significant business challenges, disruptions or failures, including as a result of natural disasters or public health emergencies such as the COVID-19 pandemic, do not meet expected deadlines, terminate their agreements with us or need to be replaced, or if the quality or accuracy of the data they obtain is compromised due to their failure to adhere to our protocols or to GLP and cGCP, or for any other reason, we may need to enter into new arrangements with alternative third parties. This could be difficult, costly or impossible, and our preclinical studies or clinical trials may need to be extended, delayed, terminated or repeated. As a result, we may not be able to obtain regulatory approval in a timely fashion, or at all, for the applicable product candidate, our financial results and the commercial prospects for our product candidates would be harmed, our costs could increase and our ability to generate revenues could be delayed.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">64</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We may depend on third-party collaborators for the discovery, development and commercialization of certain of our current and future product candidates. If our collaborations are not successful, we may not be able to capitalize on the market potential of these product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the future, we may form or seek other strategic alliances, joint ventures or collaborations, or enter into additional licensing arrangements with third parties that we believe will complement or augment our development and commercialization efforts with respect to product candidates we develop.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our collaborations pose, and potential future collaborations involving our product candidates may pose, the following risks to us:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may have significant discretion in determining the efforts and resources that they will apply to these collaborations;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators could independently develop, or develop with third parties, products that compete directly or indirectly with our products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may not properly enforce, maintain or defend our intellectual property rights or may use our proprietary information in a way that gives rise to actual or threatened litigation or that could jeopardize or invalidate our intellectual property or proprietary information, exposing us to potential litigation or other intellectual property proceedings;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaborators may infringe the intellectual property rights of third parties, which may expose us to litigation and potential liability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">disputes may arise between a collaborator and us that cause the delay or termination of the research, development or commercialization of the product candidate, or that result in costly litigation or arbitration that diverts management attention and resources;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">a collaborator with marketing and distribution rights to one or more of our product candidates that achieve regulatory approval may not commit sufficient resources to the marketing and distribution of such products;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">if a present or future collaborator were to be involved in a business combination, the continued pursuit and emphasis on our product development or commercialization program under such collaboration could be delayed, diminished or terminated; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">collaboration agreements may restrict our right to independently pursue new product candidates.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we enter into additional collaboration agreements and strategic partnerships or license our intellectual property, products or businesses, we may not be able to realize the benefit of such transactions if we are unable to successfully integrate them with our existing operations, which could delay our timelines or otherwise adversely affect our business. We also cannot be certain that, following a strategic transaction or license, we will achieve the revenue or net income that justifies such transaction. Any of the factors set forth above and any delays in entering into new collaborations or strategic partnership agreements related to any product candidate we develop could delay the development and commercialization of our product candidates, which would harm our business prospects, financial condition and results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-size:10pt;white-space:pre-wrap;"> </span><span style="font-size:10pt;">In the event a present or future collaborator terminates their agreement with us, we would be prevented from receiving the benefits of any such agreement, which could have a materially adverse effect on our results of operations</span><span style="font-family:'Arial','Helvetica','sans-serif';">.</span><span style="font-size:12pt;"> </span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We may seek to establish additional collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The advancement of our product candidates and development programs and the potential commercialization of our current and future product candidates will require substantial additional cash to fund expenses. For some of our current or future product candidates, we may decide to collaborate with additional pharmaceutical and biotechnology companies with respect to development and potential commercialization. Any of these relationships may require us to incur non-</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">65</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">recurring and other charges, increase our near- and long-term expenditures, issue securities that dilute our existing stockholders, or disrupt our management and business.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face significant competition in seeking appropriate strategic partners and the negotiation process is time-consuming and complex. Whether we reach a definitive agreement for other collaborations will depend, among other things, upon our assessment of the collaborator&#8217;s resources and expertise, the terms and conditions of the proposed collaboration and the collaborator&#8217;s evaluation of a number of factors. Those factors may include the design or results of clinical trials, the progress of our clinical trials, the likelihood of approval by the FDA or similar regulatory authorities outside the United States, the potential market for the subject product candidate, the costs and complexities of manufacturing and delivering such product candidate to patients, the potential of competing products, the existence of uncertainty with respect to our ownership of technology, which can exist if there is a challenge to such ownership without regard to the merits of the challenge and industry and market conditions generally. The collaborator may also consider alternative product candidates or technologies for similar indications that may be available to collaborate on and whether such a collaboration could be more attractive than the one with us for our product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Further, we may not be successful in our efforts to establish a strategic partnership or other alternative arrangements for future product candidates because they may be deemed to be at too early of a stage of development for collaborative effort and third parties may not view them as having the requisite potential to demonstrate safety and efficacy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may also be restricted under existing collaboration agreements from entering into future agreements on certain terms with potential collaborators. Such exclusivity could limit our ability to enter into strategic collaborations with future collaborators. In addition, there have been a significant number of recent business combinations among large pharmaceutical companies that have resulted in a reduced number of potential future collaborators.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may not be able to negotiate collaborations on a timely basis, on acceptable terms, or at all. If we are unable to do so, we may have to curtail the development of the product candidate for which we are seeking to collaborate, reduce or delay its development program or one or more of our other development programs, delay its potential commercialization or reduce the scope of any marketing or sales activities, or increase our expenditures and undertake development or commercialization activities at our own expense. If we elect to increase our expenditures to fund development or commercialization activities on our own, we may need to obtain additional capital, which may not be available to us on acceptable terms or at all. If we do not have sufficient funds, we may not be able to further develop our product candidates or bring them to market and generate product revenue.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Risks Related to Our Business</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are highly dependent on our key personnel, and if we are not successful in attracting, motivating and retaining highly qualified personnel, we may not be able to successfully implement our business strategy.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are highly dependent on members of our executive team. The loss of the services of any of them may adversely impact the achievement of our objectives. Any of our executive officers could leave our employment at any time, as all of our employees are &#8220;at-will&#8221; employees, and we do not have &#8220;key person&#8221; insurance on them. The loss of the services of one or more of our executive officers or of certain members of our SAB could impede the achievement of our research, development and commercialization objectives. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Recruiting and retaining qualified employees, consultants and advisors for our business, including scientific and technical personnel, is critical to our success. We have observed an increasingly competitive labor market. Increased employee turnover and changes in the availability of our workers could result in increased costs. We may not be able to attract and retain personnel on acceptable terms given the competition among numerous pharmaceutical and biotechnology companies and academic institutions for skilled individuals. In addition, failure to succeed in preclinical studies, clinical trials or applications for marketing approval may make it more challenging to recruit and retain qualified personnel. The inability to recruit, or the loss of services of certain executives, key employees, consultants or advisors, may impede the progress of our research, development and commercialization objectives and have a material adverse effect on our business, financial condition, results of operations and growth prospects.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">66</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We face significant competition from other biotechnology and pharmaceutical companies, and our operating results will suffer if we fail to compete effectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The biotechnology industry is intensely competitive and subject to rapid and significant technological change. Our current or future product candidates may face competition from major pharmaceutical companies, specialty pharmaceutical companies, universities and other research institutions and from products and therapies that currently exist or are being developed, some of which products and therapies we may not currently know about. Many of our competitors have significantly greater financial, manufacturing, marketing, product development, technical and human resources than we do. Large pharmaceutical companies, in particular, have extensive experience in clinical testing, obtaining marketing approvals, recruiting patients and manufacturing pharmaceutical products, and they may also have products that have been approved or are in late stages of development, and collaborative arrangements in our target markets with leading companies and research institutions. Established pharmaceutical companies may also invest heavily to accelerate discovery and development of novel compounds or to in-license novel compounds that could make the product candidates that we develop obsolete. Mergers and acquisitions in the pharmaceutical and biotechnology industries may result in even more resources being concentrated among a smaller number of our competitors. As a result of all of these factors, our competitors may succeed in obtaining patent protection and/or FDA or other regulatory approval or discovering, developing and commercializing products in our field before we do, which could result in our competitors establishing a strong market position before we are able to enter the market.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our competitors may obtain FDA or other regulatory approval of their product candidates more rapidly than we may or may obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates or platform technologies. Our competitors may also develop drugs or discovery platforms that are more effective, more convenient, more widely used or less costly than our product candidates or our FIND-IO platform or, in the case of drugs, have a better safety profile than our product candidates. These competitors may also be more successful than us in manufacturing and marketing their products and have significantly greater financial resources and expertise in research and development.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are a large number of companies developing or marketing treatments for cancer, including many major pharmaceutical and biotechnology companies. Currently marketed oncology drugs and therapeutics range from traditional cancer therapies, including chemotherapy, to antibody-drug conjugates, such as Genentech&#8217;s Kadcyla, to immune checkpoint inhibitors targeting CTLA-4, such as BMS&#8217; Yervoy, and PD-1/PD-L1, such as BMS&#8217; Opdivo, Merck&#160;&amp;&#160;Co.&#8217;s Keytruda and Genentech&#8217;s Tecentriq, to T-cell-engager immunotherapies, such as Amgen&#8217;s Blincyto. Companies are also developing treatments targeting the Siglec family of proteins, such as Celldex Therapeutics and Palleon Pharmaceuticals, both of which are currently engaged in preclinical studies. In addition, numerous compounds are in clinical development for cancer treatment. Many of these companies are well-capitalized and have significant clinical experience (see &#8220;Business&#8212;Competition&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Smaller and other early-stage companies may also prove to be significant competitors. These third parties compete with us in recruiting and retaining qualified scientific and management personnel, establishing clinical trial sites and patient registration for clinical trials, as well as in acquiring technologies complementary to, or necessary for, our current and future product candidates. In addition, the biopharmaceutical industry is characterized by rapid technological change. If we fail to stay at the forefront of technological change, we may be unable to compete effectively. Technological advances or products developed by our competitors may render our product candidates obsolete, less competitive or not economical.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our commercial opportunity could be reduced or eliminated if our competitors develop and commercialize products that are safer, more effective, have fewer or less severe side effects, are more convenient, have a broader label, are marketed more effectively, are reimbursed or are less expensive than any products that we may develop. Our competitors may also obtain patent protection or other intellectual property rights that limit our ability to develop or commercialize our product candidates or platform technologies. Even if our product candidates achieve marketing approval, they may be priced at a significant premium over competitive products if any have been approved by then, resulting in reduced competitiveness. If we do not compete successfully, we may not generate or derive sufficient revenue from any product candidate for which we obtain marketing approval and may not become or remain profitable.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">67</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We will need to grow the size of our organization, and we may experience difficulties in managing this growth.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As our development plans and strategies develop, we expect to need additional managerial, operational, marketing, sales, financial and other personnel. Future growth would impose significant added responsibilities on members of management, including: </p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">identifying, recruiting, integrating, maintaining and motivating additional employees;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">managing our internal development efforts effectively, including the clinical and FDA review process for NC410, NC762 and any future product candidates we develop, while complying with our contractual obligations to contractors and other third parties; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">improving our operational, financial and management controls, reporting systems and procedures.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our future financial performance and our ability to advance development of and, if approved, commercialize NC410, NC762, NC525 and any future product candidates we develop will depend, in part, on our ability to effectively manage any future growth, and our management may have to divert a disproportionate amount of its attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently rely, and for the foreseeable future will continue to rely, in substantial part on certain independent organizations, advisors and consultants to provide certain services. We cannot assure you that the services of independent organizations, advisors and consultants will continue to be available to us on a timely basis when needed, or that we can find qualified replacements. In addition, if we are unable to effectively manage our outsourced activities or if the quality or accuracy of the services provided by consultants is compromised for any reason, our clinical trials may be extended, delayed or terminated, and we may not be able to obtain marketing approval of any current or future product candidates or otherwise advance our business. We cannot assure you that we will be able to manage our existing consultants or find other competent outside contractors and consultants on economically reasonable terms, or at all.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are not able to effectively expand our organization by hiring new employees and expanding our groups of consultants and contractors, we may not be able to successfully implement the tasks necessary to further develop and commercialize NC410, NC762, NC525 and any future product candidates we develop and, accordingly, may not achieve our research, development and commercialization goals.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we are unable to establish marketing, sales and distribution capabilities for NC410, NC762, NC525 or any other product candidate that may receive regulatory approval, we may not be successful in commercializing those product candidates if and when they are approved.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not have sales or marketing infrastructure. To achieve commercial success for NC410, NC762, NC525 and any other product candidate for which we may obtain marketing approval, we will need to establish a sales and marketing organization. In the future, we expect to build a focused sales and marketing infrastructure to market some of our product candidates in the United States, if and when they are approved. There are risks involved with establishing our own marketing, sales and distribution capabilities. For example, recruiting and training a sales force is expensive and time consuming and could delay any product launch. If the commercial launch of a product candidate for which we recruit a sales force and establish marketing capabilities is delayed or does not occur for any reason, we would have prematurely or unnecessarily incurred these commercialization expenses. This may be costly, and our investment would be lost if we cannot retain or reposition our sales and marketing personnel.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Factors that may inhibit our efforts to market our products on our own include:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to recruit, train and retain adequate numbers of effective sales and marketing personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability of sales personnel to obtain access to physicians in order to educate physicians about our product candidates, once approved;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the lack of complementary products to be offered by sales personnel, which may put us at a competitive disadvantage relative to companies with more extensive product lines; and</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">68</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unforeseen costs and expenses associated with creating an independent sales and marketing organization.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If we are unable to establish our own marketing, sales and distribution capabilities and are forced to enter into arrangements with, and rely on, third parties to perform these services, our revenue and our profitability, if any, are likely to be lower than if we had developed such capabilities ourselves. In addition, we may not be successful in entering into arrangements with third parties to sell, market and distribute our product candidates or may be unable to do so on terms that are favorable to us. We likely will have little control over such third parties, and any of them may fail to devote the necessary resources and attention to sell and market our products effectively. If we do not establish marketing, sales and distribution capabilities successfully, either on our own or in collaboration with third parties, we will not be successful in commercializing our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Product liability lawsuits against us could cause us to incur substantial liabilities and to limit commercialization of our product candidates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We face an inherent risk of product liability exposure related to the testing of our product candidates in human trials and may face greater risk if we commercialize any products that we develop. Product liability claims may be brought against us by subjects enrolled in our trials, patients, healthcare providers or others using, administering or selling our products. If we cannot successfully defend ourselves against such claims, we could incur substantial liabilities. Regardless of merit or eventual outcome, liability claims may result in:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">decreased demand for any product candidate we may develop;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">withdrawal of trial participants; </span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">termination of clinical trial sites or entire trial programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">injury to our reputation and significant negative media attention;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">initiation of investigations by regulators;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant time and costs to defend the related litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">substantial monetary awards to trial subjects or patients;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">diversion of management and scientific resources from our business operations; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the inability to commercialize any product candidates that we may develop.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While we currently hold trial liability insurance coverage consistent with industry standards, the amount of coverage may not adequately cover all liabilities that we may incur. We may not be able to maintain insurance coverage at a reasonable cost or in an amount adequate to satisfy any liability that may arise. We intend to expand our insurance coverage for products to include the sale of commercial products if we obtain marketing approval for our product candidates, but we may be unable to obtain commercially reasonable product liability insurance. A successful product liability claim or series of claims brought against us, particularly if judgments exceed our insurance coverage, could decrease our cash and adversely affect our business and financial condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are subject to the periodic reporting requirements of the Exchange Act. We designed our disclosure controls and procedures to reasonably assure that information we must disclose in reports we file or submit under the Exchange Act is accumulated and communicated to management, and recorded, processed, summarized and reported within the time periods specified in the rules and forms of the SEC. We believe that any disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are met.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">69</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These inherent limitations include the realities that judgments in decision-making can be faulty, and that breakdowns can occur because of simple errors or mistakes. Additionally, controls can be circumvented by the individual acts of some persons, by collusion of two or more people or by an unauthorized override of the controls. Accordingly, because of the inherent limitations in our control system, misstatements due to error or fraud may occur and not be detected.</p><a id="_Hlk15053360"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our ability to use our net operating loss carryforwards to offset future taxable income may be subject to certain limitations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have incurred substantial losses during our history and do not expect to become profitable in the near future, and we may never achieve profitability. To the extent that we continue to generate taxable losses, unused losses will carry forward to offset future taxable income, if any, until such unused losses expire. As of December 31, 2022, we had federal and state net operating loss carryforwards of $180.2 million and $183.1 million, respectively. Certain federal and state net operating loss carryforwards will begin to expire, if not utilized, by 2036. Limitations imposed by the applicable jurisdictions on our ability to utilize net operating loss carryforwards could cause income taxes to be paid earlier than would be paid if such limitations were not in effect and could cause such net operating loss carryforwards to expire unused, in each case reducing or eliminating the benefit of such net operating loss carryforwards. Furthermore, we may not be able to generate sufficient taxable income to utilize our net operating loss carryforwards before they expire. If any of these events occur, we may not derive some or all of the expected benefits from our net operating loss carryforwards. In addition, we may experience ownership changes in the future as a result of subsequent shifts in our stock ownership, some of which may be outside of our control. As a result, even if we earn net taxable income, our ability to use our net operating loss and tax credit carryforwards may be materially limited, which could harm our future operating results by effectively increasing our future tax obligations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Natural disasters or other unexpected events may disrupt our operations, adversely affect our results of operations and financial condition, and may not be covered by insurance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The occurrence of one or more unexpected events, including fires, tornadoes, tsunamis, hurricanes, earthquakes, floods, and other forms of severe hazards in the United States or in other countries in which we or our suppliers or manufacturers operate or are located could adversely affect our operations and financial performance. These types of unexpected events could result in physical damage to and complete or partial closure of one or more of the manufacturing facilities operated by our contract manufacturers, or the temporary or long-term disruption in the supply of products, and/or disruption of our ability to deliver products to customers. Further, the long-term effects of climate change on general economic conditions and the pharmaceutical manufacturing and distribution industry in particular are unclear, and changes in the supply, demand or available sources of energy and the regulatory and other costs associated with energy production and delivery may affect the availability or cost of goods and services, including natural resources, necessary to run our businesses. Existing insurance arrangements may not provide protection for the costs that may arise from such events, particularly if such events are catastrophic in nature or occur in combination. Any long-term disruption in our ability to service our customers from one or more distribution centers or outsourcing facilities could have a material adverse effect on our operations, our business, results of operations and stock price.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Failure to meet investor and stakeholder expectations regarding environmental, social and corporate governance, or &#8220;ESG&#8221; matters may damage our reputation.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There is an increasing focus from certain investors, customers, consumers, employees and other stakeholders concerning ESG matters. Additionally, public interest and legislative pressure related to public companies&#8217; ESG practices continue to grow. If our ESG practices fail to meet investor, customer, consumer, employee or other stakeholders&#8217; evolving expectations and standards for responsible corporate citizenship in areas including environmental stewardship, Board of Directors and employee diversity, human capital management, corporate governance and transparency, our reputation, brand, appeal to investors and employee retention may be negatively impacted, which could have a material adverse effect on our business or financial condition.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">70</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Risks Related to Our Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">The price of our common stock has been and may continue to be volatile and fluctuate substantially.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our stock price has been and is likely to remain volatile. The stock market in general, and the market for biopharmaceutical companies in particular, have experienced extreme volatility that has often been unrelated to the operating performance or prospects of particular companies. As a result of this volatility, you may not be able to sell your common stock at or above a recently reported price, or at all. The market price for our common stock may be influenced by many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the commencement, enrollment or results of our ongoing or future clinical trials, or changes in the development status of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">any delay in our regulatory filings for our product candidates and any adverse development or perceived adverse development with respect to the applicable regulatory authority&#8217;s review of such filings, including without limitation the FDA&#8217;s issuance of a &#8220;refusal to file&#8221; letter or a request for additional information;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse results or delays in clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our decision to initiate a clinical trial, not to initiate a clinical trial or to terminate an existing clinical trial;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">adverse regulatory decisions, including failure to receive regulatory approval of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our failure to commercialize our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">unanticipated serious safety concerns related to the use of our product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the size and growth of our target markets;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the success of competitive products or technologies;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory actions with respect to our product candidates or our competitors&#8217; products or product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcements by us or our competitors of significant acquisitions, strategic collaborations, joint ventures, collaborations or capital commitments;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">regulatory or legal developments in the United States and other countries applicable to our product candidates, including but not limited to clinical trial requirements for approvals;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our inability to obtain adequate product supply for any approved product or inability to do so at acceptable prices;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">developments or disputes concerning patent applications, issued patents or other proprietary rights;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the recruitment or departure of key personnel;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the level of expenses related to our product candidates or clinical development programs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the results of our efforts to discover, develop, acquire or in-license product candidates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">actual or anticipated changes in estimates as to financial results, development timelines or recommendations by securities analysts or publications of research reports about us or our industry;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">variations in our annual or quarterly financial results or those of companies that are perceived by investors to be similar to us;</span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">71</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our cash position;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">fluctuations in the valuation of companies perceived by investors to be comparable to us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">share price and volume fluctuations attributable to inconsistent trading volume levels of our shares;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">announcement or expectation of additional financing efforts;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">sales of our common stock by us, our directors, officers or their affiliated funds or our other stockholders;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">changes in the structure of healthcare payment systems;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant lawsuits, including intellectual property or stockholder litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">market conditions in the pharmaceutical and biotechnology sectors;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">general economic, industry and market conditions; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">other events or factors, many of which are beyond our control, or unrelated to our operating performance or prospects.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In addition, the stock market in general, and Nasdaq and biotechnology companies in particular, have experienced extreme price and volume fluctuations that have often been unrelated or disproportionate to the operating performance of these companies. Broad market and industry factors may negatively affect the market price of our common stock, regardless of our actual operating performance. The realization of any of the above risks or any of a broad range of other risks, including those described in this &#8220;Risk Factors&#8221; section, could have a dramatic and material adverse impact on the market price of our common stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If securities analysts do not publish research or reports about our business or if they publish inaccurate or unfavorable research about our business, the price of our stock could decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The trading market for our common stock relies, in part, on the research and reports that industry or financial analysts publish about us or our business. We currently receive only limited coverage by equity research analysts. If additional analysts do not commence coverage of us, the trading price of our stock could decrease. In addition, if one or more of the analysts covering our business issue adverse reports about us or downgrade their evaluations of our stock, the price of our stock could decline. If one or more of these analysts cease to cover our stock or fail to publish reports on us regularly, we could lose visibility in the market for our stock, which, in turn, could cause our stock price to decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Sales of a substantial number of shares of our common stock in the public market could cause our stock price to fall, even if our business is doing well.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">If our existing stockholders sell, or indicate an intention to sell, substantial amounts of our common stock in the public market, the market price of our common stock could decline significantly.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have filed registration statements on Form S-8 shares of common stock that are either subject to options or other equity awards issued or reserved for future issuance under our equity incentive plans. The number of shares available for issuance under the 2019 Omnibus Plan is subject to an automatic annual increase on January 1st of each year, continuing until the expiration of the 2019 Omnibus Plan, in an amount equal to four percent (4%) of the total number of shares of Common Stock outstanding on December 31st of the preceding calendar year. The number of shares available for issuance under the 2019 Employee Stock Purchase Plan, or &#8220;ESPP&#8221;, is subject to an automatic annual increase on January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of each year, continuing until the expiration of the ESPP, in an amount equal to the least of (i) one percent (1%) of the total number of shares of Common Stock outstanding on December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of the preceding calendar year, (ii) 480,000 shares of Common Stock (subject to the capitalization adjustment provisions included in the ESPP) and (iii) a number of shares of Common Stock determined by the administrator of the ESPP. Shares registered under our registration statements on Form S-8 will be available for sale in the public market subject to vesting arrangements and exercise of options and the restrictions of Rule 144 in the case of our affiliates.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">72</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk59981324"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates exercise significant influence over our company, which limits your ability to influence corporate matters and could delay or prevent a change in corporate control.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our executive officers, directors and current beneficial owners of 5% or more of our common stock and their respective affiliates beneficially own, in the aggregate, a majority of our outstanding common stock. As a result, these stockholders, if they act together, will be able to influence our management and affairs and the outcome of matters submitted to our stockholders for approval, including the election of directors and any sale, merger, consolidation or sale of all or substantially all of our assets. This concentration of ownership might adversely affect the market price of our common stock by:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">delaying, deferring or preventing a change of control of us;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">impeding a merger, consolidation, takeover or other business combination involving us; or</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">discouraging a potential acquirer from making a tender offer or otherwise attempting to obtain control of us.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We are now and may in the future be subject to securities litigation, which can be expensive and could divert management&#8217;s attention.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Exchange Act and the Securities Act of 1933, as amended, with respect to statements made regarding our product candidate, NC318, and the FIND-IO platform. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys&#8217; fees and costs, declaratory relief, corporate governance changes, and restitution. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For more information regarding these proceedings, please refer to Note 8 to the Company&#8217;s Financial Statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We intend to vigorously defend these actions. However, whether or not the claims are successful, litigation is often expensive and can divert management&#8217;s attention and resources from other business concerns, which could adversely affect our business. If we are ultimately required to pay significant defense costs, damages or settlement amounts, such payments could adversely affect our operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We may be the target of similar litigation in the future. The market price of our common stock has experienced and may continue to experience volatility, and in the past, companies that have experienced volatility in the market price of their stock have been subject to securities litigation. Any future litigation could result in substantial costs and divert our management&#8217;s attention from other business concerns, which could seriously harm our business. We maintain liability insurance; however, if any costs or expenses associated with the Ye Zhou action, Liu action, or any other litigation exceed our insurance coverage, we may be forced to bear some or all costs and expenses directly, which could be substantial.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Provisions in our amended and restated certificate of incorporation and amended and restated bylaws may delay or prevent an acquisition of us or a change in our management. For example, our board of directors has the authority to issue up to 10,000,000 shares of preferred stock. The board of directors can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by our stockholders. The issuance of shares of preferred stock may delay or prevent a change of control transaction. As a result, the market price of our common stock </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">73</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">and the voting and other rights of our stockholders may be adversely affected. An issuance of shares of preferred stock may result in the loss of voting control to other stockholders.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These provisions also include a classified board of directors, a prohibition on actions by written consent of our stockholders and the ability of our board of directors to issue preferred stock without stockholder approval. In addition, because we are incorporated in Delaware, we are governed by the provisions of Section&#160;203 of the Delaware General Corporation Law, which limits the ability of stockholders owning in excess of 15% of our outstanding voting stock to merge or combine with us. Although we believe these provisions collectively provide for an opportunity to obtain greater value for stockholders by requiring potential acquirers to negotiate with our board of directors, they would apply even if an offer rejected by our board were considered beneficial by some stockholders. In addition, these provisions may frustrate or prevent any attempts by our stockholders to replace or remove our current management by making it more difficult for stockholders to replace members of our board of directors, which is responsible for appointing the members of our management.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">When we lose our status as an &#8220;emerging growth company,&#8221; our independent registered public accounting firm will be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404 of the Sarbanes Oxley Act. The rules governing the standards that must be met for management to assess our internal control over financial reporting are complex and require significant documentation, testing and possible remediation. To comply with the requirements of being a reporting company under the Exchange Act, we will need to implement additional financial and management controls, reporting systems and procedures and hire additional accounting and finance staff.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot assure you that there will not be material weaknesses or significant deficiencies in our internal control over financial reporting in the future. Our independent registered public accounting firm will not be required to provide an attestation report on the effectiveness of our internal control over financial reporting so long as we qualify as an &#8220;emerging growth company,&#8221; which may increase the risk that material weaknesses or significant deficiencies in our internal control over financial reporting go undetected. Any failure to maintain internal control over financial reporting could severely inhibit our ability to accurately report our financial condition, results of operations or cash flows. If we are unable to conclude that our internal control over financial reporting is effective, or if our independent registered public accounting firm determines we have a material weakness or significant deficiency in our internal control over financial reporting, investors may lose confidence in the accuracy and completeness of our financial reports, the market price of our common stock could decline, and we could be subject to sanctions or investigations by Nasdaq, the SEC or other regulatory authorities. Failure to remedy any material weakness in our internal control over financial reporting, or to implement or maintain other effective control systems required of public companies, could also restrict our future access to the capital markets.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We do not intend to pay dividends on our common stock, so any returns will be limited to the value of our stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We currently anticipate that we will retain future earnings for the development, operation and expansion of our business and do not anticipate declaring or paying any cash dividends for the foreseeable future. Any return to stockholders will therefore be limited to the appreciation of their stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">We have incurred and will continue to incur significantly increased costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">As a public company we have incurred, and we expect, particularly after we are no longer an emerging growth company, to continue to incur significant legal, accounting, investor relations and other expenses that we did not incur as a private company. The Sarbanes-Oxley Act, the Dodd-Frank Wall Street Reform and Consumer Protection Act, the listing requirements of Nasdaq and other applicable securities rules and regulations impose various requirements on public companies, including establishment and maintenance of effective disclosure and financial controls and corporate governance practices. Our management and other personnel devote a substantial amount of time to these compliance initiatives. We expect these rules and regulations to substantially increase our legal and financial compliance costs and to make some activities more time consuming and costly. For example, we expect that these rules and regulations may make it more difficult and more expensive for us to obtain director and officer liability insurance and we may be required to </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">74</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">incur substantial costs to maintain sufficient coverage. We cannot predict or estimate the amount or timing of additional costs we may incur to respond to these requirements. The impact of these requirements could also make it more difficult for us to attract and retain qualified persons to serve on our board of directors, our board committees or as executive officers. These rules and regulations are often subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Our amended and restated bylaws designate the Court of Chancery of the State of Delaware or the United States District Court for the District of Delaware as the exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders&#8217; ability to obtain a favorable judicial forum for disputes with us or our directors, officers or employees.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our amended and restated bylaws provide that, unless we consent in writing to an alternative forum, the Court of Chancery of the State of Delaware or, if subject matter jurisdiction over the matter that is the subject of such action is vested exclusively in the federal courts, the United States District Court for the District of Delaware will, to the fullest extent permitted by law, be the sole and exclusive forum for (i)&#160;any derivative action or proceeding brought on our behalf, (ii)&#160;any action asserting a claim of breach of a fiduciary duty owed by any of our current or former directors, officers and employees, (iii)&#160;any action asserting a claim arising pursuant to any provision of the Delaware General Corporation Law, our certificate of incorporation or our bylaws, (iv)&#160;any action or proceeding to interpret, apply, enforce or determine the validity of our certificate of incorporation or the bylaws or (v)&#160;any action asserting a claim that is governed by the internal affairs doctrine, in each case subject to the Court of Chancery or the United&#160;States District Court for the District of Delaware, as applicable, having personal jurisdiction over the indispensable parties named as defendants therein. In addition, any person holding, owning or otherwise acquiring any interest in any of our securities shall be deemed to have notice of and to have consented to this provision of our bylaws. The choice of forum provision does not apply to any actions arising under the Securities Act or the Exchange Act. The choice of forum provision may limit a stockholder&#8217;s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or employees, which may discourage such lawsuits against us and our directors, officers and employees even though an action, if successful, might benefit our stockholders. Stockholders who do bring a claim in the Court of Chancery or the United States District Court for the District of Delaware could face additional litigation costs in pursuing any such claim, particularly if they do not reside in or near the jurisdiction. The Court of Chancery or the United States District Court for the District of Delaware may also reach different judgments or results than would other courts, including courts where a stockholder considering an action may be located or would otherwise choose to bring the action, and such judgments or results may be more favorable to us than to our stockholders. Alternatively, if a court were to find this provision of our amended and restated bylaws inapplicable to, or unenforceable in respect of, one or more of the specified types of actions or proceedings, we may incur additional costs, which could have a material adverse effect on our business, financial condition or results of operations.</p><a id="_4303f06a_99ab_4ecb_ba35_3ba16db3ab51"></a><a id="Item1BUnresolvedStaffComments_216361"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 1B. Unresolved Staff Comments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not Applicable.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_3f31d5ed_26d0_449a_b8de_1579c404c856"></a><a id="Item2Properties_180608"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 2. Properties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our corporate headquarters are located in Beltsville, Maryland and consists of approximately 28,500 square feet of office, 20,600 square feet of laboratory and manufacturing and 20,200 square feet of warehouse space. The lease terms expire in March 2030. We believe that these facilities are adequate for our current needs and that suitable additional or substitute space will be available in the future if needed.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_4da50dd9_a86a_4ffd_8f4d_b75ac5dcfe53"></a><a id="Item3LegalProceedings_9287"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 3. Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information set forth under the heading &#8220;Legal Proceedings&#8221; in Note 8, Commitments and Contingencies, in Notes to Financial Statements in Part II Item 8 of this Annual Report, is incorporated herein by reference.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">75</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_338385e4_f9df_494d_9dd8_5d1cd01dc48d"></a><a id="Item4MineSafetyDisclosures_549389"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 4. Mine Safety Disclosures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Not Applicable.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_22c69c7a_72a4_4bfb_a6a1_de98b7422f55"></a><a id="PARTII_356648"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART II</p><a id="Item5MarketForRegistrantsCommonEquity"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 5. Market for Registrant&#8217;s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><b style="font-weight:bold;">Market Information and Holders of Record</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our common stock trades on the Nasdaq Global Select Market, or &#8220;Nasdaq&#8221;, under the symbol &#8220;NXTC.&#8221; As of February 24, 2023 we had 13 holders of record of our common stock. The actual number of shareholders is greater than this number of record holders and includes shareholders who are beneficial owners but whose shares are held in street name by brokers and other nominees. This number of holders of record also does not include shareholders whose shares may be held in trust by other entities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">Dividends</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have never declared or paid cash dividends on our capital stock, and we do not anticipate paying any cash dividends in the foreseeable future. We currently intend to retain all available funds and any future earnings to support our operations and finance the growth and development of our business.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_8c03b512_8fbf_458c_ba55_1d841ab0c130"></a><a id="Item6SelectedFinancialData_699531"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 6. [Reserved]</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_73c1efcb_d07b_4ac1_9281_81c00b28bd62"></a><a id="Item7ManagementsDiscussion_693637"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 7. Management&#8217;s Discussion and Analysis of Financial Condition and Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">You should read the following discussion and analysis of our financial condition and results of operations together with the financial statements and the related notes appearing elsewhere in this Annual Report. This discussion contains forward-looking statements that are based on management&#8217;s current expectations, estimates, and projections about our business and operations, and involve risks and uncertainties. Our actual results could differ materially from those discussed in these forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, those discussed in the sections entitled &#8220;Risk Factors&#8221; and &#8220;Special Note Regarding Forward-Looking Statements&#8221; and elsewhere in this Annual Report. The following discussion and analysis is expected to better allow investors to view the company from management&#8217;s perspective.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. We view the immune system holistically and, rather than target one specific immune cell type, we focus on understanding biological pathways, the interactions of cells and the role each interaction plays in an immune response. Through our proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology, or &#8220;FIND-IO&#8221;, platform, we study various immune cells to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. We are focused on patients who do not respond to current therapies, patients whose cancer progresses despite treatment and patients with cancer types not adequately addressed by available therapies. We are committed to discovering and developing first-in-class immunomedicines, which are immunomedicines that use new or unique mechanisms of action to treat a medical condition.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Our product candidate NC410 is a fusion protein of LAIR-2, a naturally occurring soluble version of and decoy protein for LAIR-1 and is designed to block immune suppression mediated by LAIR-1 In June 2020, we initiated a Phase 1/2 clinical trial of NC410 in patients with advanced or metastatic solid tumors. The Phase 1 dose-escalation portion of this open-label trial was designed to evaluate the safety and tolerability of NC410 and determine its pharmacologically </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">76</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">active and/or maximum tolerated dose. In October 2022, we announced the initiation of a Phase 1b/2 clinical trial to evaluate NC410 in combination with KEYTRUDA&#174; (pembrolizumab), Merck&#8217;s anti-PD-1 therapy, in immune checkpoint refractory patients (colorectal, esophageal, endometrial and head and neck cancers) or immune checkpoint na&#239;ve solid tumor patients (colorectal and ovarian cancers). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidate NC762 is a monoclonal antibody that binds specifically to human B7 homolog 4 protein, or &#8220;B7-H4&#8221;, a protein expressed on multiple tumor types. In July 2021, we initiated a Phase 1/2 clinical trial of NC762 in patients with lung cancer, breast cancer, ovarian cancer or potentially other tumor types. The Phase 1 dose-escalation portion of this open-label trial was designed to evaluate the safety and tolerability of NC762 and determine its pharmacologically active and/or maximum tolerated dose. In November 2022, we announced initial data from the Phase 1 portion of this trial which indicate that NC762 appears to be well tolerated. Safety expansion studies are ongoing with the intent of selecting a recommended Phase 2 dose.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our product candidate NC525 (LAIR-1 mAb) is a novel LAIR-1 antibody that selectively targets Acute Myeloid Leukemia, or &#8220;AML&#8221;, blast cells and leukemic stem cells, or &#8220;LSCs&#8221;. Preclinical data show that NC525 kills AML blast cells and LSCs while sparing hematopoietic stem and progenitor cells, or &#8220;HSPCs&#8221;. In February 2023 we initiated a Phase 1 trial for NC525 to evaluate the safety and preliminary efficacy of NC525 in AML, high-risk myelodysplastic syndrome, and chronic myelomonocytic leukemia (CMML). &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Financial Overview</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since commencing operations in 2015, we have devoted substantially all of our efforts and financial resources to organizing and staffing our company, identifying business development opportunities, raising capital, securing intellectual property rights related to our product candidates, building and optimizing our manufacturing capabilities and conducting discovery, research and development activities for our product candidates, discovery programs and FIND-IO platform. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have not generated any revenue from product sales and only limited revenue from other sources. As a result, with the exception of the three months ended March 31, 2020, for which we reported a profit due to recognition of deferred revenue in connection with the termination of our former research and development collaboration agreement with Eli Lilly and Company, or &#8220;Lilly,&#8221; we have never been profitable and have incurred net losses since the commencement of our operations. Our net losses for the years ended December 31, 2022 and 2021 were $74.9 million and $69.4 million, respectively. As of December 31, 2022, we had an accumulated deficit of $261.8, million primarily as a result of research and development and general and administrative expenses. We do not expect to generate product revenue unless and until we obtain marketing approval for and commercialize a product candidate, and we cannot make assurances that we will ever generate significant revenue or profits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have funded our operations to date primarily with proceeds from public offerings of our common stock, with private placements of our preferred stock and with upfront fees received under our former research collaboration and development agreement with Lilly, or the &#8220;Lilly Agreement,&#8221; which was terminated in March 2020. From our inception through December 31, 2022, we received gross proceeds of $164.4 million through private placements of preferred stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In November 2018, we entered into the Lilly Agreement to use our FIND-IO platform to identify novel oncology targets for additional collaborative research and drug discovery by us and Lilly. We received an upfront payment of $25.0 million in cash and an equity investment of $15.0 million from Lilly upon entering into the Lilly Agreement, and we were eligible for quarterly research and development support payments during a portion of the term of the Lilly Agreement. Effective March 3, 2020, Lilly terminated the Lilly Agreement without cause.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 13, 2019, we closed our initial public offering, or IPO, in which we sold 5,750,000 shares of common stock, at a public offering price of $15.00 per share, for aggregate gross proceeds of $86.3 million. The net offering proceeds to us were approximately $77.0 million after deducting underwriting discounts and commissions of $6.0 million and offering expenses of $3.4 million. See Note 1 to our audited financial statements included elsewhere in this Annual Report for more information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On November 19, 2019, we completed an underwritten public offering, in which we issued and sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at the public offering price of $36.75, for </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">77</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">total net proceeds to us of approximately $160.9 million after deducting underwriting discounts and commissions of approximately $10.3 million and offering expenses of approximately $1.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had cash, cash equivalents and marketable securities, excluding restricted cash, of $159.9 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into mid-2025. We have based this estimate on assumptions that may prove to be incorrect, and we could exhaust our available capital resources sooner than we currently expect.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expect to incur substantial expenditures in the foreseeable future as we advance our product candidates through clinical development, the regulatory approval process and, if approved, commercialization. Specifically, in the near term, we expect to incur substantial expenses relating to our Phase 1b/2 clinical trial of NC410 in combination with pembrolizumab, our ongoing Phase 1/2 clinical trial for NC762, our ongoing Phase 1 clinical trial for NC525, and, and other research and development activities. We expect to continue to incur significantly increased costs as a result of operating as a public company, including significant legal, accounting, investor relations and other expenses that we did not incur as a private company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will need substantial additional funding to support our continuing operations and to pursue our development strategy. Until such time as we can generate significant revenue from sales of our product candidates, if ever, we expect to finance our operations through a combination of public and private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, and licensing arrangements. Adequate funding may not be available to us on acceptable terms, or at all. If we fail to raise capital or enter into such agreements as and when needed, we may be required to delay, limit, reduce or terminate preclinical studies, clinical trials, or other research and development activities or one or more of our development programs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Components of Our Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Operating Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses consist primarily of costs incurred for our clinical trials, discovery efforts, research activities, and development and testing of our product candidates:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">expenses incurred under agreements with third parties, including agreements with third parties that conduct research, preclinical activities or clinical trials on our behalf, such as our license agreement with Yale University, or &#8220;Yale&#8221;;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">costs of outside consultants, including their fees, stock-based compensation and related travel expenses;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of laboratory supplies and acquiring, developing and manufacturing preclinical study and clinical trial materials; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">salaries, benefits and other related costs, including stock-based compensation, for personnel engaged in research and development functions;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">facility-related expenses, which include direct depreciation costs and allocated expenses for rent and maintenance of facilities and other operating costs.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We expense research and development costs as incurred. Our expenses related to clinical trials are based on actual costs incurred and estimates of other incurred costs. These estimated costs are based on several factors, including patient enrollment and related expenses at clinical investigator sites, contract services received, consulting agreement costs and efforts expended under contracts with research institutions and third-party contract research organizations that conduct and manage clinical trials on our behalf. We generally accrue estimated costs related to clinical trials based on contracted amounts applied to the level of patient enrollment and other activity according to the protocol. If future timelines or contracts are modified based on changes in the clinical trial protocol or scope of work to be performed, we would modify our estimates of accrued expenses accordingly on a prospective basis. Historically, any such modifications have not been material.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">78</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development activities are central to our business model. We expect that our research and development expenses will continue to increase substantially for the foreseeable future as we advance our product candidates through development and expand the number of trials we are conducting and the patients enrolled in those trials, as we utilize our current good manufacturing practice, or &#8220;cGMP&#8221;, manufacturing capacity, including to provide drug supply of NC410, NC762 and NC525 for future clinical trials.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We cannot determine with certainty the duration and costs of future clinical trials of NC410, NC762, NC525 or any other product candidate we may develop or if, when or to what extent we will generate revenue from the commercialization and sale of any product candidate for which we may obtain marketing approval. We may never succeed in obtaining marketing approval for any product candidate. The duration, costs and timing of clinical trials and development of NC410, NC762, NC525 and any other product candidate we may develop will depend on a variety of factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of clinical trials of NC410, NC762 and NC525, as well as of any future clinical trials of other product candidates and other research and development activities that we may conduct;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the impact of the COVID-19 pandemic, including delays and slowdowns as a result of strain on our clinical trial sites and concerns about patient safety;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">uncertainties in selection of indications, clinical trial design and patient enrollment rates;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the probability of success for our product candidates, including safety and efficacy, early clinical data, competition, ease and ability of manufacturing and commercial viability;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">significant and changing government regulation and regulatory guidance;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing and receipt of any development or marketing approvals; and</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the expense of filing, prosecuting, defending and enforcing any patent claims and other intellectual property rights.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">A change in the outcome of any of these variables with respect to the development of a product candidate could lead to a significant change in the costs and timing associated with the development of that product candidate. For example, if the FDA or another regulatory authority were to require us to conduct clinical trials beyond those that we anticipate will be required for the completion of clinical development of a product candidate, or if we experience significant delays in our clinical trials due to patient enrollment or other reasons, we would be required to expend significant additional financial resources and time to complete clinical development for any such product candidate.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses consist primarily of personnel-related costs, including payroll and stock-based compensation, for personnel in executive, finance, human resources, business and corporate development and other administrative functions, professional fees for legal, intellectual property, consulting and accounting services, rent and other facility-related costs, depreciation and other general operating expenses not otherwise classified as research and development expenses. General and administrative expenses also include all patent-related costs incurred in connection with filing and prosecuting patent applications, which are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We anticipate that our general and administrative expenses will increase during the next few years as a result of staff expansion, additional occupancy costs, higher legal and accounting fees, investor relations costs, higher insurance premiums and other compliance costs.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Other Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other income, net consists primarily of interest income earned on marketable securities and payment of interest on our term loan with a commercial bank, or the &#8220;Term Loan&#8221;, which was paid in full and closed in August 2021.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">79</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Results of Operations</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comparison of the Years Ended December&#160;31, 2022 and 2021</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table summarizes our results of operations for the periods indicated (in thousands):</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:59.53%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:59.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:25.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.1%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.72%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;width:59.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:59.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,199</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,192</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,007</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 21,710</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 20,573</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,137</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (75,909)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (70,765)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,144)</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other income, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,176</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,376</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (200)</span></p></td></tr><tr><td style="vertical-align:bottom;width:59.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.94%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (74,733)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (69,389)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.6%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (5,344)</span></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Research and Development Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes our research and development expenses by product candidate for the periods indicated (in thousands):</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:53.08%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.36%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Change</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">External research and development expenses:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NC410</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 6,211</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,533</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,678</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NC762</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,966</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,710</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,256</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">NC525</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,053</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 2,278</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 1,775</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other programs and preclinical development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 15,941</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 18,388</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (2,447)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total external research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 31,171</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 27,909</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 3,262</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total internal research and development expenses </p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 23,028</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 22,283</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 745</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:53.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total research and development expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 54,199</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 50,192</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.12%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.24%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 4,007</span></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We do not allocate personnel-related costs, including stock-based compensation costs, or other indirect costs to specific programs, as they are deployed across multiple projects under development and discovery and, as such are separately classified as internal research and development expenses in the table above.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research and development expenses for the year ended December 31, 2022 increased by $4.0 million to $54.4 million compared to $50.2 million for the year ending December 31, 2021. The increase was driven primarily by $3.3 million in clinical-related and $1.6 million in personnel-related expenses, partially offset by lower internal research costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">General and Administrative Expenses</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">General and administrative expenses for the year ended December 31, 2022 increased by $1.1 million to $21.7 million as compared to $20.6 million for the year ending December 31, 2021. The increase was driven primarily by $1.1 million higher personnel-related costs and $0.2 million in higher occupancy costs, partially offset by $0.4 million lower professional services expenses.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Other Income, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Other income, net for the year ended December 31, 2022 decreased by $0.2 million to $1.2 million from $1.4 million for the year ended December 31, 2021 due to lower interest income as a result of lower cash and investments. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Liquidity and Capital Resources</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We have financed our operations primarily with proceeds from public offerings of our common stock, with private placements of our preferred stock and with upfront fees received under the Lilly Agreement. On May 13, 2019, we closed our IPO in which we sold 5,750,000 shares of common stock at a public offering price of $15.00 per share, for aggregate </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">80</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">gross proceeds of $86.3 million. The net offering proceeds to us were approximately $77.0 million after deducting underwriting discounts and commissions and offering expenses. On November 19, 2019, we completed an underwritten public offering, in which we sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at the public offering price of $36.75 per share. The total gross proceeds to us were $172.2 million and the total net offering proceeds to us were approximately $160.9 million after deducting underwriting discounts and commissions and offering expenses. Since inception, we have received aggregate gross proceeds of $164.4 million from the sale and issuance of shares of our preferred stock. In addition, in November 2018, we received an upfront payment of $25.0 million in cash from Lilly pursuant to the Lilly Agreement. Our cash equivalents are held in money market funds. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 6, 2021, the Company entered into a sales agreement, or the &#8220;Sales Agreement,&#8221; with SVB Leerink LLC, or the &#8220;Agent&#8221;, pursuant to which the Company may sell, from time to time, up to an aggregate sales price of $75 million of its common stock through the Agent in negotiated transactions that are deemed to be an &#8220;at the market offering.&#8221; The Agent will be entitled to compensation equal to 3.0% of the gross proceeds from the sale of all shares of common stock sold through it as Agent under the Sales Agreement. Actual sales will depend on a variety of factors to be determined by the Company from time to time, including, among other things, market conditions, the trading price of the common stock, capital needs and determinations by the Company of the appropriate sources of funding for the Company. We have not yet sold any shares of our common stock pursuant to the Sales Agreement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, we had cash, cash equivalents and marketable securities, excluding restricted cash, of $159.9 million. We believe that our existing cash, cash equivalents and marketable securities will be sufficient to fund our planned operations into mid-2025. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We will continue to require additional capital to develop our product candidates and fund operations for the foreseeable future. We may seek to raise capital through sale of equity, debt financings, strategic alliances and licensing arrangements. Adequate additional funding may not be available to us on acceptable terms or at all. If we fail to raise capital or enter into such agreements as and when needed, we may have to significantly delay, scale back or discontinue the development of our product candidates or delay our efforts to expand our pipeline of product candidates. Our need to raise additional capital will depend on many factors, including:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the scope, progress, results and costs of researching and developing NC410, NC762, NC525 and our other programs, including targets identified through our FIND-IO platform, and of conducting preclinical studies and clinical trials;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing of, and the costs involved in, obtaining marketing approvals for NC410, NC762, NC525 and any future product candidates we develop, if clinical trials are successful;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of manufacturing NC410, NC762, NC525 and any future product candidates we develop for preclinical studies and clinical trials in preparation for marketing approval and commercialization;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs of commercialization activities, including marketing, sales and distribution costs, for NC410, NC762, NC525 and any future product candidates we develop, whether alone or with a collaborator, if any such product candidates are approved for sale, including marketing, sales and distribution costs;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our ability to establish and maintain additional collaborations, licenses or other arrangements on favorable terms, if at all;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the costs involved in preparing, filing, prosecuting, maintaining, expanding, defending and enforcing patent claims, including litigation costs and the outcome of any such litigation;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">our current collaboration and license agreements remaining in effect and our achievement of milestones and the timing and amount of milestone payments we are required to make, or that we may be eligible to receive, under those agreements;</span></td></tr></table><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:12pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the timing, receipt and amount of sales of, or royalties on, our future products, if any; and </span></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">81</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">&#9679;</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">the emergence of competing therapies and other adverse developments in the oncology market.</span></td></tr></table><div style="margin-top:12pt;"></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Adequate additional financing may not be available to us on acceptable terms, or at all. If we raise additional funds by issuing equity securities, our stockholders may experience dilution. Any future debt financing into which we enter may impose upon us additional covenants that restrict our operations, including limitations on our ability to incur liens or additional debt, pay dividends, repurchase our common stock, make certain investments and engage in certain merger, consolidation or asset sale transactions. Any debt financing or additional equity that we raise may contain terms that are not favorable to us or our stockholders. If we raise additional funds through government or private grants, collaborations, strategic alliances or marketing, distribution or licensing arrangements with third parties, we may be required to relinquish valuable rights to our future revenue streams, product candidates or research programs or to grant licenses on terms that may not be favorable to us. If we are unable to raise additional funds when needed, we may be required to delay, reduce or terminate some or all of our development programs and clinical trials. We may also be required to sell or license to others rights to our product candidates in certain territories or indications that we would prefer to retain for ourselves. See the section entitled &#8220;Risk Factors&#8221; for additional risks associated with our substantial capital requirements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Cash Flows</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The following table sets forth the primary sources and uses of cash and cash equivalents for each of the periods presented below (in thousands):</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:71.61%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:71.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.75%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net cash (used in) provided by:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (53,886)</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (57,283)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 67,979</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 36,601</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.61%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 200</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (3,265)</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.61%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Net increase (decrease) in cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.81%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="white-space:pre-wrap;"> 14,293</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.82%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.92%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="white-space:pre-wrap;"> (23,947)</span></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cp_text_1_212"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash Used in Operating Activities</p><a id="_cp_text_1_213"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Net cash used in operating activities was $53.9 million for the year ended December 31, 2022, which was primarily due to our net loss of $74.7 million, partially offset by non-cash charges for depreciation and amortization of $4.1 million, amortization of premiums and discounts on marketable securities of $3.0 million, stock-based compensation of $9.5 million, a $2.0 million decrease in prepaid expenses and other assets and a $2.3 million increase in accounts payable. Net cash used in operating activities was $57.3 million for the year ended December 31, 2021, which was primarily due to our net loss of $69.4 million, an increase in prepaid expenses of $4.9 million, and $2.0 million lower accounts payable, partially offset by non-cash charges for depreciation and amortization of $4.2 million, amortization of premiums and discounts on marketable securities of $3.0 million, stock-based compensation of $10.3 million and $1.7 million higher deferred rent.</p><a id="_cp_text_1_214"></a><a id="_cp_text_1_215"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash Provided by Investing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by investing activities for the year ended December 31, 2022 was $68.0 million, which was primarily due to net proceeds from marketable securities of $70.1 million, partially offset by purchases of property and equipment of $2.1 million. &#160;Cash provided by investing activities for the year ended December 31, 2021 was $36.6 million, which was primarily due to net proceeds from marketable securities of $39.0 million, partially offset by purchases of property and equipment of $2.4 million. </p><a id="_cp_text_1_216"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;margin:0pt 0pt 10pt 0pt;">Cash Used in Financing Activities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Cash provided by financing activities was $0.2 million for the year ended December 31, 2022, which was due to the exercise of stock options and sales of our stock under the Employee Stock Purchase Plan (ESPP). Cash used in financing activities was $3.3 million for the year ended December 31, 2021, which consisted primarily of payments related to the closure of the Term Loan.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">82</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cp_text_1_218"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Contractual Obligations and Commitments</p><a id="_cp_text_1_219"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Operating Leases</b></p><a id="_cp_text_1_220"></a><a id="_cp_text_1_222"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We are party to several non-cancelable lease agreements for office and laboratory space that expire in March 2030. &#160;The monthly base rent for these leases totals $89,319 as of December 31, 2022 per month plus our prorated share of operating expenses. &#160;The monthly base rent is subject to annual 3% increases through the lease term.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Term Loan</p><a id="_cp_text_1_223"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April 2016, we entered into a $1.0 million term loan, or the Term Loan. In January 2019, we amended the Term Loan to increase our borrowing capacity to $5.0 million, secured by our certificates of deposit, money market account, investment property and deposit or investment accounts. In August 2021, we fully paid the remaining principal balance of $2.4 million of the Term Loan. Interest expense under the Term Loan was approximately $77,000 for the year ended December 31, 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We also have potential contingent payment obligations upon the achievement by us of clinical, regulatory, and commercial events, as applicable, or royalty payments that we may be required to make under license agreements we have entered into with various entities pursuant to which we have in-licensed intellectual property, including our license agreement with Yale. The timing and amount (if any) of any such payments cannot be reasonably estimated at this time. See &#8220;Business&#8212;Our Collaboration Agreements&#8221; for additional information.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We enter into contracts in the normal course of business with third-party contract organizations for clinical trials, non-clinical studies and testing, manufacturing and other services and products for operating purposes. These contracts generally provide for termination following a certain period after notice, and therefore we believe that our non-cancelable obligations under these agreements are not material. </p><a id="_cp_text_1_226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Critical Accounting Policies, Significant Judgments and Use of Estimates</p><a id="_cp_text_1_227"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our financial statements have been prepared in accordance with U.S. generally accepted accounting principles, or &#8220;GAAP&#8221;. The preparation of our financial statements requires us to make estimates and assumptions that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported expenses incurred during the reporting periods. The most significant assumptions used in the financial statements are valuing share-based compensation. Our estimates are based on our historical experience and on various other factors that we believe are reasonable under the circumstances, the results of which form the basis for making judgments about the carrying value of assets and liabilities that are not readily apparent from other sources. We evaluate our estimates and assumptions on an ongoing basis. Actual results may differ from these estimates under different assumptions or conditions. </p><a id="_cp_text_1_228"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">While our significant accounting policies are described in the notes to our financial statements, we believe that the following critical accounting policies are most important to understanding and evaluating our reported financial results, as these policies relate to the more significant areas involving management&#8217;s judgments and estimates.</p><a id="_cp_text_1_229"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Research and Development Expenses, Including Clinical Trial Accruals</b></p><a id="_cp_text_1_230"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates which are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as CROs, are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, we analyze progress of the studies, including the phase or completion of events, invoices received and contracted costs. For further discussion of research and development expenses, including clinical trial accruals, see Note 2 to our audited financial statements included elsewhere in this Annual Report. </p><a id="_cp_text_1_231"></a><a id="_cp_text_1_232"></a><a id="_cp_text_1_233"></a><a id="_cp_text_1_235"></a><a id="_cp_text_1_236"></a><a id="_cp_text_1_237"></a><a id="_cp_text_1_238"></a><a id="_cp_text_1_239"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"><b style="font-style:normal;font-weight:bold;">Stock-Based Compensation</b></p><a id="_cp_text_1_240"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">We account for stock-based compensation, including stock options and restricted stock units, based on the fair value of the award as of the grant date. We utilize the Black-Scholes option-pricing model as the method for estimating </p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">83</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">the fair value of our stock option grants. The Black-Scholes option-pricing model requires the use of highly subjective and complex assumptions, including the options&#8217; expected term and the price volatility of the underlying stock. The fair value of the portion of the award that is ultimately expected to vest is recognized as compensation expense over the award&#8217;s requisite service period. We recognize stock-based compensation to expense using the straight-line method and recognize forfeitures as they occur. If there are any modifications or cancelations of stock-based awards, we may be required to accelerate, increase, or decrease any remaining unrecognized stock-based compensation expense.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For further discussion of our accounting for stock-based compensation, see Note 2 to our audited financial statements included elsewhere in this Annual Report.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Off-Balance Sheet Arrangements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Since our inception, we have not engaged in any off-balance sheet arrangements, as defined in the rules and regulations of the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">JOBS Act Accounting Election</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Jumpstart Our Business Startups Act of 2012, or &#8220;the JOBS Act&#8221;, permits an &#8220;emerging growth company&#8221; such as us to take advantage of an extended transition period to comply with new or revised accounting standards applicable to public companies. We have elected to take advantage of this extended transition period to enable us to comply with new or revised accounting standards that have different effective dates for public and private companies until the earlier of the date we (i) are no longer an emerging growth company or (ii) affirmatively and irrevocably opt out of the extended transition period provided in the JOBS Act. As a result, our financial statements may not be comparable to companies that comply with new or revised accounting pronouncements as of public company effective dates.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">For so long as we remain an emerging growth company, we are permitted and intend to rely on certain exemptions from various public company reporting requirements, including not being required to have our internal control over financial reporting audited by our independent registered public accounting firm pursuant to Section&#160;404(b) of the Sarbanes-Oxley Act of 2002. We will remain an emerging growth company until the earliest of (i)&#160;December&#160;31, 2024, (ii)&#160;the last day of the first fiscal year in which we have total annual gross revenues of at least $1.2&#160;billion, (iii)&#160;the last day of the first fiscal year in which the market value of our common stock that is held by non-affiliates exceeds $700.0&#160;million on June&#160;30<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">th</sup> and (iv)&#160;the date on which we have issued more than $1.0&#160;billion in non-convertible debt securities during the prior three-year period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Recent Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">See Note 2 to our audited financial statements included elsewhere in this Annual Report for a discussion of recent accounting pronouncements that have impacted or may impact our financial position and results of operations.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_62778d77_e5de_4947_9b0e_b8f1c78ad497"></a><a id="Item7AQuantitativeandQualitative_728376"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 7A. Quantitative and Qualitative Disclosure About Market Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As a smaller reporting company, we are not required to provide the information requested by this Item.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">84</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_2a7a84f5_1f55_4612_8fe4_ce1c8fb6bbd0"></a><a id="Item8FinancialStatements_538537"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 8. Financial Statements and Supplementary Data</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">INDEX TO FINANCIAL STATEMENTS</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.2%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Page</b></p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"><span style="font-style:normal;font-weight:normal;">Report of Independent Registered Public Accounting Firm</span></a> (PCAOB ID: <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:AuditorFirmId" id="Narr_ZOGLLnlV_0O_2Taqo1bS4g">42</ix:nonNumeric>)</p></td><td style="vertical-align:bottom;width:6.2%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">86</p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#BALANCESHEETS_873817"><span style="font-style:normal;font-weight:normal;">Balance Sheets as of December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">87</p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFOPERATIONSANDCOMPREHENSIVELO"><span style="font-style:normal;font-weight:normal;">Statements of Operations and Comprehensive Loss for the Years Ended December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">88</p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDER"><span style="font-style:normal;font-weight:normal;">Statements of Stockholders&#8217; Equity for the Years Ended December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">89</p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#STATEMENTSOFCASHFLOWS_298484"><span style="font-style:normal;font-weight:normal;">Statements of Cash Flows for the Years Ended December 31, 2021 and 2020</span></a></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">90</p></td></tr><tr><td style="vertical-align:top;width:93.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><a href="#NOTESTOFINANCIALSTATEMENTS_913411"><span style="font-style:normal;font-weight:normal;">Notes&#160;to Financial Statements</span></a></p></td><td style="vertical-align:bottom;width:6.2%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">91</p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">85</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_cf528784_aefe_416f_ba3b_9084f2442933"></a><a id="REPORTOFINDEPENDENTREGISTEREDPUBLICACCOU"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">REPORT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">To the Stockholders and the Board of Directors of NextCure,&#160;Inc.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Opinion on the Financial Statements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We have audited the accompanying balance sheets of NextCure,&#160;Inc. (the &#8220;Company&#8221;) as of December&#160;31, 2022 and 2021, the related statements of operations and comprehensive loss, stockholders&#8217; equity and cash flows for the&#160;years then ended and the related notes (collectively referred to as the &#8220;financial statements&#8221;). In our opinion, the financial statements present fairly, in all material respects, the financial position of the Company at December&#160;31, 2022 and 2021, and the results of its operations and its cash flows for the&#160;years then ended in conformity with U.S. generally accepted accounting principles.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 6pt 0pt;">Basis for Opinion</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">These financial statements are the responsibility of the Company&#8217;s management. Our responsibility is to express an opinion on the Company&#8217;s financial statements based on our audits. We are a public accounting firm registered with the Public Company Accounting Oversight Board (United States) (PCAOB) and are required to be independent with respect to the Company in accordance with the U.S. federal securities laws and the applicable rules&#160;and regulations of the Securities and Exchange Commission and the PCAOB.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">We conducted our audits in accordance with the standards of the PCAOB. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement, whether due to error or fraud. The Company is not required to have, nor were we engaged to perform, an audit of its internal control over financial reporting. As part of our audits we are required to obtain an understanding of internal control over financial reporting but not for the purpose of expressing an opinion on the effectiveness of the Company&#8217;s internal control over financial reporting. Accordingly, we express no such opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our audits included performing procedures to assess the risks of material misstatement of the financial statements, whether due to error or fraud, and performing procedures that respond to those risks. Such procedures included examining, on a test basis, evidence regarding the amounts and disclosures in the financial statements. Our audits also included evaluating the accounting principles used and significant estimates made by management, as well as evaluating the overall presentation of the financial statements. We believe that our audits provide a reasonable basis for our opinion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:AuditorName" id="Narr_evbxOb4RCk-QNn4DCuN1Sg">Ernst&#160;&amp; Young LLP</ix:nonNumeric><br /><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">We have served as the Company&#8217;s auditor since 2018.<br /><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="dei:AuditorLocation" id="Narr_wQ0UOSl9_Umd5RxNVZTTsw">Baltimore, MD</ix:nonNumeric><br />March 2, 2023</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">86</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_e2bdf989_dcae_47e0_82ef_4cebdac124ca"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><a id="BALANCESHEETS_873817"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">BALANCE SHEETS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(in thousands, except share and per share amounts)</p><a id="_13f5efca_f111_4d2f_89e5_2b0952f0e94d"></a><a id="Tc_ScPAN8TGM0aQU5QqRaNtgw_1_2"></a><a id="Tc_Oh4fWKcGbUe0-tNJI8xMqw_1_5"></a><a id="Tc_pwjAUh_2JU-ku56ckkLuFQ_2_2"></a><a id="Tc_nN2xfIsZ2U6bjyag_vI-cQ_2_5"></a><a id="Tc_Pl1kQcHjQUSpWnCiy13ruw_3_0"></a><a id="Tc_dmNIJshne0ejemcvkEidvQ_4_0"></a><a id="Tc_jR5lhEdY2UGAgspV485-qg_5_0"></a><a id="Tc_GsgfWnleMEyBMw4N5QZgFQ_5_2"></a><a id="Tc_mGxWazxMak6Z1LSF9OA1xg_5_5"></a><a id="Tc_kjxaxizuIUyfA4FnVHFQDg_6_0"></a><a id="Tc_kdgl7XJpiUWUzJDobIrtJA_7_0"></a><a id="Tc_NqAvSSHm4UiNvasqGEWsPA_8_0"></a><a id="Tc_F0BII3UfVUuE1UwepkdBvQ_9_0"></a><a id="Tc_QaSUKM2S20idqt_jWGhn6A_10_0"></a><a id="Tc_gyHiT-xMy02FcbQ-KVriOA_10_6"></a><a id="Tc_DMaeULOqtECnACTQlWplpQ_11_0"></a><a id="Tc_roPaaE_TJEG4FN5zemduKg_12_0"></a><a id="Tc_ifzLFbVkEEKiZh_uCAbMkQ_12_2"></a><a id="Tc_ld36OoEEj0qPr54UV_1Xew_12_5"></a><a id="Tc_geUrFdFx1k6DjgAu6-qICg_13_0"></a><a id="Tc_YrPB3OqBF0Gyf-896o4oZw_14_0"></a><a id="Tc_9srv0YiocECfKBqYcMpmXw_15_0"></a><a id="Tc_a-iJDtr91UGZWub8HoXQsw_15_2"></a><a id="Tc__PXsywulV0GO-895KBrElQ_15_5"></a><a id="Tc_TimbJpxnWUqmu2S3u3DPtg_16_0"></a><a id="Tc_JxRFdr9azEidefGEfqFOLg_17_0"></a><a id="Tc_Droy5uXLbUmQLCso1vKHxQ_18_0"></a><a id="Tc_WteRB7ZL3ECpF0lAF5CjwA_18_6"></a><a id="Tc_0UsR0S3ia0imZ-4Hr2ExAA_19_0"></a><a id="Tc_OJWJBEWLH0Kzu6mPCR2nNQ_20_0"></a><a id="Tc_9ODKN63qZ0OvHc6WdB8IrQ_21_0"></a><a id="Tc_6mavXYWtsEap0Cr8oW9PMw_22_0"></a><a id="_37c6d270_7c55_4285_93d1_fd773ea5432d"></a><a id="_37c6d270_7c55_4285_93d1_fd773ea5432d_2"></a><a id="_37c6d270_7c55_4285_93d1_fd773ea5432d_3"></a><a id="Tc_-2d8vhlQmUS6m7I8SKQ7Jg_23_0"></a><a id="Tc_XTmceRBztk-eSTJKaX35gg_24_0"></a><a id="Tc_p6PjdlaNiUq7b8az4I2YLg_25_0"></a><a id="Tc_FIAhBAVhbUmI7KvbUjp6LA_26_0"></a><a id="Tc_VQP1cRHiRE-MiDSxfT79aA_27_0"></a><a id="Tc_jgwjqiX9b0K-M-EBx_124w_28_0"></a><a id="Tc_GtSc3nM49kuz-fRvAioDSA_28_2"></a><a id="Tc_3PoOCYUw4EmOp3B9QyaeOw_28_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Cash and cash equivalents</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_WqZ5xQluaEuJcsKxlIHCog_5_3">26,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsAtCarryingValue" scale="3" id="Tc_wWciG5iERUKxpT8Gb0QD9A_5_6">12,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" scale="3" id="Tc_xKHkHZHRiUms_zcHN83h3A_6_3">133,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" scale="3" id="Tc_7IXctEqPlUGTkLN6rsjKnw_6_6">207,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Prepaid expenses and other current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_xa80vgHJJ0GS27he31iXWw_7_3">4,072</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PrepaidExpenseAndOtherAssetsCurrent" scale="3" id="Tc_VqTFzm8CyUSlTmw-WRdajA_7_6">8,226</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total current assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_SH6mQySWK06vkbFxR5cD6g_8_3">163,983</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AssetsCurrent" scale="3" id="Tc_nxDEFI6DxEaR1nQOh5TeHw_8_6">227,817</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_AO19nG2vOEqr_Kxgfg-Iag_9_3">11,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_ZKVN1oFmUUe-52GsExzVRA_9_6">13,992</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Right of use assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseRightOfUseAsset" scale="3" id="Tc_NMOIqOfi3UKBkQlaRIQCWg_10_3">5,016</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_0L3WlPygOEiN9SjPkIrwnQ_11_3">3,265</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherAssetsNoncurrent" scale="3" id="Tc_kYRfCZ_wdk6OJZxbnxbT2w_11_6">577</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_xHKY2a15qUatkTSJxdOZKA_12_3">184,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Assets" scale="3" id="Tc_CeZRwZGWtkGu710Rdk54DQ_12_6">242,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;"><b style="font-weight:bold;">Liabilities and Stockholders&#8217; Equity</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Current liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_mMCTWh7dgEWHzMtr3osgKA_15_3">4,270</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccountsPayableCurrent" scale="3" id="Tc_dpIhyCw27EqO_r8rFsBc3g_15_6">1,942</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accrued liabilities and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_NXVZcQxyBUiQqURNbZnCJA_16_3">4,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_WGwEbJDOOEWJESjzJqBHoA_16_6">4,666</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total current liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_9hy_jdNU8kadG4nAAuy4Ag_17_3">9,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesCurrent" scale="3" id="Tc_paywTOx2jEmigd7fU42AGw_17_6">6,608</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Lease liabilities, long term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityNoncurrent" scale="3" id="Tc_VGzpCPMsk0uVWkuQacaKrw_18_3">6,605</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_TQrLB_0oO0aje_d2_CkWZw_19_3">899</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesNoncurrent" scale="3" id="Tc_u0n6kvajKUCsd3vFi6pbZw_19_6">2,392</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_-FdEmOMyu0uqmXTSX7G-Xw_20_3">16,631</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:Liabilities" scale="3" id="Tc_dvcmLahCIUWzzweVkPQ5Fg_20_6">9,000</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Stockholders&#8217; equity:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Preferred stock, par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_DEO4EqE-NUerZHwnud1gfg"><ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_Ong1Pl9l30KKQse92PVZjw">0.001</ix:nonFraction></ix:nonFraction> per share; <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_hkV__qGtfEecP-7J3bFngA"><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_xYjkaa8zCEa1KIgTT9CzJg">10,000,000</ix:nonFraction></ix:nonFraction> shares authorized at December&#160;31,&#160;2022 and December&#160;31,&#160;2021; <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_6b1miATcLEaEOJJsBk-yaw"><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesIssued" scale="0" id="Narr_e19eoA1mukiXtyJMqUo8Bg">No</ix:nonFraction></ix:nonFraction> shares issued and outstanding at December&#160;31,&#160;2022 and December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_ckQuX0NUl067JlGreg9o-Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><span style="-sec-ix-hidden:Hidden_AVNy09DaIUuRzQxF2MJKCA;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;"> &#8212;</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:9pt;">Common stock, par value of </span><span style="font-size:9pt;">$<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_VgvoWQ15y0Sv5qw7UGkXvA"><ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_WK773u1R90KV2nrJ3Ch8_g">0.001</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> per share; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_RxXG88p9p0iuY5XB3qWryg"><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_SLrJk-phJE2B7Ogt8ZwGnQ">100,000,000</ix:nonFraction></ix:nonFraction></span><span style="font-size:9pt;"> shares authorized at December&#160;31,&#160;2022 and December&#160;31,&#160;2021; </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_d9Sd815NiEavDVu7U7FmkQ">27,774,536</ix:nonFraction></span><span style="font-size:9pt;"> and </span><span style="font-size:9pt;"><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_vDfZ2d-gYUmqbJCsFGWMRg">27,680,997</ix:nonFraction></span><span style="font-size:9pt;"> shares </span><span style="-sec-ix-hidden:Hidden_EjCt_RanekGTBb6zLZI6cg;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">issued</span></span><span style="font-size:9pt;"> and </span><span style="-sec-ix-hidden:Hidden_0ZTpWsbJLEqaeEw3VSWmxw;"><span style="font-family:'Times New Roman','Times','serif';font-size:9pt;font-style:normal;font-weight:normal;">outstanding</span></span><span style="font-size:9pt;"> at December&#160;31,&#160;2022 and December&#160;31,&#160;2021, respectively</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc__7Z7R_5lxUy6eM-4CuM8PA_23_3">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CommonStockValue" scale="3" id="Tc_uT87R6HfXUa6Leb505S6qQ_23_6">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Additional paid-in capital</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_pduc90KgnkGfUGZWaDfi0g_24_3">430,755</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdditionalPaidInCapital" scale="3" id="Tc_63l3KFOJBEe54B60roF10w_24_6">421,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated other comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_6S5SvKosKkqyxngRBkPBOA_25_3">1,494</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax" sign="-" scale="3" id="Tc_61OyH8imZkOob_-Dhha-ow_25_6">663</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt 0pt 0pt 6pt;">Accumulated deficit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_StgDNkgo8UK9y60Vm43EDQ_26_3">261,759</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RetainedEarningsAccumulatedDeficit" sign="-" scale="3" id="Tc_o3FeYiT0UkiepPUZQ6hbLg_26_6">187,026</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Wk3Zgs2MsUqv6XP6ywAorg_27_3">167,530</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_WP4Wf6Lo6UKypDdt8KoeOA_27_6">233,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:72.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">Total liabilities and stockholders&#8217; equity</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc__H6hmOgV802yhaCaT_-YaA_28_3">184,161</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.46%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:9pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LiabilitiesAndStockholdersEquity" scale="3" id="Tc_e2BG_lLpFkOywVA2xDYtjA_28_6">242,386</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:9pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">87</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_c3dae6c6_370f_4a4e_a0c5_a6adcf0ee29a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><a id="STATEMENTSOFOPERATIONSANDCOMPREHENSIVELO"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(in thousands, except share and per share amounts)</p><a id="_e92848bc_e745_4610_b772_e5b0ed31bb13"></a><a id="Tc_f0IG0xtDIESTwRneLs7qYQ_1_3"></a><a id="Tc_7hX3pnlQ_0KafMwWXJxDaA_2_3"></a><a id="Tc_ODqHgirEo0eDOmAGJqxVkA_2_6"></a><a id="Tc_o2fCVtQfhUaCR2thWHykCA_3_2"></a><a id="Tc_gP8Ay3WcvEetOT24xeNCZw_3_5"></a><a id="Tc_EXSzawA0ykSdi1x9loi1mQ_4_0"></a><a id="Tc_OiM2BoFDhUSjApb697xafA_5_0"></a><a id="Tc_V23v1WAWUUyU_jp6MpRm4g_5_2"></a><a id="Tc_23xm_Tju7Uy6RVXVSKtNCg_5_5"></a><a id="Tc_sosKgvg3OUy8B3FvGBkyzQ_6_0"></a><a id="Tc_K4aOhJZIE0GVPjqbvcNcpg_7_0"></a><a id="Tc_GtsvHIN4y0a0sNFvbZ4GcA_8_0"></a><a id="Tc_Sehbn9NU8UG0TgqRt0NiHg_9_0"></a><a id="Tc_f7mXL6QK2EGirme4ETq90A_10_0"></a><a id="Tc_eVMdSmdCe0GyJjBaGOsZFQ_10_2"></a><a id="Tc_F2xhtbJ8XEi7UlN_3qLxKw_10_5"></a><a id="Tc_8Q9YsIUzSkKtuUuoSIVJog_11_0"></a><a id="Tc_U_bIK9gy7UGmTD9vMhQZRQ_12_0"></a><a id="Tc_W881mJusPkuBdLrrbWw8WQ_13_0"></a><a id="Tc_H7LzddbQPUi4pnXjPKfi8w_14_0"></a><a id="Tc_Q4WIknD96UGleNTqpIA8Xg_14_2"></a><a id="Tc_ufI_XD_Db0uRqQIpL3T5WQ_14_5"></a><a id="Tc_99w8PeumCkacqgydjuSJWQ_15_0"></a><a id="Tc_oZMffhkakkeD2D-2IOStpw_16_0"></a><a id="Tc_HmnKlInLRU-GWBNoA2FIEw_16_2"></a><a id="Tc_8Z4qprwJak6_7tQfeZ4ESg_16_5"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:32.39%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#ffffff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.23%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses: </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_iYUyMpp5TUajdWA7qxOz2Q_5_3">54,199</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ResearchAndDevelopmentExpense" scale="3" id="Tc_7KJZu7tPyUKxb6PNo7sNVQ_5_6">50,192</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_9O8TJ3w_X0y_Y-ofpcnZew_6_3">21,710</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GeneralAndAdministrativeExpense" scale="3" id="Tc_MgmpUgQbMkaZK0mUCjSrBQ_6_6">20,573</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_izDGWN5qKUeWs7wgikNkyw_7_3">75,909</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingExpenses" scale="3" id="Tc_bGDngJ8h20qTHcAiMLKYJA_7_6">70,765</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Loss from operations</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_w57MaYMO6kmrTp-9Ws0etg_8_3">75,909</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingIncomeLoss" sign="-" scale="3" id="Tc_Lpq7dkNDjEe0GdGwSnOPlw_8_6">70,765</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Other income, net </p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_K8dYn5RczEqnnk9TGzc8zw_9_3">1,176</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherNonoperatingIncomeExpense" scale="3" id="Tc_2zq8XoRwbUemX_oY3JJwIg_9_6">1,376</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_-617HSPj1UezjTtyfQxxeg_10_3">74,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_f3tCSb8yqUebHVJDNKyOGQ_10_6">69,389</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net loss per common share - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_RXcXID7xNk6EeeFbPOwNnw;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_rxBN5QxC1k6ID1VeShzDPA_11_3">2.69</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_KIFVcKMshUCILTfOaw4l-Q;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">$</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:EarningsPerShareBasic" sign="-" scale="0" id="Tc_kbBasOFoOUKLmrTRoEfTcA_11_6">2.51</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Weighted-average shares outstanding - basic and diluted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_TSBVIz9kLESbDE2VbX0w5w_12_3">27,744,209</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:WeightedAverageNumberOfSharesOutstandingBasic" scale="0" id="Tc_VrOyQ-G_T0eJatjLE9el0w_12_6">27,615,977</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Comprehensive loss:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_mUlDCPf-30uNmcN_qMnXFw_14_3">74,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_3ZrCvKr6xUOuHXPc7J1nIg_14_6">69,389</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Unrealized (loss) on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_2DckmzqXYEaRJSYAtEnh8A_15_3">831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" sign="-" scale="3" id="Tc_V1wxB-Up_E-FYpyKGD8-Bg_15_6">1,442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:63.92%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total comprehensive loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.32%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_NcX57X96PU6AjQnE6R7qFQ_16_3">75,564</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.97%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.91%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.17%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ComprehensiveIncomeNetOfTax" sign="-" scale="3" id="Tc_AQnCSV93jUiD9UibHt5auA_16_6">70,831</ix:nonFraction>)</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">88</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:8%;padding-right:8%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_89b06f5d_3e20_4d52_842d_b7ce68c860da"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><a id="STATEMENTSOFPREFERREDSTOCKANDSTOCKHOLDER"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF STOCKHOLDERS&#8217; EQUITY</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">(in thousands, except share data)</p><a id="_d831bdf9_a97f_4d1d_abb5_116529e56eb3"></a><a id="Tc_K5q28K69LUqeDGHvvoUARA_1_2"></a><a id="Tc_RgkAeOdSD0-fLSex9-BJ9w_2_7"></a><a id="Tc_YsCtjuUZQE2Na9m8x9WMAA_2_10"></a><a id="Tc_Ko_SLKggQk6QcnikyBIg4A_3_2"></a><a id="Tc_hXaqZJXcP0CEE0KxzTjU0Q_3_7"></a><a id="Tc_3VnpDRHCH0G4VZgJSGTUCQ_3_10"></a><a id="Tc_zuyQWk4fCUS9x9psd8IOMA_3_13"></a><a id="Tc_5fIAgD2jIU-NqifWLagv4g_3_16"></a><a id="Tc_ur2z9lHgzkiafNH360yUnA_4_2"></a><a id="Tc_i0DQalYD20ueLw97LnowyA_4_4"></a><a id="Tc_Q72dEleT-UeoqHLzCBqkqg_4_7"></a><a id="Tc_huU0MbxAhEq4eIF8joDuTQ_4_10"></a><a id="Tc_5TA4rVKDM067j7SarMGf0Q_4_13"></a><a id="Tc_MT_TpQ_pMkWJNZ515K09fA_4_16"></a><a id="Tc_obJi8SlzOkaE9_BTNP-Yig_5_0"></a><a id="Tc_ugi5JzdUBEWYWP-we-MyDw_5_4"></a><a id="Tc_cV2Qg_7JCkW57DbMNqtaZQ_5_7"></a><a id="Tc_E1fu9pSm_Eerfa2pklxQNw_5_10"></a><a id="Tc_QDN1gz-2n0O0wKq1X97B1A_5_13"></a><a id="Tc_uH7GgeaGjUGq7KDvJN7QSw_5_16"></a><a id="Tc_-ev-tX5840ivJGvQx7o24Q_6_0"></a><a id="Tc_UcafqZaVrUmlWF-L28CvgQ_6_2"></a><a id="Tc_hE4gFbDvxkyQqlDNaN0Wdw_6_5"></a><a id="Tc_Hc3MiVHID0W3u-f92JeDKQ_6_11"></a><a id="Tc_l9NDUIE_XkiBBX9e0GibJQ_6_14"></a><a id="Tc_F898a7CpuEeF7g7P3QqxAQ_7_0"></a><a id="Tc_5QpKfZQ1AU-893lwQvxYMA_7_5"></a><a id="Tc_FCarOa9yZ0WW1qqogsx8FQ_7_11"></a><a id="Tc_pKE_pTDUqUqq2HXTuMFTKg_7_14"></a><a id="Tc_CrH1jazpw0-GWgpJYNHqIg_8_0"></a><a id="Tc_dhGG6IRd_E2NE7Loju9y9A_8_2"></a><a id="Tc_srf9P0FXuEuRQs-2b7MNUg_8_5"></a><a id="Tc_tTlQvWttb0ituCZWZiQYTw_8_8"></a><a id="Tc__iIZD0gjFEmjwoqkYXAnIw_8_14"></a><a id="Tc_4GEagRZ010-jg5HjmI4IKQ_9_0"></a><a id="Tc_wbs706bsSE-LV-EUZyfEMw_9_2"></a><a id="Tc_UQvEyUtjmEKOI6moGpV3Dg_9_5"></a><a id="Tc_Puq31sz3KEStJwZV4zp-jg_9_8"></a><a id="Tc_5tHNV0EApEibDRfnliYZdA_9_11"></a><a id="Tc_vSJQyHGxK0qmxqye_SaVkQ_10_0"></a><a id="Tc_oDjt57Kovk2xbiMnmvWc9Q_10_4"></a><a id="Tc_R_1Ig_KUIECPBAgImnCSUg_10_7"></a><a id="Tc_Mq3xU5pbP0a2uXlmg0ODag_10_10"></a><a id="Tc_P5-lFDGKbky9qWvT375DvQ_10_13"></a><a id="Tc_gQA8tnBG8UisVptWrUoDdw_10_16"></a><a id="Tc_thJZyp_90EaDEW8VxpZdOw_11_0"></a><a id="Tc_4CKeNusl-06VpmKLybBO7A_11_2"></a><a id="Tc_O0Q1PAkZe0qmTYe7Pf7T1w_11_5"></a><a id="Tc_q4Z6_WR5P0atHVL1p1QaqA_11_11"></a><a id="Tc_RcB-9T8C20OMK__6FCgF7w_11_14"></a><a id="Tc_1ugjOiUU-EWsJY68B66AVg_12_0"></a><a id="Tc_WkwqDDRRAEi_pTF5Q_jqcw_12_5"></a><a id="Tc_SDpPRXj-gEuAynLJRS1Chg_12_11"></a><a id="Tc_YWjLimq5k0mVJN9qPBdVYA_12_14"></a><a id="Tc_xXbkF2JdjU6LFAYGCn6rqw_13_0"></a><a id="Tc_tnSzq0WcQEac8XexQQVghw_13_5"></a><a id="Tc_mg0J5_rCxkuzsj1TfndfVA_13_11"></a><a id="Tc_DfGRWB6AcUScpncEbkZY3g_13_14"></a><a id="Tc_loEW4ZAHx0myYH9LHsWMYA_14_0"></a><a id="Tc_ggThZQgY80OOFdzipw2ACg_14_2"></a><a id="Tc_f_1jSwdvwkGTPa0PQUlJNg_14_5"></a><a id="Tc_pRxsJTxJ9UyoLAnYf4YvtQ_14_8"></a><a id="Tc_bexnymn1Skuqcv8h1FKl2g_14_14"></a><a id="Tc_1hWmxAvg2ECyzk7oL-bJmQ_15_0"></a><a id="Tc_sEGMxxmtdUeSZk3uIfTm-Q_15_2"></a><a id="Tc_D0NW_H5Lnk6jlJ2F1HNUfA_15_5"></a><a id="Tc_zbY--JbaI0m4S4AfX84nMQ_15_8"></a><a id="Tc_AYmbs-H5l0ydeaAkbEKLNw_16_0"></a><a id="Tc_0Py-xVhBZkexkc8QsLXJtA_16_4"></a><a id="Tc_rC7pbcgnzEOJ-XQyHc7gaA_16_7"></a><a id="Tc__Ulnjomp9UaGpTICTlsy2w_16_10"></a><a id="Tc_BE-2qndbSUe-PQhDfgkwIg_16_13"></a><a id="Tc_wHr-ZRTe_0K0Hw2HfvJ5QQ_16_16"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;white-space:nowrap;width:31.65%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="16" style="vertical-align:bottom;white-space:nowrap;width:66.92%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217; Equity</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Additional</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated Other</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:18.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Common&#160;Stock</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Paid-in</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Comprehensive</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Accumulated</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Stockholders&#8217;</b></p></td></tr><tr><td style="vertical-align:bottom;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amount</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.04%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Capital</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.13%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Loss) Income</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Deficit</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Equity</b></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Balance as of December&#160;31,&#160;2020</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaUNhIOQzE-uaj0TJAxBUg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_mDj03J-40UqDlKYnrzcrPg_5_2">27,568,802</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaUNhIOQzE-uaj0TJAxBUg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_kfoH4HIP8U-77o3vXkQHcA_5_5">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3vwRuWC6SU2eMxTt8KjrSg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_h0_wobe7IESm5Ko3iGmwHw_5_8">410,551</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9M-kF4_ysEuVCqAg9WPuNw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ukfoiDwkoUyBOec0cOWuTw_5_11">779</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3YsHqMa8U06STQUHwqaIeg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_oNdErvuoMkytLtClEYtG0A_5_14">117,637</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2020_QgZGOIBcMEe2uMPs4IJ4-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_ltXerjUeLUmhHJfIWJIHQA_5_17">293,721</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DQ6MmhQyV069Qs7Ih1PO6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_KSYS6Xdl_kuzKpqV3g5giA_6_8">10,288</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_hQn99iA8tEqBzv1Dd00kVA_6_17">10,288</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rOjqenRZREyd1NyoeFubKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_duOqZvbS30Cs9YFEyQkBDQ_7_2">112,195</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DQ6MmhQyV069Qs7Ih1PO6g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_Sywlr2OeTE6SKCSp85edyQ_7_8">208</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_MMSBWTKwmEevdyI05OTLng_7_17">208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss on marketable securities, net of tax $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="Narr_FoG5xbxNXEm1G7AjJUOEFA">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JLiZDuh8TkiEItJlU1AcwA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" sign="-" scale="3" id="Tc_rMjebschf0GWw5lpmPyc3w_8_11">1,442</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" sign="-" scale="3" id="Tc_0NAz-VNFx0-rcCTg7IlJtA_8_17">1,442</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gI-VD-V8dkWDjrK8eQOPfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_IymwjXPkJkKD4zy4sOotHQ_9_14">69,389</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_w8-1uLNE_U63LDF7h6HDow_9_17">69,389</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Balance as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x59fHK3h6US54LesHKMlWw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_bB85rctu2EiwmEIOkD7ZkA_10_2">27,680,997</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x59fHK3h6US54LesHKMlWw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_HkuRk1M7eku9ZCHLLvm4Iw_10_5">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AMSNidZSTkiUmUQgTX6WXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_BXQGraem1kek9V0yA9EOKQ_10_8">421,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51jEFO9m-Eapl6pE0wPajA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_jPkCIHdaY0ShgeuyESlC8Q_10_11">663</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dCZjOHvncEGYV4kEJYoMcA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_YSRoQIiLAkS7n48ee_mZTw_10_14">187,026</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_6EZj6M3hw0O2o7nHHck-_w_10_17">233,386</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Stock-based compensation</p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f-KycTXTtEGUeina0uYgfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_-OIbtXEKP0aODL5BUR3ylg_11_8">9,508</ix:nonFraction></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"><span style="font-size:7pt;margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" scale="3" id="Tc_iF76ETKxGEGlvs5dmAmFWA_11_17">9,508</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tPHNqpHq2kuQFJEI1p3JZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_TNzPbdJUlUynzGUKiiVpjA_12_2">50,420</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f-KycTXTtEGUeina0uYgfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_65jgm7rOEUiSDsZs8jfxFA_12_8">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised" scale="3" id="Tc_blEkfFh2BE2Wyj2ybLXH6Q_12_17">66</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Issuance of shares under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tPHNqpHq2kuQFJEI1p3JZQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" scale="0" id="Tc_JmqmvdIh3U2tRXS0e9cZqQ_13_2">43,119</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f-KycTXTtEGUeina0uYgfw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_kLSYcLbc9USbxuv76p-TSw_13_8">134</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" scale="3" id="Tc_rrFjNsfWfEq6y8nruooS2Q_13_17">134</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Unrealized loss on marketable securities, net of tax $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" scale="3" id="Narr_nQUwcdrYFUyndvySqwDiRg">0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QjIgQ3Cie0eiBOwS3XozJA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" sign="-" scale="3" id="Tc_HT9dc4UWGEqO0-kMOTgjLg_14_11">831</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" sign="-" scale="3" id="Tc_IfzBRvrHzEO1eJRAV8N5Xw_14_17">831</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;width:31.65%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt 0pt 0pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CQRdBMZPLEKTJoEaubbMvw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_WeqakKmxMkOgZ2gxkb7Z_A_15_14">74,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetIncomeLoss" sign="-" scale="3" id="Tc_i_bZBLRNN0mlhgLFPqK5mg_15_17">74,733</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:top;white-space:nowrap;width:31.65%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">Balance as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.4%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TgHp4cCUE06VUtY2h3ln1w" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Tc_N3NRfwUtHEm0Iz1AuPkCQw_16_2">27,774,536</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TgHp4cCUE06VUtY2h3ln1w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_Xk5Vh-SF6Eyuj7UZy8TPLQ_16_5">28</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:7.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WRaiII9KkkuLfyaPn6l8EA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_3f5OJkCHLUm30LFnNfAXSg_16_8">430,755</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.71%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_x6LhcuNomEuLDIBzS5kclw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_Uv7O7E_MDUWiV3d4gwO_SQ_16_11">1,494</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pA4TDj6OTk643-r859LTcQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" sign="-" scale="3" id="Tc_3cqx44KxTkuuEFpLkJeJlQ_16_14">261,759</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:7pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.42%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:7pt;text-align:right;margin:0pt 2.25pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:StockholdersEquity" scale="3" id="Tc_5cCWqmaUOkq_krnct8U_Hg_16_17">167,530</ix:nonFraction></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt 0pt 12pt 0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:0pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">89</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:84%;border:0;margin:30pt 8% 30pt 8%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_21fbbdb2_0d58_461a_a3a5_4995db60274a"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><a id="STATEMENTSOFCASHFLOWS_298484"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">STATEMENTS OF CASH FLOWS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">(in thousands)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_8417c588_775b_4894_92c1_75bcebad939f"></a><a id="Tc_p8m2VnPrzEOsvbdAlK4EFA_1_2"></a><a id="Tc_CIO0ubj_h06V3c2kW9T9VQ_2_2"></a><a id="Tc_5OFli2ZD0k6oyO99AWUY5Q_3_2"></a><a id="Tc_Pl75vkyv5kuQHCBHFnhpjA_3_5"></a><a id="Tc_i3Wec6DEI0W9n0FWHSmOLQ_4_0"></a><a id="Tc_PbzcbdvS50KmJuv21OqIcQ_5_0"></a><a id="Tc_jpzzeLbTqUCRP02X2uLxIA_5_2"></a><a id="Tc_JqO8GG3XFEqYqNWQvvEkaw_5_5"></a><a id="Tc_mhyUGWaqOkqK3uNCKnqg8Q_6_0"></a><a id="Tc_to_Tgm8YZ0-6aNEur6fqUQ_7_0"></a><a id="Tc_ENzv6gW5-kmB1dkNGX-2SQ_8_0"></a><a id="Tc_BOWCN676_Uu-s_MueGWbhg_9_0"></a><a id="Tc_6xYmQSlcREqY--1uvXURlQ_10_0"></a><a id="Tc_YrPmKRcff0eYzhXcMwtVTQ_10_6"></a><a id="Tc_g_DREBhHDk2uimD8jV06Gw_11_0"></a><a id="Tc_Dkxn-Ah-Vk6mReZEn8tlWQ_11_6"></a><a id="Tc_3gdsM_Yp80qH1S6rIBlrag_12_0"></a><a id="Tc_vWePlXNsq0eUQX2Snq7SwA_13_0"></a><a id="Tc_i_5Lq9NE1kmhsgHNKz5naA_14_0"></a><a id="Tc_NUHHkf6koUKZ8YhyzdoTOQ_15_0"></a><a id="Tc_R3MYZTtJgkOnuOx7NR84AQ_16_0"></a><a id="Tc_8deg9yZ2sUW9X9yaTva_Ow_16_3"></a><a id="Tc_WiFbXv5mUkiIyxtGcaQSSQ_17_0"></a><a id="Tc_1jHPx8LYQkqudLD_pz-luQ_18_0"></a><a id="Tc_8OnATvRVYkyyZGcYfI9EtA_19_0"></a><a id="Tc_qyCgCScm4k2g6DcoJgA-6g_20_0"></a><a id="Tc_P_pCn6E4IUeIisYtuauZEg_21_0"></a><a id="Tc_xECHFEZor0WgUDag91BxvA_22_0"></a><a id="Tc_S-bZsvEZMUmhwuFU24TQdg_23_0"></a><a id="Tc_1x7bDhwgrkOLzGkPD4Thtw_24_0"></a><a id="Tc_8r80y4JQq0yxD27NmZXluQ_25_0"></a><a id="Tc_Hh6MlLTQvUGiRVUND5kyxw_25_6"></a><a id="Tc_GQSP-Wa5fEyqHPHopVDQAg_26_0"></a><a id="Tc_rsvvE2OUPE6BIl-lVsr9Ng_26_3"></a><a id="Tc_5gdJaG27f0ylIOmxzjA05g_27_0"></a><a id="Tc_z3aeyGJf2kihkMuUkn3Qdw_28_0"></a><a id="Tc_Tz4a25VcK0ORH0OYFNRHsw_29_0"></a><a id="Tc_URqleZJWuEW617Lp6WgZhw_30_0"></a><a id="Tc_gdNSZjZ4Oki_60_NqDriFQ_30_2"></a><a id="Tc_-ETxH8Nz9Ui_rCUFo43aMA_30_5"></a><a id="Tc_6hp49YLs202g1hgUwQ6pRg_31_0"></a><a id="Tc_dOIFfOpEBEO6TaZzjRYK6g_32_0"></a><a id="Tc_hOeJjkrOSEmR8W5rGbEwnA_32_2"></a><a id="Tc_mKHD2l6TBU-AcAnhRHbr4w_32_5"></a><a id="Tc_JmBylYV14ECTMT-Dt6pcxQ_34_0"></a><a id="Tc_jxDw4VRCj0SJy5gokdXX5g_35_0"></a><a id="Tc_UcJy0urQBUSlOPU5BHOcrg_35_2"></a><a id="Tc_qoTW22ORcE-R7E0oHzuRPg_35_5"></a><a id="Tc_oz6I27gYsk-P-lRqmyfnnQ_35_6"></a><a id="Tc_xgX_465CekSV5e49ryppBg_36_0"></a><a id="Tc_bRrer3mKbk-nHA2QQ7FpiQ_36_2"></a><a id="Tc_DbL5xumZ1kmbGAn9ky3c3Q_36_5"></a><a id="Tc_yXyvsnV6KkWNttPHHs192Q_36_6"></a><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:50%;transform:translate(0,-50%);width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Year Ended </b></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.83%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Net loss</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_dyS0qnfj-EenWeMD6toSKQ_5_3">74,733</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProfitLoss" sign="-" scale="3" id="Tc_oz61E4FM5UesW6Px6KLoRw_5_6">69,389</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Adjustments to reconcile net loss to net cash used in operating activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DepreciationDepletionAndAmortizationAndOther" scale="3" id="Tc_5U5bOTTIrUWr7wv_Zwg74g_7_3">4,124</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DepreciationDepletionAndAmortizationAndOther" scale="3" id="Tc_JYuRPLGAOkqzVsl9pe7uNg_7_6">4,177</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Amortization of premiums and discounts on marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" sign="-" scale="3" id="Tc_D7qgOJ4H_EyZ1-LLYf2L6g_8_3">3,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments" sign="-" scale="3" id="Tc_CytUkHL4yEGpxq4PD_7lDA_8_6">3,019</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Stock-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_QsfTPgV8gEWbExfdFJ7e-g_9_3">9,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensation" scale="3" id="Tc_t9qAVyJrw0yWBz8FiHGepw_9_6">10,288</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Noncash operating lease expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:NoncashOperatingLeaseExpense" scale="3" id="Tc_hSPIGXuv_U6-Zy6RISNQvA_10_3">356</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Loss on disposal of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:GainLossOnSaleOfPropertyPlantEquipment" sign="-" scale="3" id="Tc_NRSR_kOZt0iDo-ZXXogHDw_11_3">87</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 12pt;">Changes in operating assets and liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Prepaid expenses and other assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" sign="-" scale="3" id="Tc_rRAyuB2rJ0qC7f5SX1E2Nw_13_3">2,038</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" scale="3" id="Tc_tIdIFLhJrU-o3QCWKPZNYA_13_6">4,928</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Accounts payable</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" scale="3" id="Tc_fkA-IzNTdE67NFCt2f6_Aw_14_3">2,328</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInAccountsPayable" sign="-" scale="3" id="Tc_Qz1b9PDhWkGYalCBAZUZkA_14_6">1,959</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Accrued liabilities and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:IncreaseDecreaseInAccruedAndOtherCurrentLiabilities" scale="3" id="Tc_4cVK_zNIH0Wu2latXIuJgg_15_3">641</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:IncreaseDecreaseInAccruedAndOtherCurrentLiabilities" scale="3" id="Tc_ZWkR_YayMECLvlfLrfkHLQ_15_6">178</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 18pt;">Other long-term liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities" scale="3" id="Tc_KUkjm5OQ-kyeKVgLt1INwA_16_6">1,687</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash used in operating activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_sGdyPfEypESkhDR1ky95Gw_17_3">53,886</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInOperatingActivities" sign="-" scale="3" id="Tc_0mkEXSPN4kap0MPIsdrt-w_17_6">57,283</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from investing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Sales and maturities of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_q3XqNUEvBUiQriqHmmYqrA_19_3">104,739</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities" scale="3" id="Tc_aiz2V4VXcUiKgwlcTIW5oQ_19_6">195,438</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of marketable securities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_X6JovrcMd0qugB1QKB92Mw_20_3">34,644</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquireMarketableSecurities" scale="3" id="Tc_llFXFzhB9kGWrb1r27tfTA_20_6">156,477</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Purchases of property and equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_LrEd6yxpAUidg2AgefTt1w_21_3">2,116</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PaymentsToAcquirePropertyPlantAndEquipment" scale="3" id="Tc_wl1obg3h60CMESDYfGM4kg_21_6">2,360</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash provided by investing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc__k8VTdQAKEWqgwQTRzLalg_22_3">67,979</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInInvestingActivities" scale="3" id="Tc_46hGJsdI4U-7cjDlNgumTg_22_6">36,601</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash flows from financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from exercise of stock options</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_WWRba0ZnUEKhNSglu8EmzQ_24_3">66</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockOptionsExercised" scale="3" id="Tc_vSByB2FUQUmXo4zxrdfsHQ_24_6">208</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Proceeds from shares issued under ESPP</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromStockPlans" scale="3" id="Tc_2W89MRqSvU6s8y5U99w45g_25_3">134</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Payments of the term loan</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RepaymentsOfDebt" scale="3" id="Tc_L3IxfehtFkW-c3PPhPfNXg_26_6">3,473</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 24pt;">Net cash provided by (used in) financing activities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" scale="3" id="Tc_WiQa7NWVdEWGJWo5QUOXvA_27_3">200</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:NetCashProvidedByUsedInFinancingActivities" sign="-" scale="3" id="Tc_qggd3D7VM0yZkAn9Ee_AXg_27_6">3,265</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Net increase (decrease) in cash and cash equivalents </p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" scale="3" id="Tc_ynVNtPwnLEeHgBmBA7Nlyg_28_3">14,293</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" sign="-" scale="3" id="Tc_XMtvEmf9ak2LQua3j_1sLA_28_6">23,947</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents &#8211; beginning of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_onq2RRxS8Eyp_8lcR75RDQ_29_3">12,337</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2020_QgZGOIBcMEe2uMPs4IJ4-A" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_bKdUYhskgEeRJt41cv6PPA_29_6">36,284</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Cash and cash equivalents &#8211; end of period</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_7eu_4zKt3kyXo7D-y9RJ4g_30_3">26,630</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" scale="3" id="Tc_90GWLdt4ek2VUYK7u47YIw_30_6">12,337</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosures of cash flow information:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Cash paid for interest</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_KSZXSGjgwUeUgi8kOL5l3A_32_3">90</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:InterestPaidNet" scale="3" id="Tc_ZgRqWdAw5U6o9kgOKIaFMA_32_6">162</ix:nonFraction></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"><span style="margin-left:0pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Supplemental disclosure of noncash investing and financing activities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Right-of-use assets obtained in exchange for operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" scale="3" id="Tc_X058bkxWYEKeUmu3v_xQgg_35_3">6,047</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:middle;width:73.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Recognition of initial lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount" scale="3" id="Tc_8qQmD8tcP0OZ34NNL1cb9g_36_3">7,549</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:73.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:11pt;visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:0pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;text-indent:36pt;margin:0pt;">The accompanying notes are an integral part of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">90</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="NOTESTOFINANCIALSTATEMENTS_913411"></a><a id="_cp_text_1_1262"></a><a id="_cp_text_1_1266"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" id="Tb_7a7ew52Jv06eTjD1oFdeBw" continuedAt="Tb_7a7ew52Jv06eTjD1oFdeBw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">1. Nature of the Business and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NextCure,&#160;Inc. (&#8220;NextCure&#8221; or the &#8220;Company&#8221;) was incorporated in Delaware in September&#160;2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (&#8220;FIND-IO&#8221;) platform, the Company studies various immune cells in order to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company&#8217;s product candidates, building and optimizing the Company&#8217;s manufacturing capabilities and conducting discovery, research and development activities for the Company&#8217;s product candidates, discovery programs and its FIND-IO platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Public Offerings of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 13, 2019, the Company closed its initial public offering (&#8220;IPO&#8221;), in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_DrWQ9sKhMUyebJfoMay_Jw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_8Ufn-AL5vUqdct6tHIL3CQ">5,750,000</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MInUrgAThkee5MzGS2_rNw" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_xwULGU1ZIkmt47Lc0wlonQ">15.00</ix:nonFraction> per share, for net proceeds to the Company of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_DrWQ9sKhMUyebJfoMay_Jw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceInitialPublicOffering" scale="6" id="Narr_wpP8LC0ZlUSzdFkEsNqx6A">77.0</ix:nonFraction> million after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_DrWQ9sKhMUyebJfoMay_Jw" decimals="-5" format="ixt:numdotdecimal" name="nxtc:PaymentsOfUnderwritingDiscountsAndCommissions" scale="6" id="Narr_sadayeASik2k0aNSf0WNfw">6.0</ix:nonFraction> million and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_DrWQ9sKhMUyebJfoMay_Jw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_CHJ6VwnUn0GKdsDnfKBRZg">3.4</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preparation for the IPO, on May 3, 2019, the Company effected a <span style="-sec-ix-hidden:Hidden_GEsLDUz530Gxz5k36Ixidg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>-for-8.0338 reverse stock split of its issued and outstanding common stock. The par value and authorized shares of common stock were not adjusted as a result of the reverse stock split. All of the share and per share information presented in the accompanying financial statements has been adjusted to reflect the reverse common stock split on a retroactive basis for all periods and as of all dates presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO, all of the outstanding shares of the Company&#8217;s convertible preferred stock automatically converted into <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesOutstanding" scale="0" id="Narr_LDvTKE-xzEO6wspdorNpWQ">15,560,569</ix:nonFraction> shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_LxsOE68M8EaKbgiWFcTW0A">no</ix:nonFraction> shares of preferred stock outstanding. Additionally, the Company&#8217;s certificate of incorporation was amended and restated to provide for <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_UxphsF7zNESLQfLHSPuP8Q">100,000,000</ix:nonFraction> authorized shares of common stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_7snZEX-hAEytaabfqcNa-Q">0.001</ix:nonFraction> per share and <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_7McCOIzrbEqSaPbZmNXkYA">10,000,000</ix:nonFraction> authorized shares of preferred stock with a par value of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_yvP9VehZakCOpJPAT53TSw">0.001</ix:nonFraction> per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 19, 2019, the Company completed an underwritten public offering, in which the Company issued and sold <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_11_19_2019_To_11_19_2019_k_sFpRsB_0WOgCeVqnif5g" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_kcge1ibG9kqGqtzwyxKTgA">4,077,192</ix:nonFraction> shares of common stock at a public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_11_19_2019_Zz1QYveV3kqsEGkewxdtfA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_QjM1X6IwmUea59wDgpS8gA">36.75</ix:nonFraction> per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesNewIssues" scale="0" id="Narr_JmTf1fOgC02c5wzMyM1LFQ">611,578</ix:nonFraction> shares of common stock at the public offering price of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_2_2019_o6OFQ40YgEyzamR4P8fk6Q" decimals="2" format="ixt:numdotdecimal" name="us-gaap:SharePrice" scale="0" id="Narr_dPLLbcTm_06UZ7hclg0MtA">36.75</ix:nonFraction>, for total net proceeds to the Company of $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" scale="6" id="Narr_7HAP2tmZD0ymXcF_li7yoQ">160.9</ix:nonFraction> million after deducting underwriting discounts and commissions of $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg" decimals="-5" format="ixt:numdotdecimal" name="nxtc:PaymentsOfUnderwritingDiscountsAndCommissions" scale="6" id="Narr_Dt8i3UmJ90OvloytRhVDXQ">10.3</ix:nonFraction> million and offering expenses of $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:PaymentsOfStockIssuanceCosts" scale="6" id="Narr_pMuIlUEJp0qPJ4D6I89BNQ">1.0</ix:nonFraction> million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through December 2022, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company&#8217;s former agreement with Eli Lilly and Company. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the issuance date of the financial statements for the year ended December 31, 2022, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements to mid-2025. The future viability of the Company beyond that date may depend on its ability to raise additional capital to finance its operations. </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">91</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_7a7ew52Jv06eTjD1oFdeBw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, licensing arrangements or other methods. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Although management continues to pursue these funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company, if at all, to fund continuing operations past two years from the issuance date of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The Company is subject to risks common to early-stage companies in the biotechnology industry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing; dependence on its ability to advance its current and future product candidates through clinical trials, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on the Company&#8217;s FIND-IO platform; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time-consuming and unpredictable nature of the regulatory approval process; the results of preclinical studies and early-stage clinical trials that may not be predictive of future results; dependence on its key personnel; its limited manufacturing experience as an organization and with its manufacturing facility; risks related to patent protection and the Company&#8217;s pending patent applications; dependence on third-party collaborators for the discovery, development and commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Pursuit of the Company&#8217;s business efforts will require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The impact of the COVID-19 pandemic (including the impact of emerging variant strains of the COVID-19 virus) on the Company&#8217;s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, the efficacy and global distribution of vaccines, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of &#8220;lockdown,&#8221; &#8220;social distancing&#8221; and &#8220;shelter in place&#8221; directives and other restrictions on business operations, travel and gatherings by state and federal governments in the United States, as well as governments in other regions of the world in response to the COVID-19 pandemic, has placed significant strain on the Company&#8217;s clinical trial sites, has raised concerns around monitoring patient safety, and has caused enrollment to slow in the Company&#8217;s clinical trials. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. The Company continues to closely monitor the COVID-19 situation and any potential impact to the Company&#8217;s planned activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment and Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The chief operating decision maker views the operations and manage the business in <ix:nonFraction unitRef="Unit_Standard_segment_SvUt3NvuT0moPQCiN6jnXA" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:NumberOfOperatingSegments" scale="0" id="Narr_LxYCa5qK8ke4YLIKROu1aw">one</ix:nonFraction> operating segment that operates exclusively in the United States.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:SignificantAccountingPoliciesTextBlock" id="Tb_zEmY74uvMUOIxXERfaw9YQ" continuedAt="Tb_zEmY74uvMUOIxXERfaw9YQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:BasisOfAccountingPolicyPolicyTextBlock" id="Tb_qge6rRcv8US2n5xM3LiDCQ" continuedAt="Tb_qge6rRcv8US2n5xM3LiDCQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying financial statements include the accounts of the Company. The Company&#8217;s financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8216;&#8216;GAAP&#8217;&#8217;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting </p></ix:nonNumeric></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">92</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zEmY74uvMUOIxXERfaw9YQ_cont1" continuedAt="Tb_zEmY74uvMUOIxXERfaw9YQ_cont2"><ix:continuation id="Tb_qge6rRcv8US2n5xM3LiDCQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) and Accounting Standards Update (&#8216;&#8216;ASU&#8217;&#8217;) of the Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;). </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:UseOfEstimates" id="Tb_skst5gjfFUuKKciKuwl6eA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:CashAndCashEquivalentsPolicyTextBlock" id="Tb_mMzWUYEpSUm3rbcTbUhw6g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" id="Tb_qXuuoZc6xEmbBIKC9tfZ7g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August 2021, the Company fully paid the remaining principal balance of $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_8_1_2021_To_8_31_2021_QUjo54fwz0S0O0oyBr9gCg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ProceedsFromRepaymentsOfDebt" sign="-" scale="6" id="Narr_khbdMsTU_Ua9SAAKHEGVRA">2.4</ix:nonFraction> million of its $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_08ADxLkIvEuQIT9eJDWqCA">5.0</ix:nonFraction> million term loan (the &#8220;Term Loan&#8221;). As a result of this payment, the Company has <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-5" format="ixt-sec:numwordsen" name="nxtc:RequiredReserveRestrictedCashCurrent" scale="6" id="Narr_aQpq_mneZk-2fkNjBUOAmw">no</ix:nonFraction> restricted cash held in support of the Term Loan. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:MarketableSecuritiesPolicy" id="Tb_FuFXKb7AFkGyWb-GNxO6Vw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company&#8217;s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company&#8217;s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security&#39;s relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ConcentrationRiskCreditRisk" id="Tb_TGpU08m-2UuC77rGh1Upyg" continuedAt="Tb_TGpU08m-2UuC77rGh1Upyg_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company&#39;s investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">93</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk25829333"></a><a id="Tc_3JUSEHzCskuBfFNJuNenrA_1_2"></a><a id="Tc_UuejHp8PnEekszzcZsT2AQ_2_0"></a><a id="Tc_SGHj5Cm6lkKXpOJ55kilRA_3_0"></a><a id="Tc_B4ywLuglJ0uAhUGlhGbLbg_4_0"></a><a id="Tc_mf7jjeSNQ0aCbGY4w_i89w_5_0"></a><a id="Tc_-iwB-usBwUWoqOpKpQJsfg_5_2"></a><ix:continuation id="Tb_zEmY74uvMUOIxXERfaw9YQ_cont2" continuedAt="Tb_zEmY74uvMUOIxXERfaw9YQ_cont3"><ix:continuation id="Tb_TGpU08m-2UuC77rGh1Upyg_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:FairValueOfFinancialInstrumentsPolicy" id="Tb_JHpZMgOA2ECFF2lKz5GhHQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;1&#8212;Quoted market prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:PropertyPlantAndEquipmentPolicyTextBlock" id="Tb__7aVZfGTeEOAfZNH2JFXsQ" continuedAt="Tb__7aVZfGTeEOAfZNH2JFXsQ_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimated useful lives for property and equipment are as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" id="Tb_Ot-LPIR8VEyTm3JH7WgnFw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computers and peripherals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_9gGAYZTy_U-F2bBDboUuHg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="Tc_fieTmeikU0y76cpAJD9IIQ_2_2">3&#160;years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_1bxFiSQkekaQznzCFGTEyg" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="Tc_IM-V4hceCUe0a3yv_UfAlQ_3_2">5&#160;years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5RSY3CZwm0S1VjPnBbQ2qQ" format="ixt-sec:durwordsen" name="us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives" id="Tc_7KMysowuA0W09hk-pjhEVw_4_2">7&#160;years</ix:nonNumeric></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">94</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zEmY74uvMUOIxXERfaw9YQ_cont3" continuedAt="Tb_zEmY74uvMUOIxXERfaw9YQ_cont4"><ix:continuation id="Tb__7aVZfGTeEOAfZNH2JFXsQ_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">be the rate required for a similar investment of like risk. <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="0" id="Narr_dmWy5ke07k6IgmgOmFY5Tg"><ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf" scale="0" id="Narr_GhXKKbCuyEqbPHWx3e9nXw">No</ix:nonFraction></ix:nonFraction> impairment losses were recognized during the years ended December 31, 2022 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Construction in progress (Note&#160;5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock" id="Tb_Zs6EOgzF7kquqKHcmD_0fg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On January 1, 2022 (Adoption Date), the Company adopted Accounting Standards Update (ASU) No. 2016-02, <i style="font-style:italic;">Leases</i>&#160;(Topic 842) (ASU No. 2016-02), as amended, using the modified retrospective approach, which provides a method for recording existing leases at adoption and does not require restating comparative financial information. The Company also elected the package of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" format="ixt:booleantrue" name="us-gaap:LeasePracticalExpedientsPackage" id="Narr_TDmwu3IIpUOEG69oDq4obg">practical</ix:nonNumeric> expedients permitted under the transition guidance under ASU No. 2016-02, which among other things, permits the Company to maintain the lease classification for any existing leases, as well as maintain the Company&#8217;s determination on whether any expired or existing contracts are or contain leases and initial direct costs for any existing leases. The Company did not elect the <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" format="ixt:booleanfalse" name="us-gaap:LeasePracticalExpedientUseOfHindsight" id="Narr_9-B3U3YN20WDSJ3wscQazA">hindsight</ix:nonNumeric> practical expedient to determine the lease term for existing leases. In addition, the Company elected the additional transition method permitted under ASU No. 2018-11<span style="font-family:'Arial','Helvetica','sans-serif';">&#8210;</span>Leases (Topic 842): Targeted Improvements, under which the Company initially applied the new lease standard, Accounting Standards Codification (ASC) 842, at adoption and there was no cumulative-effect adjustment to the opening balance of retained earnings on January 1, 2022. For the comparative period presented in these financial statements, lease-related disclosures continue to be in accordance with the legacy ASC 840. Adoption of ASC 842 did not materially impact the Company&#8217;s statements of operations and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company determines if an arrangement is a lease or implicitly contains a lease at inception based on the lease definition and also determines if the lease is classified as an operating lease or finance lease, each in accordance with ASC 842. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in its balance sheets. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date or the Adoption Date for existing leases based on the present value of lease payments over the lease term using an estimated discount rate. As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date or the Adoption Date in determining the present value of lease payments over a similar term. In determining the estimated incremental borrowing rate, the Company considered a rate obtained from its primary banker for discussion purposes of a potential collateralized loan with a term similar to the lease term and the Company&#8217;s historical borrowing capability in the market. For operating leases, lease expense is recognized on a straight-line basis over the lease term. Lease and non-lease components within a contract are generally accounted for separately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" id="Tb_GiRmAr0ePkuuZsMMeWcz8g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_ODxjcjDbB06KiCPCdO1vFQ"><ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_b5ePPwbHLE6CjFHmEy94SA">no</ix:nonFraction></ix:nonFraction>t have any outstanding preferred stock as of December 31, 2022 and 2021.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ResearchAndDevelopmentExpensePolicy" id="Tb_8L3pKTO9r02It09rhJyk7A" continuedAt="Tb_8L3pKTO9r02It09rhJyk7A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs, Including Clinical Trial Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (&#8220;CROs&#8221;), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and </p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">95</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zEmY74uvMUOIxXERfaw9YQ_cont4" continuedAt="Tb_zEmY74uvMUOIxXERfaw9YQ_cont5"><ix:continuation id="Tb_8L3pKTO9r02It09rhJyk7A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. </p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" id="Tb_7m95zKtZ4kapbzLdkEILig" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy" id="Tb_qUsu42raPUaL03wqplU3wA" continuedAt="Tb_qUsu42raPUaL03wqplU3wA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <i style="font-style:italic;">Compensation-Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;) for stock option grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to the lack of a public market for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No.&#160;2016-09, <i style="font-style:italic;">Improvements to Employee Share-Based Payment Accounting</i> (&#8220;ASU&#160;2016-09&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period.</p></ix:nonNumeric></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">96</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zEmY74uvMUOIxXERfaw9YQ_cont5" continuedAt="Tb_zEmY74uvMUOIxXERfaw9YQ_cont6"><ix:continuation id="Tb_qUsu42raPUaL03wqplU3wA_cont1"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:IncomeTaxPolicyTextBlock" id="Tb_v2qn8f3lV06tVrgnZl6lJA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#8217;s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" scale="0" id="Narr_ml9LzqUFVE2xhtKWiViIpg">no</ix:nonFraction> interest or penalties related to uncertain income tax benefits.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ComprehensiveIncomePolicyPolicyTextBlock" id="Tb_drzx4UDP9Eajg3BOHME-LQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2022 and 2021. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:EarningsPerSharePolicyTextBlock" id="Tb_K-9skWyXE02Eb2GKnn7NwA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company&#39;s stock option grants.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock" id="Tb_E1bassxiRU-Ovat45PNHyg" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;) as defined under the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company&#8217;s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">97</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zEmY74uvMUOIxXERfaw9YQ_cont6"></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_cd7d3b08_423d_489c_96c7_95d05ba43675"></a><a id="Tc_6grlmpKEJEGzFJuE06hSfw_1_2"></a><a id="Tc_akdzkCwsxUS7dz3YE7JtRQ_2_5"></a><a id="Tc_fNKeilTM8EadpYAo2BsrnA_2_8"></a><a id="Tc_-35h6MAIMEmCLmSoeYqmDw_3_2"></a><a id="Tc_HaYVEkMRKEOJuZoi0VtgOA_3_5"></a><a id="Tc_AdxRYP4vRUG4Tn-AibrYXQ_3_8"></a><a id="Tc_HNX4t8iGkEqc3Q9q_IaTzA_3_11"></a><a id="Tc_SKWuedjgWEKPEBrx5SgVzw_4_0"></a><a id="Tc_gzr1GMMhIECNriKoupXzTQ_4_2"></a><a id="Tc_nPHGkWphGUmd-OU4lx3F0A_4_5"></a><a id="Tc_r8ka_d0dy0yJ8ZQPA11w9A_4_8"></a><a id="Tc_Z_dbnalPY0yA87xl8YxEfw_4_11"></a><a id="Tc_D1mBo4EO80-J9MSFRpvvsA_5_0"></a><a id="Tc_VYw0Zwc5w0-sv6AKnzc7cg_5_2"></a><a id="Tc_ejxWsp1N-UKmuf7UlWHvug_5_5"></a><a id="Tc_5NuMeJPlwk2lt76bmUTsgg_5_6"></a><a id="Tc_zlOqQ1-j3UmW1_NokEiK_Q_5_8"></a><a id="Tc_ZTokIEhSsUCYxEj8nzp0MA_5_11"></a><a id="Tc_gE4p5eew-k6ue4Z2vLCA1A_6_0"></a><a id="Tc_nDeqbtafF0yb2mt_OM9lHA_6_6"></a><a id="Tc_oLL-o9sn_EaC3kIOyHppjA_7_0"></a><a id="Tc_CeUCRtbfQEavIJP7RhUGfg_7_2"></a><a id="Tc_XfAfSahLLEWh_XOaa7CPmg_7_5"></a><a id="Tc_LiTdPLKWCUaAsW7hU1qcwg_7_6"></a><a id="Tc_Kpadc0U5xEKqOlIvi2o_kg_7_8"></a><a id="Tc__kC0Pr3EXkuLFT_M_5rOkA_7_11"></a><a id="_2af83d82_9702_4d2e_a06b_a7a667e3e20b"></a><a id="Tc_12jFHJf8ek6h7ZEP6FsWzg_1_2"></a><a id="Tc_icnjOYgQm0Ggtxj7vTzthA_2_5"></a><a id="Tc_HiHS_ATIMkiF2CtwcxEUJA_2_8"></a><a id="Tc_nsisGEny_kGeg-Fj3rRXrg_3_2"></a><a id="Tc_xVtaNCYxY0SgzTMtXgLXug_3_5"></a><a id="Tc_z-FWQp6U5keACQwhAmCdKQ_3_8"></a><a id="Tc_4pCT4tiQsEKcdGJ05I_a2A_3_11"></a><a id="Tc_hvom9nyukUC-gKVoWB7QhA_4_0"></a><a id="Tc_qVhLb4SrFUCvrBPKt3Sedw_4_2"></a><a id="Tc_OJnlpSeuTUShTZaZbSP4hg_4_5"></a><a id="Tc__MC26JVgIUqOvalMxQ55HA_4_8"></a><a id="Tc_DHCskxTlb0i85vZMwOkWZg_4_11"></a><a id="Tc_4afsFOp6Ake29Qhyc4ZUvg_5_0"></a><a id="Tc_8rD8DA4_JECtm1opRS6Z4g_5_2"></a><a id="Tc_FgIXLXnZfUyGbD3-l8Nevw_5_5"></a><a id="Tc_Wsjqh4i_MEyTkqYDhCdTTQ_5_8"></a><a id="Tc_vPi7BkKeMUCTGguuPjuD9A_5_11"></a><a id="Tc_-IDifDoZXEWDwaO83HwPuw_6_0"></a><a id="Tc_dVMme4zVsUy7nOufI4rnbA_6_2"></a><a id="Tc_vBipqIdfz0aJ6cL0npeBBQ_6_5"></a><a id="Tc_irSuKkF9j0aG310n5EkOcQ_6_8"></a><a id="Tc_mCeHp63bn0WWdm46qO0_UA_6_11"></a><a id="Tc_t4PId9uDiEine7OgAAL6ZQ_1_2"></a><a id="Tc_X35a-DnDdk6U86dIoY3LBA_2_5"></a><a id="Tc_4RXKLsTgDkuNCdmfbxLCCA_3_0"></a><a id="Tc_sYovORv6dkq9OfchjHOHvQ_3_2"></a><a id="Tc_Oic5tD7pWUGGmSifY84k4w_3_5"></a><a id="Tc_oyeihWUrIkKqxnCTxVQXyA_4_0"></a><a id="Tc_w7QOcmA-REKuu7uZUmjZ5w_5_0"></a><a id="Tc_q8PQqczg902C-qlXCBRCUA_5_2"></a><a id="Tc_JuPOTOcLq0WH9spUPKKd1g_5_5"></a><a id="Tc_3sNi1ZIBs0OVHkpwIymOag_6_0"></a><a id="Tc_PVq9p5cYqU6l44-CZDoDew_7_0"></a><a id="Tc_XHgrBNRBjEml7ovC2-cT9g_7_2"></a><a id="Tc_gFo1VFmGfU-8UrhfzqcIUQ_7_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" id="Tb_UNhNtf-yOUm_aglhgWetQw" continuedAt="Tb_UNhNtf-yOUm_aglhgWetQw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">3. Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" id="Tb_tsOMvmo7sES8gv3rz8-W-Q" escape="true"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Pd5kHKPoGUawJuu7EPVYpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="3" id="Tc_Oc4q8M6Yhkqe_qVjWI_rHA_5_3">133,163</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Pd5kHKPoGUawJuu7EPVYpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_Muc2yCkdZEWCLyPuggSETg_5_9">1,457</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Pd5kHKPoGUawJuu7EPVYpQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_WbQ1zYjTQEKK3gKnzxiAsQ_5_12">131,706</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Government agencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_BevS1rj6TkCrU3_9XVnY4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="3" id="Tc_dIEj28Khi0WPLaD5K8SQvA_6_3">1,612</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_BevS1rj6TkCrU3_9XVnY4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_F0Jk3HvIp0iYeegjsQClqA_6_9">37</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_BevS1rj6TkCrU3_9XVnY4Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_jrqBpIPREEOIEem7N4tDPQ_6_12">1,575</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="3" id="Tc_-nTfucTppkSRIo5jEgAw7g_7_3">134,775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_jpFQNyUb8Uu9Jpoj6UCVDQ_7_9">1,494</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_xnQGHfWRJEuhFTKoWF4s1Q_7_12">133,281</ix:nonFraction></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_8exjrnhK4U25OrK5dhgHWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="3" id="Tc_HDCwhYiK6ESjH-vOiahFaQ_5_3">207,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_8exjrnhK4U25OrK5dhgHWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_Y4C22A6XGEqKYE46fx9xPA_5_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_8exjrnhK4U25OrK5dhgHWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_gfm-8f8xTkWK0vv9pg1xIQ_5_9">666</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_8exjrnhK4U25OrK5dhgHWg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_jkAyJwkeREiASuMqRIQRAg_5_12">207,254</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" scale="3" id="Tc_Q4n13fKBXUyZ_g-MGR7IiA_6_3">207,917</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" scale="3" id="Tc_tLysHpSggUyhJkSWT9EpOA_6_6">3</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" scale="3" id="Tc_lEVpy4mHjUOiqzpqU3QkQQ_6_9">666</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_RdvJQlc310GIO8WY-X7D4w_6_12">207,254</ix:nonFraction></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the specific identification method when calculating realized gains and losses. For the years ended December 31, 2022 and 2021, respectively, the Company recorded $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="Narr_IkriTgwtKECBovYO1ldlPg">9</ix:nonFraction> thousand and $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleRealizedGain" scale="3" id="Narr_WbZxG6U27UycUYMZRbzjPA">57</ix:nonFraction> thousand in realized gains on available-for-sale securities, which is included in other income on the statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviewed all investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. As of December&#160;31,&#160;2022, the Company had investments with a total fair market value of $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="6" id="Narr_TNlLTvP-WU6bHjrVONxXgg">133.3</ix:nonFraction> million in an unrealized loss position, of which $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" scale="6" id="Narr_WgLBYr5_N0qJAdblciGvBw">91.8</ix:nonFraction> million were in a continuous unrealized loss position for more than twelve months. The Company analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes, and such unrealized losses are temporary as the Company anticipates a full recovery of the amortized cost basis of these securities at maturity. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes maturities of the Company&#8217;s investments available-for-sale as of December 31, 2022:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="nxtc:ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" id="Tb_o5Lz7gGmx0GEdMEQgk2U9w" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maturities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Within 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" scale="3" id="Tc_FFYmr6hXBUqDqmf3l5kDuA_5_3">105,930</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" scale="3" id="Tc_NNhQDHaLVEmxYDUrDkQH2g_5_6">104,660</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Between 1 to 2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" scale="3" id="Tc_-VKqzMDgIk6zDPSCRmiSWA_6_3">28,845</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" scale="3" id="Tc_v18KRwvodEu9bG4KU3cyFQ_6_6">28,621</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total investments available-for-sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" scale="3" id="Tc_vLNPEDL5ikG0_rL8DiZp6A_7_3">134,775</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" scale="3" id="Tc_53jaCks_o0WeZ5C42LpsSQ_7_6">133,281</ix:nonFraction></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has classified all of its investments available-for-sale, including those with maturities beyond one year, as current assets on the accompanying balance sheets based on the highly liquid nature of these investment securities and because these investment securities are considered available for use in current operations.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">98</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_UNhNtf-yOUm_aglhgWetQw_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected to report interest receivable from its marketable securities with prepaid expenses and other current assets on its balance sheet. &#160;Interest receivable included in prepaid expenses and other current assets totaled $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-5" format="ixt:numdotdecimal" name="nxtc:InterestIncomeNonOperating" scale="6" id="Narr_nGbenvwnH0a4lrSopRvMmg">0.7</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-5" format="ixt:numdotdecimal" name="nxtc:InterestIncomeNonOperating" scale="6" id="Narr_dHVJCWbOpEy_UAPVB261Ug">1.0</ix:nonFraction> million as of December 31, 2022 and 2021, respectively.</p></ix:continuation><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_95c0780f_3787_4751_9683_cc9253a0c181"></a><a id="Tc_LDl4zfeIp0Cy_-4uvr-raA_1_2"></a><a id="Tc_rxQ4vLeUy0CrNkd4_pZnyg_2_8"></a><a id="Tc_7ZGvOU6D6kmk0xtQjIaj2A_3_5"></a><a id="Tc_jS1vTyE9R0qGmJhe89uh-Q_3_8"></a><a id="Tc_FKKPWH5OAkaV8f4pfJv6DQ_4_5"></a><a id="Tc_y1LtAqGgek-87pe2gXibcg_4_8"></a><a id="Tc_uCcEpuz7h0mioTk4JOhvSg_4_11"></a><a id="Tc_iQ49cP6UX0670UTkVNY9cQ_5_5"></a><a id="Tc_ohaXM9wlMUqoRtiPhuMyiQ_5_8"></a><a id="Tc_LbxkD_cHEUSo3c_2Vi_C8Q_5_11"></a><a id="Tc_ghNB8vvdo0Sev-OQawJwQg_6_0"></a><a id="Tc_bJk6z4iEfk-_2BkkOa8Rew_6_2"></a><a id="Tc_8a1mq_oriE298VIxsCyrMg_6_5"></a><a id="Tc_q7_t-0enbkaMzsHJbPNepg_6_8"></a><a id="Tc_LXGB1iiJrUWSzufYt6HD9w_6_11"></a><a id="Tc_8rDzlMiH-kCux1Gvsaj2zw_7_0"></a><a id="Tc_eZJEKdWy3k2gTE9S3n6zkw_8_0"></a><a id="Tc_nJtu0wpZUUCFWT2Xuj23bQ_8_2"></a><a id="Tc_mqdCij8DZE25QGJutRTdvQ_8_5"></a><a id="Tc_Kt--6mwgR0O_BOB9aebZiw_8_8"></a><a id="Tc_9cePKRnn-ke4mhn92wbkZA_8_9"></a><a id="Tc_Oa0FVaW1vEuoUVwnRZt0hg_8_11"></a><a id="Tc_rIa2ZbFVm06vscCZi-NEaw_8_12"></a><a id="Tc_peTGFJAyQUaxId410A59Lg_9_0"></a><a id="Tc_sb7R80nONUu-xZoHbYlp6A_10_0"></a><a id="Tc_s2U6PmO1GE2qUSYQcSU4zQ_10_6"></a><a id="Tc_w3AvPLIUCkGRd78RG-Atng_10_12"></a><a id="Tc_tFqkmJCjDEmfB2Cp1aWmzw_11_0"></a><a id="Tc_Z4wmAzS7OEmpb8X0c4tC3w_11_6"></a><a id="Tc_k37-CH2ekk-oXmmRwyiuiQ_11_12"></a><a id="Tc_orEvd0usFEO64DnerCqOow_12_0"></a><a id="Tc_cE0KFxsrLE6b_hE_ZRr7YA_12_2"></a><a id="Tc_nlVUpJEQakWA__bEvilIeg_12_5"></a><a id="Tc_dzxIBnDhJEm_oc0RYsTZjQ_12_8"></a><a id="Tc_56pJa6TXQEGAkofSpLs-8Q_12_11"></a><a id="Tc_-5DzS1lrCUKbsLCiyZeYrQ_12_12"></a><a id="_57c0a96f_0c82_4f4e_91eb_1ae91e80cbb6"></a><a id="Tc_kSLB2CTXT0aI8NKEz2hvYw_1_2"></a><a id="Tc_D97s4XzYYE26JSe7p-i96w_2_8"></a><a id="Tc_6PvhShKlLUe7lKI7O-SY3g_3_5"></a><a id="Tc_yOrhn71uqkCHkIWBPAaueA_3_8"></a><a id="Tc_3tK5K7MK_0eKB5l6UnN0AA_4_5"></a><a id="Tc_y_m_SeIAS0qrFOG4dknK2g_4_8"></a><a id="Tc_6Q_HXGgUJEmsWRr5K-7STA_4_11"></a><a id="Tc_dT0xBiMqbE2SdNev1nIYnA_5_5"></a><a id="Tc_rJWXpd-xxU-Q0EICKdtrZg_5_8"></a><a id="Tc_wmE7i_GjVkWu_656bthnjw_5_11"></a><a id="Tc_lps7V03PzUOjZp9pdRGn7g_6_0"></a><a id="Tc_f_G2y8dT0kChJYvFw9yWWg_6_2"></a><a id="Tc_NrFHZtbsJk-QoMPnMTDoSA_6_5"></a><a id="Tc_Jrfw2-Kmp0GAuXjC_7Pkog_6_8"></a><a id="Tc_neoxqmf7uUyrqOI-oUoUNQ_6_11"></a><a id="Tc_5C83uzdcIki6OoViM5O4fw_7_0"></a><a id="Tc_wklYKQqDnEqh9znShTf1EQ_8_0"></a><a id="Tc_uV3BiauTgEamV79LM0TPKw_8_2"></a><a id="Tc_8jbCVU5u70-I7ksYev55UA_8_5"></a><a id="Tc_SpcKulrGmEqe96K9yHbbWA_8_8"></a><a id="Tc_NIt12CY-HUSx1t-OJYx-BQ_8_9"></a><a id="Tc_V-tstLFiLUiCAcmJdTt92w_8_11"></a><a id="Tc_l433WwW3OE2Z0XHAW8-mrg_8_12"></a><a id="Tc_-G63f0qHSkyXSyHtWG7LZQ_9_0"></a><a id="Tc_fuUZNYhCkEGGzvk9XA7Pqg_10_0"></a><a id="Tc_5N7z9diKoEixcPueBMPxug_10_6"></a><a id="Tc_fMwAhta-NkCy9aSJDr3gIQ_10_12"></a><a id="Tc_nk9n48aT80uCnAUlEzycSA_11_0"></a><a id="Tc_8NrYyncdKEqss7KUqI35mw_11_2"></a><a id="Tc_w6pqyEqtPU-R5CuStq7nAQ_11_5"></a><a id="Tc_PcpGiTvw5EC5aUnA044opA_11_8"></a><a id="Tc_zww0vjt3s0qOtt6iHJZTbA_11_11"></a><a id="Tc_QSD3gkej-069fVCvMOPuKA_11_12"></a><a id="_a3585b14_4ace_4037_8067_ef6143a8cd48"></a><a id="_a3585b14_4ace_4037_8067_ef6143a8cd48_2"></a><a id="_a3585b14_4ace_4037_8067_ef6143a8cd48_3"></a><a id="_f4cd968a_8642_4f12_b1f3_31901822460f"></a><a id="_f4cd968a_8642_4f12_b1f3_31901822460f_2"></a><a id="_f4cd968a_8642_4f12_b1f3_31901822460f_3"></a><a id="_4d565bdd_1513_4c5f_8267_4e9cf051e9e4"></a><a id="_4d565bdd_1513_4c5f_8267_4e9cf051e9e4_2"></a><a id="_4d565bdd_1513_4c5f_8267_4e9cf051e9e4_3"></a><a id="_7ceb8742_81f6_4d16_80dc_295ef12ad078"></a><a id="_7ceb8742_81f6_4d16_80dc_295ef12ad078_2"></a><a id="_7ceb8742_81f6_4d16_80dc_295ef12ad078_3"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:FairValueDisclosuresTextBlock" id="Tb_BE-Qse057EGqHzJsTmQ41A" continuedAt="Tb_BE-Qse057EGqHzJsTmQ41A_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">4. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables set forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy as of December 31, 2022 and 2021:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:FairValueByBalanceSheetGroupingTextBlock" id="Tb_qyUIRC2jH0SEwDDl1EjSUQ" escape="true"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember__yYHlcWVlkCe8veQpXoODg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_TeBkpdJW8k-hpTcl9u13bg_8_3">6,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_RJ-xwh_wV0-uMLJTUoRWww" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_XHYvoG9DGkK2y100TkyqWw_8_6">6,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5-Bu-eXe006BJ3_wB91BDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_kqd-UJmUiUaTCFFdLBOTtA_10_3">131,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3eszyap510GTal9lTSf5TQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_KHAPhdmXSEu_T0DHxXLx0w_10_9">131,706</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Government agencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_dIyXP5BpbkGbErryI05k3w" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_Cy3cCevHMUqesxxedWroxQ_11_3">1,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_oikFh3LVykC7K0InhoySfQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_0laRjoSSiE-pqrw-tdps6w_11_9">1,575</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Ym0BL0i97UaomE43uV-bYQ" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_ydmKxGnpAk2NWndH2wyVOA_12_3">140,063</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NKtrp11L7UqjNJ0bCbPyIg" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_stVrk64cXE2mQRMAUqpdhA_12_6">6,782</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ZBgPDtK_ukm2DSu8kFg3MA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_O6UX4KkaSkWI23XZUxiwdg_12_9">133,281</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4yfMi2VPkWj9z09O5KR2g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_ggoINJRg50GRM8aCCqshlg_8_3">2,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8mxuMVEvVECi33rG7hy8TQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:CashAndCashEquivalentsFairValueDisclosure" scale="3" id="Tc_8n4r3m2io0Sp7gGzKpbfdw_8_6">2,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_C3fDpqg0Z0q1RzbPm02j9g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_dwBgba_E6ESwCjgRW6EhBQ_10_3">207,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NJQoeyaVbkORdIFR-hPZZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest" scale="3" id="Tc_IGr4PeZbokWgiqLHEJXklw_10_9">207,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_tC3N1hSTQ06SevgSev4lPA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_0BNE5Vsj3k6iyWjZUpTkew_11_3">209,934</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_PfvSQBm2r0egI8U0wsBykg" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc__UC_jjFkWkGk5LK0kf--4w_11_6">2,680</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Wm2A56lBgkCPpaUm6E_ypw" decimals="-3" format="ixt:numdotdecimal" name="nxtc:MarketableSecuritiesAndCashEquivalents" scale="3" id="Tc_77FToKz5s0q0hPF6lNd2kw_11_9">207,254</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December&#160;31, 2022 and 2021.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">99</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_BE-Qse057EGqHzJsTmQ41A_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying value of financial instruments, including trade receivables, accounts payable and accrued liabilities approximate fair value because of the short-term maturity of these items. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.</p></ix:continuation><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_NxCGc67u1UWEmEUM_rdDhQ_1_2"></a><a id="Tc_SepEAugJyEWZkQ3KBygb2Q_1_5"></a><a id="Tc_W-zjfE6Fd02_rMkOjLT3Uw_2_0"></a><a id="Tc_3msUfV0gcUukGbQgboIF2w_2_2"></a><a id="Tc_EFLbXX5FhEmDhMKg_3EJgw_2_5"></a><a id="Tc_gF4i-BYQ5Uelw4v6VzIk6g_4_0"></a><a id="Tc_TB9ufdr1OU2PPlhKONXEIQ_4_2"></a><a id="Tc_3O4ic04zKUm_NKyQ3e2lhQ_4_5"></a><a id="Tc_Su6JPQ5ZdE6s7U-myDstCg_5_0"></a><a id="Tc_6mqkRMJAKUqVuFISBH9U3Q_6_0"></a><a id="Tc_9ByaVt7b0kmCIq0W0h0t7A_7_0"></a><a id="Tc_yr3X_6Fm90-M6J-5kcffKA_8_0"></a><a id="Tc_uWmcd_Q5gUifCXx9bfuiTA_9_0"></a><a id="Tc_7-qIH8KeZ0GXszJmyW19Eg_10_0"></a><a id="Tc_g8-sdrm5t0-XE9i2aJpeYg_11_0"></a><a id="Tc_7hHc9Z-P1Ey1w-PY1pwKFQ_11_2"></a><a id="Tc_RiGs7WU8kEGaxe4r2ahS3Q_11_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock" id="Tb_qNG32M8kVE6AIYwsLBBPNw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">5. Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:PropertyPlantAndEquipmentTextBlock" id="Tb_uAFVFZE-yECGa-yQj8xZ9g" escape="true"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_s8Q9roYBs0mJ-WQs8x7lXQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_zNZV1wuCLEGtXn6qzR7ODA_4_3">17,244</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_nHuF1bXQ4UWlM6L_pFhCDA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_ztLiKYZuOUq8iW6tc3Bl2A_4_6">16,482</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-AdmtV4Y4E2el33p-R4o7Q" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_HM0_0hPPSUKfxibBeBDmvA_5_3">9,336</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vSYHseosFUeoXezPK_DwZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_0Prrow7tPEmO98qz0p2ZHQ_5_6">8,566</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_2k8diS0Dt0SajXRwD2H9pw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_b6G-SYpYu06GI8yC082ElA_6_3">908</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_B8DlzbFCLUSo9Q5ArS1Eqw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_SoQvfjWcGUWy9z5IGf2YuA_6_6">1,143</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_JFjr3X-iS0q7yBVBU-uoTQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_oDiDgPsHEEe6e0TRSU1h9A_7_3">186</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5wQASsCk1kGj8FiA4J8kUA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_t-TNOz2XNUiS5DtgYHCRnA_7_6">167</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_itU9-PmAeki7z14co80kbg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_-Ci6mGGo4EC8C_I5mG1udA_8_3">853</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jWIXUY1zdUKLE6_2RdA-vg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_YnI--x3_wUuO8LN3pz6obg_8_6">371</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_HtPSFTaY0k2oEGUUo90ZgQ_9_3">28,527</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentGross" scale="3" id="Tc_rnx5YDPbjkqcMjpMyOkmyw_9_6">26,729</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_KmshaFATDUudHF1LGP-7sQ_10_3">16,630</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" scale="3" id="Tc_bXz7DhamOE-d5B8wfXxQfg_10_6">12,737</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_Sut7KSYRUE2szA3IyTE-1A_11_3">11,897</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:PropertyPlantAndEquipmentNet" scale="3" id="Tc_vWDGNKXP6kihNTA8quYncw_11_6">13,992</ix:nonFraction></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Construction in progress at December&#160;31, 2022 and 2021 consists of the costs incurred for research equipment and for the build-out of additional lab and office space.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense was $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="Narr_V79eT4BOjkqDWRc61sg-Lw">4.1</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DepreciationDepletionAndAmortization" scale="6" id="Narr_bhvhPnqJykud8Td_QlLrKQ">4.3</ix:nonFraction> million for the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p></ix:nonNumeric><a id="Tc_ZMsT2wDoUkGG8YD53XzSMA_1_2"></a><a id="Tc_rf3DfdzZ3UacleY5jrnaHA_1_5"></a><a id="Tc__ETLDM2h_k-V2cOP45Hyzw_2_0"></a><a id="Tc_szkpB8qCyUSTSidjerq5_Q_2_2"></a><a id="Tc_99HnXWUNYUC4p3x84O3sFQ_2_5"></a><a id="Tc_blOvHYf10UK-ooYr_KwzIQ_3_0"></a><a id="Tc_T5cVXTyVwECHoCpABfntWg_3_2"></a><a id="Tc_cBk1vIp6TUOaoNDsiDz1pQ_3_5"></a><a id="Tc_G2t2SEduZEWLaVJKdjX4kA_4_0"></a><a id="Tc_geN4KWvh3kqub1zXw8TAKg_5_0"></a><a id="Tc_KjZFK77a6UOcHZoz8IzfEw_6_6"></a><a id="Tc_8HZK2ICj9E6r57kdbXaGYg_7_0"></a><a id="Tc_dwFMAVdgWUOInbl4k_eyOA_8_0"></a><a id="Tc_rqfO3mT59ECvVPnT53-NGQ_9_0"></a><a id="Tc_BYruXvcPSUSmTziyaaFIGw_9_2"></a><a id="Tc_C1_paAoz20KoAc3GBEGWHw_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" id="Tb_KARMbIb5OUy7t1ArNGy99g" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">6. Accrued Liabilities and Other Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued liabilities consist of the following:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock" id="Tb_7EVca2VYG0eGRn1bMxiy5A" escape="true"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_DUibAtYcdUKaxpyJON85ZA_3_3">1,639</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:EmployeeRelatedLiabilitiesCurrent" scale="3" id="Tc_VEuKSUVTBUSa8bZ0saomiw_3_6">1,751</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedClinicalTrialCostsCurrent" scale="3" id="Tc_EQbba1nZfUSUS6WLP-7PPQ_4_3">1,531</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedClinicalTrialCostsCurrent" scale="3" id="Tc_6hBC7L8UMUusu2iQl4zScQ_4_6">727</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sponsored research</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedSponsoredResearchExpenseCurrent" scale="3" id="Tc_vnDUiFYg1Euyh2BN2CWG8g_5_3">417</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedSponsoredResearchExpenseCurrent" scale="3" id="Tc_MGFu2HzbFk6FFmHGFmCpeg_5_6">1,315</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Y-cqdjMky0anGfcN4D8zww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liabilities, current portion</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiabilityCurrent" scale="3" id="Tc_15qlS86iwkisVse_2cCdaA_6_3">518</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedOperatingExpensesCurrent" scale="3" id="Tc_sjSWYpGAJU-tF-LwZfkVaA_7_3">647</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedOperatingExpensesCurrent" scale="3" id="Tc_vEv_Jep_jE2LT9ThtqNX_w_7_6">656</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_ub6AHmXehkiiGDlgywTOWw_8_3">105</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OtherLiabilitiesCurrent" scale="3" id="Tc_XXcJ8Ba-lUu16TZHq8beIg_8_6">217</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_ieiaDizzuEGHI5Zk8Qg_9A_9_3">4,857</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="nxtc:AccruedAndOtherLiabilitiesCurrent" scale="3" id="Tc_Tbh60BN1ZUSgS1B1iBthOg_9_6">4,666</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:LesseeOperatingLeasesTextBlock" id="Tb_IPTkqtFS8E6iMiXHQcoLjA" continuedAt="Tb_IPTkqtFS8E6iMiXHQcoLjA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">7. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company&#39;s lease portfolio consists of office space and laboratory facilities.  All of the Company&#39;s leases are classified as operating leases. The terms of the Company&#39;s lease agreements that have commenced currently extend through March 2030 and provide the Company with an option for a </span><ix:nonNumeric contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" format="ixt-sec:durwordsen" name="us-gaap:LesseeOperatingLeaseRenewalTerm" id="Narr_p-hkVgUmekml6OD5vfGCag">five-year</ix:nonNumeric> <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" format="ixt:booleantrue" name="us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend" id="Narr_3UhDFd9jlEezSlrZh9LnZA">extension</ix:nonNumeric><span style="white-space:pre-wrap;">.  Under the terms of the leases, the Company pays base annual rent subject to fixed dollar increases each year and other normal operating expenses such as taxes, repairs, and maintenance.  The Company evaluates renewal options at lease inception and on an ongoing basis and considers renewal options that the Company is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities in accordance with ASC 842.  The leases do not require variable lease payments or residual value guarantees and do not contain restrictive covenants.</span></p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">100</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_3ca1302b_2b36_416c_b956_842a90ec387f"></a><a id="Tc_-_51ZwUTQkOBj56I9-iC8g_2_1"></a><a id="Tc_KptMIGTn3UyvXlcBmAULhw_3_1"></a><a id="Tc_z7dzO7n_PEeTutwjyUWIZw_3_3"></a><a id="Tc_iR6jJV6z_0qaT_8F6jg8Xw_4_1"></a><a id="Tc_UhAxOhqA4kyPnP9Uc-Ht8Q_5_1"></a><a id="Tc_OIIBz7d640CdXT3NXHz9qA_6_1"></a><a id="Tc_YB1DRSc33kSrXBigKW-7tQ_7_1"></a><a id="Tc_ZQLf6HCA50qjosQOW6lVgQ_8_1"></a><a id="Tc_7xDRz_tQZEujScGzjGxJ9w_9_1"></a><a id="Tc_HxYjMug5q0GL38XTfOzjZA_10_1"></a><a id="Tc_kRrzWM3HhEOzsYiLbdCCDw_11_1"></a><a id="Tc_3a84ocTjYk-QWVPZFLrYfg_11_3"></a><ix:continuation id="Tb_IPTkqtFS8E6iMiXHQcoLjA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate as the discount rate when measuring the operating lease liability.  The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating lease expense was $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseExpense" scale="6" id="Narr_Tk8IiDa1OUiNmG57HI9B0g">1.0</ix:nonFraction><span style="white-space:pre-wrap;"> million for the year ended December 31, 2022.  Operating cash flows used for operating leases during the year ended December 31, 2022 were </span>$<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasePayments" scale="6" id="Narr_sc6QJ6eBCkqLt41YE3tlFg">0.9</ix:nonFraction><span style="white-space:pre-wrap;"> million.  As of December 31, 2022, the weighted-average remaining lease term was </span><ix:nonNumeric contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" format="ixt-sec:duryear" name="us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1" id="Narr_4wl4oufvXkqzgaVjKRWpSw">7.25</ix:nonNumeric> years, and the weighted average discount rate was <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="4" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent" scale="-2" id="Narr_7RlI99cK0UKvmJzWzizf6g">7.46</ix:nonFraction>%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Rent expense under operating leases was $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:OperatingLeasesRentExpenseNet" scale="6" id="Narr_AC6D7ywKXEeL-BcCFOHHjw">1.0</ix:nonFraction> million for the year ended December 31, 2021.</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock" id="Tb_fc3wpV7TF0WWYbiUXGBT-Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2022, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands), which are included in Accrued liabilities and other liabilities and Lease liabilities, long term in the accompanying balance sheet:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ending December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" scale="3" id="Tc_bTwf6VJUrkWcfVu2VLsrZQ_3_4">1,032</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" scale="3" id="Tc_LczW1NCXc0KyyPKLMYX54A_4_4">1,127</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree" scale="3" id="Tc_uyvv6E0EDkWjktFlVGrY2Q_5_4">1,214</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour" scale="3" id="Tc_WcMCJkNUzki_ct1Y474i8A_6_4">1,355</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive" scale="3" id="Tc_PtxiC0SFSE62Cvz5fgb-Dw_7_4">1,396</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" scale="3" id="Tc_i6Q2t12XE0iNGg-pMyl1dw_8_4">3,295</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue" scale="3" id="Tc_Om6145yvx0agaEqRXfMh4Q_9_4">9,419</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" scale="3" id="Tc_1PdnH-i8oES_ylNBtd8pGw_10_4">2,296</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:OperatingLeaseLiability" scale="3" id="Tc_j2iVuRpmpkiDkL-CIM75GQ_11_4">7,123</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:CommitmentsAndContingenciesDisclosureTextBlock" id="Tb_zqLTa8aym0eSqFw_6pL0xA" continuedAt="Tb_zqLTa8aym0eSqFw_6pL0xA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">8. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company, from time to time, is a party to litigation or legal proceedings arising in the ordinary course of business. The Company is not a party to any litigation or legal proceedings, nor is management aware of any pending or threatened litigation that, in the opinion of the Company&#8217;s management, are likely to have a material adverse effect on the Company&#8217;s business. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the Securities Act of 1933, as amended, with respect to statements made regarding our product candidate, NC318, and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021, and discovery is stayed pending resolution of that motion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys&#8217; fees and costs, declaratory relief, corporate governance changes, and restitution. On May 17, 2021, the Court granted the parties&#8217; joint motion to stay the derivative lawsuit pending resolution of the Ye Zhou action&#8217;s motion to dismiss.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">101</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_zqLTa8aym0eSqFw_6pL0xA_cont1"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 14, 2021, a purported misappropriation of certain trade secrets lawsuit was filed in Federal District Court for the District of Delaware, styled Immunaccel, LLC v. NextCure, Inc., Case No. 1:21-cv-01755-UNA. The lawsuit alleges that the Company misappropriated certain trade secrets belonging to Immunaccel related to a drug discovery and screening platform named IMMUNE 3D. The complaint alleges two causes of action, one under the Delaware Uniform Trade Secrets Act and another under the Federal Defend Trade Secrets Act, and seeks unspecified monetary damages, a permanent injunction and other miscellaneous relief.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company intends to vigorously defend the Ye Zhou, Liu and Immunaccel actions. Based on the Company&#8217;s assessment of the facts underlying these claims, the uncertainty of litigation, and the preliminary stage of these cases, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:DebtDisclosureTextBlock" id="Tb_pb7_--BXykC3HRKC_yHRKA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">9. Term Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2016, we entered into a $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_4_30_2016_fg7QH1JCMUKlmj0t5s8Cog" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_b2wI2p_oVEiBpVzXMzprgQ">1.0</ix:nonFraction>&#160;million term loan, or the &#8220;Term Loan&#8221;. In January 2019, we amended the Term Loan to increase our borrowing capacity to $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_1_31_2019_mPEpuuDRUUKsmnCtaVs9OA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DebtInstrumentFaceAmount" scale="6" id="Narr_hzfJg41H0kyrHlpBywnDTA">5.0</ix:nonFraction> million, which was secured by our certificates of deposit, money market account, investment property and deposit or investment accounts. In August 2021, we fully paid the remaining principal on the Term Loan, and there are <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:LongTermDebt" scale="0" id="Narr_aGfoMj6VmkOmgGzpm9MlEQ">no</ix:nonFraction> outstanding payments due from us. </p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:PreferredStockTextBlock" id="Tb_tu9Mb72XYECKCqLyF2aZXw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">10. Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockSharesAuthorized" scale="0" id="Narr_N-Xwu9MzPEyYzs3y_7w4Sw">10,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:PreferredStockParOrStatedValuePerShare" scale="0" id="Narr_BG4OLcWIEUyg-_IdjJ9rgw">0.001</ix:nonFraction> par value preferred stock, and there were <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:PreferredStockSharesOutstanding" scale="0" id="Narr_OdYMfDmQlkCoacbnANM_IA">no</ix:nonFraction> shares of preferred stock <span style="-sec-ix-hidden:Hidden_pC0KVSDrpUCOl6qY3Bjkag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> or outstanding. The Company can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by its stockholders.</p></ix:nonNumeric><a id="_cp_text_1_1369"></a><a id="_cp_text_1_1372"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="nxtc:CommonStockTextBlock" id="Tb_cBn1gnHBk0C_Dge6gvnxmA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">11. Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company&#8217;s Certificate of Incorporation, as amended and restated, authorized the Company to issue <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesAuthorized" scale="0" id="Narr_km-JZ1d3-kmv9xL1fnGVyw">100,000,000</ix:nonFraction> shares of $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockParOrStatedValuePerShare" scale="0" id="Narr_T_VliNvX5kyaFzNuOJw_-w">0.001</ix:nonFraction> par value common stock, of which <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockSharesIssued" scale="0" id="Narr_tngR-3ltN0yqlK3-EZD6rg">27,774,536</ix:nonFraction> were issued and <span style="-sec-ix-hidden:Hidden_BEloqN_kIUiSEA3CJtNPlQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each share of common stock entitles the holder to <ix:nonFraction unitRef="Unit_Standard_Vote_NTyCJtIjU0i5jZ9cnBFqVg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="INF" format="ixt-sec:numwordsen" name="nxtc:NumberOfVotesPerShare" scale="0" id="Narr_68NK3t45WEqLEKTNxpKN5A">one</ix:nonFraction> vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of any preferred stock. <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="INF" format="ixt-sec:numwordsen" name="us-gaap:CommonStockDividendsPerShareDeclared" scale="0" id="Narr_dbYE1jABpkyBjmgNvbRC1Q">No</ix:nonFraction> dividends have been declared or paid by the Company through December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any preferred stock.</p></ix:nonNumeric><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" id="Tb_sBEaDmbDc0-QSvsE1CvpgA" continuedAt="Tb_sBEaDmbDc0-QSvsE1CvpgA_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">12. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Equity Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The NextCure, Inc. 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;) was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants and directors of the Company. The 2015 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On May 3, 2019, the Company&#8217;s stockholders approved the NextCure, Inc. 2019 Omnibus Incentive Plan (as amended, the &#8220;2019 Plan&#8221;), which became effective on May 8, 2019, the date on which the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-230837) was declared effective (the &#8220;Effective Date&#8221;). The Company&#8217;s board of directors (the &#8220;Board&#8221;) determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and </p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">102</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><a id="_7a02f31d_493c_4457_918f_ec14c8c9032d"></a><a id="Tc_WUnIb5kRF0qMvZHg0r702A_1_2"></a><a id="Tc_VJ1XZPQ7iEmNFV7fjLDDLg_2_7"></a><a id="Tc_d096l5g8Xk2zrRc6Q1kSQA_3_4"></a><a id="Tc_0oK6PqAjl0Shjdhel7t0QQ_3_7"></a><a id="Tc_fCqug5aPa0eDlqbrO9TtnQ_3_9"></a><a id="Tc_qC0jsLzdoEalQzAjBgYg0g_4_4"></a><a id="Tc_XuXRbbfDA0Kl668-X87kRg_4_7"></a><a id="Tc_jeIdWTeSLUK8I2eBIMb7xQ_4_9"></a><a id="Tc_wQVEPLorqUaJXdPUf5dDTQ_5_2"></a><a id="Tc_59socSIg5ke9mtmRHlrLtQ_5_4"></a><a id="Tc_6yzQD9t4PUmzMbxXykDhTg_5_7"></a><a id="Tc_Za1Egc1pfUGqFwUAAnT48Q_5_9"></a><a id="Tc_vLPY3ML2I0u4lGUEW9jcZA_6_2"></a><a id="Tc_1cMToABxOkaXdeBBLcGAmQ_6_4"></a><a id="Tc_tSJoHK1Vx0-5ookhvywLqQ_6_7"></a><a id="Tc_1-MOC71N1E2o9IC8FLj4AA_6_9"></a><a id="Tc_cTyB1VWvOE6k0c2W1Jl0yg_7_0"></a><a id="Tc_0dP5FByWJkCK6Odb7uAI6w_7_4"></a><a id="Tc_JX_tNWGJu0KGihlKWy0seA_7_9"></a><a id="Tc_ZIUOhYDLY0e6UWjAq_wmQQ_8_0"></a><a id="Tc_caOHRbVnmE6UUU8FFIDZgg_8_4"></a><a id="Tc_mZ4d7WEQWEu-lDO44z-DpA_8_7"></a><a id="Tc_ulka5NIy3EWoK0G7vw_lQg_8_10"></a><a id="Tc_mVH4tsOX7UuZF_OoLdlQrA_9_0"></a><a id="Tc_Gs-rYij7PUWEzD-QeqOSbg_9_4"></a><a id="Tc_Jp_Tp9bgD0SP-bYVzZXong_9_7"></a><a id="Tc_0jUZE-qEfUGCJm72w-LxTQ_9_10"></a><a id="Tc_wSNMab4tWkmhz7woQbi-ug_10_0"></a><a id="Tc_vgcynGEswECd9oAfRne6kg_10_4"></a><a id="Tc_JpVGy8iog0q24jClpL7O4Q_10_7"></a><a id="Tc_jB10wbGvnkuBOtBJyYR8xA_10_10"></a><a id="Tc_yLVyNfhsZ0iqsZ9qnyz10Q_11_0"></a><a id="Tc_O9NLPPIV2EmFVWB90o8xZw_11_4"></a><a id="Tc_owWm4aHQ6UeEnyyUSqEMeA_11_9"></a><a id="Tc_uSgCdn7GTESfsVsESmFviw_12_0"></a><a id="Tc_i3n7oh_JL0mO4caHPuh7fA_12_4"></a><a id="Tc_WBGypadVW0OI_FK4NczoUw_12_7"></a><a id="Tc_gcjI3mXMQEC_o6vAXVFkNA_12_10"></a><a id="Tc_E6WykR4VFkWd4MoCyl_NCQ_13_0"></a><a id="Tc_VVccLBu0qEeUTemTfLqd7w_13_4"></a><a id="Tc_lP0QIqx5f0mJc6Jg07wyvw_13_7"></a><a id="Tc_sQ6oNdJjaUqxINQe2sTQKQ_13_10"></a><a id="Tc_6dGBc60gNkim2f_BNtrxVg_14_0"></a><a id="Tc_E86wmEWlV0K94vjHNb727g_14_4"></a><a id="Tc_Y18IFronBkauZxpM5jHaqg_14_7"></a><a id="Tc_Zk__tYoM2kOtAbApobL4iw_14_10"></a><a id="Tc_Isb_pkPWHkGXHZOM3ZDzkQ_15_0"></a><a id="Tc_1i6iIFAHZ0iKyMpV8pwipQ_15_4"></a><a id="Tc_PCFs5cte_kaEsuV69oYLgw_15_9"></a><a id="Tc_VzdLFRM4R0abagfVx3zfvg_16_0"></a><a id="Tc_YZ9UndQ3QUSo2MJUgcKk8Q_16_4"></a><a id="Tc_KEkPTzChDkOsFWGghHV1gA_16_9"></a><ix:continuation id="Tb_sBEaDmbDc0-QSvsE1CvpgA_cont1" continuedAt="Tb_sBEaDmbDc0-QSvsE1CvpgA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">cash bonus awards to the Company&#8217;s officers, employees, non-employee directors and other key persons (including consultants). The number of shares of common stock reserved for issuance under the 2019 Plan is <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_v5woPB-Gu0eGhZbi1jiBTQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_Z5_XL8KwT0yEI49mwdoHww">2,900,000</ix:nonFraction> plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan will automatically increase each January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> during the term of the 2019 Plan by <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_0wxdrOUI5Uq9n6FoN-ND_Q" decimals="2" format="ixt:numdotdecimal" name="nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" scale="-2" id="Narr_bH9riSdIEUqyFdlKaRs-XQ">4</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of the preceding calendar year or such lesser number of shares determined by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_D46SFEZZN0aTWX1Xr95ZPA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_sKPDvQCLpk2P-YseL50eJw">2,653,867</ix:nonFraction> shares were reserved for future issuance under the 2019 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options granted under the 2015 Plan and 2019 Plan (together, the &#8220;Plans&#8221;) to employees generally vest over <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_QFG6gM-uuk2TLGjd7TLz8Q" format="ixt-sec:durwordsen" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" id="Narr_IuuZ-NJv0U-IRAejv6PtTw">four years</ix:nonNumeric> and expire after <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_QFG6gM-uuk2TLGjd7TLz8Q" format="ixt-sec:durwordsen" name="nxtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" id="Narr_ZleKKYmFTUGwGKNjq0lDzQ">10 years</ix:nonNumeric>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of stock option activity for awards under the Plans is presented below:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" id="Tb_Rn3fR5At_ECxiWV8bkez3A" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding&#160;and&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_4xX7epy4hkGSbwwR_hzucA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_VhDxPe6q40SPf5Xkm66vqQ_7_2">3,112,376</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_4xX7epy4hkGSbwwR_hzucA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_yZo1J17XQ0WlF75VgJ-u7Q_7_5">16.95</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_vASUCe3mXEShFcN7roPOFw" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_KOuGXjxAPkebJlLRaog5Sw_7_7"> 8.2</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_4xX7epy4hkGSbwwR_hzucA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_jocBKNj3SUC6h-QURKSRRg_7_10">10,810</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc_B30yLOgv70iB8EEEqT_OPQ_8_2">2,020,718</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_Duxd6_jg00il1LRjBFHLTQ_8_5">10.89</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_jDHiyrmpek2fJFH0YWpyDw_9_2">105,731</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_YQ0ZAoeRqUOBuYhsKSNaEQ_9_5">1.62</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeitures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_4IC-bztxZU2NDr79njJskQ_10_2">481,569</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_pQ3PGO87BU-gx7_8Zy9VnA_10_5">21.33</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_I1bCpdmof0eokGR4x8FVCA" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_tImzPuzw9UqzxvRBVevfyg_11_2">4,545,794</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_I1bCpdmof0eokGR4x8FVCA" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_tEZMGtoJiUqnP2xySHuT9A_11_5">14.15</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_fjR0famubEqEUnl6op7z0w_11_7"> 8.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_I1bCpdmof0eokGR4x8FVCA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_iLVE2O8BX0KG7tIsenPLnQ_11_10">2,860</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" scale="0" id="Tc__PVgsvMIJE2uDol4N-E2dQ_12_2">1,739,350</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_I5xZawg83kaldMOZlGOXag_12_5">5.34</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised" scale="0" id="Tc_mtkqgjdCDk6pPdB2g4ZuAg_13_2">50,420</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_BcYU46FShUWhF8fhI8Z2gQ_13_5">1.32</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeitures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (<ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" scale="0" id="Tc_HvmJJrRaLEamWBDE7v2kDA_14_2">972,545</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" scale="0" id="Tc_EjWlJ1TqAkaX_7RNOyaJrg_14_5">13.77</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" scale="0" id="Tc_oklcoyya_kiOxxuigsBbWQ_15_2">5,262,179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" scale="0" id="Tc_rFbUPD-ii0yxbbrxzfSQwQ_15_5">11.44</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" id="Tc_ybIp1HOkaUuaLRas0ilrDQ_15_7"> 7.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" scale="3" id="Tc_zsP30AsUpEyaBKYtxtF4bw_15_10">115</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" scale="0" id="Tc_6bEqMGpuXEKbA_ydNj0SdQ_16_2">2,790,206</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" scale="0" id="Tc_k8RBDenjwkqg8zC1mKa07Q_16_5">12.97</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" id="Tc_t0X4oQeZtEyhC-5stbLwag_16_7"> 6.6</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" scale="3" id="Tc_h84qdGxjkUezAaTymX__Ng_16_10">115</ix:nonFraction></p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2022 and 2021.</span></td></tr></table><div style="margin-top:12pt;"></div></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant date fair value per share of stock options granted during the years ended December 31, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_NSGzRkapbEeEU4zM5a7Cqw">3.69</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ" decimals="2" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" scale="0" id="Narr_ttGUXNur4U-nJdbyTMx_tw">7.47</ix:nonFraction> respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="0" id="Narr_ZoFYmUBUzk-pKg0ax78LVg">13,000</ix:nonFraction> and $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" scale="6" id="Narr_HgETemE9mUmKFGKRuDNZ4g">0.5</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The aggregate grant date fair value of stock options and restricted stock vested during the year ended December 31, 2022 and 2021 was approximately $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_hE_W-pIto0SKKV3xar3wSA">11.0</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" scale="6" id="Narr_m1RU7AIk2kagytRqLguVwg">13.4</ix:nonFraction> million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 3, 2019, the Company&#8217;s stockholders approved the NextCure, Inc. 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on the Effective Date. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423(b) of the Internal Revenue Code. A total of <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_KMR2V40rz0WEvFMh7SGH2A" decimals="INF" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_LpqDK2ZK2Ui1lfvWGvjE6w">240,000</ix:nonFraction> shares of common stock were reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase each January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> until expiration of the ESPP, in an amount equal to the lesser of (i) <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_SRji9FsHhkW2MxxpNEJcRQ" decimals="2" format="ixt:numdotdecimal" name="nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" scale="-2" id="Narr_F-aUtjLrWUWOehoOQ5ghSQ">1</ix:nonFraction>% of the number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, (ii) <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_SRji9FsHhkW2MxxpNEJcRQ" decimals="0" format="ixt:numdotdecimal" name="nxtc:ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" scale="0" id="Narr_i7gP_tvnGEqP4mWK6cXWfQ">480,000</ix:nonFraction> shares of common stock and (iii) a number of shares of common stock determined by the administrator of the ESPP. As of December 31, 2022, <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_S3g67ITO1UG2PaPwVbTH0Q" decimals="0" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" scale="0" id="Narr_UAKLwH4gnkC6Es3M4clPTg">49,583</ix:nonFraction> shares of common stock had been issued pursuant to the ESPP and <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_tlc5w1VAtUGsrUcZTfo1pg" decimals="0" format="ixt:numdotdecimal" name="us-gaap:CommonStockCapitalSharesReservedForFutureIssuance" scale="0" id="Narr_KReF8w3BskOpN03hb3EIWQ">741,097</ix:nonFraction> shares were reserved for future issuance thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recorded stock-based compensation expense of $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_0DOPlfGz_UOfAujfAqY4iQ">9.5</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="6" id="Narr_SvZq03KYzkCPqXC2r78GUw">10.3</ix:nonFraction> million during the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, there was $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" scale="6" id="Narr_3MyibXrs20WPKEjwl4V5wQ">14.7</ix:nonFraction> million of unrecognized </p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">103</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="Tc_w0l1E3OMnkmypV4RJs8P7w_1_2"></a><a id="Tc_17JrUFrfTEWbM1uirXCivQ_3_0"></a><a id="Tc_nz7WSvpUzk-byqeUHgNDxQ_3_2"></a><a id="Tc_-FEucDLc5Eucp6fUxIIPEQ_3_5"></a><a id="Tc_jGRe8v8Ln0qx8FLZaIN5QA_4_0"></a><a id="Tc_UpSKur5lRkmrJl88T4R7Vw_4_2"></a><a id="Tc_EarYzpabwUu8qPgDckbb5g_4_5"></a><a id="Tc_AzRIx2wLxkCYdIUyH3Ideg_5_0"></a><a id="Tc_845XLYX6RUmc0ylSpL4SJw_6_0"></a><a id="Tc_NqwqFehZwk2M8LJIVwCoUw_6_2"></a><a id="Tc_P7wYgFACqUathiYXlNZp8Q_6_5"></a><a id="Tc_9Uxm7vb2nkCEFLQxbu02hQ_1_2"></a><a id="Tc_Wc6E8Nq3f06iCqhMlHMy5g_2_2"></a><a id="Tc_B9HoFtLk1kaTEpH7Muc_NQ_3_2"></a><a id="Tc_fzjzaxipAE2Wqb_puKCifg_3_5"></a><a id="Tc__TkffyfmKE20NHwmcUkgYg_4_0"></a><a id="Tc_y7hoxI-qykKW1jxf42MBEw_4_2"></a><a id="Tc_REFMykKmWE2HLKhU4OfWxQ_4_3"></a><a id="Tc_O4xV05APCkasKNogqeuhlA_4_5"></a><a id="Tc_m9iU6uCisU6W6uYeGtwqsg_4_6"></a><a id="Tc_bIB7P7B-50m3gLvY9Ne5fg_5_0"></a><a id="Tc_ZeMrE9oTVkWVyy0dhwBRSw_5_2"></a><a id="Tc_1DeZp1c9fUeSTtXUDxHgIw_5_3"></a><a id="Tc_bgGOjG60H0Cm1QilArC-aA_5_6"></a><a id="Tc_DwgpCIfZlES9iLQLMR65Tg_6_0"></a><a id="Tc_zKH0RhmcfUmS9lJ4DIQhIQ_6_2"></a><a id="Tc_YHXXxtVrx0iVGm1z9eBmXw_6_3"></a><a id="Tc_ng07XPEsiEmx3vYG1HaVTw_6_5"></a><a id="Tc_vYvPsQphsketnPhj1nDKtA_6_6"></a><a id="Tc_uykxrnfX30K33k0-d-K38w_7_0"></a><a id="Tc_hWOe6Anr5UGmsesmh_P2Qg_7_2"></a><a id="Tc_I6nLgi6u2E-38BXKM4hoYQ_7_3"></a><a id="Tc_bIhGmjE6U0WzaUo5B9I-Dg_7_5"></a><a id="Tc_SU88HFeemEuQBRYfC5l5yQ_7_6"></a><ix:continuation id="Tb_sBEaDmbDc0-QSvsE1CvpgA_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">compensation cost related to unvested stock-based compensation arrangements granted under the Plans. This remaining compensation expense is expected to be recognized over a weighted-average period of <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" format="ixt-sec:duryear" name="us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" id="Narr_z9ad4k0XSkOafqAu0SbByQ">2.6</ix:nonNumeric> years as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock-based compensation expense recorded as research and development and general and administrative expenses is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" id="Tb_Z-TM3wwucUeNB-PzYIblrg" escape="true"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_4Bc0BKCyvkywArPzGa-ufg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_0pY1iPHv00mpXo1oyLHv-A_4_3">3,056</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_n1J87RqwcE-D74ie7jOgeA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_lkBb8PaUqkq32YYExYWVnw_4_6">4,081</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_zu6x2W08xUuSowvqAgpX-g" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_NnK4Wk7dl0S1TeWJvxMEpQ_5_3">6,452</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ip93Wfm4iEeGxOE28jx6nw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_J4MKM-lBiE2U-S9zHvh9ig_5_6">6,207</ix:nonFraction></p></td></tr><tr><td style="vertical-align:top;width:73.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_Kk8IOW5wV0-nsPRDsYRivw_6_3">9,508</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:AllocatedShareBasedCompensationExpense" scale="3" id="Tc_vJljuV4AfU2D_djNoKZ3IA_6_6">10,288</ix:nonFraction></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The assumptions used in the Black-Scholes option-pricing model for stock options granted were as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" id="Tb_10U2t6H9O0W05OpHgmK62A" escape="true"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_gdOPWWwYIk-1_fM2ZbqmhA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_227dhRzv9UO8VoH_T8ismg">5.5</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1v3p_PfN6ku6GNiQC6D3Xg" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_bJTGn4eSjkyY-GYkulPBVQ">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_YBa26s9G0UemyPzMQSEebA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_4lkxoxf7wkuzBWiakVDZKg">5.3</ix:nonNumeric> - <ix:nonNumeric contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_6T-mMXX7Tk2kXUXSd6hCrA" format="ixt-sec:duryear" name="us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" id="Narr_ScXjmNJcqU-5P1pYgHV3NQ">6.1</ix:nonNumeric></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_gdOPWWwYIk-1_fM2ZbqmhA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="Narr_rMvBV6tQhEC-aEqPx3OGGg">79.7</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1v3p_PfN6ku6GNiQC6D3Xg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="Narr_DraHlGIL5U2irOLitIfwcA">81.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" scale="-2" id="Tc_x8qGL9ubBU67PLL5m5s16g_5_5">79.7</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_gdOPWWwYIk-1_fM2ZbqmhA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_s0TM4Jik_kqSWB879ykq0w">1.8</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1v3p_PfN6ku6GNiQC6D3Xg" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_wl5-HV3q1UScjbO4dCLFfQ">4.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"><ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_YBa26s9G0UemyPzMQSEebA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_nce8ssBcZU62SrTcJqyQng">0.8</ix:nonFraction> - <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_6T-mMXX7Tk2kXUXSd6hCrA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" scale="-2" id="Narr_8FxhjnVAZ0WOPEo9GFJ6zw">1.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table></ix:nonNumeric><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:continuation><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_gC2b4AzWw0Kf7TDKjmzQ4g_1_2"></a><a id="Tc_uswFnSDzOUuYG7uqSJ5pVg_2_2"></a><a id="Tc_4hJsnpGKhEi6QmOafepI3A_2_5"></a><a id="Tc_ydGvWhdDVkWlz2wVrjKllA_3_0"></a><a id="Tc_5fwxxs7z7UiBoU1w_Okmqw_4_0"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:EarningsPerShareTextBlock" id="Tb_buImYXeflkSJXvSr_QjE1Q" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">13. Net Loss per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potential dilutive securities, which include common stock options, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" id="Tb_CFt-abXREUqPxz5EUtHbQA" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_03bv1J6VnEK7iPOZioYxuQ" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_ZWrNdM_1FEadcQeLjIYdwg_3_3">5,262,179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eGfbitKLGk6VtkSOTwNSZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_j0_96JJWz0i7W9zDKGQNcA_3_5">4,545,794</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_cT2CmKSlnE-dYoXBtjpA7Q_4_3">5,262,179</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="0" format="ixt:numdotdecimal" name="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" scale="0" id="Tc_2Qzo8XzWM0SySVP7DSyrvw_4_5">4,545,794</ix:nonFraction></p></td></tr></table></ix:nonNumeric><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="Tc_IDVMd0PvCUuybu6QdUJU4w_1_2"></a><a id="Tc_OTPUEQNjREeTQCq3RvJaMw_2_2"></a><a id="Tc_81pJ-jUGaUipY-QFdYiKhg_2_4"></a><a id="Tc_Z8_DoA_P8EOj6Dos1JvL6A_3_0"></a><a id="Tc_Me6OtHMb2EK3n_gD6GNH3w_3_3"></a><a id="Tc_wxH6fU5qEkWgwCPbdKcJig_3_5"></a><a id="Tc_GSV9Ws2c5kymno3YCtuYbQ_4_0"></a><a id="Tc_E_84m0O4DEuyvpyjepRU5g_5_0"></a><a id="Tc_Cem9xtKNHEO2zZNIas-MlA_6_0"></a><a id="Tc_zAlp8k7O3Equz0kojrZJwg_7_0"></a><a id="Tc_7-ZdcsJ7rkCl-gfYkH07iQ_8_0"></a><a id="Tc_qXATLF3reEKxB7rKolfxkw_9_0"></a><a id="Tc_YqBdHdx6akS3fRy6uhO9sQ_9_2"></a><a id="Tc_r2H0yVhsc06MWJbSoNNDQg_9_3"></a><a id="Tc_8wuJTHCjwkWbdWG22Xf_rw_9_4"></a><a id="Tc_vOVDYXO5cECYidT9gOGYlA_9_5"></a><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:IncomeTaxDisclosureTextBlock" id="Tb_cpqeB6daz0C6TUK8BxkbBw" continuedAt="Tb_cpqeB6daz0C6TUK8BxkbBw_cont1" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">14. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" id="Tb_i6pADIKb7EObcWpFoKQZhw" escape="true"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected income tax benefit at the federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_M6fAaGKobkG_wLCHxEFQxg_3_2">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" scale="-2" id="Tc_estoHLX180CbGcJLPbtRhQ_3_4">21.0</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_QwGxKLPrkEq7GoFNoU1VTg_4_2">6.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" scale="-2" id="Tc_8zED5-1G60W3ihL2yHtWMg_4_4">6.5</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc_YoPnxbYKCk-8kNpDcjuXLQ_5_2">3.4</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" scale="-2" id="Tc__4HVWALtqEuLQcv9_NqCNQ_5_4">3.2</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_Z2NyScCcy0mOItFZHCmzqQ_6_2">1.7</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense" sign="-" scale="-2" id="Tc_upI2z7V3eEaC6iNAM2fHJw_6_4">1.8</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prior year provision to return adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" sign="-" scale="-2" id="Tc_FTVowp-Bf0eOe_Yg_V2zxA_7_2">0.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" sign="-" scale="-2" id="Tc_GESx5zD9s0qvvL0BRmS_HA_7_4">0.4</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_cvlHLcm80EG8ykiYgPYEdg_8_2">29.1</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="3" format="ixt:numdotdecimal" name="us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" sign="-" scale="-2" id="Tc_FwPMP5wL_EmLM-4yhU3kyg_8_4">28.5</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</p></ix:nonNumeric></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">104</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_Hlk25830017"></a><a id="Tc_ZOOSLS6VTE2N-lo3mcVQ3g_1_2"></a><a id="Tc_HC8rvQc6GUeOmmusFjiI6w_2_0"></a><a id="Tc_m79nvpobiUK8z9g_6wENBQ_2_3"></a><a id="Tc_dOaBfjwPHEKDDf62lJktOw_2_6"></a><a id="Tc_HxN_0hZ_yU6SXNIXUkr2oQ_3_0"></a><a id="Tc_B5nWTcC2k0Wu2DxgkO9oxQ_4_0"></a><a id="Tc_ST6vVjuUp0GWCQmIJIqYhA_4_2"></a><a id="Tc_wRZorA9PmUKeEXMCLVh6bw_4_5"></a><a id="Tc_I_4W_87vMUqeH5W13yKTGg_5_0"></a><a id="Tc_jLO8zeY2s0-wxvGJuD5fCQ_6_0"></a><a id="Tc_YBKp0YA3OUulMfcVCIYdnA_6_6"></a><a id="Tc_iED-x2l8E0avrV1QxB-oYg_7_0"></a><a id="Tc_HoybG4zBekeTNuTA_As-bQ_7_6"></a><a id="Tc_NHr0D8HFjEWWtmhzsc51Lw_8_0"></a><a id="Tc_hgx3bsyP70W8lXmrfMWlBg_9_0"></a><a id="Tc_oZ-0JIWjBEGLI8eQgvfkrA_10_0"></a><a id="Tc_piPaNrS48ke_6xXzg3NH4Q_11_0"></a><a id="Tc_XwzmtHDC_UqyQ26bMzGboQ_12_0"></a><a id="Tc_lG9FufP2PE2USDThCqKNaQ_12_2"></a><a id="Tc_mCv93tMP0kCllbuiKzUSAg_12_5"></a><a id="Tc_Fu1ay72O7Ey9fRwHB56ddw_13_0"></a><a id="Tc_4WPN6HQmGUWKbs0zVHkIAA_14_0"></a><a id="Tc_JdFWZAJERUuC7sjIRFyAxA_14_2"></a><a id="Tc_r5IcV49mXE2Mq4e2VVvsdQ_14_3"></a><a id="Tc_JqfmoZVgukaBQP0HbPoGLQ_14_5"></a><a id="Tc_S2fS_PIUTk6xsmpuTmxHgA_15_0"></a><a id="Tc_zi7oqu9dqk6yrPBfRMyomQ_15_6"></a><a id="Tc_wcUYPXvk00CFPZ47K5c4lA_16_0"></a><a id="Tc_PE93TMvqW0qY8-EAt4zetQ_16_2"></a><a id="Tc_qi1kLhh1BUaGL3x63Uei0w_16_5"></a><a id="Tc_07r1Ewgiw0qrzeXxUnIKxg_17_0"></a><a id="Tc_DhbIjL-e9EKuRcjYuWk6-w_17_2"></a><a id="Tc_CGJJIh1j5kOCj34T5ic9pQ_17_3"></a><a id="Tc_FMSXyEQbtkCOPHeegcEjmw_17_5"></a><a id="Tc_EfUPSzLfYE2_GC9PVPNH3w_17_6"></a><ix:continuation id="Tb_cpqeB6daz0C6TUK8BxkbBw_cont1" continuedAt="Tb_cpqeB6daz0C6TUK8BxkbBw_cont2"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The principal components of the Company&#8217;s deferred tax assets consisted of the following as of December&#160;31, 2021 and 2020:</p><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" id="Tb_9h3oxQW-7kOixa-BR-6tzQ" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal and state net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_fj2eiWSBSka5IXMG5rhfbQ_4_3">49,789</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwards" scale="3" id="Tc_rSjnlLpq_kWBXdyot5Uw2Q_4_6">44,451</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_frjHq8O8fkSGIPCeoav6pQ_5_3">11,395</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch" scale="3" id="Tc_epSaKpQ7QkibWmN9FiLqgg_5_6">8,862</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capitalized R&amp;D Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DeferredTaxAssetsCapitalizedResearchAndDevelopment" scale="3" id="Tc_4lbDd141_k-fZ4kMoe5B9A_6_3">12,424</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DeferredTaxAssetsOperatingLeaseLiabilities" scale="3" id="Tc_ZHpb7Kqx1USog_Hi8h_TnA_7_3">1,960</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_w1A9YNvyhkWoKj2ieqoqRA_8_3">4,389</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" scale="3" id="Tc_NseEpzBb6Eagige0WtW0qw_8_6">3,184</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accruals and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" scale="3" id="Tc_ExJDXgOIxE-Mu3-bWFCUtg_9_3">1,305</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" scale="3" id="Tc_U7VtePIQxUGy3RoTTDXMpA_9_6">1,291</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_KqRoyD6eZEOys6U_hOmhQA_10_3">81,262</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsGross" scale="3" id="Tc_DjiJQWexjky0jEy53TxaMw_10_6">57,788</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_6sgTtKfzGEuhk_mN90UvSQ_11_3">79,724</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsValuationAllowance" scale="3" id="Tc_h2ISXWVfs0ivyvL38jU-lQ_11_6">57,705</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_mYOY4TbTdEy8BiqHvix2ww_12_3">1,538</ix:nonFraction></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsNet" scale="3" id="Tc_9uVcB8CCN0OyaqAz7RNtxw_12_6">83</ix:nonFraction></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="nxtc:DeferredTaxLiabilitiesDepreciationAndAmortization" scale="3" id="Tc_4yvR1zp7GEyHAVTxzLr_fA_14_6">83</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxLiabilitiesLeasingArrangements" scale="3" id="Tc_D6SQ5tjC1kmzhkRrD2wyCQ_15_3">1,538</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_2nPm1sQ9N0mskUcCTl7EUw_16_3">1,538</ix:nonFraction>)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg" decimals="-3" format="ixt:numdotdecimal" name="us-gaap:DeferredIncomeTaxLiabilities" scale="3" id="Tc_8QfcYD2cFEGwEF0oZt1Gpw_16_6">83</ix:nonFraction>)</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2022. The Company increased its valuation allowance by approximately $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount" scale="6" id="Narr_DCprLUgMB0uV8Mo744HbYg">21.9</ix:nonFraction> million for the&#160;year ended December&#160;31, 2022. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company had federal and state net operating loss carryforwards of $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic" scale="6" id="Narr_eKknkjR01UKIjLp1n3WK8A">180.2</ix:nonFraction>&#160;million and $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" scale="6" id="Narr_65pjldn2NUmPYYYQOkit1A">183.1</ix:nonFraction>&#160;million, respectively, some of which begin to expire in the&#160;year ending December&#160;31, 2036. Approximately $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" scale="6" id="Narr_d4i1s_m7qkGaPwjZ057ZQg">157.5</ix:nonFraction> million of the federal net operating loss carryforwards do not expire. The Company had federal and state research and development tax credit carryforwards of approximately $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-5" format="ixt:numdotdecimal" name="nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" scale="6" id="Narr_9sk9Vmfa6kKjih_odO4Qyg">11.3</ix:nonFraction> million and $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="-5" format="ixt:numdotdecimal" name="nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" scale="6" id="Narr_UlWHD7E3UE2OyQAeF1K82A">0.1</ix:nonFraction>&#160;million, respectively, as of December&#160;31, 2022. The federal credits begin to expire in the&#160;year ending December&#160;31, 2036, and the state credits begin to expire in the&#160;year ending December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of Sections&#160;382 and 383 of the Internal Revenue Code (the &#8220;IRC&#8221;), certain substantial changes in the Company&#8217;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction as well as in Maryland. The tax&#160;years 2019 to 2021 remain open to examination by the major jurisdictions in which the Company is subject to tax. Fiscal&#160;years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early&#160;years, which have been carried forward and may be audited in subsequent&#160;years when utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2022, the Company had <ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA" decimals="0" format="ixt-sec:numwordsen" name="us-gaap:UnrecognizedTaxBenefits" scale="0" id="Narr_t71WrZT_KkaJuyYlX33eEw">no</ix:nonFraction> unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Coronavirus Aid, Relief, and Economic Security Act, or &#8220;CARES Act&#8221;, and the Consolidated Appropriations Act, 2021, or &#8220;Stimulus Bill&#8221;, signed into law on March 27, 2020 and December 27, 2020, respectively, have resulted in significant changes to the U.S. federal corporate tax law. Several states have also enacted tax legislation changes. We have considered the applicable tax law changes and determined there was no significant impact to the tax provision of the Company.</p></ix:continuation></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">105</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 12pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;max-width:100%;position:relative;"><ix:continuation id="Tb_cpqeB6daz0C6TUK8BxkbBw_cont2"></ix:continuation><ix:nonNumeric contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" name="us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock" id="Tb_AkzoaMvbdk2gycJw-WUwgw" escape="true"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">15. Employee Benefit Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sponsors a 401(k)&#160;plan which stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. For the year ended December 31, 2022, the Company made matching contributions of $<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA" decimals="-5" format="ixt:numdotdecimal" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_1c15gSyqyk21xtKiHKN2tw">0.3</ix:nonFraction> million. &#160;<ix:nonFraction unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg" contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw" decimals="-5" format="ixt-sec:numwordsen" name="us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount" scale="6" id="Narr_H3kIVrhm7EGZ3OeyrYo43A">No</ix:nonFraction> contributions were made for year ended December 31, 2021.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></ix:nonNumeric><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="display:none;line-height:0pt;margin:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:0pt;visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">106</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 6pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_96b45a4f_4e96_4e44_9bf1_e5a0703f2269"></a><a id="Item9ChangesinandDisagreements_266846"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 9. Changes in and Disagreements with Accountants on Accounting and Financial Disclosure</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_84ad0513_dccb_4fc7_a6d4_a53a40d903ba"></a><a id="Item9AControlsandProcedures_609124"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 9A. Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Disclosure Controls and Procedures</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended, or the Exchange Act, as of December 31, 2022. Management recognizes that any controls and procedures, no matter how well designed and operated, can provide only reasonable assurance of achieving their objectives and management necessarily applies its judgment in evaluating the cost-benefit relationship of possible controls and procedures. Based on the evaluation of our disclosure controls and procedures as of December 31, 2022, our Chief Executive Officer and Chief Financial Officer concluded that, as of such date, our disclosure controls and procedures were effective at the reasonable assurance level.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Changes in Internal Control over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Report of Management on Internal Control Over Financial Reporting</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Our management is responsible for establishing and maintaining adequate internal control over financial reporting (as defined in Rule 13a-15(f) under the Exchange Act). Under the supervision of and with the participation of our Principal Executive Officer and Principal Financial Officer, our management assessed the effectiveness of our internal control over financial report as of December 31, 2022 based on the criteria set forth by the Committee of Sponsoring Organizations of the Treadway Commission in &quot;Internal Control-Integrated Framework&quot; (2013). Based on this assessment, management concluded that our internal control over financial reporting was effective as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">This Annual Report does not include an attestation report of our independent registered public accounting firm on our internal control over financial reporting due to an exemption established by the JOBS Act for &quot;emerging growth companies.&quot;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><a id="_3a6961e2_bb6f_431c_a785_d066555ac39a"></a><a id="_Item_9B._Other"></a><a id="Item9BOtherInformation_632493"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 9B. Other Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_1d0c4d55_ad0e_4a0c_b7af_135b726e5037"></a><a id="Item9CDisclosureRegardingForeignJurisdic"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 9C. Disclosure Regarding Foreign Jurisdictions that Prevent Inspections</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_b2adf409_6ff4_417c_8be1_5a1715ad41c6"></a><a id="PARTIII_212520"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART III</p><a id="_Item_10._Directors"></a><a id="Item10DirectorsExecutiveOfficers_124962"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 10. Directors, Executive Officers and Corporate Governance</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item will be contained under the headings &#8220;Proposal No. 1: Election of Class III Directors,&#8221; &#8220;Corporate Governance and our Board of Directors,&#8221; and &#8220;Executive Officers&#8221; in our definitive proxy statement for our 2022 annual meeting of stockholders, or our &#8220;Proxy Statement,&#8221; to be filed with the SEC within 120 days of December 31, 2022 and is incorporated herein by reference.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">107</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c98dbd2e_0fc4_402f_b90c_e266758fe8d4"></a><a id="_Item_11._Executive"></a><a id="Item11ExecutiveCompensation_378389"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 11. Executive Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item will be contained in the Proxy Statement under the headings &#8220;Executive Compensation&#8221; and &#8220;Director Compensation&#8221; and is incorporated herein by reference.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_738dd128_25be_4472_9ca4_7ece3cf7852a"></a><a id="_Item_12._Security"></a><a id="Item12SecurityOwnershipofCertainBenefici"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 12. Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this Item will be contained in the Proxy Statement under the headings &#8220;Ownership of our Common Stock&#8221; and &#8220;Equity Compensation Plan Information&#8221; and is incorporated herein by reference.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_d6189742_7891_4ba2_b0d6_3efbe5580800"></a><a id="_Item_13._Certain"></a><a id="Item13CertainRelationships_29705"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 13. Certain Relationships and Related Transactions, and Director Independence</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The information required by this Item will be contained in the Proxy Statement under the headings &#8220;Certain Relationships and Related Person Transactions&#8221; and &#8220;Board Leadership and Governance Structure&#8221; and is incorporated herein by reference.</p><a id="_2b992ee8_48f2_4394_8e51_daf0e31515fa"></a><a id="_Item_14._Principal"></a><a id="Item14PrincipalAccountantFees_216711"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 14. Principal Accountant Fees and Services</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The information required by this Item will be contained in the Proxy Statement under the heading &#8220;Proposal No. 2: Ratification of Appointment of Independent Registered Public Accounting Firm&#8221; and is incorporated herein by reference.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_69215a8e_7ac2_4e8f_b391_7365dfe289ae"></a><a id="PARTIV_681968"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">PART IV</p><a id="Item15ExhibitsandFinancialStatement_2226"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 15. Exhibits and Financial Statement Schedules</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following documents are filed as part of this report:</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Statements</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">See Index to Financial Statements in Part II Item 8 of this Annual Report.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Financial Statement Schedules</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">All schedules are omitted because they are not applicable, or the required information is shown in the financial statements or notes thereto.</p><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:normal;">Exhibits</i></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 36pt;">The documents listed in the following Exhibit Index are incorporated by reference or are filed with this report, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">EXHIBIT INDEX</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:12.04%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit</b><br /><b style="font-weight:bold;">No.</b></p></td><td style="vertical-align:bottom;width:2.27%;border-bottom:1.0pt solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:85.68%;border-bottom:1.0pt solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Exhibit Description </b></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919003060/a2238817zex-3_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Certificate of Incorporation (incorporated by reference to Exhibit&#160;3.1 filed with Company&#8217;s Current Report on 8-K filed with the Commission on May&#160;13, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">3.2</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919003060/a2238817zex-3_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Bylaws (incorporated by reference to Exhibit&#160;3.2 filed with Company&#8217;s Current Report on 8-K filed with the Commission on May&#160;13, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-4_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Investors&#8217; Rights Agreement, dated as of November&#160;5, 2018, by and among the Company and the investors party thereto (incorporated by reference to Exhibit&#160;4.1 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">108</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">4.2</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000155837020002566/nxtc-20191231ex42d841f91.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Description of Registered Securities (incorporated by reference to Exhibit 4.2 filed with the Company&#39;s Annual Report on Form 10-K filed with the Commission on March 12, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">License Agreement, dated as of December&#160;29, 2015, by and between the Company and Yale University (incorporated by reference to Exhibit&#160;10.1 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.2</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Corporate Sponsored Research Agreement, dated as of December&#160;29, 2015, by and between the Company and Yale University (incorporated by reference to Exhibit&#160;10.2 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.3</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/0001661059/000155837021002384/nxtc-20201231ex10322e166.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amendment to License Agreement and SRA, dated as of April 25, 2020, by and between the Company and Yale University (incorporated by reference to Exhibit 10.3 filed with the Company&#8217;s Annual Report on Form 10-K filed with the SEC on March 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.4</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_6.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">NextCure,&#160;Inc. 2015 Omnibus Incentive Plan, as amended (incorporated by reference to Exhibit&#160;10.6 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.5</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_7.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Stock Option Agreement under the NextCure,&#160;Inc. 2015 Omnibus Incentive Plan (incorporated by reference to Exhibit&#160;10.7 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.6</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002652/a2238596zex-10_8.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">NextCure,&#160;Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit&#160;10.8 filed with Registration Statement on Form&#160;S-1/A filed with the Commission on April&#160;29, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.7</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002652/a2238596zex-10_9.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Forms of Stock Option Agreement under the NextCure,&#160;Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit&#160;10.9 filed with Company&#8217;s Registration Statement on Form&#160;S-1/A filed with the Commission on April&#160;29, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.8</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002652/a2238596zex-10_10.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Agreement under the NextCure,&#160;Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit&#160;10.10 filed with Company&#8217;s Registration Statement on Form&#160;S-1/A filed with the Commission on April&#160;29, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.9</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002652/a2238596zex-10_11.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Restricted Stock Unit Agreement under the NextCure,&#160;Inc. 2019 Omnibus Incentive Plan (incorporated by reference to Exhibit&#160;10.11 filed with Company&#8217;s Registration Statement on Form&#160;S-1/A filed with the Commission on April&#160;29, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.10</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002652/a2238596zex-10_12.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">NextCure,&#160;Inc. 2019 Employee Stock Purchase Plan (incorporated by reference to Exhibit&#160;10.12 filed with Company&#8217;s Registration Statement on Form&#160;S-1/A filed with the Commission on April&#160;29, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.11</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000110465920104856/tm2030788d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Non-Employee Director Compensation Program (incorporated by reference to Exhibit&#160;10.1 filed with the Company&#8217;s Current Report on Form&#160;8-K filed with the Commission on September 14, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.12</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_5.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Form of Indemnification Agreement by and between the Company and each of its directors and executive officers (incorporated by reference to Exhibit&#160;10.5 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.14</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000110465920089093/tm2026202d1_ex10-1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective as of July 27, 2020, by and between the Company and Michael Richman (incorporated by reference to Exhibit 10.1 filed with the Company&#8217;s Current Report on Form 8-K filed with the Commission on July 31, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.15</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000110465920089093/tm2026202d1_ex10-2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective as of July 27, 2020, by and between the Company and Steven P. Cobourn (incorporated by reference to Exhibit 10.2 filed with the Company&#8217;s Current Report on Form 8-K filed with the Commission on July 31, 2020).</span></a></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">109</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.16</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000110465920089093/tm2026202d1_ex10-3.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective as of July 27, 2020, by and between the Company and Solomon Langermann, Ph.D. (incorporated by reference to Exhibit 10.3 filed with the Company&#8217;s Current Report on Form 8-K filed with the Commission on July 31, 2020).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.18</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_14.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Lease Agreement, dated as of January&#160;30, 2019, by and between the Company and ARE-8000/9000/10000 Virginia Manor,&#160;LLC (incorporated by reference to Exhibit&#160;10.14 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.19</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000155837019010701/nxtc-20190930ex101b27cfe.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to Lease Agreement, dated August&#160;2, 2019, by and between the Company and ARE-8000/9000/10000 Virginia Manor,&#160;LLC (incorporated by reference to Exhibit&#160;10.1 filed with Company&#8217;s Quarterly Report on Form 10-Q filed on November&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.20</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/Archives/edgar/data/1661059/000155837021014632/nxtc-20210930xex10d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">First Amendment to the NextCure, Inc. 2015 Omnibus Incentive Plan dated September 30, 2021 (incorporated by reference to Exhibit 10.1 filed with Company&#8217;s Quarterly Report on Form 10-Q filed on November 4, 2021).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.21</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="http://www.sec.gov/Archives/edgar/data/1661059/000104746919002203/a2238441zex-10_4.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Amended and Restated Sublease Agreement, dated as of March&#160;15, 2019, by and between the Company and Lupin,&#160;Inc. (incorporated by reference to Exhibit&#160;10.4 filed with Company&#8217;s Registration Statement on Form&#160;S-1 filed with the Commission on April&#160;12, 2019).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.23</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1661059/000155837022002824/nxtc-20211231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to License Agreement and SRA, dated as of October 20, 2021, by and between the Company and Yale University. (incorporated by reference to Exhibit 10.23 filed with the Company&#39;s Annual Report on Form 10-K filed with the Commission on March 3, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.24</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1661059/000155837022002824/nxtc-20211231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective as of January 11, 2021, by and between the Company and Han Myint, M.D. (incorporated by reference to Exhibit 10.24 filed with the Company&#39;s Annual Report on Form 10-K filed with the Commission on March 3, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.25</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1661059/000155837022002824/nxtc-20211231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Second Amendment to Lease Agreement, dated February 19, 2020, by and between the Company and ARE-8000/9000/10000 Virginia Manor, LLC. (incorporated by reference to Exhibit 10.25 filed with the Company&#39;s Annual Report on Form 10-K filed with the Commission on March 3, 2022).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.26</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#8224;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="https://www.sec.gov/ix?doc=/Archives/edgar/data/1661059/000155837022002824/nxtc-20211231x10k.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to Lease Agreement, dated February 4, 2022, by and between the Company and ARE-8000/9000/10000 Virginia Manor, LLC. (incorporated by reference to Exhibit 10.26 filed with the Company&#39;s Annual Report on Form 10-K filed with the Commission on March 3, 2022).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.27</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20221231xex10d27.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fourth Amendment to Lease Agreement, dated June 10, 2022, by and between the Company and ARE-8000/9000/10000 Virginia Manor, LLC. (Exhibits and schedules have been omitted pursuant to Item 601 of Regulation S-K and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request**).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.28</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20221231xex10d28.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Third Amendment to License Agreement and SRA, dated as of September 14, 2022, by and between the Company and Yale University. (</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Exhibits and schedules have been omitted pursuant to Item 601 of Regulation S-K and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request**</span><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.29</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20221231xex10d29.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Fifth Amendment to Lease Agreement, dated November 28, 2022, by and between the Company and ARE-8000/9000/10000 Virginia Manor, LLC. (Exhibits and schedules have been omitted pursuant to Item 601 of Regulation S-K and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request**).</span></a></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">10.30</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">*+</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20221231xex10d30.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Employment Agreement, effective as of February 28, 2023, by and between the Company and Kevin G. Shaw (Exhibits and schedules have been omitted pursuant to Item 601 of Regulation S-K and will be furnished on a supplemental basis to the Securities and Exchange Commission upon request**).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">23.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20221231xex23d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Consent of Ernst&#160;&amp; Young&#160;LLP, independent registered public accounting firm.</span></a></p></td></tr></table></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">110</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;min-height:11.5pt;"><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">24.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a href="#SIGNATURES"><span style="font-style:normal;font-weight:normal;">Power of Attorney (included on the signature page of this Annual Report on Form 10-K).</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20221231xex31d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Michael Richman pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">31.2</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20221231xex31d2.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Steven P. Cobourn pursuant to Rule 13a-14(a) under the Securities Exchange Act of 1934 as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">32.1</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><a style="-sec-extract:exhibit;font-family:&quot;'Times New Roman','Times','serif'&quot;;" href="nxtc-20221231xex32d1.htm"><span style="font-family:'Times New Roman','Times','serif';font-style:normal;font-weight:normal;">Certification of Michael Richman and Steven P. Cobourn pursuant to 18 U.S.C. Section 1350 as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.</span></a></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.INS</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Instance Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.SCH</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Schema Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.CAL</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Calculation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.DEF</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Definition Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.LAB</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Label Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">EX-101.PRE</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Inline XBRL Taxonomy Extension Presentation Linkbase Document</p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:12.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">104</p></td><td style="vertical-align:top;width:2.27%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:top;width:85.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt;">Coverage Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101).</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;margin-top:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"></div></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">*  &#160;Filed herewith.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">+  &#160;Indicates a management contract or compensatory plan.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="white-space:pre-wrap;">&#8224;  &#160;Portions of this exhibit have been omitted in compliance with Item&#160;601 of Regulation&#160;S-K.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><a id="_c083cde9_1aaf_4ecd_accd_48f64f1387dc"></a><a id="_Item_16._Form"></a><a id="Item16Form10KSummary_696187"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;margin:0pt 0pt 12pt 36pt;">Item 16. Form 10-K Summary</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">None.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">111</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><a id="_014e2012_407c_46f7_aa70_b7be7706c491"></a><a id="SIGNATURES"></a><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">SIGNATURES</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of Section 13 or 15(d) the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">NEXTCURE, INC.</b></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;width:50.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Date: March 2, 2023</p></td><td style="vertical-align:bottom;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">By:</p></td><td style="vertical-align:bottom;width:43.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Richman</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.64%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Richman</p></td></tr><tr><td style="vertical-align:bottom;width:49.97%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:6.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.64%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">President and Chief Executive Officer</i></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each person whose signature appears below constitutes and appoints Michael Richman and Steven P. Cobourn and each of them, jointly and severally, his or her attorneys-in-fact, each with full power of substitution, for him or her in any and all capacities, to sign any and all amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the Securities and Exchange Commission.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934, this report has been signed below by the following persons on behalf of the registrant and in the capacities and on the dates indicated.</p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">112</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;page-break-after:always;width:79.3%;border:0;margin:30pt 10.35% 30pt 10.35%;"></div><div style="max-width:100%;padding-left:10.35%;padding-right:10.35%;position:relative;"><div style="margin-top:21.6pt;min-height:41.75pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 30pt 0pt;"><a href="#TOC"><span style="font-style:normal;font-weight:normal;">Table of Contents</span></a></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0pt 60pt;"><b style="font-weight:bold;">Signature</b></p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Title</b></p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Date</b></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Richman</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President, Chief Executive Officer and Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 2, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Richman</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Executive Officer)</i></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven P. Cobourn</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 2, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven P. Cobourn</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><i style="font-style:italic;">(Principal Financial and Accounting Officer)</i></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ David Kabakoff</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chair of the Board</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 2, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">David Kabakoff, Ph.D.</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Anne Borgman</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 2, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Anne Borgman, M.D.</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Ellen G. Feigal</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 2, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Ellen G. Feigal, M.D.</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ John G. Houston</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 2, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">John G. Houston, Ph.D.</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Elaine V. Jones</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 2, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Elaine V. Jones, Ph.D.</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Chau Q. Khuong</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 2, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chau Q. Khuong</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Garry Nicholson</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 2, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Garry Nicholson</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Stephen Webster</p></td><td style="vertical-align:bottom;width:2.23%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Director</p></td><td style="vertical-align:bottom;width:2.86%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;">March 2, 2023</p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;border-top:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Stephen Webster</p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:29.34%;margin:0pt;padding:0pt;"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.23%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:43.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:2.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:21.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></div><div style="clear:both;display:table;margin-bottom:27.35pt;min-height:36pt;width:100%;"><div style="display:table-cell;vertical-align:bottom;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:24pt 0pt 0pt 0pt;">113</p></div></div></div>
<div style="background-color:#000000;clear:both;height:2pt;margin-left:10.35%;margin-right:10.35%;margin-top:30pt;page-break-after:avoid;width:79.3%;border:0;"></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.27
<SEQUENCE>2
<FILENAME>nxtc-20221231xex10d27.htm
<DESCRIPTION>EX-10.27
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/2/2023 08:38:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***].</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 10.27</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FOURTH AMENDMENT TO LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-transform:uppercase;">This</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"> FOURTH AMENDMENT TO LEASE AGREEMENT</b><font style="font-family:'Arial','Helvetica','sans-serif';"> (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">this Fourth Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;) is dated as of June 10, 2022 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Effective Date</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;), by and between </font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">ARE-8000/9000/10000 VIRGINIA MANOR, LLC</b><font style="font-family:'Arial','Helvetica','sans-serif';">, a Delaware limited liability company, having an address at 26 North Euclid Avenue, Pasadena, California &#160;91101 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Landlord</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;), and </font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">NEXTCURE, INC</b><font style="font-family:'Arial','Helvetica','sans-serif';">., a Delaware corporation, having an address at Suite 140, 8000 Virginia Manor Road, Beltsville, Maryland &#160;20705 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Tenant</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">A.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Landlord and Tenant have entered into that certain Lease Agreement dated as of January&#160;30, 2019 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Original</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> </font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Lease</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;), as amended by that certain First Amendment to Lease Agreement dated as of August 2, 2019 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">First Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;), that certain Second Amendment to Lease Agreement dated as of February 19, 2020 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Second Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;), and that certain Third Amendment to Lease Agreement dated as of February 4, 2022 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Third Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;; together with the Original Lease, the First Amendment, and the Second Amendment, the &#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Lease</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;), wherein Landlord leased to Tenant approximately 63,576 rentable square feet (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Existing Premises</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;) located at Suite&#160;140, 8000 Virginia Manor Road, Beltsville, Maryland &#160;20705, as more particularly described in the Lease.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">B.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Landlord and Tenant desire to amend the Lease, among other things, to modify the 2022 Expansion Premises Commencement Date.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Now, therefore, in consideration of the foregoing Recitals, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree that the Lease is amended as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Definitions; Recitals</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;Terms used in this Fourth Amendment but not otherwise defined shall have the meanings set forth in the Lease (as amended). &#160;The Recitals form an integral part of this Fourth Amendment and are hereby incorporated by reference.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Amendment to Introductory Paragraph of Section 5 of Third Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;The introductory paragraph of Section 5 of the Third Amendment is hereby deleted in its entirety and replaced with the following new paragraph that changes the reference from July 1, 2022 to November 1, 2022:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Delivery of 2022 Expansion Premises</b><font style="font-family:'Arial','Helvetica','sans-serif';">. Landlord shall use reasonable efforts to deliver the 2022 Expansion Premises to Tenant on November 1, 2022 in their vacant, &#8220;as is&#8221; (but broom clean) condition as more fully described in </font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5.a.(i)</u><font style="font-family:'Arial','Helvetica','sans-serif';"> below (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Delivery</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221; or &#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Deliver</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;). &#160;The date on which Landlord Delivers the 2022 Expansion Premises to Tenant is referred to as the &#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">2022 Expansion Premises Commencement Date</b><font style="font-family:'Arial','Helvetica','sans-serif';">.&#8221; &#160;Upon request of Landlord, Tenant shall execute and deliver a written acknowledgement of the 2022 Expansion Premises Commencement Date when it is established in the form attached hereto as </font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit&#160;B</b><font style="font-family:'Arial','Helvetica','sans-serif';">; </font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">provided</u><font style="font-family:'Arial','Helvetica','sans-serif';">, </font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">however</u><font style="font-family:'Arial','Helvetica','sans-serif';">, that Tenant&#8217;s failure to execute and deliver such acknowledgement shall not affect Landlord&#8217;s rights under this Fourth Amendment or the Lease. &#160;If Landlord fails to Deliver timely the 2022 Expansion Premises, Landlord shall not be liable to Tenant for any loss or damage resulting therefrom, and this Fourth Amendment and the Lease with respect to the 2022 Expansion Premises shall not be void or voidable.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Amendment to Section 5.d of Third Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;Section 5.e of the Third Amendment is hereby deleted in its entirety and replaced with the following new Section 5.e:</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***].</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">e.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">As of the Effective Date, Landlord is leasing the 2022 Expansion Premises to [***] LLC, a Maryland limited liability company (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">[***]</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;), and the lease agreement (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">[***] Lease</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;) between Landlord and [***] is scheduled to expire on October 31, 2023. &#160;This Fourth Amendment is contingent on Landlord and [***] agreeing in writing to terminate the [***] Lease and [***] vacating the 2022 Expansion Premises on or before September 30, 2022 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Termination Agreement</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;), which Termination Agreement shall be on terms and conditions acceptable to Landlord in its sole and absolute discretion (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Contingency</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;). &#160;Landlord will notify Tenant promptly of the execution and delivery of the Termination Agreement. &#160;Tenant acknowledges that Landlord makes no promise, guaranty, or assurance that it will be able to enter into the Termination Agreement and, as a result, Landlord makes no guaranty, representation, or assurance that Landlord will be able to Deliver the 2022 Expansion Premises to Tenant by the 2022 Expansion Premises Commencement Date and that Landlord shall have no obligation or duty to seek the vacation or removal of [***] from the 2022 Expansion Premises. &#160;If Landlord is unable to Deliver the 2022 Expansion Premises on or before November 30, 2022, Tenant shall have the right to terminate this Fourth Amendment by sending written notice thereof to Landlord by no later than December 15, 2022, whereupon neither Landlord nor Tenant shall have any further rights, duties, or obligations under this Fourth Amendment. &#160;If Tenant does not elect to so terminate this Fourth Amendment by December 15, 2022, such right to terminate this Fourth Amendment shall be waived.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Amendment to Exhibit B of the Third Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;</font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> to the Third Amendment is hereby deleted in its entirety and replaced with </font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> attached hereto solely for the purpose of reflecting this Fourth Amendment.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">5.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Amendment to Exhibit C of the Third Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;The introductory paragraph of </font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> to the Third Amendment is hereby deleted in its entirety and replaced with </font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit B</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> attached hereto solely for the purpose of reflecting this Fourth Amendment. &#160;For clarity, the balance of </font><u style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Exhibit&#160;C</u><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> to the Third Amendment is left unchanged and in full force and effect.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">6.</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Miscellaneous</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Entire Agreement</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;The Lease, as amended by this Fourth Amendment, is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. &#160;The Lease, as so amended by this Fourth Amendment, may be amended only by an agreement in writing, signed by the parties hereto.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Binding Effect</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;This Fourth Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, members, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Broker</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Broker</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;) in connection with this Fourth Amendment and that no Broker brought about this Fourth Amendment, other than CB Richard Ellis (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">CBRE</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;). &#160;CBRE shall be paid by Landlord pursuant to a separate agreement between Landlord and CBRE. &#160;Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, other than the brokers named in this Section, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Fourth Amendment.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Counterparts</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;This Fourth Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. &#160;Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000, including DocuSign) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly </font></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***].</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">delivered and be valid and effective for all purposes. &#160;Electronic signatures shall be deemed original signatures for purposes of this Fourth Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">e.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Ratification; Conflicts</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;Except as amended and/or modified by this Fourth Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Fourth Amendment. &#160;In the event of any conflict between the provisions of this Fourth Amendment and the provisions of the Lease, the provisions of this Fourth Amendment shall prevail. &#160;Regardless of whether specifically amended by this Fourth Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Fourth Amendment.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 21pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">[SIGNATURES APPEAR ON NEXT PAGE]</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***].</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">IN WITNESS WHEREOF, the parties hereto have executed this Fourth Amendment under seal as of the day and year first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 180pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">TENANT:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-transform:uppercase;">nextcure, inc</b><font style="font-family:'Arial','Helvetica','sans-serif';">.,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">a Delaware corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">By:  </font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Timothy J. Mayer </u><font style="font-family:'Arial','Helvetica','sans-serif';">(SEAL)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">Its:  </font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Chief Operating Officer</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">X I hereby certify that the signature, name, and title</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">above are my signature, name, and title.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 180pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">LANDLORD:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">ARE-8000/9000/10000 VIRGINIA MANOR, LLC</b><font style="font-family:'Arial','Helvetica','sans-serif';">, </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">a Delaware limited liability company</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">By:</font><font style="display:inline-block;width:21.55pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';">Alexandria Real Estate Equities, L.P., </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">a Delaware limited partnership, </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">managing member</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">By:</font><font style="display:inline-block;width:21.55pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';">ARE-QRS CORP., </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">a Maryland corporation, </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">general partner</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 252pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">By:_</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Gregory Kay </u><font style="font-family:'Arial','Helvetica','sans-serif';">(SEAL)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 252pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Name:</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;"> Gregory Kay    </u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 252pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Title:_</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SVP &#8211; Real Estate Legal Affairs</u></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.28
<SEQUENCE>3
<FILENAME>nxtc-20221231xex10d28.htm
<DESCRIPTION>EX-10.28
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/2/2023 08:38:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-weight:bold;">Exhibit 10.28</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">THIRD AMENDMENT TO SRA</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>This THIRD AMENDMENT TO SRA (this &#8220;<b style="font-weight:bold;">THIRD AMENDMENT</b>&#8221;) is made and entered into effective as of September 14, 2022 (&#8220;<b style="font-weight:bold;">THIRD AMENDMENT EFFECTIVE DATE</b>&#8221;) by and between Yale University, a nonprofit corporation organized and existing under and by virtue of a charter granted by the general assembly of the Colony and State of Connecticut (&#8220;<b style="font-weight:bold;">YALE</b>&#8221;), and NextCure, Inc., a corporation organized and existing under the laws of the State of Delaware (&#8220;<b style="font-weight:bold;">NEXTCURE</b>&#8221;). &#160;YALE and NEXTCURE are each referred to herein, individually, as a &#8220;Party&#8221; and, collectively, as the &#8220;Parties.&#8221;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">WHEREAS, the Parties entered into that certain Corporate Sponsored Research Agreement effective as of December 29, 2015 (the &#8220;<font style="font-style:italic;font-weight:bold;">SRA</font>&#8221;); </p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">WHEREAS, the Parties previously amended the SRA by that certain Amendment to License Agreement and SRA effective as of January 31, 2020 and further by that certain Second Amendment to License Agreement and SRA effective as of October 20, 2021 (collectively, the &#8220;<b style="font-weight:bold;">PRIOR AMENDMENTS</b>&#8221;); and</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">WHEREAS, the Parties now desire to amend further the SRA as more particularly set forth herein.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;">NOW, THEREFORE, in consideration of the mutual promises, representations, warranties and covenants set forth in this THIRD AMENDMENT, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto hereby agree as follows:</p><p style="color:#252525;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#252525;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">1.</font></font>Definitions and Phrases. &#160;</p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.1</font>Capitalized terms used, but not defined, in this THIRD AMENDMENT shall have the respective meanings ascribed to such terms in the SRA. </div><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:12pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.2</font>Any reference to &#8220;the Agreement&#8221; or &#8220;this Agreement&#8221; or &#8220;the SRA&#8221; in this THIRD AMENDMENT shall mean the SRA (or any specifically referenced part or section thereof) in such form it was already collectively amended by the PRIOR AMENDMENTS.</div><p style="color:#252525;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#252525;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">2.</font></font><u style="text-decoration-color:#252525;text-decoration-line:underline;text-decoration-style:solid;">Amendment to Section 10(a) of the SRA</u>. &#160;Section 10(a) of the SRA is hereby amended by changing the reference to &#8220;December 31, 2020&#8221; to &#8220;March 31, 2023,&#8221; with the intent and result that the term of the SRA is extended by fifteen months. &#160;The Parties hereby agree and stipulate that the SRA remains, and has remained, in and full force in effect during the period from the EFFECTIVE DATE until March 31, 2023.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 36pt 0pt 36pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 36pt 0pt 36pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Amendment to the RESEARCH of the SRA</u>. &#160;</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 36pt 0pt 36pt;"><font style="margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">3.1.</font></font>Exhibit A of the SRA is hereby amended to add certain additional research program activities as fully described and set forth in the Attachment 1, titled &#8220;Exhibit A Supplement&#8221; and attached hereto and hereby incorporated by reference, to the RESEARCH by appending Attachment A to the end of the version of Exhibit A in effect immediately prior to the THIRD AMENDMENT EFFECTIVE DATE. &#160;The Parties hereby agree and stipulate that the budget for </p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;">all such activities described in the Attachment 1 have already been fully funded by payments previously made by NEXTCURE to YALE, and that no further payments are due from NEXTCURE.</p><p style="color:#252525;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#252525;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">4.</font></font><u style="text-decoration-color:#252525;text-decoration-line:underline;text-decoration-style:solid;">Acknowledgement</u>. &#160;Except as expressly provided herein, no other terms or provisions of the SRA are modified or changed by this THIRD AMENDMENT and its terms and provisions shall continue in full force and effect. &#160; &#160;Furthermore, pursuant to SRA Section 8(e) YALE shall promptly disclose to NEXTCURE any such invention disclosures in existence prior to the signing date of this THIRD AMENDMENT. </p><p style="color:#252525;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:12pt 0pt 0pt 0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="color:#252525;font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">5.</font></font><u style="text-decoration-color:#252525;text-decoration-line:underline;text-decoration-style:solid;">Counterparts; Facsimile Signatures</u>. &#160;This THIRD AMENDMENT may be executed in any number of counterparts, each of which shall be deemed to be an original, and all of which together shall constitute one and the same document. &#160;This THIRD AMENDMENT may be executed by facsimile or electronic transmission signatures (including .pdf copies of wet signed copies or .pdf copies bearing electronic signatures affixed by DocuSign or similar common commercially available e-signature platforms).</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;">[<i style="font-style:italic;">signature page follows</i>]</p><p style="display:none;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:0pt;margin:0pt;"><font style="font-size:0pt;line-height:1.19;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>IN WITNESS WHEREOF, the parties hereto have executed this THIRD AMENDMENT as of the THIRD AMENDMENT EFFECTIVE DATE.</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><b style="font-weight:bold;">YALE UNIVERSITY</b><font style="display:inline-block;width:32.31pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><b style="font-weight:bold;">NEXTCURE, INC. </b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">By:</font></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>/s/ Patricia Ingellis</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:18.02pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><font style="display:inline-block;width:36pt;"></font>By:<font style="display:inline-block;width:18.66pt;"></font><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>/s/ Michael Richman</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:8.02pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Name:</font></font>Patricia Ingellis<font style="display:inline-block;width:32.36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Name:<font style="display:inline-block;width:4.01pt;"></font>Michael Richman</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font>Title:<font style="display:inline-block;width:10.01pt;"></font>Contract Manager<font style="display:inline-block;width:21.04pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Title: <font style="display:inline-block;width:7.01pt;"></font>Chief Executive Officer</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"></font><font style="display:inline-block;width:36pt;"></font>Office of Sponsored Projects</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;">Read and acknowledged by</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>/s/ Lieping Chen</u><u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:28.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u>_____ &#160; &#160; &#160;<font style="display:inline-block;width:24pt;"></font> <u style="text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">10/27/2022</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;">Lieping Chen, Principal Investigator &#160;<font style="display:inline-block;width:34.71pt;"></font> Date</p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 72pt;"><b style="font-weight:bold;">[Signature Page to Third Amendment to SRA]</b></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.29
<SEQUENCE>4
<FILENAME>nxtc-20221231xex10d29.htm
<DESCRIPTION>EX-10.29
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/2/2023 08:38:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***].</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Exhibit 10.29</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">FIFTH AMENDMENT TO LEASE AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-transform:uppercase;">This</b><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;"> FIFTH AMENDMENT TO LEASE AGREEMENT</b><font style="font-family:'Arial','Helvetica','sans-serif';"> (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">this Fifth Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;) is dated as of November 28, 2022 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Effective Date</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;), by and between </font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">ARE-8000/9000/10000 VIRGINIA MANOR, LLC</b><font style="font-family:'Arial','Helvetica','sans-serif';">, a Delaware limited liability company, having an address at 26 North Euclid Avenue, Pasadena, California &#160;91101 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Landlord</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;), and </font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">NEXTCURE, INC</b><font style="font-family:'Arial','Helvetica','sans-serif';">., a Delaware corporation, having an address at Suite 140, 8000 Virginia Manor Road, Beltsville, Maryland &#160;20705 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">Tenant</b><font style="font-family:'Arial','Helvetica','sans-serif';">&#8221;).</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">RECITALS</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">A.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Landlord and Tenant have entered into that certain Lease Agreement dated as of January&#160;30, 2019 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Original</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> </font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Lease</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;), as amended by that certain First Amendment to Lease Agreement dated as of August 2, 2019 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">First Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;), that certain Second Amendment to Lease Agreement dated as of February 19, 2020 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Second Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;), that certain Third Amendment to Lease Agreement dated as of February 4, 2022 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Third Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221; &#8221;), and that certain Fourth Amendment to Lease Agreement dated as of June 10, 2022 (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Fourth Amendment</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;; together with the Original Lease, the First Amendment, the Second Amendment, and the Third Amendment, the &#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Lease</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;), wherein Landlord leased to Tenant approximately 63,576 rentable square feet (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Existing Premises</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;) located at Suite&#160;140, 8000 Virginia Manor Road, Beltsville, Maryland &#160;20705, as more particularly described in the Lease.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">B.</font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">Landlord and Tenant desire to amend the Lease, among other things, to modify the Base Rent for the 2022 Expansion Premises.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">AGREEMENT</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Now, therefore, in consideration of the foregoing Recitals, the mutual promises and conditions contained herein, and for other good and valuable consideration, the receipt and legal sufficiency of which are hereby acknowledged, Landlord and Tenant hereby agree that the Lease is amended as follows:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Definitions; Recitals</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;Terms used in this Fifth Amendment but not otherwise defined shall have the meanings set forth in the Lease (as amended). &#160;The Recitals form an integral part of this Fifth Amendment and are hereby incorporated by reference.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Amendment to Section 4.f of the Third Amendment.</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;"> &#160;Effective as of the Effective Date, Section 4.f of the Third Amendment is hereby amended by deleting &#8220;[***] per month (2022 Expansion Premises)&#8221; and replacing it with &#8220;[***] per month (2022 Expansion Premises)&#8221;.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:36pt;"></td><td style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:36pt;padding:0pt;">3.</td><td style="padding:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:bold;">Miscellaneous</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-style:normal;font-weight:normal;">.</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Entire Agreement</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;The Lease, as amended by this Fifth Amendment, is the entire agreement between the parties with respect to the subject matter hereof and supersedes all prior and contemporaneous oral and written agreements and discussions. &#160;The Lease, as so amended by this Fifth Amendment, may be amended only by an agreement in writing, signed by the parties hereto.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 72pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Binding Effect</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;This Fifth Amendment is binding upon and shall inure to the benefit of the parties hereto, their respective agents, employees, members, representatives, officers, directors, divisions, subsidiaries, affiliates, assigns, heirs, successors in interest and shareholders.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Broker</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;Landlord and Tenant each represents and warrants that it has not dealt with any broker, agent or other person (collectively, &#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Broker</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;) in connection with this Fifth Amendment and that no Broker brought about this Fifth Amendment, other than CB Richard Ellis (&#8220;</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">CBRE</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">&#8221;). &#160;CBRE shall be paid by Landlord pursuant to a separate agreement between Landlord and CBRE. &#160;Landlord and Tenant each hereby agree to indemnify and hold the other harmless from and against any claims by any Broker, </font></div></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***].</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">other than the brokers named in this Section, claiming a commission or other form of compensation by virtue of having dealt with Tenant or Landlord, as applicable, with regard to this Fifth Amendment.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Counterparts</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;This Fifth Amendment may be executed in 2 or more counterparts, each of which shall be deemed an original, but all of which together shall constitute one and the same instrument. &#160;Counterparts may be delivered via facsimile, electronic mail (including pdf or any electronic signature process complying with the U.S. federal ESIGN Act of 2000, including DocuSign) or other transmission method and any counterpart so delivered shall be deemed to have been duly and validly delivered and be valid and effective for all purposes. &#160;Electronic signatures shall be deemed original signatures for purposes of this Fifth Amendment and all matters related thereto, with such electronic signatures having the same legal effect as original signatures.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 36pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><div style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Arial','Helvetica','sans-serif';font-size:10pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">e.</font><b style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;">Ratification; Conflicts</b><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">. &#160;Except as amended and/or modified by this Fifth Amendment, the Lease is hereby ratified and confirmed and all other terms of the Lease shall remain in full force and effect, unaltered and unchanged by this Fifth Amendment. &#160;In the event of any conflict between the provisions of this Fifth Amendment and the provisions of the Lease, the provisions of this Fifth Amendment shall prevail. &#160;Regardless of whether specifically amended by this Fifth Amendment, all of the terms and provisions of the Lease are hereby amended to the extent necessary to give effect to the purpose and intent of this Fifth Amendment.</font></div><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 21pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">[SIGNATURES APPEAR ON NEXT PAGE]</b></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="margin-top:30pt;min-height:36pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;line-height:1.19;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTAIN IDENTIFIED INFORMATION HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. OMITTED INFORMATION HAS BEEN REPLACED WITH [***].</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">IN WITNESS WHEREOF, the parties hereto have executed this Fifth Amendment under seal as of the day and year first above written.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 180pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">TENANT:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;text-transform:uppercase;">nextcure, inc</b><font style="font-family:'Arial','Helvetica','sans-serif';">.,</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">a Delaware corporation</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">By:  </font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Michael Richman </u><font style="font-family:'Arial','Helvetica','sans-serif';">(SEAL)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';white-space:pre-wrap;">Its:  </font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">President and CEO</u></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">X I hereby certify that the signature, name, and title</font><font style="font-family:'Arial','Helvetica','sans-serif';"><br></font><font style="font-family:'Arial','Helvetica','sans-serif';">above are my signature, name, and title.</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;font-weight:bold;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 12pt 180pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">LANDLORD:</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><b style="font-family:'Arial','Helvetica','sans-serif';font-weight:bold;">ARE-8000/9000/10000 VIRGINIA MANOR, LLC</b><font style="font-family:'Arial','Helvetica','sans-serif';">, </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">a Delaware limited liability company</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">By:</font><font style="display:inline-block;width:21.55pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';">Alexandria Real Estate Equities, L.P., </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">a Delaware limited partnership, </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">managing member</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">By:</font><font style="display:inline-block;width:21.55pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';">ARE-QRS CORP., </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;text-indent:36pt;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">a Maryland corporation, </font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="display:inline-block;width:36pt;"></font><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;">general partner</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 216pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt 0pt 0pt 180pt;"><font style="font-family:'Arial','Helvetica','sans-serif';font-size:10pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 252pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">By:_</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Gregory Kay </u><font style="font-family:'Arial','Helvetica','sans-serif';">(SEAL)</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 252pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Name:</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;white-space:pre-wrap;"> Gregory Kay    </u></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.19;margin:0pt 0pt 0pt 252pt;"><font style="font-family:'Arial','Helvetica','sans-serif';">Title:_</font><u style="font-family:'Arial','Helvetica','sans-serif';text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">SVP &#8211; Real Estate Legal Affairs</u></p></div><div style="clear:both;margin-bottom:30pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.19;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-10.30
<SEQUENCE>5
<FILENAME>nxtc-20221231xex10d30.htm
<DESCRIPTION>EX-10.30
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/2/2023 08:38:09 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:center;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';"><img src="nxtc-20221231xex10d30001.jpg" alt="Graphic" style="display:inline-block;height:38.25pt;left:0%;padding-bottom:0.75pt;position:relative;top:0pt;width:216pt;"></font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:right;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:-0.05pt;">Exhibit 10.30</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.05pt;">February 28, 2023</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">Via Email Only</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Kevin G. Shaw</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[***]</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:bold;">RE:</b></font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">EXECUTIVE EMPLOYMENT AGREEMENT</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;">Dear Mr. Shaw:</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.1pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">On behalf of NextCure, Inc. (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">NextCure</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;, or the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Company</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), it is my pleasure to confirm the terms and conditions on which the Board of Directors of NextCure (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Board</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) and you have agreed that you will continue your employment with the Company, serving as the Company&#8217;s Senior Vice President, Legal Affairs, reporting to the Company&#8217;s Chief Operating Officer, that you started on May 23, 2022 (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Start Date</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;). &#160;During your employment with NextCure, you will devote substantially all of your professional efforts to the business of NextCure, except that you may engage in the business activities described on </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> of this employment agreement (this &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Agreement</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), and other activities that may be approved in advance by the Company&#8217;s Chief Executive Officer, with advice from the Board (which may include the for-profit board membership(s) described on </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix A</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">), in each case, so long as these activities do not interfere or conflict with your obligations to the Company. &#160;Your employment under the terms of this Agreement shall continue until it terminates in accordance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 5</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> below.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This Agreement supersedes, amends and restates in all respects all prior agreements and understandings between you and the Company regarding the subject matter herein. &#160;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This Agreement is intended to summarize some of the terms and conditions of your employment.</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">1.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Location</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. &#160;Your place of employment will be at NextCure&#8217;s principal offices, currently located in Beltsville, Maryland. &#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">2.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Compensation</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. &#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Base Salary</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. &#160;Your annualized base salary rate will be $338,000, less standard deductions and withholding and payable bi-weekly in accordance with NextCure&#8217;s regular payroll practices. &#160;Your salary shall be reviewed annually and may be adjusted in connection with any such review.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Bonus Program</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. &#160;You will be eligible for an annual target bonus of 35% of your annual base salary as determined by the Board in its sole discretion based upon, among other things, the achievement of pre-determined performance milestones. &#160;Any annual bonus, if earned, shall be paid no later than </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">March 15</font><sup style="font-family:'Times New Roman','Times','serif';font-size:9pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> of the year immediately following the year to which the applicable annual bonus relates.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Option Grants. &#160;</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">As of your Start Date, you were granted an option to purchase 35,000 shares of NextCure&#8217;s common stock, vesting 25% on the first anniversary of your Start Date, and thereafter in 36 equal, monthly installments until fully-vested, on the fourth anniversary of your Start Date. &#160;The option grant is subject to the terms of NextCure&#8217;s equity incentive arrangements, including its customary Incentive Stock Option (ISO) Grant Agreement.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Withholding. &#160;</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">NextCure shall withhold from any compensation or benefits payable to you by NextCure any federal, state and/or local income, employment and/or other similar taxes as may be required to be withheld pursuant to any applicable law or regulation.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">3.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Benefits</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.05pt;">. &#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:-0.05pt;">Vacation and Holidays</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.05pt;">. &#160;You will be eligible each year for 10 paid vacation days (excluding federal holidays), 2 paid personal days and 8 paid days of sick time, as well as paid time off from December 26 through December 30. </font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:-0.05pt;">Other</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.05pt;">. &#160;You will be eligible to participate in the benefits to be offered by NextCure on the same terms and conditions as it will make such benefits available to employees in positions similar to your position. &#160;The benefits are currently expected to include health insurance and such other benefits provided by similar companies of a similar stage, as approved by the Board.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:-0.05pt;">Expenses</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.05pt;">.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:-0.05pt;"> &#160;</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.05pt;">NextCure shall reimburse you for all reasonable expenses of the type authorized by NextCure and incurred by you in the performance of your duties under this Agreement, all in accordance with the Company&#8217;s reimbursement policies. &#160;</font></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 0pt 144pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;margin-left:0pt;text-decoration-line:underline;text-decoration-style:solid;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:-0.05pt;">As is the case of all employee benefits, such benefits will be governed by the terms and conditions of applicable NextCure plans or policies, which are subject to change or discontinuation at any time.</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">4.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Severance</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;">.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:-0.05pt;">Definitions.</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;"> &#160;For purposes of this Agreement: &#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:117pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-right:27pt;min-width:108pt;text-indent:0pt;white-space:nowrap;">i.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Accrued Benefits</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means: (i) any unpaid base salary for services rendered prior to the date of termination of employment; (ii) any earned but unpaid annual bonus for any completed fiscal year prior to the year in which termination of employment occurs; (iii) reimbursement of any unreimbursed business expenses incurred as of the date of termination of employment in accordance with NextCure&#8217;s reimbursement policy, (iv) accrued but unused vacation (if applicable), earned through the date of termination of employment; and (v) all other payments, benefits or fringe benefits to which you shall be entitled under the terms of any applicable compensation arrangement or benefit, equity or fringe benefit plan or program or grant with or by NextCure or this Agreement. </font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-right:36pt;min-width:108pt;text-indent:0pt;white-space:nowrap;">ii.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Cause</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means conduct involving one or more of the following by you: (i) failure to perform a substantial portion of your duties and responsibilities in accordance with the terms or requirements of this Agreement and your position, which failure continues for, or is not </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">permanently cured within, a period of 60 days after written notice given to you by NextCure except in the case of your physical or mental illness; (ii) disloyalty, gross negligence, willful misconduct, or dishonesty that materially injures NextCure or breach of fiduciary duty to NextCure; (iii) the conviction of (x) a felony or (y) a misdemeanor involving moral turpitude, or fraud;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;"> </b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">(iv) the commission of an act of embezzlement or fraud; or (v) the material breach of any agreement between NextCure and you. </font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:117pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-right:27pt;min-width:108pt;text-indent:0pt;white-space:nowrap;">iii.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Good Reason</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means, without your express written consent, (i) any reduction in your annual base salary other than a reduction which is proportional to general reductions affecting other senior executive officers of NextCure generally, (ii) any material reduction in your title or scope of responsibilities without your consent (other than your removal from the Board); or (iii) a requirement that the location of the office in which you perform your principal duties for NextCure be changed to a new location that is outside a radius of 50 miles from the Company&#8217;s corporate headquarters in Beltsville, Maryland.</font></div><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">b.</td><td style="padding:0pt;"><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:normal;letter-spacing:-0.05pt;">Severance Benefits and Payment</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.2pt;">. &#160;</font></td></tr></table><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:117pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-right:27pt;min-width:108pt;text-indent:0pt;white-space:nowrap;">i.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:-0.05pt;">Generally</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;">. &#160;If your employment with NextCure is terminated by NextCure for any reason other than Cause or by you for Good Reason, NextCure will pay you (1) the Accrued Benefits; (2) subject to your compliance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4(c)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;"> below, after the execution and delivery of the Separation Agreement and General Release in the form attached hereto as </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix B</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;"> (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:0.2pt;">Separation Agreement and General Release</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;">&#8221;) and the expiration of any revocation period without the release being revoked, 9 </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">months&#8217;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;"> base salary, less standard deductions, payable in a single lump sum on the 60</font><sup style="font-family:'Times New Roman','Times','serif';font-size:9pt;letter-spacing:0.2pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;"> day following the termination of your employment; and (3)</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> if you elect to continue your health insurance coverage pursuant to your rights under the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (&#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">COBRA</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;), following the termination of your employment, your monthly premium under COBRA on a monthly basis until the earlier of (x) 9 months following the effective termination date, or (y) the date upon which you commence full-time employment (or employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by NextCure). &#160;A termination of your employment by NextCure due to physical or mental illness which is not a Disability (as defined herein) shall be treated as an involuntary termination other than for Cause. &#160;The term &#8220;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;font-weight:bold;">Disability</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; shall mean that you have not been able to materially engage in your duties and responsibilities by reason of any medically determinable physical or mental impairment for a period of not less than 120 consecutive days or not less than 180 days during any one-year period.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:117pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;margin-right:27pt;min-width:108pt;text-indent:0pt;white-space:nowrap;">ii.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:-0.05pt;">In connection with the Change in Control Period</i><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:0.2pt;">.</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;">If your employment with NextCure is terminated by NextCure for any reason other than Cause or by you for Good Reason during the Change in Control Period, NextCure will pay you (1) the Accrued Benefits; (2) subject to your compliance with </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4(c)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;"> below, after </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:117pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;">the execution and delivery of the Separation Agreement and General Release and the expiration of any revocation period without the release being revoked, 12 </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">months&#8217;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;"> base salary plus your annual target bonus, less standard deductions, payable in a single lump sum on the 60</font><sup style="font-family:'Times New Roman','Times','serif';font-size:9pt;letter-spacing:0.2pt;vertical-align:top;">th</sup><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;"> day following the termination of your employment; and (3)</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> if you elect to continue your health insurance coverage pursuant to your rights under COBRA following the termination of your </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">employment</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, your monthly premium under COBRA on a monthly basis until the earlier of (x) 12 months following the effective termination date, or (y) the date upon which you commence full-time employment (or employment that provides you with eligibility for healthcare benefits substantially comparable to those provided by NextCure). &#160;A termination of your employment by NextCure due to physical or mental illness which is not a Disability shall be treated as an involuntary termination other than for Cause.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:-0.05pt;">Eligibility for Severance</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.2pt;">. &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Eligibility for receipt of the items in </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section&#160;4(b)(ii)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> &#160;above shall be conditioned on your (i) returning to NextCure promptly upon termination of your employment all of its property, including confidential information and all electronically stored information, and (ii) signing and not revoking the Separation Agreement and General Release.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:72pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">Accrued Benefits</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. &#160;The Accrued Benefits shall be paid to you (or your estate in the event of your death) upon termination of employment regardless of the circumstances giving rise to such termination. &#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">5.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">At Will Employment</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. &#160;Your employment with NextCure is at will, meaning it may be terminated by you or NextCure at any time, subject to </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 4</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> above, for any reason with or without Cause. You understand that this Agreement is not a contract for employment for a definite term. &#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">6.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Confidentiality and Proprietary Rights Agreement</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. &#160;This offer of employment is subject to the Confidentiality and Proprietary Rights Agreement attached as </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Appendix C</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, which shall be effective as of the date set forth therein.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">7.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">No Inconsistent Obligations</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. &#160;By accepting this offer of employment, you represent and warrant to NextCure that you are under no obligations or commitments, whether contractual or otherwise, that are inconsistent with your obligations set forth in this Agreement or that would be violated by your employment by NextCure. &#160;You agree that you will not take any action on behalf of NextCure or cause NextCure to take any action that will violate any agreement that you have with a prior employer.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:36pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:12pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">8.</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Delayed Commencement Date for Payments and Benefits</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">. </font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.75pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:360pt;text-indent:0pt;white-space:nowrap;">a.</font><font style="font-family:'Times New Roman','Times','serif';font-size:13.75pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.75pt;text-align:justify;margin:0pt 0pt 0pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The intent of the parties hereto is that payments and benefits under this Agreement comply with, or be exempt from, Section 409A of the Internal Revenue Code of 1986, as amended, and the regulations and guidance promulgated thereunder (collectively &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Code Section 409A</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) and, accordingly, to the maximum extent permitted, this Agreement shall be interpreted to be in compliance therewith or exempt therefrom. &#160;If you notify NextCure (with specificity as to the reason therefor) that you believe that any provision of this Agreement (or of any award of compensation, including equity compensation or benefits) would cause you to incur any </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.75pt;text-align:justify;margin:0pt 0pt 12pt 108pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">additional tax or interest under Code Section 409A and NextCure concurs with such belief or NextCure independently makes such determination, NextCure shall, after consulting with you, reform such provision to try to comply with Code Section 409A through good faith modifications to the minimum extent reasonably appropriate to conform with Code Section 409A. To the extent that any provision hereof is modified in order to comply with Code Section 409A, such modification shall be made in good faith and shall, to the maximum extent reasonably possible, maintain the original intent and economic benefit to you and NextCure of the applicable provision without violating the provisions of Code Section 409A.</font></p><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.8pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:360pt;text-indent:0pt;white-space:nowrap;">2.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">A termination of employment shall not be deemed to have occurred for purposes of any provision of this Agreement providing for the payment of any amounts or benefits upon or following a termination of employment that are considered &#8220;nonqualified deferred compensation&#8221; under Code Section 409A unless such termination is also a &#8220;separation from service&#8221; within the meaning of Code Section 409A and, for purposes of any such provision of this Agreement, references to a &#8220;termination,&#8221; &#8220;termination of employment&#8221; or like terms shall mean &#8220;separation from service.&#8221; Notwithstanding any provision to the contrary in this Agreement, no payments or benefits that are considered &#8220;nonqualified deferred compensation&#8221; under Code Section 409A to which you otherwise become entitled under this Agreement in connection with your termination of employment, shall be made or provided to you prior to the earlier of (i) the expiration of the 6 month period measured from the date of your &#8220;separation from service&#8221; with NextCure (as such term is defined in Code Section 409A) or (ii) the date of your death, if you are deemed at the time of such separation from service to be a &#8220;specified employee&#8221; under Code Section 409A and if, in the absence of such delay, the payments would be subject to additional tax under Code Section 409A. Upon the expiration of the applicable Code Section 409A(a)(2) deferral period, all payments and benefits deferred pursuant to this </font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Section 8(b)</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"> (whether they would have otherwise been payable in a single sum or in installments in the absence of such deferral) shall be paid or reimbursed to you in a lump sum, and any remaining payments and benefits due under this Agreement shall be paid or provided in accordance with the normal payment dates specified for them herein.</font></div><div style="margin-top:12pt;"></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.8pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">For purposes of Code Section 409A, your right to receive any installment</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">payment pursuant to this Agreement shall be treated as a right to receive a series of separate and distinct payments. &#160;Whenever a payment under this Agreement specifies a payment period with reference to a number of days (</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">e.g.</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">, &#8220;payment shall be made within 30 days following the date of termination&#8221;), the actual date of payment within the specified period shall be within the sole discretion of NextCure. &#160;Notwithstanding any other provision of this Agreement to the contrary, in no event shall any payment under this Agreement that constitutes &#8220;nonqualified deferred compensation&#8221; for purposes of Code Section 409A be subject to offset, counterclaim or recoupment by any other amount payable to you unless otherwise permitted by Code Section 409A.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.8pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">All in-kind benefits provided and expenses eligible for reimbursement under this Agreement shall be provided by NextCure or incurred by you during the time periods </font></div></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.8pt;margin-bottom:12pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">set forth in this Agreement. &#160;All reimbursements shall be paid as soon as administratively practicable, but in no event shall any reimbursement be paid after the last day of the taxable year following the taxable year in which the expense was incurred. &#160;The amount of in-kind benefits provided or reimbursable expenses incurred in one taxable year shall not affect the in-kind benefits to be provided or the expenses eligible for reimbursement in any other taxable year. &#160;Such right to reimbursement or in-kind benefits is not subject to liquidation or exchange for another benefit. &#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.8pt;margin-bottom:0pt;margin-left:0pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">e.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If under this Agreement an amount is to be paid in installments, each installment shall be treated as a separate payment for purposes of Treasury Regulation Section 1.409A-2(b)(2)(iii). &#160;</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt;"><font style="display:inline-block;text-align:left;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">9.</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">280G</u><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;letter-spacing:-0.05pt;">.</i><font style="font-family:'Times New Roman','Times','serif';"> &#160;</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">In the event that the amount of any compensation, payment or distribution by NextCure or its affiliates to or for your benefit, whether paid or payable or distributed or distributable pursuant to the terms of this Agreement or otherwise, calculated in a manner consistent with Section 280G of the Code and the applicable regulations thereunder (the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">Aggregate Payments</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221;) would be subject to the excise tax imposed by Section 4999 of the Code, then the Aggregate Payments shall be reduced (but not below zero) so that the sum of all of the Aggregate Payments shall be $1.00 less than the amount at which you become subject to the excise tax imposed by Section 4999 of the Code; provided that such reduction shall only occur if it would result in you receiving a higher After Tax Amount (as defined below) than you would receive if the Aggregate Payments were not subject to such reduction. &#160;In such event, the Aggregate Payments shall be reduced in the following order, in each case, in reverse chronological order beginning with the Aggregate Payments that are to be paid the furthest in time from consummation of the transaction that is subject to Section 280G of the Code: (i) cash payments not subject to Section 409A of the Code; (ii) cash payments subject to Section 409A of the Code; (iii) equity-based payments and acceleration; and (iv) non-cash forms of benefits; provided that in the case of all the foregoing Aggregate Payments all amounts or payments that are not subject to calculation under Treas. Reg. &#167; 1.280G-1, Q&amp;A-24(b) or (c) shall be reduced before any amounts that are subject to calculation under Treasury Regulation &#167;1.280G-1, Q&amp;A- 24(b) or (c). &#160;For purposes of this Section 9, the &#8220;</font><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;">After Tax Amount</b><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8221; means the amount of the Aggregate Payments less all federal, state, and local income, excise and employment taxes imposed on you as a result of your receipt of the Aggregate Payments. &#160;For purposes of determining the After Tax Amount, you shall be deemed to pay federal income taxes at the highest marginal rate of federal income taxation applicable to individuals for the calendar year in which the determination is to be made, and state and local income taxes at the highest marginal rates of individual taxation in each applicable state and locality, net of the maximum reduction in federal income taxes which could be obtained from deduction of such state and local taxes. &#160;The determination as to whether a reduction in the Aggregate Payments shall be made pursuant to this Section 9 shall be made by a nationally recognized accounting firm or a firm specializing in Section 280G calculations selected by NextCure, which shall provide detailed supporting calculations both to NextCure and you. &#160;The costs of obtaining such determination and all related fees and expenses (including related fees and expenses incurred in any later audit) shall be borne by NextCure. &#160;Notwithstanding the foregoing, if (i) NextCure is not publicly traded prior to the occurrence of a change in control such that the private company exception pursuant to Q &amp; A #7 of the regulations promulgated under Section 280G of the Code is applicable and (ii) you request that NextCure seek shareholder approval of the portion of any payments to be made to you which are parachute payments under Section 280G and exceed 2.99 times your &#8220;base amount&#8221; (as such term is defined in Section 280G) in order that, </font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">upon obtaining such approval, all of the payments will be exempt from the excise taxes imposed under Sections 280G and 4999 of the Code, NextCure shall use its reasonable best efforts to obtain such approval. &#160; </font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:12pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">10.</td><td style="padding:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">Miscellaneous</u><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">. </font></td></tr></table><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.75pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">a.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This offer of employment is made subject to you having the legal right to work in the United States. &#160;</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.75pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">b.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Your employment with NextCure is subject to all Company policies and procedures, and NextCure retains the right to change its policies or procedures at any time.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.75pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">c.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">This Agreement may be executed in several counterparts, each of which shall be deemed to be an original but all of which together will constitute one and the same instrument.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.75pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:36pt;text-indent:0pt;white-space:nowrap;">d.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Neither this Agreement nor any of your rights or obligations hereunder shall be assignable by you. &#160;NextCure may assign this Agreement or any of its obligations hereunder to any subsidiary of NextCure, or to any successor (whether by merger, purchase or otherwise) to all or substantially all of the equity, assets or businesses of NextCure. &#160;This Agreement is intended to bind and inure to the benefit of and be enforceable to you and NextCure and NextCure&#8217;s permitted successors and assigns.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.75pt;margin-bottom:12pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:360pt;text-indent:0pt;white-space:nowrap;">e.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">No provision of this Agreement may be modified, waived or discharged unless such waiver, modification or discharge is agreed to in writing and signed by you and such officer or director as may be designated by the Board. &#160;No waiver by either party hereto at any time of any breach by the other party hereto of, or compliance with, any condition or provision of this Agreement to be performed by such other party shall be deemed a waiver of similar or dissimilar provisions or conditions at the same or at any prior or subsequent time.</font></div><div style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.75pt;margin-bottom:0pt;margin-left:36pt;margin-top:0pt;text-align:justify;text-indent:72pt;"><font style="display:inline-block;font-family:'Times New Roman','Times','serif';font-size:11.5pt;min-width:360pt;text-indent:0pt;white-space:nowrap;">f.</font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">The validity, interpretation, construction and performance of this Agreement shall be governed by the laws of the State of Maryland without regard to the choice of law principles thereof.</font></div><div style="margin-top:12pt;"></div><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:13.75pt;text-align:center;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">[</font><i style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:italic;">remainder of page intentionally left blank</i><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">]</font></p><p style="display:none;line-height:0pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:0pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-bottom:30pt;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:always;width:76.47%;border-width:0;"><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">If the foregoing is acceptable, please indicate your agreement by signing below and returning the original signed Agreement (keeping a copy for your own records) to me on or before []. &#160;If you have any further questions or require additional information, please feel free to contact me.</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;">Sincerely,</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:0.05pt;">NEXTCURE, INC.</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;letter-spacing:0.05pt;">By:</font></font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Michael Richman</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:7.07pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;">Michael Richman</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;text-indent:36pt;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;">President and Chief Executive Officer</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><b style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:0.05pt;">ACCEPTED AND AGREED:</b></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-weight:bold;letter-spacing:0.05pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;">/s/ Kevin G. Shaw</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:20pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Kevin G. Shaw</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Date:</font><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:10.01pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u>February 28, 2023</u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:19.68pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u><u style="font-family:'Times New Roman','Times','serif';font-size:12pt;text-decoration-color:#000000;text-decoration-line:underline;text-decoration-style:solid;"><u style="display:inline-block;overflow:hidden;position:relative;text-align:justify;text-align-last:justify;text-decoration:underline;text-indent:0pt;vertical-align:bottom;white-space:normal;width:36pt;">&#8203; &#8203;<font style="display:inline-block;height:0pt;width:100%;"></font></u></u></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;line-height:1.28;margin-bottom:8pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:90pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;font-style:normal;font-weight:normal;">Appendices:</font></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">Appendix A &#8212; Approved Activities</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:90pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.15pt;">Appendix B </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8212; Separation Agreement and </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.15pt;">General Release</font></p><p style="font-family:'Calibri','Helvetica','sans-serif';font-size:11pt;line-height:1.19;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:90pt;"></font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;letter-spacing:0.15pt;">Appendix C </font><font style="font-family:'Times New Roman','Times','serif';font-size:12pt;">&#8212; Confidentiality and Proprietary Rights Agreement</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-23.1
<SEQUENCE>6
<FILENAME>nxtc-20221231xex23d1.htm
<DESCRIPTION>EX-23.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/2/2023 08:38:32 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:11.76%;padding-right:11.76%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Exhibit 23.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><font style="font-size:11pt;font-weight:bold;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-size:11pt;font-weight:bold;">Consent of Independent Registered Public Accounting Firm</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><font style="font-size:11pt;">We consent to the incorporation by reference in the following Registration Statements:</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-231438) pertaining to the NextCure, Inc. 2019 Employee Stock Purchase Plan,</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(2)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-231436) pertaining to the NextCure, Inc.&#160;2015 Omnibus Incentive Plan and the NextCure, Inc. 2019 Omnibus Incentive Plan,</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(3)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-260776) pertaining to the NextCure, Inc. 2019 Employee Stock Purchase Plan,</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(4)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-8 No. 333-260779) pertaining to the NextCure, Inc. 2019 Omnibus Incentive Plan, and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="font-size:11pt;margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;line-height:1.43;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:18pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:11pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(5)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:11pt;font-style:normal;font-weight:normal;">Registration Statement (Form S-3 No. 333-241706) of NextCure, Inc.;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:11pt;line-height:1.37;margin:0pt;">of our report dated March 2, 2023, with respect to the financial statements of NextCure, Inc. included in this Annual Report (Form 10-K) of NextCure, Inc. for the year ended December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">/s/ Ernst &amp; Young LLP</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">Baltimore, Maryland</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;">March 2, 2023</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:11pt;visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:11.76%;margin-right:11.76%;margin-top:30pt;page-break-after:avoid;width:76.47%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.1
<SEQUENCE>7
<FILENAME>nxtc-20221231xex31d1.htm
<DESCRIPTION>EX-31.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/2/2023 08:38:32 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Principal Executive Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Michael Richman, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of NextCure, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"><br></font><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin-left:0pt;margin-right:0pt;visibility:hidden;">&#8203;</font></td></tr></table><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">(a)&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;table-layout:auto;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="display:inline-block;text-indent:0pt;width:36pt;"></font><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: March 2, 2023</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Michael Richman</p></td><td style="vertical-align:bottom;width:50%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Richman</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-31.2
<SEQUENCE>8
<FILENAME>nxtc-20221231xex31d2.htm
<DESCRIPTION>EX-31.2
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/2/2023 08:38:35 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;31.2</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Certification of Principal Financial Officer</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Pursuant to Section 302 of the Sarbanes-Oxley Act of 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">I, Steven P. Cobourn, certify that:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">1.&#160;&#160;&#160;&#160;I have reviewed this annual report on Form 10-K of NextCure, Inc.;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">2.&#160;&#160;&#160;&#160;Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">3.&#160;&#160;&#160;&#160;Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">4.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(a)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(b)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(c)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Evaluated the effectiveness of the registrant&#8217;s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><table border="0" cellpadding="0" cellspacing="0" style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;width:100%;border:0pt;"><tr><td style="width:54pt;"></td><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(d)</td><td style="padding:0pt;"><font style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Disclosed in this report any change in the registrant&#8217;s internal control over financial reporting that occurred during the registrant&#8217;s most recent fiscal quarter (the registrant&#8217;s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant&#8217;s internal control over financial reporting; and</font></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 18pt;">5.&#160;&#160;&#160;&#160;The registrant&#8217;s other certifying officer&#160;and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant&#8217;s auditors and the audit committee of the registrant&#8217;s board of directors (or persons performing the equivalent functions):</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 36pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">(a)&#160;&#160;&#160;All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant&#8217;s ability to record, process, summarize and report financial information; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 72pt;"><font style="margin-left:0pt;visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 54pt;">(b)&#160;&#160;&#160;Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant&#8217;s internal control over financial reporting.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"></div></div></td><td style="vertical-align:bottom;width:43.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Date: March 2, 2023</p></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td colspan="2" style="vertical-align:bottom;width:50.09%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">/s/ Steven P. Cobourn</p></td><td style="vertical-align:bottom;width:49.9%;border-bottom:1px solid transparent;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Name:</p></td><td style="vertical-align:bottom;width:43.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven P. Cobourn</p></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:6.66%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Title:</p></td><td style="vertical-align:bottom;width:43.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td><td style="vertical-align:bottom;width:49.9%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-32.1
<SEQUENCE>9
<FILENAME>nxtc-20221231xex32d1.htm
<DESCRIPTION>EX-32.1
<TEXT>
<!--Enhanced HTML document created with Toppan Merrill Bridge  9.14.0.96--><!--Created on: 3/2/2023 08:38:34 PM (UTC)--><!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd"><html><head><meta charset="UTF-8"><title></title></head><body><div style="margin-top:30pt;"></div><div style="max-width:100%;padding-left:5.88%;padding-right:5.88%;position:relative;"><div style="clear:both;max-width:100%;position:relative;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><b style="font-weight:bold;">EXHIBIT&#160;32.1</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">CERTIFICATION PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">18 U.S.C. SECTION&#160;1350,</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">AS ADOPTED PURSUANT TO</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">SECTION&#160;906 OF THE SARBANES-OXLEY ACT OF 2002</b></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">In connection with the Annual Report on Form 10-K of NextCure, Inc. (the &#8220;Company&#8221;) for the year ended December 31, 2022, as filed with the Securities and Exchange Commission on the date hereof (the &#8220;Report&#8221;), the undersigned each hereby certifies pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that to the best of his knowledge, on the date hereof:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">(1)&#160;&#160;&#160;the Report fully complies with the requirements of Section&#160;13(a)&#160;or 15(d)&#160;of the Securities Exchange Act of 1934; and</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:18pt;text-indent:-18pt;margin:0pt 0pt 0pt 36pt;">(2)&#160;&#160;&#160;the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p><div><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;" align="center"><tr style="height:1pt;"><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td><td style="vertical-align:bottom;width:43.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="font-size:1pt;visibility:hidden;">&#8203;</font></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 2, 2023</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Michael Richman</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Michael Richman</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">President and Chief Executive Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;padding-left:7.2pt;text-indent:-7.2pt;margin:0pt;">Dated: March 2, 2023</p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td colspan="2" style="vertical-align:bottom;width:50%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">/s/ Steven P. Cobourn</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Name:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Steven P. Cobourn</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Title:</p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Chief Financial Officer</p></td></tr><tr><td style="vertical-align:bottom;width:50%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:bottom;width:6.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td><td style="vertical-align:top;width:43.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></td></tr></table></div><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><font style="visibility:hidden;">&#8203;</font></p></div></div><hr style="background-color:#000000;clear:both;color:#000000;height:2pt;line-height:0;margin-left:5.88%;margin-right:5.88%;margin-top:30pt;page-break-after:avoid;width:88.24%;border-width:0;"></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>10
<FILENAME>nxtc-20221231x10k005.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20221231x10k005.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" (B \L# 2(  A$! Q$!_\0
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M_P#XFD_X0;PW_P!"_I?_ (!1_P#Q-'^M]/\ Y\O[_P#@&B\.*R_YB5_X"_\
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M?ZUT_P#GR_O_ . :_P"J-3_G\ON_X)^'R]*D6OV]_P"%;^$O^A7T7_P7P_\
MQ-+_ ,*X\)?]"OHO_@OA_P#B:/\ 6NG_ ,^7]_\ P"7PA4?_ "^7W?\ !/Q$
M7K4@Z5^V_P#PKCPG_P!"OHW_ (+X?_B:/^%<^$_^A7T;_P %\7_Q-'^ME/\
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M /@!%_\ $TO_  KSPK_T+.C_ /@!%_\ $T?ZVT_^?+^__@$/@BK_ ,_U_P"
M_P#!/Q@7K3EZU^SO_"O?"W_0M:/_ . $7_Q-'_"O?"W_ $+6C_\ @!%_\31_
MK;3_ .?+^_\ X!/^H]7_ )_K_P !_P""?C,.E*.M?LQ_PK[PM_T+6C_^ $7_
M ,31_P *^\+?]"UI'_@!%_\ $T?ZVT_^?+^__@"_U&J_\_U_X#_P3\:UZ4M?
MLI_PK[PM_P!"WI'_ ( 1?_$T?\*^\+?]"WI'_@!%_P#$T_\ 6VG_ ,^7]_\
MP"/]1:O_ $$+_P !?^9^-ZTM?L?_ ,*_\+_]"WI'_@#%_P#$T?\ " >%_P#H
M6](_\ 8O_B:/];:?_/E_?_P!?ZB5?^@A?^ O_,_'1:>O6OV(_P"$ \+_ /0M
MZ1_X Q?_ !-+_P (!X8_Z%S2/_ &+_XFC_6VG_SY?W_\ G_4*K_T$+_P%_YG
MX\#K3UZU^PG_  @/AC_H7-)_\ 8O_B:/^$!\,?\ 0N:3_P" ,7_Q-'^MM/\
MY\O[_P#@$_Z@U?\ H(7_ ("_\S\?1UJ1:_7[_A ?#'_0N:3_ . ,7_Q-'_"!
M>&?^A<TG_P  8O\ XFG_ *W4_P#GR_O_ . 0^ *O_00O_ 7_ )GY!4JU^OG_
M  @7AG_H7=)_\ 8O_B:7_A _#/\ T+ND_P#@#%_\31_K=3_Y\O[_ /@"_P"(
M?U?^@A?^ O\ S/R&I1UK]>/^$#\,_P#0NZ3_ . ,7_Q-'_"!^&?^A=TG_P
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ME?\ @+_S/R:'2EK]9/\ A!O#?_0OZ5_X!1__ !-'_"#>&_\ H7]*_P# */\
M^)JO];Z?_/E_?_P"?^(<UO\ H)7_ ("_\S\G%IZU^L/_  @WAO\ Z%_2_P#P
M"C_^)H_X0?PY_P!"_I?_ (!1_P#Q-'^M]/\ Y\O[_P#@"_XAQ6_Z"5_X"_\
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M] #2_P#P#C_^)H_UOI_\^7]__ %_Q#6M_P!!2_\  7_F?E73Z_5'_A"?#O\
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M\ X_\*?^N%/_ )\O[_\ @"_XAE6_Z"E_X"_\S\N5I:_47_A"_#__ $ M,_\
M ./_  H_X0SP_P#] +3/_ ./_"C_ %PI_P#/E_?_ , 7_$,:_P#T%+_P%_YG
MY=4J]:_43_A#/#__ $ M,_\  ./_  H_X0SP_P#] +3/_ ./_"C_ %PI_P#/
ME_?_ , 7_$,*_P#T%+_P%_YGY>T#K7ZA?\(9X?\ ^@%IG_@''_A1_P (9X?_
M .@%IG_@''_A1_KA3_Y\O[_^ '_$,*__ $%+_P !?^9^8%%?I_\ \(9X?_Z
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M %;$<BRH'1@RGH16$TD_=V.NC.4HKG^(=11169N%%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %
M%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 44
M44 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !111
M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %%%% !1110!F:;J4>LP2H\>TCAESG(IB6
M5CH;&=F()X&XYQ]*D7[#H* $^7O/?DFDU6P&L6L9BD (Y4GH:Z+KFTTBSA:?
M)K9S1:2\6[M7DMFWG!Q]:YS2[B];5%!+DDG>&Z8K;TNR72+<I)*N]SDDG J7
M4[DV-E+/&H+@<4XM1;C%7N*<93C&I-V:U:*OB&QFO;=/)&XJ<E?6F>'K&6QA
MD:8;-YX4TS0=6GOIGCFPV!D,!C%1^)DN2T13<8O1?6K2E_!9FW!_[5%-^0OB
M+3;B[FCEB4R*!C [5<T:!M.LE6X8(S'(4GI3M"69=/3S\[L\;NN*RO$=I<RW
M:LJ/)'CC:,XI)N7[IO1!)*G_ +3%-M]#I0<TM4=+62WL(EN&"OZ$U>KE:L['
MH1ES13"BBBD6%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M5TF^)PZ^HK"4;-VV.R$U)*^C?0EHHHJ#0**** "BBB@ HHHH **** "BBB@
MHHHH **** "BBB@ HHI* %HHHH **** "BBB@ HHHH **** "BBB@ HHHH *
M*** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HH
MHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M"BBB@ HHHH **** "BBB@#'UC4KJSN8DACW*W4XSGVK6C8LBDC!(R1Z4N V#
MP?2LR[UK[-J$=MY18-U:M;<Z2BM4<[?LFY3EHRJJZE_;))+&'=_P';6]25B6
MEW?OK#QR*?)!((QP!3_B:[61"M0=G=\S(;J^U!-7\M WE[@ H'!%;5Y8Q7\(
MCF&1U&.QJ? SG'-8%UJ-\FL+$JD1[@ N."/6J5ZC7+I8B25%/G;DI,O,+?P_
M8LRJ2,_B34FG:C%JL18)@J>0U6+JUCO(3%*,J:JB&#0[*1XT) Y/J34W4E_>
M-+2A+2R@D5O$<MS##'Y&X(3\Q3K5G1)9Y;%6N,[L\%NI%-TG5EU02 Q["O;K
MFI-8@FGL'2 D/Z#J15/1*G)6(5FW7@[JVPS6;!M3M%6)QN4[AGH:BTJR;1K.
M9YV']XA>@%)X?M;FU@D^T94$_*K'I5U;FUU 20+(LG&&4&AMQ3AN@C&,VJS5
MI/N0:=K<.HRM&JLC#D;N]:-9]AHL&GRM(A9F/ W'I69<:K>IK!B4'8&P$V\$
M>M+D4Y/V>P_:RI03K;M]#HZ*AN+J&T4-+(L8/3-2(ZR(&4AE(R".]8V>YUW5
M[#J***0PHHHH **** "BBB@ HHHH ***9YR&7R]WSXSCVH%>P^BFNI<##%><
M\4Z@8@SCG@TM%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%
M%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110
M 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !
M1110 4444 %%%% %33+-[&U$4DGF-G.:L&)&<.44L.C$<U%?Q336KI _ERD<
M&DT^*:&TC2=]\H')JWK[U]3&*46J:6B()=8CBU!;0HQ8X^;M5_%1M;1-*)2B
MF0=&QS5:;5H8;]+4AB[=P.*=N;X4%W"[J/=Z%6VO[V35GA>(B $_P]/QK7P,
MYQS2UDFZOO[7$7E_Z/ZX[4_CVTL3?V*M)MW9#J5SJ$>IQI I,7& !P?K6S)&
MLT91P&4C!!I]9.M0WTCQ&U8A1U /?UII\[2V):=)2D[ROT+L%I%I\+^3'COC
MUK-TG6I[Z]>*2,!>2,?P_6MA6V1+YC '')/K0B(N615&>X'6I4E9\RNRG!WC
MR.R7065/,C9"<!@1FLK2]!_L^Z:8R;Q@@ 4R:+43K"LA(@SU_AQ6K/<Q6P!E
M<("<#-5[T%:+W)]RK+FFK<O<SKO7EMM06V\LD9 +?6M3:I.[ SZXJ%K*WFF6
M=HU:0=&JMK<%S/:A;8D-GD X)%+W9-):%7G!2E+7L)J^D_VF(\/L*GO4\5NU
MA8>7%F1T4XSW-+8)+!8QBX;=(H^8U'I^KPZC)(D88%.>>XHO*UMTA)4U+FVE
M(K:'>7ETTOVE"%'0D8P?2K%UK,%I=I;ON+-W'05>)52!D FH)M/MYYTEDC#2
M+T-'-%RNUH"A4C!1C*[\R9Y%C0NS!5'))I(9DG0/&P=3W%,N[9+RW>%\A6&.
M*986*:? (D)(SG)J-+>9K>7/:VA/O7?MW#=UQGFE9@@RQ 'J:I+I:KJ1N_,;
M)&-G:IKZS6^MS$Y*@G.5IVC=:B3G9Z:]"<$$9'(J..YBED9$<,R]0#TI8(1!
M"D:DD*  33(;.&"625$"O)RQ]:6FI7O:?B)=W@M/+RC/O;;\HZ5.<E3C@]J"
M,TM+0=G=W9%;))'$!*XD?/W@,5)@9SCGUIK2!&53G+=.*<>E#[@DDK"TE &!
MZTM(H**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "B
MBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH ***
M* "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M8YQ3@ZERH/S 9(I22!P,T%:/46BBD Q2&+1110 4444 %%%% !1110 4444
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M^8LI/.:P?V:?'_BO5/&_@"!O$'BN>75$O)=5'B.\$UA>0(2%^Q[V9MZMC<
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M\RBO<O%G[/W@SQEXDGUV\LKFVU&[C$-Z]A>2VRWL8Q\DZHP#KP.#UQ47AO\
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M54=25E!V;Y96OM:]K-KK9NW6UF=__8EKZ2_]_G_QH_L2U])?^_S_ .-<??\
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MKZ2_]_G_ ,:/[$M?27_O\_\ C5^BB[#E78H?V):^DO\ W^?_ !H_L2U])?\
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MDO\ W^?_ !H_L2U])?\ O\_^-7Z*+L.5=BA_8EKZ2_\ ?Y_\:/[$M?27_O\
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MKZ2_]_G_ ,:/[$M?27_O\_\ C5^BB[#E78H?V):^DO\ W^?_ !H_L2U])?\
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M!]%,\Z/_ )Z+^='G1_\ /1?SH ?13/.C_P">B_G1YT?_ #T7\Z 'T4SSH_\
MGHOYT>='_P ]%_.@!]%,\Z/_ )Z+^='G1_\ /1?SH ?13/.C_P">B_G1YT?_
M #T7\Z 'T5'Y\?\ ST7_ +Z%'GQ_\]$_[Z% $E%1^?'_ ,]$_P"^A1Y\?_/1
M/^^A0!)14?GQ_P#/1/\ OH4>?'_ST3_OH4 245'Y\?\ ST3_ +Z%'GQ_\]$_
M[Z% $E%1^?'_ ,]$_P"^A1Y\?_/1/^^A0!)14?GQ_P#/1/\ OH4>?'_ST3_O
MH4 245'Y\?\ ST7_ +Z%+YT?_/1?SH ?13/.C_YZ+^='G1_\]%_.@!]%,\Z/
M_GHOYT>='_ST7\Z 'T4SSH_^>B_G1YT?_/1?SH ?13/.C_YZ+^='G1_\]%_.
M@!]%,\Z/_GHOYT>='_ST7\Z 'T4SSH_^>B_G2>?'_P ]$_[Z% $E%1^?'_ST
M3_OH4>?'_P ]$_[Z% $E%1^?'_ST3_OH4>?'_P ]$_[Z% $E%1^?'_ST3_OH
M4>?'_P ]$_[Z% $E%1^?'_ST3_OH4>?'_P ]$_[Z% $E%1^?'_ST3_OH4>?'
M_P ]$_[Z% $E%1^?'_ST3_OH4OG1_P#/1?S% #Z*9YT?_/1?SH\Z/_GHOYT
M/HIGG1_\]%_.CSH_^>B_G0 ^BF>='_ST7\Z/.C_YZ+^= #Z*9YT?_/1?SH\Z
M/_GHOYT /HIGG1_\]%_.CSH_^>B_G0 ^BF>='_ST7\Z//C_YZ+^8H ?14?GQ
M_P#/1/\ OH4>?'_ST3_OH4 245'Y\?\ ST3_ +Z%'GQ_\]$_[Z% $E%1^?'_
M ,]$_P"^A1Y\?_/1/^^A0!)14?GQ_P#/1/\ OH4>?'_ST3_OH4 245'Y\?\
MST3_ +Z%'GQ_\]$_[Z% $E%1^?'_ ,]$_P"^A2B:,G D4GZT /HHHH ****
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M%']FVG_/K#_W[%3JZN6VL&VG!P>A]*&=44LQ"J.22< 47861!_9MI_SZP_\
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MK+\0?\>J?[_]*<7J1)+E9S?V6'_GDG_?(H^RP_\ /)/^^14M%;'+8B^RP_\
M/)/^^11]EA_YY)_WR*EHH"Q%]EA_YY)_WR*/LL/_ #R3_OD5+10%B+[+#_SR
M3_OD4?98?^>2?]\BI:* L1?98?\ GDG_ 'R*/LL/_/)/^^14M% 6(OLL/_/)
M/^^14MI;0BZA(B0$./X1ZT5+:_\ 'S#_ +X_G0-+4ZZBBBN<[0HHHH ****
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M\Y)A<JREE)[D.PS[FES1MHA\D[ZO^M#Q?0/%5UX)\+_&W6[)(I+JS\73NBS
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M 9"XWN0,UZ_9_##P[8:[H.L16(_M+1-/.EV5PS$LD& -I]2 .#_M-ZFL>_\
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M_P :7_AER+_H*W'_ 'Z7_&D^(LJ;4G+5?W7_ )%QX&XDC%PC3T>ZYX^O?R/
M_MUR3G[1+GR_*SO/W,8V_3'&*F&MZB$1!?W01!A5\YL*,8XYXXKW4_LN1 ?\
MA6X_[]+_ (UC_P##/2_]!";_ +]BJ_UBRN7V_P#R5_Y&?^HO$4?^7:_\#C_F
M>/#4KM79Q=3!V3RRPD.2G]WKT]JM^(/$=[XEN+:6\9,6UM%:01QKM2..-0J@
M#\,GU)->K?\ #/2_]!";_OV*7_AGE/\ H(3?]^Q1_K!E=U+FU7]U_P"0?ZD<
M1<KA[-6>ZYX_YGCUQJ=Y>1+%/=SSQ)]U))"RCZ FD&IW@14%W.$1#&J^8<!3
MU4<]#Z5[%_PSRG_00F_[]BC_ (9Y3_H(3?\ ?L4_]8<LVY__ "5_Y"_U&XAO
M?V:_\#C_ )GCD5_=0Q>5'<S1Q8(V*Y YQGCWP,_2@:C=!=HN9@-H3'F'[HY
M^@]*]C_X9Y3_ *"$W_?L4?\ #/*?]!";_OV*/]8<L_G_ /)7_D+_ %&X@_Y]
MK_P./^9XX+^Z66207,HDE^^X<Y?G/)[TAOKEDF0W$I28AI%+G#GU;U_&O9/^
M&>4_Z"$W_?L4?\,\I_T$)_\ OV/\:?\ K%EG\_\ Y*_\@_U%X@_Y]K_P./\
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MK_Q\P_[X_G452VO_ !\P_P"^/YT MSKJ***YSM"BBB@ HHHH **** "BBB@
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MLU+M%4O['MO27_O^_P#\51_8]MZ2_P#?]_\ XJC0-2[15+^Q[;TE_P"_[_\
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MLO3/^@C;?]_E_P :/^%EZ9_T$;;_ +_+_C7Q!11_JQ#_ )^O[O\ @ASGV_\
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MP2)5.;H?;_\ PLO3/^@C;?\ ?Y?\:/\ A9>F?]!&V_[_ "_XU\0457^K$/\
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M\>J?[_\ 2M2LOQ!_QZI_O_TJH[D3^%F!1116QRA1110 4444 %%%% !1110
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MGI6EX0\*6/@GP]:Z/IYE>W@W$RW#[Y979BS.[=V9B23[UHY1U,E"6ESR^_\
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MBKWW(_A%83Z-&Q/ KZ##9OB\+2C2I25EY(Y)).3/CW_AG37/^?VT_)O\*/\
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M,_S%;O\ 82?W:A\08]/XE]R-HTXM79\0_P##+/B'_H(V7Y/_ (4?\,M>(?\
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M1110 4444 %%%% !4MK_ ,?,/^^/YU%4MK_Q\P_[X_G0"W.NHHHKG.T****
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M\GX?SIIZDRBK,Y'[--_S]R?]\K_A1]FF_P"?N3_OE?\ "K-%;W.6Q6^S3?\
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M1_9UW_T%)_\ OW'_ /$UHT5E<Z.5&=_9UW_T%)_^_<?_ ,31_9UW_P!!2?\
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MH]ZHKY1\2?M2^+M-3P?-<IHGA"UU?P\FJW,^LZ9>W:I,TK($'D,"JE%#C<.
M>37T_H%\=2T/3KMKFVO&GMXY&N+//DRDJ"63))VGJ,D\8J94Y05V5"K&HVHE
M^BBBLS8**** "J.L_P#(/D_#^=7JHZS_ ,@^3\/YTUN3+9G-4445N<@445RW
MQ'\47?A#P];WUFD,DTFHV5H1.I*[)KF.)SP1R%<X]\=>E-*[L)NRNSJ:*X;X
MK^-=4\*:98VWAZVM[[Q'J,S1V=M<@E"L:-+*Q 8' 1"!@_>=:BLOB9_;FJ^
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M +<ZZBBBN<[0HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
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M&Y@F20)LW'KL +9S7?T4<\A^SBNAYSK7P=AUBS\96YU%XQXCU.TU)V$8/DF
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M%R!]3ZUF:A\8)M1TNXLY-.0+-H-MH1?S#G;#*LGF=.IVXQ[US_\ PK;Q1_T
M;[_OR:/^%;>*/^@#??\ ?DU/-C'%0L[>GR["YL6X\MG;T_X!V&O?'[4O$>F>
M(=(O=/MFT/4;:."VLXXT1K0Q%?);S0H=]NT?>)R,UY572_\ "MO%/_0!OO\
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M %%%% !1110 5TFB?\@]/J?YUS==)HG_ "#T^I_G42V-*>Y?HHHK(Z0HHHH
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M>_\ />#_ +Y-'_".WO\ SW@_[Y-%T'++L4**O_\ ".WO_/>#_ODT?\([>_\
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M15__ (1V]_Y[P?\ ?)H_X1V]_P">\'_?)HN@Y9=BA15__A';W_GO!_WR:/\
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MP*6DBMY0Y4 @$\=LD#\:^9Y;BY\?7/A[QKK=C/&;G6K;2XX(U+2+#%;2^=M
M&26D+GCT [5V'P'O_L'C/^PM"8:[X7M[)RNISZ=]GN;%B^?L[R8&XD@$COC.
M.*BME,*-"4^9N<5KVOK=7\MK:7UMV-<+Q-5Q6,A34$J<Y6B]>9II<KY;IV>K
MND[*UTMSZ%HHHKY@_0PHHHH **** "BBB@ HHHH **** "BBB@ HHHH ****
M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
M**** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ H
MHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BB
MB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBJMW;SSE3#=-;
M@=0$#9_.@3+5%9W]GWO_ $$W_P"_*?X4?V?>_P#03?\ [\I_A567<5WV-&BL
M[^S[W_H)O_WY3_"C^S[W_H)O_P!^4_PHLNX7?8T:*SO[/O?^@F__ 'Y3_"C^
MS[W_ *";_P#?E/\ "BR[A=]C1HK._L^]_P"@F_\ WY3_  H_L^]_Z";_ /?E
M/\*++N%WV-&BL[^S[W_H)O\ ]^4_PH_L^]_Z";_]^4_PHLNX7?8T:*SO[/O?
M^@F__?E/\*KWT%_:6S2KJ3L1C@Q)_A1;S$Y-:V-FBN1_M'4O^?X_]^E_PH_M
M'4O^?X_]^E_PJN3S(]JNQUU%<C_:.I?\_P ?^_2_X4?VCJ7_ #_'_OTO^%')
MYA[5=CKJ*Y'^T=2_Y_C_ -^E_P */[1U+_G^/_?I?\*.3S#VJ['745R/]HZE
M_P _Q_[]+_A1_:.I?\_Q_P"_2_X4<GF'M5V.NHKD?[1U+_G^/_?I?\*/[1U+
M_G^/_?I?\*.3S#VJ['745R/]HZE_S_'_ +]+_A1_:.I?\_Q_[]+_ (4<GF'M
M5V.NHK.^P7O_ $$W_P"_*?X4?V?>_P#03?\ [\I_A4V7<TN^QHT5G?V?>_\
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M?\_%^)Q?ZPT?^?;_  /UG_X2F/\ OC\Z/^$IC_OC\Z_)C_A;_C;_ *&K5?\
MP*;_ !H_X6_XV_Z&K5?_  *;_&C_ %<K?\_%^(?ZPT?^?;_ _6?_ (2F/^^/
MSH_X2F/^^/SK\F/^%O\ C;_H:M5_\"F_QH_X6_XV_P"AJU7_ ,"F_P :/]7*
MW_/Q?B'^L-'_ )]O\#]9_P#A*8_[X_.C_A*8_P"^/SK\F/\ A;_C;_H:M5_\
M"F_QH_X6_P"-O^AJU7_P*;_&C_5RM_S\7XA_K#1_Y]O\#]9_^$IC_OC\Z/\
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M%4MK_P ?,/\ OC^= +<ZZBBBN<[0HHHH **** "BBB@ HHHH **** "BBB@
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MC&C"*:7>_P#F?-8O)Z&*KRJSD[OM;_(_*W_AFCXD_P#0KW'_ ']C_P#BJ/\
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MI-$_Y!Z?4_SJ);&E/<OT445D=(4444 %%%% !1110 4444 %9?B#_CU3_?\
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M:-VFA(5@2 I]:WZ*.=A[.(4445!H%%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4
M444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !11
M10 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
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M .>3?G1RL.>/<UZ*R/\ A(8_^>3?G1_PD,?_ #R;\Z.5ASQ[FO161_PD,?\
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M "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH
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M'BD4.C#H01D&ANM8HH8>M,/6GGK3#UIDL**** "BBB@ HHHH **** "BBB@
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M0 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
M!1110 4444 %%%% !1110 4444 %*M%% #UIZT44BAR]:D'2BBD-#EZ4]>U%
M%(HE6G+112&AZT]:**10]>E2+VHHH&.IXZT45(R1:<M%%(H&IC=Z** 9$W6F
MM115$D+=:C/>BBFB1AZ4QJ**9+(6IAZT451)&U1MUHHIHD8>M,/6BBF2S__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>11
<FILENAME>nxtc-20221231x10k006.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20221231x10k006.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" &. M@# 2(  A$! Q$!_\0
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MA)WL7DN:PSK T\=3BXJ5]'NK.P4445PGMA1110 4444 %%%% !1110 4444
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MHX4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%%
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MX#FEKG-(\30WM_<VH/,3$8/M70JP901TJ6FMQ#J***0"4M%% !1110 4444
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MR2%//3VKH_#>NQ^)M'BN57&[J#ZU]50H8!UOK&%2O'1VZ7TUMH?DN8X_B*&
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MM+*.TB"(H 'I7F8G%NI[L?O[F$ZG-HB/3M/BL(%CC4*%&!BKE%%>88A1110
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M#QYY7ZUY)#K>M:)++=&T, GD9'BAR&*8Y /9>]1Z=XK.B64F^#[(+V-F^T;
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MC)W'/; K8KW+"NGL%%%5[^_M]+L;B\NY5@M;>-I997Z(BC+$_0 TAEBBN?\
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ME4>FB/JZ&%I86*]HKR9Y+-X(M5R8;[5;=^S"[+8_ U7;3O$VF<Z;X@6\4?\
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MC _&L6T6[OO$?A67Q5;_ -F:EI]T[7<<@^6:,'*!3T->W'%4,5\+O)]/*_\
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M/AQXGNOB'\ ;V'1;J2TT2!5U*54^6U.U1A_2N<^/O@+5_B3K-_%8?"34-/\
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MG/7N>:]HT\@;17XOD$_K>/KXR/PSFVM6]+Z.[[G[)EU%T,+3IRW21KAJ<#4
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MP  !5.>;&:5N4S<G494U34A:IQU/05CHDEW^\E<@>E5M9N?]/56/RTLM\%&
M>*V@M+DR3V)YHH57UK)O"J9*'!HN;_ ZUE7-X6S@ULE<(Q9I:=KS02B-V)7I
MS6\[^:@8'@UYXTQ$HP><UWNE$O81ENN*QQ%-0LUU.JF^@QXS31!N.*ENIUC!
MY%9\FLK%SQFN(Z->AK11V\$+K)$'=AP3VK-U"VM70%%VG'(K,N?$"CG=R:R+
MKQ#G/S47'&#O<KZW;(@8KQ]*\\^(6I6^F^'(-8O&938721F51EMC\$>XXKKK
MW4'NVVKEB>,"O)_C]J4EMH.G^'[9HFN;FY62<.W\7\"?4TZ<)59J$5JRZLU2
MIN4CT;PS?PZW8)<:;>0WT1&<QN"1]13M7U>YM'BM88'FO9SLBA Y8_X5\\>*
M? 6I_#FZ\/V4^L/IWB/58A.;:R;Y;13]S>>Y-?1_P8\':AH=A%>:WJ4VL:Q<
MCY)9_P#EE'[?6NBMA944G)[G'0QD:]U%'6^"_AE!8R)J&K@:GJ[<@.,QP>RC
MU]Z]3D\/3PK'ND0;AG [4W2F33[?8H5F8<L:M-=%N2<UFHI+4RG4FW[NQ FC
M1H<RR[O85:C:&U7$2!3_ 'N]5);K&>:K/<GUIW2V)Y93^)E^6Y !)-8=WJ3W
M$ACA_.H]7OC#;$@]>*IZ?.L<&\GYC6D%S:D37*6&M/ES(Y)-9E\L<8."15FY
MO_>L+4+W?D UTI$1BWN1?VK):2@JQQ73Z9J OX _\7>N"N9<D\UT?A!F,;YZ
M5->FN3G.N#L['2L 1S6-J5BLJGBM268*.M4I)/,.*\\Z4<=KGARRUNQ>QU.T
M2\M6Z*P^9#ZJ>QKR#Q9^S/INJV]K%HVL2Z4+=VE"3)OWL?[S=3Z5]'16BO("
M5R,]Z6]TZUE./*"J?XA5PG*GK%V)FH3LI*Y\]6_@KQYX9?&FW]EJ=DJ@?8YF
M../0GI3KKQ?>:(F[7O#FH:: ,M+;+YT0]\BO:;W08$SAV/TK!U!)M/P4D+1G
M^%N1^5*<N;5HTIQ4=(L\HF^-/@^UL)KI+F[U$PKN:""$[A^=<+XM^*7C#Q;:
MA?#]@VGV"8FEM(_]=+#_ !9/T]*['XI_#[1Y;JQ\1V\(LFN)?LEZD/RHQ/*M
MC^=0:7X+TBW03QWC1R(,!UDP5'I7;0EAH>]*+;.'$/$-\J:1PUO>VNC^&1>Z
M5I+7*S2J_P!BG4LT@8X<&NX@\)Z;\.O!ETEM#)#=7>ZXD5.6@#<^4OI5KPWX
M9MY?&NG+'>//;VJO<F/=E<@<?K53XJ^(C:2VMC;9GU*_E$442\]3RQ'H*VQV
M,5?EA35HH,%A7"\YZLUO@QX3N/\ A&5\T")[N8W,P8\C<>!]<5[A!!IMM*L5
MG;K;PH,D,<DMC!.:\M\!Z_#HMPVE;WN)R%5WQP-H["MK6M;D65TB;:Q[DUXL
M96U/9J4W)J+V1TFO^(=)TF%@/+WCL*\YT[6T\7:M<(1B*$]/6N;U%9;Z[+32
MDY/K5[2K^STIY/*8"4C#'UJ'*YK"BHKS.[TW2K%99</LD88P#6W=7$&AZ7:P
MV\S27,A)9<Y"+V_&O.;>ZN$F%P-P5NA/>M^#7/MUO9B4*#"S+D#!/IFMJ*YW
M8RK1<;-&VCW-TN2Q ]ZF1)88)4R&9AP<UFG5,+G=@4G]K>7'N# DG%=7*CE]
MZ]Q$U"6TE <Y'>M^V,-]$'4#.*Y*]U:&122@W?6J^D^(GANE7(QT(-9U*7-%
MM(VA+HSJ%8Z9>;P3@GUK8U_1;'QMHDMM.B-,8R(G=B-C$=>*PKXO>6I885\<
M8K-TK7IM+E"SMWK\USS U*D?:47:<=4T<&8X".,HN$E>YX+XFL9=/U6XMY"5
M^SN5WJ<J0#C(_*LTZKYD+PY 5QDDC-?0WB+P1HOC-A<MBSE/WGB ^?ZUY'XM
M^%NI:++*MHGVRV'SB:->,>_I7W>3\:8'&*&'Q<O9UK:\VB;6FCVUWMIV/Y;S
M7A7&Y;4E*$.:%]+;I>GD>77T4*>8^QP<@J!G!JI#"CNP;9&KH3O8\@UO3Z'J
M>T[K=VC VY4'"DU:T/X>:GJ]PL(MY-CR ;U0X&>.O:OL:N886G!U)U(I+K='
MBTJ=9M14&WZ,YG3YY5@DMXMSA^, <M]*^E_V8?@Y!J/FZUK-H9H\!8@YP&8'
MJ<=<"JW@K]FVXL]>234)XOLL+!U=>2WMBOJ;0K>WT^)(H(TAC'14&!^5?E6?
M<0+-X+ 95*\9V<IJZLM[+;5]>VJL?=9/DU:515L5&UME^O\ 7J=IH<*V\:*@
MV@#  ["NIM)0O.0 .]<CI]TO%1^/-8ETSP%K]U;DB:.RE*$=CM/-?0Y)EZPM
M.-.*['W\[4H.71'0>'OB9X;\3:Q<:5INK075_!G?"IY..N/7'M75AP.]?#/A
MZ[N=$L-*US2P#J6CRB=5[R1_\M4/^\N:^A]:^/>AV_A:TU>WG$J7<0DBB3ER
M2,[<>HZ&OTC,\KE@*BC%W3_/L?$<+\20XBH2GR\LXO:]]'L_T?FBQ\:_BQJ7
M@VXTK2= 2W;5+[?(TMP"RQ1KU.!U)/%8_@;]IC3M5T^>#Q \.EZS:/Y<T6["
MR#J)$]C^E>#1?$*X^)WQ,GU)GB:UMK+RXDC;<4);)#>]<#X_T*_U?QA##I+K
M%>7D4EN'/<A3(!GU.PXKV:>44ZF7\[5IK6_SV^X^>?$F(I<5?V;*7[J3Y+=I
M<J=_6^A]PV_QT\-7$RQKJ=N6/0;JZ6P\?Z7?D".[B?/]U@:_/6/2O$.MZ'%J
M"[+?5E3[0]J4"M*(R04QW) YHO-:UC3-,CUZ&TEMHMR7%U%"[*8H_P"(#TKP
MI9>TKJ72^Q^NNEYGZ20:Q;SCY9%/XU:6=''#"OSYT[XTZ_H%[ITC:E=PZ=>2
MX\VX7>L,97*EC7?Z7^T_J]A>16]XEK.)9O(B,4NWS#V()XP>M<T\%5CLKD.G
M)'V4&![TM?/OA/\ :/CUC4$LYK&:&9G,87<"2PZXQ7MVAZU'K%LLL88 ]F&#
M7).G.'Q*QFTUN:E%%%9B"BBB@ HHHH **** "BBB@ HHHH **** "BBB@#X#
M\+6[:=X2TQ'D,LDK22O(W5SN(&?<  ?A7>:'JX@0<UP-CJUEIZ/H>IW"V-Q;
M2.;::7A)8V.0,]B,UH_;K6U7+:I9JOJ9AS7@SYN=M[GZ=1E"=*-GT/3X=;1P
M/FJP-15QP:\SL]2^TC-I=P7>.HAD#'\JMQ>(7A?#Y!'8U/-W+]FNAZ,DH?O3
M^M<=8^(U<@%JW;;54D4<@U5R7%HBUO2VG'F1_>':O,/%)E_MG1K>4-L:\3(/
MM7L2W"NO4&O//B3'&D^ERJ!O6\CQZ]:VC5<8N)DXZW/2/ ^T-=N0"W0'TKJ6
MDP*X[PFS))/CA>]=$]P<=:47H<M6-ZC8^XFP#63=W0!/-37-QA2<US>H7^UL
M9YJ6S:G CUN!KI?,3EE[5SS7DT>5)/%='97/FG!.:GN='@NAG;AO45M2JJ.D
MMBIT^J.-DNRV2359[@O743>%/,/#8%26WA2*,@N<UV>WI(RY)'/Z3I<M]<*2
M#M]:[221;*W5!P * D-A%A !BN6U_7 @8*U<%:LZCN=-.%@U?6PI(#5S-SJT
MDCD+DD]A56XN/-BEN;B9+:UB&Z2>5L*H]2:\X\1_%2ZU#3+F'P% MY=88)J$
MX^5B.NP=_K65.E.O+E@KLVJ5*="-YL]&U&Y33+5KK4[V#3;91N:2X<+@?3K7
M$:O\:?!NE:/-JD,]YK5K$VPR6<7R%O3)KS[1/#$GB?2K/3/&.IR2ZMK(D8M<
M/DH1SM'IBI](BTGP,="\*W%N-2M;B*83N1SO8G!Q[D5[M+*)-)U7;_,\:IFC
MVIHV?$?QE\0WWA,7OA#P]]B>90?/N#YDJ(3C<J^M-B^'Z^*;K0-0N]162;2;
MB-[V)VRTC,-V3Z'-,=M:T/Q)9O;V930[JR:%,\1X4\D>A'2H=$\.ZO?^,]3D
MT28:O)=QQNR6Q.Q/4.>@('%>O2PF&P:YI^CO^9Y=2O6Q3Y=SH;AO#_Q<\7Z#
MJ"%SJUGJ$T%RK'DQ1\@GU7TKVK1M0Q?F08 !PH'85Y+X.^%$_P //B6=1FDC
MBMM2CDCCMPV[R7*\+GZYKOX9'LIV5@5(/>OFLPQ"KUN:.Q]!@:'LJ34MSUJT
MU%7C4YYJS]K##K7FMOX@:,#DUI6_B0-U:O/YCI=([1I]W0TS.:P;77$<#YJT
MX;U).]%Q<MANJP&>U8#J.:YD:E);#RV' KL P<=<UF:AH<5V2R_*WM6]*HHZ
M/8RG#F.9GU0L.N*H2W6[O6X_A*5F^5N*5/"(CYEF45WJK26MS'E:.>AA>[D"
MJ#7<Z5I[:?I^_;A1U8U146.DK@'S'JE?^)I+F,1!]L2]%%<=:O[33H;PIRW-
M2:]WG&:GM4WX)KG+6ZWODFMA-4AMDY85QG0U8V)'2%>N.*R=0UN&)",@G/3-
M<_X@\4+$C%&[>M>9ZQXSD$\:H))#,_EQA!G<:I)RT0**6LCU&^\2Q8P"*Y2^
MU_\ M*]2RM_W]R_W(8^2??V'UKSAOBCI&C>)Q!JUQ(;&VB,LJ!=IE?L@[GFL
M?^WO%=U/JFIZ):3O/J0W6I:+8(X1_"!UZ5WTL)&24JLTD_O.6IB)1;5.-[=7
ML=I>V]I\0[Y/#EQ/#:Z?IEPMYJ<\LV 0!\B#'7)K!\)^%-%D\3ZG=W=O+#I]
MFSI':W0*+*,?*^W/*^G-<'<:;X]\3QW4=EX>:R2Z*FX>$>4&8<9R:T+SPWXN
MT.S@CODN;](TV3@/N)7T!';%>G2Q&#PW[M??8\^KA<3B'[1LZK3(M+\$BY\:
MFYD-NY>T^S1<QNI_C49XQ7->$(!<S3>+;YC<:E?EH[4-]V"'/ 4>I]:Q3I]C
M<:%<6=I?36<(!S:R$D1CN,&NHMBMGX>TPVKJT=O"NPCD<5Y&85:=62G3Z[GL
MY92G33C/6VQZTWA./PAH;ZC?31K?W-L'ACB8,Q+=,^E><6EOK>H-*ZHS(GS.
M2>@J?3]=FU.5()&,DI ;YFX /\A3=0\51Z46C)&X=U.0:\J33VV/5IPE&]W=
MLQ=;%S:1DEB&KC3?7JSF7<QQS5[7O%YNY&YRIJ'3M1AN8=A /O6#9W*-D>NZ
M3XLTO7=(L(HFF66.("56 P&[XJ6:%CL6V8E02S,1CFO,M$E.FWK2+PAKTWPK
MJ4>K_N"I=B.B\UTTJKA*YR5**Y;(CDU1@VS.[ QFF-J+,/O?A6O>^#[EX99K
M:!YE3DE>PKEITG0[3'M /IS7NTU3J*\6>8[IV9;FNF(SDX/0U!:RM)<H%ZDU
M+!9O=P(F""&R?>NJT[PTDKV\Y0QE1\P-34J0I*S+C"4WH;$=Q]CLX%<]1UKE
M?$TS3-NAY(]*Z3Q"4^Q[0P!'2L;3[F""6-RZM(A# -R,BOF*M-3W/1Y="OHV
MOQ+;>7.QC;'.:JQ>([FUO72/S+JW/]WG%;>NRZ5JK27#PQQW$I)D*G )SV':
MF>#O$5II,T]K''!Y4PV.64,V/8GI7S6+R2AB?B1YU;"QJQUAJ68=?L-0,<5Y
M"MO %VNJ*,M]:JZYXLF\*VK7%C ]UIR<X4 LB_A5O6M+M=7>'[(J)<,P !.%
M8]LUR>M_VGX/TP7%Y;E8KABL,F04(!P1CTKQH<+T(RORZ'F/)\-?:S9WGA/X
MFPZW;I+%("#U&>E>EZ-K8N$5L^]?)6H:]::)<66HV?[B*Y.V2-1@*_>O4?#?
MQ)M+>SC:>X1?ER-S=J^ZR[+*5"*Y(GAXK!?5Y.*/I/3]4&!\U+XKU6VO/"^J
M64LJ*+BUDB&YN,E3C]:^>+WXZ000R_85:Y,2Y=EX1!ZD]JYWQ'X@USQ \0>[
M@U&"X@,D%M82Y!<]%9A_*ON<)@ZLVN56/%G34KIESP3XB5((G5A)"R[6 YY'
M!K \4^&;K2=;-UIL%Q=Z1=EBZVK9D@+#!V@G&*XKPK=:[X.\/ZCK6H6[?88;
MSR)+9H]LB,<?=7N,YKT_2_B!*=#L=4;29H=,O)/*@NF0A'?T!-?K?M\-CJ<>
M=^\[:;._D?RK'*<]X-S*I7PD&Z<6VG9N+B];2MT[WLTU<9\'_"4GA#3;TRAC
M<74A;+C! SP#[XQ7-_%J_G.J:;;:69&U&.Z2:,P, X*Y^;Z!BN?J:]$U3Q&U
ME8QI'&9;VXPL4*#YB3T%<OK'PFAN-4CMM1)N==<K-J$Z.0MJG5;92.YZL:RQ
M4E3@L+36LE9+LNK?I^9CD=ZV-GGF/E[E*7/)]YMW48^;?W(L_&[5+31[GP?_
M &#J#:MXALH@^H+I:-,J2N!N&Y<KP<@C-0?$#QS'IFMZ))I-O?W.F/;^5J*3
M6$B1.7QN#97H.N?:NJN+RQ\%:>D5LB0!1@8&,5RK>-M5\271M-*@N=3G8[1'
M A?FL891!0YZE1I=VTE^7ZGU$O$O,:U?V6#PJD^R4F_O37Y%OQW)IFEZW!X;
MNOLU[X:UO38@MS:L&,<I;Y&1AV!P#]:J>-/!^DI=Q>%KQVL-9>T66QN'7Y8W
M7C!]V -;NA_LX>+X-2T_Q-JFFI-Y5REV-&>3:5*<CGH-QZCV%6?'^@^(_%_Q
M/T_Q!XJT.>QT^*5"5TU?-;RU.=C?CWKY:K6IQJ2A&:DN^U_ZZ'[O@,54Q.%I
MUJ\.2<DFXOH^URKX=\)01:K%9PWIM_$5K EQ;H[$"0=&Y]>]?9OP]A>+2XEE
M8M*5!.3U/<U\L72#QM\8=/U6#2[G1M.C>./S)T*[XU/4>A[8KZ\T!(7)DMU9
M8< +D8R/6O*QE13U.FH[F[1117E& 4444 %%%% !1110 4444 %%%% !1110
M 4444 ?GEXNUCPWXC60-<1.RG!#CD5YAJ_A?0[@%8I$+YR-S' KVJW:SB\#/
MI2:5:6$#XW3S1+]HE)Y^3/( )!JW?^'M(L_"]K;:8D6MZJJ@2/=0*(0>Z ]6
M(K>K@9Q?-#7^N_J?1TG%:.31\]:?X DTF0WFF:A-;7.=PD@E(YKMM#^*DUBR
M6'BV+<OW4U2%>1_OC^M==XX^&>GV>G6ITZZ2WUR0!I8K G[.N3C:"W5O85C^
M,_AU::1X8M;?3W/BG5Y91%?7[R+%!9D_PA/XCZFN7^SZM6]U9K<ZH8J6':<9
M73.H294MTNK6ZBNK1QN6:)PP(JYI_B4&.26-C-%",R/&,A![FN(N3X<T_P '
MW?AKP9J-MI6J6TB2:C/<JTIN3_$J?W5'M3K_ .*5A;:9>>$Y;&72].L(4F^W
M1E46[D/WBXZM["M%D\E\4_\ )_/I]QVO-.:UH'IMIXR\W0Y]6CAF?3X3M,[+
MM5F]%SU/TK%O;RX\3:MHTDD1M[4$W6QS\S*O0X^M<7<?%+2M0M8]$CU'39K)
M(4-K!YVQ;<^N>['G-6O#NOH/&ZP2ZO:74=Y!Y-NL4JG# 9VC!K#%87#T(-PG
M=^NO_#>9I0KU:TES*R/>_#%RALF(/S,W-:TEP%&2:\WTS6FL#M)P0<$&K5]X
MQ C/S &O'4M#O=)N5SH-9UM+9&&X9KB;SQ ))3\W>L75]9DN8GN)IX[6U7[T
MTSA5_.N0;QWX6BE(?67F/3,,#LOYXK-MO8Z(QC!:L]4T_7E0@EJZ6SUR-U'S
M"O&K'Q/H%\ ;;7(E)Z+<*8_YUOVDMT5#V\D=TG]Z"0,/TIW:!J,MF>JC4XR/
MO"H9M61!]X5YT=:NHAAT<?45%)K,\O #9I\PO9G3ZSX@ 5@K5Q>M:O::7I\V
MJZM/]FL(N23]Z0_W5'<U6\2:_8^$M*DU77;@06Z#*09_>3-V517@VJ3>(_BI
MXM6^G=CIB1XL]/M5)2,'H&[;O4UTT*#K2U=H]6<]>O'#QLM66_$_Q.3Q]XF3
M0]1C>RT*6$F*UC/WF/W?,QU)J)=,UKP[K'AF72X1I^A1(Z-<.P$?'W@PKU+P
M[\$[K4(M-GN+"UT^ZM4*FY0%Y)">YSQD5UD'P@L=,7]Z6NNN5N#N!SUXKWUB
M\-A(<E-7?EH>%[&MBI<TW8\@NM'TSQ@=,O;>6\N-2M+ALI"N(VC!R,-[FNWL
M/ >I:F+1Y;>TM'MG=XY@FZ7#=B3Z5OR> -,L9/,TRYDT:?KB/YHB?]T]*IMK
M7BE-3AT;3H;76+N8[1);M@1#^^X/05Q5,UK3;Y?=OV.N.7PA\6I5F^'ZWEU:
MZ';337MTV3B1R4@4_>8CM7N_@'X>V7AW3X=*TJ%(5ZRS[<%V[EC57P1X*7P[
M:F,R?:]2G^:YNR/O-Z#T45Z/;RK96 MHU R<L_<UYSG*J[S=S:2C0C:FM6>?
M^.?AY!J=M)"SDRH<K(AY5AT(KRW4;7Q;I3&+;:ZBJ\+),F'_ !Q7T/.5D&#S
M61=:5#,22HJ6HD1G46MSYRN=9\9VIWMIMB\8ZH%-2:;X[M+R=;74[=]$O&X5
MW.86/U[5[U/X>MV4@HO-<5XN^'%GJEO(IA4Y[8K-Q70ZX59]3FVNKBP<;\E3
MR&!R"/8UJV'B,@C+5YW)%KG@!VBCC.K:3GFTF/S(/]ANWTK4TKQ%HGB#BSO!
M9771K2]/EN#Z G@_A65FCM4HRW/4K/7E?&6K3CU:-AU%>9-]ML&'F1L!V/:C
M^WY8QCD&CF!T[['I<^LQHI^8?G7/:IXC4 A6KC9=<GFX7<:K7]S%IE@^H:Q>
M1:78)RTUPVT'V'J:+M[!R*.K-6ZUEI6.&JF=0*MSDUY#KO[3GAS2KN6UT?1[
MK5FB.&N9P4C^H YQ6,W[17BG4KV"'2?#]A+Y\@CC50S%L^F:Z5AJKU:L<\L7
M1B[7/=IO$GV1<G( KE=0^)44\NR*7?M!8A>P]36(?%&LZI]J@NYK"X^S;8IH
M[)1S,QP(RW;!Z_2NF\!?#^S\)QK+-(MYJ$I+3LR?*">JK[45*/L+>T'2JK$7
M]FMNIAS^++3Q%X:F>.Z,^HRL1%:VS998QU8^Y-;/A'3;E?$1U75(EL=.L88X
M+.W)SG RSX]22>:[J'X?6%M)]HTNSMK*6XRSLJA1Q5 ^#?-NQ+J=^/LR](8S
M\S43KMPY(121I"C!2YYR;92N+S3=:U&X2P\-6=Z\IW&XEA#,#Z@]JU;'PUJE
MJ$F:3R'484*<;1Z5LZ9?V&EC[/:1+$!W Y-79]1CNP$8X%<N^[-KN.D8V1D)
MX6O+^',EZVT=@>*J:IX:O+.#?:R[Y%Y'O796Z(;1HXSC(X-4=)>;SVMKD$KG
MAO:BR%[2HMCQCQ)X8T;Q,)X-?L)+&_DC\N._M?W;+[D=&KQUM U?X37[:?>W
MO]J^'+C/V:[;H#_=/H?:ON+Q;HUC?:)%I\L=O<Q8Q]K0?O8E)YP.YKY9^(7A
MWS7U+PO<S,;*X;_1KB4;<$'Y7]J)+ET>J'1FJK<DN5_@SF=/T=-3@GN[*^*@
M$!XR2O']:R+[4D:^33K.WDU.\;.1#RD?^\:T=!\;P>%+:32=5T]UN+5A;NQC
M+++Z,I]_6O3M,O/#UI8)>0VL-L-H+,%P?QI>SB^I;Q52/V3Q%(K^&]N+#5M,
M\J55\Q'A.05/UZD59M-)F@VW5F1<0?G^!KZ8\1^#-(\7>$HY(1%#=[<I*A')
M^M> ZEX)E\*RW5R6NDMT)8S6S9V^[)W_  J9TXK9DT<=>ZD5K'S[J98F(5B<
M $X%=5X9O+WPSK*,SO;YRI9>3@C!K.L]/CUORS;RQ2AHPRW$)ZMZ,O5322W6
MK:;<?9Y8@X!'SORPQZ&N9M1>K/452-17B[GN6B^* MH\JN!L3#*QP6!]J2"Z
MT#4C(TLGERD?)&!U/IFO,]*UD2'S)&PX.3NJ/Q!?1&!IXI%$@Y^4U:J6V)=-
M2/:K3PY!;Z;'J$C0VUN_(,C#)^@KGM;^(5EINZ&W*E%/WB.37B\GCF]F@6(S
M2.$&T L2 *Q;J[O+]B02<]S3E.^PXT6OB9Z!XM^)4%X)4C(5AR'08#>V.U>=
M'QG=PWQD5VVGM5^V\-/)HU_JEU(JVMDH>7YLN<] H[FHKW38+K3H)=%T;5-0
MN7Y*RQ>4JC'<FDHRGJ-U:5+W6[DA\77-TA)8@?6J5OXHN+*Z#AR1GGFKMQJ$
M.@Z;"VHZ/96]SMPUL;DR2Y^B]/QK&M/&'A_5-5@M+O3[C25G<1),<,FX],^@
MJG2D9K%4V[,](TGQT;F %WQ@=<U/XE\<%+"/3&47MNXSA^< C^'TKE=8L]!\
M.ZI-IEWK<$31J&+QY8'/;BL36]8CL=>^PZ,KZS+&ZHEPJ%H<=<Y]JJ-.;T2)
MG5H[ME/XC:T=*T?2[06;726T_P!KO$ .5B/ !-=.WAR\/A"^O?#VE-=7!B6[
MA2;+O'%P6P#UP.U<)#=>(="\?+<7]G-J]GJ($5TQMSY:@GMQP!7HOQ$^)VI^
M!/%'A.+PFZ3PE?)N(0ORS%R%"'TXSS7V&6JC1IVF]?Q/BLQG.O4<DM#J-!TN
MW\>^']-?Q+-#H:ZS"$*0CR1O ^7CUX&:-2TJY^ _PVM[J&6.ZOQ?[89Y%^1N
M<_R%2?M.:7I-]'X8T32]<LX]8M%%S=0&0*J;\=^Q'-7?'_CMO'=GH/A?PU96
M]]H&DVZ1RWMXI_TB< ;G [C/K7O3KQA9O331_P# /"LWL;GQ9O+&]^"_ALZI
M(=.\2^)'744MT7+1*H."1Z'(K$2_;Q'8>'["97MO#/A*WV(K':;JZ/+.P]>>
MG:K=Y'=+()+VZ_M/Q#<0?\?,JY2RMD'+A>RJ.%7N<>]5M#U71+^XTZ.X=(/#
MEK'YP17WO=R9XC/^VQZY_#->AERYXO'UHWC#;O)_Y?UT/RKC#,YU7'(L')*K
M5TE)NRA%[W\VNF]O5';>%K9]#MD\47<23:S?Y31[63I"G\5PP] .E6=&6)4E
M"2&5RQ>29SEY7)RS'ZFL+5+_ %;Q+KD5E:0(^OZGB)(5/R6D(Z)GLJCDX')K
MH_'GPW/PGLO#VI6][<7WGRFWU"20_)O(RI4?PC@C\17LTZL*%:*Q3_?U>G\J
MZ+^MWJ?E&+P>(S+!3>5QM@L+>S>]27VI>??LEHC,\!?#M/C'\4;K3-5O3::7
MI\0F>!'VR3Y. J^W!R:^R?"/@70/!%@MIHFF06,0')C0;F]R>IKXK-I9W&KQ
MWL=Y<:=>*=T5Y:/M=#ZYKU#PY\:?'OAM4CF?3O%UFO\ %*_V>YQ_O#@GZC\:
MX<[R_&8JHITY7C96CM;]'^9[/!G$N3Y?AOJ]>')4N[SMS7UTO:\E]UO,^HFM
MHY,[E!S5:;0[6<?-$I_"N!^&7QRTWXB:K/H[Z?=:+K,,7G&UNBK+(F<$HZG!
MP>H.#STKTY37P=6E4H3=.HK-=#]TPV*H8RDJ^'FI1>S6J,J/PS9(X;R$)'3*
MBM6*%85"J  .PIU+6)U!1110 4444 %%%% !1110 4444 %%%% !1110 444
M4 ?.?B3P/H7BB;SK^S4S_P#/6,[37+7GPBBFEC\C5YX+>-MRP*.!]/?WKLKC
M4XXCRXJHVO0@_>KAIXJO3^"3/N70IRW1R=Q\(_M1CBDU>2*SC<.L$2XY]2?4
M^M17WP:TD R1332$<B(MA1WXKM8M5BF^ZXJ4R;QUIRQN(DDG-Z%QP].+ND>'
M^./A3IGB)7WA]+U'&!=P# ;T#@=17A'C#X>:[X89O[2L7O+3.%O+?,B$>_<5
M]I:G9"X0\ GWKE+NVE@W!%PIZJ1D'\*XW5G>[=_4ZG0IU%M9^1\/3:%I]WNV
M"/.>1C!K$D\,W<.K6K:*LS:I'()(!;DEE8'@U]FZY\./#/B(LU]HT22GK+;?
MNV_2LK0O@WI7AF:>?1[ZXMIIOO/, Y ] ?2FZJ:V,5A)1EI+0P- ^)-\-+MX
MO&>F2V.J!0'N;0;TD]V'8U/<>.M,=L6%M>:M.?NH$V+GW-=6O@.XRQ?54E)'
M5H,FFP^ Q9G<FJ.KY_AB&*QM'J=O-56B1RUC\.M<^(5\EUK/RPKQ%9J<11#Z
M=S[UZ;HWP/TNPA4R0I(X'W0HQ573]6U;PX=VY-4ME^\$&V0#UQWKT+P]XML]
M<M5EMY P/!'<'T-:IQZ''.-5OWSC=2^$FGW*$-:1$>FP5R6H?!F&U8R6;36;
MCD&&0K7O/FJXJEJ6Q+9VVCI3O<4:?+L?.MYI_BS1&\NUUJ6<#^"X0/5-Y_B!
M<J46_AMP>-\< #?A7N%OID$^Z:10W/%)-8P#HH%:*G%;H3J3V3/ +;X176L:
MBM_K=S-JET#D/<MNQ]!T%>L>%-%L_#Z*GV=$ [A<5N2B.$< "N4\0:O<37<.
MF::@FU&X.$7L@[LWH!6W+%K4<8MN_4[?5/%^G:1$B*?-G?A((AN=C]*RYH/%
M6OH6BL[?386Y4W+?-^0K8\#>!(=&BWJ#?ZDPS->2#)SZ+Z"O0'T*!(HR9RTA
M&6 [5Q6;V-Y3C!V>YXN?A9K.IR8U'74A@/WEM8_F/XUW7A'P18>&K8VVDVFP
MOS+._,DA]6:NN73[6#D@N?>I#=B-=J (/:FH]R'6;TB@MK1+&+&0TA^\:;+.
M$&2:AENP%))Z5A3WLE]*4C.%%:)7T1SN^\C3GU6*,XSGZ52DUV(=0:A-M'$O
MS'<U95_)&H.!6JIKJ2I7V-J/58;@X5AFEEQ(.G%<#/J!AN%6-LR$\(O+'\*U
M?#?C"'6_MD%NCS2V2EKAR,)&!UR:3P]1J\%<Z%4A#XW8LZQX>AOT8%!D^U>3
M^+/AE:W1D\RW61&R#Q@_GVKU'3/%TFKZ?J-W]B^PV]FVS?<OCS&[!1[UC3:W
M>WGA:;5I[2"VD\PQ06A?+S'U]A1]3KM7Y?Q7WC^M44[7\CY_?3_%?PYN-MGK
M5Y)HKG]TTI\U8O\ 9<'G\:NW/Q!\8VT(FCM]+U2(<G$6&(_.O6=66[L/"MGJ
ML]M;-/?#*:8&WNR=V;T'-<_XJ\ 6VFW&F0G3#%?ZB%;[-83\Q;NF[L":M82L
MGK#\49O$0WA4/)(?C-XRO[BY$5OIMA;HVU7CAS(OU':L?6]*F^*5MK276HSZ
MCJ>CJMPL<S?+)ZJHZ5VWBGX%R:?XV33;35Q#=W6TW4K-N2W Y(;'4@4_6M1T
M[P+\3([Z%+>73(X,0O)C?>2J,;\#L3VKVJ%.C"GS2IV[]?\ AOF>=5G5JRY5
M.YL>#](M=)\':=X=;3;>PU.\M_,OM0NH@3%'UQC'WL5PWB&.R\'7ES-H2Q0S
MR*5L\,&4 \;O]XU+K'BKQ#KS7NK?V%<MIUT"MQ*).23UX["N0DT#4].U'2KV
MX>*73F3>L*'.P _Q#U%9XC&4H4_==W8VPV"E*I9['HF@:7_8&F1WD[F2Z+><
MR* J[R.I'<C)YKT7X;1K=R7%UK$LC6^PF%(^I;MGVKS33?$T6O,UK'&653R<
M5U*:R=(58(V(3'3TKY%U)3ES2=S[14(QAR15CT^_\0Q10LJN'(4*N.,5CV5O
M)J5P)F8@>E<I80W>I7*2;R(\Y/O7:I=KI4&2A( ZT)N1#@HHO26UO9J9'P&K
M-?5E#_NUS6)<>(/[0FVN2 3^0K1L5MX\,T@:NV-&RO(XIS['0?VRUG%&5PVX
M<CTJS;:_&[;FPIK(:YC)Y4%3TJ"YB212T;;3Z4>S1CSN^IU-]K45O;"5B&C_
M (AGJ*\B^*-G#KH5H8]TCKE1W4=>#7?Z7>H^AS174 9/-&R8_JIK+NSI]U<+
M&B@N@P*YJGNZ,WIZOF70\H\/^&;J?$5P!<JI 5I%_G]*[;2]"O9+@:=!IZ77
MGH=T(4$,HY.:G?4HM"UZ&  %).37J6AP65Y&D\0"2X^\AP:^>Q>.IX:-Y2L9
M8C$NE&[2/&;+2)[V\2#2;DZ<K2D-"Q/E(?8=JO6&D3ZB-2TW5 5N5+1," !@
MC&1ZCO7H_BHZ'X>MOM-V5AE  B6,?,WM@?4<FO/M5^(EI-%]I&FSJ8SCSB.2
MBG!!_I7RD<US#&QE/ T)5(KJEI]Y\7C>(L#AIJ,YJ+?2YYKH/P#O#-<K'J!M
MIU<J<9!([?I6C%\._%^F6@MY($U=(252??ABO8'U-=S)\1;J&]M[E--41#!=
M@>9%ST]B!S77Z=\5-!NR8Y+6YMH]I96,><X.#TZ?UK>K//L.HSQ&#G9ZZ*_6
MVMKGE83C++I3<:59??\ /J?/]_;36#-'?6<]@QXW.N!^=0:+HEMJ&KV]M/>J
MD<K8 +?>]A7TGK&D:?XZT0M;%;BQER"^WG/X]*\IO?@S;Z?<0SV$TL%W;@B)
MV&X ],UZ>79I2Q<N5Z-:-=5\C] PN:>VI\T'<X3QQJ&BZ5?FTT:U:_N(<*\:
M<<^F:Y/6'UK7)8+'2[)].:0_O)'P2@KTS2? [>#M4']KPB0SN2NH8RLA/KZ&
MN^M_"UE)*+A(UW$<L*^Q2IRUB=4,35DK2/$],^'OB&RA$3:B\T+LKD,@)!%=
M8_A[7[R 17.L79BQC8A"C'X"O1+K4[.Q;[/%&UU<#CRX5W'\:SY[G6KA@MOH
MK1ANAG8+6]]+&#5VW<\VNO UMIT3R,@R.2[\D_B:P[/X?IXC;SYV\G35/! P
MTA]O;WKUN[\!ZAJH$FL744%L#DVUN<EO8FG>%=.L]>\0WEE/!C3K%1$ IPO(
M_I0WH.$=;V,71_ N@Z3IMS>30VQ0IGS+C#N2![_TIEC;?9;4/IFGOOV!Y L)
M!Y]@*Z*7PGX1TV]=(H+W5-560O&[3$Q)Q@ +74Z=I.KHAG+FV+KM.../2I4^
MVIHZ4FFV['C=QX3\=>*[R)Y1#HVE[L[YGVLP_P!WK5B\^'WB#S@\4EE?HO(@
MGP#^#5[?!X/6[037-RSD>]1ZKX,AO( ()2I'1A4WE>Z-/W5N5GRQXJ\'6>@7
M,VI7>G7NF7<; S&=&F@E/H'YQ70^&?',=L8(([)UN)<+;P(/]:QZ &O:M5\-
M>(O#&@RWTNR\T7:9)1)AD ']X&O.K$:9X.L+OQI=68M&E0G3[!>?+!'+JO9F
M["OH,HP57,<1R2TBM9/LOZ_S/SSC#.\-P_@'6IVG5F^6$5O*3\O+K\EU#6M>
MD\,7]WHMS<11ZMJ-L)9KHC<K-SB+U"+T^N36%;^'4L$;4--N?L-A&RQFTF??
M([XR74CH"3P*B\/>'+#XH,FMWEU.(E_?7\H;"J1RD$?OW8U+IEW#I>L6UWY;
M_P!A0N3;3RG<)I <9)]!VK]-_M+#X7"?7(IQA&\8*^D]M;?+[M>I_-L.'L?F
M.9O)W.,ZU11G7ERW=)W;<5+:^MK+KILF?3GP3\)_V!:OJ]_A]8OE&]CR8H^R
M _J?>O5-=T33_&OAV\T;4AOMKE,$J<,C#E64]B" :\?\)^,;:?2XY%E R,]:
M[30/$7VYLF3D>AK\SJXR=>JZ]27O-WN?T'1RO#X'#1P-&%J<5RV\O/O?KW/*
MM<_9Y\>:5<-'H[VNLV8)\N3S1&^WME3W^AIFE? #XI:HXC>UM=/C)P9)KH<>
M^!FOI[1+YD"B3.#T-=7;7*D#DU]%#BC&Q@H<Z];*Y^<UO#W()UG5=)Z]%)V_
MS_$\V^"'P"B^&%W/K&HZB=6UV>+R?,48CA0D$JH/)S@<GTKV5>E4XYU]:LI(
M#7@UL7+%5'5JSO)GVN#P6'R^A'#86"C".R1.#2U&KBG@YK*Z9V"T444P"BBB
M@ HHHH **** "BBB@ HHHH **** "BBB@#Y=%H-NZ5LL>U5[A(0.!1<7OO69
M<7F>_-<%C[Y)C9W,)W(V*U-$ULSMY4C<]C7.7$^0>:CTV9A?Q[?6M)4E.+9H
MG9GHC,"M9MW"C YJVTNV$$GM6)?7OS$ UYC.R*&-9HS=*U-.\*/?*S+A549.
M:K:-:27DH8C"#N:[.%?+A$:<+W]ZJ,;ZLRJU''2.Y@-H-G@*(R,=_6D_L>Q$
M+(T!9O[_ 'K;E14%49IXX^213M8SBV^IP6MZ(;9F>+*D<@BN+FO)]$O'U2Q!
M#Q\W=LO21.[@>HKU/6+N*2)\XZ5Y7JMU]EU5)$QPW(]1W%8MV.^*YU9GJ7A[
MQ%%J]I%-$X='4,I!K5OA]HM'4=<5XSX(U(Z-K>IZ4K8A@FW1#/1&&X#\,UZS
M97ZR*,G.:M,YW$P?M[VC-&PXS4,NI;LXK<U32$O07CX:N;N=%NH21M)%>E3G
M">[LSE<&F9FN:TFGV<L\C8"*3BCP!I;VX^W7(SJ>H8=B?^64?\*#^=8'B*SE
MO-8TO3Y01'+,&D'JJ\FNHTV^(OV<'&#@>PK#$22:C$Z*4;IL]:TV7[%;A(CC
M(^8^M6OM/'6N8L=61HER>:NB_5AUK#F,72UN:4MS55K@YZU6,X?H:3.:ELTC
M!(CU:Z,=HQ!ZUGV%T([?<#R>M7;V#[1;LGJ*Y&>6>P=D.0*Z:.NAE5@;]SJ&
M3A?F;TKDK77&U*YO6OREI:1GRK:'=A[F0]/FZ!?>J.M^*8]-MG>5OO?+L[O[
M8K 7P7XC\56C.;2+3;=FS$]RY#*IZX0>OO7J470I>]6..I3J2TIB:3XF'A-]
M3E%N]U>7,A@FG5][01GJJ-V)[59\-G5)+6[73K2;[,)MY@D'S7/'RACW [TV
M'X9>(=,4BWN]/G'4J0PR:W;#6M:\-V^R_P!)D*+UEM3O'Y"MZN:0BK4(_-[D
M0P#;O4?W%"'P[XH6-Y&BC1R[;("V44'J3GKZ 4U/"WB*&S*#RIYY$,3(S?NX
MT]O>MFR^(=AJ,GE^=Y<G>.3Y6'X&NITZY2<!@P(-<+S;$=+?U\SJ^H4EO<\]
MD\+>*5MTC6".X=@C,SMQ&5Z*G]3WI^I:1XD@DB*VZO)&WF->R-@Y/8#T%>IO
M.D:#G'%<UX@UI(K=PQ!XI_VMB.J7]?/[NPE@*3[GC/B&>\M[P/=R(.L1VG][
M<9[9]37%6WA/2!XC:YU"7^T=41#L$DF8+8==J#N1TSZUJ^)]46[\=6L<I(A\
MF9H^?XPO']:A^'L&D+K4=WJL@N) Y9+,\JP']X]J\W$XNK7M&;/8PN&I4HRF
MEJ3137NIJ(+,[8V.SR4!''KZ5?\ ^%(:IK=O,5OHK5TB+E)) N[_ &1[UU']
MN:>CE[>P@T_#LV(\YP3P.?2LOQ!X]B2V,/FY7.<>]>9HM]3UO>DO=T.4\-6W
M_".![<6;&8?Q!<YK0FTZ_P!1DCNWMI$M2V!(5^4GTS6CH/BBTD56D(8^AKIK
MSQ3%?6RQ/(L=LIW+"@"H#CJ!ZTM+%>]?871+B.UM44_>Z8I/%]S(EK&5)"D=
MJJ:8L<VH(RN"GUK;\1Z8=1L5$>,BMJ+2FF]C*JFXM(X"WNB&SGFM:VU$J/:J
M&I:3]@EC1/G(QOJK-<"*8J#P#7O.*J*\3S-M&=2NLAPHR !Q5AM8$<6\MQTZ
MUR/FD_=.X>HJ[96[W8:-U..H/I64J:@KL%9NQI76JRR+#"CD1X+D9X)-0@36
M!CNI0RQN<!ST-1O-%8(!-&&9!C=NQQ6#XF\;0:MI]IIMC;O'+&Q,DN[(([5\
M]C:JLY'9&#A!*QV=M;6^M7 D&&E QFK=_P")Y_#V_3+))%O'^43X#+'E<[MN
M0?Z5A> H9XU9BP7"DY;H..]+I4=SX@U,W,K%IFF$&^7'('3:,<+S7Q&39?#B
M7.94,1K2IJ\E=J^NBV=UT:NM-C\:X\SVKE>&Y,._?EHM+_UY;ZFCI'AZ]UR[
MDN9'-W,8RKR32%CEB, ?CC\JZR_\!)I$1MIOFGQN><YV*?3%=;H.FZ?X1T\R
MQ6\$MQ'D&=QN/U&>GX5Q7C'Q_)>W$GDHQ/?LI'MZU_15*G2PT%2PT%""V222
M^21_/4L+SP]KBY.=5[W=_P ?Z\B@WARP6W037;)-R7WIE3Z8':N8UJPMH)3'
M9NTJ8+$L,$_7TYJ:Z\1W>0TL<<CXW!5/05CWVK0W@<C<D@!:1<]#Q^E:<[ON
M>95P].*TC;S+G@[QQ<>$]1"J'DLW<M/;!\K@_P 0[ ]Z]JN9K6YTA-3:$I;.
MNY2#DD'T%?*&KWJAM[[2NX\%J]%^"?CB>X9]%N)$D23)A4MRF.JCV-?BW%V1
MQP]3^V<&N5K^(MKZ_%Z]^_Y_J/!^?5\-..#K2NOLO?Y?Y'J-\FG7^F$3@2:?
M.-I$RE0?H3WKS6^35-#UVV\/V4C7-I?$_9[K.3$@^\&^@[UW_B_5QJ4-O8ZH
M\CV\;8-N@(15'/R^_&/QKBO$&I"3Q5I\VD0VV@6"6^%D8F0L,_-OSTZ=*]?*
MJ/UJC&I3E>_]?\#8_?Z&/YTN=?<=GI^GG2K%HM,MP%09>4_><]R37 6^O:OX
MIU(Q6KK R2&.2:4$HC X_&M:X^*D)TG4-(MSOF:(^5?1+PS$XQCM3="N;/2X
M;72;4!IAS@#+NYZY/?FNVK%TM'N>S0;KMM?"B"#1?%#3O_;UQ MH@_=_82?W
MA]R>E6T@O;R8:?IEK]G21LR2XVCW)->A6I$%G%'<(HG1LLD@^Z1V-<_J6MSS
M3M%;;45C\VP8S7,_-G?&Z^%%OP]H^G>&^K+/>-]Z4\\^U:UUJ,5RH0M@>U8D
M.F^85FD8@@<\U7N[^*!RJ'<15*[T1$HK>3.OM?*:V,:G (JE86]Q8WA7<)("
M<C-8]OJDBV?F(</G[M8WB;Q;?6=G!!#(EK/>S+;+<R_=AW9RY]P!P/7%=5&A
M4KU(TH+5NR^9YV-Q=# 8:IBZ[M""<GZ)79I?$#Q/9^(I&TZ$?9]$TT[M0=7.
MV>7J(AV]"WY5XUXFT_6?&>NZ9-"RV_VAB;2"5?ECA'69AZ =*Z+4)K34GDTR
MU8KH>DC=,<_-<RDYVY[LQY/UI=3O+[2[<VT02?Q-J8"E5^[;QC[J>RJ.OJ:_
M4:>$I4:3R^,K4X:U9=_[O^?EIN?RK6S7%XO%1X@J4^;$UFX82EORIZ>U:_\
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M,BK@XR<USU8QK4I4ZBYHO=/6Z/.<'2J*=+W9+:Q]9_!3XOP^);&.TO)5348
M$?Y@=_\ M5[[IEZ)D4@Y!K\N_"7C.;P[XDM+RUE">2V2J*3NYY!'O7Z(_#SQ
M'%KVCVEW X>.9 P*],]Q7X%BL%+AG,U2IN]"I=Q\N\?\O+T/W+(,T>84+5/C
MCOY^9Z7"V<5/5*T?=MJ[7Z=A9^TIJ1]4%%%%=@!1110 4444 %%%% !1110
M4444 %%%% 'RA#JP YYITNMIC&P?G7(Q7X(ZTLE\,=:^?N?J?(=%JOBGS$58
M(E@ &"1U-<G>ZFSL3N.?K4%Q=F5MJY)]JH:WJ.F>%M.?4=?U"'3+-!DF5OF/
MT%*[92C&"'373L>YJ.>ZFGMC!(CR19&T=E]:XRX^-5GJ/ARYU'P?HSZPR%DB
M>Y^42,/05SW@KXG>.?&_A?4-0GC@TJ[$CPVUNL( W#IG/O7HT,+B6TXQ.&MC
M,.ERMGJ>J>*8/$4>G6NK%K;3[!B&LH$VC:O0@CJ3T)-7FMDUOQ/<O'=Q>'-
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M_:P7(G)QAS67/;K%;M'>T445Y1],%%%% !1110 4444 %%%% 'YOS^*]$N_
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M:L\3@:KA/NM#R\9A*.+CR5HIKS/@WQM\$_$?AB>>$6+W-O"<^?$A*,".#_\
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MADG98XP.6<X KY;,\VI8"+<F<%?$PHJ[9@VNCR2."%.,]<5W]KHS2Z9&N"&
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MTO?#C6NH7B/?F/S[ER2J '[L28Z'^=8L'C)1X>CLT@>+2HP%C$0_>3S=R3W
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MC)QUX[U^+Y]@GD>-CFF%TIU':4>BE_-\]GMKZGZ[PKFU2I'ZI7=VEH^Z_P"
M<SJO@?48?$'B*V5C/I%S#&B2/\Q;)5EV?W2I&<BL_P /^(_$VEZKK&CRZD([
MNQ($-I<Q>8''&=S#E<Y!'6NX^,VKZ=)9Z+H/A"2ZG>WF199$4^9-*!^Z'J02
M.:T?'UA;?#W4K:_UZS2'6M9,<ES'&P!55 W%CZ*#BOUK)\QE*CS4Y6Z^MS[3
M,,HR_-8I8VDI6V;W5^S6J^\R;C6[]--:XUG0O+AC(#:A8G?"I/3=@?+^(%7+
M&[FT;5-"\3Z:ADET^Z28JAP73.'7\5+"DU_XM:5I6B:UX?\ "X&K2ZIF'S0/
MW,",/FSG[S>G:K/A2PDTOP[;P2G+A.<]J_0<+.MBL-)8F%D]%YI[Z'\T<18'
M+\BS:G/*:O-*.K6_*TTUKU]'=^9J?%+XIZA\8=63S89=+\+V!\Q+1AEYG[,^
M.I[!13/%=A!X3\*1Z-+;1S^+=>1&>)P"=-M<Y51Z.>I-7?#IL?#^E3^,M50O
MIEA*8],M7X_M*]Z!L=2B'\"03VKF_#&GZAX]\:6T%_<G^VO$$Y:>YZ>3%U?;
MZ?+P*X8PHI.G3TH4=7_>DNGG;K]QZ<J^-;CBL2^;'8OW8+I3IO2]NE^GS9W_
M .SK\';;Q#KCZ]=1B;1+&4%&=>+ZZ3C=Z%$.<>K?2OK2L_0-'LO#VCVFFZ=&
MD-G:QB*-$Z  5H5\%CL9/'5G5G\EV1^Z9-E5+)\''"TM7NWW?5_UT/F;XDP1
MW7[97@*&9%DBDTBX1T89#*<@@U\[?%O3[WX7^,-/^&=R';3;?Q3;ZSH\C=#;
M2DAE'^ZV/Q+5^AUSX7T:\UNWUF?2;*;5[9#'#?R6Z-/$IZJKD;@/8&H-<\$>
M'?$U]97NL:#INJWEDP:UN+VTCFD@.0<HS E3D \>E90KJ-KKH=E3#.=VGJW^
M&A\O>)-3M_@O^VK/XF\2M]B\.^);!8(=3D!\F.01JFUFQQS&,^S9KU?XJ_%&
MV\6^"M<\/_#;6=.\2>,;JS;[/:Z;=QR$(2%=MX;8I )ZL#7JVMZ!IGB6P>QU
M?3K35+*3[]O>0K+&WU5@0:I>&O WASP8DB:!H&F:(DARZZ=:1P!C[[ ,UFZD
M79M:HU5*4>:*>C^_4^"_BD?%/@_P?\)O#M]\-[KP^-)UB*2&674X)CJ-QN4L
MOR?<+-W;CFOL/XD^.M/L?A->/XEN++PMJNI:5*RZ7?WT0D$AC^:-3D"0@D#*
MUW&N>%-%\3M9MK&D6.JFSE$]L;VV2;R)!T=-P.UN!R.:K>)_ /AGQL;<^(?#
MNE:Z;?(A.I64=QY><9V[U.,X'3TJI55.UUL1"A*GS<KO>W]:'S=^RGJ&G>(O
MV7;SPM9:I8RZ_-;7JC3EN$,XW*0"8\[@,GKBN.^%'Q4\->$/V.O%OAO5]5MK
M'Q!9P:C8-I<T@6Y>67>$VQGYB,N,D# P<]*^NO#GPQ\'^#[YKW0?"NBZ+>,I
M0W&GZ?%!(5/4;D4''M2WOPS\(:CKBZU=^%M&N=85@ZZA-I\3SAAT(D*[LCUS
M5.K%MW6C=R50FHQLU=*QP/[(WA.^\'? #PO9:C!);7DJ273PRJ59!)(S*"#T
M.T@X]Z]CHZ45S2ES2<GU.R$5"*BN@4445)9\HZS^TE8/>PP64+3_ &AS'#(Q
M")(?8FN4U']HR:U=C<6(@B$ODYDE ^;.*\JU/P+8^)=/MH;O4QI.K741N=/W
MG"M(1EUQVZU>UGP_X?T2#1['Q0DB6]^GE)<H,B*51_K"?K7T/]GTDG?\SNY$
MCT/6?BJL=XMK=Z3.LSH) % 8,IZ$'O45I\1?#\D32RJT"JVUFD3 4^A/K7!Z
M%X!N](T:=KK4#J/V9WDBNPY*^3U&/;%85KX/U/2-3M_[#U,:OX/U[=+-<@A]
MLG7:1V(/>LY9;3:5KW_(JUCW"R\7^']1&V*YB/L3BIKFWTV['#1D'T(KPO7-
M"U[2"NNVMM;W]AIG_'Y:,F79?7CG%-L+R+6H?[7L8;VVT^[7S(8//),9[@>O
M-<TLL?,XQD4FT>LZCX-L+L$A5YKF;WX96,Q/[I#^ K@/#GC^36-)DA35KVPU
MN*4J;&>,-OC!P2#V(]#6G:>-VB\2PZ1>>)&L3-'O2YN8/W8;L&(Z?6N1Y?4M
MS*UO4T4VC:?X66"-GR4_*JUWX9TK0XS),T<2CUP*P]?\2:CIFFZA>WNM,1:$
M[ELX\JZYQE2?6J5T]AK-O->Z+=W'B*>2W#0B\7;]GFQ]PJ."<U<,LJ.5I617
MM)%;7=6BO+2ZDLW6UTRUQ]IO''*@_P!T=S7>?!6]L;SP1<Z?IUV;Y-/NG99F
M&&DC?D-CZY%<GH.HO\2["^7Q/:1Z8U@JVE\D<?E +C[Y'8U6OM!O_@AX6B\3
M>%;C^VK"SN]DC ;DGMWR2IQZ>M:8K+XO#_N]7OY^AV8+$^QJ\TMF>Y:=J;6K
M]<5T=OXC&T FO/?#7C'0?'448L;E+'56B2673+E@LD989P/6M>:SNK1B'C92
M/:OCVG!V9]@N6HKH[5=?5OXJFCU@,?O5P27$B=<U:@OV4C)I7#D1Z#!J ;J:
MO),'7K7#V>IGC)XK>L=0# <U29E*)1U"9K&_=B#@FH9-45APU;6HV::E#Q]_
ML:Y*]TZXM7/RDCUKT:4HS5GN<<H6=RQ->[NAJI-<9'6JC&0<;32I!-,V%4Y-
M=:@EJV22V3,]ZFWKFO0%DV0+D\XKFM%T?[*?.EX(YP:?J7B!6M+Z2S9+@6:9
MF8-\B$\!2?4GM7!6?M9\M-7-HV@KRT+>HZFD(+.X11U)/ K"O->GDT.34=,2
M.Y3?Y4;R-M5W[@>N*PXM;2Y\)RRZK-"NK7I8I%(/W=O"IP1QU9CP#3=%L=8\
M3Z);VFF0"*QV^5'Y@^6,9^9_KZ5Z='+8PC[3$2LOO7YW//JXYR?)11<\3Z_I
M_P!@T\W06]N(&1Y#D@&;KA5[@=*:="U[QCJ\3R1&./[UY<-QO)YV@'T 45W'
MAWX8Z9HT=O+>XO[J)>LG*ANYQ717FH16L>,A5'0"M:N80I1]GAHZ:^GW'-3P
MLIRYJCU.2\/_  YL-",LLI-W=3?ZQF/RGG.,>E6=>TR-HCM4 8Z <"I;GQ+&
MF<$5BZAXEC>-AN!->!5K2JN\W<]RE25/X58\]\2:8NIP3:<Q FSOM9&_Y9RC
MI^!Z&N0\ ^/K+Q)/+I<TG]FZ_:N8IK*8XW,.#M/>NLUB],]^C)UW#&*\(^(_
MAU+KXG:U);$QRATDWQG#*Y7GD5A%<SL=%:?LDIGONJ1->6%Q878=$E7:?4>A
M_.LN>36;6TV/XE9(4'!6W4/^)S_G%>;:!\6O$'AB);37+3^W=/08$O2=!]>_
MXUH:EXNT[XCRPZ1X:NI1J%R&:2VE0J\2*,NWX 5ZF"Q6,PK]GAYN/,?-9KE&
M3YTHU<PHJ;@M+W^[0P]9\6>)K6]TZ[76[EM)N[MK82L@(X[YSZUZE\-=?O-6
MDU.POI!.UJP47"<!\C/YUY9HFI6WCSP1;^$M&M9'O(KK*LXSY8/60GMWKV+2
M/#MK\/\ 0+?3X9#+='#33L?F=NYK].R:./K57.K5<J=K);W??Y'\T^(D>',K
MPT<+@L-&&(33;CIRQ[.V[ET3V6O8XKQ?XYU'P]XBGLQ-%Y:('CBF7=YIW8(]
ML#'YUC7OB?POXCA5/$FG?V/(WRK=H=T63[CE:9X[UK1IO&8?4I%5(;5W+[AP
MQ*!1]3AORKR?6-4U+Q3K,#:;8 :=;/F'SAG<?[Q'>O#S7.\;@,QJ4(-2IZ7B
MTK;*Z_JY]?PIP3DN><.8?'U5*EB7S6J0DU+232?;;M;U/1=8^']S;Z3)9>&T
MDU1;N0R/>0L&&S@ ;O8>M5=:\3ZKHF@Z6VLW$DERT@CCBE"AO*#[0&QP2<-S
MZ8K!T<^,[/4EOK359K*<=5@4*A]BO0UW6G:I;ZA,7\7^&Q?2,NPWMCGCGDF(
M\?E7KX'.L)5LHOV4DFDOL7?6VBT?IIH?,9WPEFN%<I5X+&4G-3E)?QG96:N[
MNS7:^JN3V?A_PIXLF6Y\-:G_ &+J9.?LDF$RWIM/!_"MN.W\1:'<A=0LEN!T
M^TPKV]<5QVL_ ?2?%H^V^$M:\[RR'-H7(:,^ZG#*:WO"NN>,? \L-C?9O[)3
ML:"_RX _V9.H^AKY?B?!TZV%<\905[?Q*>WJU_FGZG9D&=XK"5/89)CG**T^
MKXC22\HRZ^B:]#N_$NJ6]QX9@M7=A<RLKI(IQY8Z$G\#C'O6WX"FDCT:Y>!H
MHXRVUU49;UZUA_$*6TU/P_I]U':BTN!,"8I!D'C.0PZX ) [U%X2UUH]-FM2
MZL0PD!VX)KXGP_H4Z.75E3;=ZCNV].FRM9:6O9O7[EYG$^,JXG,X5:\.27+M
MU7SZ^6BT+6O7KZI>NC;E13M8D_K7.:WJT>EQLZ1J[CH?6M#4;IDO9#DD>O:N
M0\0NE^^PN(E[,*_2GK<\%M**9BS^+U-WN,97'#!C576=1V)',@4;B%('<&L;
M4K3R7<'!^;[^:PM8UH3F*./(92!DGK7%S2BO>-E2C4V+NJ7BS32)@N-N0/<>
ME=K\%-26R\2Q^:2%DR" .5SQC\Z\]6;SHY99,?(/E*CJ3TYKL/@E%>W7BF-[
M2+S75MWS<@#O^E?*\2QA4RG%1GMR/K;IWU/4RR+I8R@X[\R/;=>U 17@A:50
M6Y)8X"_6N#U[Q7'8W#"WF$Z?WE&*[#Q3I\&JS3BXBE@E49#%?E->,ZP;RYU7
M^SM$T^34+LOAI)%*1(.YSW/M7YEPU&;PT;KH?U]E]:FJ2<Y="+6_%,]VQ8!L
M50TO7/F*,>OK6Z_PH\9V=Q'*&AOXI@3)"4VB,CT-88T>.:ZEBW+9W\)Q);R-
M@Y]O6OLITI0U9Z]'%T:SY8LV8\"Y2=3M*\UV_A?Q)OO8XB=Q8@8-><_9[J";
M_22W/4GO6]'IDEIY-U!,LJ'NAY'M62.E^9[=+X5_M*X,0\J*8_*=YX!KD=9\
M.W^EW,MNZ_,AVG9R#6GX9\2A4B6<O K '<_)^M:K>,[(7*_VC TL:G[PXWCZ
M_E7HTL5*GH>=.C=W1QMCI\Y9E*-AAC.*=XAT:2PTRPN"FU8;V-@QZ\Y']:]+
MT:31M7^TW(N[:QM4Y7<<GGH,5Q/Q4\7:=%H$EI9OO EB8RL.N'7I7IX+&R6,
MHSV7-'\T?-Y_A%BLGQF'6KE3FOOBRAXPD6.;56/'^D:;> ^N<1G_ -!JSJ][
M;Z?XTEDG8*+G3[>09[D;E/\ 2N.^+GBQ-$EM8_-C_P!.TJ/*,>08YB>GK\U4
M_C#J:7#>%M0LIUFCGLI(=\9R,JX./UK[C-Z;6#Q].WPSC+[U'_(_G?@_$<V;
M\.XG^>A4IO\ [=E.WYGK5OXI@6V6VD99;?\ A1^0A]1Z&ET[4[5+^-X2BL6S
MD#G.:^>],\17KM&C%L"N[\-ZC(]S&223FOP+.IOV#MV/ZMQ=-*#:/3/BAJMO
MJ3Z='YKO>19:5B>"A[$^IK8\-7$MIX:A:,0I 26#(,OGIR:X#QO\]UIMQM3=
MY9RQ."O;)'?J!70:'K?G:'!!\BM&2AV< Y[U]MX?1BLAIN-]92;N^M];:+3[
M_6Y_&O%,VL\JN6EHJUOU_I%/4;IM6O6E8LL88D;CZ=JYS7-<ATI6VP[B<@X.
M:T9KS;+*I/&<'/;WKC=?0ZA*VQQ$1G"YK] E>S[GA-I6**>*HIKIE*MM?C#G
MO6?JU]Y-P@"C;.#D>XK$N8OL\JL1MV'))[UD:CK7VG48C&3@'D,:Y.:45J:>
MPC/8GU&[$TCM@NR-\I[U]"?LB:I"FN76GSR9,\>%7LQ'K^%?.,L@^RO.X"O]
MT*IQFO>?V.XKN?Q@98[<2PJA\R9A]T>WO7PW&$8SR;$<W1)K5+5-6_KKL>UE
M"=/'4K?UH?7.N_".QUEUU.T#V>IPJ3%<6QVN#V^M?&\O@_4_&NN75SXBO+G4
M+^.9U-O>2$F$@D%=I^E?HMHB?N5R*H>)_@[X1\9S?:=4T:"6Z8#,\8V.?J1U
MKNX'S*.!H\]:'-=*WD?<\291C,YPD</A,2Z3OK;[2[.VO];'QEH7@2WT55EE
M6.!$YY(%=1H>E2^.M2:T@D:S\/6BF;5=6Z)!"HRP4_WB!@>G6OHVQ_9P\ V,
MJR?V*+@KVN)G<?D36#^TI:0>&/@O<6.D6L=E;7%W;V\D=N@4>67R0<>N*_3:
MN?RQLHT**:<FE=]+Z;'YQ@^ J>41GCL=4]I&FG)Q5_>Y5>S;Z>5CP?6]9C^(
MFM07%O#]D\,Z8@M]*LL8"QC^,C^\W6L_4/#L6H7:S_:Y+:>/B-X'*LOT(YJU
MI*QV^ALPP(H8BQ]SBN^^&G[/5K\0/AF^N7MU<6VNWQ>6QGCD(6!0<("O<$CG
M->S6K8?*Z$83^&]K;^K?ZGQ."PN8\4YA4K49+GMS-W:2MI%*VW9>AYI9^*/%
M?@6\%SHGB6]9T.3!=2-+&_L58G]*^O\ X/\ Q*A^*7@RWU=8OLUVK&&[M\_Z
MN4=<>QZBODR72;F07^DZG%Y&N:7(8;A?[^,X<>H/K7I7[).I267BCQ'I!R(I
MK>.Z"_[2L5)_(C]*\S.L'AZN#^MT$DXVVZIGU'!F=YCALX>48^3<9J5KMMQE
M'5K7R3NCZ@HHHK\[/Z#"BBB@ HHHH **** "BBB@ HHHH _.WX[:18W7A3X?
MW]O>06VIZA9?:EMY&P%1PIX/8@]_:M/XV:[I'BSPEX<T30;.XU>?3K96N-4M
MHB5CDVX.<CY@>]>Z^!_V=+1+>"?Q"5U>[2%($\Y 4BC4?*B#L!7J-C\.])TZ
M 1P6<42 8PJ@"O5GC%>Z5_U^1T.HNQ\A>%_%?AOPO\!/^$>OH;O5_$<\<L<D
M5M X*A\]"1V%<S^S;H2/XTEM=0UBWL?#<,!+Q7$@B,DO\.$;&&'?UK[@E^'^
MF%B?LL0/J$%<QK7P0\.:O(TD^EV[R'^/RQG\ZA8RW3\050^.OBYXCC\&?%34
M=;\*ZHNHV"PK!/;QMOB)'!5E[@^HKT;7?"-WHWP=;Q7!IBPLUF+N"TQ]QF.0
M,>E>F:_^S%X<OHU,-FMI*GW9(?E/X^OXU@>(_@+KVMV,=G<>*M2DLX/]3!N
M5/3IUKICCHKJ_P _N-%41XMX#&E?%SQ7;:G'I@L_%\%IB\2V_P!3.A&/, ]:
MH^+/^$9O-8USP-XELGTR>)E^R:NG#)(1]T^@->O^ _A?XO\ A+>:A<Z%'IES
M=7HVR74\)WX]L<"N+\4_ KQ9XE\1+JVM^1JLK3+-)Y?[HL <[#ZBMEC(-<K:
M^[<KG1G>(=&TWX<^$M,O-9LGU'3]T=HT&WFX!'^'-0^$? NEZ=X:\3:[X1EE
MU#2OFO8ED7)@=5SY9^E>@?$SPUX[^*EI;V=SI^GZ?I5L ([%02<@8#;O6I=!
M^&OB[3_ 4?@ZRE@T/2F8R7$MJN9YV/7<Q]:;QL-'=?J@YSA- \26OQ&^$GBS
MQ!K,,&B31Q+9231+D7$S#C ZD^HK-\*^%=0\1?"[1?!UAY]IIUO.]Y>7X!4W
M,A^ZB@]$ KV7PG\ ;;1;:**ZE>[BC<RB)P F\]6VCC/O7HEMX;@L(@D4:J .
M !7FU\8Y?#OWV#F/E^^^ 5G9VW[J-EF'/G*2'SZYZUE%O'7A ".PU=[JV3I!
M?)YJX]*^JK_2593\M<?KN@VD43RW#)%&!DL_ %>+."F]3NHXF=/X6>"?\+I\
M0V!QJ?A6SO5'5[=S&?RK5T?XT^%-:G2WO8[KP]=-P/M:YB)]-P_K6YXOTBWM
M=(74+>U^U0RDB)AQOQU(SU KG?&?PJL4\.6AS'?:K.5:[6(CRK-6QM4]RQSU
M[4X9?.KK%?UZ;GJ0S*<?BU.[+_90CB6.2%QE)4<%6'J#5VVUV"#!DN(T4G +
M, ,_6N#O8= L]'T[0-!9([#3I +Z.>1C-,QZNA_NCIBM;7/$.D:]>:.QMXX=
M/L7")IRQXW ="3U)8^M=,<GG=)R_K[^G4ZGF::NH_P!?=U/1;/Q)9J45[J)&
M?[H=@-WTK335+&Y^1IX=V,[2X!QZXKRR\\7Z?J?BJPU^]M89YH$(73?+VB':
M,*F!U'>K-AXLTZ+Q7<Z]<Q0:A>RIMB&SY(B?51Q\M6LI;5U/\OOWV,WCW_)_
MP_;8]%D33VRV^$\X.''6JO\ :-D@N/LNVY>W4O*L!#% .I/I7 Z!K^F^&YM8
M<F*;4KYS&EX_SQ0 CEPO3Z51TOQ%_9&@7EC8V7VFVNK@M?E#AI>?E0-UQWI_
MV6HJ]2=DOZUU9+QLI.T(ZG6V'B5O$/A^^OKF-+;<[065D9=CRD=7<GH .U<G
MIVMW-CHJ:?IEK'=69F9ITF(822GIN/4[1WK-_LF2_C7[860(Y:-%;.%/8^]:
M$"I9+M@C"+[#K2GC:&#3AAE>7=/3\=S:&#JXA\]9Z?C_ , Z#PIX2L@D;ZLX
MNI@^[:.% SPI]A7JUC>6UO;JD(2.,# 51@"O%[;6)(.N15]?%,BK@,17B5<5
M4KRYJCNST5A(05H(]/U/7TA0_,*X#7?%+2L0K' K(EU.\U-BJ!F'<]A]:Y'Q
M+X^\.^$F*7ET=2U =+*S^8Y]ST%<]W+1&T81I*\C?DU"ZNY-L:LS'L!39+&_
M(_>E(<_\]'"_SKR74OB-XO\ %1:'3(DT"Q;@"$9E(]VK.@^'6I:G)YMY?7EP
M[=3),Q_K5JC)[G//'4X.RU/2-?\ %FC>"8S/=7<6I:IC_1]/MGWLS]MQ' %<
M1X4TJ[U:]N=2OQON[N0RRGMD]A].E:N@?">*UE#^5ESU8C)/XUZ7H_A5;2,
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MXB=CJ-HQUZ?C7A\#8U8&K7RB=[W<X]K:)I::=]7K?1;GXMQM@9.O''1VV?\
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M !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444
M%%%% !1110 4444 %%%% !1110 4444 %%%% !1110 4444 %%%% !1110!_
"_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>12
<FILENAME>nxtc-20221231x10k007.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20221231x10k007.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" %- JP# 2(  A$! Q$!_\0
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M?>H3>QP/RQW,,[E_/^>:+(KV:-)]<\0)&69M+&!T*R_E7#Z[\>I_#\[Q7(L
MRC)PS#^9KE?B_P#$P:+;26UO,0 H:=HSM//"JI[%O7L 3VKYONO&6IW\LDL$
M\-F2V6" +QZ[B"Q/U.:\O$XN-%\JW/=P.42Q,>>6B/J_1_VCEUJZ:W233K:3
M;E/M+,@D/H">,U>NOC'XIMYX(T\+&X\RX^SN\+@K&.")"<\K@DY'I]*^-)?$
MNOPN^[4)'0<,LTX*L,9SM?@C&/SKZ)^ OC>V\0^'Q8WD\4^I0.S1J@*(T6!P
M >I4YR.."#C%<]+&^U?+L=.*R98:'M%[R.K\=_M'ZE\/[J*&_P!%299ANCEB
M;"NO][D\<YXZ\$UJ6/Q[>ZBT9)WTZPU'5X!/:Z?<;_,.XX168952QX&37)?%
MCP#J?CQ+1H+ZVMXK=PXC:',TC<\*Q8*..@QSCK7A&I:=?>&IY!J-G<P7$3BY
M038><GC/0D$%@#@=#GU-$\35A-]@H9=A:])6?O=3WR\_:SGL[R6W&CI.T;%&
M:-\ ,#@KS@Y!%%I^UG-=R,HT=(PH)9FD!QCZ'FO#-0OI]462YNW,TLQ\PO*/
MGR??K[<UCV5A<7DT\L"O';PJ6FN-A\N, 9RQ ZX' [YKEEC*R>C/3AD^$E'5
M?B?0<O[8$D1 _L0'Z2#_ !IG_#8KA2QT+ '<R#_&OEK4M06.8E6.23M!XX]Q
M6<UT]T2)&.S^Y2CC*\NII+)<'%:)W]3ZEG_;AC@8@:$TF.ZN,?SJG_PW?C@^
M%I\_]=4_QKY?>-22%P!Z5&+8N1GIZ5T?6YI;G.LGPS>WXGU1!^W0TX_Y%:9>
MWS2I_C3Y?VY#"A8^&93CL)5_QKYEMK,!>E5K^$;"16'UVK<Z?[$P=MG]Y]+-
M^WRB@?\ %+S'_MLG^-:5A^V\=0MO.C\.2+@X9#(I(]._>OCB2U+/@CDGK73>
M";5YM6%J%)2XC=&4>RE@?P(S^=;+%S9A/)L-%72?WGU[IO[6DNJC,.D)Z$%^
M1^M:,G[3%Y''N;2H@/3=_P#7KY6TDRQ217$&-V/F0\;A_C77+J"W=KG[K#JI
MZ@T/%55K<Y?[+PU[6_$]IG_:TN(&P=$#?1Q_C40_:[G/_,"_\B#_ !KY^OFR
MY/:J<;2;W#*H7(VD,22,<Y&.#FL?KE;N=:R;"6V?WGTA_P -;SG_ )@8_P"^
MQ_C2R?M;R1P[VTA-V>(PXSCUSG KYNO;$7L<8$TT&QP^8FQG'8^U6QI=QK$4
M@L5\^XAC:1[<??9%Y+(/XN.H'/%/ZY6!9-A.J_$]RN?VU6MNOAYF^DB_XUNZ
M1^U->ZQJ+6<>@B.1-H<NXPK$ E>#VSC-?'MPS1W89E)*MRK#!XKT'P]JEQI6
MLWEW%:7%Q!/*TL<L,9D5E8Y'(Z8Z8/3%7A\94J-\S(QN3X:C"+IQ>OF?5P^+
M^K%6(L[0E1D@%O\ &K4'Q1U>=%86]DN0#A@]?.D_Q#O5<C[/% O&&FN8D)^H
MW5>TCXGFUN474K>5/,&V(B52CGV<9!P.W6O05=-V3/#EEUE?E9]$+\0=98 [
M-/!)Q@[^M(_Q"UE"08K X&> ]<-9^(HM4A6:, !AG!;Y1]*?)>X&22PZC)SF
MM'59S+"1>YZ'I/BOQ!JT E2/3H@20 XD)Z^U7SJOB/ (_LLCV66L+P3<EM/*
M9!3'3\:ZA2HRPP2.I]:ZH:Q39P5*2C)I%1M5\1@\'3"?]V6D'BO5-.8/?V4%
MS:C[\EB[;T]]C#YA]#GVJ\8PS#)R,&F/;C[Q'S=F/KTS6ED8N)OV=W#?VT5Q
M;R+-#*H='0Y# ]#5;5M7ATB%&=7EED;9%!$,O*WHH_J>!WK&\$,8&UBR'$5M
M=GRU'15=%? _$G\ZL6RB\\9WKR#/V.UB2('^'S"Q8_4[5'X5!G<D2?Q#.H?[
M-I]L#TCDF=V'U( &?I2Y\0^FF_G)_A6W12'8Q,^(?[NF_G)_A1GQ#_=TW\Y/
M\*VZ* L8A/B+LNF?]]2?X4 ^(<<KIN?]Z3_"J?Q'^(FC_"WPC>^(=;F:.TMP
M%6.,;I9Y&.$BC7^)V/ %?'7CS]O3Q1X6U7<]EH&FQ@Y_LN;S+B6('^&:5650
M_J%''2O0PV!Q&,_@QN<U6O3H_&S[1SXA_NZ;^<G^%&?$/]W3?SD_PKRS]F[]
MJ;P]^T397D%D@LM<L(UDNK(2B12A.-Z,.JYXP0",CKUKVZN6K2G0FZ=16:-8
M2C4CS0=T8F?$/]W3?SD_PHSXA_NZ;^<G^%;=%8FEC$SXA_NZ;^<G^%&?$/\
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M79)OW(ECSC]VH^9R",'TSFO!M;T[5-2U9=.-O<-Y>YQ^[),K8.Z7'N5(&>@
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M\$@@9Q6CX=^!GB?6-:\0Z==O8:"OAO U34-6N?+MX"1E/F .X,OS X P03U
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MNK_#:2TMM;N=+^V7+R 6EG>>;,BKTD==HVJP(*\YYY YKK(OC/X4\+67P_\
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M4BRMR<YK6"<49SDFS3^&GPOU/XM^-[3PY93I8H8VN+F]F&\6\"8#-MXW'+
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MZ?0@U%<SB^O?,6(QH$6-%8Y("J%&3W/%5&5WH9MWU*;7TD9 C48Z8K:L+PK
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MU7BXI62;_#\CYF.3S<W)R4?17?WRN?-3?!SQ%XL\F6YTXVZ1J53[<R0H Q'
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MN<9)["CFE'X36'*]9GEEO+<66?,C(V^M7QJ@DP">:Z:]T*6R2;[9Y4$L;%!
M6S(QSSP,X ]3QZ9K$DL+>0\H%(].*EU5M)'4J5]8LJJ?.]_>I1&(ER>#C@^M
M7K/2HP1\S?G5\Z8K,H2)IG(VJB<L6/3CO_\ 7H4ET%)/J<YYTAE 4$\]J])^
M']B9&8S ]C@U6O?!\L.OFPM[*6-E3=S&V2%0,S'VSGGIR*V?"A73YPTCC:<*
MP_N^A]#_ $IJ;3M8QJ*,J=T[G1:EIZD9QCBLF*R568D$8S@#J:W[PJL 5#D
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MKB*PL=0FV/?RP%DBV,RLV<X8KC.#@!3S]TUIAL?B(8FG/%3M"ST6WE<^(S/
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M*<)NQ\%Q%@,16J1KT8N6EM-T:OA7XV^)_"L,=O=;-?LTP +MRLZCT$H!W?\
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MR?7Z?Y[4\W&X%E8XST X]/\ Z]44WHN$==N",;>@_P#K4Z-5B;/!QR2V<^U
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M''H,5RT<%[.LV]8VZ]SDH9?[*NV]8VZ]SX,T_3Y%U*\MH;N73M8A??;Y<[9
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M;5 <%G(X ^F>AKKK:]M[Q0T$\<P*AP8W#<$9!X[$53BUNAV:)Z***D04444
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M$%K",LY!/4X  ')))  ')) % %JXN(K2"2::18HHU+O([!550,DDGH!7S_\
M$;XN:CX]TOQ#8_#_ %FWTY-($::A>7MLRDB0D-MW*<(J?-O"DGMC'.+XX^(^
MH_&'0]0O/"_B(^'=$TW48K*ZBOH/*\U2K>89N&8)NVKP!A0Y/MB>)_%46H:]
M=S:9#IUM/=DK<%$WR2.B?O8O.0X92%5AN&/ER"-QKT*5!IWEN=5.GU8FJ:EI
M]AJJW.D65A9ZO-:0V,LB7> )8T53'O3*.CHHQD=E8$<BN$76[FUM9K_PY.+#
M6M.OHH_+MU>-C$V0K,1E#M<%2" ,'HV:8+N\\0:397?AZ:4ZU::DENXB@"Y!
M^>%PR')88"X(R<G!(S7TU\+_ ('VN@:Q=^)]9@CDUJ^?[1]G^5DMV."<D*JE
M@1Q@ +DXSG-=DYPH1UW_ *_ UE)16IZ%X)U#4]5\*Z7=ZQ;?8]2F@5YH<8*D
M^H['&,CL:W*0#%+7B-W9P!1112 **** "BBB@ HHHH *\Y^(W_(;@_Z]U_\
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M(\3:7&Q9(98PF63))V-O'!Z<CIBOJW]E2:^E^#.FFY!6U%S=+IQ;)(M!*?+
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MC/RJ-P(W$9) [UX?KE[?>#K:5Y+.=]7L8OLLTNC:G"MOX@B,C&*7:>=XW9#
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MARR>8Q8*?3@CBNMDN!)-Y>_H!G<, CMBLO1O$,&OZ-!J%I(MU%<1"1&C/!!
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MJ-EX7M[)&D5WO$E>/S@=S0JS.X3&>,;L#% ]#Z>!R*6D7I2TR0HHHH ****
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MF\QXPN0XR&P!G Y&<X[D]:]0L=-6UM$C48&,;EY!K2R5&XJ W S_ (4F JX
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M:7$9,GG(4#H/U'TI6A\Q6#$A!_"!^@IQ)!)(++U)XX^E,2506!!VKCYSP2:
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M22:T#2U*C%/F2U)Y8I\UM0HHHJB@HHHH **** "BBB@ HHHH **** "BBB@
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M.J'!Q\IQQQW]:S+B^D?DG..,"NR6(K5(<DY-H[\/D]-3Y^74\E^(W[-?PO\
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M>@:6L$<>RW0+'G[P4 N?4_T%83FIWERV]#Z[ X>IA:'QMW[[_>=#$3*V>!Z
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MUKX2LS;O:7$6GPR0KD@%V?(*MN8K@#&"#W)$*H['G4<]J>SC!P3GK>^B//\
M58+_ $G7[71=1@M]&OKA$D7^U;N."-$8.0SL"P7_ %9&/4@=ZRK?5X;CS$>>
MV\U)'CQ#.LBMM8C<I_B4XR#CI7N_C>2]U#X^^!8;FUCDT'YGM9C K++,;:X\
MP;\G.%"$+COFN(\&:19?$C3/'7@@+;Q7UGKCW]JX C<1-=L)E! SP W_ '\
MI*H^I-#B#$Q?M*D4XVU2Z:[GGSZI:8+?:X,>OFK_ (TZUE_M.[M+2P'V^[NI
M/*@@MV5FD;T&2!V/4\5Z3:^7XP^*'CK7=$E:*+PW:)IEO9:79V]S=7*J3O,*
M3?(/G1ER>O(R*W-?U ^$OC3\.'M[&"QFURS:WOVGMHED=LJ1N*?*) <#*D]<
M#C%/VK['5+B:KK"-*SM??ROV/%[J8Z?=WMI?>7:75G.]O/&\JG8ZG!&0<5%]
MKA>$RK-&T0ZR!AM'X]*]NT6$ZO\ %?X@OK=@L7B"TM/^)&ILHF=K4/+B:)&.
MV1]V!N)&> < \P:9;:)J_P 6_!J:GHUS;:F=/NFF?5;"*U6^E39Y4GE*2N]0
M9<<#';H,/VK[%4^*9Q2C.E=VZ/K8\DL="O\ 6/"6M^([*:R?3-)E2&93*QD<
ML$/RX!'\8ZGL:R)1@X/7I7NOB"3Q!+\$_'+>)=(LM(OS> (EI$L9EB$D85F"
MDY'!56/)51P*\+F W,*N$G+<^BR+,*V/56=79/3R_P RE*>35<RXJ6?H.E47
MD*G_ #Q5GT[/K?\ 9D.[P)(?^FY_E7H.F?\ (W:W_P!<+;_VI7G?[+QW?#]S
M_P!-S7HFF?\ (W:W_P!<+;_VI7#+=G\\9C_OM7_$_P V;U%%%0<(UF"#)( ]
MZ7/&17CW[2B7*Z!HLZL39)?;)T+':2T;!"1WPW3W(K,^%7QD&GK%HOB6Z_<#
M"6NISMP/2.5CT]G/7H>>3UK#3E2]K'4\B>94J6+^J5-&U=/HRCXK^+OB+P[\
M4-9M4F$^GV$\:#3RB[9(3&C'#8R')9B#G&<#&*]VT;5[;7M*M=1LI!-:W,:R
MQ..ZD9'T/M7RW\59(KKXQ>('MW653%;*S(<C?Y8XX[X*UWOPR^(5EX'\":@N
MH22W @U)X+.V@PSRLR+(T:#IP68DD@#/)KMQ&&7L83@M;(\7 9E*.-KT*TO=
M3;3?0]THKYL\0?'OQ+=[WMWM-#ME)(V()I /1G?Y?R6O4/@KXB\1>*/#DU]K
MBEX)) ;*XDB$<DT>.6*C VYZ' R/;!/'4PM2C#GF>SALUP^,JNC1N[=;:'H=
M%%%<9[ 4444 %%%% !1110 4444 %><_$;_D-P?]>Z_^A-7HU><_$;_D-P?]
M>Z_^A-31,C0^(+!=2\.%N@O,G\JD:?;]W/T)JO\ $DXO?#_&[_2SQZ\51\XR
M!%'[O@;0%R#QTJH[&T"T92TK!=NY@=QW9V^@_G3'*(V]P.!PS9)%0LKR1HX8
MCG! 7EO3\:FCBD:-R-A;."02.?3D\>E6:7(V8SJNU@ @W GC(]:Q/%NN)X7T
MRXU">,2!/E"&145B<!02?E )(!)Z=:ZO[*2BDH!]<=:^?OVE_&9T35/#V@S"
M"*TNV:ZN[^_M&NK6*&+D^=$I!:,MM#D<JK9 )Q5PBYR449SG&"YI;'9S?%^Q
MTAEBU33KK2[J1@GV:\3RY"V/FVH"=X!ZD<=*]/TR_6_TZ*ZB^ZRJ<9SU%? &
MMO')9Z2UBUO#82FXD<Z!<L=-8A2@Q+/F=R,@;!@ %1UR1[SX9^(.L>'/"=SX
M?(N+^0Q".ROY7!,><AO,?.25'*G!)X&>,UWSP<N5.!YN)S3#8::IU-+JYSGQ
MH\5Q>(O$=[BY9+5-UI$^"5$2!BY&WD;Y!M'L >E=I\ O#-QJFL2:IJ+-<-8_
M,68AMUQ*N2=PX.U#@<<;Q7GUWI=A);02R6_G,@WQ,#\XAC)1%!'.9)-Y]Q&O
M8U] ^'[G3/A1X'A&HRK$4C,]VP!8M*WS/P.N.GT'H*Z<1.-.BJ</3_,^7RW#
MU,7CY8BKT][YOX4^FB/16(C& N1V]A4 VJHR,,.=YZ&J%EK5KJ:*\<\9B8!D
MVN"&SR""#@CZ4LMYYDP0@L2ISCICZ_E7AV/O"=\/(^WA1Q^-,D#(!@ N3@@#
M'/M1&"P+[MN>..H/M3F;:!YA XSR1GT&: N5V7*%!F/KDCD?G4?EM,P 9D/W
M"1@FK2P G*'S"3M)).1Z\4\QK#D$!AG"C'.:!F>8-RX9BX485F;K36&Q?D)<
M?=()*Y-6YX#*Z$#KPS <@?Y%*8  I!*?7F@"BD)C9V_CR2.G(Z4B6\_R[GR<
M%N1C!_S_ #J^UFFP1R,2.2!G'^>M6# &780<#JPX% [%!3+'"$+B0=CBD68
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M,>2+U9\#C<-C,TQ7M:]+EIPV75_\.<%=SQRVTMZ'^PPDHUN6 _<QICR1@\'
M521W);UK 7QCKGBG4I-376;[4+?3Y46.XLGMUETV7"LEX]M)L66U=&DB)R0
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M3KU-7M5/7RI1LDQ[!T4_\#KTW2W,84,>HQFO(?A2)9OV@KJ2T<K:6^BW9O\
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M_P"%9Z#_ ,^\O_?]_P#&C_A6>@GK;RG_ +;/_C1S"YWV*T<^2'QWR!U]J?\
M:\QG+-UQ@9S4W_"L]! Q]GEQ_P!=W_QI#\,]!Z_9Y?\ O^_^-',+F?8B:[#
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M;!9%W(&\D'G'2M6TM-BAMI!([\FF?\*TT+_GA-_W_?\ QI?^%:Z$.D,W_?\
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M-'_"#Z)_SXK_ -]O_C0&INT5A?\ "#Z)_P ^"_\ ?;_XT?\ "#Z)_P ^*_\
M?;_XT!J;M%87_"#Z)_SX+_WV_P#C1_P@^B?\^*_]]O\ XT!J:UW>P6-N\US*
MD$2C+/(P %<-J7A2X\=71U-YY+& @1V\;*0S1CD.1VR2QQZ8KJ+7PCH]G,LT
35A#YJ'*NXW%3[9SBMB@5F]S_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>13
<FILENAME>nxtc-20221231x10k008.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20221231x10k008.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" #_ A8# 2(  A$! Q$!_\0
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M+[_^ >S9'J*,CU%>,_\ #'7P>_Z$N#_P-N?_ ([1_P ,=?![_H2X/_ VY_\
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M)6NEKFOAM_R3OPO_ -@NU_\ 1*UTM92W92^%"'J*X/X]?\D.^(7_ &+NH?\
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M?\DC\$?]@2Q_])TKL20 <\"B?QL([(/2N+^)_A6^\6:/86MCY7FPWT<[M,Q
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M-:MJ"^'-9716.U=2,2\C^]Y>=^WWQ^%9/[07C'2[SQOX:TL.^K0:=>/)J=E
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MFOAM_P D[\+_ /8+M?\ T2M=+64MV4OA04444B@HHHH **** "BBB@ HHHH
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M*_#NS\.W'VVXE$]UU5<\"KUY?06<6\+Y0Z*J]37-_P!J:CJUXT5BDDF#@LK
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MI--;Z=3\K^NK&S=23M*3=UUN>@]12=#3(YE;H:DS7TD*D:BO!W1K:PAKS?\
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MNO.,L>,>E> _$#XN^(_BO!?:G=&:7PQI]\MG;Z?: ^7+(2X1Y2/O9V$\\#(
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MF/DKGO7WO!F9UWC'A7+FBTGWM?H?1X>I*OAE4GO>U^YK&O-_VDO^3?OB+_V
M;W_T2U>D&O-_VDO^3?OB+_V ;W_T2U?O5'^+'U7YF4_A9TOPV_Y)WX7_ .P7
M:_\ HE:Z6N:^&W_)._"__8+M?_1*UTM92W92^%!1112*"BBB@ HHHH ****
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MA1@J=-6BMDC1)15D.HHHKH&%%%% !1110 4444 %%%% #&C1CDJ":=TZ4M%
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M (95^$'_ $3;PW_X+X_\*/\ AE7X0?\ 1-O#?_@OC_PHM1[O[E_F'[SLOO\
M^ =__P );HG_ $&+#_P*3_&C_A+=$_Z#%A_X%)_C7 ?\,J_"#_HFWAO_ ,%\
M?^%'_#*OP@_Z)MX;_P#!?'_A1:CW?W+_ ##]YV7W_P# ._\ ^$MT3_H,6'_@
M4G^-'_"6Z)_T&+#_ ,"D_P :X#_AE7X0?]$V\-_^"^/_  H_X95^$'_1-O#?
M_@OC_P *+4>[^Y?YA^\[+[_^ =__ ,);HG_08L/_  *3_&C_ (2W1/\ H,6'
M_@4G^-<!_P ,J_"#_HFWAO\ \%\?^%'_  RK\(/^B;>&_P#P7Q_X46H]W]R_
MS#]YV7W_ / ._P#^$MT3_H,6'_@4G^-'_"6Z)_T&+#_P*3_&N _X95^$'_1-
MO#?_ (+X_P#"C_AE7X0?]$V\-_\ @OC_ ,*+4>[^Y?YA^\[+[_\ @'?_ /"6
MZ)_T&+#_ ,"D_P :/^$MT3_H,6'_ (%)_C7 ?\,J_"#_ *)MX;_\%\?^%'_#
M*OP@_P"B;>&__!?'_A1:CW?W+_,/WG9??_P#O_\ A+=$_P"@Q8?^!2?XT?\
M"6Z)_P!!BP_\"D_QK@/^&5?A!_T3;PW_ ."^/_"C_AE7X0?]$V\-_P#@OC_P
MHM1[O[E_F'[SLOO_ . =_P#\);HG_08L/_ I/\:/^$MT3_H,6'_@4G^-<!_P
MRK\(/^B;>&__  7Q_P"%'_#*OP@_Z)MX;_\ !?'_ (46H]W]R_S#]YV7W_\
M .__ .$MT3_H,6'_ (%)_C1_PENB?]!BP_\  I/\:X#_ (95^$'_ $3;PW_X
M+X_\*/\ AE7X0?\ 1-O#?_@OC_PHM1[O[E_F'[SLOO\ ^ =__P );HG_ $&+
M#_P*3_&C_A+=$_Z#%A_X%)_C7 ?\,J_"#_HFWAO_ ,%\?^%'_#*OP@_Z)MX;
M_P#!?'_A1:CW?W+_ ##]YV7W_P# ._\ ^$MT3_H,6'_@4G^-'_"6Z)_T&+#_
M ,"D_P :X#_AE7X0?]$V\-_^"^/_  H_X95^$'_1-O#?_@OC_P *+4>[^Y?Y
MA^\[+[_^ :'C?X^_#_X?6GG:QXKTV.4G;'9VTXN+F9CT5(8\NQ)XX%<-X0\-
M^(_CAX\TOQ]XQTJX\.>&-#=IO#/AB\XN7G(*_;[M>BN%)$<?)3))YZ^D>$/@
MOX#\ 7)N?#G@[0]$NCUN+*PBCE_[["[OUKM>!2YZ<$U33N^K_1!RRD_>V["B
MEHHK V"BBB@ HHHH **** "BBB@ HHHH **** "BBB@ HHHH **** "BBB@
*HHHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>14
<FILENAME>nxtc-20221231xex10d30001.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 nxtc-20221231xex10d30001.jpg
M_]C_X  02D9)1@ ! @   0 !  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !, ; # 2(  A$! Q$!_\0
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MAL_\-5?$;_H+V_\ X!1?_$U]3_ /QCJGCOX;6.L:S.MQ?RRS*TB1J@(5R!P
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M]&CB9QG[*MN?HY124M?/GJ!1110 4444 %%%% !1110 4444 %%%% !1110
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M):PIS@LS #/MW/TK]POV?O@GHWP%^&^F^&M*A7ST027MUCY[F<CYW8_7@>@
M K\A_P!D+_DY7X?_ /81'_H#5^X-=6=59<T:2VW,,!!6<^H5^=W_  51^+4R
MR^&_AW9S%82G]J7X5N&.2L2GZ ,W_ A7Z(U^.'_!0J_FOOVI_% E;(ACMHD
MZ!1"M<.54U/$IOHKG1C9.-*RZGT__P $O?@G;:7X/U+XDW]L&U+4I7LM/=QG
MR[=#AROH6<$'V05]X5^7/P6_X*20_!SX8:!X/A^&HU%=*MQ"UV-=\GSFZL^S
M[,VW)).,GZUVW_#W+_JE'_EQ_P#W)6^*P6+KUI3Y=.FJV^\SHXBA3IJ-_P &
M?HA2&OSP_P"'N7_5*/\ RX__ +DH_P"'N7_5*/\ RX__ +DKD_LS%_R?BO\
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MS2NOO3_ K^&]-@UG7]/L;JX-I;W,RQ/.%W% 3C.,C/YU].#]B6Q/_,V7&/\
MKQ7_ .+KY35BC!E)5@<@CJ#7UE\'OVK-*;2;72?%[O8W4""--15"\<H' WA0
M2I]\8^E=>>O,J<(U<OD[+=))OUU3_ \W@Y9!6J3PV=P5W;EDVTO--II+NF_O
M(O\ AB2Q_P"ALN/_  !7_P"+H_X8DL?^ALN/_ %?_BZ]8OOC]\/M.M/M#^*+
M*5,9"0%I7/\ P%03^E?-OQQ_:2G\?K%IGAY;G3=*AD$C7#-LFF8=#P?E ^N:
M^7P-;B#&U%#G<8]6XI)?AJ?HF<83@G**#J^RC4GTC&I)M_=)V7FSNO\ AB2R
M_P"ALN/_  !7_P"+K6\(_LB6/A;Q-IVK_P#"1SW?V.82B V@0/CMD/Q7@_AC
M]I#Q_P"%]BIK;ZE O_+'4E$X/_ C\_Y-7UC\#OB9K/Q/\,S:KJNCP:9$C^7'
M-#(VV;'WB%8< ?[QJ\T>>8&DYU:RE!Z:6Z^5D_N,N'5PAG&)C3PV$E"JO>2;
MDUIK>ZDU;UMV.S\5^*+'P;X?O-7U*416MJA=CGECV4>I)XK\]/B)X[O_ (B^
M*KS6;YCF5L119^6*,?=4?A7IG[3?QA_X3C7SH6F3;M$T]\,RGB>4<%OH.@KP
MZO;X<RGZE1^L55[\OP7^;ZGR''G$W]JXKZCAI?N:;_\  I=_1;+YL*?#-);3
M1S1.T4L;!T=#AE(Y!!]:^A_A+^S3_P )=\-=1U35 ;?4=0CW:8&&/+"\AS[-
MT^F#7S_JVE76B:G=:?>Q-!=VTABEC88*L#@U]%A\?A\75J4:4KN#L_Z_ ^%Q
MV2XW+,/0Q>(A:-57C_P>SM9KR?J?='[/OQ<C^)WA18[J11KE@!'=)T\P?PR#
MV./S!KU:OS=^'7CR^^''BRSUJQ8L8FVS0YP)HS]Y#_3W K]"_"OB:Q\9>'[+
M6--E\VSNHPZ'N/53Z$'@BORKB#*O[/K^UI+]W/;R?;_+_@'](\$<2K.L']7Q
M$OW]-:_WETE^C\]>IKU^?7[00(^,/B;M_I/]!7Z"U\5?M=>$Y=&^)"ZN$(M=
M5@5PX''F( C+]<!3_P "KIX3JQACI0E]J+M]Z?Y'#XEX>=7)X58+2$TWZ--7
M^]I?,\,K[B_9,O(;GX/VD4;AI+>ZGCD _A8ON _)@?QKX=KM/AI\7/$/PJO9
MIM&FB:"?'GVERI>*3'0D @@CU!%??9WE]3,L(Z-)^\FFK^7_  Y^*<(9W1R'
M,UBL0FX.+B[;J]G?[U]Q^B9KX@_X*>_!&;Q;X#TKXA:7;^9?>'<V^H!!\S6<
MC<-[^7(>GI(QZ"M^[_;2\2/;[;;0M+AF_OR&1Q^6X?SKS/QI\</&?CV&6WU/
M695L905:SM0(864]58+RP_WB:^'P'#>84ZT:DVHI>=_R/VG,?$7)HT7&@I5)
M/LK+YM_HF>/?L+?$SQ+\#_%FJW\^DSW/A75;39<02/Y1:9,F&1 1S@EE)QC#
MMU( KU_XF?&'7?BCK$%YJ1B@M[8M]EM(%PL0.,\GEB<#)/IT%<+2U^@8?*L-
MAZOMU&\^[_3L?BF<\69CG$/83ER4OY5]^KW?Y>1ZCX,\<B-421]K#CFO5-+\
M<KY8_><?6O"_AM\+?$7Q*U,0:+:L($;$U])E88?JW<^PR:]TO/V3O$U@JC2O
M%%E=_*,B\A>'GORN_BO"S/\ L^G5]G5JJ,GT_P"&V^9]=P[6SVMAO:T</*=-
M:7T5_2[5_E<M7OCE?+/[S]:\\\5^.5<%$8O(QP%7DD^E=M8_LK^,;R3;J7B/
M3+2(]6M5DG;\F5/YUZK\/_@#X7^'DJ:E)OU;58AN^WWY&(O4HOW5^IR1ZUXL
ML;EN"7-&7/+LO\]OS/K(Y=G^;/V<J7L8/>4FOPBFVWZV7F<]^SM\([KPU')X
MHUZ$Q:Q=IM@MW^];Q'KN]&/IV'UKT+PM\7_!7C;7M2T30_$^FZEK&FRM#=6,
M,X\Z-EZ_*>2 >"1D9XS7R3^V#^W_ *1X7TO4/!WPXO8]6UZ=&@N=:MVW6]D#
MPPC8</)[C@>Y&*^)_P!F3X+^)OCM\6-/LM(FNK6.WF6[U#6(W=3:QALL^\<[
MST'())ZUX56A5S#GQF+?+V\E_D?H^7X>AD]"&!PBYDMWU;>[?F_^ ?L)\=5+
M_!OQF%!8G2Y\ #/\!K\A?V,+F.V_:=^'YD)&_44C7CN0<5^RVM>'4N_!-[H:
M-+<(]@]HK3RL\C_N]H+.3EB>,DG)-?A=X9U.Z^$WQ7L;N0%;K0=5 D&.\<F&
M_D:G*EST:M-;O_)GH8SW9PDS][Z*RO"WB2Q\8>'--UO39DN+"_MTN(9$8,"K
M#/4=QT/N*U:^;:L[,]5:A7RS_P %(M2M;+]F?4()YTCFN;ZW2%"?FD()) %?
M3FJ:I::)IUS?W]S%9V5M&99KB=@J1J!DDD]!7Y%?MG?M$W?[3'Q".G>&8IKG
MPGH"2-;"-2?.Q_K+EO1>P]J]/+J$JM>,EM'5G)BJBA3:ZL[#_@EG_P ELUS_
M +!9_P#0J_23XL?\DL\9?]@:\_\ 1#U^;?\ P2S_ .2UZY_V"S_Z%7Z2?%C_
M ))9XR_[ UY_Z(>NC,O]\^XRPG\#[S\:?V0O^3E?A_\ ]A$?^@-7[@U^'W[(
M7_)ROP__ .PB/_0&K]P:USK^-'T_4C ? _40U^0W_!2+PQ-H/[3&I7KJRV^J
MV5O=0D]P$",1_P "5J_7JOCG_@I+\"KCXB_#*U\8Z1;F?5O#6YKA(QEI+1N7
M/J=A^; [%CVKCRRLJ.(7-L]#?%P<Z3MTU,K]BKX$?"'XN?L_:#K&K>"M)U/6
MHFEM;Z>9#YAD1R 6P0,E=I_&O=?^&-O@I_T3C1?^_;?_ !5? /\ P3R_:4M?
MA#XYN?"?B&[%KX:\0.OEW$K8CM;L?*K-Z*XPI/;:O;)K]8D<. RD,I&01WK3
M'^WP]=KF=GJM63AO9U::T5T>-_\ #&WP4_Z)QHO_ '[;_P"*H_X8V^"G_1.-
M%_[]M_\ %5[-2'I7G?6*W\[^]G5[*G_*CQK_ (8V^"G_ $3C1?\ OVW_ ,55
MK2OV2?@]H>J6>HV/P_T>VO;.9+B"9(VS'(C!E8<]00#7$?M8_MG:7^S1=Z)I
MMMIL/B77;Q_.N=,^U>28+7! <L%;:S-C:"#D*WM7<_LW?M"6/[2'@F?Q)I^@
M:EH5O!<FT87^QDED"AF\IE.74;@"2J\\=CCHDL4J2JMOE?F9+V+GR)*_H?'7
MQ5_Y*AXP_P"PS>?^CWKEJ_0G4_@+X"UC4KJ_O/#D$]W=2O/-*9907=B69L!L
M<DDU6_X9T^'/_0KV_P#W^E_^+K]$H\68.G3C!PEHDNG^9_/6*\-,TKXBI5C6
MIVDV]Y=7?^4SOV6O^2+Z-_UTG_\ 1K5ZS67X;\,Z9X1TB+2](M%LK"(L4A1B
M0"22>22>IK4K\WQE:.)Q-2M':3;^]G[UE6$G@,!0PE1IRA&,7;:Z26@5YY\:
M/A/:?%7PN]JVV'5;<&2RN2/NO_=/^R>A_/M7H=%94*]3#58UJ3M);'1C,'0S
M##SPN)CS0DK-?UU['YAZSH]YX?U2ZTZ_@>VO+:0QRQ.,%2/\]>^:IU^B_BCX
M0^#_ !IJ?]H:SH4%[>[ AF+.C$#IG:PS^-9'_#.GPY_Z%>W_ ._TO_Q=?IU/
MB_"\B]I3ES=;6M\M3^>J_A?F'M9>PKPY+Z7YKVZ7M%JYK?!S_DEWAK_KS2N=
M^-_P/L?BOIBSP,EGKUNN(+HCY7']Q\=O?M7I.DZ5::'IUO86,(M[2W0)%$I)
M"KZ<\U;K\ZCC*E'%/%4'9W;7S[G[O/*J&*RZ.7XV*E'E2?JDE==5Y,_-3QAX
M&USP)J;6.MZ?+93 D*S+^[D'JC=&'TK"K].M6T73]?LFM-2LK?4+5_O0W,2R
M*?P(KS'6/V6?A[J\C2)I<^G.QR?L=RZC_OEMP'X"OT3!<5TZJ4,13:EY6:_%
MJWXGX5F_AK7PSE5P5>+AVE=-?-)I_@?"=%?;47[('@*.0,S:K*!_ ]T,'\D!
MKM/"WP0\$>#I$FT[P_;"Y3E;BYS/(#Z@N3@_3%=V*XGPV'6D)-_)?K^AXV7^
M'V88Z=G5A&*W?O-_)67YH^6?@W^S=K'CRZM]1UF&72O#X(<M(-LMP/1 >0#_
M 'C^%>N_M#_$NS^%_A"W\'>' EI>W$/E;8>/LT&,?FW^-?00]*X?7?@CX)\3
M:K<:EJF@QWM].=TDTD\N6/X-@?A7Q4L[CC,9&OCTW3CJHK:_G=JY^MPX1GE6
M5U,'DTDJU3252=T[=;63MY+IO=L_/ DL23U[UZ;\ OA3)\3O&$8N(S_8UD1+
M=N1P_I']3_*OK/\ X9S^'/\ T*]O_P!_I?\ XNNN\*>#=%\$:<;'0]/BTZU9
MS(T<9)W,>Y)))KWL;Q92J4)0PL9*;TN[:?<WKV/C,I\-<10QM.MF%2$J<7=J
M-[OLM4M._EH:L$$=M!'%$@CBC4*JKP !T%?-?[6/PA-];?\ "9:5 3/" FH1
MH.63HLF/;H?P]Z^F:AN;:*]MY;>>-98)4*/&XR&4C!!'I7PV7XZIE^)CB(=-
MUW75'[%G>3T,[P$\%6TOL_Y6MFOZVNC\O:]Q_9C^,/\ PA'B :!J<Y71-1D
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?- %5$& H'0 =A3Z\[%XR>*:3TBMD=5'#QHKNWU/_V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>15
<FILENAME>nxtc-20221231.xsd
<DESCRIPTION>EX-101.SCH
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2023 8:38:22 PM-->
<!--Modified on: 3/2/2023 8:38:22 PM-->
<xsd:schema targetNamespace="http://www.nextcure.com/20221231" attributeFormDefault="unqualified" elementFormDefault="qualified" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:ref="http://www.xbrl.org/2006/ref" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xl="http://www.xbrl.org/2003/XLink" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:net="http://www.xbrl.org/2009/role/net" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:attributeFormDefault="unqualified" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:country="http://xbrl.sec.gov/country/2022" xmlns:currency="http://xbrl.sec.gov/currency/2022" xmlns:us-gaap="http://fasb.org/us-gaap/2022" xmlns:us-types="http://fasb.org/us-types/2022" xmlns:stpr="http://xbrl.sec.gov/stpr/2022" xmlns:us-roles="http://fasb.org/us-roles/2022" xmlns:negated="http://www.xbrl.org/2009/role/negated" xmlns:srt-types="http://fasb.org/srt-types/2022" xmlns:nxtc="http://www.nextcure.com/20221231" xmlns:enum2="http://xbrl.org/2020/extensible-enumerations-2.0" xmlns:dtr-types="http://www.xbrl.org/dtr/type/2020-01-21" xmlns:sic="http://xbrl.sec.gov/sic/2022" xmlns:srt-roles="http://fasb.org/srt-roles/2022" xmlns:utr="http://www.xbrl.org/2009/utr" xmlns:exch="http://xbrl.sec.gov/exch/2022" xmlns:naics="http://xbrl.sec.gov/naics/2022" xmlns:srt="http://fasb.org/srt/2022" xmlns:deprecated="http://www.xbrl.org/2009/role/deprecated" xmlns:dei="http://xbrl.sec.gov/dei/2022" xmlns:dtr="http://www.xbrl.org/2009/dtr" xmlns:cef="http://xbrl.sec.gov/cef/2022" xmlns:xbrldi="http://xbrl.org/2006/xbrldi">
  <xsd:annotation>
    <xsd:appinfo>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" id="DisclosureStandardAndCustomAxisDomainDefaults">
        <link:definition>99900 - Disclosure - Standard And Custom Axis Domain Defaults</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementBalanceSheets" id="StatementBalanceSheets">
        <link:definition>00100 - Statement - BALANCE SHEETS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" id="StatementStatementsOfOperationsAndComprehensiveLoss">
        <link:definition>00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementStatementsOfCashFlows" id="StatementStatementsOfCashFlows">
        <link:definition>00400 - Statement - STATEMENTS OF CASH FLOWS</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails">
        <link:definition>40201 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" id="DisclosureMarketableSecuritiesDetails">
        <link:definition>40301 - Disclosure - Marketable Securities - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" id="DisclosureFairValueMeasurementsDetails">
        <link:definition>40401 - Disclosure - Fair Value Measurements - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" id="DisclosurePropertyAndEquipmentNetDetails">
        <link:definition>40501 - Disclosure - Property and Equipment, Net - (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails" id="DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails">
        <link:definition>40601 - Disclosure - Accrued Liabilities and Other Liabilities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureLeasesMaturitiesCalc2Details" id="DisclosureLeasesMaturitiesCalc2Details">
        <link:definition>40702 - Disclosure - Leases - Maturities (Calc 2) (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails" id="DisclosureLeasesMaturitiesDetails">
        <link:definition>40702 - Disclosure - Leases - Maturities (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails" id="DisclosureIncomeTaxesReconciliationDetails">
        <link:definition>41401 - Disclosure - Income Taxes - Reconciliation (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" id="DisclosureIncomeTaxesDeferredTaxAssetsDetails">
        <link:definition>41402 - Disclosure - Income Taxes - Deferred tax assets (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DocumentDocumentAndEntityInformation" id="DocumentDocumentAndEntityInformation">
        <link:definition>00090 - Document - Document and Entity Information</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementBalanceSheetsParenthetical" id="StatementBalanceSheetsParenthetical">
        <link:definition>00105 - Statement - BALANCE SHEETS - (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity" id="StatementStatementsOfStockholdersEquity">
        <link:definition>00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical" id="StatementStatementsOfStockholdersEquityParenthetical">
        <link:definition>00305 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureMarketableSecurities" id="DisclosureMarketableSecurities">
        <link:definition>10301 - Disclosure - Marketable Securities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureTermLoan" id="DisclosureTermLoan">
        <link:definition>10901 - Disclosure - Term Loan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosurePreferredStock" id="DisclosurePreferredStock">
        <link:definition>11001 - Disclosure - Preferred Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureCommonStock" id="DisclosureCommonStock">
        <link:definition>11101 - Disclosure - Common Stock</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensation" id="DisclosureStockBasedCompensation">
        <link:definition>11201 - Disclosure - Stock-Based Compensation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" id="DisclosureNetLossPerShareAttributableToCommonStockholders">
        <link:definition>11301 - Disclosure - Net Loss per Share Attributable to Common Stockholders</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxes" id="DisclosureIncomeTaxes">
        <link:definition>11401 - Disclosure - Income Taxes</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan" id="DisclosureEmployeeBenefitPlan">
        <link:definition>11501 - Disclosure - Employee Benefit Plan</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables" id="DisclosureMarketableSecuritiesTables">
        <link:definition>30303 - Disclosure - Marketable Securities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationTables" id="DisclosureStockBasedCompensationTables">
        <link:definition>31203 - Disclosure - Stock-Based Compensation (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" id="DisclosureNetLossPerShareAttributableToCommonStockholdersTables">
        <link:definition>31303 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesTables" id="DisclosureIncomeTaxesTables">
        <link:definition>31403 - Disclosure - Income Taxes (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" id="DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails">
        <link:definition>40101 - Disclosure - Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" id="DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails">
        <link:definition>40102 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails">
        <link:definition>40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Leases (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureTermLoanOtherDetails" id="DisclosureTermLoanOtherDetails">
        <link:definition>40901 - Disclosure - Term Loan - Other (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosurePreferredStockDetails" id="DisclosurePreferredStockDetails">
        <link:definition>41001 - Disclosure - Preferred Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureCommonStockDetails" id="DisclosureCommonStockDetails">
        <link:definition>41101 - Disclosure - Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails" id="DisclosureStockBasedCompensationStockOptionsDetails">
        <link:definition>41201 - Disclosure - Stock-Based Compensation - Stock options (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" id="DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails">
        <link:definition>41202 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails" id="DisclosureStockBasedCompensationAssumptionsDetails">
        <link:definition>41203 - Disclosure - Stock-Based Compensation - Assumptions (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails" id="DisclosureStockBasedCompensationRestrictedCommonStockDetails">
        <link:definition>41204 - Disclosure - Stock-Based Compensation - Restricted Common Stock (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" id="DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails">
        <link:definition>41301 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails" id="DisclosureEmployeeBenefitPlanDetails">
        <link:definition>41501 - Disclosure - Employee Benefit Plan (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" id="DisclosureNatureOfBusinessAndBasisOfPresentation">
        <link:definition>10101 - Disclosure - Nature of the Business and Basis of Presentation</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies" id="DisclosureSummaryOfSignificantAccountingPolicies">
        <link:definition>10201 - Disclosure - Summary of Significant Accounting Policies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurements" id="DisclosureFairValueMeasurements">
        <link:definition>10401 - Disclosure - Fair Value Measurements</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet" id="DisclosurePropertyAndEquipmentNet">
        <link:definition>10501 - Disclosure - Property and Equipment, Net</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilities" id="DisclosureAccruedLiabilitiesAndOtherLiabilities">
        <link:definition>10601 - Disclosure - Accrued Liabilities and Other Liabilities</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureLeases" id="DisclosureLeases">
        <link:definition>10701 - Disclosure - Leases</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies" id="DisclosureCommitmentsAndContingencies">
        <link:definition>10801 - Disclosure - Commitments and Contingencies</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" id="DisclosureSummaryOfSignificantAccountingPoliciesPolicies">
        <link:definition>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" id="DisclosureSummaryOfSignificantAccountingPoliciesTables">
        <link:definition>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables" id="DisclosureFairValueMeasurementsTables">
        <link:definition>30403 - Disclosure - Fair Value Measurements (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables" id="DisclosurePropertyAndEquipmentNetTables">
        <link:definition>30503 - Disclosure - Property and Equipment, Net (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesTables" id="DisclosureAccruedLiabilitiesAndOtherLiabilitiesTables">
        <link:definition>30603 - Disclosure - Accrued Liabilities and Other Liabilities (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureLeasesTables" id="DisclosureLeasesTables">
        <link:definition>30703 - Disclosure - Leases (Tables)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" id="DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails">
        <link:definition>40203 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:roleType roleURI="http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails" id="DisclosureLeasesOtherInformationDetails">
        <link:definition>40701 - Disclosure - Leases - Other Information (Details)</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20221231_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20221231_def.xml" xlink:role="http://www.xbrl.org/2003/role/definitionLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20221231_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" />
      <link:linkbaseRef xlink:type="simple" xlink:href="nxtc-20221231_cal.xml" xlink:role="http://www.xbrl.org/2003/role/calculationLinkbaseRef" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:title="Calculation Links, all" />
    </xsd:appinfo>
  </xsd:annotation>
  <xsd:import namespace="http://xbrl.sec.gov/dei/2022" schemaLocation="https://xbrl.sec.gov/dei/2022/dei-2022.xsd" />
  <xsd:import namespace="http://fasb.org/us-roles/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2009/role/negated" schemaLocation="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd" />
  <xsd:import namespace="http://www.xbrl.org/dtr/type/2020-01-21" schemaLocation="https://www.xbrl.org/dtr/type/2020-01-21/types.xsd" />
  <xsd:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd" />
  <xsd:import namespace="http://xbrl.org/2005/xbrldt" schemaLocation="http://www.xbrl.org/2005/xbrldt-2005.xsd" />
  <xsd:import namespace="http://fasb.org/us-gaap/2022" schemaLocation="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd" />
  <xsd:import namespace="http://fasb.org/srt/2022" schemaLocation="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd" />
  <xsd:element id="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" name="PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_ResearchEquipmentMember" name="ResearchEquipmentMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_AccruedClinicalTrialCostsCurrent" name="AccruedClinicalTrialCostsCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="nxtc_AccruedOperatingExpensesCurrent" name="AccruedOperatingExpensesCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="nxtc_CommonStockTextBlock" name="CommonStockTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_NumberOfVotesPerShare" name="NumberOfVotesPerShare" nillable="true" type="xbrli:integerItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_A2015OmnibusIncentivePlanMember" name="A2015OmnibusIncentivePlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" name="DeferredTaxLiabilitiesDepreciationAndAmortization" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="credit" />
  <xsd:element id="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" name="DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" name="PaymentsOfUnderwritingDiscountsAndCommissions" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="nxtc_OmnibusIncentive2019PlanMember" name="OmnibusIncentive2019PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_EmployeeStockPurchase2019PlanMember" name="EmployeeStockPurchase2019PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" name="ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" nillable="true" type="dtr-types:percentItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" name="ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" nillable="true" type="xbrli:sharesItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_RequiredReserveRestrictedCashCurrent" name="RequiredReserveRestrictedCashCurrent" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_PreferredStockAbstract" name="PreferredStockAbstract" nillable="true" type="xbrli:stringItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" name="ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" nillable="true" type="xbrli:durationItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" name="OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" nillable="true" type="dtr-types:domainItemType" substitutionGroup="xbrli:item" abstract="true" xbrli:periodType="duration" />
  <xsd:element id="nxtc_MarketableSecuritiesAndCashEquivalents" name="MarketableSecuritiesAndCashEquivalents" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" name="ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" nillable="true" type="dtr-types:textBlockItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" />
  <xsd:element id="nxtc_InterestIncomeNonOperating" name="InterestIncomeNonOperating" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" name="DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" name="OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="duration" xbrli:balance="credit" />
  <xsd:element id="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element id="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" name="AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" nillable="true" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" xbrli:periodType="instant" xbrli:balance="debit" />
  <xsd:element name="AccruedSponsoredResearchExpenseCurrent" id="nxtc_AccruedSponsoredResearchExpenseCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DepreciationDepletionAndAmortizationAndOther" id="nxtc_DepreciationDepletionAndAmortizationAndOther" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="EarningsPerSharesBasicAndDilutedAbstract" id="nxtc_EarningsPerSharesBasicAndDilutedAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="FairValuesAssetsLevel1ToLevel2TransfersAmount" id="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="FairValuesAssetsLevel2ToLevel1TransfersAmount" id="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract" id="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract" type="xbrli:stringItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="true" />
  <xsd:element name="NoncashOperatingLeaseExpense" id="nxtc_NoncashOperatingLeaseExpense" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="debit" />
  <xsd:element name="OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount" id="nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="AccruedAndOtherLiabilitiesCurrent" id="nxtc_AccruedAndOtherLiabilitiesCurrent" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="credit" />
  <xsd:element name="IncreaseDecreaseInAccruedAndOtherCurrentLiabilities" id="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="duration" abstract="false" xbrli:balance="credit" />
  <xsd:element name="DeferredTaxAssetsOperatingLeaseLiabilities" id="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
  <xsd:element name="DeferredTaxAssetsCapitalizedResearchAndDevelopment" id="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment" type="xbrli:monetaryItemType" substitutionGroup="xbrli:item" nillable="true" xbrli:periodType="instant" abstract="false" xbrli:balance="debit" />
</xsd:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.CAL
<SEQUENCE>16
<FILENAME>nxtc-20221231_cal.xml
<DESCRIPTION>EX-101.CAL
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2023 8:38:22 PM-->
<!--Modified on: 3/2/2023 8:38:22 PM-->
<link:linkbase xmlns="http://www.xbrl.org/2003/linkbase" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:xlink="http://www.w3.org/1999/xlink" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance">
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#StatementBalanceSheets" roleURI="http://www.nextcure.com/role/StatementBalanceSheets" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.nextcure.com/role/StatementStatementsOfCashFlows" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails" roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureLeasesMaturitiesCalc2Details" roleURI="http://www.nextcure.com/role/DisclosureLeasesMaturitiesCalc2Details" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureLeasesMaturitiesDetails" roleURI="http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" />
  <calculationLink xlink:role="http://www.nextcure.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638133863013397973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_AssetsCurrent_638133863013397973" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638133863013397973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638133863013397973" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638133863013397973" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_638133863013397973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638133863013397973" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_638133863013397973" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638133863013397973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AssetsCurrent_638133863013397973" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638133863013397973" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638133863013397973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638133863013397973" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638133863013397973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638133863013397973" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638133863013397973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Assets" xlink:to="us-gaap_OtherAssetsNoncurrent_638133863013397973" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638133863013397973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_StockholdersEquity_638133863013397973" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638133863013407973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638133863013397973" xlink:to="us-gaap_PreferredStockValue_638133863013407973" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638133863013407973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638133863013397973" xlink:to="us-gaap_CommonStockValue_638133863013407973" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638133863013407973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638133863013397973" xlink:to="us-gaap_AdditionalPaidInCapital_638133863013407973" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638133863013407973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638133863013397973" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638133863013407973" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638133863013407973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_StockholdersEquity_638133863013397973" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638133863013407973" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638133863013407973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_Liabilities_638133863013407973" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638133863013407973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638133863013407973" xlink:to="us-gaap_LiabilitiesCurrent_638133863013407973" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638133863013407973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638133863013407973" xlink:to="us-gaap_AccountsPayableCurrent_638133863013407973" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedAndOtherLiabilitiesCurrent" xlink:label="nxtc_AccruedAndOtherLiabilitiesCurrent_638133863013417973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LiabilitiesCurrent_638133863013407973" xlink:to="nxtc_AccruedAndOtherLiabilitiesCurrent_638133863013417973" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638133863013417973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638133863013407973" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638133863013417973" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638133863013417973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_Liabilities_638133863013407973" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638133863013417973" order="3" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638133863013417973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638133863013417973" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638133863013417973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_NetIncomeLoss_638133863013417973" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638133863013417973" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638133863013417973" xlink:to="us-gaap_OperatingIncomeLoss_638133863013417973" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638133863013427972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingIncomeLoss_638133863013417973" xlink:to="us-gaap_OperatingExpenses_638133863013427972" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638133863013427972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638133863013427972" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638133863013427972" order="1" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638133863013427972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_OperatingExpenses_638133863013427972" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638133863013427972" order="2" use="optional" weight="1" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638133863013427972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetIncomeLoss_638133863013417973" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638133863013427972" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" order="1" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638133863013427972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638133863013427972" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DepreciationDepletionAndAmortizationAndOther" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther_638133863013427972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" xlink:to="nxtc_DepreciationDepletionAndAmortizationAndOther_638133863013427972" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_NoncashOperatingLeaseExpense" xlink:label="nxtc_NoncashOperatingLeaseExpense_638133863013427972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" xlink:to="nxtc_NoncashOperatingLeaseExpense_638133863013427972" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638133863013437972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638133863013437972" order="4" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638133863013437972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638133863013437972" order="5" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities" xlink:label="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities_638133863013437972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" xlink:to="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities_638133863013437972" order="6" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638133863013437972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638133863013437972" order="7" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638133863013437972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638133863013437972" order="8" use="optional" weight="-1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638133863013437972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" xlink:to="us-gaap_ProfitLoss_638133863013437972" order="9" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638133863013437972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013427972" xlink:to="us-gaap_ShareBasedCompensation_638133863013437972" order="10" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638133863013437972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638133863013437972" order="2" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638133863013437972" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638133863013437972" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638133863013437972" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638133863013447967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638133863013437972" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638133863013447967" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638133863013447967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities_638133863013437972" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638133863013447967" order="3" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638133863013447967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638133863013447967" order="3" use="optional" weight="1" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638133863013447967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638133863013447967" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638133863013447967" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638133863013447967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638133863013447967" xlink:to="us-gaap_ProceedsFromStockPlans_638133863013447967" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638133863013447967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638133863013447967" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638133863013447967" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638133863013447967" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities_638133863013447967" xlink:to="us-gaap_RepaymentsOfDebt_638133863013447967" order="4" use="optional" weight="-1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638133863013457969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638133863013457969" order="1" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable Securities - (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_638133863013457969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_638133863013457969" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638133863013457969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638133863013457969" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638133863013457969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638133863013457969" order="3" use="optional" weight="-1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638133863013457969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638133863013457969" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_638133863013457969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_638133863013457969" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_638133863013467969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_638133863013467969" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_638133863013467969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_638133863013467969" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - (Details)">
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_MarketableSecuritiesAndCashEquivalents" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638133863013467969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nxtc_MarketableSecuritiesAndCashEquivalents" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638133863013467969" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_638133863013467969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nxtc_MarketableSecuritiesAndCashEquivalents" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_638133863013467969" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment, Net - (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638133863013467969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638133863013467969" order="1" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638133863013467969" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638133863013467969" order="2" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Liabilities and Other Liabilities (Details)">
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedAndOtherLiabilitiesCurrent" xlink:label="nxtc_AccruedAndOtherLiabilitiesCurrent_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638133863013477970" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nxtc_AccruedAndOtherLiabilitiesCurrent_1" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638133863013477970" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedClinicalTrialCostsCurrent" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent_638133863013477970" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nxtc_AccruedAndOtherLiabilitiesCurrent_1" xlink:to="nxtc_AccruedClinicalTrialCostsCurrent_638133863013477970" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedSponsoredResearchExpenseCurrent" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent_638133863013477970" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nxtc_AccruedAndOtherLiabilitiesCurrent_1" xlink:to="nxtc_AccruedSponsoredResearchExpenseCurrent_638133863013477970" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638133863013477970" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nxtc_AccruedAndOtherLiabilitiesCurrent_1" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638133863013477970" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedOperatingExpensesCurrent" xlink:label="nxtc_AccruedOperatingExpensesCurrent_638133863013477970" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nxtc_AccruedAndOtherLiabilitiesCurrent_1" xlink:to="nxtc_AccruedOperatingExpensesCurrent_638133863013477970" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638133863013477970" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="nxtc_AccruedAndOtherLiabilitiesCurrent_1" xlink:to="us-gaap_OtherLiabilitiesCurrent_638133863013477970" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureLeasesMaturitiesCalc2Details" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Maturities (Calc 2) (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638133863013477970" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638133863013477970" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638133863013477970" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_1" xlink:to="us-gaap_OperatingLeaseLiability_638133863013477970" order="2" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Maturities (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638133863013487971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638133863013487971" order="1" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638133863013487971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638133863013487971" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638133863013487971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638133863013487971" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638133863013487971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638133863013487971" order="4" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638133863013487971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638133863013487971" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638133863013487971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638133863013487971" order="6" use="optional" weight="1" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income Taxes - Reconciliation (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638133863013487971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638133863013487971" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638133863013487971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638133863013487971" order="2" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638133863013487971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638133863013487971" order="3" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_638133863013497971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_638133863013497971" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638133863013497971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638133863013497971" order="5" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638133863013497971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638133863013497971" order="6" use="optional" weight="1" priority="2" />
  </calculationLink>
  <calculationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Income Taxes - Deferred tax assets (Details)">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638133863013497971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsNet_638133863013497971" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638133863013497971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638133863013497971" xlink:to="us-gaap_DeferredTaxAssetsGross_638133863013497971" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638133863013497971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638133863013497971" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638133863013497971" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment_638133863013497971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638133863013497971" xlink:to="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment_638133863013497971" order="2" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities_638133863013497971" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638133863013497971" xlink:to="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities_638133863013497971" order="3" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638133863013507981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638133863013497971" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638133863013507981" order="4" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638133863013507981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638133863013497971" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638133863013507981" order="5" use="optional" weight="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_638133863013507981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsGross_638133863013497971" xlink:to="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_638133863013507981" order="6" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638133863013507981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsNet_638133863013497971" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638133863013507981" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638133863013507981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638133863013507981" order="2" use="optional" weight="-1" priority="2" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_638133863013507981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638133863013507981" xlink:to="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_638133863013507981" order="1" use="optional" weight="1" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638133863013507981" />
    <calculationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/summation-item" xlink:from="us-gaap_DeferredIncomeTaxLiabilities_638133863013507981" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638133863013507981" order="2" use="optional" weight="1" />
  </calculationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.DEF
<SEQUENCE>17
<FILENAME>nxtc-20221231_def.xml
<DESCRIPTION>EX-101.DEF
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2023 8:38:22 PM-->
<!--Modified on: 3/2/2023 8:38:22 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrldt="http://xbrl.org/2005/xbrldt" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://www.esma.europa.eu/xbrl/esef/arcrole/wider-narrower" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd#wider-narrower" />
  <link:roleRef roleURI="http://www.nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:href="nxtc-20221231.xsd#DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="simple" />
  <roleRef xlink:type="simple" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd#eedm" roleURI="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/all" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#all" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-domain" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-domain" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/domain-member" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#domain-member" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/hypercube-dimension" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#hypercube-dimension" />
  <link:arcroleRef arcroleURI="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:type="simple" xlink:href="http://www.xbrl.org/2005/xbrldt-2005.xsd#dimension-default" />
  <definitionLink xlink:role="http://fasb.org/us-gaap/role/eedm/ExtensibleEnumerationLists" xlink:type="extended" xlink:title="Extensible Enumeration Domain Members" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_1" xlink:title="us-gaap_LiabilitiesCurrentAbstract_1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedAndOtherLiabilitiesCurrent" xlink:label="nxtc_AccruedAndOtherLiabilitiesCurrent_1" xlink:title="nxtc_AccruedAndOtherLiabilitiesCurrent_1" />
    <definitionArc xlink:type="arc" xlink:from="us-gaap_LiabilitiesCurrentAbstract_1" xlink:to="nxtc_AccruedAndOtherLiabilitiesCurrent_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" xlink:title="definition:us-gaap_LiabilitiesCurrentAbstract_1 To nxtc_AccruedAndOtherLiabilitiesCurrent_1" order="2" priority="0" />
  </definitionLink>
  <link:definitionLink xlink:role="http://www.nextcure.com/role/DisclosureStandardAndCustomAxisDomainDefaults" xlink:type="extended" xlink:title="99900 - Disclosure - Standard And Custom Axis Domain Defaults">
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LegalEntityAxis" xlink:label="dei_LegalEntityAxis_1" xlink:title="dei_LegalEntityAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityDomain" xlink:label="dei_EntityDomain_1" xlink:title="dei_EntityDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="dei_LegalEntityAxis_1" xlink:to="dei_EntityDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:dei_LegalEntityAxis_1 To dei_EntityDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementClassOfStockAxis" xlink:label="us-gaap_StatementClassOfStockAxis_1" xlink:title="us-gaap_StatementClassOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockDomain" xlink:label="us-gaap_ClassOfStockDomain_1" xlink:title="us-gaap_ClassOfStockDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementClassOfStockAxis_1" xlink:to="us-gaap_ClassOfStockDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementClassOfStockAxis_1 To us-gaap_ClassOfStockDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_1" xlink:title="us-gaap_StatementEquityComponentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_1" xlink:title="us-gaap_EquityComponentDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_StatementEquityComponentsAxis_1" xlink:to="us-gaap_EquityComponentDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_StatementEquityComponentsAxis_1 To us-gaap_EquityComponentDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_1" xlink:title="us-gaap_FinancialInstrumentAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" xlink:title="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FinancialInstrumentAxis_1" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FinancialInstrumentAxis_1 To us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_1" xlink:title="us-gaap_CashAndCashEquivalentsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" xlink:title="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_CashAndCashEquivalentsAxis_1" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_CashAndCashEquivalentsAxis_1 To us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:title="us-gaap_FairValueByMeasurementBasisAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" xlink:title="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_1" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByMeasurementBasisAxis_1 To us-gaap_PortionAtFairValueFairValueDisclosureMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:title="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" xlink:title="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_1" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_FairValueByFairValueHierarchyLevelAxis_1 To us-gaap_FairValueMeasurementsFairValueHierarchyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfArrangementAxis" xlink:label="us-gaap_TypeOfArrangementAxis_1" xlink:title="us-gaap_TypeOfArrangementAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ArrangementsAndNonarrangementTransactionsMember" xlink:label="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" xlink:title="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_TypeOfArrangementAxis_1" xlink:to="us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_TypeOfArrangementAxis_1 To us-gaap_ArrangementsAndNonarrangementTransactionsMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CounterpartyNameAxis" xlink:label="srt_CounterpartyNameAxis_1" xlink:title="srt_CounterpartyNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RepurchaseAgreementCounterpartyNameDomain" xlink:label="srt_RepurchaseAgreementCounterpartyNameDomain_1" xlink:title="srt_RepurchaseAgreementCounterpartyNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CounterpartyNameAxis_1" xlink:to="srt_RepurchaseAgreementCounterpartyNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CounterpartyNameAxis_1 To srt_RepurchaseAgreementCounterpartyNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:title="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_1" xlink:title="us-gaap_AntidilutiveSecuritiesNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_1 To us-gaap_AntidilutiveSecuritiesNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_1" xlink:title="us-gaap_PlanNameAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_1" xlink:title="us-gaap_PlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PlanNameAxis_1" xlink:to="us-gaap_PlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PlanNameAxis_1 To us-gaap_PlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_1" xlink:title="srt_RangeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_1" xlink:title="srt_RangeMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_RangeAxis_1" xlink:to="srt_RangeMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_RangeAxis_1 To srt_RangeMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AwardTypeAxis" xlink:label="us-gaap_AwardTypeAxis_1" xlink:title="us-gaap_AwardTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" xlink:title="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AwardTypeAxis_1" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AwardTypeAxis_1 To us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardAwardTypeAndPlanNameDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_1" xlink:title="us-gaap_IncomeStatementLocationAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_1" xlink:title="us-gaap_IncomeStatementLocationDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_IncomeStatementLocationAxis_1" xlink:to="us-gaap_IncomeStatementLocationDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_IncomeStatementLocationAxis_1 To us-gaap_IncomeStatementLocationDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_StatementScenarioAxis" xlink:label="srt_StatementScenarioAxis_1" xlink:title="srt_StatementScenarioAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_ScenarioUnspecifiedDomain" xlink:label="srt_ScenarioUnspecifiedDomain_1" xlink:title="srt_ScenarioUnspecifiedDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_StatementScenarioAxis_1" xlink:to="srt_ScenarioUnspecifiedDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_StatementScenarioAxis_1 To srt_ScenarioUnspecifiedDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeAxis" xlink:label="us-gaap_SubsequentEventTypeAxis_1" xlink:title="us-gaap_SubsequentEventTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTypeDomain" xlink:label="us-gaap_SubsequentEventTypeDomain_1" xlink:title="us-gaap_SubsequentEventTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsequentEventTypeAxis_1" xlink:to="us-gaap_SubsequentEventTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsequentEventTypeAxis_1 To us-gaap_SubsequentEventTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:title="us-gaap_SubsidiarySaleOfStockAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_1" xlink:title="us-gaap_SaleOfStockNameOfTransactionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_1" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_SubsidiarySaleOfStockAxis_1 To us-gaap_SaleOfStockNameOfTransactionDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:title="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" xlink:title="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_1" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_PropertyPlantAndEquipmentByTypeAxis_1 To us-gaap_PropertyPlantAndEquipmentTypeDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateAxis" xlink:label="us-gaap_VariableRateAxis_1" xlink:title="us-gaap_VariableRateAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_VariableRateDomain" xlink:label="us-gaap_VariableRateDomain_1" xlink:title="us-gaap_VariableRateDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_VariableRateAxis_1" xlink:to="us-gaap_VariableRateDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_VariableRateAxis_1 To us-gaap_VariableRateDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyTransactionsByRelatedPartyAxis" xlink:label="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:title="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RelatedPartyDomain" xlink:label="us-gaap_RelatedPartyDomain_1" xlink:title="us-gaap_RelatedPartyDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1" xlink:to="us-gaap_RelatedPartyDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_RelatedPartyTransactionsByRelatedPartyAxis_1 To us-gaap_RelatedPartyDomain_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsForNewAccountingPronouncementsAxis" xlink:label="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:title="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TypeOfAdoptionMember" xlink:label="us-gaap_TypeOfAdoptionMember_1" xlink:title="us-gaap_TypeOfAdoptionMember_1" />
    <link:definitionArc xlink:type="arc" xlink:from="us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1" xlink:to="us-gaap_TypeOfAdoptionMember_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:us-gaap_AdjustmentsForNewAccountingPronouncementsAxis_1 To us-gaap_TypeOfAdoptionMember_1" order="1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionAxis" xlink:label="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionAxis_1" />
    <link:loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_CumulativeEffectPeriodOfAdoptionDomain" xlink:label="srt_CumulativeEffectPeriodOfAdoptionDomain_1" xlink:title="srt_CumulativeEffectPeriodOfAdoptionDomain_1" />
    <link:definitionArc xlink:type="arc" xlink:from="srt_CumulativeEffectPeriodOfAdoptionAxis_1" xlink:to="srt_CumulativeEffectPeriodOfAdoptionDomain_1" use="optional" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-default" xlink:title="definition:srt_CumulativeEffectPeriodOfAdoptionAxis_1 To srt_CumulativeEffectPeriodOfAdoptionDomain_1" order="1" />
  </link:definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementEquityComponentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_EquityComponentDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_CommonStockMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AdditionalPaidInCapitalMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_RetainedEarningsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockholdersEquity" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_NetIncomeLoss" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsidiarySaleOfStockAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_IPOMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SharePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="11" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="12" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="13" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockSharesAuthorized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="14" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_EquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeasePracticalExpedientsPackage" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_LeasePracticalExpedientUseOfHindsight" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable Securities - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_InterestIncomeNonOperating" xlink:label="nxtc_InterestIncomeNonOperating" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="nxtc_InterestIncomeNonOperating" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_CashAndCashEquivalentsAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_MoneyMarketFundsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="2" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByMeasurementBasisAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="3" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel1Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueInputsLevel2Member" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="4" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FinancialInstrumentAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" use="optional" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_CorporateDebtSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_MarketableSecuritiesAndCashEquivalents" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="nxtc_MarketableSecuritiesAndCashEquivalents" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount" xlink:label="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount" xlink:label="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment, Net - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ResearchEquipmentMember" xlink:label="nxtc_ResearchEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="nxtc_ResearchEquipmentMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_LeaseholdImprovementsMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ComputerEquipmentMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_FurnitureAndFixturesMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_ConstructionInProgressMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNet" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_DepreciationDepletionAndAmortization" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stock-Based Compensation - Stock options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_PlanNameAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_A2015OmnibusIncentivePlanMember" xlink:label="nxtc_A2015OmnibusIncentivePlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_PlanNameDomain" xlink:to="nxtc_A2015OmnibusIncentivePlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OmnibusIncentive2019PlanMember" xlink:label="nxtc_OmnibusIncentive2019PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_PlanNameDomain" xlink:to="nxtc_OmnibusIncentive2019PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" xlink:label="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_PlanNameDomain" xlink:to="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_EmployeeStockPurchase2019PlanMember" xlink:label="nxtc_EmployeeStockPurchase2019PlanMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_PlanNameDomain" xlink:to="nxtc_EmployeeStockPurchase2019PlanMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="9" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="10" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="4" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="5" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="6" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="7" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="8" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_IncomeStatementLocationAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_StatementTable" xlink:to="srt_RangeAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="srt_RangeAxis" xlink:to="srt_RangeMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="srt_RangeMember" xlink:to="srt_MinimumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="srt_RangeMember" xlink:to="srt_MaximumMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" priority="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="3" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" priority="1" use="optional" />
  </definitionLink>
  <definitionLink xlink:role="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/hypercube-dimension" order="1" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/dimension-domain" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_EmployeeStockOptionMember" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/all" order="1" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" use="optional" xbrldt:contextElement="segment" xbrldt:closed="true" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" />
    <definitionArc xlink:type="arc" xlink:arcrole="http://xbrl.org/int/dim/arcrole/domain-member" order="2" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" priority="1" use="optional" />
  </definitionLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>18
<FILENAME>nxtc-20221231_lab.xml
<DESCRIPTION>EX-101.LAB
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2023 8:38:22 PM-->
<!--Modified on: 3/2/2023 8:38:22 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xbrldt="http://xbrl.org/2005/xbrldt">
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel" roleURI="http://www.xbrl.org/2009/role/negatedLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel" roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xmlns="http://www.xbrl.org/2003/linkbase" />
  <link:labelLink xlink:type="extended" xlink:role="http://www.xbrl.org/2003/role/link">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CoverAbstract" xlink:to="dei_CoverAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CoverAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cover Abstract</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementTable" xlink:to="us-gaap_StatementTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementLineItems" xlink:to="us-gaap_StatementLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Statement [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentType" xlink:to="dei_DocumentType_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentType_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Type</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentAnnualReport" xlink:to="dei_DocumentAnnualReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentAnnualReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Annual Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentPeriodEndDate" xlink:to="dei_DocumentPeriodEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentPeriodEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Period End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentTransitionReport" xlink:to="dei_DocumentTransitionReport_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentTransitionReport_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Transition Report</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFileNumber" xlink:to="dei_EntityFileNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFileNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity File Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityRegistrantName" xlink:to="dei_EntityRegistrantName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityRegistrantName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Registrant Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCentralIndexKey" xlink:to="dei_EntityCentralIndexKey_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCentralIndexKey_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Central Index Key</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityIncorporationStateCountryCode" xlink:to="dei_EntityIncorporationStateCountryCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityIncorporationStateCountryCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Incorporation, State or Country Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityTaxIdentificationNumber" xlink:to="dei_EntityTaxIdentificationNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityTaxIdentificationNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Tax Identification Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressAddressLine1" xlink:to="dei_EntityAddressAddressLine1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressAddressLine1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Address Line One</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressCityOrTown" xlink:to="dei_EntityAddressCityOrTown_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressCityOrTown_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, City or Town</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressStateOrProvince" xlink:to="dei_EntityAddressStateOrProvince_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressStateOrProvince_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, State or Province</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityAddressPostalZipCode" xlink:to="dei_EntityAddressPostalZipCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityAddressPostalZipCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Address, Postal Zip Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CityAreaCode" xlink:to="dei_CityAreaCode_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CityAreaCode_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">City Area Code</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_LocalPhoneNumber" xlink:to="dei_LocalPhoneNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_LocalPhoneNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Local Phone Number</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_Security12bTitle" xlink:to="dei_Security12bTitle_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_Security12bTitle_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Title of 12(b) Security</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_TradingSymbol" xlink:to="dei_TradingSymbol_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_TradingSymbol_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Trading Symbol</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_SecurityExchangeName" xlink:to="dei_SecurityExchangeName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_SecurityExchangeName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Security Exchange Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityWellKnownSeasonedIssuer" xlink:to="dei_EntityWellKnownSeasonedIssuer_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityWellKnownSeasonedIssuer_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Well-known Seasoned Issuer</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityVoluntaryFilers" xlink:to="dei_EntityVoluntaryFilers_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityVoluntaryFilers_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Voluntary Filers</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCurrentReportingStatus" xlink:to="dei_EntityCurrentReportingStatus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCurrentReportingStatus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Current Reporting Status</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityInteractiveDataCurrent" xlink:to="dei_EntityInteractiveDataCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityInteractiveDataCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Interactive Data Current</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityFilerCategory" xlink:to="dei_EntityFilerCategory_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityFilerCategory_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Filer Category</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntitySmallBusiness" xlink:to="dei_EntitySmallBusiness_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntitySmallBusiness_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Small Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityEmergingGrowthCompany" xlink:to="dei_EntityEmergingGrowthCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityEmergingGrowthCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Emerging Growth Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityExTransitionPeriod" xlink:to="dei_EntityExTransitionPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityExTransitionPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Ex Transition Period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_IcfrAuditorAttestationFlag" xlink:to="dei_IcfrAuditorAttestationFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_IcfrAuditorAttestationFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">ICFR Auditor Attestation Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityShellCompany" xlink:to="dei_EntityShellCompany_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityShellCompany_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Shell Company</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityPublicFloat" xlink:to="dei_EntityPublicFloat_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityPublicFloat_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Public Float</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_EntityCommonStockSharesOutstanding" xlink:to="dei_EntityCommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_EntityCommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Entity Common Stock, Shares Outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_CurrentFiscalYearEndDate" xlink:to="dei_CurrentFiscalYearEndDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_CurrentFiscalYearEndDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current Fiscal Year End Date</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalYearFocus" xlink:to="dei_DocumentFiscalYearFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalYearFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Year Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_DocumentFiscalPeriodFocus" xlink:to="dei_DocumentFiscalPeriodFocus_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_DocumentFiscalPeriodFocus_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Document Fiscal Period Focus</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AmendmentFlag" xlink:to="dei_AmendmentFlag_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AmendmentFlag_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amendment Flag</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorName" xlink:to="dei_AuditorName_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorName_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Name</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorFirmId" xlink:to="dei_AuditorFirmId_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorFirmId_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Firm ID</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="dei_AuditorLocation" xlink:to="dei_AuditorLocation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="dei_AuditorLocation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Auditor Location</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_StatementOfFinancialPositionAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfFinancialPositionAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">BALANCE SHEETS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsAbstract" xlink:to="us-gaap_AssetsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrentAbstract" xlink:to="us-gaap_AssetsCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AssetsCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, at Carrying Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid Expense and Other Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetsCurrent" xlink:to="us-gaap_AssetsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AssetsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNet" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseRightOfUseAsset" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Right-of-Use Asset</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right of use assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherAssetsNoncurrent" xlink:to="us-gaap_OtherAssetsNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Assets, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherAssetsNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Assets" xlink:to="us-gaap_Assets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Assets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Stockholders' Equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrentAbstract" xlink:to="us-gaap_LiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Current liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableCurrent" xlink:to="us-gaap_AccountsPayableCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedAndOtherLiabilitiesCurrent" xlink:label="nxtc_AccruedAndOtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AccruedAndOtherLiabilitiesCurrent" xlink:to="nxtc_AccruedAndOtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities and amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued and Other Liabilities Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities and other liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="nxtc_AccruedAndOtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total accrued liabilities and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesCurrent" xlink:to="us-gaap_LiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total current liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, long term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesNoncurrent" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Noncurrent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_Liabilities" xlink:to="us-gaap_Liabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_Liabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityAbstract" xlink:to="us-gaap_StockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockValue" xlink:to="us-gaap_PreferredStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PreferredStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock; par value of $0.001 per share; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, No shares issued and outstanding at December 31, 2022 and December 31, 2021</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockValue" xlink:to="us-gaap_CommonStockValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Value, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value of $0.001 per share; 100,000,000 shares authorized at December 31, 2022 and December 31, 2021. 27,774,536 and 27,680,997 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapital" xlink:to="us-gaap_AdditionalPaidInCapital_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid in Capital</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdditionalPaidInCapital_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional paid-in capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss), Net of Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated other comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsAccumulatedDeficit" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Retained Earnings (Accumulated Deficit)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquity" xlink:to="us-gaap_StockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_StockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LiabilitiesAndStockholdersEquity" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Liabilities and Equity</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total liabilities and stockholders' equity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockParOrStatedValuePerShare" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, par value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesAuthorized" xlink:to="us-gaap_PreferredStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesIssued" xlink:to="us-gaap_PreferredStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockSharesOutstanding" xlink:to="us-gaap_PreferredStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock, Shares Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockParOrStatedValuePerShare" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Par or Stated Value Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, par value per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesAuthorized" xlink:to="us-gaap_CommonStockSharesAuthorized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares Authorized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesAuthorized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, number of shares authorized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesIssued" xlink:to="us-gaap_CommonStockSharesIssued_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Issued</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesIssued_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockSharesOutstanding" xlink:to="us-gaap_CommonStockSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Shares, Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Balance at the beginning (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common stock, shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_IncomeStatementAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpensesAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingExpensesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpense" xlink:to="us-gaap_ResearchAndDevelopmentExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpense" xlink:to="us-gaap_GeneralAndAdministrativeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and Administrative Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GeneralAndAdministrativeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingExpenses" xlink:to="us-gaap_OperatingExpenses_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Expenses</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingExpenses_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingIncomeLoss" xlink:to="us-gaap_OperatingIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Income (Loss)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss from operations</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherNonoperatingIncomeExpense" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Nonoperating Income (Expense)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other income, net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetIncomeLoss" xlink:to="us-gaap_NetIncomeLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss) Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetIncomeLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_EarningsPerSharesBasicAndDilutedAbstract" xlink:label="nxtc_EarningsPerSharesBasicAndDilutedAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_EarningsPerSharesBasicAndDilutedAbstract" xlink:to="nxtc_EarningsPerSharesBasicAndDilutedAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_EarningsPerSharesBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Not available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_EarningsPerSharesBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Shares Basic And Diluted Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_EarningsPerSharesBasicAndDilutedAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss per common share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareBasic" xlink:to="us-gaap_EarningsPerShareBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareDiluted" xlink:to="us-gaap_EarningsPerShareDiluted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EarningsPerShareDiluted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract" xlink:label="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract" xlink:to="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Not available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Shares Basic And Diluted Other Disclosures Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average shares outstanding</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Basic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basic (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Number of Shares Outstanding, Diluted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Diluted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive loss:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized (loss) on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomeNetOfTax" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss), Net of Tax, Attributable to Parent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total comprehensive loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF STOCKHOLDERS EQUITY</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementEquityComponentsAxis" xlink:to="us-gaap_StatementEquityComponentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementEquityComponentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Components [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquityComponentDomain" xlink:to="us-gaap_EquityComponentDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquityComponentDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equity Component [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockMember" xlink:to="us-gaap_CommonStockMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdditionalPaidInCapitalMember" xlink:to="us-gaap_AdditionalPaidInCapitalMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdditionalPaidInCapitalMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Additional Paid-in Capital</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Other Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RetainedEarningsMember" xlink:to="us-gaap_RetainedEarningsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RetainedEarningsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Equity [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Stockholders' Deficit</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercise of stock options (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, New Issues</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of common stock (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Value, Employee Stock Purchase Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Issued During Period, Shares, Employee Stock Purchase Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Issuance of shares under ESPP (in shares)</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" xlink:to="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjusted amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on marketable securities, net of tax $0</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized gain (loss) on marketable securities, tax expense (benefit)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_StatementOfCashFlowsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StatementOfCashFlowsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">STATEMENTS OF CASH FLOWS</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from operating activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProfitLoss" xlink:to="us-gaap_ProfitLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Income (Loss), Including Portion Attributable to Noncontrolling Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProfitLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Adjustments to reconcile net loss to net cash used in operating activities:</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DepreciationDepletionAndAmortizationAndOther" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DepreciationDepletionAndAmortizationAndOther" xlink:to="nxtc_DepreciationDepletionAndAmortizationAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets and other items.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation Depletion And Amortization And Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accretion (Amortization) of Discounts and Premiums, Investments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortization of premiums and discounts on marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensation" xlink:to="us-gaap_ShareBasedCompensation_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensation_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-based compensation</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_NoncashOperatingLeaseExpense" xlink:label="nxtc_NoncashOperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_NoncashOperatingLeaseExpense" xlink:to="nxtc_NoncashOperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the amount of noncash operating lease expense.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Operating Lease Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_NoncashOperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash operating lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gain (Loss) on Disposition of Property Plant Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Loss on disposal of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Operating Capital [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Changes in operating assets and liabilities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Prepaid Expense and Other Assets</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prepaid expenses and other assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInAccountsPayable" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Accounts Payable</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts payable</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities" xlink:label="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities" xlink:to="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and Other Current Liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase Decrease In Accrued And Other Current Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued liabilities and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase (Decrease) in Other Noncurrent Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other long-term liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash used in operating activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from investing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Sale and Maturity of Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sales and maturities of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquireMarketableSecurities" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Marketable Securities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of marketable securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments to Acquire Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Purchases of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Investing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by investing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash flows from financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance Initial Public Offering</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of shares, net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from public offering of common stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockOptionsExercised" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Options Exercised</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from exercise of stock options</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromStockPlans" xlink:to="us-gaap_ProceedsFromStockPlans_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Stock Plans</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromStockPlans_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from shares issued under ESPP</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RepaymentsOfDebt" xlink:to="us-gaap_RepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayments of Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_RepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of the term loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Cash Provided by (Used in) Financing Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net cash provided by (used in) financing activities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net increase (decrease) in cash and cash equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents - end of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and cash equivalents - beginning of period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental Cash Flow Information [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of cash flow information:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InterestPaidNet" xlink:to="us-gaap_InterestPaidNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Paid, Excluding Capitalized Interest, Operating Activities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_InterestPaidNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash paid for interest</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Noncash Investing and Financing Items [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Supplemental disclosures of noncash investing and financing activities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-of-Use Asset Obtained in Exchange for Operating Lease Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Right-o-use assets obtained in exchange for operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount" xlink:label="nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount" xlink:to="nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The amount of operating lease liabilities initial lease recognition amount.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease Liabilities Initial Lease Recognition Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recognition of initial lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business and Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AccountingPoliciesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountingPoliciesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SignificantAccountingPoliciesTextBlock" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Accounting Policies [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of Significant Accounting Policies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueDisclosuresTextBlock" xlink:to="us-gaap_FairValueDisclosuresTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Disclosures [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueDisclosuresTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Measurements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accounts Payable and Accrued Liabilities Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Liabilities and Other Liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LeasesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeasesTextBlock" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Leases [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Commitments and Contingencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtDisclosureTextBlock" xlink:to="us-gaap_DebtDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Term Loan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock.</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PreferredStockTextBlock" xlink:to="us-gaap_PreferredStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PreferredStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock.</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_CommonStockTextBlock" xlink:label="nxtc_CommonStockTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_CommonStockTextBlock" xlink:to="nxtc_CommonStockTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_CommonStockTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Disclosure of Compensation Related Costs, Share-based Payments [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock-Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerShareTextBlock" xlink:to="us-gaap_EarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share Attributable to Common Stockholders</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxDisclosureTextBlock" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Pension and Other Postretirement Benefits Disclosure [Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Benefit Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Accounting, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Basis of Presentation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UseOfEstimates" xlink:to="us-gaap_UseOfEstimates_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UseOfEstimates_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Use of Estimates</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MarketableSecuritiesPolicy" xlink:to="us-gaap_MarketableSecuritiesPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_MarketableSecuritiesPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConcentrationRiskCreditRisk" xlink:to="us-gaap_ConcentrationRiskCreditRisk_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration Risk, Credit Risk, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ConcentrationRiskCreditRisk_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Concentration of Credit Risk</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value of Financial Instruments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock" xlink:label="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock" xlink:to="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Separation of Lease and Nonlease Components [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Expense, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and Development Costs, Including Clinical Trial Accruals</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Patent Costs</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxPolicyTextBlock" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue from Contract with Customer [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Revenue Recognition</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Comprehensive Income (Loss)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EarningsPerSharePolicyTextBlock" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Earnings Per Share, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net Loss per Share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">New Accounting Pronouncements, Policy [Policy Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Recently Issued Accounting Pronouncements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents and Investments [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of reconciliation cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:to="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the tabular disclosure of estimated useful lives for property and equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of estimated useful lives for property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Available-for-sale Securities Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of marketable securities</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" xlink:label="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" xlink:to="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tabular disclosure of the maturities of available-for-sale securities from cost basis to fair value.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule Of Available For Sale Securities Maturities Table Text Block</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of available-for-sale maturities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of fair value of the Company's financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of property and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Accrued Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of accrued liabilities and other liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Maturity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of future minimum lease payments under non-cancellable leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation, Stock Options, Activity [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock option activity</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of stock based compensation expense recorded</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of assumptions used in the Black Scholes option pricing model for stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of shares excluded from the computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of reconciliation of federal statutory income tax rate to the Company's effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Deferred Tax Assets and Liabilities [Table Text Block]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Summary of components of deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventTable" xlink:to="us-gaap_SubsequentEventTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsidiarySaleOfStockAxis" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sale of Stock [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IPOMember" xlink:to="us-gaap_IPOMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IPOMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">IPO</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SubsequentEventLineItems" xlink:to="us-gaap_SubsequentEventLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Subsequent Event [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SubsequentEventLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Nature of the Business</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stockholders' Equity Note, Stock Split, Conversion Ratio</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reverse stock split ratio</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharePrice" xlink:to="us-gaap_SharePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_SharePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from Issuance of Preferred Stock and Preference Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from issuance of preferred stock, net of issuance costs</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:to="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The cash outflow for payment of underwriting discounts and commissions.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments Of Underwriting Discounts And Commissions</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Underwriting discounts and commissions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PaymentsOfStockIssuanceCosts" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payments of Stock Issuance Costs</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Offering expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfStockByClassTable" xlink:label="us-gaap_ScheduleOfStockByClassTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfStockByClassTable" xlink:to="us-gaap_ScheduleOfStockByClassTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfStockByClassTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Stock by Class [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ClassOfStockLineItems" xlink:label="us-gaap_ClassOfStockLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ClassOfStockLineItems" xlink:to="us-gaap_ClassOfStockLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Class of Stock [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ClassOfStockLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_NumberOfOperatingSegments" xlink:to="us-gaap_NumberOfOperatingSegments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Operating Segments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_NumberOfOperatingSegments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of operating segment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAbstract" xlink:label="us-gaap_RestrictedCashAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAbstract" xlink:to="us-gaap_RestrictedCashAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Cash</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ProceedsFromRepaymentsOfDebt" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Proceeds from (Repayments of) Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Repayment of principal debt balance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtInstrumentFaceAmount" xlink:to="us-gaap_DebtInstrumentFaceAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Instrument, Face Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtInstrumentFaceAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Face amount</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_RequiredReserveRestrictedCashCurrent" xlink:label="nxtc_RequiredReserveRestrictedCashCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_RequiredReserveRestrictedCashCurrent" xlink:to="nxtc_RequiredReserveRestrictedCashCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_RequiredReserveRestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of required reserve of restricted cash.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_RequiredReserveRestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Required Reserve Restricted Cash Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_RequiredReserveRestrictedCashCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted cash required reserve</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Type [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComputerEquipmentMember" xlink:to="us-gaap_ComputerEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComputerEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Computer equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EquipmentMember" xlink:to="us-gaap_EquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FurnitureAndFixturesMember" xlink:to="us-gaap_FurnitureAndFixturesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FurnitureAndFixturesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Furniture and fixtures</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, plant and equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Estimated Useful Lives</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientsPackage" xlink:to="us-gaap_LeasePracticalExpedientsPackage_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientsPackage_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Practical Expedients, Package [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:to="us-gaap_LeasePracticalExpedientUseOfHindsight_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease, Practical Expedient, Use of Hindsight [true false]</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_PreferredStockAbstract" xlink:label="nxtc_PreferredStockAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_PreferredStockAbstract" xlink:to="nxtc_PreferredStockAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_PreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Not available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_PreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock Abstract</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_PreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Redeemable preferred stock:</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="nxtc_PreferredStockAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Preferred Stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AssetImpairmentChargesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AssetImpairmentChargesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long Lived Assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment of Long-Lived Assets to be Disposed of</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Impairment loss recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Tax Uncertainties [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Taxes</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Uncertain income tax benefits, interest or penalties</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentAxis" xlink:to="us-gaap_FinancialInstrumentAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instrument [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CorporateDebtSecuritiesMember" xlink:to="us-gaap_CorporateDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CorporateDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Corporate bonds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">U.S. Government agencies</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Investments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized Cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Gain</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross Unrealized Loss</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Excluding Accrued Interest</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Estimated Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrealized losses in a continuous loss position for more than twelve consecutive months</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Realized Gain</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross realized gains</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_InterestIncomeNonOperating" xlink:label="nxtc_InterestIncomeNonOperating" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_InterestIncomeNonOperating" xlink:to="nxtc_InterestIncomeNonOperating_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_InterestIncomeNonOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the total non-operating interest income.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_InterestIncomeNonOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest Income Non Operating</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_InterestIncomeNonOperating_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Interest income</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available-for-sale Securities, Debt Maturities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cost Maturities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within 1 year</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year to year two. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Between 1 to 2 years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total investments available for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Maturities:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Within 1 year</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Available For Sale Securities Debt Maturities After One Through Two Years Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Between 1 to 2 years</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total investments available for sale</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, by Balance Sheet Grouping [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsAxis" xlink:to="us-gaap_CashAndCashEquivalentsAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_MoneyMarketFundsMember" xlink:to="us-gaap_MoneyMarketFundsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_MoneyMarketFundsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds (cash equivalents)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Agency bonds</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByMeasurementBasisAxis" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Measurement Basis [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Portion at Fair Value Measurement [Member]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value Hierarchy and NAV [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel1Member" xlink:to="us-gaap_FairValueInputsLevel1Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel1Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Quoted Prices in Active Markets (Level 1)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueInputsLevel2Member" xlink:to="us-gaap_FairValueInputsLevel2Member_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueInputsLevel2Member_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Significant Other Observable Inputs (Level 2)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value of the Company's financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Cash and Cash Equivalents, Fair Value Disclosure</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Money market funds (cash equivalents)</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_MarketableSecuritiesAndCashEquivalents" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_MarketableSecuritiesAndCashEquivalents" xlink:to="nxtc_MarketableSecuritiesAndCashEquivalents_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">1</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Marketable Securities And Cash Equivalents</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total financial assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets transferred into level 3</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets transferred out of level 3</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount" xlink:label="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount" xlink:to="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Values Assets Level 1 To Level 2 Transfers Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets transferred from level 1 to level 2</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount" xlink:label="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount" xlink:to="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amounts of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair Values Assets Level 2 To Level 1 Transfers Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Assets transferred from level 2 to level 1</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ResearchEquipmentMember" xlink:label="nxtc_ResearchEquipmentMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ResearchEquipmentMember" xlink:to="nxtc_ResearchEquipmentMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ResearchEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Tangible research equipment.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ResearchEquipmentMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research equipment</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LeaseholdImprovementsMember" xlink:to="us-gaap_LeaseholdImprovementsMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LeaseholdImprovementsMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Leasehold improvements</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ConstructionInProgressMember" xlink:to="us-gaap_ConstructionInProgressMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ConstructionInProgressMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Construction in progress</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and Equipment, Net</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PropertyPlantAndEquipmentGross" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property, Plant and Equipment, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Property and equipment, gross</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: accumulated depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DepreciationDepletionAndAmortization" xlink:to="us-gaap_DepreciationDepletionAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation, Depletion and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DepreciationDepletionAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee-related Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Payroll and related benefits</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedClinicalTrialCostsCurrent" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AccruedClinicalTrialCostsCurrent" xlink:to="nxtc_AccruedClinicalTrialCostsCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Clinical Trial Costs, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Clinical trial costs</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedSponsoredResearchExpenseCurrent" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AccruedSponsoredResearchExpenseCurrent" xlink:to="nxtc_AccruedSponsoredResearchExpenseCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for sponsored research expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Sponsored Research Expense, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Sponsored research</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrent" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease liabilities, current portion</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedOperatingExpensesCurrent" xlink:label="nxtc_AccruedOperatingExpensesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_AccruedOperatingExpensesCurrent" xlink:to="nxtc_AccruedOperatingExpensesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_AccruedOperatingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_AccruedOperatingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accrued Operating Expenses, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_AccruedOperatingExpensesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating expenses</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OtherLiabilitiesCurrent" xlink:to="us-gaap_OtherLiabilitiesCurrent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other Liabilities, Current</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OtherLiabilitiesCurrent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Renewal Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lease extension period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Existence of Option to Extend [true false]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseExpense" xlink:to="us-gaap_OperatingLeaseExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasePayments" xlink:to="us-gaap_OperatingLeasePayments_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Payments</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_OperatingLeasePayments_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating cash flows used for operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Remaining Lease Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted=average remaining lease term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Weighted Average Discount Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average discount rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeasesRentExpenseNet" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Leases, Rent Expense, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Rent expenses operating leases</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Future minimum lease payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year One</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2023</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Two</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2024</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Three</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2025</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Four</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2026</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2027</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid, after Year Five</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Thereafter</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, to be Paid</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total future minimum payments</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Lessee, Operating Lease, Liability, Undiscounted Excess Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: present value discount</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_OperatingLeaseLiability" xlink:to="us-gaap_OperatingLeaseLiability_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating Lease, Liability</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_OperatingLeaseLiability_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Present value of lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_LongTermDebt" xlink:to="us-gaap_LongTermDebt_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Long-term Debt</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_LongTermDebt_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding balance</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_NumberOfVotesPerShare" xlink:label="nxtc_NumberOfVotesPerShare" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_NumberOfVotesPerShare" xlink:to="nxtc_NumberOfVotesPerShare_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_NumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents the number of votes per share.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_NumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number Of Votes Per Share</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_NumberOfVotesPerShare_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of votes per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockDividendsPerShareDeclared" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Dividends, Per Share, Declared</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Dividends declared</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameAxis" xlink:to="us-gaap_PlanNameAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_PlanNameDomain" xlink:to="us-gaap_PlanNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_PlanNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Plan Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_A2015OmnibusIncentivePlanMember" xlink:label="nxtc_A2015OmnibusIncentivePlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_A2015OmnibusIncentivePlanMember" xlink:to="nxtc_A2015OmnibusIncentivePlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_A2015OmnibusIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2015 omnibus incentive plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_A2015OmnibusIncentivePlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Plan</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OmnibusIncentive2019PlanMember" xlink:label="nxtc_OmnibusIncentive2019PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_OmnibusIncentive2019PlanMember" xlink:to="nxtc_OmnibusIncentive2019PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_OmnibusIncentive2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to Omnibus Incentive 2019 Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_OmnibusIncentive2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Omnibus Incentive Plan</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" xlink:label="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" xlink:to="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2015 omnibus incentive plan and the information pertaining to 2019 Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2015 Plan and 2019 Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_EmployeeStockPurchase2019PlanMember" xlink:label="nxtc_EmployeeStockPurchase2019PlanMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_EmployeeStockPurchase2019PlanMember" xlink:to="nxtc_EmployeeStockPurchase2019PlanMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_EmployeeStockPurchase2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Represents information pertaining to 2019 Employee Stock Purchase Plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_EmployeeStockPurchase2019PlanMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">2019 Employee Stock Purchase Plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Restricted Common Stock</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock Based Compensation</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares issued</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Vesting period</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:to="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Period which an employee's right to exercise an award is no longer available.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expiration period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Common Stock, Capital Shares Reserved for Future Issuance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of shares reserved for issuance under the plan</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" xlink:to="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The increase in shares available for issuance as a percentage of number of shares of the company's common stock outstanding on December 31st of the preceding calendar year.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement, Increase In Shares For Issuance As A Percentage Of Number Of Common Stock Outstanding</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Annual increase in number of share reserved for issuance (as percent)</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" xlink:to="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">The threshold number of shares of the company's common stock available for issuance under the plan.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Arrangement, Threshold Number Of Common Stock For Issuance Under The Plan</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum annual increase in shares available for issuance under the plan</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Number of Shares</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in shares)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeitures (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in shares)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Exercise Price</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars per share)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Granted (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercised (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Forfeited (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in dollars per share)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted Average Remaining Contractual Life (Years) And Aggregate Intrinsic Value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in years)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the end (in dollars)</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodStartLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Outstanding at the beginning (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/periodEndLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Exercisable at the end (in dollars)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Weighted average grant date fair value per share of stock options granted</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate intrinsic value of stock options exercised</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Aggregate grant date fair value</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Additional Disclosure [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share Based Compensation Expense Not Recognized</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized compensation cost</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Compensation expense recognition period</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationAxis" xlink:to="us-gaap_IncomeStatementLocationAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_IncomeStatementLocationDomain" xlink:to="us-gaap_IncomeStatementLocationDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_IncomeStatementLocationDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Income Statement Location [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ResearchAndDevelopmentExpenseMember" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_GeneralAndAdministrativeExpenseMember" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">General and administrative</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Stock based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AllocatedShareBasedCompensationExpense" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Allocated Share-based Compensation Expense</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total stock-based compensation expense</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeAxis" xlink:to="srt_RangeAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_RangeMember" xlink:to="srt_RangeMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_RangeMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Range [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MinimumMember" xlink:to="srt_MinimumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MinimumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Minimum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="srt_MaximumMember" xlink:to="srt_MaximumMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="srt_MaximumMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Maximum</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Fair value assumptions</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected term</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected volatility</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Risk free interest rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities [Axis]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities, Name [Domain]</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EmployeeStockOptionMember" xlink:to="us-gaap_EmployeeStockOptionMember_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EmployeeStockOptionMember_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Option to purchase common stock</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Antidilutive securities excluded from computation of diluted net loss per share</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of federal statutory income tax rate to the Company's effective income tax rate</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Reconciliation of federal statutory income tax rate to the Company's effective income tax rate</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/verboseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Expected income tax benefit at the federal statutory rate (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State taxes, net of federal benefit (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development credit, net (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Non-deductible items (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Prior year provision to return adjustments (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Change in valuation allowance (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Effective Income Tax Rate Reconciliation, Percent</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total (as a percent)</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Components of Deferred Tax Assets and Liabilities [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Principal components of the Company's deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax assets:</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal and state net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Research and development tax credits</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:to="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax
 asset attributable to capitalized research and development costs.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Capitalized Research And Development</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Capitalized R&amp;D Costs</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:to="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Operating Lease Liabilities</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Share-based compensation</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:to="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Accruals and other</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsGross" xlink:to="us-gaap_DeferredTaxAssetsGross_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsGross_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsValuationAllowance" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Less: valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsNet" xlink:to="us-gaap_DeferredTaxAssetsNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net of Valuation Allowance</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Total deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Net [Abstract]</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred tax liabilities:</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:to="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount of deferred tax consequences attributable to taxable temporary differences derived from depreciation and amortization.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Depreciation and Amortization</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Depreciation and amortization</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Leasing Arrangements</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedLabel" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Operating lease assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredIncomeTaxLiabilities" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Liabilities, Gross</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Gross deferred tax liabilities</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Net</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/totalLabel" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Net deferred tax assets</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Increase in valuation allowance</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Domestic</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, State and Local</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State net operating loss carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal net operating loss carryforwards that do not expire</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" xlink:to="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic research and development tax credit carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research And Development, Federal</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Federal research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" xlink:to="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/documentation" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state research and development tax credit carryforwards.</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Deferred Tax Assets, Tax Credit Carryforwards, Research And Development, State</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">State research and development tax credit carryforwards</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_UnrecognizedTaxBenefits" xlink:to="us-gaap_UnrecognizedTaxBenefits_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized Tax Benefits</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_UnrecognizedTaxBenefits_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Unrecognized income tax benefits</label>
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xmlns="http://www.xbrl.org/2003/linkbase" />
    <labelArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xmlns="http://www.xbrl.org/2003/linkbase" />
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/label" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Defined Contribution Plan, Employer Discretionary Contribution Amount</label>
    <label xlink:type="resource" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_lbl" xml:lang="en-US" xmlns="http://www.xbrl.org/2003/linkbase">Employer contributions amount</label>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>19
<FILENAME>nxtc-20221231_pre.xml
<DESCRIPTION>EX-101.PRE
<TEXT>
<XBRL>
<?xml version="1.0" encoding="us-ascii"?>
<!--XBRL document created with Toppan Merrill Bridge  10.2.0.4 -->
<!--Based on XBRL 2.1-->
<!--Created on: 3/2/2023 8:38:22 PM-->
<!--Modified on: 3/2/2023 8:38:22 PM-->
<link:linkbase xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:xlink="http://www.w3.org/1999/xlink">
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DocumentDocumentAndEntityInformation" roleURI="http://www.nextcure.com/role/DocumentDocumentAndEntityInformation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#StatementBalanceSheets" roleURI="http://www.nextcure.com/role/StatementBalanceSheets" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#StatementBalanceSheetsParenthetical" roleURI="http://www.nextcure.com/role/StatementBalanceSheetsParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#StatementStatementsOfOperationsAndComprehensiveLoss" roleURI="http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#StatementStatementsOfStockholdersEquity" roleURI="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#StatementStatementsOfStockholdersEquityParenthetical" roleURI="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#StatementStatementsOfCashFlows" roleURI="http://www.nextcure.com/role/StatementStatementsOfCashFlows" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentation" roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureSummaryOfSignificantAccountingPolicies" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureMarketableSecurities" roleURI="http://www.nextcure.com/role/DisclosureMarketableSecurities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureFairValueMeasurements" roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurements" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosurePropertyAndEquipmentNet" roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureAccruedLiabilitiesAndOtherLiabilities" roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilities" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureLeases" roleURI="http://www.nextcure.com/role/DisclosureLeases" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureCommitmentsAndContingencies" roleURI="http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureTermLoan" roleURI="http://www.nextcure.com/role/DisclosureTermLoan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosurePreferredStock" roleURI="http://www.nextcure.com/role/DisclosurePreferredStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureCommonStock" roleURI="http://www.nextcure.com/role/DisclosureCommonStock" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureStockBasedCompensation" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensation" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholders" roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureIncomeTaxes" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxes" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureEmployeeBenefitPlan" roleURI="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPolicies" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesTables" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureMarketableSecuritiesTables" roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureFairValueMeasurementsTables" roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosurePropertyAndEquipmentNetTables" roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureAccruedLiabilitiesAndOtherLiabilitiesTables" roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureLeasesTables" roleURI="http://www.nextcure.com/role/DisclosureLeasesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureStockBasedCompensationTables" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersTables" roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureIncomeTaxesTables" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesTables" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" roleURI="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" roleURI="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureMarketableSecuritiesDetails" roleURI="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureFairValueMeasurementsDetails" roleURI="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosurePropertyAndEquipmentNetDetails" roleURI="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails" roleURI="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureLeasesOtherInformationDetails" roleURI="http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureLeasesMaturitiesDetails" roleURI="http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureTermLoanOtherDetails" roleURI="http://www.nextcure.com/role/DisclosureTermLoanOtherDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosurePreferredStockDetails" roleURI="http://www.nextcure.com/role/DisclosurePreferredStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureCommonStockDetails" roleURI="http://www.nextcure.com/role/DisclosureCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureStockBasedCompensationStockOptionsDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureStockBasedCompensationAssumptionsDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureStockBasedCompensationRestrictedCommonStockDetails" roleURI="http://www.nextcure.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" roleURI="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureIncomeTaxesReconciliationDetails" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureIncomeTaxesDeferredTaxAssetsDetails" roleURI="http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <roleRef xlink:type="simple" xlink:href="nxtc-20221231.xsd#DisclosureEmployeeBenefitPlanDetails" roleURI="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails" xmlns="http://www.xbrl.org/2003/linkbase" />
  <presentationLink xlink:role="http://www.nextcure.com/role/DocumentDocumentAndEntityInformation" xlink:type="extended" xlink:title="00090 - Document - Document and Entity Information" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CoverAbstract" xlink:label="dei_CoverAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentType" xlink:label="dei_DocumentType_638133863013837983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentType_638133863013837983" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentAnnualReport" xlink:label="dei_DocumentAnnualReport_638133863013837983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentAnnualReport_638133863013837983" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentPeriodEndDate" xlink:label="dei_DocumentPeriodEndDate_638133863013837983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentPeriodEndDate_638133863013837983" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentTransitionReport" xlink:label="dei_DocumentTransitionReport_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentTransitionReport_638133863013847983" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFileNumber" xlink:label="dei_EntityFileNumber_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFileNumber_638133863013847983" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityRegistrantName" xlink:label="dei_EntityRegistrantName_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityRegistrantName_638133863013847983" order="6" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCentralIndexKey" xlink:label="dei_EntityCentralIndexKey_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCentralIndexKey_638133863013847983" order="7" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityIncorporationStateCountryCode" xlink:label="dei_EntityIncorporationStateCountryCode_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityIncorporationStateCountryCode_638133863013847983" order="8" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityTaxIdentificationNumber" xlink:label="dei_EntityTaxIdentificationNumber_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityTaxIdentificationNumber_638133863013847983" order="9" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressAddressLine1" xlink:label="dei_EntityAddressAddressLine1_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressAddressLine1_638133863013847983" order="10" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressCityOrTown" xlink:label="dei_EntityAddressCityOrTown_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressCityOrTown_638133863013847983" order="11" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressStateOrProvince" xlink:label="dei_EntityAddressStateOrProvince_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressStateOrProvince_638133863013847983" order="12" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityAddressPostalZipCode" xlink:label="dei_EntityAddressPostalZipCode_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityAddressPostalZipCode_638133863013847983" order="13" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CityAreaCode" xlink:label="dei_CityAreaCode_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CityAreaCode_638133863013847983" order="14" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_LocalPhoneNumber" xlink:label="dei_LocalPhoneNumber_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_LocalPhoneNumber_638133863013847983" order="15" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_Security12bTitle" xlink:label="dei_Security12bTitle_638133863013847983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_Security12bTitle_638133863013847983" order="16" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_TradingSymbol" xlink:label="dei_TradingSymbol_638133863013857984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_TradingSymbol_638133863013857984" order="17" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_SecurityExchangeName" xlink:label="dei_SecurityExchangeName_638133863013857984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_SecurityExchangeName_638133863013857984" order="18" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityWellKnownSeasonedIssuer" xlink:label="dei_EntityWellKnownSeasonedIssuer_638133863013857984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityWellKnownSeasonedIssuer_638133863013857984" order="19" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityVoluntaryFilers" xlink:label="dei_EntityVoluntaryFilers_638133863013857984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityVoluntaryFilers_638133863013857984" order="20" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCurrentReportingStatus" xlink:label="dei_EntityCurrentReportingStatus_638133863013857984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCurrentReportingStatus_638133863013857984" order="21" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityInteractiveDataCurrent" xlink:label="dei_EntityInteractiveDataCurrent_638133863013857984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityInteractiveDataCurrent_638133863013857984" order="22" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityFilerCategory" xlink:label="dei_EntityFilerCategory_638133863013857984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityFilerCategory_638133863013857984" order="23" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntitySmallBusiness" xlink:label="dei_EntitySmallBusiness_638133863013857984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntitySmallBusiness_638133863013857984" order="24" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityEmergingGrowthCompany" xlink:label="dei_EntityEmergingGrowthCompany_638133863013857984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityEmergingGrowthCompany_638133863013857984" order="25" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityExTransitionPeriod" xlink:label="dei_EntityExTransitionPeriod_638133863013867984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityExTransitionPeriod_638133863013867984" order="26" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_IcfrAuditorAttestationFlag" xlink:label="dei_IcfrAuditorAttestationFlag_638133863013867984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_IcfrAuditorAttestationFlag_638133863013867984" order="27" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityShellCompany" xlink:label="dei_EntityShellCompany_638133863013867984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityShellCompany_638133863013867984" order="28" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityPublicFloat" xlink:label="dei_EntityPublicFloat_638133863013867984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityPublicFloat_638133863013867984" order="29" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_EntityCommonStockSharesOutstanding" xlink:label="dei_EntityCommonStockSharesOutstanding_638133863013867984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_EntityCommonStockSharesOutstanding_638133863013867984" order="30" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_CurrentFiscalYearEndDate" xlink:label="dei_CurrentFiscalYearEndDate_638133863013867984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_CurrentFiscalYearEndDate_638133863013867984" order="31" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalYearFocus" xlink:label="dei_DocumentFiscalYearFocus_638133863013867984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalYearFocus_638133863013867984" order="32" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_DocumentFiscalPeriodFocus" xlink:label="dei_DocumentFiscalPeriodFocus_638133863013867984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_DocumentFiscalPeriodFocus_638133863013867984" order="33" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AmendmentFlag" xlink:label="dei_AmendmentFlag_638133863013877983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AmendmentFlag_638133863013877983" order="34" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorName" xlink:label="dei_AuditorName_638133863013877983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorName_638133863013877983" order="35" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorFirmId" xlink:label="dei_AuditorFirmId_638133863013877983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorFirmId_638133863013877983" order="36" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.sec.gov/dei/2022/dei-2022.xsd#dei_AuditorLocation" xlink:label="dei_AuditorLocation_638133863013877983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="dei_CoverAbstract" xlink:to="dei_AuditorLocation_638133863013877983" order="37" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementBalanceSheets" xlink:type="extended" xlink:title="00100 - Statement - BALANCE SHEETS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsAbstract" xlink:label="us-gaap_AssetsAbstract_638133863013877983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_AssetsAbstract_638133863013877983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrentAbstract" xlink:label="us-gaap_AssetsCurrentAbstract_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638133863013877983" xlink:to="us-gaap_AssetsCurrentAbstract_638133863013887984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638133863013887984" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638133863013887984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638133863013887984" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent_638133863013887984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PrepaidExpenseAndOtherAssetsCurrent" xlink:label="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638133863013887984" xlink:to="us-gaap_PrepaidExpenseAndOtherAssetsCurrent_638133863013887984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetsCurrent" xlink:label="us-gaap_AssetsCurrent_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsCurrentAbstract_638133863013887984" xlink:to="us-gaap_AssetsCurrent_638133863013887984" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638133863013877983" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638133863013887984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseRightOfUseAsset" xlink:label="us-gaap_OperatingLeaseRightOfUseAsset_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638133863013877983" xlink:to="us-gaap_OperatingLeaseRightOfUseAsset_638133863013887984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherAssetsNoncurrent" xlink:label="us-gaap_OtherAssetsNoncurrent_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638133863013877983" xlink:to="us-gaap_OtherAssetsNoncurrent_638133863013887984" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Assets" xlink:label="us-gaap_Assets_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetsAbstract_638133863013877983" xlink:to="us-gaap_Assets_638133863013887984" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquityAbstract" xlink:label="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638133863013887984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrentAbstract" xlink:label="us-gaap_LiabilitiesCurrentAbstract_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638133863013887984" xlink:to="us-gaap_LiabilitiesCurrentAbstract_638133863013887984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableCurrent" xlink:label="us-gaap_AccountsPayableCurrent_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638133863013887984" xlink:to="us-gaap_AccountsPayableCurrent_638133863013887984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedAndOtherLiabilitiesCurrent" xlink:label="nxtc_AccruedAndOtherLiabilitiesCurrent_638133863013887984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638133863013887984" xlink:to="nxtc_AccruedAndOtherLiabilitiesCurrent_638133863013887984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesCurrent" xlink:label="us-gaap_LiabilitiesCurrent_638133863013897984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesCurrentAbstract_638133863013887984" xlink:to="us-gaap_LiabilitiesCurrent_638133863013897984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityNoncurrent" xlink:label="us-gaap_OperatingLeaseLiabilityNoncurrent_638133863013897984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638133863013887984" xlink:to="us-gaap_OperatingLeaseLiabilityNoncurrent_638133863013897984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesNoncurrent" xlink:label="us-gaap_OtherLiabilitiesNoncurrent_638133863013897984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638133863013887984" xlink:to="us-gaap_OtherLiabilitiesNoncurrent_638133863013897984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_Liabilities" xlink:label="us-gaap_Liabilities_638133863013897984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638133863013887984" xlink:to="us-gaap_Liabilities_638133863013897984" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityAbstract" xlink:label="us-gaap_StockholdersEquityAbstract_638133863013897984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LiabilitiesAndStockholdersEquityAbstract_638133863013887984" xlink:to="us-gaap_StockholdersEquityAbstract_638133863013897984" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockValue" xlink:label="us-gaap_PreferredStockValue_638133863013897984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638133863013897984" xlink:to="us-gaap_PreferredStockValue_638133863013897984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockValue" xlink:label="us-gaap_CommonStockValue_638133863013897984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638133863013897984" xlink:to="us-gaap_CommonStockValue_638133863013897984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapital" xlink:label="us-gaap_AdditionalPaidInCapital_638133863013897984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638133863013897984" xlink:to="us-gaap_AdditionalPaidInCapital_638133863013897984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638133863013897984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638133863013897984" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax_638133863013897984" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsAccumulatedDeficit" xlink:label="us-gaap_RetainedEarningsAccumulatedDeficit_638133863013897984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638133863013897984" xlink:to="us-gaap_RetainedEarningsAccumulatedDeficit_638133863013897984" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638133863013907985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638133863013897984" xlink:to="us-gaap_StockholdersEquity_638133863013907985" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LiabilitiesAndStockholdersEquity" xlink:label="us-gaap_LiabilitiesAndStockholdersEquity_638133863013907985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockholdersEquityAbstract_638133863013897984" xlink:to="us-gaap_LiabilitiesAndStockholdersEquity_638133863013907985" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementBalanceSheetsParenthetical" xlink:type="extended" xlink:title="00105 - Statement - BALANCE SHEETS - (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfFinancialPositionAbstract" xlink:label="us-gaap_StatementOfFinancialPositionAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638133863013907985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638133863013907985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638133863013907985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638133863013907985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638133863013907985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638133863013907985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638133863013907985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638133863013907985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638133863013907985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638133863013907985" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638133863013907985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638133863013907985" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638133863013907985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638133863013907985" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638133863013907985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfFinancialPositionAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638133863013907985" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss" xlink:type="extended" xlink:title="00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementAbstract" xlink:label="us-gaap_IncomeStatementAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpensesAbstract" xlink:label="us-gaap_OperatingExpensesAbstract_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingExpensesAbstract_638133863013917985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpense" xlink:label="us-gaap_ResearchAndDevelopmentExpense_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638133863013917985" xlink:to="us-gaap_ResearchAndDevelopmentExpense_638133863013917985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpense" xlink:label="us-gaap_GeneralAndAdministrativeExpense_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638133863013917985" xlink:to="us-gaap_GeneralAndAdministrativeExpense_638133863013917985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingExpenses" xlink:label="us-gaap_OperatingExpenses_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingExpensesAbstract_638133863013917985" xlink:to="us-gaap_OperatingExpenses_638133863013917985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingIncomeLoss" xlink:label="us-gaap_OperatingIncomeLoss_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OperatingIncomeLoss_638133863013917985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherNonoperatingIncomeExpense" xlink:label="us-gaap_OtherNonoperatingIncomeExpense_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherNonoperatingIncomeExpense_638133863013917985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_NetIncomeLoss_638133863013917985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_EarningsPerSharesBasicAndDilutedAbstract" xlink:label="nxtc_EarningsPerSharesBasicAndDilutedAbstract_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="nxtc_EarningsPerSharesBasicAndDilutedAbstract_638133863013917985" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareBasic" xlink:label="us-gaap_EarningsPerShareBasic_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nxtc_EarningsPerSharesBasicAndDilutedAbstract_638133863013917985" xlink:to="us-gaap_EarningsPerShareBasic_638133863013917985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareDiluted" xlink:label="us-gaap_EarningsPerShareDiluted_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nxtc_EarningsPerSharesBasicAndDilutedAbstract_638133863013917985" xlink:to="us-gaap_EarningsPerShareDiluted_638133863013917985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract" xlink:label="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract_638133863013917985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract_638133863013917985" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfSharesOutstandingBasic" xlink:label="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638133863013927984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract_638133863013917985" xlink:to="us-gaap_WeightedAverageNumberOfSharesOutstandingBasic_638133863013927984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding" xlink:label="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638133863013927984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract_638133863013917985" xlink:to="us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding_638133863013927984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract" xlink:label="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638133863013927984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638133863013927984" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638133863013927984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638133863013927984" xlink:to="us-gaap_NetIncomeLoss_638133863013927984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638133863013927984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638133863013927984" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax_638133863013927984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomeNetOfTax" xlink:label="us-gaap_ComprehensiveIncomeNetOfTax_638133863013927984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract_638133863013927984" xlink:to="us-gaap_ComprehensiveIncomeNetOfTax_638133863013927984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity" xlink:type="extended" xlink:title="00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638133863013927984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_StatementTable_638133863013927984" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementEquityComponentsAxis" xlink:label="us-gaap_StatementEquityComponentsAxis_638133863013927984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638133863013927984" xlink:to="us-gaap_StatementEquityComponentsAxis_638133863013927984" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockMember" xlink:label="us-gaap_CommonStockMember_638133863013927984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638133863013927984" xlink:to="us-gaap_CommonStockMember_638133863013927984" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdditionalPaidInCapitalMember" xlink:label="us-gaap_AdditionalPaidInCapitalMember_638133863013927984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638133863013927984" xlink:to="us-gaap_AdditionalPaidInCapitalMember_638133863013927984" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedOtherComprehensiveIncomeMember" xlink:label="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638133863013927984" xlink:to="us-gaap_AccumulatedOtherComprehensiveIncomeMember_638133863013937982" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RetainedEarningsMember" xlink:label="us-gaap_RetainedEarningsMember_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638133863013927984" xlink:to="us-gaap_RetainedEarningsMember_638133863013937982" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquityComponentDomain" xlink:label="us-gaap_EquityComponentDomain_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementEquityComponentsAxis_638133863013927984" xlink:to="us-gaap_EquityComponentDomain_638133863013937982" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638133863013927984" xlink:to="us-gaap_StatementLineItems_638133863013937982" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInStockholdersEquityRollForward" xlink:label="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638133863013937982" xlink:to="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" xlink:to="us-gaap_StockholdersEquity_638133863013937982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" xlink:to="us-gaap_CommonStockSharesOutstanding_638133863013937982" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue" xlink:label="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" xlink:to="us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_638133863013937982" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" xlink:to="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638133863013937982" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised_638133863013937982" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638133863013937982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodValueNewIssues_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" xlink:to="us-gaap_StockIssuedDuringPeriodValueNewIssues_638133863013937982" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638133863013937982" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueNewIssues_638133863013937982" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638133863013937982" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan" xlink:label="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638133863013947986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" xlink:to="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638133863013947986" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans" xlink:label="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638133863013947986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_638133863013947986" xlink:to="us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans_638133863013947986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted" xlink:label="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_638133863013947986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" xlink:to="nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted_638133863013947986" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetIncomeLoss" xlink:label="us-gaap_NetIncomeLoss_638133863013947986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" xlink:to="us-gaap_NetIncomeLoss_638133863013947986" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquity" xlink:label="us-gaap_StockholdersEquity_638133863013947986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" xlink:to="us-gaap_StockholdersEquity_638133863013947986" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638133863013947986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInStockholdersEquityRollForward_638133863013937982" xlink:to="us-gaap_CommonStockSharesOutstanding_638133863013947986" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical" xlink:type="extended" xlink:title="00305 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfStockholdersEquityAbstract" xlink:label="us-gaap_StatementOfStockholdersEquityAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax" xlink:label="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_638133863013947986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfStockholdersEquityAbstract" xlink:to="us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax_638133863013947986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/StatementStatementsOfCashFlows" xlink:type="extended" xlink:title="00400 - Statement - STATEMENTS OF CASH FLOWS" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementOfCashFlowsAbstract" xlink:label="us-gaap_StatementOfCashFlowsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProfitLoss" xlink:label="us-gaap_ProfitLoss_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" xlink:to="us-gaap_ProfitLoss_638133863013957983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract" xlink:label="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" xlink:to="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DepreciationDepletionAndAmortizationAndOther" xlink:label="nxtc_DepreciationDepletionAndAmortizationAndOther_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" xlink:to="nxtc_DepreciationDepletionAndAmortizationAndOther_638133863013957983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments" xlink:label="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" xlink:to="us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments_638133863013957983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensation" xlink:label="us-gaap_ShareBasedCompensation_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" xlink:to="us-gaap_ShareBasedCompensation_638133863013957983" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_NoncashOperatingLeaseExpense" xlink:label="nxtc_NoncashOperatingLeaseExpense_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" xlink:to="nxtc_NoncashOperatingLeaseExpense_638133863013957983" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GainLossOnSaleOfPropertyPlantEquipment" xlink:label="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" xlink:to="us-gaap_GainLossOnSaleOfPropertyPlantEquipment_638133863013957983" order="5" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOperatingCapitalAbstract" xlink:label="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract_638133863013957983" xlink:to="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638133863013957983" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets" xlink:label="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638133863013957983" xlink:to="us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_638133863013957983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInAccountsPayable" xlink:label="us-gaap_IncreaseDecreaseInAccountsPayable_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638133863013957983" xlink:to="us-gaap_IncreaseDecreaseInAccountsPayable_638133863013957983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities" xlink:label="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638133863013957983" xlink:to="nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities_638133863013957983" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities" xlink:label="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638133863013957983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638133863013957983" xlink:to="us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities_638133863013957983" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInOperatingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013967984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncreaseDecreaseInOperatingCapitalAbstract_638133863013957983" xlink:to="us-gaap_NetCashProvidedByUsedInOperatingActivities_638133863013967984" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638133863013967984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638133863013967984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities" xlink:label="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638133863013967984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638133863013967984" xlink:to="us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities_638133863013967984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquireMarketableSecurities" xlink:label="us-gaap_PaymentsToAcquireMarketableSecurities_638133863013967984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638133863013967984" xlink:to="us-gaap_PaymentsToAcquireMarketableSecurities_638133863013967984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsToAcquirePropertyPlantAndEquipment" xlink:label="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638133863013967984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638133863013967984" xlink:to="us-gaap_PaymentsToAcquirePropertyPlantAndEquipment_638133863013967984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInInvestingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInInvestingActivities_638133863013967984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract_638133863013967984" xlink:to="us-gaap_NetCashProvidedByUsedInInvestingActivities_638133863013967984" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638133863013967984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638133863013967984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638133863013967984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638133863013967984" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638133863013967984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockOptionsExercised" xlink:label="us-gaap_ProceedsFromStockOptionsExercised_638133863013967984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638133863013967984" xlink:to="us-gaap_ProceedsFromStockOptionsExercised_638133863013967984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromStockPlans" xlink:label="us-gaap_ProceedsFromStockPlans_638133863013967984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638133863013967984" xlink:to="us-gaap_ProceedsFromStockPlans_638133863013967984" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RepaymentsOfDebt" xlink:label="us-gaap_RepaymentsOfDebt_638133863013977985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638133863013967984" xlink:to="us-gaap_RepaymentsOfDebt_638133863013977985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NetCashProvidedByUsedInFinancingActivities" xlink:label="us-gaap_NetCashProvidedByUsedInFinancingActivities_638133863013977985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract_638133863013967984" xlink:to="us-gaap_NetCashProvidedByUsedInFinancingActivities_638133863013977985" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638133863013977985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_638133863013977985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638133863013977985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638133863013977985" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381338630139779851" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_6381338630139779851" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SupplementalCashFlowInformationAbstract" xlink:label="us-gaap_SupplementalCashFlowInformationAbstract_638133863013977985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_SupplementalCashFlowInformationAbstract_638133863013977985" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InterestPaidNet" xlink:label="us-gaap_InterestPaidNet_638133863013977985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SupplementalCashFlowInformationAbstract_638133863013977985" xlink:to="us-gaap_InterestPaidNet_638133863013977985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NoncashInvestingAndFinancingItemsAbstract" xlink:label="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638133863013977985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementOfCashFlowsAbstract" xlink:to="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638133863013977985" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability" xlink:label="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638133863013987984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638133863013977985" xlink:to="us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability_638133863013987984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount" xlink:label="nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount_638133863013987984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_NoncashInvestingAndFinancingItemsAbstract_638133863013977985" xlink:to="nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount_638133863013987984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation" xlink:type="extended" xlink:title="10101 - Disclosure - Nature of the Business and Basis of Presentation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638133863013987984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock_638133863013987984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies" xlink:type="extended" xlink:title="10201 - Disclosure - Summary of Significant Accounting Policies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SignificantAccountingPoliciesTextBlock" xlink:label="us-gaap_SignificantAccountingPoliciesTextBlock_638133863013987984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SignificantAccountingPoliciesTextBlock_638133863013987984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureMarketableSecurities" xlink:type="extended" xlink:title="10301 - Disclosure - Marketable Securities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637082170090458325" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock" xlink:label="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638133863013997983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637082170090458325" xlink:to="us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock_638133863013997983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureFairValueMeasurements" xlink:type="extended" xlink:title="10401 - Disclosure - Fair Value Measurements" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresTextBlock" xlink:label="us-gaap_FairValueDisclosuresTextBlock_638133863013997983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueDisclosuresTextBlock_638133863013997983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet" xlink:type="extended" xlink:title="10501 - Disclosure - Property and Equipment, Net" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638133863013997983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock_638133863013997983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilities" xlink:type="extended" xlink:title="10601 - Disclosure - Accrued Liabilities and Other Liabilities" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock" xlink:label="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638133863013997983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock_638133863013997983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureLeases" xlink:type="extended" xlink:title="10701 - Disclosure - Leases" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeasesTextBlock" xlink:label="us-gaap_LesseeOperatingLeasesTextBlock_638133863013997983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract" xlink:to="us-gaap_LesseeOperatingLeasesTextBlock_638133863013997983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies" xlink:type="extended" xlink:title="10801 - Disclosure - Commitments and Contingencies" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommitmentsAndContingenciesDisclosureTextBlock" xlink:label="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638133863014007987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommitmentsAndContingenciesDisclosureAbstract" xlink:to="us-gaap_CommitmentsAndContingenciesDisclosureTextBlock_638133863014007987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureTermLoan" xlink:type="extended" xlink:title="10901 - Disclosure - Term Loan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureTextBlock" xlink:label="us-gaap_DebtDisclosureTextBlock_638133863014007987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtDisclosureTextBlock_638133863014007987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosurePreferredStock" xlink:type="extended" xlink:title="11001 - Disclosure - Preferred Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockTextBlock" xlink:label="us-gaap_PreferredStockTextBlock_638133863014007987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockTextBlock_638133863014007987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureCommonStock" xlink:type="extended" xlink:title="11101 - Disclosure - Common Stock" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_CommonStockTextBlock" xlink:label="nxtc_CommonStockTextBlock_638133863014007987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="nxtc_CommonStockTextBlock_638133863014007987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensation" xlink:type="extended" xlink:title="11201 - Disclosure - Stock-Based Compensation" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638133863014007987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock_638133863014007987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders" xlink:type="extended" xlink:title="11301 - Disclosure - Net Loss per Share Attributable to Common Stockholders" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareTextBlock" xlink:label="us-gaap_EarningsPerShareTextBlock_638133863014017983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_EarningsPerShareTextBlock_638133863014017983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxes" xlink:type="extended" xlink:title="11401 - Disclosure - Income Taxes" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureTextBlock" xlink:label="us-gaap_IncomeTaxDisclosureTextBlock_638133863014017983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_IncomeTaxDisclosureTextBlock_638133863014017983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan" xlink:type="extended" xlink:title="11501 - Disclosure - Employee Benefit Plan" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock" xlink:label="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638133863014017983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock_638133863014017983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies" xlink:type="extended" xlink:title="20202 - Disclosure - Summary of Significant Accounting Policies (Policies)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_BasisOfAccountingPolicyPolicyTextBlock" xlink:label="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638133863014017983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_BasisOfAccountingPolicyPolicyTextBlock_638133863014017983" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UseOfEstimates" xlink:label="us-gaap_UseOfEstimates_638133863014017983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_UseOfEstimates_638133863014017983" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsPolicyTextBlock" xlink:label="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638133863014017983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsPolicyTextBlock_638133863014017983" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy" xlink:label="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638133863014017983" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy_638133863014017983" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MarketableSecuritiesPolicy" xlink:label="us-gaap_MarketableSecuritiesPolicy_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_MarketableSecuritiesPolicy_638133863014027984" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConcentrationRiskCreditRisk" xlink:label="us-gaap_ConcentrationRiskCreditRisk_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ConcentrationRiskCreditRisk_638133863014027984" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueOfFinancialInstrumentsPolicy" xlink:label="us-gaap_FairValueOfFinancialInstrumentsPolicy_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_FairValueOfFinancialInstrumentsPolicy_638133863014027984" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentPolicyTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentPolicyTextBlock_638133863014027984" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock" xlink:label="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock_638133863014027984" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy" xlink:label="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy_638133863014027984" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpensePolicy" xlink:label="us-gaap_ResearchAndDevelopmentExpensePolicy_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ResearchAndDevelopmentExpensePolicy_638133863014027984" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy" xlink:label="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy_638133863014027984" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy" xlink:label="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy_638133863014027984" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxPolicyTextBlock" xlink:label="us-gaap_IncomeTaxPolicyTextBlock_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxPolicyTextBlock_638133863014027984" order="14" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RevenueFromContractWithCustomerPolicyTextBlock" xlink:label="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RevenueFromContractWithCustomerPolicyTextBlock_638133863014027984" order="15" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComprehensiveIncomePolicyPolicyTextBlock" xlink:label="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638133863014027984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ComprehensiveIncomePolicyPolicyTextBlock_638133863014027984" order="16" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerSharePolicyTextBlock" xlink:label="us-gaap_EarningsPerSharePolicyTextBlock_638133863014037984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_EarningsPerSharePolicyTextBlock_638133863014037984" order="17" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock" xlink:label="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638133863014037984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock_638133863014037984" order="18" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables" xlink:type="extended" xlink:title="30203 - Disclosure - Summary of Significant Accounting Policies (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock" xlink:label="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_638133863014037984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock_638133863014037984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock" xlink:label="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_638133863014037984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock_638133863014037984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables" xlink:type="extended" xlink:title="30303 - Disclosure - Marketable Securities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637082170524028796" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638133863014037984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637082170524028796" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock_638133863014037984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock" xlink:label="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_638133863014037984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract_637082170524028796" xlink:to="nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock_638133863014037984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables" xlink:type="extended" xlink:title="30403 - Disclosure - Fair Value Measurements (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTextBlock" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638133863014047985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTextBlock_638133863014047985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables" xlink:type="extended" xlink:title="30503 - Disclosure - Property and Equipment, Net (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTextBlock" xlink:label="us-gaap_PropertyPlantAndEquipmentTextBlock_638133863014047985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_PropertyPlantAndEquipmentTextBlock_638133863014047985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesTables" xlink:type="extended" xlink:title="30603 - Disclosure - Accrued Liabilities and Other Liabilities (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638133863014047985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock_638133863014047985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureLeasesTables" xlink:type="extended" xlink:title="30703 - Disclosure - Leases (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638133863014047985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_1" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock_638133863014047985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationTables" xlink:type="extended" xlink:title="31203 - Disclosure - Stock-Based Compensation (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638133863014057985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_638133863014057985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638133863014057985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock_638133863014057985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock" xlink:label="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638133863014057985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock_638133863014057985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables" xlink:type="extended" xlink:title="31303 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638133863014057985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock_638133863014057985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxesTables" xlink:type="extended" xlink:title="31403 - Disclosure - Income Taxes (Tables)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock" xlink:label="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638133863014057985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock_638133863014057985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock" xlink:label="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638133863014057985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock_638133863014057985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails" xlink:type="extended" xlink:title="40101 - Disclosure - Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventTable" xlink:label="us-gaap_SubsequentEventTable_638133863014057985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_SubsequentEventTable_638133863014057985" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsidiarySaleOfStockAxis" xlink:label="us-gaap_SubsidiarySaleOfStockAxis_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638133863014057985" xlink:to="us-gaap_SubsidiarySaleOfStockAxis_638133863014067985" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SaleOfStockNameOfTransactionDomain" xlink:label="us-gaap_SaleOfStockNameOfTransactionDomain_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsidiarySaleOfStockAxis_638133863014067985" xlink:to="us-gaap_SaleOfStockNameOfTransactionDomain_638133863014067985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IPOMember" xlink:label="us-gaap_IPOMember_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SaleOfStockNameOfTransactionDomain_638133863014067985" xlink:to="us-gaap_IPOMember_638133863014067985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SubsequentEventLineItems" xlink:label="us-gaap_SubsequentEventLineItems_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventTable_638133863014057985" xlink:to="us-gaap_SubsequentEventLineItems_638133863014067985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockholdersEquityNoteStockSplitConversionRatio1" xlink:label="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_StockholdersEquityNoteStockSplitConversionRatio1_638133863014067985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesNewIssues" xlink:label="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_StockIssuedDuringPeriodSharesNewIssues_638133863014067985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharePrice" xlink:label="us-gaap_SharePrice_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_SharePrice_638133863014067985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock" xlink:label="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock_638133863014067985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromIssuanceInitialPublicOffering" xlink:label="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_ProceedsFromIssuanceInitialPublicOffering_638133863014067985" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_PaymentsOfUnderwritingDiscountsAndCommissions" xlink:label="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="nxtc_PaymentsOfUnderwritingDiscountsAndCommissions_638133863014067985" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PaymentsOfStockIssuanceCosts" xlink:label="us-gaap_PaymentsOfStockIssuanceCosts_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_PaymentsOfStockIssuanceCosts_638133863014067985" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_CommonStockSharesOutstanding_638133863014067985" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638133863014067985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_PreferredStockSharesOutstanding_638133863014067985" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638133863014077984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_CommonStockSharesAuthorized_638133863014077984" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638133863014077984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638133863014077984" order="11" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638133863014077984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_PreferredStockSharesAuthorized_638133863014077984" order="12" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638133863014077984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_SubsequentEventLineItems_638133863014067985" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638133863014077984" order="13" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails" xlink:type="extended" xlink:title="40102 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:label="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_NumberOfOperatingSegments" xlink:label="us-gaap_NumberOfOperatingSegments_638133863014077984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract" xlink:to="us-gaap_NumberOfOperatingSegments_638133863014077984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails" xlink:type="extended" xlink:title="40201 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAbstract" xlink:label="us-gaap_RestrictedCashAbstract_638133863014077984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_RestrictedCashAbstract_638133863014077984" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ProceedsFromRepaymentsOfDebt" xlink:label="us-gaap_ProceedsFromRepaymentsOfDebt_638133863014077984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAbstract_638133863014077984" xlink:to="us-gaap_ProceedsFromRepaymentsOfDebt_638133863014077984" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638133863014077984" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAbstract_638133863014077984" xlink:to="us-gaap_DebtInstrumentFaceAmount_638133863014077984" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_RequiredReserveRestrictedCashCurrent" xlink:label="nxtc_RequiredReserveRestrictedCashCurrent_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAbstract_638133863014077984" xlink:to="nxtc_RequiredReserveRestrictedCashCurrent_638133863014087986" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638133863014087986" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAtCarryingValue" xlink:label="us-gaap_CashAndCashEquivalentsAtCarryingValue_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638133863014087986" xlink:to="us-gaap_CashAndCashEquivalentsAtCarryingValue_638133863014087986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents" xlink:label="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract_638133863014087986" xlink:to="us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_638133863014087986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails" xlink:type="extended" xlink:title="40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Leases (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638133863014087986" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638133863014087986" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638133863014087986" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638133863014087986" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014087986" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014087986" xlink:to="us-gaap_ComputerEquipmentMember_638133863014087986" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EquipmentMember" xlink:label="us-gaap_EquipmentMember_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014087986" xlink:to="us-gaap_EquipmentMember_638133863014087986" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014087986" xlink:to="us-gaap_FurnitureAndFixturesMember_638133863014087986" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638133863014087986" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638133863014087986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives" xlink:label="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_638133863014087986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638133863014087986" xlink:to="us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives_638133863014087986" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage_638133863014097985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638133863014087986" xlink:to="us-gaap_LeasePracticalExpedientsPackage_638133863014097985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight_638133863014097985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638133863014087986" xlink:to="us-gaap_LeasePracticalExpedientUseOfHindsight_638133863014097985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails" xlink:type="extended" xlink:title="40203 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccountingPoliciesAbstract" xlink:label="us-gaap_AccountingPoliciesAbstract" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_PreferredStockAbstract" xlink:label="nxtc_PreferredStockAbstract_638133863014097985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="nxtc_PreferredStockAbstract_638133863014097985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638133863014097985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="nxtc_PreferredStockAbstract_638133863014097985" xlink:to="us-gaap_PreferredStockSharesOutstanding_638133863014097985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AssetImpairmentChargesAbstract" xlink:label="us-gaap_AssetImpairmentChargesAbstract_638133863014097985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_AssetImpairmentChargesAbstract_638133863014097985" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf" xlink:label="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638133863014097985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AssetImpairmentChargesAbstract_638133863014097985" xlink:to="us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf_638133863014097985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxUncertaintiesAbstract" xlink:label="us-gaap_IncomeTaxUncertaintiesAbstract_638133863014097985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccountingPoliciesAbstract" xlink:to="us-gaap_IncomeTaxUncertaintiesAbstract_638133863014097985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense" xlink:label="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638133863014097985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxUncertaintiesAbstract_638133863014097985" xlink:to="us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense_638133863014097985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails" xlink:type="extended" xlink:title="40301 - Disclosure - Marketable Securities - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:label="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleTable" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleTable_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleTable_638133863014107987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_638133863014107987" xlink:to="us-gaap_FinancialInstrumentAxis_638133863014107987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638133863014107987" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638133863014107987" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638133863014107987" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638133863014107987" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638133863014107987" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_638133863014107987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems" xlink:label="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtSecuritiesAvailableForSaleTable_638133863014107987" xlink:to="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss_638133863014107987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_638133863014107987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax" xlink:label="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" xlink:to="us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_638133863014107987" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_638133863014107987" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger_638133863014107987" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleRealizedGain" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleRealizedGain_638133863014107987" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_InterestIncomeNonOperating" xlink:label="nxtc_InterestIncomeNonOperating_638133863014107987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" xlink:to="nxtc_InterestIncomeNonOperating_638133863014107987" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_638133863014117986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_638133863014117986" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638133863014117986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_638133863014117986" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost_638133863014117986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_638133863014117986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_638133863014117986" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost_638133863014117986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_638133863014117986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract_638133863014117986" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis_638133863014117986" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_638133863014117986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems_638133863014107987" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_638133863014117986" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_638133863014117986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_638133863014117986" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue_638133863014117986" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue" xlink:label="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_638133863014117986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_638133863014117986" xlink:to="nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue_638133863014117986" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate" xlink:label="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_638133863014117986" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract_638133863014117986" xlink:to="us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate_638133863014117986" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails" xlink:type="extended" xlink:title="40401 - Disclosure - Fair Value Measurements - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueDisclosuresAbstract" xlink:label="us-gaap_FairValueDisclosuresAbstract_637082166474633472" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByBalanceSheetGroupingTable" xlink:label="us-gaap_FairValueByBalanceSheetGroupingTable_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueDisclosuresAbstract_637082166474633472" xlink:to="us-gaap_FairValueByBalanceSheetGroupingTable_638133863014127985" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsAxis" xlink:label="us-gaap_CashAndCashEquivalentsAxis_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638133863014127985" xlink:to="us-gaap_CashAndCashEquivalentsAxis_638133863014127985" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember" xlink:label="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CashAndCashEquivalentsAxis_638133863014127985" xlink:to="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638133863014127985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_MoneyMarketFundsMember" xlink:label="us-gaap_MoneyMarketFundsMember_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638133863014127985" xlink:to="us-gaap_MoneyMarketFundsMember_638133863014127985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentAgenciesDebtSecuritiesMember" xlink:label="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638133863014127985" xlink:to="us-gaap_USGovernmentAgenciesDebtSecuritiesMember_638133863014127985" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember_638133863014127985" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638133863014127985" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByMeasurementBasisAxis" xlink:label="us-gaap_FairValueByMeasurementBasisAxis_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638133863014127985" xlink:to="us-gaap_FairValueByMeasurementBasisAxis_638133863014127985" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PortionAtFairValueFairValueDisclosureMember" xlink:label="us-gaap_PortionAtFairValueFairValueDisclosureMember_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByMeasurementBasisAxis_638133863014127985" xlink:to="us-gaap_PortionAtFairValueFairValueDisclosureMember_638133863014127985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EstimateOfFairValueFairValueDisclosureMember" xlink:label="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PortionAtFairValueFairValueDisclosureMember_638133863014127985" xlink:to="us-gaap_EstimateOfFairValueFairValueDisclosureMember_638133863014127985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueByFairValueHierarchyLevelAxis" xlink:label="us-gaap_FairValueByFairValueHierarchyLevelAxis_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638133863014127985" xlink:to="us-gaap_FairValueByFairValueHierarchyLevelAxis_638133863014127985" order="3" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementsFairValueHierarchyDomain" xlink:label="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByFairValueHierarchyLevelAxis_638133863014127985" xlink:to="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638133863014127985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel1Member" xlink:label="us-gaap_FairValueInputsLevel1Member_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638133863014127985" xlink:to="us-gaap_FairValueInputsLevel1Member_638133863014127985" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueInputsLevel2Member" xlink:label="us-gaap_FairValueInputsLevel2Member_638133863014127985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueMeasurementsFairValueHierarchyDomain_638133863014127985" xlink:to="us-gaap_FairValueInputsLevel2Member_638133863014127985" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentAxis" xlink:label="us-gaap_FinancialInstrumentAxis_638133863014137985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638133863014127985" xlink:to="us-gaap_FinancialInstrumentAxis_638133863014137985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain" xlink:label="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638133863014137985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentAxis_638133863014137985" xlink:to="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638133863014137985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CorporateDebtSecuritiesMember" xlink:label="us-gaap_CorporateDebtSecuritiesMember_638133863014137985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638133863014137985" xlink:to="us-gaap_CorporateDebtSecuritiesMember_638133863014137985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember" xlink:label="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_638133863014137985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain_638133863014137985" xlink:to="us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_638133863014137985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems" xlink:label="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638133863014137985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueByBalanceSheetGroupingTable_638133863014127985" xlink:to="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638133863014137985" order="5" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract" xlink:label="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638133863014137985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems_638133863014137985" xlink:to="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638133863014137985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CashAndCashEquivalentsFairValueDisclosure" xlink:label="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638133863014137985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638133863014137985" xlink:to="us-gaap_CashAndCashEquivalentsFairValueDisclosure_638133863014137985" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest" xlink:label="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_638133863014137985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638133863014137985" xlink:to="us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest_638133863014137985" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_MarketableSecuritiesAndCashEquivalents" xlink:label="nxtc_MarketableSecuritiesAndCashEquivalents_638133863014137985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638133863014137985" xlink:to="nxtc_MarketableSecuritiesAndCashEquivalents_638133863014137985" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_638133863014137985" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638133863014137985" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3_638133863014137985" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3" xlink:label="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_638133863014147987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638133863014137985" xlink:to="us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3_638133863014147987" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount" xlink:label="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount_638133863014147987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638133863014137985" xlink:to="nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount_638133863014147987" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount" xlink:label="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount_638133863014147987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract_638133863014137985" xlink:to="nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount_638133863014147987" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails" xlink:type="extended" xlink:title="40501 - Disclosure - Property and Equipment, Net - (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfPropertyPlantAndEquipmentTable" xlink:label="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638133863014147987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentAbstract" xlink:to="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638133863014147987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentByTypeAxis" xlink:label="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638133863014147987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638133863014147987" xlink:to="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638133863014147987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentTypeDomain" xlink:label="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014147987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentByTypeAxis_638133863014147987" xlink:to="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014147987" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ResearchEquipmentMember" xlink:label="nxtc_ResearchEquipmentMember_638133863014147987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014147987" xlink:to="nxtc_ResearchEquipmentMember_638133863014147987" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeaseholdImprovementsMember" xlink:label="us-gaap_LeaseholdImprovementsMember_638133863014147987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014147987" xlink:to="us-gaap_LeaseholdImprovementsMember_638133863014147987" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComputerEquipmentMember" xlink:label="us-gaap_ComputerEquipmentMember_638133863014147987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014147987" xlink:to="us-gaap_ComputerEquipmentMember_638133863014147987" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_FurnitureAndFixturesMember" xlink:label="us-gaap_FurnitureAndFixturesMember_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014147987" xlink:to="us-gaap_FurnitureAndFixturesMember_638133863014157988" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ConstructionInProgressMember" xlink:label="us-gaap_ConstructionInProgressMember_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentTypeDomain_638133863014147987" xlink:to="us-gaap_ConstructionInProgressMember_638133863014157988" order="5" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentLineItems" xlink:label="us-gaap_PropertyPlantAndEquipmentLineItems_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfPropertyPlantAndEquipmentTable_638133863014147987" xlink:to="us-gaap_PropertyPlantAndEquipmentLineItems_638133863014157988" order="2" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNetAbstract" xlink:label="us-gaap_PropertyPlantAndEquipmentNetAbstract_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentLineItems_638133863014157988" xlink:to="us-gaap_PropertyPlantAndEquipmentNetAbstract_638133863014157988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentGross" xlink:label="us-gaap_PropertyPlantAndEquipmentGross_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_638133863014157988" xlink:to="us-gaap_PropertyPlantAndEquipmentGross_638133863014157988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment" xlink:label="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_638133863014157988" xlink:to="us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_638133863014157988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PropertyPlantAndEquipmentNet" xlink:label="us-gaap_PropertyPlantAndEquipmentNet_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_638133863014157988" xlink:to="us-gaap_PropertyPlantAndEquipmentNet_638133863014157988" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DepreciationDepletionAndAmortization" xlink:label="us-gaap_DepreciationDepletionAndAmortization_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PropertyPlantAndEquipmentNetAbstract_638133863014157988" xlink:to="us-gaap_DepreciationDepletionAndAmortization_638133863014157988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails" xlink:type="extended" xlink:title="40601 - Disclosure - Accrued Liabilities and Other Liabilities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:label="us-gaap_AccruedLiabilitiesCurrentAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeRelatedLiabilitiesCurrent" xlink:label="us-gaap_EmployeeRelatedLiabilitiesCurrent_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_EmployeeRelatedLiabilitiesCurrent_638133863014157988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedClinicalTrialCostsCurrent" xlink:label="nxtc_AccruedClinicalTrialCostsCurrent_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nxtc_AccruedClinicalTrialCostsCurrent_638133863014157988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedSponsoredResearchExpenseCurrent" xlink:label="nxtc_AccruedSponsoredResearchExpenseCurrent_638133863014157988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nxtc_AccruedSponsoredResearchExpenseCurrent_638133863014157988" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrent" xlink:label="us-gaap_OperatingLeaseLiabilityCurrent_638133863014167988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrent_638133863014167988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList" xlink:label="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638133863014167988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList_638133863014167988" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedOperatingExpensesCurrent" xlink:label="nxtc_AccruedOperatingExpensesCurrent_638133863014167988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nxtc_AccruedOperatingExpensesCurrent_638133863014167988" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OtherLiabilitiesCurrent" xlink:label="us-gaap_OtherLiabilitiesCurrent_638133863014167988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="us-gaap_OtherLiabilitiesCurrent_638133863014167988" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_AccruedAndOtherLiabilitiesCurrent" xlink:label="nxtc_AccruedAndOtherLiabilitiesCurrent_638133863014167988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AccruedLiabilitiesCurrentAbstract" xlink:to="nxtc_AccruedAndOtherLiabilitiesCurrent_638133863014167988" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails" xlink:type="extended" xlink:title="40701 - Disclosure - Leases - Other Information (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientsPackage" xlink:label="us-gaap_LeasePracticalExpedientsPackage_638133863014167988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_LeasePracticalExpedientsPackage_638133863014167988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasePracticalExpedientUseOfHindsight" xlink:label="us-gaap_LeasePracticalExpedientUseOfHindsight_638133863014167988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_LeasePracticalExpedientUseOfHindsight_638133863014167988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseRenewalTerm" xlink:label="us-gaap_LesseeOperatingLeaseRenewalTerm_638133863014167988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_LesseeOperatingLeaseRenewalTerm_638133863014167988" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend" xlink:label="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638133863014167988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend_638133863014167988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/label" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseExpense" xlink:label="us-gaap_OperatingLeaseExpense_638133863014167988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_OperatingLeaseExpense_638133863014167988" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasePayments" xlink:label="us-gaap_OperatingLeasePayments_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_OperatingLeasePayments_638133863014177987" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1" xlink:label="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1_638133863014177987" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent" xlink:label="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent_638133863014177987" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeasesRentExpenseNet" xlink:label="us-gaap_OperatingLeasesRentExpenseNet_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_2" xlink:to="us-gaap_OperatingLeasesRentExpenseNet_638133863014177987" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails" xlink:type="extended" xlink:title="40702 - Disclosure - Leases - Maturities (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LeasesAbstract" xlink:label="us-gaap_LeasesAbstract_3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract" xlink:label="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_LeasesAbstract_3" xlink:to="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_638133863014177987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_638133863014177987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree_638133863014177987" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour_638133863014177987" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive_638133863014177987" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638133863014177987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive_638133863014177987" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638133863014187988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue_638133863014187988" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount" xlink:label="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638133863014187988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" xlink:to="us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_638133863014187988" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_OperatingLeaseLiability" xlink:label="us-gaap_OperatingLeaseLiability_638133863014187988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract_638133863014177987" xlink:to="us-gaap_OperatingLeaseLiability_638133863014187988" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="1" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureTermLoanOtherDetails" xlink:type="extended" xlink:title="40901 - Disclosure - Term Loan - Other (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtDisclosureAbstract" xlink:label="us-gaap_DebtDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DebtInstrumentFaceAmount" xlink:label="us-gaap_DebtInstrumentFaceAmount_638133863014187988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_DebtInstrumentFaceAmount_638133863014187988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_LongTermDebt" xlink:label="us-gaap_LongTermDebt_638133863014187988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DebtDisclosureAbstract" xlink:to="us-gaap_LongTermDebt_638133863014187988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosurePreferredStockDetails" xlink:type="extended" xlink:title="41001 - Disclosure - Preferred Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesAuthorized" xlink:label="us-gaap_PreferredStockSharesAuthorized_638133863014187988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesAuthorized_638133863014187988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockParOrStatedValuePerShare" xlink:label="us-gaap_PreferredStockParOrStatedValuePerShare_638133863014187988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockParOrStatedValuePerShare_638133863014187988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesIssued" xlink:label="us-gaap_PreferredStockSharesIssued_638133863014187988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesIssued_638133863014187988" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PreferredStockSharesOutstanding" xlink:label="us-gaap_PreferredStockSharesOutstanding_638133863014187988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_PreferredStockSharesOutstanding_638133863014187988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureCommonStockDetails" xlink:type="extended" xlink:title="41101 - Disclosure - Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:label="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesAuthorized" xlink:label="us-gaap_CommonStockSharesAuthorized_638133863014197987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesAuthorized_638133863014197987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockParOrStatedValuePerShare" xlink:label="us-gaap_CommonStockParOrStatedValuePerShare_638133863014197987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockParOrStatedValuePerShare_638133863014197987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesIssued" xlink:label="us-gaap_CommonStockSharesIssued_638133863014197987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesIssued_638133863014197987" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockSharesOutstanding" xlink:label="us-gaap_CommonStockSharesOutstanding_638133863014197987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockSharesOutstanding_638133863014197987" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_NumberOfVotesPerShare" xlink:label="nxtc_NumberOfVotesPerShare_638133863014197987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="nxtc_NumberOfVotesPerShare_638133863014197987" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockDividendsPerShareDeclared" xlink:label="us-gaap_CommonStockDividendsPerShareDeclared_638133863014197987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract" xlink:to="us-gaap_CommonStockDividendsPerShareDeclared_638133863014197987" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails" xlink:type="extended" xlink:title="41201 - Disclosure - Stock-Based Compensation - Stock options (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636915319547421245" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable" xlink:label="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638133863014197987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636915319547421245" xlink:to="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638133863014197987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameAxis" xlink:label="us-gaap_PlanNameAxis_638133863014197987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638133863014197987" xlink:to="us-gaap_PlanNameAxis_638133863014197987" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_PlanNameDomain" xlink:label="us-gaap_PlanNameDomain_638133863014197987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameAxis_638133863014197987" xlink:to="us-gaap_PlanNameDomain_638133863014197987" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_A2015OmnibusIncentivePlanMember" xlink:label="nxtc_A2015OmnibusIncentivePlanMember_638133863014197987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638133863014197987" xlink:to="nxtc_A2015OmnibusIncentivePlanMember_638133863014197987" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OmnibusIncentive2019PlanMember" xlink:label="nxtc_OmnibusIncentive2019PlanMember_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638133863014197987" xlink:to="nxtc_OmnibusIncentive2019PlanMember_638133863014207988" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember" xlink:label="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638133863014197987" xlink:to="nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_638133863014207988" order="3" use="optional" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_EmployeeStockPurchase2019PlanMember" xlink:label="nxtc_EmployeeStockPurchase2019PlanMember_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_PlanNameDomain_638133863014197987" xlink:to="nxtc_EmployeeStockPurchase2019PlanMember_638133863014207988" order="4" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable_638133863014197987" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638133863014207988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638133863014207988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod" xlink:label="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" xlink:to="nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod_638133863014207988" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CommonStockCapitalSharesReservedForFutureIssuance" xlink:label="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" xlink:to="us-gaap_CommonStockCapitalSharesReservedForFutureIssuance_638133863014207988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding" xlink:label="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" xlink:to="nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding_638133863014207988" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan" xlink:label="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" xlink:to="nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan_638133863014207988" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638133863014207988" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638133863014207988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638133863014207988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638133863014207988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638133863014217991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638133863014207988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_638133863014217991" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised" xlink:label="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638133863014217991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638133863014207988" xlink:to="us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised_638133863014217991" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638133863014217991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638133863014207988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod_638133863014217991" order="4" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="5" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638133863014217991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638133863014207988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_638133863014217991" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_638133863014217991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward_638133863014207988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber_638133863014217991" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638133863014217991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638133863014217991" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638133863014217991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638133863014217991" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638133863014217991" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638133863014217991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638133863014217991" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_638133863014217991" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638133863014217991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638133863014217991" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice_638133863014217991" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638133863014227988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638133863014217991" xlink:to="us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice_638133863014227988" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638133863014227988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638133863014217991" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_638133863014227988" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_638133863014227988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward_638133863014217991" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice_638133863014227988" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems_638133863014207988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638133863014227988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2_638133863014227988" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="9" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638133863014227988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_638133863014227988" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638133863014227988" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_638133863014227988" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodStartLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6381338630142279881" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue_6381338630142279881" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_638133863014237987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_638133863014237987" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/periodEndLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638133863014237987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue_638133863014237987" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638133863014237987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue_638133863014237987" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638133863014237987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1_638133863014237987" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_638133863014237987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract_638133863014227988" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_638133863014237987" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638133863014237987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_638133863014237987" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized_638133863014237987" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638133863014237987" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract_638133863014237987" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_638133863014237987" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails" xlink:type="extended" xlink:title="41202 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable" xlink:label="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638133863014247990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638133863014247990" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationAxis" xlink:label="us-gaap_IncomeStatementLocationAxis_638133863014247990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638133863014247990" xlink:to="us-gaap_IncomeStatementLocationAxis_638133863014247990" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeStatementLocationDomain" xlink:label="us-gaap_IncomeStatementLocationDomain_638133863014247990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationAxis_638133863014247990" xlink:to="us-gaap_IncomeStatementLocationDomain_638133863014247990" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ResearchAndDevelopmentExpenseMember" xlink:label="us-gaap_ResearchAndDevelopmentExpenseMember_638133863014247990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638133863014247990" xlink:to="us-gaap_ResearchAndDevelopmentExpenseMember_638133863014247990" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_GeneralAndAdministrativeExpenseMember" xlink:label="us-gaap_GeneralAndAdministrativeExpenseMember_638133863014247990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeStatementLocationDomain_638133863014247990" xlink:to="us-gaap_GeneralAndAdministrativeExpenseMember_638133863014247990" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems" xlink:label="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638133863014247990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable_638133863014247990" xlink:to="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638133863014247990" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AllocatedShareBasedCompensationExpense" xlink:label="us-gaap_AllocatedShareBasedCompensationExpense_638133863014247990" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems_638133863014247990" xlink:to="us-gaap_AllocatedShareBasedCompensationExpense_638133863014247990" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="5" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails" xlink:type="extended" xlink:title="41203 - Disclosure - Stock-Based Compensation - Assumptions (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementTable" xlink:label="us-gaap_StatementTable_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:to="us-gaap_StatementTable_638133863014257993" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeAxis" xlink:label="srt_RangeAxis_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638133863014257993" xlink:to="srt_RangeAxis_638133863014257993" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_RangeMember" xlink:label="srt_RangeMember_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeAxis_638133863014257993" xlink:to="srt_RangeMember_638133863014257993" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MinimumMember" xlink:label="srt_MinimumMember_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638133863014257993" xlink:to="srt_MinimumMember_638133863014257993" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd#srt_MaximumMember" xlink:label="srt_MaximumMember_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="srt_RangeMember_638133863014257993" xlink:to="srt_MaximumMember_638133863014257993" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_StatementLineItems" xlink:label="us-gaap_StatementLineItems_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementTable_638133863014257993" xlink:to="us-gaap_StatementLineItems_638133863014257993" order="2" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_StatementLineItems_638133863014257993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638133863014257993" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1" xlink:label="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638133863014257993" xlink:to="us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1_638133863014257993" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638133863014257993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate_638133863014257993" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract_638133863014257993" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate_638133863014257993" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails" xlink:type="extended" xlink:title="41204 - Disclosure - Stock-Based Compensation - Restricted Common Stock (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract" xlink:label="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636915394149059079" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638133863014257993" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636915394149059079" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod_638133863014257993" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1" xlink:label="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638133863014267991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract_636915394149059079" xlink:to="us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1_638133863014267991" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails" xlink:type="extended" xlink:title="41301 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EarningsPerShareAbstract" xlink:label="us-gaap_EarningsPerShareAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable" xlink:label="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638133863014267991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EarningsPerShareAbstract" xlink:to="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638133863014267991" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638133863014267991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638133863014267991" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638133863014267991" order="1" use="optional" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesNameDomain" xlink:label="us-gaap_AntidilutiveSecuritiesNameDomain_638133863014267991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_638133863014267991" xlink:to="us-gaap_AntidilutiveSecuritiesNameDomain_638133863014267991" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EmployeeStockOptionMember" xlink:label="us-gaap_EmployeeStockOptionMember_638133863014267991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesNameDomain_638133863014267991" xlink:to="us-gaap_EmployeeStockOptionMember_638133863014267991" order="1" use="optional" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638133863014267991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable_638133863014267991" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638133863014267991" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="2" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount" xlink:label="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638133863014267991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems_638133863014267991" xlink:to="us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_638133863014267991" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="7" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails" xlink:type="extended" xlink:title="41401 - Disclosure - Income Taxes - Reconciliation (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638133863014267991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638133863014267991" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638133863014267991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638133863014267991" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_638133863014267991" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/verboseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638133863014267991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638133863014267991" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes_638133863014267991" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638133863014267991" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch_638133863014277991" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638133863014267991" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense_638133863014277991" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638133863014267991" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes_638133863014277991" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638133863014267991" xlink:to="us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance_638133863014277991" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_EffectiveIncomeTaxRateContinuingOperations" xlink:label="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract_638133863014267991" xlink:to="us-gaap_EffectiveIncomeTaxRateContinuingOperations_638133863014277991" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails" xlink:type="extended" xlink:title="41402 - Disclosure - Income Taxes - Deferred tax assets (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_IncomeTaxDisclosureAbstract" xlink:label="us-gaap_IncomeTaxDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract" xlink:label="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_IncomeTaxDisclosureAbstract" xlink:to="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNetAbstract" xlink:label="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwards" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwards_638133863014277991" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch" xlink:label="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch_638133863014277991" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment" xlink:label="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" xlink:to="nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment_638133863014277991" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsOperatingLeaseLiabilities" xlink:label="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities_638133863014277991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" xlink:to="nxtc_DeferredTaxAssetsOperatingLeaseLiabilities_638133863014277991" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost" xlink:label="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost_638133863014287992" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther" xlink:label="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" xlink:to="nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther_638133863014287992" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsGross" xlink:label="us-gaap_DeferredTaxAssetsGross_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsGross_638133863014287992" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsValuationAllowance" xlink:label="us-gaap_DeferredTaxAssetsValuationAllowance_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsValuationAllowance_638133863014287992" order="8" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsNet" xlink:label="us-gaap_DeferredTaxAssetsNet_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxAssetsNetAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsNet_638133863014287992" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesNetAbstract" xlink:label="us-gaap_DeferredTaxLiabilitiesNetAbstract_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxLiabilitiesNetAbstract_638133863014287992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization" xlink:label="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638133863014287992" xlink:to="nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization_638133863014287992" order="1" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="3" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxLiabilitiesLeasingArrangements" xlink:label="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638133863014287992" xlink:to="us-gaap_DeferredTaxLiabilitiesLeasingArrangements_638133863014287992" order="2" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredIncomeTaxLiabilities" xlink:label="us-gaap_DeferredIncomeTaxLiabilities_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_DeferredTaxLiabilitiesNetAbstract_638133863014287992" xlink:to="us-gaap_DeferredIncomeTaxLiabilities_638133863014287992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2009/role/negatedTotalLabel" priority="6" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsLiabilitiesNet" xlink:label="us-gaap_DeferredTaxAssetsLiabilitiesNet_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsLiabilitiesNet_638133863014287992" order="3" use="optional" preferredLabel="http://www.xbrl.org/2003/role/totalLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount" xlink:label="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638133863014287992" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" xlink:to="us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount_638133863014287992" order="4" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638133863014297991" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic_638133863014297991" order="5" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638133863014357994" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal_638133863014357994" order="6" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration" xlink:label="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638133863014367974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" xlink:to="us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration_638133863014367974" order="7" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_638133863014367974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" xlink:to="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal_638133863014367974" order="8" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="nxtc-20221231.xsd#nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState" xlink:label="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_638133863014367974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" xlink:to="nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState_638133863014367974" order="9" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="1" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_UnrecognizedTaxBenefits" xlink:label="us-gaap_UnrecognizedTaxBenefits_638133863014367974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract_638133863014277991" xlink:to="us-gaap_UnrecognizedTaxBenefits_638133863014367974" order="10" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" priority="4" />
  </presentationLink>
  <presentationLink xlink:role="http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails" xlink:type="extended" xlink:title="41501 - Disclosure - Employee Benefit Plan (Details)" xmlns="http://www.xbrl.org/2003/linkbase">
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:label="us-gaap_CompensationAndRetirementDisclosureAbstract" />
    <loc xlink:type="locator" xlink:href="https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd#us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount" xlink:label="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638133863014367974" />
    <presentationArc xlink:type="arc" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="us-gaap_CompensationAndRetirementDisclosureAbstract" xlink:to="us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount_638133863014367974" order="1" use="optional" preferredLabel="http://www.xbrl.org/2003/role/terseLabel" />
  </presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>20
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603355200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Document and Entity Information - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Feb. 24, 2023</div></th>
<th class="th"><div>Jun. 30, 2022</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover Abstract</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">10-K<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentAnnualReport', window );">Document Annual Report</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">Dec. 31,  2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentTransitionReport', window );">Document Transition Report</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity File Number</a></td>
<td class="text">001-38905<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">NextCure, Inc.<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001661059<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">47-5231247<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9000 Virginia Manor Road, Suite 200<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Beltsville<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20705<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">240<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">399-4900<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">NXTC<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityWellKnownSeasonedIssuer', window );">Entity Well-known Seasoned Issuer</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityVoluntaryFilers', window );">Entity Voluntary Filers</a></td>
<td class="text">No<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCurrentReportingStatus', window );">Entity Current Reporting Status</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityInteractiveDataCurrent', window );">Entity Interactive Data Current</a></td>
<td class="text">Yes<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFilerCategory', window );">Entity Filer Category</a></td>
<td class="text">Non-accelerated Filer<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntitySmallBusiness', window );">Entity Small Business</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityExTransitionPeriod', window );">Entity Ex Transition Period</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_IcfrAuditorAttestationFlag', window );">ICFR Auditor Attestation Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityShellCompany', window );">Entity Shell Company</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityPublicFloat', window );">Entity Public Float</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115.5<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCommonStockSharesOutstanding', window );">Entity Common Stock, Shares Outstanding</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,774,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CurrentFiscalYearEndDate', window );">Current Fiscal Year End Date</a></td>
<td class="text">--12-31<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalYearFocus', window );">Document Fiscal Year Focus</a></td>
<td class="text">2022<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentFiscalPeriodFocus', window );">Document Fiscal Period Focus</a></td>
<td class="text">FY<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorName', window );">Auditor Name</a></td>
<td class="text">Ernst&#160;& Young LLP<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorFirmId', window );">Auditor Firm ID</a></td>
<td class="text">42<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AuditorLocation', window );">Auditor Location</a></td>
<td class="text">Baltimore, MD<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorFirmId">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>PCAOB issued Audit Firm Identifier</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorFirmId</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:nonemptySequenceNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorLocation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorLocation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AuditorName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AuditorName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:internationalNameItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CurrentFiscalYearEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>End date of current fiscal year in the format --MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CurrentFiscalYearEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gMonthDayItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentAnnualReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as an annual report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentAnnualReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalPeriodFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalPeriodFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fiscalPeriodItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentFiscalYearFocus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentFiscalYearFocus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:gYearItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentTransitionReport">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true only for a form used as a transition report.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Forms 10-K, 10-Q, 20-F<br> -Number 240<br> -Section 13<br> -Subsection a-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentTransitionReport</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCurrentReportingStatus">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCurrentReportingStatus</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityExTransitionPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 7A<br> -Section B<br> -Subsection 2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityExTransitionPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFilerCategory">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFilerCategory</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:filerCategoryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityInteractiveDataCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Regulation S-T<br> -Number 232<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityInteractiveDataCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityPublicFloat">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityPublicFloat</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityShellCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityShellCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntitySmallBusiness">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates that the company is a Smaller Reporting Company (SRC).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntitySmallBusiness</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityVoluntaryFilers">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityVoluntaryFilers</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityWellKnownSeasonedIssuer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 405<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityWellKnownSeasonedIssuer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:yesNoItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_IcfrAuditorAttestationFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 10-K<br> -Number 249<br> -Section 310<br><br>Reference 2: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 20-F<br> -Number 249<br> -Section 220<br> -Subsection f<br><br>Reference 3: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Form 40-F<br> -Number 249<br> -Section 240<br> -Subsection f<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_IcfrAuditorAttestationFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>21
<FILENAME>R2.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148602686160">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrentAbstract', window );"><strong>Current assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="nump">$ 26,630<span></span>
</td>
<td class="nump">$ 12,337<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent', window );">Marketable securities</a></td>
<td class="nump">133,281<span></span>
</td>
<td class="nump">207,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent', window );">Prepaid expenses and other current assets</a></td>
<td class="nump">4,072<span></span>
</td>
<td class="nump">8,226<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetsCurrent', window );">Total current assets</a></td>
<td class="nump">163,983<span></span>
</td>
<td class="nump">227,817<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11,897<span></span>
</td>
<td class="nump">13,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseRightOfUseAsset', window );">Right of use assets</a></td>
<td class="nump">5,016<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherAssetsNoncurrent', window );">Other assets</a></td>
<td class="nump">3,265<span></span>
</td>
<td class="nump">577<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Assets', window );">Total assets</a></td>
<td class="nump">184,161<span></span>
</td>
<td class="nump">242,386<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrentAbstract', window );"><strong>Current liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableCurrent', window );">Accounts payable</a></td>
<td class="nump">4,270<span></span>
</td>
<td class="nump">1,942<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_AccruedAndOtherLiabilitiesCurrent', window );">Accrued liabilities and other liabilities</a></td>
<td class="nump">4,857<span></span>
</td>
<td class="nump">4,666<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesCurrent', window );">Total current liabilities</a></td>
<td class="nump">9,127<span></span>
</td>
<td class="nump">6,608<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityNoncurrent', window );">Lease liabilities, long term</a></td>
<td class="nump">6,605<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesNoncurrent', window );">Other long-term liabilities</a></td>
<td class="nump">899<span></span>
</td>
<td class="nump">2,392<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_Liabilities', window );">Total liabilities</a></td>
<td class="nump">16,631<span></span>
</td>
<td class="nump">9,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityAbstract', window );"><strong>Stockholders' equity</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockValue', window );">Preferred stock; par value of $0.001 per share; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, No shares issued and outstanding at December 31, 2022 and December 31, 2021</a></td>
<td class="text"> <span></span>
</td>
<td class="text"> <span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockValue', window );">Common stock, par value of $0.001 per share; 100,000,000 shares authorized at December 31, 2022 and December 31, 2021. 27,774,536 and 27,680,997 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively</a></td>
<td class="nump">28<span></span>
</td>
<td class="nump">28<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdditionalPaidInCapital', window );">Additional paid-in capital</a></td>
<td class="nump">430,755<span></span>
</td>
<td class="nump">421,047<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax', window );">Accumulated other comprehensive loss</a></td>
<td class="num">(1,494)<span></span>
</td>
<td class="num">(663)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RetainedEarningsAccumulatedDeficit', window );">Accumulated deficit</a></td>
<td class="num">(261,759)<span></span>
</td>
<td class="num">(187,026)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Total stockholders' equity</a></td>
<td class="nump">167,530<span></span>
</td>
<td class="nump">233,386<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LiabilitiesAndStockholdersEquity', window );">Total liabilities and stockholders' equity</a></td>
<td class="nump">$ 184,161<span></span>
</td>
<td class="nump">$ 242,386<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities and amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14A<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669686-108580<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e681-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdditionalPaidInCapital">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdditionalPaidInCapital</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Assets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(11))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(12))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Assets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetsCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetsCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_Liabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19-26)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 20: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_Liabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesAndStockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(32))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesAndStockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124433192&amp;loc=SL2890621-112765<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=116870748&amp;loc=SL6758485-165988<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (bb)<br> -URI https://asc.fasb.org/extlink&amp;oid=123419778&amp;loc=d3e5710-111685<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6904-107765<br><br>Reference 21: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.21)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseRightOfUseAsset">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's right to use underlying asset under operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseRightOfUseAsset</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherAssetsNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncurrent assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(17))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherAssetsNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesNoncurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesNoncurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PrepaidExpenseAndOtherAssetsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(9))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PrepaidExpenseAndOtherAssetsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RetainedEarningsAccumulatedDeficit">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cumulative amount of the reporting entity's undistributed earnings or deficit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30)(a)(3))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(23)(a)(4))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 40<br> -Section 65<br> -Paragraph 2<br> -Subparagraph (g)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=124501264&amp;loc=SL117420844-207641<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RetainedEarningsAccumulatedDeficit</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>22
<FILENAME>R3.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148602667008">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>BALANCE SHEETS - (Parenthetical) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfFinancialPositionAbstract', window );"><strong>BALANCE SHEETS</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, number of shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, number of shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">27,774,536<span></span>
</td>
<td class="nump">27,680,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">27,774,536<span></span>
</td>
<td class="nump">27,680,997<span></span>
</td>
<td class="nump">15,560,569<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfFinancialPositionAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfFinancialPositionAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>23
<FILENAME>R4.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603309424">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpensesAbstract', window );"><strong>Operating expenses:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpense', window );">Research and development</a></td>
<td class="nump">$ 54,199<span></span>
</td>
<td class="nump">$ 50,192<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GeneralAndAdministrativeExpense', window );">General and administrative</a></td>
<td class="nump">21,710<span></span>
</td>
<td class="nump">20,573<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingExpenses', window );">Total operating expenses</a></td>
<td class="nump">75,909<span></span>
</td>
<td class="nump">70,765<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingIncomeLoss', window );">Loss from operations</a></td>
<td class="num">(75,909)<span></span>
</td>
<td class="num">(70,765)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherNonoperatingIncomeExpense', window );">Other income, net</a></td>
<td class="nump">1,176<span></span>
</td>
<td class="nump">1,376<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (74,733)<span></span>
</td>
<td class="num">$ (69,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_EarningsPerSharesBasicAndDilutedAbstract', window );"><strong>Net loss per common share</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareBasic', window );">Basic (in dollars per share)</a></td>
<td class="num">$ (2.69)<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareDiluted', window );">Diluted (in dollars per share)</a></td>
<td class="num">$ (2.69)<span></span>
</td>
<td class="num">$ (2.51)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract', window );"><strong>Weighted average shares outstanding</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic', window );">Basic (in shares)</a></td>
<td class="nump">27,744,209<span></span>
</td>
<td class="nump">27,615,977<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding', window );">Diluted (in shares)</a></td>
<td class="nump">27,744,209<span></span>
</td>
<td class="nump">27,615,977<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract', window );"><strong>Comprehensive loss:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="num">$ (74,733)<span></span>
</td>
<td class="num">$ (69,389)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax', window );">Unrealized (loss) on marketable securities</a></td>
<td class="num">(831)<span></span>
</td>
<td class="num">(1,442)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomeNetOfTax', window );">Total comprehensive loss</a></td>
<td class="num">$ (75,564)<span></span>
</td>
<td class="num">$ (70,831)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_EarningsPerSharesBasicAndDilutedAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Not available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_EarningsPerSharesBasicAndDilutedAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Not available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomeNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(24))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e557-108580<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(26))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomeNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 9: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareDiluted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 52<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e4984-109258<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22644-107794<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 55<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=128363288&amp;loc=d3e3842-109258<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1252-109256<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(27))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(23))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1337-109256<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (e)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(25))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareDiluted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GeneralAndAdministrativeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GeneralAndAdministrativeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpenses">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpenses</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingExpensesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingExpensesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net result for the period of deducting operating expenses from operating revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e637-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherNonoperatingIncomeExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of income (expense) related to nonoperating activities, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03.9)<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherNonoperatingIncomeExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 912<br> -SubTopic 730<br> -Section 25<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6472174&amp;loc=d3e58812-109433<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 985<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6501960&amp;loc=d3e128462-111756<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 16<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1505-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_WeightedAverageNumberOfSharesOutstandingBasic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=d3e1448-109256<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_WeightedAverageNumberOfSharesOutstandingBasic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>24
<FILENAME>R5.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148601615376">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS EQUITY - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Common Stock</div></th>
<th class="th"><div>Additional Paid-in Capital</div></th>
<th class="th"><div>Accumulated Other Comprehensive Income (Loss)</div></th>
<th class="th"><div>Accumulated Deficit</div></th>
<th class="th"><div>Total</div></th>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the beginning at Dec. 31, 2020</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 410,551<span></span>
</td>
<td class="nump">$ 779<span></span>
</td>
<td class="num">$ (117,637)<span></span>
</td>
<td class="nump">$ 293,721<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at the beginning (in shares) at Dec. 31, 2020</a></td>
<td class="nump">27,568,802<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,288<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">112,195<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted', window );">Unrealized gain (loss) on marketable securities, net of tax $0</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,442)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(1,442)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(69,389)<span></span>
</td>
<td class="num">(69,389)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2021</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">421,047<span></span>
</td>
<td class="num">(663)<span></span>
</td>
<td class="num">(187,026)<span></span>
</td>
<td class="nump">$ 233,386<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at the end (in shares) at Dec. 31, 2021</a></td>
<td class="nump">27,680,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,680,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward', window );"><strong>Increase (Decrease) in Stockholders' Deficit</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue', window );">Stock based compensation</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">9,508<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 9,508<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised', window );">Exercise of stock options</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">66<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercise of stock options (in shares)</a></td>
<td class="nump">50,420<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan', window );">Issuance of shares under ESPP</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">134<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans', window );">Issuance of shares under ESPP (in shares)</a></td>
<td class="nump">43,119<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted', window );">Unrealized gain (loss) on marketable securities, net of tax $0</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(831)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(831)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetIncomeLoss', window );">Net loss</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(74,733)<span></span>
</td>
<td class="num">(74,733)<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquity', window );">Balance at the end at Dec. 31, 2022</a></td>
<td class="nump">$ 28<span></span>
</td>
<td class="nump">$ 430,755<span></span>
</td>
<td class="num">$ (1,494)<span></span>
</td>
<td class="num">$ (261,759)<span></span>
</td>
<td class="nump">$ 167,530<span></span>
</td>
</tr>
<tr class="rc">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Balance at the end (in shares) at Dec. 31, 2022</a></td>
<td class="nump">27,774,536<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,774,536<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Adjusted amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11149-113907<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 20<br> -Section 55<br> -Paragraph 13<br> -URI https://asc.fasb.org/extlink&amp;oid=126964447&amp;loc=d3e11178-113907<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 35<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126961718&amp;loc=d3e4534-113899<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInStockholdersEquityRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInStockholdersEquityRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetIncomeLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-04(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399700&amp;loc=SL114874048-224260<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22595-107794<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 220<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-04(18))<br> -URI https://asc.fasb.org/extlink&amp;oid=120400993&amp;loc=SL114874131-224263<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 8: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SX 210.5-03(20))<br> -URI https://asc.fasb.org/extlink&amp;oid=126953954&amp;loc=SL114868664-224227<br><br>Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 17: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22583-107794<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 45<br> -Paragraph 60B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126958026&amp;loc=SL5780133-109256<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 23: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22694-107794<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 29: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 31: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 32: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 34: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 35: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetIncomeLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued during the period as a result of an employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Value of stock issued as a result of the exercise of stock options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29-31)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquity">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 310<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 4.E)<br> -URI https://asc.fasb.org/extlink&amp;oid=122038336&amp;loc=d3e74512-122707<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(31))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(30))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquity</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>25
<FILENAME>R6.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603353280">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StatementOfStockholdersEquityAbstract', window );"><strong>STATEMENTS OF STOCKHOLDERS EQUITY</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax', window );">Unrealized gain (loss) on marketable securities, tax expense (benefit)</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=d3e640-108580<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10A<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669646-108580<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StatementOfStockholdersEquityAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StatementOfStockholdersEquityAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>26
<FILENAME>R7.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148598199552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>STATEMENTS OF CASH FLOWS - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Cash flows from operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProfitLoss', window );">Net loss</a></td>
<td class="num">$ (74,733)<span></span>
</td>
<td class="num">$ (69,389)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract', window );"><strong>Adjustments to reconcile net loss to net cash used in operating activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_DepreciationDepletionAndAmortizationAndOther', window );">Depreciation and amortization</a></td>
<td class="nump">4,124<span></span>
</td>
<td class="nump">4,177<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments', window );">Amortization of premiums and discounts on marketable securities</a></td>
<td class="nump">3,047<span></span>
</td>
<td class="nump">3,019<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensation', window );">Stock-based compensation</a></td>
<td class="nump">9,508<span></span>
</td>
<td class="nump">10,288<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_NoncashOperatingLeaseExpense', window );">Noncash operating lease expense</a></td>
<td class="nump">356<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment', window );">Loss on disposal of property and equipment</a></td>
<td class="nump">87<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract', window );"><strong>Changes in operating assets and liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets', window );">Prepaid expenses and other assets</a></td>
<td class="nump">2,038<span></span>
</td>
<td class="num">(4,928)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInAccountsPayable', window );">Accounts payable</a></td>
<td class="nump">2,328<span></span>
</td>
<td class="num">(1,959)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities', window );">Accrued liabilities and other liabilities</a></td>
<td class="num">(641)<span></span>
</td>
<td class="num">(178)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities', window );">Other long-term liabilities</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,687<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInOperatingActivities', window );">Net cash used in operating activities</a></td>
<td class="num">(53,886)<span></span>
</td>
<td class="num">(57,283)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract', window );"><strong>Cash flows from investing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities', window );">Sales and maturities of marketable securities</a></td>
<td class="nump">104,739<span></span>
</td>
<td class="nump">195,438<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquireMarketableSecurities', window );">Purchases of marketable securities</a></td>
<td class="num">(34,644)<span></span>
</td>
<td class="num">(156,477)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment', window );">Purchases of property and equipment</a></td>
<td class="num">(2,116)<span></span>
</td>
<td class="num">(2,360)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInInvestingActivities', window );">Net cash provided by investing activities</a></td>
<td class="nump">67,979<span></span>
</td>
<td class="nump">36,601<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract', window );"><strong>Cash flows from financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockOptionsExercised', window );">Proceeds from exercise of stock options</a></td>
<td class="nump">66<span></span>
</td>
<td class="nump">208<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromStockPlans', window );">Proceeds from shares issued under ESPP</a></td>
<td class="nump">134<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RepaymentsOfDebt', window );">Payments of the term loan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(3,473)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NetCashProvidedByUsedInFinancingActivities', window );">Net cash provided by (used in) financing activities</a></td>
<td class="nump">200<span></span>
</td>
<td class="num">(3,265)<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect', window );">Net increase (decrease) in cash and cash equivalents</a></td>
<td class="nump">14,293<span></span>
</td>
<td class="num">(23,947)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - beginning of period</a></td>
<td class="nump">12,337<span></span>
</td>
<td class="nump">36,284<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Cash and cash equivalents - end of period</a></td>
<td class="nump">26,630<span></span>
</td>
<td class="nump">12,337<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SupplementalCashFlowInformationAbstract', window );"><strong>Supplemental disclosures of cash flow information:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InterestPaidNet', window );">Cash paid for interest</a></td>
<td class="nump">90<span></span>
</td>
<td class="nump">$ 162<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract', window );"><strong>Supplemental disclosures of noncash investing and financing activities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability', window );">Right-o-use assets obtained in exchange for operating lease liabilities</a></td>
<td class="nump">6,047<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount', window );">Recognition of initial lease liabilities</a></td>
<td class="nump">$ 7,549<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DepreciationDepletionAndAmortizationAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets and other items.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DepreciationDepletionAndAmortizationAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and Other Current Liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_NoncashOperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the amount of noncash operating lease expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_NoncashOperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The amount of operating lease liabilities initial lease recognition amount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 830<br> -SubTopic 230<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123444420&amp;loc=d3e33268-110906<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GainLossOnSaleOfPropertyPlantEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GainLossOnSaleOfPropertyPlantEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInAccountsPayable">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInAccountsPayable</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOperatingCapitalAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOperatingCapitalAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in noncurrent operating liabilities classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in prepaid expenses, and assets classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InterestPaidNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4297-108586<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 17<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3367-108585<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InterestPaidNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3536-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NoncashInvestingAndFinancingItemsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NoncashInvestingAndFinancingItemsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquireMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow for purchase of marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 45<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=124260329&amp;loc=d3e26853-111562<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquireMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsToAcquirePropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 13<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3213-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsToAcquirePropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash inflow from exercise of option under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=SL79508275-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromStockPlans">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from the stock plan during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromStockPlans</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProfitLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(g)(1)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669619-108580<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22663-107794<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(i))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 815<br> -SubTopic 40<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126732423&amp;loc=SL123482106-238011<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL124452729-227067<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 30<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8906-108599<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3000-108585<br><br>Reference 15: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 45<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=126929396&amp;loc=SL4569616-111683<br><br>Reference 16: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 323<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=114001798&amp;loc=d3e33918-111571<br><br>Reference 17: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 32<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8933-108599<br><br>Reference 18: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 19: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -SubTopic 20<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=109222650&amp;loc=SL51721683-107760<br><br>Reference 20: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22499-107794<br><br>Reference 21: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 28<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=123596393&amp;loc=d3e14064-108612<br><br>Reference 22: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 235<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-05(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120399901&amp;loc=d3e537907-122884<br><br>Reference 23: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 31<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8924-108599<br><br>Reference 24: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126968391&amp;loc=SL7669625-108580<br><br>Reference 25: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iv))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 26: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(iii)(A))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 27: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(5))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 28: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1B<br> -Subparagraph (SX 210.13-02(a)(4)(iii)(B))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442552-122756<br><br>Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1A<br> -Subparagraph (SX 210.13-01(a)(4)(ii))<br> -URI https://asc.fasb.org/extlink&amp;oid=126975872&amp;loc=SL124442526-122756<br><br>Reference 30: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1A<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=109239629&amp;loc=SL4573702-111684<br><br>Reference 31: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4J<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591551-111686<br><br>Reference 32: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -SubTopic 10<br> -Section 55<br> -Paragraph 4K<br> -URI https://asc.fasb.org/extlink&amp;oid=120409616&amp;loc=SL4591552-111686<br><br>Reference 33: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 250<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=124431687&amp;loc=d3e22658-107794<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProfitLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase in right-of-use asset obtained in exchange for operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensation">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of noncash expense for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensation</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SupplementalCashFlowInformationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SupplementalCashFlowInformationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>27
<FILENAME>R8.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148608590112">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock', window );">Nature of the Business and Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;">NEXTCURE,&#160;INC.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;">NOTES&#160;TO FINANCIAL STATEMENTS</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">1. Nature of the Business and Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Organization</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">NextCure,&#160;Inc. (&#8220;NextCure&#8221; or the &#8220;Company&#8221;) was incorporated in Delaware in September&#160;2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (&#8220;FIND-IO&#8221;) platform, the Company studies various immune cells in order to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company&#8217;s product candidates, building and optimizing the Company&#8217;s manufacturing capabilities and conducting discovery, research and development activities for the Company&#8217;s product candidates, discovery programs and its FIND-IO platform.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Public Offerings of Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 13, 2019, the Company closed its initial public offering (&#8220;IPO&#8221;), in which the Company issued and sold 5,750,000 shares of common stock at a public offering price of $15.00 per share, for net proceeds to the Company of approximately $77.0 million after deducting underwriting discounts and commissions of $6.0 million and offering expenses of $3.4 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In preparation for the IPO, on May 3, 2019, the Company effected a <span style="-sec-ix-hidden:Hidden_GEsLDUz530Gxz5k36Ixidg;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">1</span></span>-for-8.0338 reverse stock split of its issued and outstanding common stock. The par value and authorized shares of common stock were not adjusted as a result of the reverse stock split. All of the share and per share information presented in the accompanying financial statements has been adjusted to reflect the reverse common stock split on a retroactive basis for all periods and as of all dates presented.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Upon the closing of the IPO, all of the outstanding shares of the Company&#8217;s convertible preferred stock automatically converted into 15,560,569 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding. Additionally, the Company&#8217;s certificate of incorporation was amended and restated to provide for 100,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On November 19, 2019, the Company completed an underwritten public offering, in which the Company issued and sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at the public offering price of $36.75, for total net proceeds to the Company of $160.9 million after deducting underwriting discounts and commissions of $10.3 million and offering expenses of $1.0 million.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Liquidity</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through December 2022, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company&#8217;s former agreement with Eli Lilly and Company. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of the issuance date of the financial statements for the year ended December 31, 2022, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements to mid-2025. The future viability of the Company beyond that date may depend on its ability to raise additional capital to finance its operations. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, licensing arrangements or other methods. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#8217;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">Although management continues to pursue these funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company, if at all, to fund continuing operations past two years from the issuance date of these financial statements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">Risks and Uncertainties</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;">The Company is subject to risks common to early-stage companies in the biotechnology industry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing; dependence on its ability to advance its current and future product candidates through clinical trials, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on the Company&#8217;s FIND-IO platform; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time-consuming and unpredictable nature of the regulatory approval process; the results of preclinical studies and early-stage clinical trials that may not be predictive of future results; dependence on its key personnel; its limited manufacturing experience as an organization and with its manufacturing facility; risks related to patent protection and the Company&#8217;s pending patent applications; dependence on third-party collaborators for the discovery, development and commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Pursuit of the Company&#8217;s business efforts will require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company&#8217;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;">COVID-19</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The impact of the COVID-19 pandemic (including the impact of emerging variant strains of the COVID-19 virus) on the Company&#8217;s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, the efficacy and global distribution of vaccines, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of &#8220;lockdown,&#8221; &#8220;social distancing&#8221; and &#8220;shelter in place&#8221; directives and other restrictions on business operations, travel and gatherings by state and federal governments in the United States, as well as governments in other regions of the world in response to the COVID-19 pandemic, has placed significant strain on the Company&#8217;s clinical trial sites, has raised concerns around monitoring patient safety, and has caused enrollment to slow in the Company&#8217;s clinical trials. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. The Company continues to closely monitor the COVID-19 situation and any potential impact to the Company&#8217;s planned activities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Segment and Geographic Information</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The chief operating decision maker views the operations and manage the business in one operating segment that operates exclusively in the United States.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 205<br> -URI https://asc.fasb.org/topic&amp;trid=2122149<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 810<br> -URI https://asc.fasb.org/topic&amp;trid=2197479<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>28
<FILENAME>R9.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148689022192">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SignificantAccountingPoliciesTextBlock', window );">Summary of Significant Accounting Policies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">2. Summary of Significant Accounting Policies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying financial statements include the accounts of the Company. The Company&#8217;s financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8216;&#8216;GAAP&#8217;&#8217;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) and Accounting Standards Update (&#8216;&#8216;ASU&#8217;&#8217;) of the Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;). </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August 2021, the Company fully paid the remaining principal balance of $2.4 million of its $5.0 million term loan (the &#8220;Term Loan&#8221;). As a result of this payment, the Company has no restricted cash held in support of the Term Loan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company&#8217;s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company&#8217;s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;1&#8212;Quoted market prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computers and peripherals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">be the rate required for a similar investment of like risk. No impairment losses were recognized during the years ended December 31, 2022 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Construction in progress (Note&#160;5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On January 1, 2022 (Adoption Date), the Company adopted Accounting Standards Update (ASU) No. 2016-02, <i style="font-style:italic;">Leases</i>&#160;(Topic 842) (ASU No. 2016-02), as amended, using the modified retrospective approach, which provides a method for recording existing leases at adoption and does not require restating comparative financial information. The Company also elected the package of practical expedients permitted under the transition guidance under ASU No. 2016-02, which among other things, permits the Company to maintain the lease classification for any existing leases, as well as maintain the Company&#8217;s determination on whether any expired or existing contracts are or contain leases and initial direct costs for any existing leases. The Company did not elect the hindsight practical expedient to determine the lease term for existing leases. In addition, the Company elected the additional transition method permitted under ASU No. 2018-11<span style="font-family:'Arial','Helvetica','sans-serif';">&#8210;</span>Leases (Topic 842): Targeted Improvements, under which the Company initially applied the new lease standard, Accounting Standards Codification (ASC) 842, at adoption and there was no cumulative-effect adjustment to the opening balance of retained earnings on January 1, 2022. For the comparative period presented in these financial statements, lease-related disclosures continue to be in accordance with the legacy ASC 840. Adoption of ASC 842 did not materially impact the Company&#8217;s statements of operations and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company determines if an arrangement is a lease or implicitly contains a lease at inception based on the lease definition and also determines if the lease is classified as an operating lease or finance lease, each in accordance with ASC 842. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in its balance sheets. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date or the Adoption Date for existing leases based on the present value of lease payments over the lease term using an estimated discount rate. As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date or the Adoption Date in determining the present value of lease payments over a similar term. In determining the estimated incremental borrowing rate, the Company considered a rate obtained from its primary banker for discussion purposes of a potential collateralized loan with a term similar to the lease term and the Company&#8217;s historical borrowing capability in the market. For operating leases, lease expense is recognized on a straight-line basis over the lease term. Lease and non-lease components within a contract are generally accounted for separately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not have any outstanding preferred stock as of December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs, Including Clinical Trial Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (&#8220;CROs&#8221;), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <i style="font-style:italic;">Compensation-Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;) for stock option grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to the lack of a public market for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No.&#160;2016-09, <i style="font-style:italic;">Improvements to Employee Share-Based Payment Accounting</i> (&#8220;ASU&#160;2016-09&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#8217;s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2022 and 2021. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;) as defined under the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company&#8217;s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SignificantAccountingPoliciesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for all significant accounting policies of the reporting entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126899994&amp;loc=d3e18726-107790<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -URI https://asc.fasb.org/topic&amp;trid=2122369<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SignificantAccountingPoliciesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>29
<FILENAME>R10.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603344304">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock', window );">Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">3. Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities consist of the following:</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,457)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131,706</p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Government agencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,575</p></td></tr><tr><td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 134,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,494)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,281</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the specific identification method when calculating realized gains and losses. For the years ended December 31, 2022 and 2021, respectively, the Company recorded $9 thousand and $57 thousand in realized gains on available-for-sale securities, which is included in other income on the statements of operations and comprehensive loss. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company reviewed all investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. As of December&#160;31,&#160;2022, the Company had investments with a total fair market value of $133.3 million in an unrealized loss position, of which $91.8 million were in a continuous unrealized loss position for more than twelve months. The Company analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes, and such unrealized losses are temporary as the Company anticipates a full recovery of the amortized cost basis of these securities at maturity. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following table summarizes maturities of the Company&#8217;s investments available-for-sale as of December 31, 2022:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maturities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Within 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,660</p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Between 1 to 2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,621</p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total investments available-for-sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 134,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,281</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has classified all of its investments available-for-sale, including those with maturities beyond one year, as current assets on the accompanying balance sheets based on the highly liquid nature of these investment securities and because these investment securities are considered available for use in current operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has elected to report interest receivable from its marketable securities with prepaid expenses and other current assets on its balance sheet. &#160;Interest receivable included in prepaid expenses and other current assets totaled $0.7 million and $1.0 million as of December 31, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for investments in certain debt and equity securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2209399<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 946<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2324412<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -URI https://asc.fasb.org/topic&amp;trid=2196928<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 940<br> -SubTopic 320<br> -URI https://asc.fasb.org/subtopic&amp;trid=2176304<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher SEC<br> -Name Regulation S-K (SK)<br> -Number 229<br> -Section 1403<br> -Paragraph (b)<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>30
<FILENAME>R11.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603354144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresTextBlock', window );">Fair Value Measurements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">4. Fair Value Measurements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 1&#8212;Quoted market prices in active markets for identical assets or liabilities. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 2&#8212;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level 3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The following tables set forth the fair value of the Company&#8217;s financial assets by level within the fair value hierarchy as of December 31, 2022 and 2021:</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Government agencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 209,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December&#160;31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The carrying value of financial instruments, including trade receivables, accounts payable and accrued liabilities approximate fair value because of the short-term maturity of these items. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>31
<FILENAME>R12.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148605110752">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">5. Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment consist of the following:</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,482</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,566</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,143</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 167</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,729</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,630)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,737)</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,992</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Construction in progress at December&#160;31, 2022 and 2021 consists of the costs incurred for research equipment and for the build-out of additional lab and office space.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Depreciation and amortization expense was $4.1 million and $4.3 million for the&#160;years ended December&#160;31, 2022 and 2021, respectively.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -URI https://asc.fasb.org/topic&amp;trid=2155823<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=SL120174063-112916<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>32
<FILENAME>R13.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148605080064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities and Other Liabilities<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities and Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock', window );">Accrued Liabilities and Other Liabilities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">6. Accrued Liabilities and Other Liabilities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Accrued liabilities consist of the following:</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,751</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 727</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sponsored research</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,315</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Y-cqdjMky0anGfcN4D8zww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liabilities, current portion</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 656</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,666</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.19(a),20,24)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>33
<FILENAME>R14.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148605081296">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeasesTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">7. Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="white-space:pre-wrap;">The Company's lease portfolio consists of office space and laboratory facilities.  All of the Company's leases are classified as operating leases. The terms of the Company's lease agreements that have commenced currently extend through March 2030 and provide the Company with an option for a </span>five-year extension<span style="white-space:pre-wrap;">.  Under the terms of the leases, the Company pays base annual rent subject to fixed dollar increases each year and other normal operating expenses such as taxes, repairs, and maintenance.  The Company evaluates renewal options at lease inception and on an ongoing basis and considers renewal options that the Company is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities in accordance with ASC 842.  The leases do not require variable lease payments or residual value guarantees and do not contain restrictive covenants.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"><span style="white-space:pre-wrap;">The leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate as the discount rate when measuring the operating lease liability.  The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease.</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Operating lease expense was $1.0<span style="white-space:pre-wrap;"> million for the year ended December 31, 2022.  Operating cash flows used for operating leases during the year ended December 31, 2022 were </span>$0.9<span style="white-space:pre-wrap;"> million.  As of December 31, 2022, the weighted-average remaining lease term was </span>7.25 years, and the weighted average discount rate was 7.46%.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;">Rent expense under operating leases was $1.0 million for the year ended December 31, 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2022, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands), which are included in Accrued liabilities and other liabilities and Lease liabilities, long term in the accompanying balance sheet:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ending December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,296)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeasesTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -URI https://asc.fasb.org/subtopic&amp;trid=77888251<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeasesTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>34
<FILENAME>R15.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148605012800">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Commitments and Contingencies<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract', window );"><strong>Commitments and Contingencies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock', window );">Commitments and Contingencies</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">8. Commitments and Contingencies</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Legal Proceedings</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company, from time to time, is a party to litigation or legal proceedings arising in the ordinary course of business. The Company is not a party to any litigation or legal proceedings, nor is management aware of any pending or threatened litigation that, in the opinion of the Company&#8217;s management, are likely to have a material adverse effect on the Company&#8217;s business. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, as amended (the &#8220;Exchange Act&#8221;), and the Securities Act of 1933, as amended, with respect to statements made regarding our product candidate, NC318, and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021, and discovery is stayed pending resolution of that motion.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys&#8217; fees and costs, declaratory relief, corporate governance changes, and restitution. On May 17, 2021, the Court granted the parties&#8217; joint motion to stay the derivative lawsuit pending resolution of the Ye Zhou action&#8217;s motion to dismiss.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On December 14, 2021, a purported misappropriation of certain trade secrets lawsuit was filed in Federal District Court for the District of Delaware, styled Immunaccel, LLC v. NextCure, Inc., Case No. 1:21-cv-01755-UNA. The lawsuit alleges that the Company misappropriated certain trade secrets belonging to Immunaccel related to a drug discovery and screening platform named IMMUNE 3D. The complaint alleges two causes of action, one under the Delaware Uniform Trade Secrets Act and another under the Federal Defend Trade Secrets Act, and seeks unspecified monetary damages, a permanent injunction and other miscellaneous relief.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company intends to vigorously defend the Ye Zhou, Liu and Immunaccel actions. Based on the Company&#8217;s assessment of the facts underlying these claims, the uncertainty of litigation, and the preliminary stage of these cases, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommitmentsAndContingenciesDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for commitments and contingencies.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -URI https://asc.fasb.org/topic&amp;trid=2144648<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 954<br> -SubTopic 440<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6491277&amp;loc=d3e6429-115629<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 450<br> -URI https://asc.fasb.org/topic&amp;trid=2127136<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 440<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123406679&amp;loc=d3e25336-109308<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommitmentsAndContingenciesDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>35
<FILENAME>R16.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603354144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Term Loan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureTextBlock', window );">Term Loan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">9. Term Loan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In April&#160;2016, we entered into a $1.0&#160;million term loan, or the &#8220;Term Loan&#8221;. In January 2019, we amended the Term Loan to increase our borrowing capacity to $5.0 million, which was secured by our certificates of deposit, money market account, investment property and deposit or investment accounts. In August 2021, we fully paid the remaining principal on the Term Loan, and there are no outstanding payments due from us. </p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -URI https://asc.fasb.org/topic&amp;trid=2208564<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (h)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1C<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495334-112611<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1E<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495348-112611<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1I<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495371-112611<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>36
<FILENAME>R17.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148608533040">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Preferred Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockTextBlock', window );">Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">10. Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, the Company&#8217;s certificate of incorporation, as amended and restated, authorized the Company to issue 10,000,000 shares of $0.001 par value preferred stock, and there were no shares of preferred stock <span style="-sec-ix-hidden:Hidden_pC0KVSDrpUCOl6qY3Bjkag;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">issued</span></span> or outstanding. The Company can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by its stockholders.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -URI https://asc.fasb.org/topic&amp;trid=2208762<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>37
<FILENAME>R18.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148605054432">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_CommonStockTextBlock', window );">Common Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">11. Common Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company&#8217;s Certificate of Incorporation, as amended and restated, authorized the Company to issue 100,000,000 shares of $0.001 par value common stock, of which 27,774,536 were issued and <span style="-sec-ix-hidden:Hidden_BEloqN_kIUiSEA3CJtNPlQ;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">outstanding</span></span>.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#8217;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of any preferred stock. No dividends have been declared or paid by the Company through December&#160;31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any preferred stock.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_CommonStockTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_CommonStockTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>38
<FILENAME>R19.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148608567440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock', window );">Stock-Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">12. Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Employee Equity Plans</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The NextCure, Inc. 2015 Omnibus Incentive Plan (the &#8220;2015 Plan&#8221;) was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants and directors of the Company. The 2015 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">On May 3, 2019, the Company&#8217;s stockholders approved the NextCure, Inc. 2019 Omnibus Incentive Plan (as amended, the &#8220;2019 Plan&#8221;), which became effective on May 8, 2019, the date on which the Company&#8217;s Registration Statement on Form S-1 (Reg. No. 333-230837) was declared effective (the &#8220;Effective Date&#8221;). The Company&#8217;s board of directors (the &#8220;Board&#8221;) determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">cash bonus awards to the Company&#8217;s officers, employees, non-employee directors and other key persons (including consultants). The number of shares of common stock reserved for issuance under the 2019 Plan is 2,900,000 plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan will automatically increase each January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> during the term of the 2019 Plan by 4% of the number of shares of the Company&#8217;s common stock outstanding on December 31<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> of the preceding calendar year or such lesser number of shares determined by the Board.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December 31, 2022, 2,653,867 shares were reserved for future issuance under the 2019 Plan. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Stock options granted under the 2015 Plan and 2019 Plan (together, the &#8220;Plans&#8221;) to employees generally vest over four years and expire after 10 years.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">A summary of stock option activity for awards under the Plans is presented below:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding&#160;and&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,112,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,810</p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,020,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105,731)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeitures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (481,569)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,545,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,860</p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,739,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,420)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeitures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (972,545)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,262,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115</p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,790,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2022 and 2021.</span></td></tr></table><div style="margin-top:12pt;"/><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The weighted average grant date fair value per share of stock options granted during the years ended December 31, 2022 and 2021 was $3.69 and $7.47 respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was $13,000 and $0.5 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;">The aggregate grant date fair value of stock options and restricted stock vested during the year ended December 31, 2022 and 2021 was approximately $11.0 million and $13.4 million, respectively.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">On May 3, 2019, the Company&#8217;s stockholders approved the NextCure, Inc. 2019 Employee Stock Purchase Plan (the &#8220;ESPP&#8221;), which became effective on the Effective Date. The ESPP is intended to qualify as an &#8220;employee stock purchase plan&#8221; within the meaning of Section 423(b) of the Internal Revenue Code. A total of 240,000 shares of common stock were reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase each January 1<sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;">st</sup> until expiration of the ESPP, in an amount equal to the lesser of (i) 1% of the number of shares of the Company&#8217;s common stock outstanding on December 31st of the preceding calendar year, (ii) 480,000 shares of common stock and (iii) a number of shares of common stock determined by the administrator of the ESPP. As of December 31, 2022, 49,583 shares of common stock had been issued pursuant to the ESPP and 741,097 shares were reserved for future issuance thereunder.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company recorded stock-based compensation expense of $9.5 million and $10.3 million during the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, there was $14.7 million of unrecognized </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">compensation cost related to unvested stock-based compensation arrangements granted under the Plans. This remaining compensation expense is expected to be recognized over a weighted-average period of 2.6 years as of December 31, 2022.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Stock-based compensation expense recorded as research and development and general and administrative expenses is as follows:</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,056</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,081</p></td></tr><tr><td style="vertical-align:top;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,207</p></td></tr><tr><td style="vertical-align:top;width:73.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,288</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The assumptions used in the Black-Scholes option-pricing model for stock options granted were as follows:</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.3 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">79.7 - 81.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.8 - 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.8 - 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>39
<FILENAME>R20.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148607915968">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share Attributable to Common Stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareTextBlock', window );">Net Loss per Share Attributable to Common Stockholders</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">13. Net Loss per Share Attributable to Common Stockholders</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company&#8217;s potential dilutive securities, which include common stock options, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,262,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,545,794</p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,262,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,545,794</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for earnings per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=109243012&amp;loc=SL65017193-207537<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -URI https://asc.fasb.org/topic&amp;trid=2144383<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>40
<FILENAME>R21.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148605039984">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">14. Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The reconciliation of federal statutory income tax rate to the Company&#8217;s effective income tax rate is as follows:</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected income tax benefit at the federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prior year provision to return adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The principal components of the Company&#8217;s deferred tax assets consisted of the following as of December&#160;31, 2021 and 2020:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal and state net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,451</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,862</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capitalized R&amp;D Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,184</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accruals and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,291</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,788</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (79,724)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,705)</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (83)</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,538)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,538)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (83)</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Based on the Company&#8217;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2022. The Company increased its valuation allowance by approximately $21.9 million for the&#160;year ended December&#160;31, 2022. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">As of December&#160;31, 2022, the Company had federal and state net operating loss carryforwards of $180.2&#160;million and $183.1&#160;million, respectively, some of which begin to expire in the&#160;year ending December&#160;31, 2036. Approximately $157.5 million of the federal net operating loss carryforwards do not expire. The Company had federal and state research and development tax credit carryforwards of approximately $11.3 million and $0.1&#160;million, respectively, as of December&#160;31, 2022. The federal credits begin to expire in the&#160;year ending December&#160;31, 2036, and the state credits begin to expire in the&#160;year ending December&#160;31, 2024.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Under the provisions of Sections&#160;382 and 383 of the Internal Revenue Code (the &#8220;IRC&#8221;), certain substantial changes in the Company&#8217;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company files income tax returns in the U.S. federal jurisdiction as well as in Maryland. The tax&#160;years 2019 to 2021 remain open to examination by the major jurisdictions in which the Company is subject to tax. Fiscal&#160;years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early&#160;years, which have been carried forward and may be audited in subsequent&#160;years when utilized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2022, the Company had no unrecognized income tax benefits that would affect the Company&#8217;s effective tax rate if recognized.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Coronavirus Aid, Relief, and Economic Security Act, or &#8220;CARES Act&#8221;, and the Consolidated Appropriations Act, 2021, or &#8220;Stimulus Bill&#8221;, signed into law on March 27, 2020 and December 27, 2020, respectively, have resulted in significant changes to the U.S. federal corporate tax law. Several states have also enacted tax legislation changes. We have considered the applicable tax law changes and determined there was no significant impact to the tax provision of the Company.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 21<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32857-109319<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 2<br> -Subparagraph (SAB Topic 11.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330215-122817<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB TOPIC 6.I.5.Q1)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 14<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32705-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 270<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6424409&amp;loc=d3e44925-109338<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -URI https://asc.fasb.org/topic&amp;trid=2144680<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 30<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=6424122&amp;loc=d3e41874-109331<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>41
<FILENAME>R22.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148602821184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock', window );">Employee Benefit Plan</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;">15. Employee Benefit Plan</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company sponsors a 401(k)&#160;plan which stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. For the year ended December 31, 2022, the Company made matching contributions of $0.3 million. &#160;No contributions were made for year ended December 31, 2021.</p><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The entire disclosure for retirement benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 55<br> -Paragraph 17<br> -URI https://asc.fasb.org/extlink&amp;oid=123450688&amp;loc=d3e4179-114921<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section S99<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=21916913&amp;loc=d3e273930-122802<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (o)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (p)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 70<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=49170846&amp;loc=d3e28014-114942<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -URI https://asc.fasb.org/topic&amp;trid=2235017<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 60<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6414203&amp;loc=d3e39689-114964<br><br>Reference 9: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 10: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (q)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 11: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 12: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)(iii)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 13: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (l)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br><br>Reference 14: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 715<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (r)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=123447040&amp;loc=d3e1928-114920<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>42
<FILENAME>R23.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148601635488">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Policies)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock', window );">Basis of Presentation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Basis of Presentation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The accompanying financial statements include the accounts of the Company. The Company&#8217;s financial statements have been prepared in accordance with United States generally accepted accounting principles (&#8216;&#8216;GAAP&#8217;&#8217;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;">Standards Codification (&#8216;&#8216;ASC&#8217;&#8217;) and Accounting Standards Update (&#8216;&#8216;ASU&#8217;&#8217;) of the Financial Accounting Standards Board (&#8216;&#8216;FASB&#8217;&#8217;). </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UseOfEstimates', window );">Use of Estimates</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Use of Estimates</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock', window );">Cash and Cash Equivalents</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Cash and Cash Equivalents</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy', window );">Restricted Cash</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;">Restricted Cash</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;">In August 2021, the Company fully paid the remaining principal balance of $2.4 million of its $5.0 million term loan (the &#8220;Term Loan&#8221;). As a result of this payment, the Company has no restricted cash held in support of the Term Loan. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_MarketableSecuritiesPolicy', window );">Marketable Securities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Marketable Securities</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company&#8217;s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders&#8217; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company&#8217;s statements of operations.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company&#8217;s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ConcentrationRiskCreditRisk', window );">Concentration of Credit Risk</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Concentration of Credit Risk</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. </p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueOfFinancialInstrumentsPolicy', window );">Fair Value of Financial Instruments</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Fair Value of Financial Instruments</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">ASC Topic 820, <i style="font-style:italic;">Fair Value Measurement</i> (&#8220;ASC 820&#8221;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#8217;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#8217;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;1&#8212;Quoted market prices in active markets for identical assets or liabilities.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;2&#8212;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Level&#160;3&#8212;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#8211; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#8217;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock', window );">Property and Equipment, Net</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Property and Equipment, Net</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Estimated useful lives for property and equipment are as follows:</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computers and peripherals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">be the rate required for a similar investment of like risk. No impairment losses were recognized during the years ended December 31, 2022 or 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Construction in progress (Note&#160;5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock', window );">Leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Leases</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">On January 1, 2022 (Adoption Date), the Company adopted Accounting Standards Update (ASU) No. 2016-02, <i style="font-style:italic;">Leases</i>&#160;(Topic 842) (ASU No. 2016-02), as amended, using the modified retrospective approach, which provides a method for recording existing leases at adoption and does not require restating comparative financial information. The Company also elected the package of practical expedients permitted under the transition guidance under ASU No. 2016-02, which among other things, permits the Company to maintain the lease classification for any existing leases, as well as maintain the Company&#8217;s determination on whether any expired or existing contracts are or contain leases and initial direct costs for any existing leases. The Company did not elect the hindsight practical expedient to determine the lease term for existing leases. In addition, the Company elected the additional transition method permitted under ASU No. 2018-11<span style="font-family:'Arial','Helvetica','sans-serif';">&#8210;</span>Leases (Topic 842): Targeted Improvements, under which the Company initially applied the new lease standard, Accounting Standards Codification (ASC) 842, at adoption and there was no cumulative-effect adjustment to the opening balance of retained earnings on January 1, 2022. For the comparative period presented in these financial statements, lease-related disclosures continue to be in accordance with the legacy ASC 840. Adoption of ASC 842 did not materially impact the Company&#8217;s statements of operations and cash flows. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">The Company determines if an arrangement is a lease or implicitly contains a lease at inception based on the lease definition and also determines if the lease is classified as an operating lease or finance lease, each in accordance with ASC 842. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in its balance sheets. ROU assets represent the Company&#8217;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#8217;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date or the Adoption Date for existing leases based on the present value of lease payments over the lease term using an estimated discount rate. As the Company&#8217;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date or the Adoption Date in determining the present value of lease payments over a similar term. In determining the estimated incremental borrowing rate, the Company considered a rate obtained from its primary banker for discussion purposes of a potential collateralized loan with a term similar to the lease term and the Company&#8217;s historical borrowing capability in the market. For operating leases, lease expense is recognized on a straight-line basis over the lease term. Lease and non-lease components within a contract are generally accounted for separately.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy', window );">Preferred Stock</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;">Preferred Stock</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company did not have any outstanding preferred stock as of December 31, 2022 and 2021.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ResearchAndDevelopmentExpensePolicy', window );">Research and Development Costs, Including Clinical Trial Accruals</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Research and Development Costs, Including Clinical Trial Accruals</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (&#8220;CROs&#8221;), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;">Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;">other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy', window );">Patent Costs</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Patent Costs</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy', window );">Stock Based Compensation</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Stock-Based Compensation</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company accounts for its stock-based compensation in accordance with ASC Topic 718, <i style="font-style:italic;">Compensation-Stock Compensation</i> (&#8220;ASC 718&#8221;). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#8220;Black-Scholes&#8221;) for stock option grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to the lack of a public market for the Company&#8217;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No.&#160;2016-09, <i style="font-style:italic;">Improvements to Employee Share-Based Payment Accounting</i> (&#8220;ASU&#160;2016-09&#8221;).</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">There are significant judgments and estimates inherent in the determination of the fair value of the Company&#8217;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period.</p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxPolicyTextBlock', window );">Income Taxes</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Income Taxes</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#8217;s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2022 and 2021.</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock', window );">Comprehensive Income (Loss)</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Comprehensive Income (Loss)</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2022 and 2021. </p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerSharePolicyTextBlock', window );">Net Loss per Share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Net Loss per Share</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.</p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock', window );">Recently Issued Accounting Pronouncements</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;">Recently Issued Accounting Pronouncements</p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company qualifies as an emerging growth company (&#8220;EGC&#8221;) as defined under the Jumpstart Our Business Startups Act (the &#8220;JOBS Act&#8221;). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. </p><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;">The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company&#8217;s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company&#8217;s financial position or results of operations.</p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_BasisOfAccountingPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_BasisOfAccountingPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(1)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=d3e4273-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ComprehensiveIncomePolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for comprehensive income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ComprehensiveIncomePolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ConcentrationRiskCreditRisk">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for credit risk.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 825<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126941378&amp;loc=d3e61044-112788<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ConcentrationRiskCreditRisk</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerSharePolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3630-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerSharePolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueOfFinancialInstrumentsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for determining the fair value of financial instruments.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 60<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=7493716&amp;loc=d3e21868-110260<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13279-108611<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueOfFinancialInstrumentsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 350<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=66006027&amp;loc=d3e16265-109275<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 25<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32247-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 20<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32847-109319<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 19<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32840-109319<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 220<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124431353&amp;loc=SL116659661-227067<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32639-109319<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=d3e32280-109318<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 17<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32809-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_MarketableSecuritiesPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for investment classified as marketable security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62652-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_MarketableSecuritiesPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99779-112916<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 958<br> -SubTopic 360<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=126982197&amp;loc=d3e99893-112916<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ResearchAndDevelopmentExpensePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 730<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6420194&amp;loc=d3e21568-108373<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ResearchAndDevelopmentExpensePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy election of practical expedient not to separate lease component from nonlease component.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918707-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(v)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 5: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -URI https://asc.fasb.org/topic&amp;trid=2228938<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 14.D.2.Q6)<br> -URI https://asc.fasb.org/extlink&amp;oid=122041274&amp;loc=d3e301413-122809<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 8: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 05<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=126960819&amp;loc=d3e20905-112640<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(27)(c))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UseOfEstimates">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6191-108592<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6161-108592<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6143-108592<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6061-108592<br><br>Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e6132-108592<br><br>Reference 7: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 275<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=99393423&amp;loc=d3e5967-108592<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UseOfEstimates</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>43
<FILENAME>R24.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603354144">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccountingPoliciesAbstract', window );"><strong>Summary of Significant Accounting Policies</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock', window );">Summary of estimated useful lives for property and equipment</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated&#160;Useful&#160;Life</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computers and peripherals</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">3&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">7&#160;years</p></td></tr><tr><td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">Lesser of estimated useful life or remaining lease term</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the tabular disclosure of estimated useful lives for property and equipment.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccountingPoliciesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccountingPoliciesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>44
<FILENAME>R25.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148608603408">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract', window );"><strong>Marketable Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock', window );">Schedule of marketable securities</a></td>
<td class="text"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,163</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,457)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131,706</p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">U.S. Government agencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,612</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (37)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,575</p></td></tr><tr><td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 134,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,494)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,281</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gross</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Amortized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unrealized</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Estimated</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Gain</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Loss</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair Value</b></p></td></tr><tr><td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td></tr><tr><td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,917</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (666)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock', window );">Schedule of available-for-sale maturities</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Fair</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Cost</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Value</b></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Maturities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Within 1 year</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105,930</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 104,660</p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Between 1 to 2 years</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,845</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,621</p></td></tr><tr><td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total investments available-for-sale</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 134,775</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,281</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the maturities of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>45
<FILENAME>R26.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148607919680">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueDisclosuresAbstract', window );"><strong>Fair Value Measurements</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock', window );">Summary of fair value of the Company's financial assets</a></td>
<td class="text"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2022</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 131,706</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">U.S. Government agencies</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,575</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 140,063</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,782</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 133,281</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="position:absolute;top:0pt;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Quoted Prices in </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Other </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Active Markets or</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Observable</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Significant</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Identical Assets</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Inputs</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Unobservable</b></p></td></tr><tr><td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Total</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 1)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 2)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">(Level 3)</b></p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Cash equivalents:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Money market funds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Marketable securities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Corporate bonds</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 209,934</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 2,680</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 207,254</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByBalanceSheetGroupingTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 825<br> -SubTopic 10<br> -Section 50<br> -Paragraph 11<br> -URI https://asc.fasb.org/extlink&amp;oid=123594938&amp;loc=d3e13467-108611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByBalanceSheetGroupingTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>46
<FILENAME>R27.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148608629392">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentTextBlock', window );">Summary of property and equipment</a></td>
<td class="text"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:70.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 17,244</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 16,482</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Leasehold improvements</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,336</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,566</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Computer equipment</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 908</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,143</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Furniture and fixtures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 186</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 167</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Construction in progress</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 853</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 371</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, gross</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 28,527</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 26,729</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: accumulated depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (16,630)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (12,737)</p></td></tr><tr><td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Property and equipment, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,897</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 13,992</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>47
<FILENAME>R28.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148602821184">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Accrued Liabilities and Other Liabilities (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities and Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock', window );">Summary of accrued liabilities and other liabilities</a></td>
<td class="text"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Payroll and related benefits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,639</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,751</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Clinical trial costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,531</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 727</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Sponsored research</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 417</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,315</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="-sec-ix-hidden:Hidden_Y-cqdjMky0anGfcN4D8zww;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">Lease liabilities, current portion</span></span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 518</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Operating expenses</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 647</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 656</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:70.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 105</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 217</p></td></tr><tr><td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total accrued liabilities and other liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,857</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,666</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of accrued liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>48
<FILENAME>R29.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148605080064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock', window );">Schedule of future minimum lease payments under non-cancellable leases</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;">As of December 31, 2022, the maturities of the Company&#8217;s operating lease liabilities were as follows (in thousands), which are included in Accrued liabilities and other liabilities and Lease liabilities, long term in the accompanying balance sheet:</p><table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Year Ending December 31,</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2023</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,032</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2024</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,127</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2025</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,214</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2026</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,355</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">2027</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,396</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Thereafter</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,295</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total future minimum payments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,419</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: present value discount</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (2,296)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Present value of lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 7,123</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>49
<FILENAME>R30.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148602503328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract', window );"><strong>Stock-Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock', window );">Summary of stock option activity</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"><span style="margin-bottom:12pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Options&#160;Outstanding&#160;and&#160;Exercisable</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Weighted</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Aggregate</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Average</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Remaining</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Intrinsic</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Number&#160;of</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Exercise</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Contractual</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Value</b><sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;">(1)</sup></p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Shares</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Price</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">Life&#160;(Years)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;">&#160;&#160;&#160;&#160;</p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"><b style="font-weight:bold;">(in&#160;thousands)</b></p></td></tr><tr><td style="vertical-align:bottom;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of January 1, 2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 3,112,376</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 16.95</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10,810</p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,020,718</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 10.89</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (105,731)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.62</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeitures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (481,569)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 21.33</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2021</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 4,545,794</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 14.15</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 8.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,860</p></td></tr><tr><td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Granted</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1,739,350</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5.34</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Exercised</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (50,420)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 1.32</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;">Forfeitures</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"> (972,545)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 13.77</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Outstanding as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 5,262,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 11.44</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 7.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115</p></td></tr><tr><td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">Exercisable as of December&#160;31,&#160;2022</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 2,790,206</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 12.97</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 6.6</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"> 115</p></td></tr></table><div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"><div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/></div><table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"><tr><td style="width:18pt;"/><td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;">(1)</td><td style="padding:0pt;"><span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;">The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2022 and 2021.</span></td></tr></table><div style="margin-top:12pt;"/><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock', window );">Summary of stock based compensation expense recorded</a></td>
<td class="text"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:middle;white-space:nowrap;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"><b style="font-weight:bold;">(in thousands)</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:top;width:73.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,056</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,081</p></td></tr><tr><td style="vertical-align:top;width:73.46%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">General and administrative</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,452</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6,207</p></td></tr><tr><td style="vertical-align:top;width:73.46%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total stock-based compensation expense</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 9,508</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 10,288</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock', window );">Summary of assumptions used in the Black Scholes option pricing model for stock options granted</a></td>
<td class="text"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">Year Ended </b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected term</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.5 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years<span style="font-family:'Calibri','Helvetica','sans-serif';">&#160;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">5.3 - 6.1</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">years&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected volatility</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">79.7 - 81.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 79.7</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Risk free interest rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">1.8 - 4.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;">0.8 - 1.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected dividend yield</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td><td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>50
<FILENAME>R31.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603237200">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EarningsPerShareAbstract', window );"><strong>Net Loss per Share Attributable to Common Stockholders</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock', window );">Summary of shares excluded from the computation of diluted net loss per share</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.57%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Outstanding options to purchase common stock</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,262,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,545,794</p></td></tr><tr><td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 5,262,179</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,545,794</p></td></tr></table><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EarningsPerShareAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EarningsPerShareAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>51
<FILENAME>R32.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603496400">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes (Tables)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxDisclosureAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock', window );">Summary of reconciliation of federal statutory income tax rate to the Company's effective income tax rate</a></td>
<td class="text"><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Expected income tax benefit at the federal statutory rate</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 21.0</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">State taxes, net of federal benefit</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 6.5</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Research and development credit, net</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.4</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3.2</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Non-deductible items</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.7)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1.8)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Prior year provision to return adjustments</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (0.4)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Change in valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (29.1)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (28.5)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Total</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">%</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock', window );">Summary of components of deferred tax assets</a></td>
<td class="text"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"><span style="font-size:0pt;visibility:hidden;">&#8203;</span></p><table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"><tr style="height:1pt;"><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"><div style="bottom:0pt;position:absolute;width:100%;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:1pt;visibility:hidden;">&#8203;</span></p></div></div></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="font-size:8pt;font-weight:bold;visibility:hidden;">&#8203;</span></p></td><td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">December&#160;31,&#160;</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;">(in thousands)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2022</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;&#160;&#160;&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"><b style="font-weight:bold;">&#160;</b></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"><b style="font-weight:bold;">2021</b></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax assets:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;">&#160;&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;&#160;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Federal and state net operating loss carryforwards</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 49,789</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 44,451</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Research and development tax credits</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 11,395</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 8,862</p></td></tr><tr><td style="vertical-align:bottom;white-space:nowrap;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Capitalized R&amp;D Costs</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 12,424</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,960</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Share-based compensation</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 4,389</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 3,184</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Accruals and other</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,305</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,291</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;">Gross deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 81,262</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 57,788</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Less: valuation allowance</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (79,724)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (57,705)</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Total deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 1,538</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> 83</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Deferred tax liabilities:</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Depreciation and amortization</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (83)</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Operating lease assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,538)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;">Gross deferred tax liabilities</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (1,538)</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"> (83)</p></td></tr><tr><td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">Net deferred tax assets</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">&#160;</p></td><td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;">$</p></td><td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"><p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"> &#8212;</p></td></tr></table><p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"><span style="visibility:hidden;">&#8203;</span></p><span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:textBlockItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>52
<FILENAME>R33.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148598059504">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)<br> $ / shares in Units, $ in Millions</strong></div></th>
<th class="th">
<div>Dec. 02, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Nov. 19, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2019 </div>
<div>USD ($) </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th"><div>May 03, 2019</div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Nature of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1', window );">Reverse stock split ratio</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0.1245<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="nump">611,578<span></span>
</td>
<td class="nump">4,077,192<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="nump">$ 36.75<span></span>
</td>
<td class="nump">$ 36.75<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock', window );">Proceeds from issuance of preferred stock, net of issuance costs | $</a></td>
<td class="nump">$ 160.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions | $</a></td>
<td class="nump">10.3<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses | $</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">15,560,569<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">27,774,536<span></span>
</td>
<td class="nump">27,680,997<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, number of shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, number of shares authorized | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember', window );">IPO</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SubsequentEventLineItems', window );"><strong>Nature of the Business</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues', window );">Issuance of common stock (in shares) | shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,750,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharePrice', window );">Share price | $ / shares</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 15.00<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering', window );">Proceeds from issuance of shares, net | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 77.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_PaymentsOfUnderwritingDiscountsAndCommissions', window );">Underwriting discounts and commissions | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">6.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PaymentsOfStockIssuanceCosts', window );">Offering expenses | $</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.4<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_PaymentsOfUnderwritingDiscountsAndCommissions">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for payment of underwriting discounts and commissions.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_PaymentsOfUnderwritingDiscountsAndCommissions</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PaymentsOfStockIssuanceCosts">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash outflow for cost incurred directly with the issuance of an equity security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3291-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PaymentsOfStockIssuanceCosts</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceInitialPublicOffering">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The cash inflow associated with the amount received from entity's first offering of stock to the public.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceInitialPublicOffering</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 14<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3255-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Price of a single share of a number of saleable stocks of a company.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesNewIssues">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of new stock issued during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesNewIssues</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockholdersEquityNoteStockSplitConversionRatio1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 4<br> -Subparagraph (SAB TOPIC 4.C)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187143-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockholdersEquityNoteStockSplitConversionRatio1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:pureItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsequentEventLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsequentEventLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SubsidiarySaleOfStockAxis=us-gaap_IPOMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>53
<FILENAME>R34.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148605080064">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Nature of the Business and Basis of Presentation - Liquidity (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th">
<div>Dec. 31, 2022 </div>
<div>segment</div>
</th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract', window );"><strong>Nature of the Business and Basis of Presentation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_NumberOfOperatingSegments', window );">Number of operating segment</a></td>
<td class="nump">1<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_NumberOfOperatingSegments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 18<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8672-108599<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_NumberOfOperatingSegments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>54
<FILENAME>R35.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148602469440">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Restricted Cash (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="1">1 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Aug. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_RestrictedCashAbstract', window );"><strong>Restricted Cash</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ProceedsFromRepaymentsOfDebt', window );">Repayment of principal debt balance</a></td>
<td class="nump">$ 2,400<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 5,000<span></span>
</td>
<td class="nump">$ 1,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_RequiredReserveRestrictedCashCurrent', window );">Restricted cash required reserve</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract', window );"><strong>Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAtCarryingValue', window );">Cash and cash equivalents</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">26,630<span></span>
</td>
<td class="nump">$ 12,337<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents', window );">Total</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 26,630<span></span>
</td>
<td class="nump">$ 12,337<span></span>
</td>
<td class="nump">$ 36,284<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_RequiredReserveRestrictedCashCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of required reserve of restricted cash.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_RequiredReserveRestrictedCashCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAtCarryingValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=124098289&amp;loc=d3e6676-107765<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(1))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAtCarryingValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 24<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3521-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3044-108585<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=126999549&amp;loc=SL98516268-108586<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ProceedsFromRepaymentsOfDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ProceedsFromRepaymentsOfDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_RestrictedCashAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_RestrictedCashAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>55
<FILENAME>R36.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148601574160">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Property and Equipment and Leases (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
</tr>
<tr><th class="th"><div>Dec. 31, 2022</div></th></tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientsPackage', window );">Lease, Practical Expedients, Package [true false]</a></td>
<td class="text">true<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientUseOfHindsight', window );">Lease, Practical Expedient, Use of Hindsight [true false]</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">P3Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember', window );">Equipment</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">P5Y<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentLineItems', window );"><strong>Property, plant and equipment</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives', window );">Property, Plant and Equipment, Estimated Useful Lives</a></td>
<td class="text">P7Y<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientUseOfHindsight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient is elected to use hindsight in determining lease term and in assessing impairment of right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientUseOfHindsight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientsPackage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientsPackage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 35<br> -Paragraph 4<br> -URI https://asc.fasb.org/extlink&amp;oid=126905813&amp;loc=d3e1205-110223<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_EquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>56
<FILENAME>R37.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148601811872">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Summary of Significant Accounting Policies - Additional Information (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_PreferredStockAbstract', window );"><strong>Preferred Stock</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AssetImpairmentChargesAbstract', window );"><strong>Impairment of Long Lived Assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf', window );">Impairment loss recognized</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeTaxUncertaintiesAbstract', window );"><strong>Income Taxes</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense', window );">Uncertain income tax benefits, interest or penalties</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_PreferredStockAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Not available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_PreferredStockAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AssetImpairmentChargesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AssetImpairmentChargesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 45<br> -Paragraph 15<br> -URI https://asc.fasb.org/extlink&amp;oid=126905981&amp;loc=d3e2611-110228<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeTaxUncertaintiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeTaxUncertaintiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32718-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>57
<FILENAME>R38.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148601504320">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Marketable Securities - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">$ 134,775<span></span>
</td>
<td class="nump">$ 207,917<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(1,494)<span></span>
</td>
<td class="num">(666)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">133,281<span></span>
</td>
<td class="nump">207,254<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger', window );">Unrealized losses in a continuous loss position for more than twelve consecutive months</a></td>
<td class="nump">91,800<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain', window );">Gross realized gains</a></td>
<td class="nump">9<span></span>
</td>
<td class="nump">57<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_InterestIncomeNonOperating', window );">Interest income</a></td>
<td class="nump">700<span></span>
</td>
<td class="nump">1,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract', window );"><strong>Cost Maturities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost', window );">Within 1 year</a></td>
<td class="nump">105,930<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost', window );">Between 1 to 2 years</a></td>
<td class="nump">28,845<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis', window );">Total investments available for sale</a></td>
<td class="nump">134,775<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract', window );"><strong>Fair Value Maturities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue', window );">Within 1 year</a></td>
<td class="nump">104,660<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue', window );">Between 1 to 2 years</a></td>
<td class="nump">28,621<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate', window );">Total investments available for sale</a></td>
<td class="nump">133,281<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">133,163<span></span>
</td>
<td class="nump">207,917<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax', window );">Gross Unrealized Gain</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">3<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(1,457)<span></span>
</td>
<td class="num">(666)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">131,706<span></span>
</td>
<td class="nump">$ 207,254<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems', window );"><strong>Investments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss', window );">Amortized Cost</a></td>
<td class="nump">1,612<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax', window );">Gross Unrealized Loss</a></td>
<td class="num">(37)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Estimated Fair Value</a></td>
<td class="nump">$ 1,575<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year to year two. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_InterestIncomeNonOperating">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the total non-operating interest income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_InterestIncomeNonOperating</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=d3e62586-112803<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 320<br> -Section 50<br> -Paragraph 3A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126980459&amp;loc=SL120269850-112803<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27198-111563<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27161-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 50<br> -Paragraph 5<br> -URI https://asc.fasb.org/extlink&amp;oid=124269663&amp;loc=SL82922890-210455<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 7<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27337-111563<br><br>Reference 3: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121590138&amp;loc=SL82922954-210456<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleRealizedGain">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 320<br> -SubTopic 10<br> -Section 50<br> -Paragraph 9<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126970911&amp;loc=d3e27357-111563<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleRealizedGain</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>58
<FILENAME>R39.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148598092896">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Fair Value Measurements - (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="nump">$ 133,281,000<span></span>
</td>
<td class="nump">$ 207,254,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3', window );">Assets transferred into level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3', window );">Assets transferred out of level 3</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount', window );">Assets transferred from level 1 to level 2</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount', window );">Assets transferred from level 2 to level 1</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="nump">131,706,000<span></span>
</td>
<td class="nump">207,254,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember', window );">U.S. Government agencies</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="nump">1,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_MarketableSecuritiesAndCashEquivalents', window );">Total financial assets</a></td>
<td class="nump">140,063,000<span></span>
</td>
<td class="nump">209,934,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_MarketableSecuritiesAndCashEquivalents', window );">Total financial assets</a></td>
<td class="nump">6,782,000<span></span>
</td>
<td class="nump">2,680,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember', window );">Fair Value | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_MarketableSecuritiesAndCashEquivalents', window );">Total financial assets</a></td>
<td class="nump">133,281,000<span></span>
</td>
<td class="nump">207,254,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds (cash equivalents) | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">6,782,000<span></span>
</td>
<td class="nump">2,680,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember', window );">Money market funds (cash equivalents) | Fair Value | Quoted Prices in Active Markets (Level 1)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure', window );">Money market funds (cash equivalents)</a></td>
<td class="nump">6,782,000<span></span>
</td>
<td class="nump">2,680,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bonds | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="nump">1,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember', window );">Agency bonds | Fair Value | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="nump">1,575,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds | Fair Value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="nump">131,706,000<span></span>
</td>
<td class="nump">207,254,000<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember', window );">Corporate bonds | Fair Value | Significant Other Observable Inputs (Level 2)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract', window );"><strong>Fair value of the Company's financial assets</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest', window );">Marketable Securities</a></td>
<td class="nump">$ 131,706,000<span></span>
</td>
<td class="nump">$ 207,254,000<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amounts of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_MarketableSecuritiesAndCashEquivalents">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>1</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_MarketableSecuritiesAndCashEquivalents</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsFairValueDisclosure">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsFairValueDisclosure</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 326<br> -SubTopic 30<br> -Section 45<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124258926&amp;loc=SL82898722-210454<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 820<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=126976982&amp;loc=d3e19207-110258<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FinancialInstrumentAxis=us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByMeasurementBasisAxis=us-gaap_EstimateOfFairValueFairValueDisclosureMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel1Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_FairValueByFairValueHierarchyLevelAxis=us-gaap_FairValueInputsLevel2Member</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_MoneyMarketFundsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_USGovernmentAgenciesDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CashAndCashEquivalentsAxis=us-gaap_CorporateDebtSecuritiesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>59
<FILENAME>R40.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148598038912">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Property and Equipment, Net - (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 28,527<span></span>
</td>
<td class="nump">$ 26,729<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment', window );">Less: accumulated depreciation and amortization</a></td>
<td class="num">(16,630)<span></span>
</td>
<td class="num">(12,737)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNet', window );">Property and equipment, net</a></td>
<td class="nump">11,897<span></span>
</td>
<td class="nump">13,992<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DepreciationDepletionAndAmortization', window );">Depreciation and amortization expense</a></td>
<td class="nump">4,100<span></span>
</td>
<td class="nump">4,300<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nxtc_ResearchEquipmentMember', window );">Research equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">17,244<span></span>
</td>
<td class="nump">16,482<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember', window );">Leasehold improvements</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">9,336<span></span>
</td>
<td class="nump">8,566<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember', window );">Computer equipment</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">908<span></span>
</td>
<td class="nump">1,143<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember', window );">Furniture and fixtures</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">186<span></span>
</td>
<td class="nump">167<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember', window );">Construction in progress</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentNetAbstract', window );"><strong>Property and Equipment, Net</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PropertyPlantAndEquipmentGross', window );">Property and equipment, gross</a></td>
<td class="nump">$ 853<span></span>
</td>
<td class="nump">$ 371<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(14))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DepreciationDepletionAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 280<br> -SubTopic 10<br> -Section 50<br> -Paragraph 22<br> -Subparagraph (e)<br> -URI https://asc.fasb.org/extlink&amp;oid=126901519&amp;loc=d3e8736-108599<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 230<br> -SubTopic 10<br> -Section 45<br> -Paragraph 28<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=126954810&amp;loc=d3e3602-108585<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DepreciationDepletionAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(13))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 360<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=6391035&amp;loc=d3e2868-110229<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(8))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 360<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429447&amp;loc=SL124453093-239630<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=nxtc_ResearchEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=nxtc_ResearchEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_LeaseholdImprovementsMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ComputerEquipmentMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_FurnitureAndFixturesMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PropertyPlantAndEquipmentByTypeAxis=us-gaap_ConstructionInProgressMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>60
<FILENAME>R41.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148601773856">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Accrued Liabilities and Other Liabilities (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AccruedLiabilitiesCurrentAbstract', window );"><strong>Accrued Liabilities and Other Liabilities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeRelatedLiabilitiesCurrent', window );">Payroll and related benefits</a></td>
<td class="nump">$ 1,639<span></span>
</td>
<td class="nump">$ 1,751<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_AccruedClinicalTrialCostsCurrent', window );">Clinical trial costs</a></td>
<td class="nump">1,531<span></span>
</td>
<td class="nump">727<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_AccruedSponsoredResearchExpenseCurrent', window );">Sponsored research</a></td>
<td class="nump">417<span></span>
</td>
<td class="nump">$ 1,315<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrent', window );">Lease liabilities, current portion</a></td>
<td class="nump">$ 518<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList', window );">Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]</a></td>
<td class="text">Total accrued liabilities and other liabilities<span></span>
</td>
<td class="text">Total accrued liabilities and other liabilities<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_AccruedOperatingExpensesCurrent', window );">Operating expenses</a></td>
<td class="nump">$ 647<span></span>
</td>
<td class="nump">$ 656<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OtherLiabilitiesCurrent', window );">Other</a></td>
<td class="nump">105<span></span>
</td>
<td class="nump">217<span></span>
</td>
</tr>
<tr class="reu">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_AccruedAndOtherLiabilitiesCurrent', window );">Total accrued liabilities and other liabilities</a></td>
<td class="nump">$ 4,857<span></span>
</td>
<td class="nump">$ 4,666<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AccruedAndOtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities and amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AccruedAndOtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AccruedClinicalTrialCostsCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AccruedClinicalTrialCostsCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AccruedOperatingExpensesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AccruedOperatingExpensesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_AccruedSponsoredResearchExpenseCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Carrying value as of the balance sheet date of obligations incurred through that date and payable for sponsored research expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_AccruedSponsoredResearchExpenseCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AccruedLiabilitiesCurrentAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AccruedLiabilitiesCurrentAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeRelatedLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeRelatedLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates line item in statement of financial position that includes current operating lease liability.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918631-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>enum2:enumerationSetItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OtherLiabilitiesCurrent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 852<br> -SubTopic 10<br> -Section 55<br> -Paragraph 10<br> -URI https://asc.fasb.org/extlink&amp;oid=84165509&amp;loc=d3e56426-112766<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.20)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OtherLiabilitiesCurrent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>61
<FILENAME>R42.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148602472944">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Leases - Other Information (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasesAbstract', window );"><strong>Leases</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientsPackage', window );">Lease, Practical Expedients, Package [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LeasePracticalExpedientUseOfHindsight', window );">Lease, Practical Expedient, Use of Hindsight [true false]</a></td>
<td class="text">false<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseRenewalTerm', window );">Lease extension period</a></td>
<td class="text">5 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend', window );">Lessee, Operating Lease, Existence of Option to Extend [true false]</a></td>
<td class="text">true<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseExpense', window );">Operating lease expense</a></td>
<td class="nump">$ 1.0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasePayments', window );">Operating cash flows used for operating leases</a></td>
<td class="nump">$ 0.9<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1', window );">Weighted=average remaining lease term</a></td>
<td class="text">7 years 3 months<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent', window );">Weighted average discount rate (as a percent)</a></td>
<td class="nump">7.46%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeasesRentExpenseNet', window );">Rent expenses operating leases</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 1.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientUseOfHindsight">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedient is elected to use hindsight in determining lease term and in assessing impairment of right-of-use asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (g)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientUseOfHindsight</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasePracticalExpedientsPackage">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (j)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 10<br> -Section 65<br> -Paragraph 1<br> -Subparagraph (f)<br> -URI https://asc.fasb.org/extlink&amp;oid=128293352&amp;loc=SL77916155-209984<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasePracticalExpedientsPackage</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LeasesAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LeasesAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicates (true false) whether lessee has option to extend operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseRenewalTerm">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918673-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseRenewalTerm</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of operating lease expense. Excludes sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 4<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918638-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasePayments">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 5<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918643-209977<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasePayments</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average discount rate for operating lease calculated at point in time.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(4)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 55<br> -Paragraph 53<br> -URI https://asc.fasb.org/extlink&amp;oid=123414884&amp;loc=SL77918982-209971<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (g)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918686-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeasesRentExpenseNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/otherTransitionRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 840<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=123406913&amp;loc=d3e41499-112717<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeasesRentExpenseNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>62
<FILENAME>R43.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148602471792">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Leases - Maturities (Details)<br> $ in Thousands</strong></div></th>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>USD ($)</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract', window );"><strong>Future minimum lease payments</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths', window );">2023</a></td>
<td class="nump">$ 1,032<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo', window );">2024</a></td>
<td class="nump">1,127<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree', window );">2025</a></td>
<td class="nump">1,214<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour', window );">2026</a></td>
<td class="nump">1,355<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive', window );">2027</a></td>
<td class="nump">1,396<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive', window );">Thereafter</a></td>
<td class="nump">3,295<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue', window );">Total future minimum payments</a></td>
<td class="nump">9,419<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount', window );">Less: present value discount</a></td>
<td class="num">(2,296)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_OperatingLeaseLiability', window );">Present value of lease liabilities</a></td>
<td class="nump">$ 7,123<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=128292326&amp;loc=SL77918701-209980<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_OperatingLeaseLiability">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Present value of lessee's discounted obligation for lease payments from operating lease.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 842<br> -SubTopic 20<br> -Section 45<br> -Paragraph 1<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123391704&amp;loc=SL77918627-209977<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_OperatingLeaseLiability</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>63
<FILENAME>R44.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148601780528">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Term Loan - Other (Details) - USD ($)<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Jan. 31, 2019</div></th>
<th class="th"><div>Apr. 30, 2016</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtDisclosureAbstract', window );"><strong>Term Loan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DebtInstrumentFaceAmount', window );">Face amount</a></td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">$ 5,000,000.0<span></span>
</td>
<td class="nump">$ 1,000,000.0<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_LongTermDebt', window );">Outstanding balance</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DebtInstrumentFaceAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face (par) amount of debt instrument at time of issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1B<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495323-112611<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 45<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=124435984&amp;loc=d3e28551-108399<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 55<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=114775985&amp;loc=d3e28878-108400<br><br>Reference 4: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 835<br> -SubTopic 30<br> -Section 50<br> -Paragraph 1<br> -URI https://asc.fasb.org/extlink&amp;oid=124429444&amp;loc=SL124452920-239629<br><br>Reference 5: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 6: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DebtInstrumentFaceAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_LongTermDebt">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 4<br> -Subparagraph (b)(3)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466204&amp;loc=SL6031897-161870<br><br>Reference 2: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69C<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495737-112612<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(a)(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 55<br> -Paragraph 69B<br> -URI https://asc.fasb.org/extlink&amp;oid=123466577&amp;loc=SL123495735-112612<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(16))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 6: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 470<br> -SubTopic 20<br> -Section 50<br> -Paragraph 1D<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=123466505&amp;loc=SL123495340-112611<br><br>Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(22))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_LongTermDebt</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>64
<FILENAME>R45.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148598081904">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Preferred Stock (Details) - $ / shares<br></strong></div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>May 13, 2019</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Preferred Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesAuthorized', window );">Preferred stock, number of shares authorized</a></td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
<td class="nump">10,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockParOrStatedValuePerShare', window );">Preferred stock, par value per share</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesIssued', window );">Preferred stock, shares issued</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PreferredStockSharesOutstanding', window );">Preferred stock, shares outstanding</a></td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
<td class="nump">0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 13<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=SL123496158-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PreferredStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PreferredStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>65
<FILENAME>R46.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603539504">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Common Stock (Details)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th">
<div>Dec. 31, 2022 </div>
<div>Vote </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>Dec. 31, 2021 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
<th class="th">
<div>May 13, 2019 </div>
<div>$ / shares </div>
<div>shares</div>
</th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract', window );"><strong>Common Stock.</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesAuthorized', window );">Common stock, number of shares authorized</a></td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
<td class="nump">100,000,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockParOrStatedValuePerShare', window );">Common stock, par value per share | $ / shares</a></td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
<td class="nump">$ 0.001<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesIssued', window );">Common stock, shares issued</a></td>
<td class="nump">27,774,536<span></span>
</td>
<td class="nump">27,680,997<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockSharesOutstanding', window );">Common stock, shares outstanding</a></td>
<td class="nump">27,774,536<span></span>
</td>
<td class="nump">27,680,997<span></span>
</td>
<td class="nump">15,560,569<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_NumberOfVotesPerShare', window );">Number of votes per share | Vote</a></td>
<td class="nump">1<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockDividendsPerShareDeclared', window );">Dividends declared | $ / shares</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_NumberOfVotesPerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Represents the number of votes per share.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_NumberOfVotesPerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:integerItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockDividendsPerShareDeclared">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate dividends declared during the period for each share of common stock outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockDividendsPerShareDeclared</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockParOrStatedValuePerShare">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Face amount or stated value per share of common stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockParOrStatedValuePerShare</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesAuthorized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The maximum number of common shares permitted to be issued by an entity's charter and bylaws.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesAuthorized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesIssued">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesIssued</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockSharesOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockSharesOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>66
<FILENAME>R47.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148599155552">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock options (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1"></th>
<th class="th" colspan="3">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>May 03, 2019</div></th>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
<th class="th"><div>Dec. 31, 2020</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract', window );"><strong>Share Based Compensation Expense Not Recognized</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized', window );">Unrecognized compensation cost</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14,700,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1', window );">Compensation expense recognition period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">2 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nxtc_A2015OmnibusIncentivePlanMember', window );">2015 Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward', window );"><strong>Number of Shares</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the beginning (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">4,545,794<span></span>
</td>
<td class="nump">3,112,376<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross', window );">Granted (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1,739,350<span></span>
</td>
<td class="nump">2,020,718<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised', window );">Exercised (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(50,420)<span></span>
</td>
<td class="num">(105,731)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod', window );">Forfeitures (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(972,545)<span></span>
</td>
<td class="num">(481,569)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber', window );">Outstanding at the end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5,262,179<span></span>
</td>
<td class="nump">4,545,794<span></span>
</td>
<td class="nump">3,112,376<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber', window );">Exercisable at the end (in shares)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,790,206<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward', window );"><strong>Weighted Average Exercise Price</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the beginning (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 14.15<span></span>
</td>
<td class="nump">$ 16.95<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice', window );">Granted (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">5.34<span></span>
</td>
<td class="nump">10.89<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice', window );">Exercised (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">1.32<span></span>
</td>
<td class="nump">1.62<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice', window );">Forfeited (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">13.77<span></span>
</td>
<td class="nump">21.33<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice', window );">Outstanding at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">11.44<span></span>
</td>
<td class="nump">$ 14.15<span></span>
</td>
<td class="nump">$ 16.95<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice', window );">Exercisable at the end (in dollars per share)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 12.97<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract', window );"><strong>Weighted Average Remaining Contractual Life (Years) And Aggregate Intrinsic Value</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2', window );">Outstanding (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">7 years 7 months 6 days<span></span>
</td>
<td class="text">8 years 1 month 6 days<span></span>
</td>
<td class="text">8 years 2 months 12 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1', window );">Exercisable at the end (in years)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">6 years 7 months 6 days<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the beginning (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 2,860,000<span></span>
</td>
<td class="nump">$ 10,810,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue', window );">Outstanding at the end (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">115,000<span></span>
</td>
<td class="nump">$ 2,860,000<span></span>
</td>
<td class="nump">$ 10,810,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue', window );">Exercisable at the end (in dollars)</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 115,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue', window );">Weighted average grant date fair value per share of stock options granted</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 3.69<span></span>
</td>
<td class="nump">$ 7.47<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue', window );">Aggregate intrinsic value of stock options exercised</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 13,000<span></span>
</td>
<td class="nump">$ 500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1', window );">Aggregate grant date fair value</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">$ 11,000,000.0<span></span>
</td>
<td class="nump">$ 13,400,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2019PlanMember', window );">Omnibus Incentive Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under the plan</a></td>
<td class="nump">2,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding', window );">Annual increase in number of share reserved for issuance (as percent)</a></td>
<td class="nump">4.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember', window );">2015 Plan and 2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1', window );">Vesting period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">4 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod', window );">Expiration period</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">10 years<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under the plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">2,653,867<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_PlanNameAxis=nxtc_EmployeeStockPurchase2019PlanMember', window );">2019 Employee Stock Purchase Plan</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems', window );"><strong>Stock Based Compensation</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod', window );">Number of shares issued</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">49,583<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance', window );">Number of shares reserved for issuance under the plan</a></td>
<td class="nump">240,000<span></span>
</td>
<td class="nump">741,097<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding', window );">Annual increase in number of share reserved for issuance (as percent)</a></td>
<td class="nump">1.00%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan', window );">Maximum annual increase in shares available for issuance under the plan</a></td>
<td class="nump">480,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period which an employee's right to exercise an award is no longer available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The increase in shares available for issuance as a percentage of number of shares of the company's common stock outstanding on December 31st of the preceding calendar year.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The threshold number of shares of the company's common stock available for issuance under the plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CommonStockCapitalSharesReservedForFutureIssuance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Aggregate number of common shares reserved for future issuance.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02.29)<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CommonStockCapitalSharesReservedForFutureIssuance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of cost not yet recognized for nonvested award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/exampleRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Gross number of share options (or share units) granted during the period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of options outstanding, including both vested and non-vested options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of shares issued under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which option holders acquired shares when converting their stock options into shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(03)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(01)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:perShareItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(1)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (e)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (d)(2)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Number of share options (or share units) exercised during the current period.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)(1)(iv)(02)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.3-04)<br> -URI https://asc.fasb.org/extlink&amp;oid=120397183&amp;loc=d3e187085-122770<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(28))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(29))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 505<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=126973232&amp;loc=d3e21463-112644<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nxtc_A2015OmnibusIncentivePlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nxtc_A2015OmnibusIncentivePlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_PlanNameAxis=nxtc_EmployeeStockPurchase2019PlanMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_PlanNameAxis=nxtc_EmployeeStockPurchase2019PlanMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>67
<FILENAME>R48.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148602795520">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Stock based compensation expense (Details) - USD ($)<br> $ in Thousands</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 9,508<span></span>
</td>
<td class="nump">$ 10,288<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember', window );">Research and development</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">3,056<span></span>
</td>
<td class="nump">4,081<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember', window );">General and administrative</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems', window );"><strong>Stock based compensation expense</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AllocatedShareBasedCompensationExpense', window );">Total stock-based compensation expense</a></td>
<td class="nump">$ 6,452<span></span>
</td>
<td class="nump">$ 6,207<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AllocatedShareBasedCompensationExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (h)(1)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AllocatedShareBasedCompensationExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_IncomeStatementLocationAxis=us-gaap_GeneralAndAdministrativeExpenseMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>68
<FILENAME>R49.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148598043024">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Stock-Based Compensation - Assumptions (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="nump">79.70%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MinimumMember', window );">Minimum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">5 years 6 months<span></span>
</td>
<td class="text">5 years 3 months 18 days<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">79.70%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">1.80%<span></span>
</td>
<td class="nump">0.80%<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_srt_RangeAxis=srt_MaximumMember', window );">Maximum</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract', window );"><strong>Fair value assumptions</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1', window );">Expected term</a></td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
<td class="text">6 years 1 month 6 days<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate', window );">Expected volatility</a></td>
<td class="nump">81.40%<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate', window );">Risk free interest rate</a></td>
<td class="nump">4.20%<span></span>
</td>
<td class="nump">1.40%<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The risk-free interest rate assumption that is used in valuing an option on its own shares.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(iv)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Rate of weighted-average expected volatility for award under share-based payment arrangement.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(ii)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 718<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (f)(2)(i)<br> -URI https://asc.fasb.org/extlink&amp;oid=128089324&amp;loc=d3e5070-113901<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:durationItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MinimumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MinimumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_srt_RangeAxis=srt_MaximumMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">srt_RangeAxis=srt_MaximumMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>69
<FILENAME>R50.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603458608">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details) - shares<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">5,262,179<span></span>
</td>
<td class="nump">4,545,794<span></span>
</td>
</tr>
<tr class="rh">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember', window );">Option to purchase common stock</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems', window );"><strong>Antidilutive Securities</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount', window );">Antidilutive securities excluded from computation of diluted net loss per share</a></td>
<td class="nump">5,262,179<span></span>
</td>
<td class="nump">4,545,794<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 260<br> -SubTopic 10<br> -Section 50<br> -Paragraph 1<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=124432515&amp;loc=d3e3550-109257<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:sharesItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Details</a><div><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis=us-gaap_EmployeeStockOptionMember</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td></td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td></td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>70
<FILENAME>R51.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148603409328">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Reconciliation (Details)<br></strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract', window );"><strong>Reconciliation of federal statutory income tax rate to the Company's effective income tax rate</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate', window );">Expected income tax benefit at the federal statutory rate (as a percent)</a></td>
<td class="nump">21.00%<span></span>
</td>
<td class="nump">21.00%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes', window );">State taxes, net of federal benefit (as a percent)</a></td>
<td class="nump">6.50%<span></span>
</td>
<td class="nump">6.50%<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch', window );">Research and development credit, net (as a percent)</a></td>
<td class="nump">3.40%<span></span>
</td>
<td class="nump">3.20%<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense', window );">Non-deductible items (as a percent)</a></td>
<td class="num">(1.70%)<span></span>
</td>
<td class="num">(1.80%)<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes', window );">Prior year provision to return adjustments (as a percent)</a></td>
<td class="num">(0.10%)<span></span>
</td>
<td class="num">(0.40%)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance', window );">Change in valuation allowance (as a percent)</a></td>
<td class="num">(29.10%)<span></span>
</td>
<td class="num">(28.50%)<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of domestic federal statutory tax rate applicable to pretax income (loss).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 235<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.4-08(h)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=120395691&amp;loc=d3e23780-122690<br><br>Reference 3: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SAB Topic 6.I.Fact.4)<br> -URI https://asc.fasb.org/extlink&amp;oid=122134291&amp;loc=d3e330036-122817<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 12<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32687-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dtr-types:percentItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>71
<FILENAME>R52.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148601691264">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Income Taxes - Deferred tax assets (Details) - USD ($)<br></strong></div></th>
<th class="th" colspan="1">12 Months Ended</th>
<th class="th" colspan="1"></th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNetAbstract', window );"><strong>Deferred tax assets:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards', window );">Federal and state net operating loss carryforwards</a></td>
<td class="nump">$ 49,789,000<span></span>
</td>
<td class="nump">$ 44,451,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch', window );">Research and development tax credits</a></td>
<td class="nump">11,395,000<span></span>
</td>
<td class="nump">8,862,000<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment', window );">Capitalized R&amp;D Costs</a></td>
<td class="nump">12,424,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_DeferredTaxAssetsOperatingLeaseLiabilities', window );">Operating lease liabilities</a></td>
<td class="nump">1,960,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost', window );">Share-based compensation</a></td>
<td class="nump">4,389,000<span></span>
</td>
<td class="nump">3,184,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther', window );">Accruals and other</a></td>
<td class="nump">1,305,000<span></span>
</td>
<td class="nump">1,291,000<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsGross', window );">Gross deferred tax assets</a></td>
<td class="nump">81,262,000<span></span>
</td>
<td class="nump">57,788,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsValuationAllowance', window );">Less: valuation allowance</a></td>
<td class="num">(79,724,000)<span></span>
</td>
<td class="num">(57,705,000)<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsNet', window );">Total deferred tax assets</a></td>
<td class="nump">1,538,000<span></span>
</td>
<td class="nump">83,000<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesNetAbstract', window );"><strong>Deferred tax liabilities:</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization', window );">Depreciation and amortization</a></td>
<td class="text">&#160;<span></span>
</td>
<td class="num">(83,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements', window );">Operating lease assets</a></td>
<td class="num">(1,538,000)<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="rou">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredIncomeTaxLiabilities', window );">Gross deferred tax liabilities</a></td>
<td class="num">(1,538,000)<span></span>
</td>
<td class="num">$ (83,000)<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount', window );">Increase in valuation allowance</a></td>
<td class="nump">21,900,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic', window );">Federal net operating loss carryforwards</a></td>
<td class="nump">180,200,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal', window );">State net operating loss carryforwards</a></td>
<td class="nump">183,100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration', window );">Federal net operating loss carryforwards that do not expire</a></td>
<td class="nump">157,500,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal', window );">Federal research and development tax credit carryforwards</a></td>
<td class="nump">11,300,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl custom" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState', window );">State research and development tax credit carryforwards</a></td>
<td class="nump">100,000<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_UnrecognizedTaxBenefits', window );">Unrecognized income tax benefits</a></td>
<td class="nump">$ 0<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax
 asset attributable to capitalized research and development costs.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DeferredTaxAssetsOperatingLeaseLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DeferredTaxAssetsOperatingLeaseLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic research and development tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state research and development tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax consequences attributable to taxable temporary differences derived from depreciation and amortization.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>nxtc_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredIncomeTaxLiabilities">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(b))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br><br>Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 944<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.7-03(15)(b)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126734703&amp;loc=d3e572229-122910<br><br>Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 942<br> -SubTopic 210<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.9-03(15)(2))<br> -URI https://asc.fasb.org/extlink&amp;oid=126897435&amp;loc=d3e534808-122878<br><br>Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 210<br> -SubTopic 10<br> -Section S99<br> -Paragraph 1<br> -Subparagraph (SX 210.5-02(26)(a))<br> -URI https://asc.fasb.org/extlink&amp;oid=120391452&amp;loc=d3e13212-122682<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredIncomeTaxLiabilities</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsGross">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (b)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsGross</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNet">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNet</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwards">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwards</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 3<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32559-109319<br><br>Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br><br>Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxAssetsValuationAllowance">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -Subparagraph (c)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxAssetsValuationAllowance</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesLeasingArrangements">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 8<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32632-109319<br><br>Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 6<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32621-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesLeasingArrangements</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DeferredTaxLiabilitiesNetAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DeferredTaxLiabilitiesNetAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_UnrecognizedTaxBenefits">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of unrecognized tax benefits.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 45<br> -Paragraph 10B<br> -URI https://asc.fasb.org/extlink&amp;oid=123427490&amp;loc=SL37586934-109318<br><br>Reference 2: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 15A<br> -Subparagraph (a)<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=SL6600010-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_UnrecognizedTaxBenefits</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>instant</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/disclosureRef<br> -Publisher FASB<br> -Name Accounting Standards Codification<br> -Topic 740<br> -SubTopic 10<br> -Section 50<br> -Paragraph 2<br> -URI https://asc.fasb.org/extlink&amp;oid=121826272&amp;loc=d3e32537-109319<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>credit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>72
<FILENAME>R53.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.22.4</span><table class="report" border="0" cellspacing="2" id="idm140148601817728">
<tr>
<th class="tl" colspan="1" rowspan="2"><div style="width: 200px;"><strong>Employee Benefit Plan (Details) - USD ($)<br> $ in Millions</strong></div></th>
<th class="th" colspan="2">12 Months Ended</th>
</tr>
<tr>
<th class="th"><div>Dec. 31, 2022</div></th>
<th class="th"><div>Dec. 31, 2021</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_CompensationAndRetirementDisclosureAbstract', window );"><strong>Employee Benefit Plan</strong></a></td>
<td class="text">&#160;<span></span>
</td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount', window );">Employer contributions amount</a></td>
<td class="nump">$ 0.3<span></span>
</td>
<td class="nump">$ 0.0<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_CompensationAndRetirementDisclosureAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- References</a><div><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_CompensationAndRetirementDisclosureAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Amount of discretionary contributions made by an employer to a defined contribution plan.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>us-gaap_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:monetaryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>debit</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>73
<FILENAME>nxtc-20221231x10k_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2022"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:nxtc="http://www.nextcure.com/20221231"
  xmlns:srt="http://fasb.org/srt/2022"
  xmlns:us-gaap="http://fasb.org/us-gaap/2022"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="nxtc-20221231.xsd" xlink:type="simple"/>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rOjqenRZREyd1NyoeFubKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_11_19_2019_To_11_19_2019_k_sFpRsB_0WOgCeVqnif5g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2019-11-19</startDate>
            <endDate>2019-11-19</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tPHNqpHq2kuQFJEI1p3JZQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_3_2019_To_5_3_2019_ffq9d8PSt0mdc28BJxL5QQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2019-05-03</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pA4TDj6OTk643-r859LTcQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WRaiII9KkkuLfyaPn6l8EA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_x6LhcuNomEuLDIBzS5kclw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dCZjOHvncEGYV4kEJYoMcA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AMSNidZSTkiUmUQgTX6WXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51jEFO9m-Eapl6pE0wPajA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3YsHqMa8U06STQUHwqaIeg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3vwRuWC6SU2eMxTt8KjrSg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9M-kF4_ysEuVCqAg9WPuNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_2_2019_o6OFQ40YgEyzamR4P8fk6Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2019-12-02</instant>
        </period>
    </context>
    <context id="As_Of_11_19_2019_Zz1QYveV3kqsEGkewxdtfA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2019-11-19</instant>
        </period>
    </context>
    <context id="As_Of_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MInUrgAThkee5MzGS2_rNw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-13</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_S3g67ITO1UG2PaPwVbTH0Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_vASUCe3mXEShFcN7roPOFw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-01</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_I1bCpdmof0eokGR4x8FVCA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_4xX7epy4hkGSbwwR_hzucA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:A2015OmnibusIncentivePlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_gdOPWWwYIk-1_fM2ZbqmhA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1v3p_PfN6ku6GNiQC6D3Xg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_YBa26s9G0UemyPzMQSEebA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_6T-mMXX7Tk2kXUXSd6hCrA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-AdmtV4Y4E2el33p-R4o7Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_JFjr3X-iS0q7yBVBU-uoTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_itU9-PmAeki7z14co80kbg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_2k8diS0Dt0SajXRwD2H9pw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_s8Q9roYBs0mJ-WQs8x7lXQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nxtc:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vSYHseosFUeoXezPK_DwZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5wQASsCk1kGj8FiA4J8kUA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jWIXUY1zdUKLE6_2RdA-vg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ConstructionInProgressMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_B8DlzbFCLUSo9Q5ArS1Eqw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_nHuF1bXQ4UWlM6L_pFhCDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">nxtc:ResearchEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5RSY3CZwm0S1VjPnBbQ2qQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_1bxFiSQkekaQznzCFGTEyg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:EquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_9gGAYZTy_U-F2bBDboUuHg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:ComputerEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_8_1_2021_To_8_31_2021_QUjo54fwz0S0O0oyBr9gCg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2021-08-01</startDate>
            <endDate>2021-08-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CQRdBMZPLEKTJoEaubbMvw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gI-VD-V8dkWDjrK8eQOPfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_oikFh3LVykC7K0InhoySfQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3eszyap510GTal9lTSf5TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_dIyXP5BpbkGbErryI05k3w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:USGovernmentAgenciesDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5-Bu-eXe006BJ3_wB91BDA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NJQoeyaVbkORdIFR-hPZZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_C3fDpqg0Z0q1RzbPm02j9g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_1_31_2019_mPEpuuDRUUKsmnCtaVs9OA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2019-01-31</instant>
        </period>
    </context>
    <context id="As_Of_4_30_2016_fg7QH1JCMUKlmj0t5s8Cog">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2016-04-30</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TgHp4cCUE06VUtY2h3ln1w">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x59fHK3h6US54LesHKMlWw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaUNhIOQzE-uaj0TJAxBUg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2019-05-13</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_D46SFEZZN0aTWX1Xr95ZPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_tlc5w1VAtUGsrUcZTfo1pg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_v5woPB-Gu0eGhZbi1jiBTQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-03</instant>
        </period>
    </context>
    <context id="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_KMR2V40rz0WEvFMh7SGH2A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-03</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2020_QgZGOIBcMEe2uMPs4IJ4-A">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_RJ-xwh_wV0-uMLJTUoRWww">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember__yYHlcWVlkCe8veQpXoODg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8mxuMVEvVECi33rG7hy8TQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4yfMi2VPkWj9z09O5KR2g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CashAndCashEquivalentsAxis">us-gaap:MoneyMarketFundsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_BevS1rj6TkCrU3_9XVnY4Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:USGovernmentCorporationsAndAgenciesSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Pd5kHKPoGUawJuu7EPVYpQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_8exjrnhK4U25OrK5dhgHWg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FinancialInstrumentAxis">us-gaap:CorporateDebtSecuritiesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_03bv1J6VnEK7iPOZioYxuQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eGfbitKLGk6VtkSOTwNSZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis">us-gaap:EmployeeStockOptionMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_4Bc0BKCyvkywArPzGa-ufg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_zu6x2W08xUuSowvqAgpX-g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_n1J87RqwcE-D74ie7jOgeA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:ResearchAndDevelopmentExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ip93Wfm4iEeGxOE28jx6nw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeStatementLocationAxis">us-gaap:GeneralAndAdministrativeExpenseMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f-KycTXTtEGUeina0uYgfw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DQ6MmhQyV069Qs7Ih1PO6g">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_0wxdrOUI5Uq9n6FoN-ND_Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-03</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_SRji9FsHhkW2MxxpNEJcRQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:EmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-03</startDate>
            <endDate>2019-05-03</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_QFG6gM-uuk2TLGjd7TLz8Q">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PlanNameAxis">nxtc:OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2019-12-02</startDate>
            <endDate>2019-12-02</endDate>
        </period>
    </context>
    <context id="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_DrWQ9sKhMUyebJfoMay_Jw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:SubsidiarySaleOfStockAxis">us-gaap:IPOMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-05-13</startDate>
            <endDate>2019-05-13</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QjIgQ3Cie0eiBOwS3XozJA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JLiZDuh8TkiEItJlU1AcwA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AccumulatedOtherComprehensiveIncomeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ZBgPDtK_ukm2DSu8kFg3MA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NKtrp11L7UqjNJ0bCbPyIg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Ym0BL0i97UaomE43uV-bYQ">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Wm2A56lBgkCPpaUm6E_ypw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_PfvSQBm2r0egI8U0wsBykg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByFairValueHierarchyLevelAxis">us-gaap:FairValueInputsLevel1Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_tC3N1hSTQ06SevgSev4lPA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FairValueByMeasurementBasisAxis">us-gaap:EstimateOfFairValueFairValueDisclosureMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-12-31</endDate>
        </period>
    </context>
    <context id="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2022-12-31</instant>
        </period>
    </context>
    <context id="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="As_Of_6_30_2022_VAIVvh0mOE-2MiNUaNezsg">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2022-06-30</instant>
        </period>
    </context>
    <context id="As_Of_2_24_2023_1fR9h1Abg0u8OQ_Y5NgKhw">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <instant>2023-02-24</instant>
        </period>
    </context>
    <context id="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001661059</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-12-31</endDate>
        </period>
    </context>
    <unit id="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">
        <measure>shares</measure>
    </unit>
    <unit id="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Unit_Standard_Vote_NTyCJtIjU0i5jZ9cnBFqVg">
        <measure>nxtc:Vote</measure>
    </unit>
    <unit id="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">
        <measure>pure</measure>
    </unit>
    <unit id="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Unit_Standard_segment_SvUt3NvuT0moPQCiN6jnXA">
        <measure>nxtc:segment</measure>
    </unit>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="2"
      id="Hidden_RXcXID7xNk6EeeFbPOwNnw"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">-2.69</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareDiluted
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="2"
      id="Hidden_KIFVcKMshUCILTfOaw4l-Q"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">-2.51</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="0"
      id="Hidden_b0KSGAix2UKsmGKHFGsxaQ"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27744209</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="0"
      id="Hidden_rS5K0gsUw0ydwct3CpK7vg"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27615977</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      id="Hidden_ckQuX0NUl067JlGreg9o-Q"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      id="Hidden_AVNy09DaIUuRzQxF2MJKCA"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg"
      xsi:nil="true"/>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      id="Hidden_Y-cqdjMky0anGfcN4D8zww">http://www.nextcure.com/20221231#AccruedAndOtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      id="Hidden_TUuyXS3SSEeIh0Y1lSNfqQ">http://www.nextcure.com/20221231#AccruedAndOtherLiabilitiesCurrent</us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Hidden_0ZTpWsbJLEqaeEw3VSWmxw"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27774536</us-gaap:CommonStockSharesOutstanding>
    <dei:EntityCentralIndexKey
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_sA3mG-8AnU2jzNb4yHAB8g">0001661059</dei:EntityCentralIndexKey>
    <dei:CurrentFiscalYearEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_oJCjLWonE0G9wSZtRd3Hng">--12-31</dei:CurrentFiscalYearEndDate>
    <dei:DocumentFiscalYearFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_TdMgNGir9UuSJB50aMCnJQ">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_GFPpG8BcmUqeqIz-SA1fkQ">FY</dei:DocumentFiscalPeriodFocus>
    <dei:AmendmentFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_rNyQUEv2X0qaR4DX94rVJQ">false</dei:AmendmentFlag>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="INF"
      id="Hidden_VHnfYaVN4EiAQyRH9rcAqA"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Hidden_IK3tc8XvT0W_mIMyRwi_tw"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="INF"
      id="Hidden_EjCt_RanekGTBb6zLZI6cg"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27680997</us-gaap:CommonStockSharesIssued>
    <nxtc:FairValuesAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="0"
      id="Hidden_ALFYw5z460y6TXowa2XL9Q"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</nxtc:FairValuesAssetsLevel1ToLevel2TransfersAmount>
    <nxtc:FairValuesAssetsLevel1ToLevel2TransfersAmount
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="0"
      id="Hidden_xz6FFA6uT0mQ6fRBaD7AoQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</nxtc:FairValuesAssetsLevel1ToLevel2TransfersAmount>
    <nxtc:FairValuesAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="0"
      id="Hidden_FFzONT6OAUCKHJSioasszQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</nxtc:FairValuesAssetsLevel2ToLevel1TransfersAmount>
    <nxtc:FairValuesAssetsLevel2ToLevel1TransfersAmount
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="0"
      id="Hidden_sF1qYAy1vUqAHu_dZdjC0w"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</nxtc:FairValuesAssetsLevel2ToLevel1TransfersAmount>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="0"
      id="Hidden_BEloqN_kIUiSEA3CJtNPlQ"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27774536</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquityNoteStockSplitConversionRatio1
      contextRef="Duration_5_3_2019_To_5_3_2019_ffq9d8PSt0mdc28BJxL5QQ"
      decimals="4"
      id="Hidden_GEsLDUz530Gxz5k36Ixidg"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.1245</us-gaap:StockholdersEquityNoteStockSplitConversionRatio1>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="0"
      id="Hidden_ZrMEVCBOgkqTt6a3SIdRRA"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="0"
      id="Hidden_HRbFi8ke60aH_3jsKm7FlA"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="0"
      id="Hidden_KHCh8U0vHE-yYnQcworSUA"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="0"
      id="Hidden_HIlaRUEnF0qbB1XconopJw"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Hidden_pC0KVSDrpUCOl6qY3Bjkag"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">0</us-gaap:PreferredStockSharesIssued>
    <dei:DocumentType
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_agu6uoZHqUe6Iu1IFuSE8Q">10-K</dei:DocumentType>
    <dei:DocumentAnnualReport
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tc_Xm9sqddsMUycUw2CEvJ_4g_1_0">true</dei:DocumentAnnualReport>
    <dei:DocumentPeriodEndDate
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_lZCjPJvjTU6bPjKh02GAZw">2022-12-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tc_V1Gz5zv0J0OnYRYiXoBf-g_1_0">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_prXysED14UKc3BoHQJenSQ">001-38905</dei:EntityFileNumber>
    <dei:EntityRegistrantName
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_GtWmpXwiyk-3IUGUGGefMQ">NextCure, Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tc_Hr0SdvmK30eTOcM9vRPLhQ_0_0">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tc_lfCuz-mTDkC_tvFZS6UZHg_0_1">47-5231247</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_tjDEmH33XESh5BAyXYL3EQ">9000 Virginia Manor Road, Suite 200</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_yq2RI-VOL0GZwOmTIdij9g">Beltsville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_ka8zp53ZwEWBzf1eSNzQ_w">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tc_RjN37S0WO02qUJ2XOl9yKQ_3_1">20705</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_dolGVVS7VUW8nQEkML6ufQ">240</dei:CityAreaCode>
    <dei:LocalPhoneNumber
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr__uDLDP79GE6c579vxfGZ9w">399-4900</dei:LocalPhoneNumber>
    <dei:Security12bTitle
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tc_JqmDCjjyz0CWI6rt4MMiVg_1_0">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tc_v5XmRrDa1EyuSL4CVaLM3Q_1_1">NXTC</dei:TradingSymbol>
    <dei:SecurityExchangeName
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tc__WmsMax4_UeLWxBsjuuk-Q_1_2">NASDAQ</dei:SecurityExchangeName>
    <dei:EntityWellKnownSeasonedIssuer
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_WdV1u0lY6EaJnYM2zrfslw">No</dei:EntityWellKnownSeasonedIssuer>
    <dei:EntityVoluntaryFilers
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_281UFUIN70WrbRFvZCApXA">No</dei:EntityVoluntaryFilers>
    <dei:EntityCurrentReportingStatus
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_nicgsjoT8ECThx6p0g49dQ">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_Qr1OuKL2xUif4gtPA5raqQ">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_jnGSe3jI1Umog9HMOdgqdw">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_fzNCCLNxtUyRRpTIGZFnhA">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_irNh-FKHx0Crg9ktGKwjfw">true</dei:EntityEmergingGrowthCompany>
    <dei:EntityExTransitionPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_KbAV9gSypUy31jNXNLFijQ">false</dei:EntityExTransitionPeriod>
    <dei:IcfrAuditorAttestationFlag
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_jFxun91o60GIH8rkTH6Cxg">false</dei:IcfrAuditorAttestationFlag>
    <dei:EntityShellCompany
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_jjEQLX6g3kuzf2MHqZbSOg">false</dei:EntityShellCompany>
    <dei:EntityPublicFloat
      contextRef="As_Of_6_30_2022_VAIVvh0mOE-2MiNUaNezsg"
      decimals="-5"
      id="Narr__XWlirJAx0uQvvSe5CjcTQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">115500000</dei:EntityPublicFloat>
    <dei:EntityCommonStockSharesOutstanding
      contextRef="As_Of_2_24_2023_1fR9h1Abg0u8OQ_Y5NgKhw"
      decimals="INF"
      id="Narr_cPkwgvhk30KzNWFN0k23zw"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27774536</dei:EntityCommonStockSharesOutstanding>
    <dei:AuditorFirmId
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_ZOGLLnlV_0O_2Taqo1bS4g">42</dei:AuditorFirmId>
    <dei:AuditorName
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_evbxOb4RCk-QNn4DCuN1Sg">Ernst&#160;&amp; Young LLP</dei:AuditorName>
    <dei:AuditorLocation
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_wQ0UOSl9_Umd5RxNVZTTsw">Baltimore, MD</dei:AuditorLocation>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_WqZ5xQluaEuJcsKxlIHCog_5_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">26630000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_wWciG5iERUKxpT8Gb0QD9A_5_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">12337000</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_xKHkHZHRiUms_zcHN83h3A_6_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">133281000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_7IXctEqPlUGTkLN6rsjKnw_6_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">207254000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_xa80vgHJJ0GS27he31iXWw_7_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4072000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:PrepaidExpenseAndOtherAssetsCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_VqTFzm8CyUSlTmw-WRdajA_7_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">8226000</us-gaap:PrepaidExpenseAndOtherAssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_SH6mQySWK06vkbFxR5cD6g_8_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">163983000</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_nxDEFI6DxEaR1nQOh5TeHw_8_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">227817000</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_AO19nG2vOEqr_Kxgfg-Iag_9_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">11897000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_ZKVN1oFmUUe-52GsExzVRA_9_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">13992000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:OperatingLeaseRightOfUseAsset
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_NMOIqOfi3UKBkQlaRIQCWg_10_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">5016000</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_0L3WlPygOEiN9SjPkIrwnQ_11_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">3265000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_kYRfCZ_wdk6OJZxbnxbT2w_11_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">577000</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_xHKY2a15qUatkTSJxdOZKA_12_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">184161000</us-gaap:Assets>
    <us-gaap:Assets
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_CeZRwZGWtkGu710Rdk54DQ_12_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">242386000</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_mMCTWh7dgEWHzMtr3osgKA_15_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4270000</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_dpIhyCw27EqO_r8rFsBc3g_15_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1942000</us-gaap:AccountsPayableCurrent>
    <nxtc:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_NXVZcQxyBUiQqURNbZnCJA_16_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4857000</nxtc:AccruedAndOtherLiabilitiesCurrent>
    <nxtc:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_WGwEbJDOOEWJESjzJqBHoA_16_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4666000</nxtc:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_9hy_jdNU8kadG4nAAuy4Ag_17_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">9127000</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_paywTOx2jEmigd7fU42AGw_17_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">6608000</us-gaap:LiabilitiesCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_VGzpCPMsk0uVWkuQacaKrw_18_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">6605000</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_TQrLB_0oO0aje_d2_CkWZw_19_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">899000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_u0n6kvajKUCsd3vFi6pbZw_19_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">2392000</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_-FdEmOMyu0uqmXTSX7G-Xw_20_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">16631000</us-gaap:Liabilities>
    <us-gaap:Liabilities
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_dvcmLahCIUWzzweVkPQ5Fg_20_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">9000000</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="INF"
      id="Narr_DEO4EqE-NUerZHwnud1gfg"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_Ong1Pl9l30KKQse92PVZjw"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="INF"
      id="Narr_hkV__qGtfEecP-7J3bFngA"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_xYjkaa8zCEa1KIgTT9CzJg"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="INF"
      id="Narr_6b1miATcLEaEOJJsBk-yaw"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_e19eoA1mukiXtyJMqUo8Bg"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="INF"
      id="Narr_VgvoWQ15y0Sv5qw7UGkXvA"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_WK773u1R90KV2nrJ3Ch8_g"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="INF"
      id="Narr_RxXG88p9p0iuY5XB3qWryg"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_SLrJk-phJE2B7Ogt8ZwGnQ"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_d9Sd815NiEavDVu7U7FmkQ"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27774536</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="INF"
      id="Narr_vDfZ2d-gYUmqbJCsFGWMRg"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27680997</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc__7Z7R_5lxUy6eM-4CuM8PA_23_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">28000</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_uT87R6HfXUa6Leb505S6qQ_23_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">28000</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_pduc90KgnkGfUGZWaDfi0g_24_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">430755000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AdditionalPaidInCapital
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_63l3KFOJBEe54B60roF10w_24_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">421047000</us-gaap:AdditionalPaidInCapital>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_6S5SvKosKkqyxngRBkPBOA_25_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-1494000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_61OyH8imZkOob_-Dhha-ow_25_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-663000</us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_StgDNkgo8UK9y60Vm43EDQ_26_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-261759000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_o3FeYiT0UkiepPUZQ6hbLg_26_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-187026000</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_Wk3Zgs2MsUqv6XP6ywAorg_27_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">167530000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_WP4Wf6Lo6UKypDdt8KoeOA_27_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">233386000</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc__H6hmOgV802yhaCaT_-YaA_28_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">184161000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_e2BG_lLpFkOywVA2xDYtjA_28_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">242386000</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_iYUyMpp5TUajdWA7qxOz2Q_5_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">54199000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_7KJZu7tPyUKxb6PNo7sNVQ_5_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">50192000</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_9O8TJ3w_X0y_Y-ofpcnZew_6_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">21710000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_MgmpUgQbMkaZK0mUCjSrBQ_6_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">20573000</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_izDGWN5qKUeWs7wgikNkyw_7_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">75909000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_bGDngJ8h20qTHcAiMLKYJA_7_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">70765000</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_w57MaYMO6kmrTp-9Ws0etg_8_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-75909000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_Lpq7dkNDjEe0GdGwSnOPlw_8_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-70765000</us-gaap:OperatingIncomeLoss>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_K8dYn5RczEqnnk9TGzc8zw_9_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1176000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:OtherNonoperatingIncomeExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_2zq8XoRwbUemX_oY3JJwIg_9_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1376000</us-gaap:OtherNonoperatingIncomeExpense>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_-617HSPj1UezjTtyfQxxeg_10_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-74733000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_f3tCSb8yqUebHVJDNKyOGQ_10_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-69389000</us-gaap:NetIncomeLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="2"
      id="Tc_rxBN5QxC1k6ID1VeShzDPA_11_3"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">-2.69</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="2"
      id="Tc_kbBasOFoOUKLmrTRoEfTcA_11_6"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">-2.51</us-gaap:EarningsPerShareBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="0"
      id="Tc_TSBVIz9kLESbDE2VbX0w5w_12_3"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27744209</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="0"
      id="Tc_VrOyQ-G_T0eJatjLE9el0w_12_6"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27615977</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_mUlDCPf-30uNmcN_qMnXFw_14_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-74733000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_3ZrCvKr6xUOuHXPc7J1nIg_14_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-69389000</us-gaap:NetIncomeLoss>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_2DckmzqXYEaRJSYAtEnh8A_15_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-831000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_V1wxB-Up_E-FYpyKGD8-Bg_15_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-1442000</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_NcX57X96PU6AjQnE6R7qFQ_16_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-75564000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:ComprehensiveIncomeNetOfTax
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_AQnCSV93jUiD9UibHt5auA_16_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-70831000</us-gaap:ComprehensiveIncomeNetOfTax>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaUNhIOQzE-uaj0TJAxBUg"
      decimals="0"
      id="Tc_mDj03J-40UqDlKYnrzcrPg_5_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27568802</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaUNhIOQzE-uaj0TJAxBUg"
      decimals="-3"
      id="Tc_kfoH4HIP8U-77o3vXkQHcA_5_5"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_3vwRuWC6SU2eMxTt8KjrSg"
      decimals="-3"
      id="Tc_h0_wobe7IESm5Ko3iGmwHw_5_8"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">410551000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_9M-kF4_ysEuVCqAg9WPuNw"
      decimals="-3"
      id="Tc_ukfoiDwkoUyBOec0cOWuTw_5_11"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">779000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_3YsHqMa8U06STQUHwqaIeg"
      decimals="-3"
      id="Tc_oNdErvuoMkytLtClEYtG0A_5_14"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-117637000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2020_QgZGOIBcMEe2uMPs4IJ4-A"
      decimals="-3"
      id="Tc_ltXerjUeLUmhHJfIWJIHQA_5_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">293721000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DQ6MmhQyV069Qs7Ih1PO6g"
      decimals="-3"
      id="Tc_KSYS6Xdl_kuzKpqV3g5giA_6_8"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">10288000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_hQn99iA8tEqBzv1Dd00kVA_6_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">10288000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_rOjqenRZREyd1NyoeFubKA"
      decimals="0"
      id="Tc_duOqZvbS30Cs9YFEyQkBDQ_7_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">112195</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_DQ6MmhQyV069Qs7Ih1PO6g"
      decimals="-3"
      id="Tc_Sywlr2OeTE6SKCSp85edyQ_7_8"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">208000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_MMSBWTKwmEevdyI05OTLng_7_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">208000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Narr_FoG5xbxNXEm1G7AjJUOEFA"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_JLiZDuh8TkiEItJlU1AcwA"
      decimals="-3"
      id="Tc_rMjebschf0GWw5lpmPyc3w_8_11"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-1442000</nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted>
    <nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_0NAz-VNFx0-rcCTg7IlJtA_8_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-1442000</nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_gI-VD-V8dkWDjrK8eQOPfw"
      decimals="-3"
      id="Tc_IymwjXPkJkKD4zy4sOotHQ_9_14"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-69389000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_w8-1uLNE_U63LDF7h6HDow_9_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-69389000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x59fHK3h6US54LesHKMlWw"
      decimals="0"
      id="Tc_bB85rctu2EiwmEIOkD7ZkA_10_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27680997</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_x59fHK3h6US54LesHKMlWw"
      decimals="-3"
      id="Tc_HkuRk1M7eku9ZCHLLvm4Iw_10_5"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_AMSNidZSTkiUmUQgTX6WXQ"
      decimals="-3"
      id="Tc_BXQGraem1kek9V0yA9EOKQ_10_8"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">421047000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_51jEFO9m-Eapl6pE0wPajA"
      decimals="-3"
      id="Tc_jPkCIHdaY0ShgeuyESlC8Q_10_11"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-663000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_dCZjOHvncEGYV4kEJYoMcA"
      decimals="-3"
      id="Tc_YSRoQIiLAkS7n48ee_mZTw_10_14"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-187026000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_6EZj6M3hw0O2o7nHHck-_w_10_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">233386000</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f-KycTXTtEGUeina0uYgfw"
      decimals="-3"
      id="Tc_-OIbtXEKP0aODL5BUR3ylg_11_8"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">9508000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_iF76ETKxGEGlvs5dmAmFWA_11_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">9508000</us-gaap:AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tPHNqpHq2kuQFJEI1p3JZQ"
      decimals="0"
      id="Tc_TNzPbdJUlUynzGUKiiVpjA_12_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">50420</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f-KycTXTtEGUeina0uYgfw"
      decimals="-3"
      id="Tc_65jgm7rOEUiSDsZs8jfxFA_12_8"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">66000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_blEkfFh2BE2Wyj2ybLXH6Q_12_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">66000</us-gaap:StockIssuedDuringPeriodValueStockOptionsExercised>
    <us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_tPHNqpHq2kuQFJEI1p3JZQ"
      decimals="0"
      id="Tc_JmqmvdIh3U2tRXS0e9cZqQ_13_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">43119</us-gaap:StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_f-KycTXTtEGUeina0uYgfw"
      decimals="-3"
      id="Tc_kLSYcLbc9USbxuv76p-TSw_13_8"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">134000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_rrFjNsfWfEq6y8nruooS2Q_13_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">134000</us-gaap:StockIssuedDuringPeriodValueEmployeeStockPurchasePlan>
    <us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Narr_nQUwcdrYFUyndvySqwDiRg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax>
    <nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_QjIgQ3Cie0eiBOwS3XozJA"
      decimals="-3"
      id="Tc_HT9dc4UWGEqO0-kMOTgjLg_14_11"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-831000</nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted>
    <nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_IfzBRvrHzEO1eJRAV8N5Xw_14_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-831000</nxtc:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_CQRdBMZPLEKTJoEaubbMvw"
      decimals="-3"
      id="Tc_WeqakKmxMkOgZ2gxkb7Z_A_15_14"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-74733000</us-gaap:NetIncomeLoss>
    <us-gaap:NetIncomeLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_i_bZBLRNN0mlhgLFPqK5mg_15_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-74733000</us-gaap:NetIncomeLoss>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TgHp4cCUE06VUtY2h3ln1w"
      decimals="0"
      id="Tc_N3NRfwUtHEm0Iz1AuPkCQw_16_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27774536</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_TgHp4cCUE06VUtY2h3ln1w"
      decimals="-3"
      id="Tc_Xk5Vh-SF6Eyuj7UZy8TPLQ_16_5"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">28000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AdditionalPaidInCapitalMember_WRaiII9KkkuLfyaPn6l8EA"
      decimals="-3"
      id="Tc_3f5OJkCHLUm30LFnNfAXSg_16_8"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">430755000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_AccumulatedOtherComprehensiveIncomeMember_x6LhcuNomEuLDIBzS5kclw"
      decimals="-3"
      id="Tc_Uv7O7E_MDUWiV3d4gwO_SQ_16_11"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-1494000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_us-gaap_StatementEquityComponentsAxis_us-gaap_RetainedEarningsMember_pA4TDj6OTk643-r859LTcQ"
      decimals="-3"
      id="Tc_3cqx44KxTkuuEFpLkJeJlQ_16_14"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-261759000</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_5cCWqmaUOkq_krnct8U_Hg_16_17"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">167530000</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_dyS0qnfj-EenWeMD6toSKQ_5_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-74733000</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_oz61E4FM5UesW6Px6KLoRw_5_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-69389000</us-gaap:ProfitLoss>
    <nxtc:DepreciationDepletionAndAmortizationAndOther
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_5U5bOTTIrUWr7wv_Zwg74g_7_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4124000</nxtc:DepreciationDepletionAndAmortizationAndOther>
    <nxtc:DepreciationDepletionAndAmortizationAndOther
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_JYuRPLGAOkqzVsl9pe7uNg_7_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4177000</nxtc:DepreciationDepletionAndAmortizationAndOther>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_D7qgOJ4H_EyZ1-LLYf2L6g_8_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-3047000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_CytUkHL4yEGpxq4PD_7lDA_8_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-3019000</us-gaap:AccretionAmortizationOfDiscountsAndPremiumsInvestments>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_QsfTPgV8gEWbExfdFJ7e-g_9_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">9508000</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_t9qAVyJrw0yWBz8FiHGepw_9_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">10288000</us-gaap:ShareBasedCompensation>
    <nxtc:NoncashOperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_hSPIGXuv_U6-Zy6RISNQvA_10_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">356000</nxtc:NoncashOperatingLeaseExpense>
    <us-gaap:GainLossOnSaleOfPropertyPlantEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_NRSR_kOZt0iDo-ZXXogHDw_11_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-87000</us-gaap:GainLossOnSaleOfPropertyPlantEquipment>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_rRAyuB2rJ0qC7f5SX1E2Nw_13_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-2038000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_tIdIFLhJrU-o3QCWKPZNYA_13_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4928000</us-gaap:IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_fkA-IzNTdE67NFCt2f6_Aw_14_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">2328000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_Qz1b9PDhWkGYalCBAZUZkA_14_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-1959000</us-gaap:IncreaseDecreaseInAccountsPayable>
    <nxtc:IncreaseDecreaseInAccruedAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_4cVK_zNIH0Wu2latXIuJgg_15_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">641000</nxtc:IncreaseDecreaseInAccruedAndOtherCurrentLiabilities>
    <nxtc:IncreaseDecreaseInAccruedAndOtherCurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_ZWkR_YayMECLvlfLrfkHLQ_15_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">178000</nxtc:IncreaseDecreaseInAccruedAndOtherCurrentLiabilities>
    <us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_KUkjm5OQ-kyeKVgLt1INwA_16_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1687000</us-gaap:IncreaseDecreaseInOtherNoncurrentLiabilities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_sGdyPfEypESkhDR1ky95Gw_17_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-53886000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_0mkEXSPN4kap0MPIsdrt-w_17_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-57283000</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_q3XqNUEvBUiQriqHmmYqrA_19_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">104739000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_aiz2V4VXcUiKgwlcTIW5oQ_19_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">195438000</us-gaap:ProceedsFromSaleAndMaturityOfMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_X6JovrcMd0qugB1QKB92Mw_20_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">34644000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquireMarketableSecurities
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_llFXFzhB9kGWrb1r27tfTA_20_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">156477000</us-gaap:PaymentsToAcquireMarketableSecurities>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_LrEd6yxpAUidg2AgefTt1w_21_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">2116000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:PaymentsToAcquirePropertyPlantAndEquipment
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_wl1obg3h60CMESDYfGM4kg_21_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">2360000</us-gaap:PaymentsToAcquirePropertyPlantAndEquipment>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc__k8VTdQAKEWqgwQTRzLalg_22_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">67979000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_46hGJsdI4U-7cjDlNgumTg_22_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">36601000</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_WWRba0ZnUEKhNSglu8EmzQ_24_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">66000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_vSByB2FUQUmXo4zxrdfsHQ_24_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">208000</us-gaap:ProceedsFromStockOptionsExercised>
    <us-gaap:ProceedsFromStockPlans
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_2W89MRqSvU6s8y5U99w45g_25_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">134000</us-gaap:ProceedsFromStockPlans>
    <us-gaap:RepaymentsOfDebt
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_L3IxfehtFkW-c3PPhPfNXg_26_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">3473000</us-gaap:RepaymentsOfDebt>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_WiQa7NWVdEWGJWo5QUOXvA_27_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">200000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_qggd3D7VM0yZkAn9Ee_AXg_27_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-3265000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_ynVNtPwnLEeHgBmBA7Nlyg_28_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">14293000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_XMtvEmf9ak2LQua3j_1sLA_28_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-23947000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_onq2RRxS8Eyp_8lcR75RDQ_29_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">12337000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2020_QgZGOIBcMEe2uMPs4IJ4-A"
      decimals="-3"
      id="Tc_bKdUYhskgEeRJt41cv6PPA_29_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">36284000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_7eu_4zKt3kyXo7D-y9RJ4g_30_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">26630000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_90GWLdt4ek2VUYK7u47YIw_30_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">12337000</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_KSZXSGjgwUeUgi8kOL5l3A_32_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">90000</us-gaap:InterestPaidNet>
    <us-gaap:InterestPaidNet
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_ZgRqWdAw5U6o9kgOKIaFMA_32_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">162000</us-gaap:InterestPaidNet>
    <us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_X058bkxWYEKeUmu3v_xQgg_35_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">6047000</us-gaap:RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability>
    <nxtc:OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_8qQmD8tcP0OZ34NNL1cb9g_36_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">7549000</nxtc:OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount>
    <us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_7a7ew52Jv06eTjD1oFdeBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt;"&gt;NEXTCURE,&#160;INC.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;text-align:center;margin:0pt 0pt 12pt 0pt;"&gt;NOTES&#160;TO FINANCIAL STATEMENTS&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;1. Nature of the Business and Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Organization&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;NextCure,&#160;Inc. (&#x201c;NextCure&#x201d; or the &#x201c;Company&#x201d;) was incorporated in Delaware in September&#160;2015 and is headquartered in Beltsville, Maryland. The Company is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Through its proprietary Functional, Integrated, NextCure Discovery in Immuno-Oncology (&#x201c;FIND-IO&#x201d;) platform, the Company studies various immune cells in order to discover and understand targets and structural components of immune cells and their functional impact in order to develop immunomedicines. Since inception, the Company has devoted substantially all of its efforts and financial resources to organizing and staffing the Company, identifying business development opportunities, raising capital, securing intellectual property rights related to the Company&#x2019;s product candidates, building and optimizing the Company&#x2019;s manufacturing capabilities and conducting discovery, research and development activities for the Company&#x2019;s product candidates, discovery programs and its FIND-IO platform.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Public Offerings of Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 13, 2019, the Company closed its initial public offering (&#x201c;IPO&#x201d;), in which the Company issued and sold 5,750,000 shares of common stock at a public offering price of $15.00 per share, for net proceeds to the Company of approximately $77.0 million after deducting underwriting discounts and commissions of $6.0 million and offering expenses of $3.4 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In preparation for the IPO, on May 3, 2019, the Company effected a &lt;span style="-sec-ix-hidden:Hidden_GEsLDUz530Gxz5k36Ixidg;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;1&lt;/span&gt;&lt;/span&gt;-for-8.0338 reverse stock split of its issued and outstanding common stock. The par value and authorized shares of common stock were not adjusted as a result of the reverse stock split. All of the share and per share information presented in the accompanying financial statements has been adjusted to reflect the reverse common stock split on a retroactive basis for all periods and as of all dates presented.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Upon the closing of the IPO, all of the outstanding shares of the Company&#x2019;s convertible preferred stock automatically converted into 15,560,569 shares of common stock at the applicable conversion ratio then in effect. Subsequent to the closing of the IPO, there were no shares of preferred stock outstanding. Additionally, the Company&#x2019;s certificate of incorporation was amended and restated to provide for 100,000,000 authorized shares of common stock with a par value of $0.001 per share and 10,000,000 authorized shares of preferred stock with a par value of $0.001 per share.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On November 19, 2019, the Company completed an underwritten public offering, in which the Company issued and sold 4,077,192 shares of common stock at a public offering price of $36.75 per share. On December 2, 2019, the underwriters exercised in full their option to purchase an additional 611,578 shares of common stock at the public offering price of $36.75, for total net proceeds to the Company of $160.9 million after deducting underwriting discounts and commissions of $10.3 million and offering expenses of $1.0 million.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Liquidity&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has not generated any revenue to date from product sales and does not expect to generate any revenues from product sales in the foreseeable future. Through December 2022, the Company has funded its operations primarily with proceeds from public offerings of its common stock, private placements of its preferred stock and upfront fees received under the Company&#x2019;s former agreement with Eli Lilly and Company. The Company expects to incur additional operating losses and negative operating cash flows for the foreseeable future.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of the issuance date of the financial statements for the year ended December 31, 2022, the Company expects that its cash and cash equivalents will be sufficient to fund its operating expenses and capital expenditure requirements to mid-2025. The future viability of the Company beyond that date may depend on its ability to raise additional capital to finance its operations. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"&gt;The Company plans to seek additional funding through public or private equity offerings, debt financings, marketing and distribution arrangements, other collaborations, strategic alliances, licensing arrangements or other methods. The Company may not be able to obtain financing on acceptable terms, or at all, and the Company may not be able to enter into strategic alliances or other arrangements on favorable terms, or at all. The terms of any financing may adversely affect the holdings or the rights of the Company&#x2019;s stockholders. If the Company is unable to obtain funding, the Company could be required to delay, reduce or eliminate research and development programs, product portfolio expansion or future commercialization efforts, which could adversely affect its business prospects.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"&gt;Although management continues to pursue these funding plans, there is no assurance that the Company will be successful in obtaining sufficient funding on terms acceptable to the Company, if at all, to fund continuing operations past two years from the issuance date of these financial statements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;"&gt;Risks and Uncertainties&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 8pt 0pt;"&gt;The Company is subject to risks common to early-stage companies in the biotechnology industry including, but not limited to: having a limited operating history and no products approved for commercial sale; having a history of significant losses; its need to obtain additional financing; dependence on its ability to advance its current and future product candidates through clinical trials, marketing approval and commercialization; the unproven approach to the discovery and development of product candidates based on the Company&#x2019;s FIND-IO platform; the lengthy and expensive nature and uncertain outcomes of the clinical development process; the lengthy, time-consuming and unpredictable nature of the regulatory approval process; the results of preclinical studies and early-stage clinical trials that may not be predictive of future results; dependence on its key personnel; its limited manufacturing experience as an organization and with its manufacturing facility; risks related to patent protection and the Company&#x2019;s pending patent applications; dependence on third-party collaborators for the discovery, development and commercialization of current and future product candidates; and significant competition from other biotechnology and pharmaceutical companies. Pursuit of the Company&#x2019;s business efforts will require significant amounts of additional capital, adequate personnel, infrastructure and extensive compliance-reporting capabilities. Even if the Company&#x2019;s development efforts are successful, it is uncertain when, if ever, the Company will realize significant revenue from product sales.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 8pt 0pt;"&gt;COVID-19&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The impact of the COVID-19 pandemic (including the impact of emerging variant strains of the COVID-19 virus) on the Company&#x2019;s business and financial performance is uncertain and depends on various factors, including the scope and duration of the pandemic, the efficacy and global distribution of vaccines, government restrictions and other actions, including relief measures, implemented to address the impact of the pandemic, and resulting impacts on the financial markets and overall economy. The imposition of &#x201c;lockdown,&#x201d; &#x201c;social distancing&#x201d; and &#x201c;shelter in place&#x201d; directives and other restrictions on business operations, travel and gatherings by state and federal governments in the United States, as well as governments in other regions of the world in response to the COVID-19 pandemic, has placed significant strain on the Company&#x2019;s clinical trial sites, has raised concerns around monitoring patient safety, and has caused enrollment to slow in the Company&#x2019;s clinical trials. Any rise of COVID-19 infection rates, especially in the United States, could continue to negatively affect enrollment going forward. The Company continues to closely monitor the COVID-19 situation and any potential impact to the Company&#x2019;s planned activities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Segment and Geographic Information&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating segments are defined as components of an entity about which separate discrete information is available for evaluation by the chief operating decision maker, or decision-making group, in deciding how to allocate resources and in assessing performance. The chief operating decision maker views the operations and manage the business in one operating segment that operates exclusively in the United States.&lt;/p&gt;</us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_DrWQ9sKhMUyebJfoMay_Jw"
      decimals="0"
      id="Narr_8Ufn-AL5vUqdct6tHIL3CQ"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">5750000</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_MInUrgAThkee5MzGS2_rNw"
      decimals="2"
      id="Narr_xwULGU1ZIkmt47Lc0wlonQ"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">15.00</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceInitialPublicOffering
      contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_DrWQ9sKhMUyebJfoMay_Jw"
      decimals="-5"
      id="Narr_wpP8LC0ZlUSzdFkEsNqx6A"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">77000000.0</us-gaap:ProceedsFromIssuanceInitialPublicOffering>
    <nxtc:PaymentsOfUnderwritingDiscountsAndCommissions
      contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_DrWQ9sKhMUyebJfoMay_Jw"
      decimals="-5"
      id="Narr_sadayeASik2k0aNSf0WNfw"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">6000000.0</nxtc:PaymentsOfUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_5_13_2019_To_5_13_2019_us-gaap_SubsidiarySaleOfStockAxis_us-gaap_IPOMember_DrWQ9sKhMUyebJfoMay_Jw"
      decimals="-5"
      id="Narr_CHJ6VwnUn0GKdsDnfKBRZg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">3400000</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:CommonStockSharesOutstanding
      contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g"
      decimals="0"
      id="Narr_LDvTKE-xzEO6wspdorNpWQ"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">15560569</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g"
      decimals="0"
      id="Narr_LxsOE68M8EaKbgiWFcTW0A"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g"
      decimals="0"
      id="Narr_UxphsF7zNESLQfLHSPuP8Q"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g"
      decimals="INF"
      id="Narr_7snZEX-hAEytaabfqcNa-Q"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g"
      decimals="0"
      id="Narr_7McCOIzrbEqSaPbZmNXkYA"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g"
      decimals="INF"
      id="Narr_yvP9VehZakCOpJPAT53TSw"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_11_19_2019_To_11_19_2019_k_sFpRsB_0WOgCeVqnif5g"
      decimals="0"
      id="Narr_kcge1ibG9kqGqtzwyxKTgA"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">4077192</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_11_19_2019_Zz1QYveV3kqsEGkewxdtfA"
      decimals="2"
      id="Narr_QjM1X6IwmUea59wDgpS8gA"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">36.75</us-gaap:SharePrice>
    <us-gaap:StockIssuedDuringPeriodSharesNewIssues
      contextRef="Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg"
      decimals="0"
      id="Narr_JmTf1fOgC02c5wzMyM1LFQ"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">611578</us-gaap:StockIssuedDuringPeriodSharesNewIssues>
    <us-gaap:SharePrice
      contextRef="As_Of_12_2_2019_o6OFQ40YgEyzamR4P8fk6Q"
      decimals="2"
      id="Narr_dPLLbcTm_06UZ7hclg0MtA"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">36.75</us-gaap:SharePrice>
    <us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
      contextRef="Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg"
      decimals="-5"
      id="Narr_7HAP2tmZD0ymXcF_li7yoQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">160900000</us-gaap:ProceedsFromIssuanceOfPreferredStockAndPreferenceStock>
    <nxtc:PaymentsOfUnderwritingDiscountsAndCommissions
      contextRef="Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg"
      decimals="-5"
      id="Narr_Dt8i3UmJ90OvloytRhVDXQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">10300000</nxtc:PaymentsOfUnderwritingDiscountsAndCommissions>
    <us-gaap:PaymentsOfStockIssuanceCosts
      contextRef="Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg"
      decimals="-5"
      id="Narr_pMuIlUEJp0qPJ4D6I89BNQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1000000.0</us-gaap:PaymentsOfStockIssuanceCosts>
    <us-gaap:NumberOfOperatingSegments
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="INF"
      id="Narr_LxYCa5qK8ke4YLIKROu1aw"
      unitRef="Unit_Standard_segment_SvUt3NvuT0moPQCiN6jnXA">1</us-gaap:NumberOfOperatingSegments>
    <us-gaap:SignificantAccountingPoliciesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_zEmY74uvMUOIxXERfaw9YQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;2. Summary of Significant Accounting Policies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The accompanying financial statements include the accounts of the Company. The Company&#x2019;s financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x2018;&#x2018;GAAP&#x2019;&#x2019;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Standards Codification (&#x2018;&#x2018;ASC&#x2019;&#x2019;) and Accounting Standards Update (&#x2018;&#x2018;ASU&#x2019;&#x2019;) of the Financial Accounting Standards Board (&#x2018;&#x2018;FASB&#x2019;&#x2019;). &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;In August 2021, the Company fully paid the remaining principal balance of $2.4 million of its $5.0 million term loan (the &#x201c;Term Loan&#x201d;). As a result of this payment, the Company has no restricted cash held in support of the Term Loan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company&#x2019;s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company&#x2019;s statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company&#x2019;s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;2&#x2014;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;3&#x2014;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computers and peripherals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;be the rate required for a similar investment of like risk. No impairment losses were recognized during the years ended December 31, 2022 or 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Construction in progress (Note&#160;5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On January 1, 2022 (Adoption Date), the Company adopted Accounting Standards Update (ASU) No. 2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&#160;(Topic 842) (ASU No. 2016-02), as amended, using the modified retrospective approach, which provides a method for recording existing leases at adoption and does not require restating comparative financial information. The Company also elected the package of practical expedients permitted under the transition guidance under ASU No. 2016-02, which among other things, permits the Company to maintain the lease classification for any existing leases, as well as maintain the Company&#x2019;s determination on whether any expired or existing contracts are or contain leases and initial direct costs for any existing leases. The Company did not elect the hindsight practical expedient to determine the lease term for existing leases. In addition, the Company elected the additional transition method permitted under ASU No. 2018-11&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2012;&lt;/span&gt;Leases (Topic 842): Targeted Improvements, under which the Company initially applied the new lease standard, Accounting Standards Codification (ASC) 842, at adoption and there was no cumulative-effect adjustment to the opening balance of retained earnings on January 1, 2022. For the comparative period presented in these financial statements, lease-related disclosures continue to be in accordance with the legacy ASC 840. Adoption of ASC 842 did not materially impact the Company&#x2019;s statements of operations and cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company determines if an arrangement is a lease or implicitly contains a lease at inception based on the lease definition and also determines if the lease is classified as an operating lease or finance lease, each in accordance with ASC 842. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in its balance sheets. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date or the Adoption Date for existing leases based on the present value of lease payments over the lease term using an estimated discount rate. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date or the Adoption Date in determining the present value of lease payments over a similar term. In determining the estimated incremental borrowing rate, the Company considered a rate obtained from its primary banker for discussion purposes of a potential collateralized loan with a term similar to the lease term and the Company&#x2019;s historical borrowing capability in the market. For operating leases, lease expense is recognized on a straight-line basis over the lease term. Lease and non-lease components within a contract are generally accounted for separately.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not have any outstanding preferred stock as of December 31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs, Including Clinical Trial Accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (&#x201c;CROs&#x201d;), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;i style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#x201c;Black-Scholes&#x201d;) for stock option grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No.&#160;2016-09, &lt;i style="font-style:italic;"&gt;Improvements to Employee Share-Based Payment Accounting&lt;/i&gt; (&#x201c;ASU&#160;2016-09&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&#x2019;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#x2019;s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Income (Loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2022 and 2021. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company qualifies as an emerging growth company (&#x201c;EGC&#x201d;) as defined under the Jumpstart Our Business Startups Act (the &#x201c;JOBS Act&#x201d;). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company&#x2019;s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company&#x2019;s financial position or results of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_qge6rRcv8US2n5xM3LiDCQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Basis of Presentation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The accompanying financial statements include the accounts of the Company. The Company&#x2019;s financial statements have been prepared in accordance with United States generally accepted accounting principles (&#x2018;&#x2018;GAAP&#x2019;&#x2019;). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the Accounting &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 10pt 0pt;"&gt;Standards Codification (&#x2018;&#x2018;ASC&#x2019;&#x2019;) and Accounting Standards Update (&#x2018;&#x2018;ASU&#x2019;&#x2019;) of the Financial Accounting Standards Board (&#x2018;&#x2018;FASB&#x2019;&#x2019;). &lt;/p&gt;</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:UseOfEstimates
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_skst5gjfFUuKKciKuwl6eA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Use of Estimates&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The preparation of financial statements in accordance with GAAP requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. These estimates and assumptions affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements and the reported amounts of revenues and expenses for the period presented. Although actual results could differ from those estimates, management does not believe that such differences would be material.&lt;/p&gt;</us-gaap:UseOfEstimates>
    <us-gaap:CashAndCashEquivalentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_mMzWUYEpSUm3rbcTbUhw6g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Cash and Cash Equivalents&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;The Company considers all highly liquid investments with an original maturity of three&#160;months or less at the date of purchase to be cash equivalents. The Company deposits its cash primarily in checking, sweep account and money market accounts. Cash equivalents are stated at amortized cost, plus accrued interest, which approximates fair value. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsPolicyTextBlock>
    <us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_qXuuoZc6xEmbBIKC9tfZ7g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 10pt 0pt;"&gt;Restricted Cash&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 10pt 0pt;"&gt;In August 2021, the Company fully paid the remaining principal balance of $2.4 million of its $5.0 million term loan (the &#x201c;Term Loan&#x201d;). As a result of this payment, the Company has no restricted cash held in support of the Term Loan. &lt;/p&gt;</us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy>
    <us-gaap:ProceedsFromRepaymentsOfDebt
      contextRef="Duration_8_1_2021_To_8_31_2021_QUjo54fwz0S0O0oyBr9gCg"
      decimals="-5"
      id="Narr_khbdMsTU_Ua9SAAKHEGVRA"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">-2400000</us-gaap:ProceedsFromRepaymentsOfDebt>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-5"
      id="Narr_08ADxLkIvEuQIT9eJDWqCA"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <nxtc:RequiredReserveRestrictedCashCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-5"
      id="Narr_aQpq_mneZk-2fkNjBUOAmw"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</nxtc:RequiredReserveRestrictedCashCurrent>
    <us-gaap:MarketableSecuritiesPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_FuFXKb7AFkGyWb-GNxO6Vw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities primarily consist of government debt securities, corporate bonds and agency bonds. These marketable securities are classified as available-for-sale, and as such, are carried at fair value as determined by prices for identical or similar securities at the balance sheet date. Marketable securities consist of Level 2 financial instruments in the fair-value hierarchy. The Company&#x2019;s policy is to classify all investments with contractual maturities within one year as current. At each reporting date, the Company evaluates the classification of its investments with maturities beyond one year based on the nature of the investment securities and whether the investments are considered available for use in current operations. Investment income is recognized when earned and reported net of investment expenses. Unrealized holding gains and losses are reported within accumulated other comprehensive income (loss) as a separate component of stockholders&#x2019; equity. The amortized cost of debt securities is adjusted for amortization of premiums and accretion of discounts to maturity. Such amortization and interest on securities are included in other income, net, on the Company&#x2019;s statements of operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;At each balance sheet date, the Company assesses available-for-sale securities in an unrealized loss position to determine whether the unrealized loss is other-than-temporary. If a decline in the fair value of a marketable security below the Company&#x2019;s cost basis is determined to be other-than-temporary, such marketable security is written down to its estimated fair value as a new cost basis and the amount of the write-down is included in earnings as an impairment charge. The Company considers factors including the significance of the decline in value compared to the cost basis, underlying factors contributing to a decline in the prices of securities in a single asset class, the length of time the market value of the security has been less than its cost basis, the security's relative performance versus its peers, sector or asset class, expected market volatility and the market and economy in general. The Company also evaluates whether it is more likely than not that it will be required to sell a security prior to recovery of its fair value. The cost of securities sold is based on the specific identification method.&lt;/p&gt;</us-gaap:MarketableSecuritiesPolicy>
    <us-gaap:ConcentrationRiskCreditRisk
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_TGpU08m-2UuC77rGh1Upyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Concentration of Credit Risk&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Financial instruments that potentially expose the Company to concentrations of credit risk primarily consist of cash and cash equivalents. The Company maintains its cash and cash equivalents at one accredited financial institution that is federally insured. While balances deposited often exceed federally insured limits, the Company does not believe that it is subject to unusual credit risk beyond the normal credit risk associated with commercial banking relationships. The Company's investment policy limits investments to certain types of debt securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The counterparties are various corporations, financial institutions and government agencies of high credit standing. &lt;/p&gt;</us-gaap:ConcentrationRiskCreditRisk>
    <us-gaap:FairValueOfFinancialInstrumentsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_JHpZMgOA2ECFF2lKz5GhHQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Fair Value of Financial Instruments&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;ASC Topic 820, &lt;i style="font-style:italic;"&gt;Fair Value Measurement&lt;/i&gt; (&#x201c;ASC 820&#x201d;), establishes a fair value hierarchy for instruments measured at fair value that distinguishes between assumptions based on market data (observable inputs) and the Company&#x2019;s own assumptions (unobservable inputs). Observable inputs are inputs that market participants would use in pricing the asset or liability based on market data obtained from sources independent of the Company. Unobservable inputs are inputs that reflect the Company&#x2019;s assumptions about the inputs that market participants would use in pricing the asset or liability and are developed based on the best information available in the circumstances. ASC 820 identifies fair value as the exchange price, or exit price, representing the amount that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants. As a basis for considering market participant assumptions in fair value measurements, ASC 820 establishes a three-tier value hierarchy that distinguishes between the following:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;1&#x2014;Quoted market prices in active markets for identical assets or liabilities.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;2&#x2014;Inputs other than Level&#160;1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level&#160;3&#x2014;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use. Use of these inputs involves significant and subjective judgments to be made by a reporting entity &#x2013; e.g., determining an appropriate adjustment to a discount factor for illiquidity associated with a given security.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level&#160;3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;</us-gaap:FairValueOfFinancialInstrumentsPolicy>
    <us-gaap:PropertyPlantAndEquipmentPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb__7aVZfGTeEOAfZNH2JFXsQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment are valued at cost less accumulated depreciation. Depreciation is recognized on a straight-line basis over the estimated useful lives of the related assets. Leasehold improvements are amortized on a straight-line basis over the shorter of the useful life or term of the lease. Upon retirement or disposal, the cost and related accumulated depreciation are removed from the balance sheet and the resulting gain or loss is recorded to general and administrative expenses in the accompanying statement of operations and comprehensive loss. Routine expenditures for maintenance and repairs are expensed as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Estimated useful lives for property and equipment are as follows:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computers and peripherals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company reviews long-lived assets, which primarily consist of property and equipment, for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset or group of assets may not be fully recoverable based on the criteria for accounting for the impairment or disposal of long-lived assets under ASC Topic 360, Property, Plant and Equipment. These events or changes in circumstances may include a significant deterioration of operating results, changes in business plans, or changes in anticipated future cash flows. If an impairment indicator is present, the Company evaluates recoverability by comparing the carrying amount of the assets group to future undiscounted net cash flows expected to be generated by the assets group. Assets are grouped at the lowest level for which there is identifiable cash flows that are largely independent of the cash flows generated by other asset groups. If the total of the expected undiscounted future cash flows is less than the carrying amount of the asset, an impairment loss is recognized for the difference between the fair value and carrying value of assets within the group. Fair value is generally determined by estimates of discounted cash flows. The discount rate used in any estimate of discounted cash flows would &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;be the rate required for a similar investment of like risk. No impairment losses were recognized during the years ended December 31, 2022 or 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Construction in progress (Note&#160;5) is carried at cost and consists of specifically identifiable direct and indirect development and construction costs. While under construction, costs of the property are included in construction in progress until the property is placed in service, at which time costs are transferred to the appropriate property and equipment account including, but not limited to, leasehold improvements or other such accounts.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentPolicyTextBlock>
    <nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_Ot-LPIR8VEyTm3JH7WgnFw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&#160;Useful&#160;Life&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computers and peripherals&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;3&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;7&#160;years&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.09%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:56.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;Lesser of estimated useful life or remaining lease term&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_9gGAYZTy_U-F2bBDboUuHg"
      id="Tc_fieTmeikU0y76cpAJD9IIQ_2_2">P3Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_EquipmentMember_1bxFiSQkekaQznzCFGTEyg"
      id="Tc_IM-V4hceCUe0a3yv_UfAlQ_3_2">P5Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5RSY3CZwm0S1VjPnBbQ2qQ"
      id="Tc_7KMysowuA0W09hk-pjhEVw_4_2">P7Y</us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="0"
      id="Narr_dmWy5ke07k6IgmgOmFY5Tg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="0"
      id="Narr_GhXKKbCuyEqbPHWx3e9nXw"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf>
    <us-gaap:SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_Zs6EOgzF7kquqKHcmD_0fg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;On January 1, 2022 (Adoption Date), the Company adopted Accounting Standards Update (ASU) No. 2016-02, &lt;i style="font-style:italic;"&gt;Leases&lt;/i&gt;&#160;(Topic 842) (ASU No. 2016-02), as amended, using the modified retrospective approach, which provides a method for recording existing leases at adoption and does not require restating comparative financial information. The Company also elected the package of practical expedients permitted under the transition guidance under ASU No. 2016-02, which among other things, permits the Company to maintain the lease classification for any existing leases, as well as maintain the Company&#x2019;s determination on whether any expired or existing contracts are or contain leases and initial direct costs for any existing leases. The Company did not elect the hindsight practical expedient to determine the lease term for existing leases. In addition, the Company elected the additional transition method permitted under ASU No. 2018-11&lt;span style="font-family:'Arial','Helvetica','sans-serif';"&gt;&#x2012;&lt;/span&gt;Leases (Topic 842): Targeted Improvements, under which the Company initially applied the new lease standard, Accounting Standards Codification (ASC) 842, at adoption and there was no cumulative-effect adjustment to the opening balance of retained earnings on January 1, 2022. For the comparative period presented in these financial statements, lease-related disclosures continue to be in accordance with the legacy ASC 840. Adoption of ASC 842 did not materially impact the Company&#x2019;s statements of operations and cash flows. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;The Company determines if an arrangement is a lease or implicitly contains a lease at inception based on the lease definition and also determines if the lease is classified as an operating lease or finance lease, each in accordance with ASC 842. Operating leases are included in operating lease right-of-use (ROU) assets and operating lease liabilities in its balance sheets. ROU assets represent the Company&#x2019;s right to use an underlying asset for the lease term and lease liabilities represent the Company&#x2019;s obligation to make lease payments arising from the lease. ROU assets and lease liabilities are recognized at the commencement date or the Adoption Date for existing leases based on the present value of lease payments over the lease term using an estimated discount rate. As the Company&#x2019;s leases do not provide an implicit rate, the Company uses an incremental borrowing rate based on the information available at commencement date or the Adoption Date in determining the present value of lease payments over a similar term. In determining the estimated incremental borrowing rate, the Company considered a rate obtained from its primary banker for discussion purposes of a potential collateralized loan with a term similar to the lease term and the Company&#x2019;s historical borrowing capability in the market. For operating leases, lease expense is recognized on a straight-line basis over the lease term. Lease and non-lease components within a contract are generally accounted for separately.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock>
    <us-gaap:LeasePracticalExpedientsPackage
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_TDmwu3IIpUOEG69oDq4obg">true</us-gaap:LeasePracticalExpedientsPackage>
    <us-gaap:LeasePracticalExpedientUseOfHindsight
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_9-B3U3YN20WDSJ3wscQazA">false</us-gaap:LeasePracticalExpedientUseOfHindsight>
    <us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_GiRmAr0ePkuuZsMMeWcz8g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not have any outstanding preferred stock as of December 31, 2022 and 2021.&lt;/p&gt;</us-gaap:StockholdersEquityNoteRedeemablePreferredStockIssuePolicy>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="INF"
      id="Narr_ODxjcjDbB06KiCPCdO1vFQ"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_b5ePPwbHLE6CjFHmEy94SA"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:ResearchAndDevelopmentExpensePolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_8L3pKTO9r02It09rhJyk7A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Research and Development Costs, Including Clinical Trial Accruals&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Research costs consist of employee-related costs, contractor expenses, laboratory supplies and facility costs, for research and development of product candidates are expensed as incurred. Development costs, including clinical trial-related expenses, incurred by third parties, such as clinical research organizations (&#x201c;CROs&#x201d;), are expensed as the contracted work is performed. Where contingent milestone payments are due to third parties under research and development arrangements, the milestone payment obligations are expensed when the milestone results are probable of being achieved. When evaluating the adequacy of the accrued liabilities, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Clinical trial expenses are a significant component of research and development expenses, and the Company outsources a significant portion of these costs to third parties. Third-party clinical trial expenses include investigator fees, site and patient costs, CRO costs, and costs for central laboratory testing and data management. The accrual for site and patient costs includes inputs such as estimates of patient enrollment, patient cycles incurred, clinical site activations, and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;other pass-through costs. These inputs are required to be estimated due to a lag in receiving the actual clinical information from third parties. Payments for these activities are based on the terms of the individual arrangements, which may differ from the pattern of costs incurred, and are reflected on the balance sheets as a prepaid asset or accrued expenses. These third-party agreements are generally cancelable, and related costs are recorded as research and development expenses as incurred. Non-refundable advance clinical payments for goods or services that will be used or rendered for future research and development activities are recorded as a prepaid asset and recognized as expense as the related goods are delivered or the related services are performed. When evaluating the adequacy of the accrued expenses, the Company analyzes progress of the studies, including the phase or completion of events, invoices received and contracted costs. Significant judgments and estimates may be made in determining the accrued balances at the end of any reporting period. Actual results could differ from the estimates made. The historical clinical accrual estimates have not been materially different from the actual costs. &lt;/p&gt;</us-gaap:ResearchAndDevelopmentExpensePolicy>
    <us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_7m95zKtZ4kapbzLdkEILig">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Patent Costs&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;All patent-related costs incurred in connection with filing and prosecuting patent applications are expensed as incurred due to the uncertainty about the recovery of the expenditure. Amounts incurred are classified as general and administrative expenses in the accompanying statement of operations and comprehensive loss.&lt;/p&gt;</us-gaap:GoodwillAndIntangibleAssetsIntangibleAssetsPolicy>
    <us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_qUsu42raPUaL03wqplU3wA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company accounts for its stock-based compensation in accordance with ASC Topic 718, &lt;i style="font-style:italic;"&gt;Compensation-Stock Compensation&lt;/i&gt; (&#x201c;ASC 718&#x201d;). ASC 718 requires all share-based payments to employees, consultants and directors, including grants of incentive stock options, nonqualified stock options, restricted stock awards, unrestricted stock awards or restricted stock units to employees, consultants and directors of the Company, to be recognized as expense in the statement of operations and comprehensive loss based on their grant date fair values. The Company estimates the fair value of options granted using the Black-Scholes option pricing model (&#x201c;Black-Scholes&#x201d;) for stock option grants to both employees and non-employees and the fair value of common stock to determine the fair value of restricted stock.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Black-Scholes option pricing model requires inputs based on certain subjective assumptions, including (i)&#160;the expected stock price volatility, (ii)&#160;the expected term of the award, (iii)&#160;the risk-free interest rate and (iv)&#160;expected dividends. Due to the lack of a public market for the Company&#x2019;s common stock and lack of company-specific historical and implied volatility data, the Company has based its computation of expected volatility on the historical volatility of a representative group of public companies with similar characteristics to the Company, including stage of product development and life science industry focus. The historical volatility is calculated based on a period of time commensurate with expected term assumption. The Company uses the simplified method as prescribed by the SEC Staff Accounting Bulletin No.&#160;107, Share-Based Payment, to calculate the expected term for options granted to employees as it does not have sufficient historical exercise data to provide a reasonable basis upon which to estimate the expected term. The expected term is applied to the stock option grant group as a whole, as the Company does not expect substantially different exercise or post-vesting termination behavior among its employee population. For options granted to non-employees, the Company utilizes the simplified method also as the basis for the expected term assumption. The risk-free interest rate is based on a treasury instrument whose term is consistent with the expected term of the stock options. The expected dividend yield is assumed to be zero because the Company has never paid dividends and has no current plans to pay any dividends on its common stock. The Company recognizes forfeitures as they occur as allowed by ASU No.&#160;2016-09, &lt;i style="font-style:italic;"&gt;Improvements to Employee Share-Based Payment Accounting&lt;/i&gt; (&#x201c;ASU&#160;2016-09&#x201d;).&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;There are significant judgments and estimates inherent in the determination of the fair value of the Company&#x2019;s common stock. These estimates and assumptions include a number of objective and subjective factors, including external market conditions, the prices at which the Company sold shares of preferred stock, the superior rights and preferences of securities senior to its common stock at the time of a liquidity event, such as the IPO or a sale, and the likelihood of such an event. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company expenses the fair value of its share-based compensation awards on a straight-line basis over the requisite service period, which is generally the vesting period.&lt;/p&gt;</us-gaap:ShareBasedCompensationOptionAndIncentivePlansPolicy>
    <us-gaap:IncomeTaxPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_v2qn8f3lV06tVrgnZl6lJA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the asset and liability method of accounting for income taxes. Deferred tax assets and liabilities are recognized for the estimated future tax consequences attributable to temporary differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax base. Deferred tax assets and liabilities, which relate primarily to the carrying amount of the Company&#x2019;s its net operating loss carryforwards, are measured using enacted tax rates expected to apply to taxable income in the years in which those temporary differences are expected to be recovered or settled. Deferred tax expense or benefit is the result of changes in the deferred tax assets and liabilities. Valuation allowances are established when necessary to reduce deferred tax assets where, based upon the available evidence, the Company concludes that it is more-likely-than-not that the deferred tax assets will not be realized. In evaluating its ability to recover deferred tax assets, the Company considers all available positive and negative evidence, including its operating results, ongoing tax planning and forecasts of future taxable income on a jurisdiction-by-jurisdiction basis. Because of the uncertainty of the realization of deferred tax assets, the Company has recorded a full valuation allowance against its deferred tax assets as of December 31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Reserves are provided for tax benefits for which realization is uncertain. Such benefits are only recognized when the underlying tax position is considered more-likely-than-not to be sustained on examination by a taxing authority, assuming they possess full knowledge of the position and facts. Interest and penalties related to uncertain tax positions are recognized in the provision of income taxes; however, the Company currently has no interest or penalties related to uncertain income tax benefits.&lt;/p&gt;</us-gaap:IncomeTaxPolicyTextBlock>
    <us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="0"
      id="Narr_ml9LzqUFVE2xhtKWiViIpg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense>
    <us-gaap:ComprehensiveIncomePolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_drzx4UDP9Eajg3BOHME-LQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive Income (Loss)&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Comprehensive income (loss) is the change in equity of a business enterprise during a period from transactions and other events and circumstances from non-owner sources. Comprehensive income (loss) includes net income (loss) and the change in accumulated other comprehensive income (loss) for the period. Accumulated other comprehensive income (loss) consisted entirely of unrealized gains and losses on available-for-sale marketable securities at December 31, 2022 and 2021. &lt;/p&gt;</us-gaap:ComprehensiveIncomePolicyPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_K-9skWyXE02Eb2GKnn7NwA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Net Loss per Share&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Basic loss per common share is determined by dividing loss attributable to common stockholders by the weighted-average number of common shares outstanding during the period, without consideration of common stock equivalents. Diluted loss per share is computed by dividing the loss attributable to common stockholders by the weighted-average number of common share equivalents outstanding for the period. The treasury stock method is used to determine the dilutive effect of the Company's stock option grants.&lt;/p&gt;</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_E1bassxiRU-Ovat45PNHyg">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Recently Issued Accounting Pronouncements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company qualifies as an emerging growth company (&#x201c;EGC&#x201d;) as defined under the Jumpstart Our Business Startups Act (the &#x201c;JOBS Act&#x201d;). Using exemptions provided under the JOBS Act provided to EGCs, the Company has elected to defer compliance with new or revised financial accounting standards until it is required to comply with such standards, which is generally consistent with required adoption dates of private companies. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company considers the applicability and impact of all ASUs issued by the FASB. All other ASUs issued subsequent to the filing of the Company&#x2019;s Annual Report were assessed and determined to be either inapplicable or not expected to have a material impact on the Company&#x2019;s financial position or results of operations.&lt;/p&gt;</us-gaap:NewAccountingPronouncementsPolicyPolicyTextBlock>
    <us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_UNhNtf-yOUm_aglhgWetQw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;3. Marketable Securities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Marketable securities consist of the following:&lt;/p&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gain&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,457)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131,706&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Government agencies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 134,775&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,494)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gain&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company uses the specific identification method when calculating realized gains and losses. For the years ended December 31, 2022 and 2021, respectively, the Company recorded $9 thousand and $57 thousand in realized gains on available-for-sale securities, which is included in other income on the statements of operations and comprehensive loss. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company reviewed all investments which were in a loss position at the respective balance sheet dates, as well as the remainder of the portfolio. As of December&#160;31,&#160;2022, the Company had investments with a total fair market value of $133.3 million in an unrealized loss position, of which $91.8 million were in a continuous unrealized loss position for more than twelve months. The Company analyzed the unrealized losses and determined that market conditions were the primary factor driving these changes, and such unrealized losses are temporary as the Company anticipates a full recovery of the amortized cost basis of these securities at maturity. After analyzing the securities in an unrealized loss position, the portion of these losses that relate to changes in credit quality is insignificant. The Company does not intend to sell these securities, nor is it more likely than not that the Company will be required to sell them prior to the end of their contractual terms. Furthermore, the Company does not believe that these securities expose the Company to undue market risk or counterparty credit risk.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following table summarizes maturities of the Company&#x2019;s investments available-for-sale as of December 31, 2022:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maturities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Within 1 year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Between 1 to 2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,621&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total investments available-for-sale&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 134,775&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has classified all of its investments available-for-sale, including those with maturities beyond one year, as current assets on the accompanying balance sheets based on the highly liquid nature of these investment securities and because these investment securities are considered available for use in current operations.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has elected to report interest receivable from its marketable securities with prepaid expenses and other current assets on its balance sheet. &#160;Interest receivable included in prepaid expenses and other current assets totaled $0.7 million and $1.0 million as of December 31, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_tsOMvmo7sES8gv3rz8-W-Q">&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gain&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,163&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,457)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131,706&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;U.S. Government agencies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,612&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (37)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,575&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 134,775&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,494)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:50.01%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gross&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Amortized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unrealized&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Estimated&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.85%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.21%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Gain&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.42%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Loss&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:9.79%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:47.88%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.54%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,917&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.9%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.44%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.98%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (666)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.1%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.31%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:8.47%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Pd5kHKPoGUawJuu7EPVYpQ"
      decimals="-3"
      id="Tc_Oc4q8M6Yhkqe_qVjWI_rHA_5_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">133163000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Pd5kHKPoGUawJuu7EPVYpQ"
      decimals="-3"
      id="Tc_Muc2yCkdZEWCLyPuggSETg_5_9"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1457000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_Pd5kHKPoGUawJuu7EPVYpQ"
      decimals="-3"
      id="Tc_WbQ1zYjTQEKK3gKnzxiAsQ_5_12"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">131706000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_BevS1rj6TkCrU3_9XVnY4Q"
      decimals="-3"
      id="Tc_dIEj28Khi0WPLaD5K8SQvA_6_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1612000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_BevS1rj6TkCrU3_9XVnY4Q"
      decimals="-3"
      id="Tc_F0Jk3HvIp0iYeegjsQClqA_6_9"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">37000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2022_us-gaap_FinancialInstrumentAxis_us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember_BevS1rj6TkCrU3_9XVnY4Q"
      decimals="-3"
      id="Tc_jrqBpIPREEOIEem7N4tDPQ_6_12"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1575000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_-nTfucTppkSRIo5jEgAw7g_7_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">134775000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_jpFQNyUb8Uu9Jpoj6UCVDQ_7_9"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1494000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_xnQGHfWRJEuhFTKoWF4s1Q_7_12"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">133281000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_8exjrnhK4U25OrK5dhgHWg"
      decimals="-3"
      id="Tc_HDCwhYiK6ESjH-vOiahFaQ_5_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">207917000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_8exjrnhK4U25OrK5dhgHWg"
      decimals="-3"
      id="Tc_Y4C22A6XGEqKYE46fx9xPA_5_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_8exjrnhK4U25OrK5dhgHWg"
      decimals="-3"
      id="Tc_gfm-8f8xTkWK0vv9pg1xIQ_5_9"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">666000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2021_us-gaap_FinancialInstrumentAxis_us-gaap_CorporateDebtSecuritiesMember_8exjrnhK4U25OrK5dhgHWg"
      decimals="-3"
      id="Tc_jkAyJwkeREiASuMqRIQRAg_5_12"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">207254000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_Q4n13fKBXUyZ_g-MGR7IiA_6_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">207917000</us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_tLysHpSggUyhJkSWT9EpOA_6_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">3000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax>
    <us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_lEVpy4mHjUOiqzpqU3QkQQ_6_9"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">666000</us-gaap:AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_RdvJQlc310GIO8WY-X7D4w_6_12"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">207254000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Narr_IkriTgwtKECBovYO1ldlPg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">9000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleRealizedGain
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Narr_WbZxG6U27UycUYMZRbzjPA"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">57000</us-gaap:DebtSecuritiesAvailableForSaleRealizedGain>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-5"
      id="Narr_TNlLTvP-WU6bHjrVONxXgg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">133300000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-5"
      id="Narr_WgLBYr5_N0qJAdblciGvBw"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">91800000</us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger>
    <nxtc:ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_o5Lz7gGmx0GEdMEQgk2U9w">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:32.58%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Fair&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:13.29%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Cost&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.44%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Maturities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Within 1 year&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105,930&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.68%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 104,660&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Between 1 to 2 years&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,845&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.68%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,621&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:64.58%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total investments available-for-sale&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.83%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.52%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 134,775&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.84%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.76%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.68%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,281&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</nxtc:ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_FFYmr6hXBUqDqmf3l5kDuA_5_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">105930000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_NNhQDHaLVEmxYDUrDkQH2g_5_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">104660000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue>
    <nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_-VKqzMDgIk6zDPSCRmiSWA_6_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">28845000</nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost>
    <nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_v18KRwvodEu9bG4KU3cyFQ_6_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">28621000</nxtc:AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_vLNPEDL5ikG0_rL8DiZp6A_7_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">134775000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis>
    <us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_53jaCks_o0WeZ5C42LpsSQ_7_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">133281000</us-gaap:AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate>
    <nxtc:InterestIncomeNonOperating
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-5"
      id="Narr_nGbenvwnH0a4lrSopRvMmg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">700000</nxtc:InterestIncomeNonOperating>
    <nxtc:InterestIncomeNonOperating
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-5"
      id="Narr_dHVJCWbOpEy_UAPVB261Ug"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1000000.0</nxtc:InterestIncomeNonOperating>
    <us-gaap:FairValueDisclosuresTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_BE-Qse057EGqHzJsTmQ41A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;4. Fair Value Measurements&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company has certain financial assets recorded at fair value, which have been classified as Level 1, 2 or 3 within the fair value hierarchy as described in the accounting standards for fair value measurements.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 1&#x2014;Quoted market prices in active markets for identical assets or liabilities. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 2&#x2014;Inputs other than Level 1 inputs that are either directly or indirectly observable, such as quoted market prices, interest rates and yield curves. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Level 3&#x2014;Unobservable inputs developed using estimates of assumptions developed by the Company, which reflect those that a market participant would use.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;To the extent the valuation is based on models or inputs that are less observable or unobservable in the market, the determination of fair values requires more judgment. Accordingly, the degree of judgment exercised by the Company in determining fair value is greatest for instruments categorized as Level 3. A financial instrument&#x2019;s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The following tables set forth the fair value of the Company&#x2019;s financial assets by level within the fair value hierarchy as of December 31, 2022 and 2021:&lt;/p&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active Markets or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131,706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131,706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. Government agencies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 140,063&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active Markets or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 209,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company did not transfer any assets measured at fair value on a recurring basis between levels during the&#160;years ended December&#160;31, 2022 and 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The carrying value of financial instruments, including trade receivables, accounts payable and accrued liabilities approximate fair value because of the short-term maturity of these items. The estimated fair values may not represent actual values of the financial instruments that could be realized as of the balance sheet date or that will be realized in the future.&lt;/p&gt;</us-gaap:FairValueDisclosuresTextBlock>
    <us-gaap:FairValueByBalanceSheetGroupingTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_qyUIRC2jH0SEwDDl1EjSUQ">&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active Markets or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131,706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 131,706&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;U.S. Government agencies&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,575&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 140,063&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,782&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 133,281&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="position:absolute;top:0pt;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="11" style="vertical-align:bottom;white-space:nowrap;width:56.49%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Quoted Prices in &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Other &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Active Markets or&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Observable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Significant&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Identical Assets&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Inputs&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Unobservable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Total&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:16.02%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 1)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:11.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 2)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.14%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(Level 3)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Cash equivalents:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Money market funds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Marketable securities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Corporate bonds&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:41.44%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 209,934&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.73%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:14.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 2,680&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.78%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 207,254&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.63%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.5%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:FairValueByBalanceSheetGroupingTextBlock>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember__yYHlcWVlkCe8veQpXoODg"
      decimals="-3"
      id="Tc_TeBkpdJW8k-hpTcl9u13bg_8_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">6782000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_RJ-xwh_wV0-uMLJTUoRWww"
      decimals="-3"
      id="Tc_XHYvoG9DGkK2y100TkyqWw_8_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">6782000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_5-Bu-eXe006BJ3_wB91BDA"
      decimals="-3"
      id="Tc_kqd-UJmUiUaTCFFdLBOTtA_10_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">131706000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_3eszyap510GTal9lTSf5TQ"
      decimals="-3"
      id="Tc_KHAPhdmXSEu_T0DHxXLx0w_10_9"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">131706000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_dIyXP5BpbkGbErryI05k3w"
      decimals="-3"
      id="Tc_Cy3cCevHMUqesxxedWroxQ_11_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1575000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2022_us-gaap_CashAndCashEquivalentsAxis_us-gaap_USGovernmentAgenciesDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_oikFh3LVykC7K0InhoySfQ"
      decimals="-3"
      id="Tc_0laRjoSSiE-pqrw-tdps6w_11_9"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1575000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Ym0BL0i97UaomE43uV-bYQ"
      decimals="-3"
      id="Tc_ydmKxGnpAk2NWndH2wyVOA_12_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">140063000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NKtrp11L7UqjNJ0bCbPyIg"
      decimals="-3"
      id="Tc_stVrk64cXE2mQRMAUqpdhA_12_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">6782000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2022_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_ZBgPDtK_ukm2DSu8kFg3MA"
      decimals="-3"
      id="Tc_O6UX4KkaSkWI23XZUxiwdg_12_9"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">133281000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_d4yfMi2VPkWj9z09O5KR2g"
      decimals="-3"
      id="Tc_ggoINJRg50GRM8aCCqshlg_8_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">2680000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:CashAndCashEquivalentsFairValueDisclosure
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_MoneyMarketFundsMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_8mxuMVEvVECi33rG7hy8TQ"
      decimals="-3"
      id="Tc_8n4r3m2io0Sp7gGzKpbfdw_8_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">2680000</us-gaap:CashAndCashEquivalentsFairValueDisclosure>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_C3fDpqg0Z0q1RzbPm02j9g"
      decimals="-3"
      id="Tc_dwBgba_E6ESwCjgRW6EhBQ_10_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">207254000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest
      contextRef="As_Of_12_31_2021_us-gaap_CashAndCashEquivalentsAxis_us-gaap_CorporateDebtSecuritiesMember_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_NJQoeyaVbkORdIFR-hPZZA"
      decimals="-3"
      id="Tc_IGr4PeZbokWgiqLHEJXklw_10_9"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">207254000</us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_tC3N1hSTQ06SevgSev4lPA"
      decimals="-3"
      id="Tc_0BNE5Vsj3k6iyWjZUpTkew_11_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">209934000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel1Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_PfvSQBm2r0egI8U0wsBykg"
      decimals="-3"
      id="Tc__UC_jjFkWkGk5LK0kf--4w_11_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">2680000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <nxtc:MarketableSecuritiesAndCashEquivalents
      contextRef="As_Of_12_31_2021_us-gaap_FairValueByFairValueHierarchyLevelAxis_us-gaap_FairValueInputsLevel2Member_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Wm2A56lBgkCPpaUm6E_ypw"
      decimals="-3"
      id="Tc_77FToKz5s0q0hPF6lNd2kw_11_9"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">207254000</nxtc:MarketableSecuritiesAndCashEquivalents>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_qNG32M8kVE6AIYwsLBBPNw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;5. Property and Equipment, Net&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Property and equipment consist of the following:&lt;/p&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,482&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,336&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,566&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 908&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 853&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,729&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,630)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,737)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,992&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Construction in progress at December&#160;31, 2022 and 2021 consists of the costs incurred for research equipment and for the build-out of additional lab and office space.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Depreciation and amortization expense was $4.1 million and $4.3 million for the&#160;years ended December&#160;31, 2022 and 2021, respectively.&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_uAFVFZE-yECGa-yQj8xZ9g">&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 17,244&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 16,482&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Leasehold improvements&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,336&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,566&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Computer equipment&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 908&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,143&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Furniture and fixtures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 186&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 167&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Construction in progress&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 853&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 371&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, gross&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 28,527&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 26,729&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: accumulated depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (16,630)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (12,737)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Property and equipment, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,897&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 13,992&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_s8Q9roYBs0mJ-WQs8x7lXQ"
      decimals="-3"
      id="Tc_zNZV1wuCLEGtXn6qzR7ODA_4_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">17244000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_nxtc_ResearchEquipmentMember_nHuF1bXQ4UWlM6L_pFhCDA"
      decimals="-3"
      id="Tc_ztLiKYZuOUq8iW6tc3Bl2A_4_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">16482000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_-AdmtV4Y4E2el33p-R4o7Q"
      decimals="-3"
      id="Tc_HM0_0hPPSUKfxibBeBDmvA_5_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">9336000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_LeaseholdImprovementsMember_vSYHseosFUeoXezPK_DwZA"
      decimals="-3"
      id="Tc_0Prrow7tPEmO98qz0p2ZHQ_5_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">8566000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_2k8diS0Dt0SajXRwD2H9pw"
      decimals="-3"
      id="Tc_b6G-SYpYu06GI8yC082ElA_6_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">908000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_B8DlzbFCLUSo9Q5ArS1Eqw"
      decimals="-3"
      id="Tc_SoQvfjWcGUWy9z5IGf2YuA_6_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1143000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_JFjr3X-iS0q7yBVBU-uoTQ"
      decimals="-3"
      id="Tc_oDiDgPsHEEe6e0TRSU1h9A_7_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">186000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_FurnitureAndFixturesMember_5wQASsCk1kGj8FiA4J8kUA"
      decimals="-3"
      id="Tc_t-TNOz2XNUiS5DtgYHCRnA_7_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">167000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_itU9-PmAeki7z14co80kbg"
      decimals="-3"
      id="Tc_-Ci6mGGo4EC8C_I5mG1udA_8_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">853000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ConstructionInProgressMember_jWIXUY1zdUKLE6_2RdA-vg"
      decimals="-3"
      id="Tc_YnI--x3_wUuO8LN3pz6obg_8_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">371000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_HtPSFTaY0k2oEGUUo90ZgQ_9_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">28527000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_rnx5YDPbjkqcMjpMyOkmyw_9_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">26729000</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_KmshaFATDUudHF1LGP-7sQ_10_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">16630000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_bXz7DhamOE-d5B8wfXxQfg_10_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">12737000</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_Sut7KSYRUE2szA3IyTE-1A_11_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">11897000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_vWDGNKXP6kihNTA8quYncw_11_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">13992000</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-5"
      id="Narr_V79eT4BOjkqDWRc61sg-Lw"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4100000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-5"
      id="Narr_bhvhPnqJykud8Td_QlLrKQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4300000</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_KARMbIb5OUy7t1ArNGy99g">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;6. Accrued Liabilities and Other Liabilities&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Accrued liabilities consist of the following:&lt;/p&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payroll and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,639&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Clinical trial costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 727&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sponsored research&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Y-cqdjMky0anGfcN4D8zww;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lease liabilities, current portion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 656&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued liabilities and other liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,666&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>
    <us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_7EVca2VYG0eGRn1bMxiy5A">&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.53%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Payroll and related benefits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,639&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,751&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Clinical trial costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,531&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 727&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Sponsored research&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 417&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,315&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="-sec-ix-hidden:Hidden_Y-cqdjMky0anGfcN4D8zww;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;Lease liabilities, current portion&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 518&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Operating expenses&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 647&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 656&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:70.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 105&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 217&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:70.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total accrued liabilities and other liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,857&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.08%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.57%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.95%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,666&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_DUibAtYcdUKaxpyJON85ZA_3_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1639000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <us-gaap:EmployeeRelatedLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_VEuKSUVTBUSa8bZ0saomiw_3_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1751000</us-gaap:EmployeeRelatedLiabilitiesCurrent>
    <nxtc:AccruedClinicalTrialCostsCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_EQbba1nZfUSUS6WLP-7PPQ_4_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1531000</nxtc:AccruedClinicalTrialCostsCurrent>
    <nxtc:AccruedClinicalTrialCostsCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_6hBC7L8UMUusu2iQl4zScQ_4_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">727000</nxtc:AccruedClinicalTrialCostsCurrent>
    <nxtc:AccruedSponsoredResearchExpenseCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_vnDUiFYg1Euyh2BN2CWG8g_5_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">417000</nxtc:AccruedSponsoredResearchExpenseCurrent>
    <nxtc:AccruedSponsoredResearchExpenseCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_MGFu2HzbFk6FFmHGFmCpeg_5_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1315000</nxtc:AccruedSponsoredResearchExpenseCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_15qlS86iwkisVse_2cCdaA_6_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">518000</us-gaap:OperatingLeaseLiabilityCurrent>
    <nxtc:AccruedOperatingExpensesCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_sjSWYpGAJU-tF-LwZfkVaA_7_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">647000</nxtc:AccruedOperatingExpensesCurrent>
    <nxtc:AccruedOperatingExpensesCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_vEv_Jep_jE2LT9ThtqNX_w_7_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">656000</nxtc:AccruedOperatingExpensesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_ub6AHmXehkiiGDlgywTOWw_8_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">105000</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_XXcJ8Ba-lUu16TZHq8beIg_8_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">217000</us-gaap:OtherLiabilitiesCurrent>
    <nxtc:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_ieiaDizzuEGHI5Zk8Qg_9A_9_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4857000</nxtc:AccruedAndOtherLiabilitiesCurrent>
    <nxtc:AccruedAndOtherLiabilitiesCurrent
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_Tbh60BN1ZUSgS1B1iBthOg_9_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4666000</nxtc:AccruedAndOtherLiabilitiesCurrent>
    <us-gaap:LesseeOperatingLeasesTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_IPTkqtFS8E6iMiXHQcoLjA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;7. Leases&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The Company's lease portfolio consists of office space and laboratory facilities.  All of the Company's leases are classified as operating leases. The terms of the Company's lease agreements that have commenced currently extend through March 2030 and provide the Company with an option for a &lt;/span&gt;five-year extension&lt;span style="white-space:pre-wrap;"&gt;.  Under the terms of the leases, the Company pays base annual rent subject to fixed dollar increases each year and other normal operating expenses such as taxes, repairs, and maintenance.  The Company evaluates renewal options at lease inception and on an ongoing basis and considers renewal options that the Company is reasonably certain to exercise in its expected lease terms when classifying leases and measuring lease liabilities in accordance with ASC 842.  The leases do not require variable lease payments or residual value guarantees and do not contain restrictive covenants.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;&lt;span style="white-space:pre-wrap;"&gt;The leases do not provide an implicit rate, therefore the Company uses its incremental borrowing rate as the discount rate when measuring the operating lease liability.  The incremental borrowing rate represents an estimate of the interest rate the Company would incur at lease commencement to borrow an amount equal to the lease payments on a collateralized basis over the term of the lease.&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Operating lease expense was $1.0&lt;span style="white-space:pre-wrap;"&gt; million for the year ended December 31, 2022.  Operating cash flows used for operating leases during the year ended December 31, 2022 were &lt;/span&gt;$0.9&lt;span style="white-space:pre-wrap;"&gt; million.  As of December 31, 2022, the weighted-average remaining lease term was &lt;/span&gt;7.25 years, and the weighted average discount rate was 7.46%.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt 0pt 12pt 0pt;"&gt;Rent expense under operating leases was $1.0 million for the year ended December 31, 2021.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2022, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands), which are included in Accrued liabilities and other liabilities and Lease liabilities, long term in the accompanying balance sheet:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,214&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,296)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRenewalTerm
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      id="Narr_p-hkVgUmekml6OD5vfGCag">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_3UhDFd9jlEezSlrZh9LnZA">true</us-gaap:LesseeOperatingLeaseExistenceOfOptionToExtend>
    <us-gaap:OperatingLeaseExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-5"
      id="Narr_Tk8IiDa1OUiNmG57HI9B0g"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1000000.0</us-gaap:OperatingLeaseExpense>
    <us-gaap:OperatingLeasePayments
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-5"
      id="Narr_sc6QJ6eBCkqLt41YE3tlFg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">900000</us-gaap:OperatingLeasePayments>
    <us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      id="Narr_4wl4oufvXkqzgaVjKRWpSw">P7Y3M</us-gaap:OperatingLeaseWeightedAverageRemainingLeaseTerm1>
    <us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="4"
      id="Narr_7RlI99cK0UKvmJzWzizf6g"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.0746</us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent>
    <us-gaap:OperatingLeasesRentExpenseNet
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-5"
      id="Narr_AC6D7ywKXEeL-BcCFOHHjw"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1000000.0</us-gaap:OperatingLeasesRentExpenseNet>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_fc3wpV7TF0WWYbiUXGBT-Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:18pt;margin:0pt;"&gt;As of December 31, 2022, the maturities of the Company&#x2019;s operating lease liabilities were as follows (in thousands), which are included in Accrued liabilities and other liabilities and Lease liabilities, long term in the accompanying balance sheet:&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Year Ending December 31,&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2023&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,032&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2024&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,127&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2025&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,214&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2026&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,355&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;2027&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,396&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Thereafter&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,295&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total future minimum payments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,419&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: present value discount&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (2,296)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Present value of lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 7,123&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.71%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;width:54.82%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:13.59%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.29%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.7%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_bTwf6VJUrkWcfVu2VLsrZQ_3_4"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1032000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_LczW1NCXc0KyyPKLMYX54A_4_4"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1127000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_uyvv6E0EDkWjktFlVGrY2Q_5_4"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1214000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_WcMCJkNUzki_ct1Y474i8A_6_4"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1355000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFour>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_PtxiC0SFSE62Cvz5fgb-Dw_7_4"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1396000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_i6Q2t12XE0iNGg-pMyl1dw_8_4"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">3295000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_Om6145yvx0agaEqRXfMh4Q_9_4"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">9419000</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_1PdnH-i8oES_ylNBtd8pGw_10_4"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">2296000</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <us-gaap:OperatingLeaseLiability
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_j2iVuRpmpkiDkL-CIM75GQ_11_4"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">7123000</us-gaap:OperatingLeaseLiability>
    <us-gaap:CommitmentsAndContingenciesDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_zqLTa8aym0eSqFw_6pL0xA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;8. Commitments and Contingencies&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Legal Proceedings&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company, from time to time, is a party to litigation or legal proceedings arising in the ordinary course of business. The Company is not a party to any litigation or legal proceedings, nor is management aware of any pending or threatened litigation that, in the opinion of the Company&#x2019;s management, are likely to have a material adverse effect on the Company&#x2019;s business. At each reporting date, the Company evaluates whether a potential loss amount or a potential range of loss is probable and reasonably estimable under the provisions of the authoritative guidance that addresses accounting for contingencies. The Company expenses the costs related to its legal proceedings as incurred.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On September 21, 2020, a putative stockholder class action was filed in the U.S. District Court for the Southern District of New York styled Ye Zhou v. NextCure, Inc., et. al., Case 1:20-cv-0772 (S.D.N.Y.). On February 26, 2021, the Lead Plaintiff filed a consolidated amended complaint that asserts claims against us, certain of our officers and members of our board of directors, and the underwriters in our May 2019 initial public offering and November 2019 underwritten secondary public offering. The complaint alleges that the defendants violated provisions of the Securities Exchange Act of 1934, as amended (the &#x201c;Exchange Act&#x201d;), and the Securities Act of 1933, as amended, with respect to statements made regarding our product candidate, NC318, and the FIND-IO platform. The complaint seeks unspecified damages on behalf of a purported class of purchasers of our securities between May 8, 2019 and July 14, 2020. Defendants filed a motion to dismiss the consolidated amended complaint on April 27, 2021, and discovery is stayed pending resolution of that motion.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On March 24, 2021, a purported shareholder derivative lawsuit was filed in the U.S. District Court for the District of Maryland, Southern Division, styled Zach Liu v. Richman et. al., Case:21-cv-00754, alleging breaches of fiduciary duty by officers and/or directors, unjust enrichment, abuse of control, gross mismanagement, waste of corporate assets, and violations of the Exchange Act and the Securities Act of 1933. The Complaint seeks unspecified damages, attorneys&#x2019; fees and costs, declaratory relief, corporate governance changes, and restitution. On May 17, 2021, the Court granted the parties&#x2019; joint motion to stay the derivative lawsuit pending resolution of the Ye Zhou action&#x2019;s motion to dismiss.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On December 14, 2021, a purported misappropriation of certain trade secrets lawsuit was filed in Federal District Court for the District of Delaware, styled Immunaccel, LLC v. NextCure, Inc., Case No. 1:21-cv-01755-UNA. The lawsuit alleges that the Company misappropriated certain trade secrets belonging to Immunaccel related to a drug discovery and screening platform named IMMUNE 3D. The complaint alleges two causes of action, one under the Delaware Uniform Trade Secrets Act and another under the Federal Defend Trade Secrets Act, and seeks unspecified monetary damages, a permanent injunction and other miscellaneous relief.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company intends to vigorously defend the Ye Zhou, Liu and Immunaccel actions. Based on the Company&#x2019;s assessment of the facts underlying these claims, the uncertainty of litigation, and the preliminary stage of these cases, the Company cannot estimate the reasonably possible loss or range of loss that may result from these actions.&lt;/p&gt;</us-gaap:CommitmentsAndContingenciesDisclosureTextBlock>
    <us-gaap:DebtDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_pb7_--BXykC3HRKC_yHRKA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;9. Term Loan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In April&#160;2016, we entered into a $1.0&#160;million term loan, or the &#x201c;Term Loan&#x201d;. In January 2019, we amended the Term Loan to increase our borrowing capacity to $5.0 million, which was secured by our certificates of deposit, money market account, investment property and deposit or investment accounts. In August 2021, we fully paid the remaining principal on the Term Loan, and there are no outstanding payments due from us. &lt;/p&gt;</us-gaap:DebtDisclosureTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_4_30_2016_fg7QH1JCMUKlmj0t5s8Cog"
      decimals="-5"
      id="Narr_b2wI2p_oVEiBpVzXMzprgQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="As_Of_1_31_2019_mPEpuuDRUUKsmnCtaVs9OA"
      decimals="-5"
      id="Narr_hzfJg41H0kyrHlpBywnDTA"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">5000000.0</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:LongTermDebt
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="0"
      id="Narr_aGfoMj6VmkOmgGzpm9MlEQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:LongTermDebt>
    <us-gaap:PreferredStockTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_tu9Mb72XYECKCqLyF2aZXw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;10. Preferred Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, the Company&#x2019;s certificate of incorporation, as amended and restated, authorized the Company to issue 10,000,000 shares of $0.001 par value preferred stock, and there were no shares of preferred stock &lt;span style="-sec-ix-hidden:Hidden_pC0KVSDrpUCOl6qY3Bjkag;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;issued&lt;/span&gt;&lt;/span&gt; or outstanding. The Company can fix the price, rights, preferences, privileges and restrictions of the preferred stock without any further vote or action by its stockholders.&lt;/p&gt;</us-gaap:PreferredStockTextBlock>
    <us-gaap:PreferredStockSharesAuthorized
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_N-Xwu9MzPEyYzs3y_7w4Sw"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">10000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_BG4OLcWIEUyg-_IdjJ9rgw"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesOutstanding
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_OdYMfDmQlkCoacbnANM_IA"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">0</us-gaap:PreferredStockSharesOutstanding>
    <nxtc:CommonStockTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_cBn1gnHBk0C_Dge6gvnxmA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;11. Common Stock&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, the Company&#x2019;s Certificate of Incorporation, as amended and restated, authorized the Company to issue 100,000,000 shares of $0.001 par value common stock, of which 27,774,536 were issued and &lt;span style="-sec-ix-hidden:Hidden_BEloqN_kIUiSEA3CJtNPlQ;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;outstanding&lt;/span&gt;&lt;/span&gt;.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Each share of common stock entitles the holder to one vote on all matters submitted to a vote of the Company&#x2019;s stockholders. Common stockholders are entitled to receive dividends, as may be declared by the board of directors, if any, subject to the preferential dividend rights of any preferred stock. No dividends have been declared or paid by the Company through December&#160;31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;In the event of any liquidation or dissolution of the Company, the holders of common stock are entitled to the remaining assets of the Company legally available for distribution after the payment of the full liquidation preference for any preferred stock.&lt;/p&gt;</nxtc:CommonStockTextBlock>
    <us-gaap:CommonStockSharesAuthorized
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="0"
      id="Narr_km-JZ1d3-kmv9xL1fnGVyw"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">100000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="INF"
      id="Narr_T_VliNvX5kyaFzNuOJw_-w"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesIssued
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="0"
      id="Narr_tngR-3ltN0yqlK3-EZD6rg"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">27774536</us-gaap:CommonStockSharesIssued>
    <nxtc:NumberOfVotesPerShare
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="INF"
      id="Narr_68NK3t45WEqLEKTNxpKN5A"
      unitRef="Unit_Standard_Vote_NTyCJtIjU0i5jZ9cnBFqVg">1</nxtc:NumberOfVotesPerShare>
    <us-gaap:CommonStockDividendsPerShareDeclared
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="INF"
      id="Narr_dbYE1jABpkyBjmgNvbRC1Q"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">0</us-gaap:CommonStockDividendsPerShareDeclared>
    <us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_sBEaDmbDc0-QSvsE1CvpgA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;12. Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Employee Equity Plans&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The NextCure, Inc. 2015 Omnibus Incentive Plan (the &#x201c;2015 Plan&#x201d;) was adopted in December 2015 and provides for the grant of awards of stock options, restricted stock awards, unrestricted stock awards and restricted stock units to employees, consultants and directors of the Company. The 2015 Plan is administered by the board of directors or, at the discretion of the board of directors, by a committee of the board of directors.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;On May 3, 2019, the Company&#x2019;s stockholders approved the NextCure, Inc. 2019 Omnibus Incentive Plan (as amended, the &#x201c;2019 Plan&#x201d;), which became effective on May 8, 2019, the date on which the Company&#x2019;s Registration Statement on Form S-1 (Reg. No. 333-230837) was declared effective (the &#x201c;Effective Date&#x201d;). The Company&#x2019;s board of directors (the &#x201c;Board&#x201d;) determined not to make additional awards under the 2015 Plan following the effectiveness of the 2019 Plan. The 2019 Plan provides for the grant of awards of stock options, stock appreciation rights, restricted stock, restricted stock units, deferred stock units, unrestricted stock, dividend equivalent rights, other equity-based awards and &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;cash bonus awards to the Company&#x2019;s officers, employees, non-employee directors and other key persons (including consultants). The number of shares of common stock reserved for issuance under the 2019 Plan is 2,900,000 plus the number of shares of stock related to awards outstanding under the 2015 Plan that subsequently terminate by expiration or forfeiture, cancellation or otherwise without the issuance of such shares. The number of shares reserved for issuance under the 2019 Plan will automatically increase each January 1&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;st&lt;/sup&gt; during the term of the 2019 Plan by 4% of the number of shares of the Company&#x2019;s common stock outstanding on December 31&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;st&lt;/sup&gt; of the preceding calendar year or such lesser number of shares determined by the Board.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December 31, 2022, 2,653,867 shares were reserved for future issuance under the 2019 Plan. &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Stock options granted under the 2015 Plan and 2019 Plan (together, the &#x201c;Plans&#x201d;) to employees generally vest over four years and expire after 10 years.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;A summary of stock option activity for awards under the Plans is presented below:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&#160;and&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,112,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,020,718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (105,731)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeitures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (481,569)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,739,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,420)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeitures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (972,545)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,262,179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,790,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2022 and 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The weighted average grant date fair value per share of stock options granted during the years ended December 31, 2022 and 2021 was $3.69 and $7.47 respectively. The aggregate intrinsic value of stock options exercised during the years ended December 31, 2022 and 2021 was $13,000 and $0.5 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;The aggregate grant date fair value of stock options and restricted stock vested during the year ended December 31, 2022 and 2021 was approximately $11.0 million and $13.4 million, respectively.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-indent:36pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;On May 3, 2019, the Company&#x2019;s stockholders approved the NextCure, Inc. 2019 Employee Stock Purchase Plan (the &#x201c;ESPP&#x201d;), which became effective on the Effective Date. The ESPP is intended to qualify as an &#x201c;employee stock purchase plan&#x201d; within the meaning of Section 423(b) of the Internal Revenue Code. A total of 240,000 shares of common stock were reserved for issuance under this plan. In addition, the number of shares of common stock that may be issued under the ESPP will automatically increase each January 1&lt;sup style="font-size:7.5pt;line-height:100%;top:0pt;vertical-align:top;"&gt;st&lt;/sup&gt; until expiration of the ESPP, in an amount equal to the lesser of (i) 1% of the number of shares of the Company&#x2019;s common stock outstanding on December 31st of the preceding calendar year, (ii) 480,000 shares of common stock and (iii) a number of shares of common stock determined by the administrator of the ESPP. As of December 31, 2022, 49,583 shares of common stock had been issued pursuant to the ESPP and 741,097 shares were reserved for future issuance thereunder.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:italic;font-weight:bold;margin:0pt 0pt 12pt 0pt;"&gt;Stock-Based Compensation&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The Company recorded stock-based compensation expense of $9.5 million and $10.3 million during the years ended December 31, 2022 and 2021, respectively. As of December 31, 2022, there was $14.7 million of unrecognized &lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;margin:0pt 0pt 12pt 0pt;"&gt;compensation cost related to unvested stock-based compensation arrangements granted under the Plans. This remaining compensation expense is expected to be recognized over a weighted-average period of 2.6 years as of December 31, 2022.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;Stock-based compensation expense recorded as research and development and general and administrative expenses is as follows:&lt;/p&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,056&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,207&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,288&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The assumptions used in the Black-Scholes option-pricing model for stock options granted were as follows:&lt;/p&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.3 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;79.7 - 81.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.8 - 4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.8 - 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_v5woPB-Gu0eGhZbi1jiBTQ"
      decimals="0"
      id="Narr_Z5_XL8KwT0yEI49mwdoHww"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">2900000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding
      contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2019PlanMember_0wxdrOUI5Uq9n6FoN-ND_Q"
      decimals="2"
      id="Narr_bH9riSdIEUqyFdlKaRs-XQ"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.04</nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_D46SFEZZN0aTWX1Xr95ZPA"
      decimals="0"
      id="Narr_sKPDvQCLpk2P-YseL50eJw"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">2653867</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_QFG6gM-uuk2TLGjd7TLz8Q"
      id="Narr_IuuZ-NJv0U-IRAejv6PtTw">P4Y</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1>
    <nxtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember_QFG6gM-uuk2TLGjd7TLz8Q"
      id="Narr_ZleKKYmFTUGwGKNjq0lDzQ">P10Y</nxtc:ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_Rn3fR5At_ECxiWV8bkez3A">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;&lt;span style="margin-bottom:12pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:100%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="9" style="vertical-align:bottom;white-space:nowrap;width:46.64%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Options&#160;Outstanding&#160;and&#160;Exercisable&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Weighted&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Aggregate&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Average&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Remaining&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Intrinsic&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Number&#160;of&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Exercise&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Contractual&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Value&lt;/b&gt;&lt;sup style="font-size:6pt;font-weight:bold;line-height:100%;top:0pt;vertical-align:top;"&gt;(1)&lt;/sup&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Shares&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.57%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Price&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Life&#160;(Years)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&#160;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.55%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in&#160;thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of January 1, 2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 3,112,376&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 16.95&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10,810&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,020,718&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 10.89&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (105,731)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.62&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeitures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (481,569)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 21.33&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2021&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 14.15&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 8.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,860&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Granted&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1,739,350&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5.34&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Exercised&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (50,420)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 1.32&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 6pt;"&gt;Forfeitures&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 0pt 0.05pt 0pt;"&gt; (972,545)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 13.77&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Outstanding as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 5,262,179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 11.44&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 7.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;Exercisable as of December&#160;31,&#160;2022&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.37%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 2,790,206&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.5%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 12.97&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 6.6&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.35%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0.05pt 0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.03%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0.05pt 0pt;"&gt; 115&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="font-family:'Times New Roman','Times','serif';font-size:10.0pt;margin-bottom:0pt;min-height:1.19em;position:relative;width:100%;"&gt;&lt;div style="background-color:#000000;height:1pt;position:relative;top:0.6em;width:25.0%;border:none;margin:0 auto 0 0;"/&gt;&lt;/div&gt;&lt;table style="border-collapse:collapse;font-family:'Times New Roman','Times','serif';font-size:10pt;margin-bottom:0pt;margin-top:0pt;table-layout:fixed;text-align:justify;width:100%;border:0pt;"&gt;&lt;tr&gt;&lt;td style="width:18pt;"/&gt;&lt;td style="font-family:'Times New Roman','Times','serif';font-size:10pt;vertical-align:text-top;white-space:nowrap;width:18pt;padding:0pt;"&gt;(1)&lt;/td&gt;&lt;td style="padding:0pt;"&gt;&lt;span style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-style:normal;font-weight:normal;"&gt;The aggregate intrinsic value is calculated as the difference between the exercise price of the underlying options and the fair value of the common stock for the options that were in the money at December 31, 2022 and 2021.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;div style="margin-top:12pt;"/&gt;</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_4xX7epy4hkGSbwwR_hzucA"
      decimals="INF"
      id="Tc_VhDxPe6q40SPf5Xkm66vqQ_7_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">3112376</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_4xX7epy4hkGSbwwR_hzucA"
      decimals="2"
      id="Tc_yZo1J17XQ0WlF75VgJ-u7Q_7_5"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">16.95</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2020_To_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_vASUCe3mXEShFcN7roPOFw"
      id="Tc_KOuGXjxAPkebJlLRaog5Sw_7_7">P8Y2M12D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2020_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_4xX7epy4hkGSbwwR_hzucA"
      decimals="-3"
      id="Tc_jocBKNj3SUC6h-QURKSRRg_7_10"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">10810000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"
      decimals="INF"
      id="Tc_B30yLOgv70iB8EEEqT_OPQ_8_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">2020718</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"
      decimals="2"
      id="Tc_Duxd6_jg00il1LRjBFHLTQ_8_5"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">10.89</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"
      decimals="INF"
      id="Tc_jDHiyrmpek2fJFH0YWpyDw_9_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">105731</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"
      decimals="2"
      id="Tc_YQ0ZAoeRqUOBuYhsKSNaEQ_9_5"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">1.62</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"
      decimals="INF"
      id="Tc_4IC-bztxZU2NDr79njJskQ_10_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">481569</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"
      decimals="2"
      id="Tc_pQ3PGO87BU-gx7_8Zy9VnA_10_5"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">21.33</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_I1bCpdmof0eokGR4x8FVCA"
      decimals="INF"
      id="Tc_tImzPuzw9UqzxvRBVevfyg_11_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">4545794</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_I1bCpdmof0eokGR4x8FVCA"
      decimals="2"
      id="Tc_tEZMGtoJiUqnP2xySHuT9A_11_5"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">14.15</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"
      id="Tc_fjR0famubEqEUnl6op7z0w_11_7">P8Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_I1bCpdmof0eokGR4x8FVCA"
      decimals="-3"
      id="Tc_iLVE2O8BX0KG7tIsenPLnQ_11_10"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">2860000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      decimals="INF"
      id="Tc__PVgsvMIJE2uDol4N-E2dQ_12_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">1739350</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      decimals="2"
      id="Tc_I5xZawg83kaldMOZlGOXag_12_5"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">5.34</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice>
    <us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      decimals="INF"
      id="Tc_mtkqgjdCDk6pPdB2g4ZuAg_13_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">50420</us-gaap:StockIssuedDuringPeriodSharesStockOptionsExercised>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      decimals="2"
      id="Tc_BcYU46FShUWhF8fhI8Z2gQ_13_5"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">1.32</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      decimals="INF"
      id="Tc_HvmJJrRaLEamWBDE7v2kDA_14_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">972545</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod>
    <us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      decimals="2"
      id="Tc_EjWlJ1TqAkaX_7RNOyaJrg_14_5"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">13.77</us-gaap:ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ"
      decimals="INF"
      id="Tc_oklcoyya_kiOxxuigsBbWQ_15_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">5262179</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ"
      decimals="2"
      id="Tc_rFbUPD-ii0yxbbrxzfSQwQ_15_5"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">11.44</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      id="Tc_ybIp1HOkaUuaLRas0ilrDQ_15_7">P7Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ"
      decimals="-3"
      id="Tc_zsP30AsUpEyaBKYtxtF4bw_15_10"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">115000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ"
      decimals="INF"
      id="Tc_6bEqMGpuXEKbA_ydNj0SdQ_16_2"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">2790206</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ"
      decimals="2"
      id="Tc_k8RBDenjwkqg8zC1mKa07Q_16_5"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">12.97</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      id="Tc_t0X4oQeZtEyhC-5stbLwag_16_7">P6Y7M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_5_9wx3ocREmKrJcPKUl-cQ"
      decimals="-3"
      id="Tc_h84qdGxjkUezAaTymX__Ng_16_10"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">115000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      decimals="2"
      id="Narr_NSGzRkapbEeEU4zM5a7Cqw"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">3.69</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"
      decimals="2"
      id="Narr_ttGUXNur4U-nJdbyTMx_tw"
      unitRef="Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw">7.47</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      decimals="0"
      id="Narr_ZoFYmUBUzk-pKg0ax78LVg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">13000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"
      decimals="-5"
      id="Narr_HgETemE9mUmKFGKRuDNZ4g"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">500000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember_EyhaGYoguEeYObS_5Cdemg"
      decimals="-5"
      id="Narr_hE_W-pIto0SKKV3xar3wSA"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">11000000.0</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_PlanNameAxis_nxtc_A2015OmnibusIncentivePlanMember__cK_ktWNjEGNUZW0AswudQ"
      decimals="-5"
      id="Narr_m1RU7AIk2kagytRqLguVwg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">13400000</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_KMR2V40rz0WEvFMh7SGH2A"
      decimals="INF"
      id="Narr_LpqDK2ZK2Ui1lfvWGvjE6w"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">240000</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding
      contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_SRji9FsHhkW2MxxpNEJcRQ"
      decimals="2"
      id="Narr_F-aUtjLrWUWOehoOQ5ghSQ"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.01</nxtc:ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding>
    <nxtc:ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan
      contextRef="Duration_5_3_2019_To_5_3_2019_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_SRji9FsHhkW2MxxpNEJcRQ"
      decimals="0"
      id="Narr_i7gP_tvnGEqP4mWK6cXWfQ"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">480000</nxtc:ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_S3g67ITO1UG2PaPwVbTH0Q"
      decimals="0"
      id="Narr_UAKLwH4gnkC6Es3M4clPTg"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">49583</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod>
    <us-gaap:CommonStockCapitalSharesReservedForFutureIssuance
      contextRef="As_Of_12_31_2022_us-gaap_PlanNameAxis_nxtc_EmployeeStockPurchase2019PlanMember_tlc5w1VAtUGsrUcZTfo1pg"
      decimals="0"
      id="Narr_KReF8w3BskOpN03hb3EIWQ"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">741097</us-gaap:CommonStockCapitalSharesReservedForFutureIssuance>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-5"
      id="Narr_0DOPlfGz_UOfAujfAqY4iQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">9500000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-5"
      id="Narr_SvZq03KYzkCPqXC2r78GUw"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">10300000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-5"
      id="Narr_3MyibXrs20WPKEjwl4V5wQ"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">14700000</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Narr_z9ad4k0XSkOafqAu0SbByQ">P2Y7M6D</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_Z-TM3wwucUeNB-PzYIblrg">&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.36%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:24.11%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:73.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:center;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:middle;white-space:nowrap;width:73.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:justify;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;(in thousands)&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:10.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,056&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,081&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.46%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;General and administrative&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,452&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6,207&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:top;width:73.46%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total stock-based compensation expense&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 9,508&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.42%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.56%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.28%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 10,288&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_4Bc0BKCyvkywArPzGa-ufg"
      decimals="-3"
      id="Tc_0pY1iPHv00mpXo1oyLHv-A_4_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">3056000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_ResearchAndDevelopmentExpenseMember_n1J87RqwcE-D74ie7jOgeA"
      decimals="-3"
      id="Tc_lkBb8PaUqkq32YYExYWVnw_4_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4081000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_zu6x2W08xUuSowvqAgpX-g"
      decimals="-3"
      id="Tc_NnK4Wk7dl0S1TeWJvxMEpQ_5_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">6452000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_IncomeStatementLocationAxis_us-gaap_GeneralAndAdministrativeExpenseMember_Ip93Wfm4iEeGxOE28jx6nw"
      decimals="-3"
      id="Tc_J4MKM-lBiE2U-S9zHvh9ig_5_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">6207000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-3"
      id="Tc_Kk8IOW5wV0-nsPRDsYRivw_6_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">9508000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:AllocatedShareBasedCompensationExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-3"
      id="Tc_vJljuV4AfU2D_djNoKZ3IA_6_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">10288000</us-gaap:AllocatedShareBasedCompensationExpense>
    <us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_10U2t6H9O0W05OpHgmK62A">&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;Year Ended &lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:35.86%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:17.96%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:15.84%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected term&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.5 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&lt;span style="font-family:'Calibri','Helvetica','sans-serif';"&gt;&#160;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;5.3 - 6.1&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;years&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected volatility&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;79.7 - 81.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 79.7&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Risk free interest rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;1.8 - 4.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt;0.8 - 1.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:56.72%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected dividend yield&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.93%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.06%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:9.76%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:6.07%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:5.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_gdOPWWwYIk-1_fM2ZbqmhA"
      id="Narr_227dhRzv9UO8VoH_T8ismg">P5Y6M</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1v3p_PfN6ku6GNiQC6D3Xg"
      id="Narr_bJTGn4eSjkyY-GYkulPBVQ">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_YBa26s9G0UemyPzMQSEebA"
      id="Narr_4lkxoxf7wkuzBWiakVDZKg">P5Y3M18D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_6T-mMXX7Tk2kXUXSd6hCrA"
      id="Narr_ScXjmNJcqU-5P1pYgHV3NQ">P6Y1M6D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_gdOPWWwYIk-1_fM2ZbqmhA"
      decimals="3"
      id="Narr_rMvBV6tQhEC-aEqPx3OGGg"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.797</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1v3p_PfN6ku6GNiQC6D3Xg"
      decimals="3"
      id="Narr_DraHlGIL5U2irOLitIfwcA"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.814</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="3"
      id="Tc_x8qGL9ubBU67PLL5m5s16g_5_5"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.797</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MinimumMember_gdOPWWwYIk-1_fM2ZbqmhA"
      decimals="3"
      id="Narr_s0TM4Jik_kqSWB879ykq0w"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.018</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2022_To_12_31_2022_srt_RangeAxis_srt_MaximumMember_1v3p_PfN6ku6GNiQC6D3Xg"
      decimals="3"
      id="Narr_wl5-HV3q1UScjbO4dCLFfQ"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.042</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MinimumMember_YBa26s9G0UemyPzMQSEebA"
      decimals="3"
      id="Narr_nce8ssBcZU62SrTcJqyQng"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.008</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
      contextRef="Duration_1_1_2021_To_12_31_2021_srt_RangeAxis_srt_MaximumMember_6T-mMXX7Tk2kXUXSd6hCrA"
      decimals="3"
      id="Narr_8FxhjnVAZ0WOPEo9GFJ6zw"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.014</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate>
    <us-gaap:EarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_buImYXeflkSJXvSr_QjE1Q">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;13. Net Loss per Share Attributable to Common Stockholders&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company&#x2019;s potential dilutive securities, which include common stock options, have been excluded from the computation of diluted net loss per share as the effect would be anti-dilutive. Therefore, the weighted average number of common shares outstanding used to calculate both basic and diluted net loss per share attributable to common stockholders is the same. The Company excluded the following potential common shares, presented based on amounts outstanding at period end, from the computation of diluted net loss per share attributable to common stockholders for the period indicated because including them would have had an anti-dilutive effect:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.57%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,262,179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,262,179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:EarningsPerShareTextBlock>
    <us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_CFt-abXREUqPxz5EUtHbQA">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80.57%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="4" style="vertical-align:bottom;white-space:nowrap;width:25.99%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="2" style="vertical-align:bottom;white-space:nowrap;width:12.31%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Outstanding options to purchase common stock&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,262,179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.96%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:0.67%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 5,262,179&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.04%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:11.63%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,545,794&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;</us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_03bv1J6VnEK7iPOZioYxuQ"
      decimals="0"
      id="Tc_ZWrNdM_1FEadcQeLjIYdwg_3_3"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">5262179</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis_us-gaap_EmployeeStockOptionMember_eGfbitKLGk6VtkSOTwNSZA"
      decimals="0"
      id="Tc_j0_96JJWz0i7W9zDKGQNcA_3_5"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">4545794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="0"
      id="Tc_cT2CmKSlnE-dYoXBtjpA7Q_4_3"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">5262179</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="0"
      id="Tc_2Qzo8XzWM0SySVP7DSyrvw_4_5"
      unitRef="Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww">4545794</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:IncomeTaxDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_cpqeB6daz0C6TUK8BxkbBw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;14. Income Taxes&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt;"&gt;The reconciliation of federal statutory income tax rate to the Company&#x2019;s effective income tax rate is as follows:&lt;/p&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected income tax benefit at the federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-deductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prior year provision to return adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Deferred income taxes reflect the net effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The principal components of the Company&#x2019;s deferred tax assets consisted of the following as of December&#160;31, 2021 and 2020:&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal and state net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,789&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,862&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Capitalized R&amp;amp;D Costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,389&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,184&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accruals and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,305&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,291&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,788&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (79,724)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57,705)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,538&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (83)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,538)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,538)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (83)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Based on the Company&#x2019;s history of losses, the Company recorded a full valuation allowance against its deferred tax assets as of December&#160;31, 2022. The Company increased its valuation allowance by approximately $21.9 million for the&#160;year ended December&#160;31, 2022. The Company intends to maintain a valuation allowance until sufficient positive evidence exists to support a reversal of the allowance.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;As of December&#160;31, 2022, the Company had federal and state net operating loss carryforwards of $180.2&#160;million and $183.1&#160;million, respectively, some of which begin to expire in the&#160;year ending December&#160;31, 2036. Approximately $157.5 million of the federal net operating loss carryforwards do not expire. The Company had federal and state research and development tax credit carryforwards of approximately $11.3 million and $0.1&#160;million, respectively, as of December&#160;31, 2022. The federal credits begin to expire in the&#160;year ending December&#160;31, 2036, and the state credits begin to expire in the&#160;year ending December&#160;31, 2024.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;Under the provisions of Sections&#160;382 and 383 of the Internal Revenue Code (the &#x201c;IRC&#x201d;), certain substantial changes in the Company&#x2019;s ownership may have limited, or may limit in the future, the amount of net operating loss and credit carryforwards that can be used to reduce future income taxes if there has been a significant change in ownership of the Company, as defined by the IRC. Future owner or equity shifts could result in limitations on net operating loss and credit carryforwards.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company files income tax returns in the U.S. federal jurisdiction as well as in Maryland. The tax&#160;years 2019 to 2021 remain open to examination by the major jurisdictions in which the Company is subject to tax. Fiscal&#160;years outside the normal statute of limitation remain open to audit by tax authorities due to tax attributes generated in those early&#160;years, which have been carried forward and may be audited in subsequent&#160;years when utilized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company evaluates tax positions for recognition using a more-likely-than-not recognition threshold, and those tax positions eligible for recognition are measured as the largest amount of tax benefit that is greater than 50% likely of being realized upon the effective settlement with a taxing authority that has full knowledge of all relevant information. As of December&#160;31, 2022, the Company had no unrecognized income tax benefits that would affect the Company&#x2019;s effective tax rate if recognized.&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Coronavirus Aid, Relief, and Economic Security Act, or &#x201c;CARES Act&#x201d;, and the Consolidated Appropriations Act, 2021, or &#x201c;Stimulus Bill&#x201d;, signed into law on March 27, 2020 and December 27, 2020, respectively, have resulted in significant changes to the U.S. federal corporate tax law. Several states have also enacted tax legislation changes. We have considered the applicable tax law changes and determined there was no significant impact to the tax provision of the Company.&lt;/p&gt;</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_i6pADIKb7EObcWpFoKQZhw">&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="3" style="vertical-align:bottom;white-space:nowrap;width:24.4%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Expected income tax benefit at the federal statutory rate&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 21.0&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;State taxes, net of federal benefit&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 6.5&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Research and development credit, net&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.4&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3.2&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Non-deductible items&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.7)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1.8)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Prior year provision to return adjustments&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (0.4)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Change in valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (29.1)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (28.5)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.3%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Total&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.13%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:3.43%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.48%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.15%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;%&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="3"
      id="Tc_M6fAaGKobkG_wLCHxEFQxg_3_2"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="3"
      id="Tc_estoHLX180CbGcJLPbtRhQ_3_4"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.210</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="3"
      id="Tc_QwGxKLPrkEq7GoFNoU1VTg_4_2"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="3"
      id="Tc_8zED5-1G60W3ihL2yHtWMg_4_4"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.065</us-gaap:EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="3"
      id="Tc_YoPnxbYKCk-8kNpDcjuXLQ_5_2"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.034</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="3"
      id="Tc__4HVWALtqEuLQcv9_NqCNQ_5_4"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">0.032</us-gaap:EffectiveIncomeTaxRateReconciliationTaxCreditsResearch>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="3"
      id="Tc_Z2NyScCcy0mOItFZHCmzqQ_6_2"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">-0.017</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="3"
      id="Tc_upI2z7V3eEaC6iNAM2fHJw_6_4"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">-0.018</us-gaap:EffectiveIncomeTaxRateReconciliationNondeductibleExpense>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="3"
      id="Tc_FTVowp-Bf0eOe_Yg_V2zxA_7_2"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">-0.001</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="3"
      id="Tc_GESx5zD9s0qvvL0BRmS_HA_7_4"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">-0.004</us-gaap:EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="3"
      id="Tc_cvlHLcm80EG8ykiYgPYEdg_8_2"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">-0.291</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="3"
      id="Tc_FwPMP5wL_EmLM-4yhU3kyg_8_4"
      unitRef="Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ">-0.285</us-gaap:EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance>
    <us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_9h3oxQW-7kOixa-BR-6tzQ">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;min-height:0.0pt;margin:0pt;"&gt;&lt;span style="font-size:0pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;table style="border-collapse:collapse;font-size:16pt;height:max-content;margin-left:auto;margin-right:auto;padding-left:0pt;padding-right:0pt;width:80%;"&gt;&lt;tr style="height:1pt;"&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;div style="height:1pt;overflow:hidden;overflow-wrap:break-word;position:relative;"&gt;&lt;div style="bottom:0pt;position:absolute;width:100%;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:1pt;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/div&gt;&lt;/div&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="font-size:8pt;font-weight:bold;visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td colspan="5" style="vertical-align:bottom;white-space:nowrap;width:26.63%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;December&#160;31,&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;(in thousands)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2022&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&#160;&#160;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;&#160;&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:8pt;text-align:center;margin:0pt;"&gt;&lt;b style="font-weight:bold;"&gt;2021&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax assets:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&#160;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Federal and state net operating loss carryforwards&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 49,789&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 44,451&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Research and development tax credits&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 11,395&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 8,862&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Capitalized R&amp;amp;D Costs&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 12,424&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,960&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Share-based compensation&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 4,389&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 3,184&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Accruals and other&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,305&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,291&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 12pt;"&gt;Gross deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 81,262&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 57,788&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Less: valuation allowance&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (79,724)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (57,705)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Total deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 1,538&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; 83&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Deferred tax liabilities:&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Depreciation and amortization&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (83)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Operating lease assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,538)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:1px solid #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt 0pt 0pt 6pt;"&gt;Gross deferred tax liabilities&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (1,538)&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt;"&gt; (83)&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;tr&gt;&lt;td style="vertical-align:bottom;width:71.02%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;Net deferred tax assets&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:2.34%;background:#cceeff;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;&#160;&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:1.51%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;margin:0pt;"&gt;$&lt;/p&gt;&lt;/td&gt;&lt;td style="vertical-align:bottom;white-space:nowrap;width:10.62%;background:#cceeff;border-bottom:3px double #000000;margin:0pt;padding:0pt;"&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:right;margin:0pt 3pt 0pt 0pt;"&gt; &#x2014;&lt;/p&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_fj2eiWSBSka5IXMG5rhfbQ_4_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">49789000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwards
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_rSjnlLpq_kWBXdyot5Uw2Q_4_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">44451000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwards>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_frjHq8O8fkSGIPCeoav6pQ_5_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">11395000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_epSaKpQ7QkibWmN9FiLqgg_5_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">8862000</us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch>
    <nxtc:DeferredTaxAssetsCapitalizedResearchAndDevelopment
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_4lbDd141_k-fZ4kMoe5B9A_6_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">12424000</nxtc:DeferredTaxAssetsCapitalizedResearchAndDevelopment>
    <nxtc:DeferredTaxAssetsOperatingLeaseLiabilities
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_ZHpb7Kqx1USog_Hi8h_TnA_7_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1960000</nxtc:DeferredTaxAssetsOperatingLeaseLiabilities>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_w1A9YNvyhkWoKj2ieqoqRA_8_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">4389000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_NseEpzBb6Eagige0WtW0qw_8_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">3184000</us-gaap:DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost>
    <nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_ExJDXgOIxE-Mu3-bWFCUtg_9_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1305000</nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther>
    <nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_U7VtePIQxUGy3RoTTDXMpA_9_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1291000</nxtc:DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_KqRoyD6eZEOys6U_hOmhQA_10_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">81262000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsGross
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_DjiJQWexjky0jEy53TxaMw_10_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">57788000</us-gaap:DeferredTaxAssetsGross>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_6sgTtKfzGEuhk_mN90UvSQ_11_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">79724000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsValuationAllowance
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_h2ISXWVfs0ivyvL38jU-lQ_11_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">57705000</us-gaap:DeferredTaxAssetsValuationAllowance>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_mYOY4TbTdEy8BiqHvix2ww_12_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1538000</us-gaap:DeferredTaxAssetsNet>
    <us-gaap:DeferredTaxAssetsNet
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_9uVcB8CCN0OyaqAz7RNtxw_12_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">83000</us-gaap:DeferredTaxAssetsNet>
    <nxtc:DeferredTaxLiabilitiesDepreciationAndAmortization
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_4yvR1zp7GEyHAVTxzLr_fA_14_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">83000</nxtc:DeferredTaxLiabilitiesDepreciationAndAmortization>
    <us-gaap:DeferredTaxLiabilitiesLeasingArrangements
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_D6SQ5tjC1kmzhkRrD2wyCQ_15_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1538000</us-gaap:DeferredTaxLiabilitiesLeasingArrangements>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-3"
      id="Tc_2nPm1sQ9N0mskUcCTl7EUw_16_3"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">1538000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:DeferredIncomeTaxLiabilities
      contextRef="As_Of_12_31_2021_N14_jSJprEm4uYHeqAkHQg"
      decimals="-3"
      id="Tc_8QfcYD2cFEGwEF0oZt1Gpw_16_6"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">83000</us-gaap:DeferredIncomeTaxLiabilities>
    <us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-5"
      id="Narr_DCprLUgMB0uV8Mo744HbYg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">21900000</us-gaap:ValuationAllowanceDeferredTaxAssetChangeInAmount>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-5"
      id="Narr_eKknkjR01UKIjLp1n3WK8A"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">180200000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsDomestic>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-5"
      id="Narr_65pjldn2NUmPYYYQOkit1A"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">183100000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal>
    <us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-5"
      id="Narr_d4i1s_m7qkGaPwjZ057ZQg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">157500000</us-gaap:DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration>
    <nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-5"
      id="Narr_9sk9Vmfa6kKjih_odO4Qyg"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">11300000</nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal>
    <nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="-5"
      id="Narr_UlWHD7E3UE2OyQAeF1K82A"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">100000</nxtc:DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState>
    <us-gaap:UnrecognizedTaxBenefits
      contextRef="As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA"
      decimals="0"
      id="Narr_t71WrZT_KkaJuyYlX33eEw"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:UnrecognizedTaxBenefits>
    <us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      id="Tb_AkzoaMvbdk2gycJw-WUwgw">&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;font-weight:bold;padding-left:54pt;text-indent:-54pt;margin:0pt 0pt 12pt 0pt;"&gt;15. Employee Benefit Plan&lt;/p&gt;&lt;p style="font-family:'Times New Roman','Times','serif';font-size:10pt;text-align:justify;text-indent:36pt;margin:0pt 0pt 12pt 0pt;"&gt;The Company sponsors a 401(k)&#160;plan which stipulates that eligible employees can elect to contribute to the 401(k) plan, subject to certain limitations, up to the lesser of the statutory maximum or 100% of eligible compensation on a pre-tax basis. For the year ended December 31, 2022, the Company made matching contributions of $0.3 million. &#160;No contributions were made for year ended December 31, 2021.&lt;/p&gt;&lt;p style="color:#ff0000;font-family:'Times New Roman','Times','serif';font-size:14pt;font-weight:bold;margin:0pt;"&gt;&lt;span style="visibility:hidden;"&gt;&#x200b;&lt;/span&gt;&lt;/p&gt;</us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA"
      decimals="-5"
      id="Narr_1c15gSyqyk21xtKiHKN2tw"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">300000</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
    <us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount
      contextRef="Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw"
      decimals="-5"
      id="Narr_H3kIVrhm7EGZ3OeyrYo43A"
      unitRef="Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg">0</us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>74
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
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M=V]R:W-H965T<R]S:&5E=#(N>&ULM5AK;]LV%/TKA%?L 3BQ2+U3QT#J=NB
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M$.+(W0WEKJ'%MK[DNQ5:BZ)^S!@%V,8 _M\(H9\;YMZPN2=>_0M02P,$%
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ME\]L_95N$O*57LQR4?U%ZSHV]"P4+X5DQ:8Q$!196?^2]\U M!K@X$0#=]/
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M2NVJ7MS)U'7Z ^'SK!0HIS.0=*Y"V):\+GWK&\D65?7XRB34HM5E2DE"N0J
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M ^#O"RGU]H?YP.YV>?(?4$L#!!0    ( "B%8E8)S9]4) X  (TE   8
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M1D1;\@Q97 2Z)+ +HLN/70"-")SKI<61XQ8OA1;"&".N*M7IZ.QT,II,)BJ
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M;39\-]3G2;B#7S@SEP^-(21*L.?*+[\=H*@#TD=J6UW ?24>+%O?P9IG!NF
M8D]#Y8(N!)6+RLV($8?E-E;=H7 @54=J03'4L ]I#N5M(55!__9%%ZD$[]5!
M]%LS1WFM4=60%$NC'1(BE !T>K)#O.>47M4T^0*E\62>GPK9LKWQ)',E?: J
M328-F-O5J5_%2A=L/EB:*%>H8DNW;D;Y_5JZ'AP+)7-("L[W27Q^9FDJ*=VE
M)<^/E A'YN2A<;9L!A4Z"/0%%KSB-2)%_*%I&=?CLXU44((64]+9!N[H:I\O
M#1/Y3901/GA[;6 $_-UY.&NTR(,;6KUVON)1%31=X7I?*.Z&QXC'''SD;0J4
M8'@(]-NY# M92Q+%_2A7G0 \00K%"8Z*>L^F=W9(!%S7!CTW<2.8H)6%;FFE
M:3RHOT[M=ZC<.MOD<26H<*=Y$+7#],XBGQ1DF#*4%UL:JO/EO=5^8TN[D"M^
MTB)/.?K>8:#EPG&N='ZM_<Z;U:VN@=^-0$(RQ;8_8,&VS\?<F#O*E[9_@??0
M*RKT'0W-U+J70V-U8Q9=7OR[H6YJA49(73;R&QA^7]U5Q4$>%AHO#:*0I(6=
M]XPH&T@=9&9D993=TED%>2$AB=F;2.\.^SWHQ?*=MI7,?:CYHUFRW$,@</FV
M)$[I2_02KN'VKM:WE"N<[RX=XA(]L@"B5CPNICM,34N A!BH @6DUC*];N07
M70UU8HA/1E_/R^*KQS4 ^9NU<-J@>R*ITAQ*HY+CGP-F. M+MI5:3RX;FB:#
M4X/@:1\$Q_M^4G$T^(D,92[^(1!Y"=6!_%JFN]K]UNB-_,2F?UQ^J/1!4^)#
MN6CF6#H9GYT>R(0@?XENQ3^XF;D87<T?Z7<%QM,#N#]W &?Z0AMTO\!Z_1]0
M2P,$%     @ *(5B5GN H1\7'   'E0  !@   !X;"]W;W)K<VAE971S+W-H
M965T.2YX;6S-7&V3TTB2_BN*WHU=B'";IF%>;I@AHFE@EXV9@:/IW<^R5+8U
MR"I/E=2-Y]=?/IE9+Y)E8.-B+^X+M*U2559F5N:3+^4?[ZW[Z+?&],6G7=OY
MG\ZV?;__X=$C7VW-KO1+NS<=/5E;MRM[^N@VC_S>F;+FEW;MH\N+BV\?[<JF
M.WO^(W_WSCW_T0Y]VW3FG2O\L-N5[O#"M/;^I[/'9^&+]\UFV^.+1\]_W)<;
M<V/ZV_T[1Y\>Q5GJ9F<ZW]BN<&;]T]G5XQ]>/,5X'O#/QMS[[.\".UE9^Q$?
MWM0_G5V (-.:JL<,)?UW9ZY-VV(B(N-WG?,L+HD7\[_#[*]Y[[275>G-M6W_
MU=3]]J>S[\^*VJS+H>W?V_N_&]W/-YBOLJWG?XM[&?OTR5E1#;ZW.WV9*-@U
MG?Q??E(^9"]\?W'BA4M]X9+IEH68RI=E7S[_T=G[PF$TS88_>*O\-A'7=!#*
M3>_H:4/O]<]O1!B%71<WS:9KUDU5=GUQ555VZ/JFVQ3O;-M4C?$_/NII/;SU
MJ-*Y7\C<ER?F?GQ9_&*[?NN+5UUMZO$$CXC02.UEH/;%Y6=G?&FJ9?'D\:*X
MO+B\_,Q\3^+NG_!\3_XCNY>YG\[/C=/T@]^7E?GIC(Z+-^[.G#W_RY\>?WOQ
M[#.4/XV4/_W<[/]+RC\_]^6R^/KIBQ>E;SP&OL,NN[[DT_9A:^C$57:W+[L#
MQJ^;KNRJIFP+3T,,G>O>%TU7M4-MBEY'#_B2IL+G:WEWR5/IA[_\Z?O+Q]\]
M\_.S;<L[4ZR,Z0IB^+YTIJ8%>%Y7TVA#1ZO?%K==T].3&[SGBXWIC"O;]H!Q
M9H\G9=KDWA&%S;ZE@0]X[6^?Z7]_N[IZI]3H?P^7Q55W@*$RSF U6IOVX4W1
M6:S4VZ+<[XEIY:HUQ69HA";BW<Z M_2<W\4?S(^AWUK7@)^T+:Q7E+1Q(JW6
MJ7-QT':ZNG2U)U;5+"X6PX3JJYOK"=$%O38_S^V^)@X=SW [G4'E]3J*9':Z
M%Y;^F\[V^NKFQ1$7;XEE-.<KWS<[EA$40"0JFZ*')[3I2-C,-F=^'QI23K*;
M'3D:# :3=^5'4YBX"AA1>G).>RQ"\MJ6?5&NU^0^1!X[44\BQ+K>1"',DL*3
MY>K/.L"Z[#^W:+9>7"<L3-NFH49G;YMRU;1-3T=PP>/KQE>M]8-C[E66!8"M
MSK]4E+(,"UE%>'(KI^AQYLYT@^[#?"*DX UTU/$;>^,:6Q=[L0NFI@/2DDX/
MFRV<\4#+T!/RGIZH'=J:=K"&_J^=W='[-F?4(I==;6D18BB=];8A"D14?JBV
M.@6.GR<X@$E7IL ,CG:U+*Y+OV5:^8]7I!9W9<N[S(P,>.>;VCC:5ML66_+K
M9![:AD9#Z'=$E'"&-:PD?73-ACC78J&!3NQ!^.D,+2W^CQA"-N2(Y_O!55N"
M%-!&HK,"4281-3)]!#7VUC=0<S ,0\DZD9%NB#A214)KU4>2^*+P]\;L@Q7C
MW1(5YD#4N8^$\H*=56YDZQ5D,D7R-2@E.;N^^8,^5-;WBV+?#AYONX&5GWAJ
M\/7]MB'&DVES]I-J];IL7$&3#F99O*=!KJDP)Z_WIBNNA@T!&_CPQXO<U!?K
M 89X7S9!XX J,SM,+%Z5+9]NXMZ?+Y=/"1*UK=H$\.7/WRPOXG=$X:YH+4GH
M ::#A;F\>/8!W_Y,W_+GQVRW:5^JBR(Z,LK[\@ ICPDD89'B86C8$PMB:UHV
M!W[8XXR$XQ176A:_,._9\M^8"DJ"(YA]Z].W2:RLB)[GV]@[XSI1?[/JL_$+
M&N9H6>C4RG:U&A4Z^M5!O@AF9S>['(1>M60DR&M \/3-7=FT&'9.)_G<DW(L
MU%#Q(5O(*Z5SC2A*$C>&U 9\)TA!9^^ S51J$NA(D4VJ2(CTP3<DI=*-")'#
M$20L,0F.RO($HS+V_$QFH"TN,PO6="2C(3H&-F]$Y[G0N6W(Z]/A.P$O]@ W
M!_AF.IG*G -;@Z/S#T/KU)SI^0=M>$;+TL$K#H;V28PANLDR]:1N?6%*.C-B
M4:'?V.58TPSHY,.$;X-\JN@ V1!,:<G67YD#B3ZMC\@%'WFZ#N.BU4_3C*1!
M;]]O#0UPDU&J,FHDH0)!7UC,@V?HH[LM*'P4MTUJ^":M1.?9[AC].%-90IBP
M,[1>1ZQQT!VL'UU.9UC*&:7!V1!<Z"@8;?G]K6UKL'-#9D,=GO5>=3Q.IJ(A
M2S;LAI:MG>5MPET[LT7$>6<"A0\PQ4,^%L0>QB"&1Q)K.Z:*8K3J(Y8FCZ$:
MQ%:U5^4:VU&\,3G!X$)9_T8VD<: A?I&%#91M6N&7805SH0G</KBC1G0B/L!
M?(=)SF<INV2SH083 Z! G*V8,$.VOP#K%T%OIL<D0PE$2R[IH.+'AWFLYL F
M(J$CFS-B$#90#$G2$$K!_I -O4U69Z2TTS<0J.#A.2&&[IQHA]UTQ+ WA*UH
MC@JA4&XNU*P!>LV8SP,0",5M<[QA6:\X-FI&1E%\_1P9"\$P<^O0%/?T1T_G
MH[;WO&-8@("/ZHD-+DEL]SD) <0)=@LG'U.:<YZP\2,=P"&DD^1Y,GI*>VL<
M'SP"+&YCEB< TYHLH75A+IQ%K.-C"%E%JY,Q6\AFL.R$06SS(O4+DB/-WDH<
MJ2NPW6U6 ]M/Q%93\:GGP0$=*Q*1TVU:([A83*LH)8&@#5E1$-CL)"A5S!2U
M@'<3A (TP.$F8SO(4K!91G@^_J^P=:V$<W14.*$&AI!C]X/ NKVAOQ=X@_8(
M-SFB$3:/04>@RF*V%J0$^0:,!SA.'+([QH8:Y(Z%5K;>9FXF')NFYY#4DE%H
MFX^&4 AO#'";838]OR=\!1W6N(HEY@U]5R;>$/>MDYBV G0Y!*>58\,/0<QC
M(7D+..7'/LO3WJ%#"B.B+]P1V99"BVM+O(0K#J;QFB@C8M\W_F,6F^:P@/>S
MI\",YN,4 #$844=NH.#_\YE9H2J9VF'J6;16A3CC\Y >\+9G7Q4Q_=Q+0$9P
MY&SY:\Y>C'%.TP]B!UE Q&-3:U*#GI*G)_;\:]NT$5OY$$R O6L8%?.I,IAV
M^B+IP(YH&QOM^?A+%,</J]\X@K5T: </5)1S2V$)@Q#H__@I:;FE304G#9.P
M,XZWN2H[1#=Z@HC3VV8_YN9?<T 4$)R0/P(OD*AQ8'O1'_9B(8X=LA\$OX+2
MV^7-,@/@"Y86 ^P E#(A*!1+*YYO7%F;N,^R%[M*;^W;$K((T81H5Y>C.-:&
MD6*#)*):5@65+ARC =Z=+&CTZ7>DEG;P,3S _(MYS9&5LA@C[HZ8@P XD.^1
MSZ$-+(O7.,?_#'8Q'; WV0&[NKDN/M@]'=KO+R\6^2N_F!+ZQ6L)=G_,GO/R
MV7\/-C-Q:L2;D+[7[Z<!A:8X$&:G#,<R1 4Z\YMN/_0* ,2HZ<HT/3^1C ]Q
MSC0\IB;C5O5T&+!6ESZMD,R%?U:'36[@]QFJ%PEPN9CL.32(%4G1[A*!3Y3
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M:-:TW6>*.EM<*5$EJ3C:K]\=*<E*XKH9@F(;MB\V7^X>WAV/CXX\66OSV>8
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MT;]?$5\6W'(>VXZ+\B^<= Z"E25W#)@@@FV]G:HJ7@#Q+6*"5"X=%CS@F#5
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MY*TC4V_!K*"6NO\5K]MSV -<)!\ LBT@"[K[0D'EK2 QGUK3@?79S.87P6I
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M6?& 1^L3^'EI#.TVOL#PES'_"U!+ P04    "  HA6)6T=?PH&H"  !^!0
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M@D3K WB^-(;V';_ >.5F?P%02P,$%     @ *(5B5I!6;TQ[ P  \P<  !D
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MV0>%O!''YU$<S.*I<\-4)!DGVW1<]'WWIIU%&A6- ,[.3_DX8M8^J6MZW89
M*N 2< V<7"A#_I;S3P+NDDJ2@V>-DU;0IXN!SJ^6*D/5E,7*SK><%Z)L/;)5
M>NN3;O@MH54'#=Q")-*I65-5.Q)U1^+0!I1')5%H_73V,#BQ4A*#"#.!!/3
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MN9(6X/U2*=,,Z(#V*^C57U!+ P04    "  HA6)6JR2QU%P#  "J"   &0
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MI@"7<.*"X2_V4N!K0GCZ_-]AZVI)#)"J<.(5#"''[GI!OEM#?\_P!JT1;G)
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MY99B)T9*4-+AKZ2*+2W*(PG8K8VQO,Q%WB!*534G3J^K[9";?T]1FX>90OX
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M)9A+6_3@9XK1LB</P;FD^A=0@]IK2;EJMD[2-*D$2QBH"0G]H+&7.$D=*9"
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M)0W.8/4VQZ$7E%7 ^[64YGBP#[1C]/QO4$L#!!0    ( "B%8E8Y1G$A30,
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MLG3=K\F,WE>HG0#MIXI:><<X ^V+;?X+4$L#!!0    ( "B%8E;B&5#.[0(
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MZL+<R\TGV.8SM'BI+'3S)9O6-XP=DM;:R'(;C Q*+MJ5O6SKT M(_'<"Z#:
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M--[7[##'"S)(LP#_KX30NXG9H+UR+WX"4$L#!!0    ( "B%8E: <H()^P4
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M+C\(NBL>4'VB0M"L>+LED=QAJ %R^892\?)!/?-:/Z<]_Q]02P,$%     @
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MT-@,Y<,U]K<@C0%^CX70AXG9H.J8)[\!4$L#!!0    ( "B%8E9:LLZ:$@4
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M\(/IJI8=>S722 QBEQA[[]9(5V/ =FU#.U<8#<-V[M=(HQV(73OLNV,C)JV
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MBC/)!1@;)6"1%RYVR5'A?C@X()<<NQ>'B9M=VK)+.]E=@>Y^B#X>ZI[N-T(
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M*)+$@F^1,&BM9AHV3,O6]FEEEGVAA!ZEFJ>2N8X9A( <+13/[M'[%!2A3'Y
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ML1UT0W.1</0YCR'>)S!E4DUFSBZS*V>0,81HA%S[ CF6XZ '*@"]12;B"6;
MZT=/GM?'L]I'$8;#A#?X&=FNXK-GK_'M^> V%7+U!NX1%1KU%::"C_OAZMJX
MY 6.8&'(>X$#VX 1O'MC>];'/O?.21:>B6S/MG%CVWB(?6<;5[9=H+S,EL 0
M7>W*@TN14$9^=X]J96E%[6EJ=7%N MNJ_^;FINW7T9'A,9%[2B>-TLD)2@O,
MT :G):!""M9JT9_6P>R36_%/6ZE9(\NR.U*/B@I?B]J3Z#42O1,DUB4DG)?]
MY?->6.WXOC^>N%Y'4E^@-[5F,[^C:C"]_SS)?B/>/UV\_ 7G N<QR==]#OC'
M.M 7V.O RT![,O&LB3?K+^VT43<=5/>]^3(W\HKG>Z=67?I]ZJ8O<^G(&MSS
MU&OL3&1[]LP:>V:#]H1D0V+(8RZ;F2B5ML2O?LT5H=_^ CON#&YYJCMG(JO<
M,5N=3 9LK3M"CB):YJ)J:IK5ING\I'LM\U]XU;'>8+8F.4<IK"34&OGR9F)5
M%UA-!"UT7[2D0G99>IC(QAF8"I#O5U0>OWJB-FA:\> O4$L#!!0    ( "B%
M8E;/5QIPE @  (]"   9    >&PO=V]R:W-H965T<R]S:&5E=#0W+GAM;,6<
M:X^C.!:&_XJ57:VJI>T$&PA);U6DJH+9'6EZIM2M[M%^=!$G0<TE"TY=]M>/
M#12.P7'"Z-1N?^@BQ'YMWH,O#W:X?B[*']6.,8Y>LC2O;B8[SO>?9K,JWK&,
M5M-BSW+QS:8H,\K%QW([J_8EH^LZ4Y;.B./,9QE-\LGJNC[W4*ZNBP-/DYP]
ME*@Z9!DM7^]86CS?3/#D[<279+OC\L1L=;VG6_:5\6_[AU)\FG4JZR1C>944
M.2K9YF9RBS]%GB<SU"F^)^RY.CI&\E(>B^*'_/#S^F;BR!JQE,5<2E#QYXG=
MLS252J(>_VE%)UV9,N/Q\9OZ3_7%BXMYI!6[+]+?DS7?W4P6$[1F&WI(^9?B
M^5^LO2!?ZL5%6M7_H^<VK3-!\:'B1=9F%C7(DKSY2U]:(XXR8/=$!M)F(+T,
MQ#N1P6TSN/T,ITKPV@Q>/X-_(H/?9J@O?=9<>VU<2#E=79?%,RIE:J$F#VKW
MZ]S"KR27-\I77HIO$Y&/K[[R(O[Q\4Y8O4;W12;NOXK6$?R(ZJ]0L9<?*W05
M,DZ3M/H@OOGV-417?_UP/>.B!E)G%K>EW3>ED1.E88(^%SG?52C*UVRM"\Q$
MU;OZD[?ZWQ&KXF?ZBASW[X@X>&FJCSUWR.(I<K',3H@A>WAY=FS('EV>W;%X
MX7:Q=&L]]U0L=[1DR!#+Z$4>,_1KP=$7%A?;//EOW_W&[*8 SUR [+0^57L:
MLYN)Z)4J5CZQR>IO?\%SYQ\F[R'%0DBQ"$A,BY+71<FSJ:^^Y647 A0?ARDN
M*FX*BE5O;% :L: 6DZ/(TPI[@2/_7<^>C@V'+#4"$M,,]SO#?:OA6E-@;5-H
M8U"?V[,R*8S-P2H\UGE[+0EZ9;2L4("RIH><HS5]K4Q- ;)6$9"8%IEY%YFY
M_9H=[*.'E.8F[ZU9QWH/*19"BD5 8IK_0>=_8!TP?CUDCZQ$Q0;50X?I9KL+
M(,, *19"BD5 8EH8%ET8%M9F\-N!5YSFZR3?(LH1WS'TR+9)GLL35TF.JCHZ
MIOG6G55Y;'@:L?G1V.#YGA\LO=[0,$SG8DS<8*ZGBX JIYFZ[$Q=6DW]9TES
M+D;8,_Y91<;ZMQSX@@-WZ?K]H7683LX  [SH^0=4.<T_["@R<*P.1B^LC)/J
MO(=VG;$FMFK'[GST'8_T332EPXX?N+CG(E3U=!N/  M;;10\NV$)/PCMLT9:
ME48;B8<&+0,B6G3?24-";X']^;+O)%#]=">)<I*,[2=9?O[NM(J.-I4,O/+)
MG.!@V3=UF-#8F4:&A/W>5/=+X2"V<LQ; Z:/*1OC%R@#MFI:7Q<L16\W[_L%
M"GA0:KKS"O&P9YU8_5X_GQ(]Y^T3*^F6H;>^%#V42<R,MH-2'JA:"*H60:GI
ML5$TB.V@=7:VM2[25)*8P,*FG9B;"2@;MFI+#<NG>-!3&Y+-ITN_WZ6\!]1A
M1778CG7'4Z\+S02%O58-N\>=]-3MSV)-R; S70Q&O?= -*P8#5O9HS<-N]!/
M4&IKU72CIB[I^VE,-B=].]\#M;!B+6R'K78Z-LY.4,IJU72?W&D0]/TTI"/"
M=[=OZ'M@%E:<A>V@99F57>@N*(.U:KJ[>.H-6O_RDAXW,B73>EQ]U4+!%;D(
MKDQSL\M<L^N/=:U5TRZ33)?]6Q*TT A*30^! C."QTW2OC"YLBKOX_LBYR6-
M^8&FZ)=DP]#5O^7#V0_H5L3H=KLMV99RAGX6J9*\2F+TG:8'X[2.@"(=J%H(
MJA9!J>G15'!(+H=#V8KJI^GFE@,*A&>J%5S^6/^,TJ)5PHW2::'H0B'R5B5,
M#%)Z&!1SDC_-G):(@"+GF1K.1T0$E$FAU/3(*"8E]G7'2[G''"%0.B7#14BR
MF!O6( T)L;/ PY015 5U<Q54DM%0V1O.S;:"0F2KICU_QK[!5?\R^R-#PH']
MNF&*$8F=$<_/?\R&@8)BJQ:<-0QTQ0]*37=>\22Q\V0W[:'MM&<K<5WT@6)"
MLZ%)B9[D7$;-/N7R8*5M!=HV?&^,#RAXMFK'LU)WVG\J'1I2!5,OZ-_+[X&=
M1&$GL6.GFC0FW:2Q,7I@+WL#?J/!H"C:JFD-P#7<_\-DOF'+2 15.=UC1:+$
M3J+*8^,M;;03E#U;-;T_<4R;:TPI7<_HZ7LL KJ*4UT[I_Z6Y<GCH1*H$[-<
M[ND\N5_#+C1Z[QBD6@BJ%D&IZ2%1W.K:N;79ESG<YF<,"BA^@JJ%H&H1E)H>
M%(6?KAVJU%::9FD-M86LT:8H45)5!RI:$#KD:Y%*SG;VIYK1<#F0+ T=P[V]
M0J.# :D60:GIP3C:!VM'O-L\ET]NDCPNF6@FX@#E>GQ.A.>*UH_=9%=GG'ZV
MY6+O*#K.U/'ZH8'=^0J[]?4]*-15%.K:*;3;\H<$+=6[ME&4[=/BE;%VP_G#
MH8QW,FHG!QI0%@55"T'5(B@U/58*:ET?;J !)5E0M1!4+8)2TX.BP-FU@_-W
M5G'YE.'TIF6[P.A0V*OC-4_3C+:#4C.4FFZ[HF;WW"KL/BGIF>WB=HW1SMMK
MA!V+]:![8Z'4=.L5.KMV=(:;6H&RLSO<!4OFOKN8]Q?-0(N-H-3T8"C&=NV,
M_>=&;%#*!E4+0=4B*#7]ET6*UCT';,3V0'D=5"T$58N@U/2@*%[W[!N !_V7
M[++,3_?L2J-C,MS7ZRW]16__2 A:: 2EIINM.-S['W&X9^!PSX#AAG2!AYW!
MU@E[O4>[_!Z [2G ]OY/@.V9 1OW30<%;%"U"$I-#\W1KTOM@/V9OB39(1-X
M/0A1VR+H$TW2>N%M;)/PAOW)PM0D0)$:5"V"4FNB,SOZX7W&RFW]QH,*Q<4A
MY\UOV+NSW5L5;NMW"?3.W^-/4?-N!"73O*KA,RVW25ZAE&V$I#,-!'Z6S=L/
MF@^\V-<_[W\L."^R^G#'J(BE3""^WQ0%?_L@"^C>0;'Z U!+ P04    "  H
MA6)6-)O\D?$"   R"P  &0   'AL+W=O<FMS:&5E=',O<VAE970T."YX;6RU
M5EUOFS 4_2L6JZ966HLA"4FZ!*E)UFT/E:JFW9Y=N FH@)GM)-V_W[4AE*04
MK1)]2?QQ[^&<R\&^DQT73S("4.0Y33(YM2*E\DO;ED$$*9,7/(<,=U9<I$SA
M5*QMF0M@H4E*$]NEU+-3%F>6/S%KM\*?\(U*X@QN!9&;-&7B[PP2OIM:CK5?
MN(O7D=(+MC_)V1J6H![R6X$SNT()XQ0R&?.,"%A-K2OG<NY0G6 B?L6PD[4Q
MT5(>.7_2DY_AU**:$200* W!\&\+<T@2C80\_I2@5O5,G5@?[]&OC7@4\\@D
MS'GR.PY5-+5&%@EAQ3:)NN.['U *&FB\@"?2_))=&4LM$FRDXFF9C S2."O^
MV7-9B%J"X[V1X)8)[G%"_XV$7IG0,T(+9D;6@BGF3P3?$:&C$4T/3&U,-JJ)
M,_T:ETK@;HQYRE\J'CR=S[ 0(9GS%-TAF:GO.3%;ID8A">I;\*S'0$X7H%B<
MR#,,?E@NR.G)&3DA<4;N([Z1+ OEQ%;(43_)#DH^LX*/^P8?QR4W/%.1)-^R
M$,)# !O%50K=O<*9VXJX@.""])POQ*6NVT!H_O_I3@N=7E7PGL'KM16\I:I-
M)2L0^\V(^D._E#D+8&KAERQ!;,'R/W]R//JU26Y'8 ?B^Y7X?ANZ?\\52X@T
MGGM?"0K<H<'51]/6'P_H:&)OZ])>!SG4';U$'7 >5)P'K9SOL I,!!%!0^,!
ML<63+\=S3#6Q;$5Z[XOJ".Q M%>)]CIWJ=>E^([ #L0/*_'##W)I@>O5#-BC
M ^_(I:^#^G3D-)MT5%$>M5+^#AD()*T]RD*\)V*I!-,W9!/-5JSWOJF.P YD
MCRO9X\YM.NY2?$=@!^(=^G)WTP\R:@E</RJ]_L ]<FI3E$N'1U:U:]U'"F)M
MFC*)5#:9*J[I:K5J_*Y,NW.T/M,-H>EJ7F"*;O*&B76<29+ "B'IQ1#/1E$T
M:,5$\=ST.(]<8<=DAA$VM2!T .ZO.%?[B7Y U2;[_P!02P,$%     @ *(5B
M5K"9TU=$ P  +PX  !D   !X;"]W;W)K<VAE971S+W-H965T-#DN>&ULK9=M
M;]HP$,>_BI5)TR:M39SP$#J(5&BK[46EJM6VUVYR@$429[9Y^O:SG1 ("RFT
MX07$CN_O^]F^XSQ<,[X0<P")-DF<BI$UES*[L6T1SB$AXIIED*HW4\83(E63
MSVR1<2"1,4IBVW6<GIT0FEK!T/0]\6#(EC*F*3QQ))9)0OAV##%;CRQL[3J>
MZ6PN=8<=##,R@Q>0O[(GKEIVJ1+1!%)!68HX3$?6+;Z9X(XV,"-^4UB+@V>D
M45X96^C&SVAD.=HCB"&46H*HGQ5,((ZUDO+C;R%JE7-JP\/GG?J#@5<PKT3
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MZX)YG*L;'7 ]0+V?,B9W#3U!>4<,_@%02P,$%     @ *(5B5A$G!=#- @
MV@@  !D   !X;"]W;W)K<VAE971S+W-H965T-3 N>&ULQ59K;],P%/TK5I 0
M2&QYM$W92".U'0@D!M,JX+.;W#36[#C83CO^/==.&MJMK4"JQ)?6CWM.SKF^
MSDVRD>I!EP"&/ I>Z8E7&E-?^[[.2A!47\H:*MPII!+4X%2M?%TKH+D#">Y'
M01#[@K+*2Q.W=J?21#:&LPKN%-&-$%3]F@&7FXD7>MN%>[8JC5WPTZ2F*UB
M^5;?*9SY/4O.!%2:R8HH*";>-+R>CVV\"_C.8*-WQL0Z64KY8">?\HD76$'
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M3+5$P\-$]H)?ZYIF,/'P!FM0:_#2ER_".'AWR.69R/8\#WO/PU/L^YYU[YG
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M'G_:5*0:TGW1"Y"0"60<78A>QM(%L,<-XZP"G8#$DW]ELW/8;&USV"H.^O;
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MOGI( @  H04  !D   !X;"]W;W)K<VAE971S+W-H965T-3,N>&ULK53;;MI
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MD#(97*-F'09"V%C5^IY:*HL=ZI<-SE#0+@#O5TK9_<8EZ*=R^0)02P,$%
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M;64O=&AE;64Q+GAM;%!+ 0(4 Q0    ( "B%8E9CKML1FP<  /LQ   8
M          " @0T(  !X;"]W;W)K<VAE971S+W-H965T,2YX;6Q02P$"% ,4
M    "  HA6)6!K#AVE<%   S%@  &               @('>#P  >&PO=V]R
M:W-H965T<R]S:&5E=#(N>&UL4$L! A0#%     @ *(5B5@G:[Q\' P  (PP
M !@              ("!:Q4  'AL+W=O<FMS:&5E=',O<VAE970S+GAM;%!+
M 0(4 Q0    ( "B%8E;?<64+700  (P0   8              " @:@8  !X
M;"]W;W)K<VAE971S+W-H965T-"YX;6Q02P$"% ,4    "  HA6)6\PLSD<4%
M   A)0  &               @($['0  >&PO=V]R:W-H965T<R]S:&5E=#4N
M>&UL4$L! A0#%     @ *(5B5G0"8KE\ @  YP4  !@              ("!
M-B,  'AL+W=O<FMS:&5E=',O<VAE970V+GAM;%!+ 0(4 Q0    ( "B%8E;(
MI^D/Q 8  &D>   8              " @>@E  !X;"]W;W)K<VAE971S+W-H
M965T-RYX;6Q02P$"% ,4    "  HA6)6"<V?5"0.  "-)0  &
M    @('B+   >&PO=V]R:W-H965T<R]S:&5E=#@N>&UL4$L! A0#%     @
M*(5B5GN H1\7'   'E0  !@              ("!/#L  'AL+W=O<FMS:&5E
M=',O<VAE970Y+GAM;%!+ 0(4 Q0    ( "B%8E9Z#]*1@08  *$3   9
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M970Q-"YX;6Q02P$"% ,4    "  HA6)6&H_@C[<'  !W$@  &0
M    @(&O<   >&PO=V]R:W-H965T<R]S:&5E=#$U+GAM;%!+ 0(4 Q0    (
M "B%8E:L^K^QT@(  #X&   9              " @9UX  !X;"]W;W)K<VAE
M971S+W-H965T,38N>&UL4$L! A0#%     @ *(5B5M'7\*!J @  ?@4  !D
M             ("!IGL  'AL+W=O<FMS:&5E=',O<VAE970Q-RYX;6Q02P$"
M% ,4    "  HA6)6D%9O3'L#  #S!P  &0              @(%'?@  >&PO
M=V]R:W-H965T<R]S:&5E=#$X+GAM;%!+ 0(4 Q0    ( "B%8E9((QHX<@D
M !$=   9              " @?F!  !X;"]W;W)K<VAE971S+W-H965T,3DN
M>&UL4$L! A0#%     @ *(5B5JLDL=1< P  J@@  !D              ("!
MHHL  'AL+W=O<FMS:&5E=',O<VAE970R,"YX;6Q02P$"% ,4    "  HA6)6
MGL#4^0$)   %&   &0              @($UCP  >&PO=V]R:W-H965T<R]S
M:&5E=#(Q+GAM;%!+ 0(4 Q0    ( "B%8E:?-QN:OP(  $(&   9
M      " @6V8  !X;"]W;W)K<VAE971S+W-H965T,C(N>&UL4$L! A0#%
M  @ *(5B5H+.HGY2'0  1UT  !D              ("!8YL  'AL+W=O<FMS
M:&5E=',O<VAE970R,RYX;6Q02P$"% ,4    "  HA6)6PSP^XH4"  #/!0
M&0              @('LN   >&PO=V]R:W-H965T<R]S:&5E=#(T+GAM;%!+
M 0(4 Q0    ( "B%8E;YWI7$3 ,  %(+   9              " @:B[  !X
M;"]W;W)K<VAE971S+W-H965T,C4N>&UL4$L! A0#%     @ *(5B5CE&<2%-
M P  O0T  !D              ("!*[\  'AL+W=O<FMS:&5E=',O<VAE970R
M-BYX;6Q02P$"% ,4    "  HA6)6XAE0SNT"   Z!P  &0
M@(&OP@  >&PO=V]R:W-H965T<R]S:&5E=#(W+GAM;%!+ 0(4 Q0    ( "B%
M8E9/%MJ>R@(   D'   9              " @=/%  !X;"]W;W)K<VAE971S
M+W-H965T,C@N>&UL4$L! A0#%     @ *(5B5D(=9VHD P  ?P@  !D
M         ("!U,@  'AL+W=O<FMS:&5E=',O<VAE970R.2YX;6Q02P$"% ,4
M    "  HA6)6XA?\0P<%  !>#P  &0              @($OS   >&PO=V]R
M:W-H965T<R]S:&5E=#,P+GAM;%!+ 0(4 Q0    ( "B%8E;N9!F'A (  /(%
M   9              " @6W1  !X;"]W;W)K<VAE971S+W-H965T,S$N>&UL
M4$L! A0#%     @ *(5B5D(E;J9)!   ?@L  !D              ("!*-0
M 'AL+W=O<FMS:&5E=',O<VAE970S,BYX;6Q02P$"% ,4    "  HA6)6@'*"
M"?L%  "S+0  &0              @(&HV   >&PO=V]R:W-H965T<R]S:&5E
M=#,S+GAM;%!+ 0(4 Q0    ( "B%8E;HT?@2*@(  -@$   9
M  " @=K>  !X;"]W;W)K<VAE971S+W-H965T,S0N>&UL4$L! A0#%     @
M*(5B5G]'*Y?& P  CA,  !D              ("!.^$  'AL+W=O<FMS:&5E
M=',O<VAE970S-2YX;6Q02P$"% ,4    "  HA6)6L^>[60@#  "K"P  &0
M            @($XY0  >&PO=V]R:W-H965T<R]S:&5E=#,V+GAM;%!+ 0(4
M Q0    ( "B%8E:S41GS(P,  #T+   9              " @7?H  !X;"]W
M;W)K<VAE971S+W-H965T,S<N>&UL4$L! A0#%     @ *(5B5EJRSIH2!0
MG1D  !D              ("!T>L  'AL+W=O<FMS:&5E=',O<VAE970S."YX
M;6Q02P$"% ,4    "  HA6)69&FG#*P%  "@)P  &0              @($:
M\0  >&PO=V]R:W-H965T<R]S:&5E=#,Y+GAM;%!+ 0(4 Q0    ( "B%8E:H
MYC?J' 0  .<4   9              " @?WV  !X;"]W;W)K<VAE971S+W-H
M965T-# N>&UL4$L! A0#%     @ *(5B5BZ?=@ Z P  C H  !D
M     ("!4/L  'AL+W=O<FMS:&5E=',O<VAE970T,2YX;6Q02P$"% ,4
M"  HA6)6PI2(H(<#   T#0  &0              @('!_@  >&PO=V]R:W-H
M965T<R]S:&5E=#0R+GAM;%!+ 0(4 Q0    ( "B%8E8:%T:[KP(  ,<'   9
M              " @7\" 0!X;"]W;W)K<VAE971S+W-H965T-#,N>&UL4$L!
M A0#%     @ *(5B5E'N@LY# @  S08  !D              ("!904! 'AL
M+W=O<FMS:&5E=',O<VAE970T-"YX;6Q02P$"% ,4    "  HA6)68'-]NX8"
M  !]"   &0              @('?!P$ >&PO=V]R:W-H965T<R]S:&5E=#0U
M+GAM;%!+ 0(4 Q0    ( "B%8E:E6EX!(0,  )8+   9              "
M@9P* 0!X;"]W;W)K<VAE971S+W-H965T-#8N>&UL4$L! A0#%     @ *(5B
M5L]7&G"4"   CT(  !D              ("!] T! 'AL+W=O<FMS:&5E=',O
M<VAE970T-RYX;6Q02P$"% ,4    "  HA6)6-)O\D?$"   R"P  &0
M        @(&_%@$ >&PO=V]R:W-H965T<R]S:&5E=#0X+GAM;%!+ 0(4 Q0
M   ( "B%8E:PF=-71 ,  "\.   9              " @><9 0!X;"]W;W)K
M<VAE971S+W-H965T-#DN>&UL4$L! A0#%     @ *(5B5A$G!=#- @  V@@
M !D              ("!8AT! 'AL+W=O<FMS:&5E=',O<VAE970U,"YX;6Q0
M2P$"% ,4    "  HA6)66FS!X$P#   ["@  &0              @(%F( $
M>&PO=V]R:W-H965T<R]S:&5E=#4Q+GAM;%!+ 0(4 Q0    ( "B%8E9(:]/1
MM00  "$5   9              " @>DC 0!X;"]W;W)K<VAE971S+W-H965T
M-3(N>&UL4$L! A0#%     @ *(5B5G1EOGI( @  H04  !D
M ("!U2@! 'AL+W=O<FMS:&5E=',O<VAE970U,RYX;6Q02P$"% ,4    "  H
MA6)6Q(# =D\#  "N%0  #0              @ %4*P$ >&PO<W1Y;&5S+GAM
M;%!+ 0(4 Q0    ( "B%8E:7BKL<P    !,"   +              "  <XN
M 0!?<F5L<R\N<F5L<U!+ 0(4 Q0    ( "B%8E:@Q#L%H@0  $(C   /
M          "  ;<O 0!X;"]W;W)K8F]O:RYX;6Q02P$"% ,4    "  HA6)6
M?'[I&]0!  #&'P  &@              @ &&- $ >&PO7W)E;',O=V]R:V)O
M;VLN>&UL+G)E;'-02P$"% ,4    "  HA6)6*F32ILH!  ";'P  $P
M        @ &2-@$ 6T-O;G1E;G1?5'EP97-=+GAM;%!+!08     /0 ] *(0
(  "-. $    !

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>75
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>76
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
..report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

..report table.authRefData a {
	display: block;
	font-weight: bold;
}

..report table.authRefData p {
	margin-top: 0px;
}

..report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

..report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

..report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

..report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
..pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
..report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

..report hr {
	border: 1px solid #acf;
}

/* Top labels */
..report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

..report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

..report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

..report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

..report td.pl div.a {
	width: 200px;
}

..report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
..report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
..report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
..report .re, .report .reu {
	background-color: #def;
}

..report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
..report .ro, .report .rou {
	background-color: white;
}

..report .rou td {
	border-bottom: 1px solid black;
}

..report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
..report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
..report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

..report .nump {
	padding-left: 2em;
}

..report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
..report .text {
	text-align: left;
	white-space: normal;
}

..report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

..report .text .more {
	display: none;
}

..report .text .note {
	font-style: italic;
	font-weight: bold;
}

..report .text .small {
	width: 10em;
}

..report sup {
	font-style: italic;
}

..report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>77
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.22.4</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>94</ContextCount>
  <ElementCount>273</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>28</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>6</UnitCount>
  <MyReports>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>00090 - Document - Document and Entity Information</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DocumentDocumentAndEntityInformation</Role>
      <ShortName>Document and Entity Information</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R2.htm</HtmlFileName>
      <LongName>00100 - Statement - BALANCE SHEETS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementBalanceSheets</Role>
      <ShortName>BALANCE SHEETS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>2</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R3.htm</HtmlFileName>
      <LongName>00105 - Statement - BALANCE SHEETS - (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementBalanceSheetsParenthetical</Role>
      <ShortName>BALANCE SHEETS - (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>3</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R4.htm</HtmlFileName>
      <LongName>00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss</Role>
      <ShortName>STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>4</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R5.htm</HtmlFileName>
      <LongName>00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS EQUITY</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>5</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R6.htm</HtmlFileName>
      <LongName>00305 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical</Role>
      <ShortName>STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>6</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R7.htm</HtmlFileName>
      <LongName>00400 - Statement - STATEMENTS OF CASH FLOWS</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/StatementStatementsOfCashFlows</Role>
      <ShortName>STATEMENTS OF CASH FLOWS</ShortName>
      <MenuCategory>Statements</MenuCategory>
      <Position>7</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R8.htm</HtmlFileName>
      <LongName>10101 - Disclosure - Nature of the Business and Basis of Presentation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</Role>
      <ShortName>Nature of the Business and Basis of Presentation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>8</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R9.htm</HtmlFileName>
      <LongName>10201 - Disclosure - Summary of Significant Accounting Policies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>9</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R10.htm</HtmlFileName>
      <LongName>10301 - Disclosure - Marketable Securities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureMarketableSecurities</Role>
      <ShortName>Marketable Securities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>10</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R11.htm</HtmlFileName>
      <LongName>10401 - Disclosure - Fair Value Measurements</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureFairValueMeasurements</Role>
      <ShortName>Fair Value Measurements</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>11</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R12.htm</HtmlFileName>
      <LongName>10501 - Disclosure - Property and Equipment, Net</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet</Role>
      <ShortName>Property and Equipment, Net</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>12</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R13.htm</HtmlFileName>
      <LongName>10601 - Disclosure - Accrued Liabilities and Other Liabilities</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilities</Role>
      <ShortName>Accrued Liabilities and Other Liabilities</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>13</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R14.htm</HtmlFileName>
      <LongName>10701 - Disclosure - Leases</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureLeases</Role>
      <ShortName>Leases</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>14</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R15.htm</HtmlFileName>
      <LongName>10801 - Disclosure - Commitments and Contingencies</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies</Role>
      <ShortName>Commitments and Contingencies</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>15</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R16.htm</HtmlFileName>
      <LongName>10901 - Disclosure - Term Loan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureTermLoan</Role>
      <ShortName>Term Loan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>16</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R17.htm</HtmlFileName>
      <LongName>11001 - Disclosure - Preferred Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosurePreferredStock</Role>
      <ShortName>Preferred Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>17</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R18.htm</HtmlFileName>
      <LongName>11101 - Disclosure - Common Stock</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureCommonStock</Role>
      <ShortName>Common Stock</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>18</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R19.htm</HtmlFileName>
      <LongName>11201 - Disclosure - Stock-Based Compensation</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureStockBasedCompensation</Role>
      <ShortName>Stock-Based Compensation</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>19</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R20.htm</HtmlFileName>
      <LongName>11301 - Disclosure - Net Loss per Share Attributable to Common Stockholders</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>20</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R21.htm</HtmlFileName>
      <LongName>11401 - Disclosure - Income Taxes</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureIncomeTaxes</Role>
      <ShortName>Income Taxes</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>21</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R22.htm</HtmlFileName>
      <LongName>11501 - Disclosure - Employee Benefit Plan</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan</Role>
      <ShortName>Employee Benefit Plan</ShortName>
      <MenuCategory>Notes</MenuCategory>
      <Position>22</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R23.htm</HtmlFileName>
      <LongName>20202 - Disclosure - Summary of Significant Accounting Policies (Policies)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies</Role>
      <ShortName>Summary of Significant Accounting Policies (Policies)</ShortName>
      <MenuCategory>Policies</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>23</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R24.htm</HtmlFileName>
      <LongName>30203 - Disclosure - Summary of Significant Accounting Policies (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables</Role>
      <ShortName>Summary of Significant Accounting Policies (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies</ParentRole>
      <Position>24</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R25.htm</HtmlFileName>
      <LongName>30303 - Disclosure - Marketable Securities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables</Role>
      <ShortName>Marketable Securities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureMarketableSecurities</ParentRole>
      <Position>25</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R26.htm</HtmlFileName>
      <LongName>30403 - Disclosure - Fair Value Measurements (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables</Role>
      <ShortName>Fair Value Measurements (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureFairValueMeasurements</ParentRole>
      <Position>26</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R27.htm</HtmlFileName>
      <LongName>30503 - Disclosure - Property and Equipment, Net (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables</Role>
      <ShortName>Property and Equipment, Net (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet</ParentRole>
      <Position>27</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R28.htm</HtmlFileName>
      <LongName>30603 - Disclosure - Accrued Liabilities and Other Liabilities (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesTables</Role>
      <ShortName>Accrued Liabilities and Other Liabilities (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilities</ParentRole>
      <Position>28</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R29.htm</HtmlFileName>
      <LongName>30703 - Disclosure - Leases (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureLeasesTables</Role>
      <ShortName>Leases (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureLeases</ParentRole>
      <Position>29</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R30.htm</HtmlFileName>
      <LongName>31203 - Disclosure - Stock-Based Compensation (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureStockBasedCompensationTables</Role>
      <ShortName>Stock-Based Compensation (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureStockBasedCompensation</ParentRole>
      <Position>30</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R31.htm</HtmlFileName>
      <LongName>31303 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders</ParentRole>
      <Position>31</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R32.htm</HtmlFileName>
      <LongName>31403 - Disclosure - Income Taxes (Tables)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureIncomeTaxesTables</Role>
      <ShortName>Income Taxes (Tables)</ShortName>
      <MenuCategory>Tables</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureIncomeTaxes</ParentRole>
      <Position>32</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R33.htm</HtmlFileName>
      <LongName>40101 - Disclosure - Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>33</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R34.htm</HtmlFileName>
      <LongName>40102 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails</Role>
      <ShortName>Nature of the Business and Basis of Presentation - Liquidity (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation</ParentRole>
      <Position>34</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R35.htm</HtmlFileName>
      <LongName>40201 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Restricted Cash (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>35</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R36.htm</HtmlFileName>
      <LongName>40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Leases (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Property and Equipment and Leases (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>36</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R37.htm</HtmlFileName>
      <LongName>40203 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails</Role>
      <ShortName>Summary of Significant Accounting Policies - Additional Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>37</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R38.htm</HtmlFileName>
      <LongName>40301 - Disclosure - Marketable Securities - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails</Role>
      <ShortName>Marketable Securities - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables</ParentRole>
      <Position>38</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R39.htm</HtmlFileName>
      <LongName>40401 - Disclosure - Fair Value Measurements - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails</Role>
      <ShortName>Fair Value Measurements - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables</ParentRole>
      <Position>39</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R40.htm</HtmlFileName>
      <LongName>40501 - Disclosure - Property and Equipment, Net - (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails</Role>
      <ShortName>Property and Equipment, Net - (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables</ParentRole>
      <Position>40</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R41.htm</HtmlFileName>
      <LongName>40601 - Disclosure - Accrued Liabilities and Other Liabilities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails</Role>
      <ShortName>Accrued Liabilities and Other Liabilities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesTables</ParentRole>
      <Position>41</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R42.htm</HtmlFileName>
      <LongName>40701 - Disclosure - Leases - Other Information (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails</Role>
      <ShortName>Leases - Other Information (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>42</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R43.htm</HtmlFileName>
      <LongName>40702 - Disclosure - Leases - Maturities (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails</Role>
      <ShortName>Leases - Maturities (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>43</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R44.htm</HtmlFileName>
      <LongName>40901 - Disclosure - Term Loan - Other (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureTermLoanOtherDetails</Role>
      <ShortName>Term Loan - Other (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>44</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R45.htm</HtmlFileName>
      <LongName>41001 - Disclosure - Preferred Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosurePreferredStockDetails</Role>
      <ShortName>Preferred Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosurePreferredStock</ParentRole>
      <Position>45</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R46.htm</HtmlFileName>
      <LongName>41101 - Disclosure - Common Stock (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureCommonStockDetails</Role>
      <ShortName>Common Stock (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureCommonStock</ParentRole>
      <Position>46</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R47.htm</HtmlFileName>
      <LongName>41201 - Disclosure - Stock-Based Compensation - Stock options (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Stock options (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>47</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R48.htm</HtmlFileName>
      <LongName>41202 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails</Role>
      <ShortName>Stock-Based Compensation - Stock based compensation expense (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>48</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R49.htm</HtmlFileName>
      <LongName>41203 - Disclosure - Stock-Based Compensation - Assumptions (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails</Role>
      <ShortName>Stock-Based Compensation - Assumptions (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>49</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R50.htm</HtmlFileName>
      <LongName>41301 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails</Role>
      <ShortName>Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>50</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R51.htm</HtmlFileName>
      <LongName>41401 - Disclosure - Income Taxes - Reconciliation (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails</Role>
      <ShortName>Income Taxes - Reconciliation (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>51</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R52.htm</HtmlFileName>
      <LongName>41402 - Disclosure - Income Taxes - Deferred tax assets (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails</Role>
      <ShortName>Income Taxes - Deferred tax assets (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <Position>52</Position>
    </Report>
    <Report instance="nxtc-20221231x10k.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R53.htm</HtmlFileName>
      <LongName>41501 - Disclosure - Employee Benefit Plan (Details)</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails</Role>
      <ShortName>Employee Benefit Plan (Details)</ShortName>
      <MenuCategory>Details</MenuCategory>
      <ParentRole>http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan</ParentRole>
      <Position>53</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <Logs>
    <Log type="Warning">[ix-0514-Hidden-Fact-Eligible-For-Transform] WARN: 20 fact(s) appearing in ix:hidden were eligible for transformation: dei:CurrentFiscalYearEndDate, nxtc:FairValuesAssetsLevel1ToLevel2TransfersAmount, nxtc:FairValuesAssetsLevel2ToLevel1TransfersAmount, us-gaap:CommonStockSharesIssued, us-gaap:CommonStockSharesOutstanding, us-gaap:EarningsPerShareDiluted, us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3, us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3, us-gaap:PreferredStockSharesIssued, us-gaap:PreferredStockSharesOutstanding, us-gaap:StockholdersEquityNoteStockSplitConversionRatio1, us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding -  nxtc-20221231x10k.htm 9</Log>
    <Log type="Warning">[ix-0514-Hidden-Fact-Not-Referenced] WARN: 1 fact(s) appearing in ix:hidden were not referenced by any -sec-ix-hidden style property: us-gaap:OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList -  nxtc-20221231x10k.htm 9</Log>
  </Logs>
  <InputFiles>
    <File doctype="10-K" original="nxtc-20221231x10k.htm">nxtc-20221231x10k.htm</File>
    <File>nxtc-20221231.xsd</File>
    <File>nxtc-20221231_cal.xml</File>
    <File>nxtc-20221231_def.xml</File>
    <File>nxtc-20221231_lab.xml</File>
    <File>nxtc-20221231_pre.xml</File>
    <File>nxtc-20221231xex10d27.htm</File>
    <File>nxtc-20221231xex10d28.htm</File>
    <File>nxtc-20221231xex10d29.htm</File>
    <File>nxtc-20221231xex10d30.htm</File>
    <File>nxtc-20221231xex23d1.htm</File>
    <File>nxtc-20221231xex31d1.htm</File>
    <File>nxtc-20221231xex31d2.htm</File>
    <File>nxtc-20221231xex32d1.htm</File>
  </InputFiles>
  <SupplementalFiles>
    <File>nxtc-20221231x10k005.jpg</File>
    <File>nxtc-20221231x10k006.jpg</File>
    <File>nxtc-20221231x10k007.jpg</File>
    <File>nxtc-20221231x10k008.jpg</File>
  </SupplementalFiles>
  <BaseTaxonomies>
    <BaseTaxonomy items="417">http://fasb.org/us-gaap/2022</BaseTaxonomy>
    <BaseTaxonomy items="37">http://xbrl.sec.gov/dei/2022</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>true</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>80
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "instance": {
  "nxtc-20221231x10k.htm": {
   "axisCustom": 0,
   "axisStandard": 11,
   "baseTaxonomies": {
    "http://fasb.org/us-gaap/2022": 417,
    "http://xbrl.sec.gov/dei/2022": 37
   },
   "contextCount": 94,
   "dts": {
    "calculationLink": {
     "local": [
      "nxtc-20221231_cal.xml"
     ]
    },
    "definitionLink": {
     "local": [
      "nxtc-20221231_def.xml"
     ]
    },
    "inline": {
     "local": [
      "nxtc-20221231x10k.htm"
     ]
    },
    "labelLink": {
     "local": [
      "nxtc-20221231_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "nxtc-20221231_pre.xml"
     ]
    },
    "schema": {
     "local": [
      "nxtc-20221231.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/2006/ref-2006-02-27.xsd",
      "http://www.xbrl.org/lrr/arcrole/esma-arcrole-2018-11-21.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/reference-2009-12-16.xsd",
      "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd",
      "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-roles-2022.xsd",
      "https://xbrl.fasb.org/srt/2022/elts/srt-types-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-gaap-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-roles-2022.xsd",
      "https://xbrl.fasb.org/us-gaap/2022/elts/us-types-2022.xsd",
      "https://xbrl.sec.gov/country/2022/country-2022.xsd",
      "https://xbrl.sec.gov/dei/2022/dei-2022.xsd"
     ]
    }
   },
   "elementCount": 399,
   "entityCount": 1,
   "hidden": {
    "http://fasb.org/us-gaap/2022": 19,
    "http://www.nextcure.com/20221231": 4,
    "http://xbrl.sec.gov/dei/2022": 5,
    "total": 28
   },
   "keyCustom": 30,
   "keyStandard": 243,
   "memberCustom": 5,
   "memberStandard": 22,
   "nsprefix": "nxtc",
   "nsuri": "http://www.nextcure.com/20221231",
   "report": {
    "R1": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "document",
     "isDefault": "true",
     "longName": "00090 - Document - Document and Entity Information",
     "menuCat": "Cover",
     "order": "1",
     "role": "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation",
     "shortName": "Document and Entity Information",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "dei:DocumentType",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R10": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10301 - Disclosure - Marketable Securities",
     "menuCat": "Notes",
     "order": "10",
     "role": "http://www.nextcure.com/role/DisclosureMarketableSecurities",
     "shortName": "Marketable Securities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R11": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10401 - Disclosure - Fair Value Measurements",
     "menuCat": "Notes",
     "order": "11",
     "role": "http://www.nextcure.com/role/DisclosureFairValueMeasurements",
     "shortName": "Fair Value Measurements",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueDisclosuresTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R12": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10501 - Disclosure - Property and Equipment, Net",
     "menuCat": "Notes",
     "order": "12",
     "role": "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet",
     "shortName": "Property and Equipment, Net",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R13": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10601 - Disclosure - Accrued Liabilities and Other Liabilities",
     "menuCat": "Notes",
     "order": "13",
     "role": "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilities",
     "shortName": "Accrued Liabilities and Other Liabilities",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R14": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10701 - Disclosure - Leases",
     "menuCat": "Notes",
     "order": "14",
     "role": "http://www.nextcure.com/role/DisclosureLeases",
     "shortName": "Leases",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeasesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R15": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10801 - Disclosure - Commitments and Contingencies",
     "menuCat": "Notes",
     "order": "15",
     "role": "http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies",
     "shortName": "Commitments and Contingencies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:CommitmentsAndContingenciesDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R16": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10901 - Disclosure - Term Loan",
     "menuCat": "Notes",
     "order": "16",
     "role": "http://www.nextcure.com/role/DisclosureTermLoan",
     "shortName": "Term Loan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DebtDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R17": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11001 - Disclosure - Preferred Stock",
     "menuCat": "Notes",
     "order": "17",
     "role": "http://www.nextcure.com/role/DisclosurePreferredStock",
     "shortName": "Preferred Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PreferredStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R18": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nxtc:CommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11101 - Disclosure - Common Stock",
     "menuCat": "Notes",
     "order": "18",
     "role": "http://www.nextcure.com/role/DisclosureCommonStock",
     "shortName": "Common Stock",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nxtc:CommonStockTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R19": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11201 - Disclosure - Stock-Based Compensation",
     "menuCat": "Notes",
     "order": "19",
     "role": "http://www.nextcure.com/role/DisclosureStockBasedCompensation",
     "shortName": "Stock-Based Compensation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R2": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:CashAndCashEquivalentsAtCarryingValue",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00100 - Statement - BALANCE SHEETS",
     "menuCat": "Statements",
     "order": "2",
     "role": "http://www.nextcure.com/role/StatementBalanceSheets",
     "shortName": "BALANCE SHEETS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R20": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11301 - Disclosure - Net Loss per Share Attributable to Common Stockholders",
     "menuCat": "Notes",
     "order": "20",
     "role": "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders",
     "shortName": "Net Loss per Share Attributable to Common Stockholders",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:EarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R21": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11401 - Disclosure - Income Taxes",
     "menuCat": "Notes",
     "order": "21",
     "role": "http://www.nextcure.com/role/DisclosureIncomeTaxes",
     "shortName": "Income Taxes",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:IncomeTaxDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R22": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "11501 - Disclosure - Employee Benefit Plan",
     "menuCat": "Notes",
     "order": "22",
     "role": "http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan",
     "shortName": "Employee Benefit Plan",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R23": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "20202 - Disclosure - Summary of Significant Accounting Policies (Policies)",
     "menuCat": "Policies",
     "order": "23",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies",
     "shortName": "Summary of Significant Accounting Policies (Policies)",
     "subGroupType": "policies",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:SignificantAccountingPoliciesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:BasisOfAccountingPolicyPolicyTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R24": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30203 - Disclosure - Summary of Significant Accounting Policies (Tables)",
     "menuCat": "Tables",
     "order": "24",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables",
     "shortName": "Summary of Significant Accounting Policies (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R25": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30303 - Disclosure - Marketable Securities (Tables)",
     "menuCat": "Tables",
     "order": "25",
     "role": "http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables",
     "shortName": "Marketable Securities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R26": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30403 - Disclosure - Fair Value Measurements (Tables)",
     "menuCat": "Tables",
     "order": "26",
     "role": "http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables",
     "shortName": "Fair Value Measurements (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R27": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30503 - Disclosure - Property and Equipment, Net (Tables)",
     "menuCat": "Tables",
     "order": "27",
     "role": "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables",
     "shortName": "Property and Equipment, Net (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R28": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30603 - Disclosure - Accrued Liabilities and Other Liabilities (Tables)",
     "menuCat": "Tables",
     "order": "28",
     "role": "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesTables",
     "shortName": "Accrued Liabilities and Other Liabilities (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R29": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "30703 - Disclosure - Leases (Tables)",
     "menuCat": "Tables",
     "order": "29",
     "role": "http://www.nextcure.com/role/DisclosureLeasesTables",
     "shortName": "Leases (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R3": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockParOrStatedValuePerShare",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockParOrStatedValuePerShare",
      "reportCount": 1,
      "unitRef": "Unit_Divide_USD_shares_7zGXPefSLk2zd2qv05uGjw",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00105 - Statement - BALANCE SHEETS - (Parenthetical)",
     "menuCat": "Statements",
     "order": "3",
     "role": "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical",
     "shortName": "BALANCE SHEETS - (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": null
    },
    "R30": {
     "firstAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31203 - Disclosure - Stock-Based Compensation (Tables)",
     "menuCat": "Tables",
     "order": "30",
     "role": "http://www.nextcure.com/role/DisclosureStockBasedCompensationTables",
     "shortName": "Stock-Based Compensation (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R31": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31303 - Disclosure - Net Loss per Share Attributable to Common Stockholders (Tables)",
     "menuCat": "Tables",
     "order": "31",
     "role": "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables",
     "shortName": "Net Loss per Share Attributable to Common Stockholders (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R32": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "31403 - Disclosure - Income Taxes (Tables)",
     "menuCat": "Tables",
     "order": "32",
     "role": "http://www.nextcure.com/role/DisclosureIncomeTaxesTables",
     "shortName": "Income Taxes (Tables)",
     "subGroupType": "tables",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R33": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40101 - Disclosure - Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)",
     "menuCat": "Details",
     "order": "33",
     "role": "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
     "shortName": "Nature of the Business and Basis of Presentation - Public Offerings and Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_12_2_2019_To_12_2_2019_poKPEsa7RUinDCjWTkdvlg",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockIssuedDuringPeriodSharesNewIssues",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww",
      "xsiNil": "false"
     }
    },
    "R34": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_SvUt3NvuT0moPQCiN6jnXA",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40102 - Disclosure - Nature of the Business and Basis of Presentation - Liquidity (Details)",
     "menuCat": "Details",
     "order": "34",
     "role": "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails",
     "shortName": "Nature of the Business and Basis of Presentation - Liquidity (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:NumberOfOperatingSegments",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_segment_SvUt3NvuT0moPQCiN6jnXA",
      "xsiNil": "false"
     }
    },
    "R35": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_8_1_2021_To_8_31_2021_QUjo54fwz0S0O0oyBr9gCg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromRepaymentsOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40201 - Disclosure - Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "menuCat": "Details",
     "order": "35",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails",
     "shortName": "Summary of Significant Accounting Policies - Restricted Cash (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_8_1_2021_To_8_31_2021_QUjo54fwz0S0O0oyBr9gCg",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProceedsFromRepaymentsOfDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R36": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasePracticalExpedientsPackage",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40202 - Disclosure - Summary of Significant Accounting Policies - Property and Equipment and Leases (Details)",
     "menuCat": "Details",
     "order": "36",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails",
     "shortName": "Summary of Significant Accounting Policies - Property and Equipment and Leases (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "nxtc:PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
       "us-gaap:PropertyPlantAndEquipmentPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_us-gaap_PropertyPlantAndEquipmentByTypeAxis_us-gaap_ComputerEquipmentMember_9gGAYZTy_U-F2bBDboUuHg",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:PropertyPlantAndEquipmentEstimatedUsefulLives",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R37": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_5_13_2019_FmtkLFGS6EOs9ri8CulN1g",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesOutstanding",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40203 - Disclosure - Summary of Significant Accounting Policies - Additional Information (Details)",
     "menuCat": "Details",
     "order": "37",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
     "shortName": "Summary of Significant Accounting Policies - Additional Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
       "p",
       "ix:continuation",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:ImpairmentOfLongLivedAssetsToBeDisposedOf",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R38": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40301 - Disclosure - Marketable Securities - (Details)",
     "menuCat": "Details",
     "order": "38",
     "role": "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails",
     "shortName": "Marketable Securities - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R39": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
       "us-gaap:InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40401 - Disclosure - Fair Value Measurements - (Details)",
     "menuCat": "Details",
     "order": "39",
     "role": "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails",
     "shortName": "Fair Value Measurements - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:FairValueByBalanceSheetGroupingTextBlock",
       "us-gaap:FairValueDisclosuresTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_us-gaap_FairValueByMeasurementBasisAxis_us-gaap_EstimateOfFairValueFairValueDisclosureMember_Ym0BL0i97UaomE43uV-bYQ",
      "decimals": "-3",
      "lang": null,
      "name": "nxtc:MarketableSecuritiesAndCashEquivalents",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R4": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00200 - Statement - STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "menuCat": "Statements",
     "order": "4",
     "role": "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
     "shortName": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ResearchAndDevelopmentExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R40": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40501 - Disclosure - Property and Equipment, Net - (Details)",
     "menuCat": "Details",
     "order": "40",
     "role": "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
     "shortName": "Property and Equipment, Net - (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:PropertyPlantAndEquipmentTextBlock",
       "us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:PropertyPlantAndEquipmentGross",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R41": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40601 - Disclosure - Accrued Liabilities and Other Liabilities (Details)",
     "menuCat": "Details",
     "order": "41",
     "role": "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails",
     "shortName": "Accrued Liabilities and Other Liabilities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAccruedLiabilitiesTableTextBlock",
       "us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeRelatedLiabilitiesCurrent",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R42": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:LeasePracticalExpedientsPackage",
      "reportCount": 1,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40701 - Disclosure - Leases - Other Information (Details)",
     "menuCat": "Details",
     "order": "42",
     "role": "http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails",
     "shortName": "Leases - Other Information (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:LesseeOperatingLeasesTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": null,
      "lang": "en-US",
      "name": "us-gaap:LesseeOperatingLeaseRenewalTerm",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R43": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40702 - Disclosure - Leases - Maturities (Details)",
     "menuCat": "Details",
     "order": "43",
     "role": "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails",
     "shortName": "Leases - Maturities (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R44": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DebtInstrumentFaceAmount",
      "reportCount": 1,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "40901 - Disclosure - Term Loan - Other (Details)",
     "menuCat": "Details",
     "order": "44",
     "role": "http://www.nextcure.com/role/DisclosureTermLoanOtherDetails",
     "shortName": "Term Loan - Other (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:DebtDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "0",
      "lang": null,
      "name": "us-gaap:LongTermDebt",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R45": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:PreferredStockSharesAuthorized",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:PreferredStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41001 - Disclosure - Preferred Stock (Details)",
     "menuCat": "Details",
     "order": "45",
     "role": "http://www.nextcure.com/role/DisclosurePreferredStockDetails",
     "shortName": "Preferred Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": null
    },
    "R46": {
     "firstAnchor": {
      "ancestors": [
       "us-gaap:CommonStockSharesAuthorized",
       "span",
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "INF",
      "first": true,
      "lang": null,
      "name": "us-gaap:CommonStockSharesAuthorized",
      "reportCount": 1,
      "unitRef": "Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41101 - Disclosure - Common Stock (Details)",
     "menuCat": "Details",
     "order": "46",
     "role": "http://www.nextcure.com/role/DisclosureCommonStockDetails",
     "shortName": "Common Stock (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "nxtc:CommonStockTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "INF",
      "lang": null,
      "name": "nxtc:NumberOfVotesPerShare",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_Vote_NTyCJtIjU0i5jZ9cnBFqVg",
      "xsiNil": "false"
     }
    },
    "R47": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41201 - Disclosure - Stock-Based Compensation - Stock options (Details)",
     "menuCat": "Details",
     "order": "47",
     "role": "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
     "shortName": "Stock-Based Compensation - Stock options (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R48": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41202 - Disclosure - Stock-Based Compensation - Stock based compensation expense (Details)",
     "menuCat": "Details",
     "order": "48",
     "role": "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails",
     "shortName": "Stock-Based Compensation - Stock based compensation expense (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:AllocatedShareBasedCompensationExpense",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R49": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41203 - Disclosure - Stock-Based Compensation - Assumptions (Details)",
     "menuCat": "Details",
     "order": "49",
     "role": "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
     "shortName": "Stock-Based Compensation - Assumptions (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2021_To_12_31_2021_A7lXncY9u0qJcLxdJnOozw",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ",
      "xsiNil": "false"
     }
    },
    "R5": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaUNhIOQzE-uaj0TJAxBUg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00300 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY",
     "menuCat": "Statements",
     "order": "5",
     "role": "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity",
     "shortName": "STATEMENTS OF STOCKHOLDERS EQUITY",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2020_us-gaap_StatementEquityComponentsAxis_us-gaap_CommonStockMember_ZaUNhIOQzE-uaj0TJAxBUg",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:StockholdersEquity",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R50": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41301 - Disclosure - Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)",
     "menuCat": "Details",
     "order": "50",
     "role": "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails",
     "shortName": "Net Loss per Share Attributable to Common Stockholders - Anti-dilutive effect (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
       "us-gaap:EarningsPerShareTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "0",
      "first": true,
      "lang": null,
      "name": "us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_shares_lqHHwAjY8kyvrwV_76Juww",
      "xsiNil": "false"
     }
    },
    "R51": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41401 - Disclosure - Income Taxes - Reconciliation (Details)",
     "menuCat": "Details",
     "order": "51",
     "role": "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails",
     "shortName": "Income Taxes - Reconciliation (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
       "us-gaap:IncomeTaxDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "3",
      "first": true,
      "lang": null,
      "name": "us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_pure_6LFUlUmQ9Eei8jt2uBUtzQ",
      "xsiNil": "false"
     }
    },
    "R52": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41402 - Disclosure - Income Taxes - Deferred tax assets (Details)",
     "menuCat": "Details",
     "order": "52",
     "role": "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails",
     "shortName": "Income Taxes - Deferred tax assets (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "us-gaap:ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
       "ix:continuation",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "As_Of_12_31_2022_p3RLvl4W6kW51r8uVj8IKA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:DeferredTaxAssetsOperatingLossCarryforwards",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R53": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "41501 - Disclosure - Employee Benefit Plan (Details)",
     "menuCat": "Details",
     "order": "53",
     "role": "http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails",
     "shortName": "Employee Benefit Plan (Details)",
     "subGroupType": "details",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "us-gaap:PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "-5",
      "first": true,
      "lang": null,
      "name": "us-gaap:DefinedContributionPlanEmployerDiscretionaryContributionAmount",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R6": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00305 - Statement - STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)",
     "menuCat": "Statements",
     "order": "6",
     "role": "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical",
     "shortName": "STATEMENTS OF STOCKHOLDERS EQUITY (Parenthetical)",
     "subGroupType": "parenthetical",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R7": {
     "firstAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     },
     "groupType": "statement",
     "isDefault": "false",
     "longName": "00400 - Statement - STATEMENTS OF CASH FLOWS",
     "menuCat": "Statements",
     "order": "7",
     "role": "http://www.nextcure.com/role/StatementStatementsOfCashFlows",
     "shortName": "STATEMENTS OF CASH FLOWS",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "p",
       "td",
       "tr",
       "table",
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": "-3",
      "first": true,
      "lang": null,
      "name": "us-gaap:ProfitLoss",
      "reportCount": 1,
      "unique": true,
      "unitRef": "Unit_Standard_USD_DEGsWlv2Ckm6Dkyz0omiyg",
      "xsiNil": "false"
     }
    },
    "R8": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10101 - Disclosure - Nature of the Business and Basis of Presentation",
     "menuCat": "Notes",
     "order": "8",
     "role": "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation",
     "shortName": "Nature of the Business and Basis of Presentation",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    },
    "R9": {
     "firstAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     },
     "groupType": "disclosure",
     "isDefault": "false",
     "longName": "10201 - Disclosure - Summary of Significant Accounting Policies",
     "menuCat": "Notes",
     "order": "9",
     "role": "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies",
     "shortName": "Summary of Significant Accounting Policies",
     "subGroupType": "",
     "uniqueAnchor": {
      "ancestors": [
       "div",
       "div",
       "body",
       "html"
      ],
      "baseRef": "nxtc-20221231x10k.htm",
      "contextRef": "Duration_1_1_2022_To_12_31_2022_WRledxq1KkOjdxVXXhuIZA",
      "decimals": null,
      "first": true,
      "lang": "en-US",
      "name": "us-gaap:SignificantAccountingPoliciesTextBlock",
      "reportCount": 1,
      "unique": true,
      "unitRef": null,
      "xsiNil": "false"
     }
    }
   },
   "segmentCount": 28,
   "tag": {
    "dei_AmendmentFlag": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.",
        "label": "Amendment Flag"
       }
      }
     },
     "localname": "AmendmentFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_AuditorFirmId": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "PCAOB issued Audit Firm Identifier",
        "label": "Auditor Firm ID"
       }
      }
     },
     "localname": "AuditorFirmId",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "nonemptySequenceNumberItemType"
    },
    "dei_AuditorLocation": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Location"
       }
      }
     },
     "localname": "AuditorLocation",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_AuditorName": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Auditor Name"
       }
      }
     },
     "localname": "AuditorName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "internationalNameItemType"
    },
    "dei_CityAreaCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Area code of city",
        "label": "City Area Code"
       }
      }
     },
     "localname": "CityAreaCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_CoverAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Cover page.",
        "label": "Cover Abstract"
       }
      }
     },
     "localname": "CoverAbstract",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "xbrltype": "stringItemType"
    },
    "dei_CurrentFiscalYearEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "End date of current fiscal year in the format --MM-DD.",
        "label": "Current Fiscal Year End Date"
       }
      }
     },
     "localname": "CurrentFiscalYearEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gMonthDayItemType"
    },
    "dei_DocumentAnnualReport": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as an annual report.",
        "label": "Document Annual Report"
       }
      }
     },
     "localname": "DocumentAnnualReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentFiscalPeriodFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fiscal period values are FY, Q1, Q2, and Q3.  1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.",
        "label": "Document Fiscal Period Focus"
       }
      }
     },
     "localname": "DocumentFiscalPeriodFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fiscalPeriodItemType"
    },
    "dei_DocumentFiscalYearFocus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.",
        "label": "Document Fiscal Year Focus"
       }
      }
     },
     "localname": "DocumentFiscalYearFocus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "gYearItemType"
    },
    "dei_DocumentPeriodEndDate": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period.  The format of the date is YYYY-MM-DD.",
        "label": "Document Period End Date"
       }
      }
     },
     "localname": "DocumentPeriodEndDate",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "dateItemType"
    },
    "dei_DocumentTransitionReport": {
     "auth_ref": [
      "r458"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true only for a form used as a transition report.",
        "label": "Document Transition Report"
       }
      }
     },
     "localname": "DocumentTransitionReport",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_DocumentType": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.",
        "label": "Document Type"
       }
      }
     },
     "localname": "DocumentType",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "submissionTypeItemType"
    },
    "dei_EntityAddressAddressLine1": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name",
        "label": "Entity Address, Address Line One"
       }
      }
     },
     "localname": "EntityAddressAddressLine1",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressCityOrTown": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the City or Town",
        "label": "Entity Address, City or Town"
       }
      }
     },
     "localname": "EntityAddressCityOrTown",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressPostalZipCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Code for the postal or zip code",
        "label": "Entity Address, Postal Zip Code"
       }
      }
     },
     "localname": "EntityAddressPostalZipCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityAddressStateOrProvince": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the state or province.",
        "label": "Entity Address, State or Province"
       }
      }
     },
     "localname": "EntityAddressStateOrProvince",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "stateOrProvinceItemType"
    },
    "dei_EntityCentralIndexKey": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.",
        "label": "Entity Central Index Key"
       }
      }
     },
     "localname": "EntityCentralIndexKey",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "centralIndexKeyItemType"
    },
    "dei_EntityCommonStockSharesOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.",
        "label": "Entity Common Stock, Shares Outstanding"
       }
      }
     },
     "localname": "EntityCommonStockSharesOutstanding",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "sharesItemType"
    },
    "dei_EntityCurrentReportingStatus": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Current Reporting Status"
       }
      }
     },
     "localname": "EntityCurrentReportingStatus",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityEmergingGrowthCompany": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if registrant meets the emerging growth company criteria.",
        "label": "Entity Emerging Growth Company"
       }
      }
     },
     "localname": "EntityEmergingGrowthCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityExTransitionPeriod": {
     "auth_ref": [
      "r461"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.",
        "label": "Entity Ex Transition Period"
       }
      }
     },
     "localname": "EntityExTransitionPeriod",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityFileNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.",
        "label": "Entity File Number"
       }
      }
     },
     "localname": "EntityFileNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "fileNumberItemType"
    },
    "dei_EntityFilerCategory": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.",
        "label": "Entity Filer Category"
       }
      }
     },
     "localname": "EntityFilerCategory",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "filerCategoryItemType"
    },
    "dei_EntityIncorporationStateCountryCode": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Two-character EDGAR code representing the state or country of incorporation.",
        "label": "Entity Incorporation, State or Country Code"
       }
      }
     },
     "localname": "EntityIncorporationStateCountryCode",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarStateCountryItemType"
    },
    "dei_EntityInteractiveDataCurrent": {
     "auth_ref": [
      "r459"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).",
        "label": "Entity Interactive Data Current"
       }
      }
     },
     "localname": "EntityInteractiveDataCurrent",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityPublicFloat": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter.",
        "label": "Entity Public Float"
       }
      }
     },
     "localname": "EntityPublicFloat",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "monetaryItemType"
    },
    "dei_EntityRegistrantName": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.",
        "label": "Entity Registrant Name"
       }
      }
     },
     "localname": "EntityRegistrantName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_EntityShellCompany": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.",
        "label": "Entity Shell Company"
       }
      }
     },
     "localname": "EntityShellCompany",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntitySmallBusiness": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates that the company is a Smaller Reporting Company (SRC).",
        "label": "Entity Small Business"
       }
      }
     },
     "localname": "EntitySmallBusiness",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_EntityTaxIdentificationNumber": {
     "auth_ref": [
      "r453"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.",
        "label": "Entity Tax Identification Number"
       }
      }
     },
     "localname": "EntityTaxIdentificationNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "employerIdItemType"
    },
    "dei_EntityVoluntaryFilers": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act.",
        "label": "Entity Voluntary Filers"
       }
      }
     },
     "localname": "EntityVoluntaryFilers",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_EntityWellKnownSeasonedIssuer": {
     "auth_ref": [
      "r460"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A.",
        "label": "Entity Well-known Seasoned Issuer"
       }
      }
     },
     "localname": "EntityWellKnownSeasonedIssuer",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "yesNoItemType"
    },
    "dei_IcfrAuditorAttestationFlag": {
     "auth_ref": [
      "r455",
      "r456",
      "r457"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "ICFR Auditor Attestation Flag"
       }
      }
     },
     "localname": "IcfrAuditorAttestationFlag",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "booleanItemType"
    },
    "dei_LocalPhoneNumber": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Local phone number for entity.",
        "label": "Local Phone Number"
       }
      }
     },
     "localname": "LocalPhoneNumber",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "normalizedStringItemType"
    },
    "dei_Security12bTitle": {
     "auth_ref": [
      "r452"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Title of a 12(b) registered security.",
        "label": "Title of 12(b) Security"
       }
      }
     },
     "localname": "Security12bTitle",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "securityTitleItemType"
    },
    "dei_SecurityExchangeName": {
     "auth_ref": [
      "r454"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Name of the Exchange on which a security is registered.",
        "label": "Security Exchange Name"
       }
      }
     },
     "localname": "SecurityExchangeName",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "edgarExchangeCodeItemType"
    },
    "dei_TradingSymbol": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Trading symbol of an instrument as listed on an exchange.",
        "label": "Trading Symbol"
       }
      }
     },
     "localname": "TradingSymbol",
     "nsuri": "http://xbrl.sec.gov/dei/2022",
     "presentation": [
      "http://www.nextcure.com/role/DocumentDocumentAndEntityInformation"
     ],
     "xbrltype": "tradingSymbolItemType"
    },
    "nxtc_A2015OmnibusIncentivePlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2015 omnibus incentive plan.",
        "label": "2015 Plan"
       }
      }
     },
     "localname": "A2015OmnibusIncentivePlanMember",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_AccruedAndOtherLiabilitiesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities and amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Accrued and Other Liabilities Current",
        "terseLabel": "Accrued liabilities and other liabilities",
        "totalLabel": "Total accrued liabilities and other liabilities"
       }
      }
     },
     "localname": "AccruedAndOtherLiabilitiesCurrent",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails",
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_AccruedClinicalTrialCostsCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails": {
       "order": 2.0,
       "parentTag": "nxtc_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for clinical trial costs. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Clinical Trial Costs, Current",
        "terseLabel": "Clinical trial costs"
       }
      }
     },
     "localname": "AccruedClinicalTrialCostsCurrent",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_AccruedOperatingExpensesCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails": {
       "order": 5.0,
       "parentTag": "nxtc_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for operating expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Operating Expenses, Current",
        "terseLabel": "Operating expenses"
       }
      }
     },
     "localname": "AccruedOperatingExpensesCurrent",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_AccruedSponsoredResearchExpenseCurrent": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails": {
       "order": 3.0,
       "parentTag": "nxtc_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of obligations incurred through that date and payable for sponsored research expenses. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accrued Sponsored Research Expense, Current",
        "terseLabel": "Sponsored research"
       }
      }
     },
     "localname": "AccruedSponsoredResearchExpenseCurrent",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in second through fifth fiscal year following current fiscal year to year two. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Amortized Cost",
        "terseLabel": "Between 1 to 2 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsAmortizedCost",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in through second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Available For Sale Securities Debt Maturities After One Through Two Years Fair Value",
        "terseLabel": "Between 1 to 2 years"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAfterOneThroughTwoYearsFairValue",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_CommonStockTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to common stock.",
        "label": "Common Stock [Text Block]",
        "terseLabel": "Common Stock"
       }
      }
     },
     "localname": "CommonStockTextBlock",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nxtc_DeferredTaxAssetsCapitalizedResearchAndDevelopment": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax\n asset attributable to capitalized research and development costs.",
        "label": "Deferred Tax Assets Capitalized Research And Development",
        "terseLabel": "Capitalized R&amp;D Costs"
       }
      }
     },
     "localname": "DeferredTaxAssetsCapitalizedResearchAndDevelopment",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_DeferredTaxAssetsOperatingLeaseLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from operating lease liabilities.",
        "label": "Deferred Tax Assets Operating Lease Liabilities",
        "terseLabel": "Operating lease liabilities"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLeaseLiabilities",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic research and development tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research And Development, Federal",
        "terseLabel": "Federal research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentFederal",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state research and development tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research And Development, State",
        "terseLabel": "State research and development tax credit carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearchAndDevelopmentState",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from reserves and accruals and amount, before allocation of valuation allowance, of deferred tax asset attributable to deductible temporary differences, classified as other.",
        "label": "Deferred Tax Assets Tax Deferred Expense Reserves And Accruals And Other",
        "terseLabel": "Accruals and other"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAndOther",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_DeferredTaxLiabilitiesDepreciationAndAmortization": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax consequences attributable to taxable temporary differences derived from depreciation and amortization.",
        "label": "Deferred Tax Liabilities, Depreciation and Amortization",
        "negatedLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesDepreciationAndAmortization",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_DepreciationDepletionAndAmortizationAndOther": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets and other items.",
        "label": "Depreciation Depletion And Amortization And Other",
        "terseLabel": "Depreciation and amortization"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortizationAndOther",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_EarningsPerSharesBasicAndDilutedAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not available.",
        "label": "Earnings Per Shares Basic And Diluted Abstract",
        "terseLabel": "Net loss per common share"
       }
      }
     },
     "localname": "EarningsPerSharesBasicAndDilutedAbstract",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "nxtc_EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not available.",
        "label": "Earnings Per Shares Basic And Diluted Other Disclosures Abstract",
        "terseLabel": "Weighted average shares outstanding"
       }
      }
     },
     "localname": "EarningsPerSharesBasicAndDilutedOtherDisclosuresAbstract",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "nxtc_EmployeeStockPurchase2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2019 Employee Stock Purchase Plan.",
        "label": "2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "EmployeeStockPurchase2019PlanMember",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_FairValuesAssetsLevel1ToLevel2TransfersAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts of transfers of assets measured on a recurring basis out of Level 1 of the fair value hierarchy into Level 2.",
        "label": "Fair Values Assets Level 1 To Level 2 Transfers Amount",
        "terseLabel": "Assets transferred from level 1 to level 2"
       }
      }
     },
     "localname": "FairValuesAssetsLevel1ToLevel2TransfersAmount",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_FairValuesAssetsLevel2ToLevel1TransfersAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amounts of transfers of assets measured on a recurring basis out of Level 2 of the fair value hierarchy into Level 1.",
        "label": "Fair Values Assets Level 2 To Level 1 Transfers Amount",
        "terseLabel": "Assets transferred from level 2 to level 1"
       }
      }
     },
     "localname": "FairValuesAssetsLevel2ToLevel1TransfersAmount",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_IncreaseDecreaseInAccruedAndOtherCurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 6.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of expenses incurred but not yet paid and Other Current Liabilities.",
        "label": "Increase Decrease In Accrued And Other Current Liabilities",
        "negatedLabel": "Accrued liabilities and other liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccruedAndOtherCurrentLiabilities",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_InterestIncomeNonOperating": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the total non-operating interest income.",
        "label": "Interest Income Non Operating",
        "terseLabel": "Interest income"
       }
      }
     },
     "localname": "InterestIncomeNonOperating",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_MarketableSecuritiesAndCashEquivalents": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "1",
        "label": "Marketable Securities And Cash Equivalents",
        "totalLabel": "Total financial assets"
       }
      }
     },
     "localname": "MarketableSecuritiesAndCashEquivalents",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_NoncashOperatingLeaseExpense": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the amount of noncash operating lease expense.",
        "label": "Noncash Operating Lease Expense",
        "terseLabel": "Noncash operating lease expense"
       }
      }
     },
     "localname": "NoncashOperatingLeaseExpense",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_NumberOfVotesPerShare": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the number of votes per share.",
        "label": "Number Of Votes Per Share",
        "terseLabel": "Number of votes per share"
       }
      }
     },
     "localname": "NumberOfVotesPerShare",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "nxtc_OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to 2015 omnibus incentive plan and the information pertaining to 2019 Employee Stock Purchase Plan.",
        "label": "2015 Plan and 2019 Employee Stock Purchase Plan"
       }
      }
     },
     "localname": "OmnibusIncentive2015PlanAndEmployeeStockPurchase2019PlanMember",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_OmnibusIncentive2019PlanMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents information pertaining to Omnibus Incentive 2019 Plan.",
        "label": "Omnibus Incentive Plan"
       }
      }
     },
     "localname": "OmnibusIncentive2019PlanMember",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of operating lease liabilities initial lease recognition amount.",
        "label": "Operating Lease Liabilities Initial Lease Recognition Amount",
        "terseLabel": "Recognition of initial lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesInitialLeaseRecognitionAmount",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Adjusted amount after tax, before reclassification adjustments, of unrealized holding gain (loss) on available-for-sale securities.",
        "label": "Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax Adjusted",
        "verboseLabel": "Unrealized gain (loss) on marketable securities, net of tax $0"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTaxAdjusted",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_PaymentsOfUnderwritingDiscountsAndCommissions": {
     "auth_ref": [],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for payment of underwriting discounts and commissions.",
        "label": "Payments Of Underwriting Discounts And Commissions",
        "terseLabel": "Underwriting discounts and commissions"
       }
      }
     },
     "localname": "PaymentsOfUnderwritingDiscountsAndCommissions",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_PreferredStockAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Not available.",
        "label": "Preferred Stock Abstract",
        "terseLabel": "Redeemable preferred stock:",
        "verboseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockAbstract",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "nxtc_PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Represents the tabular disclosure of estimated useful lives for property and equipment.",
        "label": "Property, Plant and Equipment, Estimated Useful Lives [Table Text Block]",
        "terseLabel": "Summary of estimated useful lives for property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLivesTableTextBlock",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nxtc_RequiredReserveRestrictedCashCurrent": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of required reserve of restricted cash.",
        "label": "Required Reserve Restricted Cash Current",
        "terseLabel": "Restricted cash required reserve"
       }
      }
     },
     "localname": "RequiredReserveRestrictedCashCurrent",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "nxtc_ResearchEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible research equipment.",
        "label": "Research equipment"
       }
      }
     },
     "localname": "ResearchEquipmentMember",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "nxtc_ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the maturities of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule Of Available For Sale Securities Maturities Table Text Block",
        "terseLabel": "Schedule of available-for-sale maturities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesMaturitiesTableTextBlock",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "nxtc_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period which an employee's right to exercise an award is no longer available.",
        "label": "Share Based Compensation Arrangement By Share Based Payment Award Award Expiration Period",
        "terseLabel": "Expiration period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardExpirationPeriod",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "nxtc_ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase in shares available for issuance as a percentage of number of shares of the company's common stock outstanding on December 31st of the preceding calendar year.",
        "label": "Share Based Compensation Arrangement, Increase In Shares For Issuance As A Percentage Of Number Of Common Stock Outstanding",
        "terseLabel": "Annual increase in number of share reserved for issuance (as percent)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementIncreaseInSharesForIssuanceAsPercentageOfNumberOfCommonStockOutstanding",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "nxtc_ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The threshold number of shares of the company's common stock available for issuance under the plan.",
        "label": "Share Based Compensation Arrangement, Threshold Number Of Common Stock For Issuance Under The Plan",
        "terseLabel": "Maximum annual increase in shares available for issuance under the plan"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementThresholdNumberOfCommonStockForIssuanceUnderPlan",
     "nsuri": "http://www.nextcure.com/20221231",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "srt_MaximumMember": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r267",
      "r408",
      "r418",
      "r429",
      "r430",
      "r441",
      "r445",
      "r451",
      "r483",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Maximum"
       }
      }
     },
     "localname": "MaximumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_MinimumMember": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r267",
      "r408",
      "r418",
      "r429",
      "r430",
      "r441",
      "r445",
      "r451",
      "r483",
      "r522",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Minimum"
       }
      }
     },
     "localname": "MinimumMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "srt_RangeAxis": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r250",
      "r267",
      "r298",
      "r299",
      "r300",
      "r384",
      "r408",
      "r418",
      "r429",
      "r430",
      "r441",
      "r445",
      "r451",
      "r479",
      "r483",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Axis]"
       }
      }
     },
     "localname": "RangeAxis",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "srt_RangeMember": {
     "auth_ref": [
      "r209",
      "r210",
      "r211",
      "r212",
      "r250",
      "r267",
      "r298",
      "r299",
      "r300",
      "r384",
      "r408",
      "r418",
      "r429",
      "r430",
      "r441",
      "r445",
      "r451",
      "r479",
      "r483",
      "r523",
      "r524",
      "r525",
      "r526",
      "r527"
     ],
     "lang": {
      "en-us": {
       "role": {
        "label": "Range [Domain]"
       }
      }
     },
     "localname": "RangeMember",
     "nsuri": "http://fasb.org/srt/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AccountingPoliciesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "AccountingPoliciesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock": {
     "auth_ref": [
      "r14"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for accounts payable and accrued liabilities at the end of the reporting period.",
        "label": "Accounts Payable and Accrued Liabilities Disclosure [Text Block]",
        "terseLabel": "Accrued Liabilities and Other Liabilities"
       }
      }
     },
     "localname": "AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_AccountsPayableCurrent": {
     "auth_ref": [
      "r13",
      "r450"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Carrying value as of the balance sheet date of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Accounts Payable, Current",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "AccountsPayableCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccretionAmortizationOfDiscountsAndPremiumsInvestments": {
     "auth_ref": [
      "r38"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 5.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The sum of the periodic adjustments of the differences between securities' face values and purchase prices that are charged against earnings. This is called accretion if the security was purchased at a discount and amortization if it was purchased at premium. As a noncash item, this element is an adjustment to net income when calculating cash provided by or used in operations using the indirect method.",
        "label": "Accretion (Amortization) of Discounts and Premiums, Investments",
        "negatedLabel": "Amortization of premiums and discounts on marketable securities"
       }
      }
     },
     "localname": "AccretionAmortizationOfDiscountsAndPremiumsInvestments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccruedLiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Accrued Liabilities and Other Liabilities"
       }
      }
     },
     "localname": "AccruedLiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment": {
     "auth_ref": [
      "r59",
      "r122"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated depreciation, depletion and amortization for physical assets used in the normal conduct of business to produce goods and services.",
        "label": "Accumulated Depreciation, Depletion and Amortization, Property, Plant, and Equipment",
        "negatedLabel": "Less: accumulated depreciation and amortization"
       }
      }
     },
     "localname": "AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeLossNetOfTax": {
     "auth_ref": [
      "r22",
      "r24",
      "r25",
      "r125",
      "r415",
      "r423",
      "r424"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated change in equity from transactions and other events and circumstances from non-owner sources, net of tax effect, at period end. Excludes Net Income (Loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners. Includes foreign currency translation items, certain pension adjustments, unrealized gains and losses on certain investments in debt and equity securities, other than temporary impairment (OTTI) losses related to factors other than credit losses on available-for-sale and held-to-maturity debt securities that an entity does not intend to sell and it is not more likely than not that the entity will be required to sell before recovery of the amortized cost basis, as well as changes in the fair value of derivatives related to the effective portion of a designated cash flow hedge.",
        "label": "Accumulated Other Comprehensive Income (Loss), Net of Tax",
        "verboseLabel": "Accumulated other comprehensive loss"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeLossNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AccumulatedOtherComprehensiveIncomeMember": {
     "auth_ref": [
      "r21",
      "r25",
      "r85",
      "r376",
      "r419",
      "r420",
      "r463",
      "r464",
      "r465",
      "r468",
      "r469",
      "r470"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Accumulated increase (decrease) in equity from transactions and other events and circumstances from non-owner sources, attributable to the parent. Excludes net income (loss), and accumulated changes in equity from transactions resulting from investments by owners and distributions to owners.",
        "label": "Accumulated Other Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "AccumulatedOtherComprehensiveIncomeMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdditionalPaidInCapital": {
     "auth_ref": [
      "r8",
      "r450"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of excess of issue price over par or stated value of stock and from other transaction involving stock or stockholder. Includes, but is not limited to, additional paid-in capital (APIC) for common and preferred stock.",
        "label": "Additional Paid in Capital",
        "terseLabel": "Additional paid-in capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapital",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdditionalPaidInCapitalMember": {
     "auth_ref": [
      "r307",
      "r308",
      "r309",
      "r468",
      "r469",
      "r470",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Excess of issue price over par or stated value of the entity's capital stock and amounts received from other transactions involving the entity's stock or stockholders.",
        "label": "Additional Paid-in Capital"
       }
      }
     },
     "localname": "AdditionalPaidInCapitalMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue": {
     "auth_ref": [
      "r78",
      "r79",
      "r270"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.",
        "label": "Adjustments to Additional Paid in Capital, Share-based Compensation, Requisite Service Period Recognition",
        "terseLabel": "Stock based compensation"
       }
      }
     },
     "localname": "AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Adjustments to Reconcile Net Income (Loss) to Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Adjustments to reconcile net loss to net cash used in operating activities:"
       }
      }
     },
     "localname": "AdjustmentsToReconcileNetIncomeLossToCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AllocatedShareBasedCompensationExpense": {
     "auth_ref": [
      "r302"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for award under share-based payment arrangement. Excludes amount capitalized.",
        "label": "Allocated Share-based Compensation Expense",
        "terseLabel": "Total stock-based compensation expense"
       }
      }
     },
     "localname": "AllocatedShareBasedCompensationExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount": {
     "auth_ref": [
      "r169"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) or earnings per unit (EPU) in the future that were not included in the computation of diluted EPS or EPU because to do so would increase EPS or EPU amounts or decrease loss per share or unit amounts for the period presented.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount",
        "terseLabel": "Antidilutive securities excluded from computation of diluted net loss per share"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of antidilutive security.",
        "label": "Antidilutive Securities [Axis]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareByAntidilutiveSecuritiesAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]",
        "verboseLabel": "Antidilutive Securities"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AntidilutiveSecuritiesNameDomain": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Incremental common shares attributable to securities that were not included in diluted earnings per share (EPS) because to do so would increase EPS amounts or decrease loss per share amounts for the period presented.",
        "label": "Antidilutive Securities, Name [Domain]"
       }
      }
     },
     "localname": "AntidilutiveSecuritiesNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_AssetImpairmentChargesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Impairment of Long Lived Assets"
       }
      }
     },
     "localname": "AssetImpairmentChargesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_Assets": {
     "auth_ref": [
      "r98",
      "r107",
      "r124",
      "r147",
      "r181",
      "r183",
      "r185",
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r337",
      "r341",
      "r352",
      "r450",
      "r481",
      "r482",
      "r520"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are recognized. Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets",
        "totalLabel": "Total assets"
       }
      }
     },
     "localname": "Assets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets [Abstract]",
        "terseLabel": "Assets"
       }
      }
     },
     "localname": "AssetsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AssetsCurrent": {
     "auth_ref": [
      "r118",
      "r126",
      "r147",
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r337",
      "r341",
      "r352",
      "r450",
      "r481",
      "r482",
      "r520"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all assets that are expected to be realized in cash, sold, or consumed within one year (or the normal operating cycle, if longer). Assets are probable future economic benefits obtained or controlled by an entity as a result of past transactions or events.",
        "label": "Assets, Current",
        "totalLabel": "Total current assets"
       }
      }
     },
     "localname": "AssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AssetsCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Assets, Current [Abstract]",
        "terseLabel": "Current assets:"
       }
      }
     },
     "localname": "AssetsCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax": {
     "auth_ref": [
      "r50"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized gain in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Gain, before Tax",
        "terseLabel": "Gross Unrealized Gain"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax": {
     "auth_ref": [
      "r51"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before tax, of unrealized loss in accumulated other comprehensive income (AOCI) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Accumulated Gross Unrealized Loss, before Tax",
        "negatedLabel": "Gross Unrealized Loss"
       }
      }
     },
     "localname": "AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Available-for-sale Securities, Debt Maturities [Abstract]",
        "terseLabel": "Cost Maturities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate": {
     "auth_ref": [
      "r472",
      "r473",
      "r531"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value",
        "totalLabel": "Total investments available for sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Fair Value [Abstract]",
        "terseLabel": "Fair Value Maturities:"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis": {
     "auth_ref": [
      "r472",
      "r473",
      "r530"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date.",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, Amortized Cost",
        "totalLabel": "Total investments available for sale"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost": {
     "auth_ref": [
      "r53"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDateAmortizedCostBasis",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Amortized Cost",
        "terseLabel": "Within 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearAmortizedCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue": {
     "auth_ref": [
      "r52",
      "r187",
      "r413"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_AvailableForSaleSecuritiesDebtMaturitiesSingleMaturityDate",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), with single maturity date and allocated without single maturity date, maturing in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Debt Securities, Available-for-sale, Maturity, Allocated and Single Maturity Date, within One Year, Fair Value",
        "terseLabel": "Within 1 year"
       }
      }
     },
     "localname": "AvailableForSaleSecuritiesDebtMaturitiesWithinOneYearFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_BasisOfAccountingPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for basis of accounting, or basis of presentation, used to prepare the financial statements (for example, US Generally Accepted Accounting Principles, Other Comprehensive Basis of Accounting, IFRS).",
        "label": "Basis of Accounting, Policy [Policy Text Block]",
        "verboseLabel": "Basis of Presentation"
       }
      }
     },
     "localname": "BasisOfAccountingPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsAtCarryingValue": {
     "auth_ref": [
      "r39",
      "r120",
      "r432"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
       "weight": 1.0
      },
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates. Excludes cash and cash equivalents within disposal group and discontinued operation.",
        "label": "Cash and Cash Equivalents, at Carrying Value",
        "terseLabel": "Cash and cash equivalents",
        "verboseLabel": "Cash and cash equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAtCarryingValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails",
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsAxis": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of cash and cash equivalent balance.",
        "label": "Cash and Cash Equivalents [Axis]"
       }
      }
     },
     "localname": "CashAndCashEquivalentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashAndCashEquivalentsFairValueDisclosure": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": 1.0,
       "parentTag": "nxtc_MarketableSecuritiesAndCashEquivalents",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value portion of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents, Fair Value Disclosure",
        "terseLabel": "Money market funds (cash equivalents)"
       }
      }
     },
     "localname": "CashAndCashEquivalentsFairValueDisclosure",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashAndCashEquivalentsPolicyTextBlock": {
     "auth_ref": [
      "r40"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for cash and cash equivalents, including the policy for determining which items are treated as cash equivalents. Other information that may be disclosed includes (1) the nature of any restrictions on the entity's use of its cash and cash equivalents, (2) whether the entity's cash and cash equivalents are insured or expose the entity to credit risk, (3) the classification of any negative balance accounts (overdrafts), and (4) the carrying basis of cash equivalents (for example, at cost) and whether the carrying amount of cash equivalents approximates fair value.",
        "label": "Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Cash and Cash Equivalents"
       }
      }
     },
     "localname": "CashAndCashEquivalentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy": {
     "auth_ref": [
      "r40",
      "r97"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Entity's cash and cash equivalents accounting policy with respect to restricted balances. Restrictions may include legally restricted deposits held as compensating balances against short-term borrowing arrangements, contracts entered into with others, or company statements of intention with regard to particular deposits; however, time deposits and short-term certificates of deposit are not generally included in legally restricted deposits.",
        "label": "Cash and Cash Equivalents, Restricted Cash and Cash Equivalents, Policy [Policy Text Block]",
        "terseLabel": "Restricted Cash"
       }
      }
     },
     "localname": "CashAndCashEquivalentsRestrictedCashAndCashEquivalentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents": {
     "auth_ref": [
      "r34",
      "r39",
      "r41"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash and cash equivalents, and cash and cash equivalents restricted to withdrawal or usage. Excludes amount for disposal group and discontinued operations. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents",
        "periodEndLabel": "Cash and cash equivalents - end of period",
        "periodStartLabel": "Cash and cash equivalents - beginning of period",
        "totalLabel": "Total"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails",
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents [Abstract]"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect": {
     "auth_ref": [
      "r34",
      "r93"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in cash, cash equivalents, and cash and cash equivalents restricted to withdrawal or usage; including effect from exchange rate change. Cash includes, but is not limited to, currency on hand, demand deposits with banks or financial institutions, and other accounts with general characteristics of demand deposits. Cash equivalents include, but are not limited to, short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect",
        "totalLabel": "Net increase (decrease) in cash and cash equivalents"
       }
      }
     },
     "localname": "CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommitmentsAndContingenciesDisclosureTextBlock": {
     "auth_ref": [
      "r62",
      "r207",
      "r208",
      "r425",
      "r480"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for commitments and contingencies.",
        "label": "Commitments and Contingencies Disclosure [Text Block]",
        "terseLabel": "Commitments and Contingencies"
       }
      }
     },
     "localname": "CommitmentsAndContingenciesDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommitmentsAndContingencies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_CommonStockCapitalSharesReservedForFutureIssuance": {
     "auth_ref": [
      "r19"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate number of common shares reserved for future issuance.",
        "label": "Common Stock, Capital Shares Reserved for Future Issuance",
        "terseLabel": "Number of shares reserved for issuance under the plan"
       }
      }
     },
     "localname": "CommonStockCapitalSharesReservedForFutureIssuance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockDividendsPerShareDeclared": {
     "auth_ref": [
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate dividends declared during the period for each share of common stock outstanding.",
        "label": "Common Stock, Dividends, Per Share, Declared",
        "terseLabel": "Dividends declared"
       }
      }
     },
     "localname": "CommonStockDividendsPerShareDeclared",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockMember": {
     "auth_ref": [
      "r468",
      "r469",
      "r515"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Stock that is subordinate to all other stock of the issuer.",
        "label": "Common Stock"
       }
      }
     },
     "localname": "CommonStockMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Common Stock."
       }
      }
     },
     "localname": "CommonStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_CommonStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of common stock.",
        "label": "Common Stock, Par or Stated Value Per Share",
        "terseLabel": "Common stock, par value per share"
       }
      }
     },
     "localname": "CommonStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_CommonStockSharesAuthorized": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of common shares permitted to be issued by an entity's charter and bylaws.",
        "label": "Common Stock, Shares Authorized",
        "terseLabel": "Common stock, number of shares authorized"
       }
      }
     },
     "localname": "CommonStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesIssued": {
     "auth_ref": [
      "r7"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of common shares of an entity that have been sold or granted to shareholders (includes common shares that were issued, repurchased and remain in the treasury). These shares represent capital invested by the firm's shareholders and owners, and may be all or only a portion of the number of shares authorized. Shares issued include shares outstanding and shares held in the treasury.",
        "label": "Common Stock, Shares, Issued",
        "terseLabel": "Common stock, shares issued"
       }
      }
     },
     "localname": "CommonStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockSharesOutstanding": {
     "auth_ref": [
      "r7",
      "r65"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares of common stock outstanding. Common stock represent the ownership interest in a corporation.",
        "label": "Common Stock, Shares, Outstanding",
        "periodEndLabel": "Balance at the end (in shares)",
        "periodStartLabel": "Balance at the beginning (in shares)",
        "terseLabel": "Common stock, shares outstanding"
       }
      }
     },
     "localname": "CommonStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_CommonStockValue": {
     "auth_ref": [
      "r7",
      "r450"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable common stock (or common stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable common shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Common Stock, Value, Issued",
        "terseLabel": "Common stock, par value of $0.001 per share; 100,000,000 shares authorized at December 31, 2022 and December 31, 2021. 27,774,536 and 27,680,997 shares issued and outstanding at December 31, 2022 and December 31, 2021, respectively"
       }
      }
     },
     "localname": "CommonStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_CompensationAndRetirementDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Employee Benefit Plan"
       }
      }
     },
     "localname": "CompensationAndRetirementDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Components of Deferred Tax Assets and Liabilities [Abstract]",
        "terseLabel": "Principal components of the Company's deferred tax assets"
       }
      }
     },
     "localname": "ComponentsOfDeferredTaxAssetsAndLiabilitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ComprehensiveIncomeNetOfTax": {
     "auth_ref": [
      "r26",
      "r131",
      "r133",
      "r138",
      "r410",
      "r416"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after tax of increase (decrease) in equity from transactions and other events and circumstances from net income and other comprehensive income, attributable to parent entity. Excludes changes in equity resulting from investments by owners and distributions to owners.",
        "label": "Comprehensive Income (Loss), Net of Tax, Attributable to Parent",
        "totalLabel": "Total comprehensive loss"
       }
      }
     },
     "localname": "ComprehensiveIncomeNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ComprehensiveIncomePolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for comprehensive income.",
        "label": "Comprehensive Income, Policy [Policy Text Block]",
        "terseLabel": "Comprehensive Income (Loss)"
       }
      }
     },
     "localname": "ComprehensiveIncomePolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ComputerEquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Long lived, depreciable assets that are used in the creation, maintenance and utilization of information systems.",
        "label": "Computer equipment"
       }
      }
     },
     "localname": "ComputerEquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ConcentrationRiskCreditRisk": {
     "auth_ref": [
      "r105",
      "r177"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for credit risk.",
        "label": "Concentration Risk, Credit Risk, Policy [Policy Text Block]",
        "terseLabel": "Concentration of Credit Risk"
       }
      }
     },
     "localname": "ConcentrationRiskCreditRisk",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ConstructionInProgressMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Structure or a modification to a structure under construction. Includes recently completed structures or modifications to structures that have not been placed into service.",
        "label": "Construction in progress"
       }
      }
     },
     "localname": "ConstructionInProgressMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_CorporateDebtSecuritiesMember": {
     "auth_ref": [
      "r442",
      "r444",
      "r532"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debt securities issued by domestic or foreign corporate business, banks and other entities with a promise of repayment.",
        "label": "Corporate bonds"
       }
      }
     },
     "localname": "CorporateDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_DebtDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Term Loan"
       }
      }
     },
     "localname": "DebtDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_DebtDisclosureTextBlock": {
     "auth_ref": [
      "r63",
      "r146",
      "r223",
      "r224",
      "r225",
      "r226",
      "r227",
      "r228",
      "r229",
      "r232",
      "r233",
      "r234",
      "r236"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.",
        "label": "Debt Disclosure [Text Block]",
        "terseLabel": "Term Loan"
       }
      }
     },
     "localname": "DebtDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureTermLoan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DebtInstrumentFaceAmount": {
     "auth_ref": [
      "r94",
      "r95",
      "r222",
      "r360",
      "r439",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face (par) amount of debt instrument at time of issuance.",
        "label": "Debt Instrument, Face Amount",
        "terseLabel": "Face amount"
       }
      }
     },
     "localname": "DebtInstrumentFaceAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails",
      "http://www.nextcure.com/role/DisclosureTermLoanOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss": {
     "auth_ref": [
      "r200"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amortized cost excluding accrued interest, before allowance for credit loss, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Amortized Cost, Excluding Accrued Interest, before Allowance for Credit Loss",
        "totalLabel": "Amortized Cost"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger": {
     "auth_ref": [
      "r190",
      "r202",
      "r438"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), in continuous unrealized loss position for more than 12 months, without allowance for credit loss. Includes beneficial interest in securitized financial asset.",
        "label": "Debt Securities, Available-for-Sale, Continuous Unrealized Loss Position, 12 Months or Longer",
        "terseLabel": "Unrealized losses in a continuous loss position for more than twelve consecutive months"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterest": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails": {
       "order": 2.0,
       "parentTag": "nxtc_MarketableSecuritiesAndCashEquivalents",
       "weight": 1.0
      },
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DebtSecuritiesAvailableForSaleAmortizedCostExcludingAccruedInterestBeforeAllowanceForCreditLoss",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest",
        "terseLabel": "Estimated Fair Value",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterest",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent": {
     "auth_ref": [
      "r478"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount excluding accrued interest, of investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale), classified as current.",
        "label": "Debt Securities, Available-for-Sale, Excluding Accrued Interest, Current",
        "terseLabel": "Marketable securities"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleExcludingAccruedInterestCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleRealizedGain": {
     "auth_ref": [
      "r191"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of realized gain on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale, Realized Gain",
        "terseLabel": "Gross realized gains"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleRealizedGain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DebtSecuritiesAvailableForSaleTable": {
     "auth_ref": [
      "r192"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale).",
        "label": "Debt Securities, Available-for-sale [Table]"
       }
      }
     },
     "localname": "DebtSecuritiesAvailableForSaleTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredIncomeTaxLiabilities": {
     "auth_ref": [
      "r2",
      "r3",
      "r99",
      "r106",
      "r321"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences.",
        "label": "Deferred Tax Liabilities, Gross",
        "negatedTotalLabel": "Gross deferred tax liabilities"
       }
      }
     },
     "localname": "DeferredIncomeTaxLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsGross": {
     "auth_ref": [
      "r322"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Gross",
        "totalLabel": "Gross deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsLiabilitiesNet": {
     "auth_ref": [
      "r512"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after allocation of valuation allowances and deferred tax liability, of deferred tax asset attributable to deductible differences and carryforwards, without jurisdictional netting.",
        "label": "Deferred Tax Assets, Net",
        "totalLabel": "Net deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsLiabilitiesNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNet": {
     "auth_ref": [
      "r512"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsLiabilitiesNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences and carryforwards.",
        "label": "Deferred Tax Assets, Net of Valuation Allowance",
        "totalLabel": "Total deferred tax assets"
       }
      }
     },
     "localname": "DeferredTaxAssetsNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Assets, Net [Abstract]",
        "terseLabel": "Deferred tax assets:"
       }
      }
     },
     "localname": "DeferredTaxAssetsNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwards": {
     "auth_ref": [
      "r84",
      "r513"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards",
        "terseLabel": "Federal and state net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwards",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsDomestic": {
     "auth_ref": [
      "r84",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible domestic operating loss carryforwards. Excludes state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Domestic",
        "terseLabel": "Federal net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsDomestic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible operating loss carryforwards that are not subject to expiration dates.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, Not Subject to Expiration",
        "terseLabel": "Federal net operating loss carryforwards that do not expire"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsNotSubjectToExpiration",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal": {
     "auth_ref": [
      "r84",
      "r513"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible state and local operating loss carryforwards.",
        "label": "Deferred Tax Assets, Operating Loss Carryforwards, State and Local",
        "terseLabel": "State net operating loss carryforwards"
       }
      }
     },
     "localname": "DeferredTaxAssetsOperatingLossCarryforwardsStateAndLocal",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxCreditCarryforwardsResearch": {
     "auth_ref": [
      "r83",
      "r84",
      "r513"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible research tax credit carryforwards.",
        "label": "Deferred Tax Assets, Tax Credit Carryforwards, Research",
        "terseLabel": "Research and development tax credits"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxCreditCarryforwardsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost": {
     "auth_ref": [
      "r84",
      "r513"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_DeferredTaxAssetsGross",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before allocation of valuation allowances of deferred tax asset attributable to deductible temporary differences from share-based compensation.",
        "label": "Deferred Tax Assets, Tax Deferred Expense, Compensation and Benefits, Share-based Compensation Cost",
        "terseLabel": "Share-based compensation"
       }
      }
     },
     "localname": "DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r323"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredTaxAssetsNet",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax assets for which it is more likely than not that a tax benefit will not be realized.",
        "label": "Deferred Tax Assets, Valuation Allowance",
        "negatedLabel": "Less: valuation allowance"
       }
      }
     },
     "localname": "DeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesLeasingArrangements": {
     "auth_ref": [
      "r84",
      "r513"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_DeferredIncomeTaxLiabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of deferred tax liability attributable to taxable temporary differences from leasing arrangements.",
        "label": "Deferred Tax Liabilities, Leasing Arrangements",
        "negatedLabel": "Operating lease assets"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesLeasingArrangements",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DeferredTaxLiabilitiesNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Deferred Tax Liabilities, Net [Abstract]",
        "terseLabel": "Deferred tax liabilities:"
       }
      }
     },
     "localname": "DeferredTaxLiabilitiesNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_DefinedContributionPlanEmployerDiscretionaryContributionAmount": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of discretionary contributions made by an employer to a defined contribution plan.",
        "label": "Defined Contribution Plan, Employer Discretionary Contribution Amount",
        "terseLabel": "Employer contributions amount"
       }
      }
     },
     "localname": "DefinedContributionPlanEmployerDiscretionaryContributionAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureEmployeeBenefitPlanDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DepreciationDepletionAndAmortization": {
     "auth_ref": [
      "r37",
      "r180"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate expense recognized in the current period that allocates the cost of tangible assets, intangible assets, or depleting assets to periods that benefit from use of the assets.",
        "label": "Depreciation, Depletion and Amortization",
        "terseLabel": "Depreciation and amortization expense"
       }
      }
     },
     "localname": "DepreciationDepletionAndAmortization",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock": {
     "auth_ref": [
      "r272",
      "r303",
      "r304",
      "r306",
      "r311",
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for share-based payment arrangement.",
        "label": "Disclosure of Compensation Related Costs, Share-based Payments [Text Block]",
        "terseLabel": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsShareBasedPaymentsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stock-Based Compensation"
       }
      }
     },
     "localname": "DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_EarningsPerShareBasic": {
     "auth_ref": [
      "r139",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r162",
      "r164",
      "r166",
      "r167",
      "r168",
      "r172",
      "r345",
      "r346",
      "r411",
      "r417",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.",
        "label": "Earnings Per Share, Basic",
        "verboseLabel": "Basic (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerShareDiluted": {
     "auth_ref": [
      "r139",
      "r154",
      "r155",
      "r156",
      "r157",
      "r158",
      "r164",
      "r166",
      "r167",
      "r168",
      "r172",
      "r345",
      "r346",
      "r411",
      "r417",
      "r435"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.",
        "label": "Earnings Per Share, Diluted",
        "verboseLabel": "Diluted (in dollars per share)"
       }
      }
     },
     "localname": "EarningsPerShareDiluted",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_EarningsPerSharePolicyTextBlock": {
     "auth_ref": [
      "r43",
      "r44"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for computing basic and diluted earnings or loss per share for each class of common stock and participating security. Addresses all significant policy factors, including any antidilutive items that have been excluded from the computation and takes into account stock dividends, splits and reverse splits that occur after the balance sheet date of the latest reporting period but before the issuance of the financial statements.",
        "label": "Earnings Per Share, Policy [Policy Text Block]",
        "terseLabel": "Net Loss per Share"
       }
      }
     },
     "localname": "EarningsPerSharePolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EarningsPerShareTextBlock": {
     "auth_ref": [
      "r169",
      "r170",
      "r171",
      "r173"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for earnings per share.",
        "label": "Earnings Per Share [Text Block]",
        "terseLabel": "Net Loss per Share Attributable to Common Stockholders"
       }
      }
     },
     "localname": "EarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholders"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperations": {
     "auth_ref": [
      "r315"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.",
        "label": "Effective Income Tax Rate Reconciliation, Percent",
        "totalLabel": "Total (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperations",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Reconciliation of federal statutory income tax rate to the Company's effective income tax rate",
        "terseLabel": "Reconciliation of federal statutory income tax rate to the Company's effective income tax rate"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateContinuingOperationsTaxRateReconciliationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate": {
     "auth_ref": [
      "r148",
      "r315",
      "r331"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of domestic federal statutory tax rate applicable to pretax income (loss).",
        "label": "Effective Income Tax Rate Reconciliation, at Federal Statutory Income Tax Rate, Percent",
        "verboseLabel": "Expected income tax benefit at the federal statutory rate (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance": {
     "auth_ref": [
      "r511",
      "r514"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to changes in the valuation allowance for deferred tax assets.",
        "label": "Effective Income Tax Rate Reconciliation, Change in Deferred Tax Assets Valuation Allowance, Percent",
        "terseLabel": "Change in valuation allowance (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationNondeductibleExpense": {
     "auth_ref": [
      "r511",
      "r514"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to nondeductible expenses.",
        "label": "Effective Income Tax Rate Reconciliation, Nondeductible Expense, Percent",
        "terseLabel": "Non-deductible items (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationNondeductibleExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes": {
     "auth_ref": [
      "r511",
      "r514"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to revisions of previously reported income tax expense.",
        "label": "Effective Income Tax Rate Reconciliation, Prior Year Income Taxes, Percent",
        "terseLabel": "Prior year provision to return adjustments (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationPriorYearIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes": {
     "auth_ref": [
      "r511",
      "r514"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations applicable to state and local income tax expense (benefit), net of federal tax expense (benefit).",
        "label": "Effective Income Tax Rate Reconciliation, State and Local Income Taxes, Percent",
        "terseLabel": "State taxes, net of federal benefit (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EffectiveIncomeTaxRateReconciliationTaxCreditsResearch": {
     "auth_ref": [
      "r511",
      "r514"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_EffectiveIncomeTaxRateContinuingOperations",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Percentage of the difference between reported income tax expense (benefit) and expected income tax expense (benefit) computed by applying the domestic federal statutory income tax rates to pretax income (loss) from continuing operations attributable to research tax credit.",
        "label": "Effective Income Tax Rate Reconciliation, Tax Credit, Research, Percent",
        "terseLabel": "Research and development credit, net (as a percent)"
       }
      }
     },
     "localname": "EffectiveIncomeTaxRateReconciliationTaxCreditsResearch",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesReconciliationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_EmployeeRelatedLiabilitiesCurrent": {
     "auth_ref": [
      "r16"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails": {
       "order": 1.0,
       "parentTag": "nxtc_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of the carrying values as of the balance sheet date of obligations incurred through that date and payable for obligations related to services received from employees, such as accrued salaries and bonuses, payroll taxes and fringe benefits. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).",
        "label": "Employee-related Liabilities, Current",
        "terseLabel": "Payroll and related benefits"
       }
      }
     },
     "localname": "EmployeeRelatedLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Payment Arrangement, Additional Disclosure [Abstract]",
        "terseLabel": "Share Based Compensation Expense Not Recognized"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAggregateDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]",
        "terseLabel": "Stock based compensation expense"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized": {
     "auth_ref": [
      "r305"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cost not yet recognized for nonvested award under share-based payment arrangement.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized",
        "terseLabel": "Unrecognized compensation cost"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1": {
     "auth_ref": [
      "r305"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition",
        "terseLabel": "Compensation expense recognition period"
       }
      }
     },
     "localname": "EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_EmployeeStockOptionMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Share-based payment arrangement granting right, subject to vesting and other restrictions, to purchase or sell certain number of shares at predetermined price for specified period of time.",
        "label": "Option to purchase common stock"
       }
      }
     },
     "localname": "EmployeeStockOptionMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquipmentMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tangible personal property used to produce goods and services.",
        "label": "Equipment"
       }
      }
     },
     "localname": "EquipmentMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EquityComponentDomain": {
     "auth_ref": [
      "r65",
      "r116",
      "r135",
      "r136",
      "r137",
      "r149",
      "r150",
      "r151",
      "r153",
      "r159",
      "r161",
      "r174",
      "r194",
      "r240",
      "r307",
      "r308",
      "r309",
      "r328",
      "r329",
      "r344",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r376",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Components of equity are the parts of the total Equity balance including that which is allocated to common, preferred, treasury stock, retained earnings, etc.",
        "label": "Equity Component [Domain]"
       }
      }
     },
     "localname": "EquityComponentDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_EstimateOfFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r231",
      "r351",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured as an estimate of fair value.",
        "label": "Fair Value"
       }
      }
     },
     "localname": "EstimateOfFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Fair Value, Balance Sheet Grouping, Financial Statement Captions [Line Items]"
       }
      }
     },
     "localname": "FairValueBalanceSheetGroupingFinancialStatementCaptionsLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTable": {
     "auth_ref": [
      "r87",
      "r91",
      "r92"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table]"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByBalanceSheetGroupingTextBlock": {
     "auth_ref": [
      "r87",
      "r91"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the fair value of financial instruments, including financial assets and financial liabilities, and the measurements of those instruments, assets, and liabilities.",
        "label": "Fair Value, by Balance Sheet Grouping [Table Text Block]",
        "terseLabel": "Summary of fair value of the Company's financial assets"
       }
      }
     },
     "localname": "FairValueByBalanceSheetGroupingTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueByFairValueHierarchyLevelAxis": {
     "auth_ref": [
      "r231",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r347",
      "r381",
      "r382",
      "r383",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by level within fair value hierarchy and fair value measured at net asset value per share as practical expedient.",
        "label": "Fair Value Hierarchy and NAV [Axis]"
       }
      }
     },
     "localname": "FairValueByFairValueHierarchyLevelAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueByMeasurementBasisAxis": {
     "auth_ref": [
      "r87",
      "r88",
      "r231",
      "r439",
      "r440"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by measurement basis.",
        "label": "Measurement Basis [Axis]"
       }
      }
     },
     "localname": "FairValueByMeasurementBasisAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_FairValueDisclosuresTextBlock": {
     "auth_ref": [
      "r349"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.",
        "label": "Fair Value Disclosures [Text Block]",
        "terseLabel": "Fair Value Measurements"
       }
      }
     },
     "localname": "FairValueDisclosuresTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurements"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FairValueInputsLevel1Member": {
     "auth_ref": [
      "r231",
      "r252",
      "r257",
      "r347",
      "r381",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Quoted prices in active markets for identical assets or liabilities that the reporting entity can access at the measurement date.",
        "label": "Quoted Prices in Active Markets (Level 1)"
       }
      }
     },
     "localname": "FairValueInputsLevel1Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueInputsLevel2Member": {
     "auth_ref": [
      "r231",
      "r252",
      "r257",
      "r347",
      "r382",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Inputs other than quoted prices included within level 1 that are observable for an asset or liability, either directly or indirectly, including, but not limited to, quoted prices for similar assets or liabilities in active markets, or quoted prices for identical or similar assets or liabilities in inactive markets.",
        "label": "Significant Other Observable Inputs (Level 2)"
       }
      }
     },
     "localname": "FairValueInputsLevel2Member",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfer of financial instrument classified as an asset into level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset Transfers Into Level 3",
        "terseLabel": "Assets transferred into level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersIntoLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3": {
     "auth_ref": [
      "r348"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of transfers of financial instrument classified as an asset out of level 3 of the fair value hierarchy.",
        "label": "Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Asset, Transfers out of Level 3",
        "terseLabel": "Assets transferred out of level 3"
       }
      }
     },
     "localname": "FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisAssetTransfersOutOfLevel3",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_FairValueMeasurementsFairValueHierarchyDomain": {
     "auth_ref": [
      "r231",
      "r252",
      "r253",
      "r254",
      "r255",
      "r256",
      "r257",
      "r381",
      "r382",
      "r383",
      "r439",
      "r440",
      "r442",
      "r443",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Categories used to prioritize the inputs to valuation techniques to measure fair value.",
        "label": "Fair Value Hierarchy and NAV [Domain]"
       }
      }
     },
     "localname": "FairValueMeasurementsFairValueHierarchyDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_FairValueOfFinancialInstrumentsPolicy": {
     "auth_ref": [
      "r89",
      "r90"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for determining the fair value of financial instruments.",
        "label": "Fair Value of Financial Instruments, Policy [Policy Text Block]",
        "terseLabel": "Fair Value of Financial Instruments"
       }
      }
     },
     "localname": "FairValueOfFinancialInstrumentsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_FinancialInstrumentAxis": {
     "auth_ref": [
      "r188",
      "r189",
      "r195",
      "r196",
      "r197",
      "r198",
      "r199",
      "r201",
      "r203",
      "r204",
      "r235",
      "r239",
      "r343",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r438",
      "r474",
      "r475",
      "r476",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of financial instrument.",
        "label": "Financial Instrument [Axis]"
       }
      }
     },
     "localname": "FinancialInstrumentAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Financial Instruments, Financial Assets, Balance Sheet Groupings [Abstract]",
        "terseLabel": "Fair value of the Company's financial assets"
       }
      }
     },
     "localname": "FinancialInstrumentsFinancialAssetsBalanceSheetGroupingsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_FurnitureAndFixturesMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equipment commonly used in offices and stores that have no permanent connection to the structure of a building or utilities. Examples include, but are not limited to, desks, chairs, tables, and bookcases.",
        "label": "Furniture and fixtures"
       }
      }
     },
     "localname": "FurnitureAndFixturesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GainLossOnSaleOfPropertyPlantEquipment": {
     "auth_ref": [
      "r37"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of gain (loss) on sale or disposal of property, plant and equipment assets, including oil and gas property and timber property.",
        "label": "Gain (Loss) on Disposition of Property Plant Equipment",
        "negatedLabel": "Loss on disposal of property and equipment"
       }
      }
     },
     "localname": "GainLossOnSaleOfPropertyPlantEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpense": {
     "auth_ref": [
      "r29"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.",
        "label": "General and Administrative Expense",
        "terseLabel": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_GeneralAndAdministrativeExpenseMember": {
     "auth_ref": [
      "r28"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption encompassing general and administrative expense.",
        "label": "General and administrative"
       }
      }
     },
     "localname": "GeneralAndAdministrativeExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_GoodwillAndIntangibleAssetsIntangibleAssetsPolicy": {
     "auth_ref": [
      "r55"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for intangible assets. This accounting policy may address both intangible assets subject to amortization and those that are not. The following also may be disclosed: (1) a description of intangible assets (2) the estimated useful lives of those assets (3) the amortization method used (4) how the entity assesses and measures impairment of such assets (5) how future cash flows are estimated (6) how the fair values of such asset are determined.",
        "label": "Goodwill and Intangible Assets, Intangible Assets, Policy [Policy Text Block]",
        "terseLabel": "Patent Costs"
       }
      }
     },
     "localname": "GoodwillAndIntangibleAssetsIntangibleAssetsPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IPOMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "First sale of stock by a private company to the public.",
        "label": "IPO"
       }
      }
     },
     "localname": "IPOMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ImpairmentOfLongLivedAssetsToBeDisposedOf": {
     "auth_ref": [
      "r37",
      "r57"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate amount of write-downs for impairments recognized during the period for long-lived assets held for abandonment, exchange or sale.",
        "label": "Impairment of Long-Lived Assets to be Disposed of",
        "terseLabel": "Impairment loss recognized"
       }
      }
     },
     "localname": "ImpairmentOfLongLivedAssetsToBeDisposedOf",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncomeStatementAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS"
       }
      }
     },
     "localname": "IncomeStatementAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationAxis": {
     "auth_ref": [
      "r205",
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by location in the income statement.",
        "label": "Income Statement Location [Axis]"
       }
      }
     },
     "localname": "IncomeStatementLocationAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeStatementLocationDomain": {
     "auth_ref": [
      "r206"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Location in the income statement.",
        "label": "Income Statement Location [Domain]"
       }
      }
     },
     "localname": "IncomeStatementLocationDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_IncomeTaxDisclosureAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncomeTaxDisclosureTextBlock": {
     "auth_ref": [
      "r148",
      "r316",
      "r319",
      "r326",
      "r330",
      "r332",
      "r333",
      "r334",
      "r335"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for income taxes. Disclosures may include net deferred tax liability or asset recognized in an enterprise's statement of financial position, net change during the year in the total valuation allowance, approximate tax effect of each type of temporary difference and carryforward that gives rise to a significant portion of deferred tax liabilities and deferred tax assets, utilization of a tax carryback, and tax uncertainties information.",
        "label": "Income Tax Disclosure [Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxes"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxPolicyTextBlock": {
     "auth_ref": [
      "r134",
      "r313",
      "r314",
      "r319",
      "r320",
      "r325",
      "r327"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for income taxes, which may include its accounting policies for recognizing and measuring deferred tax assets and liabilities and related valuation allowances, recognizing investment tax credits, operating loss carryforwards, tax credit carryforwards, and other carryforwards, methodologies for determining its effective income tax rate and the characterization of interest and penalties in the financial statements.",
        "label": "Income Tax, Policy [Policy Text Block]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_IncomeTaxUncertaintiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Income Tax Uncertainties [Abstract]",
        "terseLabel": "Income Taxes"
       }
      }
     },
     "localname": "IncomeTaxUncertaintiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInAccountsPayable": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The increase (decrease) during the reporting period in the aggregate amount of liabilities incurred (and for which invoices have typically been received) and payable to vendors for goods and services received that are used in an entity's business.",
        "label": "Increase (Decrease) in Accounts Payable",
        "terseLabel": "Accounts payable"
       }
      }
     },
     "localname": "IncreaseDecreaseInAccountsPayable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInOperatingCapitalAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Increase (Decrease) in Operating Capital [Abstract]",
        "terseLabel": "Changes in operating assets and liabilities:"
       }
      }
     },
     "localname": "IncreaseDecreaseInOperatingCapitalAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_IncreaseDecreaseInOtherNoncurrentLiabilities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 7.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in noncurrent operating liabilities classified as other.",
        "label": "Increase (Decrease) in Other Noncurrent Liabilities",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "IncreaseDecreaseInOtherNoncurrentLiabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 8.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in prepaid expenses, and assets classified as other.",
        "label": "Increase (Decrease) in Prepaid Expense and Other Assets",
        "negatedLabel": "Prepaid expenses and other assets"
       }
      }
     },
     "localname": "IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_IncreaseDecreaseInStockholdersEquityRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Increase (Decrease) in Stockholders' Equity [Roll Forward]",
        "terseLabel": "Increase (Decrease) in Stockholders' Deficit"
       }
      }
     },
     "localname": "IncreaseDecreaseInStockholdersEquityRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_InterestPaidNet": {
     "auth_ref": [
      "r140",
      "r143",
      "r144"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash paid for interest, excluding capitalized interest, classified as operating activity. Includes, but is not limited to, payment to settle zero-coupon bond for accreted interest of debt discount and debt instrument with insignificant coupon interest rate in relation to effective interest rate of borrowing attributable to accreted interest of debt discount.",
        "label": "Interest Paid, Excluding Capitalized Interest, Operating Activities",
        "terseLabel": "Cash paid for interest"
       }
      }
     },
     "localname": "InterestPaidNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_InvestmentsDebtAndEquitySecuritiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsDebtAndEquitySecuritiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock": {
     "auth_ref": [
      "r54",
      "r96",
      "r104",
      "r113",
      "r431"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for investments in certain debt and equity securities.",
        "label": "Investments in Debt and Marketable Equity Securities (and Certain Trading Assets) Disclosure [Text Block]",
        "verboseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "InvestmentsInDebtAndMarketableEquitySecuritiesAndCertainTradingAssetsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecurities"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LeasePracticalExpedientUseOfHindsight": {
     "auth_ref": [
      "r362",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedient is elected to use hindsight in determining lease term and in assessing impairment of right-of-use asset.",
        "label": "Lease, Practical Expedient, Use of Hindsight [true false]"
       }
      }
     },
     "localname": "LeasePracticalExpedientUseOfHindsight",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LeasePracticalExpedientsPackage": {
     "auth_ref": [
      "r361",
      "r363"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether practical expedients are elected for not reassessing whether any expired or existing contract is or contains lease, lease classification for expired or existing lease, and initial direct cost for any existing lease.",
        "label": "Lease, Practical Expedients, Package [true false]"
       }
      }
     },
     "localname": "LeasePracticalExpedientsPackage",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LeaseholdImprovementsMember": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Additions or improvements to assets held under a lease arrangement.",
        "label": "Leasehold improvements"
       }
      }
     },
     "localname": "LeaseholdImprovementsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_LeasesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Leases"
       }
      }
     },
     "localname": "LeasesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_LesseeOperatingLeaseExistenceOfOptionToExtend": {
     "auth_ref": [
      "r368"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates (true false) whether lessee has option to extend operating lease.",
        "label": "Lessee, Operating Lease, Existence of Option to Extend [true false]"
       }
      }
     },
     "localname": "LesseeOperatingLeaseExistenceOfOptionToExtend",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails"
     ],
     "xbrltype": "booleanItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityMaturityTableTextBlock": {
     "auth_ref": [
      "r519"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of undiscounted cash flows of lessee's operating lease liability. Includes, but is not limited to, reconciliation of undiscounted cash flows to operating lease liability recognized in statement of financial position.",
        "label": "Lessee, Operating Lease, Liability, Maturity [Table Text Block]",
        "terseLabel": "Schedule of future minimum lease payments under non-cancellable leases"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityMaturityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesCalc2Details": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease.",
        "label": "Lessee, Operating Lease, Liability, to be Paid",
        "totalLabel": "Total future minimum payments"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails": {
       "order": 6.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease due after fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, after Year Five",
        "terseLabel": "Thereafter"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in next fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year One",
        "terseLabel": "2023"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFive": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails": {
       "order": 5.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fifth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Five",
        "terseLabel": "2027"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFive",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearFour": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails": {
       "order": 4.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in fourth fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Four",
        "terseLabel": "2026"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearFour",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearThree": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails": {
       "order": 3.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in third fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Three",
        "terseLabel": "2025"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearThree",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDueYearTwo": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payment for operating lease to be paid in second fiscal year following current fiscal year. Excludes interim and annual periods when interim periods are reported from current statement of financial position date (rolling approach).",
        "label": "Lessee, Operating Lease, Liability, to be Paid, Year Two",
        "terseLabel": "2024"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityPaymentsDueYearTwo",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseLiabilityUndiscountedExcessAmount": {
     "auth_ref": [
      "r373"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesCalc2Details": {
       "order": 1.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's undiscounted obligation for lease payments in excess of discounted obligation for lease payments for operating lease.",
        "label": "Lessee, Operating Lease, Liability, Undiscounted Excess Amount",
        "negatedLabel": "Less: present value discount"
       }
      }
     },
     "localname": "LesseeOperatingLeaseLiabilityUndiscountedExcessAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LesseeOperatingLeaseRenewalTerm": {
     "auth_ref": [
      "r518"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Term of lessee's operating lease renewal, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Lessee, Operating Lease, Renewal Term",
        "terseLabel": "Lease extension period"
       }
      }
     },
     "localname": "LesseeOperatingLeaseRenewalTerm",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_LesseeOperatingLeasesTextBlock": {
     "auth_ref": [
      "r375"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for operating leases of lessee. Includes, but is not limited to, description of operating lease and maturity analysis of operating lease liability.",
        "label": "Lessee, Operating Leases [Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "LesseeOperatingLeasesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeases"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_Liabilities": {
     "auth_ref": [
      "r15",
      "r147",
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r338",
      "r341",
      "r342",
      "r352",
      "r436",
      "r481",
      "r520",
      "r521"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sum of the carrying amounts as of the balance sheet date of all liabilities that are recognized. Liabilities are probable future sacrifices of economic benefits arising from present obligations of an entity to transfer assets or provide services to other entities in the future.",
        "label": "Liabilities",
        "totalLabel": "Total liabilities"
       }
      }
     },
     "localname": "Liabilities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquity": {
     "auth_ref": [
      "r12",
      "r101",
      "r110",
      "r450",
      "r467",
      "r477",
      "r516"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities and equity items, including the portion of equity attributable to noncontrolling interests, if any.",
        "label": "Liabilities and Equity",
        "totalLabel": "Total liabilities and stockholders' equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesAndStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities and Equity [Abstract]",
        "terseLabel": "Liabilities and Stockholders' Equity"
       }
      }
     },
     "localname": "LiabilitiesAndStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LiabilitiesCurrent": {
     "auth_ref": [
      "r17",
      "r119",
      "r147",
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r338",
      "r341",
      "r342",
      "r352",
      "r450",
      "r481",
      "r520",
      "r521"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total obligations incurred as part of normal operations that are expected to be paid during the following twelve months or within one business cycle, if longer.",
        "label": "Liabilities, Current",
        "totalLabel": "Total current liabilities"
       }
      }
     },
     "localname": "LiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_LiabilitiesCurrentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Liabilities, Current [Abstract]",
        "terseLabel": "Current liabilities:"
       }
      }
     },
     "localname": "LiabilitiesCurrentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_LongTermDebt": {
     "auth_ref": [
      "r1",
      "r100",
      "r108",
      "r230",
      "r237",
      "r439",
      "r440"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, excluding unamortized premium (discount) and debt issuance cost, of long-term debt. Excludes lease obligation.",
        "label": "Long-term Debt",
        "terseLabel": "Outstanding balance"
       }
      }
     },
     "localname": "LongTermDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureTermLoanOtherDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_MarketableSecuritiesPolicy": {
     "auth_ref": [
      "r103"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for investment classified as marketable security.",
        "label": "Marketable Securities, Policy [Policy Text Block]",
        "terseLabel": "Marketable Securities"
       }
      }
     },
     "localname": "MarketableSecuritiesPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_MoneyMarketFundsMember": {
     "auth_ref": [
      "r484"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fund that invests in short-term money-market instruments, for example, but not limited to, commercial paper, banker's acceptances, repurchase agreements, government securities, certificates of deposit, and other highly liquid securities.",
        "label": "Money market funds (cash equivalents)"
       }
      }
     },
     "localname": "MoneyMarketFundsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivities": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.",
        "label": "Net Cash Provided by (Used in) Financing Activities",
        "totalLabel": "Net cash provided by (used in) financing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInFinancingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Financing Activities [Abstract]",
        "terseLabel": "Cash flows from financing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInFinancingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivities": {
     "auth_ref": [
      "r142"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from investing activities, including discontinued operations. Investing activity cash flows include making and collecting loans and acquiring and disposing of debt or equity instruments and property, plant, and equipment and other productive assets.",
        "label": "Net Cash Provided by (Used in) Investing Activities",
        "totalLabel": "Net cash provided by investing activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInInvestingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Investing Activities [Abstract]",
        "terseLabel": "Cash flows from investing activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInInvestingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivities": {
     "auth_ref": [
      "r34",
      "r35",
      "r38"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect",
       "weight": 1.0
      }
     },
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow (outflow) from operating activities, including discontinued operations. Operating activity cash flows include transactions, adjustments, and changes in value not defined as investing or financing activities.",
        "label": "Net Cash Provided by (Used in) Operating Activities",
        "totalLabel": "Net cash used in operating activities"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NetCashProvidedByUsedInOperatingActivitiesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Net Cash Provided by (Used in) Operating Activities [Abstract]",
        "terseLabel": "Cash flows from operating activities:"
       }
      }
     },
     "localname": "NetCashProvidedByUsedInOperatingActivitiesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NetIncomeLoss": {
     "auth_ref": [
      "r27",
      "r38",
      "r102",
      "r112",
      "r117",
      "r130",
      "r132",
      "r137",
      "r147",
      "r152",
      "r154",
      "r155",
      "r156",
      "r157",
      "r160",
      "r161",
      "r165",
      "r181",
      "r182",
      "r184",
      "r186",
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r346",
      "r352",
      "r437",
      "r481"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.",
        "label": "Net Income (Loss) Attributable to Parent",
        "terseLabel": "Net loss",
        "totalLabel": "Net loss"
       }
      }
     },
     "localname": "NetIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_NewAccountingPronouncementsPolicyPolicyTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy pertaining to new accounting pronouncements that may impact the entity's financial reporting. Includes, but is not limited to, quantification of the expected or actual impact.",
        "label": "New Accounting Pronouncements, Policy [Policy Text Block]",
        "terseLabel": "Recently Issued Accounting Pronouncements"
       }
      }
     },
     "localname": "NewAccountingPronouncementsPolicyPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_NoncashInvestingAndFinancingItemsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Noncash Investing and Financing Items [Abstract]",
        "terseLabel": "Supplemental disclosures of noncash investing and financing activities:"
       }
      }
     },
     "localname": "NoncashInvestingAndFinancingItemsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_NumberOfOperatingSegments": {
     "auth_ref": [
      "r471"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of operating segments. An operating segment is a component of an enterprise: (a) that engages in business activities from which it may earn revenues and incur expenses (including revenues and expenses relating to transactions with other components of the same enterprise), (b) whose operating results are regularly reviewed by the enterprise's chief operating decision maker to make decisions about resources to be allocated to the segment and assess its performance, and (c) for which discrete financial information is available. An operating segment may engage in business activities for which it has yet to earn revenues, for example, start-up operations may be operating segments before earning revenues.",
        "label": "Number of Operating Segments",
        "terseLabel": "Number of operating segment"
       }
      }
     },
     "localname": "NumberOfOperatingSegments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationLiquidityDetails"
     ],
     "xbrltype": "integerItemType"
    },
    "us-gaap_OperatingExpenses": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingIncomeLoss",
       "weight": -1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Generally recurring costs associated with normal operations except for the portion of these expenses which can be clearly related to production and included in cost of sales or services. Includes selling, general and administrative expense.",
        "label": "Operating Expenses",
        "totalLabel": "Total operating expenses"
       }
      }
     },
     "localname": "OperatingExpenses",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingExpensesAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Operating Expenses [Abstract]",
        "terseLabel": "Operating expenses:"
       }
      }
     },
     "localname": "OperatingExpensesAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingIncomeLoss": {
     "auth_ref": [
      "r181",
      "r182",
      "r184",
      "r186",
      "r437"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net result for the period of deducting operating expenses from operating revenues.",
        "label": "Operating Income (Loss)",
        "totalLabel": "Loss from operations"
       }
      }
     },
     "localname": "OperatingIncomeLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseExpense": {
     "auth_ref": [
      "r517"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of operating lease expense. Excludes sublease income.",
        "label": "Operating Lease, Expense",
        "terseLabel": "Operating lease expense"
       }
      }
     },
     "localname": "OperatingLeaseExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilitiesPaymentsDueAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Lessee, Operating Lease, Liability, to be Paid [Abstract]",
        "terseLabel": "Future minimum lease payments"
       }
      }
     },
     "localname": "OperatingLeaseLiabilitiesPaymentsDueAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OperatingLeaseLiability": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesCalc2Details": {
       "order": 2.0,
       "parentTag": "us-gaap_LesseeOperatingLeaseLiabilityPaymentsDue",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease.",
        "label": "Operating Lease, Liability",
        "totalLabel": "Present value of lease liabilities"
       }
      }
     },
     "localname": "OperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesMaturitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrent": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails": {
       "order": 4.0,
       "parentTag": "nxtc_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as current.",
        "label": "Operating Lease, Liability, Current",
        "verboseLabel": "Lease liabilities, current portion"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList": {
     "auth_ref": [
      "r366"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Indicates line item in statement of financial position that includes current operating lease liability.",
        "label": "Operating Lease, Liability, Current, Statement of Financial Position [Extensible Enumeration]"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityCurrentStatementOfFinancialPositionExtensibleList",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "enumerationSetItemType"
    },
    "us-gaap_OperatingLeaseLiabilityNoncurrent": {
     "auth_ref": [
      "r365"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Present value of lessee's discounted obligation for lease payments from operating lease, classified as noncurrent.",
        "label": "Operating Lease, Liability, Noncurrent",
        "verboseLabel": "Lease liabilities, long term"
       }
      }
     },
     "localname": "OperatingLeaseLiabilityNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeasePayments": {
     "auth_ref": [
      "r367",
      "r369"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow from operating lease, excluding payments to bring another asset to condition and location necessary for its intended use.",
        "label": "Operating Lease, Payments",
        "verboseLabel": "Operating cash flows used for operating leases"
       }
      }
     },
     "localname": "OperatingLeasePayments",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseRightOfUseAsset": {
     "auth_ref": [
      "r364"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of lessee's right to use underlying asset under operating lease.",
        "label": "Operating Lease, Right-of-Use Asset",
        "verboseLabel": "Right of use assets"
       }
      }
     },
     "localname": "OperatingLeaseRightOfUseAsset",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageDiscountRatePercent": {
     "auth_ref": [
      "r372",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average discount rate for operating lease calculated at point in time.",
        "label": "Operating Lease, Weighted Average Discount Rate, Percent",
        "terseLabel": "Weighted average discount rate (as a percent)"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageDiscountRatePercent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_OperatingLeaseWeightedAverageRemainingLeaseTerm1": {
     "auth_ref": [
      "r371",
      "r449"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining lease term for operating lease, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Operating Lease, Weighted Average Remaining Lease Term",
        "terseLabel": "Weighted=average remaining lease term"
       }
      }
     },
     "localname": "OperatingLeaseWeightedAverageRemainingLeaseTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_OperatingLeasesRentExpenseNet": {
     "auth_ref": [
      "r115"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rental expense for the reporting period incurred under operating leases, including minimum and any contingent rent expense, net of related sublease income.",
        "label": "Operating Leases, Rent Expense, Net",
        "terseLabel": "Rent expenses operating leases"
       }
      }
     },
     "localname": "OperatingLeasesRentExpenseNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureLeasesOtherInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock": {
     "auth_ref": [
      "r0",
      "r86"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for organization, consolidation and basis of presentation of financial statements disclosure.",
        "label": "Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]",
        "verboseLabel": "Nature of the Business and Basis of Presentation"
       }
      }
     },
     "localname": "OrganizationConsolidationAndPresentationOfFinancialStatementsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentation"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_OtherAssetsNoncurrent": {
     "auth_ref": [
      "r123"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 4.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncurrent assets classified as other.",
        "label": "Other Assets, Noncurrent",
        "terseLabel": "Other assets"
       }
      }
     },
     "localname": "OtherAssetsNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Other Comprehensive Income (Loss), Net of Tax, Portion Attributable to Parent [Abstract]",
        "terseLabel": "Comprehensive loss:"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax": {
     "auth_ref": [
      "r127",
      "r129"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_ComprehensiveIncomeNetOfTax",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, after tax and before adjustment, of unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, after Tax",
        "terseLabel": "Unrealized (loss) on marketable securities"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax": {
     "auth_ref": [
      "r23",
      "r128"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount, before adjustment, of tax expense (benefit) for unrealized holding gain (loss) on investment in debt security measured at fair value with change in fair value recognized in other comprehensive income (available-for-sale). Excludes tax expense (benefit) for unrealized gain (loss) on investment in debt security measured at amortized cost (held-to-maturity) from transfer to available-for-sale.",
        "label": "Other Comprehensive Income (Loss), Securities, Available-for-Sale, Unrealized Holding Gain (Loss) Arising During Period, Tax",
        "terseLabel": "Unrealized gain (loss) on marketable securities, tax expense (benefit)"
       }
      }
     },
     "localname": "OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodTax",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquityParenthetical"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesCurrent": {
     "auth_ref": [
      "r16",
      "r450"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails": {
       "order": 6.0,
       "parentTag": "nxtc_AccruedAndOtherLiabilitiesCurrent",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due within one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Current",
        "verboseLabel": "Other"
       }
      }
     },
     "localname": "OtherLiabilitiesCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherLiabilitiesNoncurrent": {
     "auth_ref": [
      "r18"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_Liabilities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of liabilities classified as other, due after one year or the normal operating cycle, if longer.",
        "label": "Other Liabilities, Noncurrent",
        "terseLabel": "Other long-term liabilities"
       }
      }
     },
     "localname": "OtherLiabilitiesNoncurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_OtherNonoperatingIncomeExpense": {
     "auth_ref": [
      "r30"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 2.0,
       "parentTag": "us-gaap_NetIncomeLoss",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of income (expense) related to nonoperating activities, classified as other.",
        "label": "Other Nonoperating Income (Expense)",
        "terseLabel": "Other income, net"
       }
      }
     },
     "localname": "OtherNonoperatingIncomeExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsOfStockIssuanceCosts": {
     "auth_ref": [
      "r33"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow for cost incurred directly with the issuance of an equity security.",
        "label": "Payments of Stock Issuance Costs",
        "terseLabel": "Offering expenses"
       }
      }
     },
     "localname": "PaymentsOfStockIssuanceCosts",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquireMarketableSecurities": {
     "auth_ref": [
      "r49"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash outflow for purchase of marketable security.",
        "label": "Payments to Acquire Marketable Securities",
        "negatedLabel": "Purchases of marketable securities"
       }
      }
     },
     "localname": "PaymentsToAcquireMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PaymentsToAcquirePropertyPlantAndEquipment": {
     "auth_ref": [
      "r31"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.",
        "label": "Payments to Acquire Property, Plant, and Equipment",
        "negatedLabel": "Purchases of property and equipment"
       }
      }
     },
     "localname": "PaymentsToAcquirePropertyPlantAndEquipment",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PensionAndOtherPostretirementBenefitsDisclosureTextBlock": {
     "auth_ref": [
      "r250",
      "r251",
      "r257",
      "r258",
      "r259",
      "r260",
      "r261",
      "r262",
      "r263",
      "r264",
      "r265",
      "r266",
      "r268",
      "r444"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for retirement benefits.",
        "label": "Pension and Other Postretirement Benefits Disclosure [Text Block]",
        "terseLabel": "Employee Benefit Plan"
       }
      }
     },
     "localname": "PensionAndOtherPostretirementBenefitsDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureEmployeeBenefitPlan"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PlanNameAxis": {
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by plan name for share-based payment arrangement.",
        "label": "Plan Name [Axis]"
       }
      }
     },
     "localname": "PlanNameAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PlanNameDomain": {
     "auth_ref": [
      "r485",
      "r486",
      "r487",
      "r488",
      "r489",
      "r490",
      "r491",
      "r492",
      "r493",
      "r494",
      "r495",
      "r496",
      "r497",
      "r498",
      "r499",
      "r500",
      "r501",
      "r502",
      "r503",
      "r504",
      "r505",
      "r506",
      "r507",
      "r508",
      "r509",
      "r510"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Plan name for share-based payment arrangement.",
        "label": "Plan Name [Domain]"
       }
      }
     },
     "localname": "PlanNameDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PortionAtFairValueFairValueDisclosureMember": {
     "auth_ref": [
      "r350"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Measured at fair value for financial reporting purposes.",
        "label": "Portion at Fair Value Measurement [Member]"
       }
      }
     },
     "localname": "PortionAtFairValueFairValueDisclosureMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Preferred Stock."
       }
      }
     },
     "localname": "PreferredStockNumberOfSharesParValueAndOtherDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PreferredStockParOrStatedValuePerShare": {
     "auth_ref": [
      "r6",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Face amount or stated value per share of preferred stock nonredeemable or redeemable solely at the option of the issuer.",
        "label": "Preferred Stock, Par or Stated Value Per Share",
        "terseLabel": "Preferred stock, par value per share"
       }
      }
     },
     "localname": "PreferredStockParOrStatedValuePerShare",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/DisclosurePreferredStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_PreferredStockSharesAuthorized": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The maximum number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) permitted to be issued by an entity's charter and bylaws.",
        "label": "Preferred Stock, Shares Authorized",
        "terseLabel": "Preferred stock, number of shares authorized"
       }
      }
     },
     "localname": "PreferredStockSharesAuthorized",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/DisclosurePreferredStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesIssued": {
     "auth_ref": [
      "r6",
      "r238"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total number of nonredeemable preferred shares (or preferred stock redeemable solely at the option of the issuer) issued to shareholders (includes related preferred shares that were issued, repurchased, and remain in the treasury). May be all or portion of the number of preferred shares authorized. Excludes preferred shares that are classified as debt.",
        "label": "Preferred Stock, Shares Issued",
        "terseLabel": "Preferred stock, shares issued"
       }
      }
     },
     "localname": "PreferredStockSharesIssued",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePreferredStockDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockSharesOutstanding": {
     "auth_ref": [
      "r6"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate share number for all nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer) held by stockholders. Does not include preferred shares that have been repurchased.",
        "label": "Preferred Stock, Shares Outstanding",
        "terseLabel": "Preferred stock, shares outstanding"
       }
      }
     },
     "localname": "PreferredStockSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/DisclosurePreferredStockDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails",
      "http://www.nextcure.com/role/StatementBalanceSheetsParenthetical"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_PreferredStockTextBlock": {
     "auth_ref": [
      "r68"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for terms, amounts, nature of changes, rights and privileges, dividends, and other matters related to preferred stock.",
        "label": "Preferred Stock [Text Block]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "PreferredStockTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePreferredStock"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PreferredStockValue": {
     "auth_ref": [
      "r6",
      "r450"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate par or stated value of issued nonredeemable preferred stock (or preferred stock redeemable solely at the option of the issuer). This item includes treasury stock repurchased by the entity. Note: elements for number of nonredeemable preferred shares, par value and other disclosure concepts are in another section within stockholders' equity.",
        "label": "Preferred Stock, Value, Issued",
        "verboseLabel": "Preferred stock; par value of $0.001 per share; 10,000,000 shares authorized at December 31, 2022 and December 31, 2021, No shares issued and outstanding at December 31, 2022 and December 31, 2021"
       }
      }
     },
     "localname": "PreferredStockValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PrepaidExpenseAndOtherAssetsCurrent": {
     "auth_ref": [
      "r462"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 3.0,
       "parentTag": "us-gaap_AssetsCurrent",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of asset related to consideration paid in advance for costs that provide economic benefits in future periods, and amount of other assets that are expected to be realized or consumed within one year or the normal operating cycle, if longer.",
        "label": "Prepaid Expense and Other Assets, Current",
        "terseLabel": "Prepaid expenses and other current assets"
       }
      }
     },
     "localname": "PrepaidExpenseAndOtherAssetsCurrent",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceInitialPublicOffering": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 1.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from entity's first offering of stock to the public.",
        "label": "Proceeds from Issuance Initial Public Offering",
        "terseLabel": "Proceeds from issuance of shares, net",
        "verboseLabel": "Proceeds from public offering of common stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceInitialPublicOffering",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromIssuanceOfPreferredStockAndPreferenceStock": {
     "auth_ref": [
      "r32"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Proceeds from issuance of capital stock which provides for a specific dividend that is paid to the shareholders before any dividends to common stockholders and which takes precedence over common stockholders in the event of liquidation.",
        "label": "Proceeds from Issuance of Preferred Stock and Preference Stock",
        "terseLabel": "Proceeds from issuance of preferred stock, net of issuance costs"
       }
      }
     },
     "localname": "ProceedsFromIssuanceOfPreferredStockAndPreferenceStock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromRepaymentsOfDebt": {
     "auth_ref": [],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The net cash inflow or outflow in aggregate debt due to repayments and proceeds from additional borrowings.",
        "label": "Proceeds from (Repayments of) Debt",
        "negatedLabel": "Repayment of principal debt balance"
       }
      }
     },
     "localname": "ProceedsFromRepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromSaleAndMaturityOfMarketableSecurities": {
     "auth_ref": [],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInInvestingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the aggregate amount received by the entity through sale or maturity of marketable securities (held-to-maturity or available-for-sale) during the period.",
        "label": "Proceeds from Sale and Maturity of Marketable Securities",
        "terseLabel": "Sales and maturities of marketable securities"
       }
      }
     },
     "localname": "ProceedsFromSaleAndMaturityOfMarketableSecurities",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockOptionsExercised": {
     "auth_ref": [
      "r32",
      "r76"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 3.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of cash inflow from exercise of option under share-based payment arrangement.",
        "label": "Proceeds from Stock Options Exercised",
        "terseLabel": "Proceeds from exercise of stock options"
       }
      }
     },
     "localname": "ProceedsFromStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProceedsFromStockPlans": {
     "auth_ref": [
      "r32"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 2.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash inflow associated with the amount received from the stock plan during the period.",
        "label": "Proceeds from Stock Plans",
        "terseLabel": "Proceeds from shares issued under ESPP"
       }
      }
     },
     "localname": "ProceedsFromStockPlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ProfitLoss": {
     "auth_ref": [
      "r117",
      "r130",
      "r132",
      "r141",
      "r147",
      "r152",
      "r160",
      "r161",
      "r181",
      "r182",
      "r184",
      "r186",
      "r193",
      "r213",
      "r214",
      "r215",
      "r216",
      "r217",
      "r218",
      "r219",
      "r220",
      "r221",
      "r336",
      "r339",
      "r340",
      "r346",
      "r352",
      "r412",
      "r437",
      "r447",
      "r448",
      "r465",
      "r481"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 9.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The consolidated profit or loss for the period, net of income taxes, including the portion attributable to the noncontrolling interest.",
        "label": "Net Income (Loss), Including Portion Attributable to Noncontrolling Interest",
        "terseLabel": "Net loss"
       }
      }
     },
     "localname": "ProfitLoss",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentByTypeAxis": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of long-lived, physical assets used to produce goods and services and not intended for resale.",
        "label": "Property, Plant and Equipment, Type [Axis]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentByTypeAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentDisclosureTextBlock": {
     "auth_ref": [
      "r61",
      "r426",
      "r427",
      "r428"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment Disclosure [Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentDisclosureTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNet"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentEstimatedUsefulLives": {
     "auth_ref": [
      "r56"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Describes the periods of time over which an entity anticipates to receive utility from its property, plant and equipment (that is, the periods of time over which an entity allocates the initial cost of its property, plant and equipment).",
        "label": "Property, Plant and Equipment, Estimated Useful Lives"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentEstimatedUsefulLives",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentGross": {
     "auth_ref": [
      "r58",
      "r121"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": 2.0,
       "parentTag": "us-gaap_PropertyPlantAndEquipmentNet",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount before accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Gross",
        "terseLabel": "Property and equipment, gross"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Property, Plant and Equipment [Line Items]",
        "terseLabel": "Property, plant and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNet": {
     "auth_ref": [
      "r60",
      "r111",
      "r414",
      "r450"
     ],
     "calculation": {
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails": {
       "order": null,
       "parentTag": null,
       "root": true,
       "weight": null
      },
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 2.0,
       "parentTag": "us-gaap_Assets",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount after accumulated depreciation, depletion and amortization of physical assets used in the normal conduct of business to produce goods and services and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, and furniture and fixtures.",
        "label": "Property, Plant and Equipment, Net",
        "terseLabel": "Property and equipment, net",
        "totalLabel": "Property and equipment, net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNet",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentNetAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Property, Plant and Equipment, Net [Abstract]",
        "verboseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentNetAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentPolicyTextBlock": {
     "auth_ref": [
      "r60",
      "r426",
      "r427"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for long-lived, physical asset used in normal conduct of business and not intended for resale. Includes, but is not limited to, work of art, historical treasure, and similar asset classified as collections.",
        "label": "Property, Plant and Equipment, Policy [Policy Text Block]",
        "terseLabel": "Property and Equipment, Net"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTextBlock": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table Text Block]",
        "terseLabel": "Summary of property and equipment"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_PropertyPlantAndEquipmentTypeDomain": {
     "auth_ref": [
      "r58"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Listing of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale. Examples include land, buildings, machinery and equipment, and other types of furniture and equipment including, but not limited to, office equipment, furniture and fixtures, and computer equipment and software.",
        "label": "Property, Plant and Equipment, Type [Domain]"
       }
      }
     },
     "localname": "PropertyPlantAndEquipmentTypeDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RepaymentsOfDebt": {
     "auth_ref": [
      "r466"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 4.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInFinancingActivities",
       "weight": -1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cash outflow during the period from the repayment of aggregate short-term and long-term debt. Excludes payment of capital lease obligations.",
        "label": "Repayments of Debt",
        "negatedLabel": "Payments of the term loan"
       }
      }
     },
     "localname": "RepaymentsOfDebt",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpense": {
     "auth_ref": [
      "r80",
      "r114",
      "r528"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss": {
       "order": 1.0,
       "parentTag": "us-gaap_OperatingExpenses",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.",
        "label": "Research and Development Expense",
        "terseLabel": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpenseMember": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Primary financial statement caption in which the reported facts about research and development expense have been included.",
        "label": "Research and development"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpenseMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ResearchAndDevelopmentExpensePolicy": {
     "auth_ref": [
      "r80"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for costs it has incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process.",
        "label": "Research and Development Expense, Policy [Policy Text Block]",
        "terseLabel": "Research and Development Costs, Including Clinical Trial Accruals"
       }
      }
     },
     "localname": "ResearchAndDevelopmentExpensePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RestrictedCashAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Restricted Cash"
       }
      }
     },
     "localname": "RestrictedCashAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesRestrictedCashDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember": {
     "auth_ref": [
      "r120"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Type of cash and cash equivalent. Cash is currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Also includes short-term, highly liquid investments that are both readily convertible to known amounts of cash and so near their maturity that they present insignificant risk of changes in value because of changes in interest rates.",
        "label": "Cash and Cash Equivalents [Domain]"
       }
      }
     },
     "localname": "RestrictedCashAndCashEquivalentsCashAndCashEquivalentsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RetainedEarningsAccumulatedDeficit": {
     "auth_ref": [
      "r9",
      "r66",
      "r109",
      "r422",
      "r424",
      "r450"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 5.0,
       "parentTag": "us-gaap_StockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Retained Earnings (Accumulated Deficit)",
        "terseLabel": "Accumulated deficit"
       }
      }
     },
     "localname": "RetainedEarningsAccumulatedDeficit",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_RetainedEarningsMember": {
     "auth_ref": [
      "r116",
      "r149",
      "r150",
      "r151",
      "r153",
      "r159",
      "r161",
      "r194",
      "r307",
      "r308",
      "r309",
      "r328",
      "r329",
      "r344",
      "r419",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The cumulative amount of the reporting entity's undistributed earnings or deficit.",
        "label": "Accumulated Deficit"
       }
      }
     },
     "localname": "RetainedEarningsMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_RevenueFromContractWithCustomerPolicyTextBlock": {
     "auth_ref": [
      "r241",
      "r242",
      "r243",
      "r244",
      "r245",
      "r246",
      "r247",
      "r248",
      "r249",
      "r433"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for revenue from contract with customer.",
        "label": "Revenue from Contract with Customer [Policy Text Block]",
        "terseLabel": "Revenue Recognition"
       }
      }
     },
     "localname": "RevenueFromContractWithCustomerPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability": {
     "auth_ref": [
      "r370",
      "r449"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase in right-of-use asset obtained in exchange for operating lease liability.",
        "label": "Right-of-Use Asset Obtained in Exchange for Operating Lease Liability",
        "terseLabel": "Right-o-use assets obtained in exchange for operating lease liabilities"
       }
      }
     },
     "localname": "RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SaleOfStockNameOfTransactionDomain": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Sale of the entity's stock, including, but not limited to, initial public offering (IPO) and private placement.",
        "label": "Sale of Stock [Domain]"
       }
      }
     },
     "localname": "SaleOfStockNameOfTransactionDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_ScheduleOfAccruedLiabilitiesTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of accrued liabilities.",
        "label": "Schedule of Accrued Liabilities [Table Text Block]",
        "terseLabel": "Summary of accrued liabilities and other liabilities"
       }
      }
     },
     "localname": "ScheduleOfAccruedLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureAccruedLiabilitiesAndOtherLiabilitiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule for securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by Antidilutive Securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table]"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersAntiDilutiveEffectDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock": {
     "auth_ref": [
      "r43"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.",
        "label": "Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]",
        "terseLabel": "Summary of shares excluded from the computation of diluted net loss per share"
       }
      }
     },
     "localname": "ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNetLossPerShareAttributableToCommonStockholdersTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Debt Securities, Available-for-sale [Line Items]",
        "terseLabel": "Investments"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation of available-for-sale securities from cost basis to fair value.",
        "label": "Schedule of Available-for-sale Securities Reconciliation [Table Text Block]",
        "terseLabel": "Schedule of marketable securities"
       }
      }
     },
     "localname": "ScheduleOfAvailableForSaleSecuritiesReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of cash, cash equivalents, and investments.",
        "label": "Cash, Cash Equivalents and Investments [Table Text Block]",
        "terseLabel": "Summary of reconciliation cash and cash equivalents and restricted cash per the balance sheet to the statement of cash flows"
       }
      }
     },
     "localname": "ScheduleOfCashCashEquivalentsAndShortTermInvestmentsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock": {
     "auth_ref": [
      "r82"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the components of net deferred tax asset or liability recognized in an entity's statement of financial position, including the following: the total of all deferred tax liabilities, the total of all deferred tax assets, the total valuation allowance recognized for deferred tax assets.",
        "label": "Schedule of Deferred Tax Assets and Liabilities [Table Text Block]",
        "terseLabel": "Summary of components of deferred tax assets"
       }
      }
     },
     "localname": "ScheduleOfDeferredTaxAssetsAndLiabilitiesTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock": {
     "auth_ref": [
      "r81"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the reconciliation using percentage or dollar amounts of the reported amount of income tax expense attributable to continuing operations for the year to the amount of income tax expense that would result from applying domestic federal statutory tax rates to pretax income from continuing operations.",
        "label": "Schedule of Effective Income Tax Rate Reconciliation [Table Text Block]",
        "terseLabel": "Summary of reconciliation of federal statutory income tax rate to the Company's effective income tax rate"
       }
      }
     },
     "localname": "ScheduleOfEffectiveIncomeTaxRateReconciliationTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable": {
     "auth_ref": [
      "r74",
      "r77"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about amount recognized for award under share-based payment arrangement. Includes, but is not limited to, amount expensed in statement of income or comprehensive income, amount capitalized in statement of financial position, and corresponding reporting line item in financial statements.",
        "label": "Share-based Payment Arrangement, Expensed and Capitalized, Amount [Table]"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockBasedCompensationExpenseDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock": {
     "auth_ref": [
      "r74"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of allocation of amount expensed and capitalized for award under share-based payment arrangement to statement of income or comprehensive income and statement of financial position. Includes, but is not limited to, corresponding line item in financial statement.",
        "label": "Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]",
        "terseLabel": "Summary of stock based compensation expense recorded"
       }
      }
     },
     "localname": "ScheduleOfEmployeeServiceShareBasedCompensationAllocationOfRecognizedPeriodCostsTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfPropertyPlantAndEquipmentTable": {
     "auth_ref": [
      "r60"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about physical assets used in the normal conduct of business and not intended for resale. Includes, but is not limited to, balances by class of assets, depreciation and depletion expense and method used, including composite depreciation, and accumulated deprecation.",
        "label": "Property, Plant and Equipment [Table]"
       }
      }
     },
     "localname": "ScheduleOfPropertyPlantAndEquipmentTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosurePropertyAndEquipmentNetDetails",
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPropertyAndEquipmentAndLeasesDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable": {
     "auth_ref": [
      "r269",
      "r271",
      "r273",
      "r274",
      "r275",
      "r277",
      "r278",
      "r279",
      "r280",
      "r281",
      "r282",
      "r283",
      "r284",
      "r285",
      "r286",
      "r287",
      "r288",
      "r289",
      "r290",
      "r291",
      "r292",
      "r293",
      "r294",
      "r297",
      "r298",
      "r299",
      "r300",
      "r301"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of information about share-based payment arrangement.",
        "label": "Schedule of Share-based Compensation Arrangements by Share-based Payment Award [Table]"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationArrangementsByShareBasedPaymentAwardTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock": {
     "auth_ref": [
      "r69",
      "r70",
      "r71"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure for stock option plans. Includes, but is not limited to, outstanding awards at beginning and end of year, grants, exercises, forfeitures, and weighted-average grant date fair value.",
        "label": "Share-based Compensation, Stock Options, Activity [Table Text Block]",
        "terseLabel": "Summary of stock option activity"
       }
      }
     },
     "localname": "ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock": {
     "auth_ref": [
      "r73"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Tabular disclosure of the significant assumptions used during the year to estimate the fair value of stock options, including, but not limited to: (a) expected term of share options and similar instruments, (b) expected volatility of the entity's shares, (c) expected dividends, (d) risk-free rate(s), and (e) discount for post-vesting restrictions.",
        "label": "Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]",
        "terseLabel": "Summary of assumptions used in the Black Scholes option pricing model for stock options granted"
       }
      }
     },
     "localname": "ScheduleOfShareBasedPaymentAwardStockOptionsValuationAssumptionsTableTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationTables"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock": {
     "auth_ref": [
      "r374"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy election of practical expedient not to separate lease component from nonlease component.",
        "label": "Separation of Lease and Nonlease Components [Policy Text Block]",
        "terseLabel": "Leases"
       }
      }
     },
     "localname": "SeparationOfLeaseAndNonleaseComponentsPolicyTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ShareBasedCompensation": {
     "auth_ref": [
      "r36"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows": {
       "order": 10.0,
       "parentTag": "us-gaap_NetCashProvidedByUsedInOperatingActivities",
       "weight": 1.0
      }
     },
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of noncash expense for share-based payment arrangement.",
        "label": "Share-based Compensation",
        "terseLabel": "Stock-based compensation"
       }
      }
     },
     "localname": "ShareBasedCompensation",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1": {
     "auth_ref": [
      "r446"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Period over which grantee's right to exercise award under share-based payment arrangement is no longer contingent on satisfaction of service or performance condition, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, combination of market, performance or service condition.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Award Vesting Period",
        "terseLabel": "Vesting period"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardAwardVestingPeriod1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions and Methodology [Abstract]",
        "terseLabel": "Fair value assumptions"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsAndMethodologyAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate": {
     "auth_ref": [
      "r300"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The risk-free interest rate assumption that is used in valuing an option on its own shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Risk Free Interest Rate",
        "terseLabel": "Risk free interest rate"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate": {
     "auth_ref": [
      "r298"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Rate of weighted-average expected volatility for award under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Weighted Average Volatility Rate",
        "terseLabel": "Expected volatility"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "percentItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award [Line Items]",
        "terseLabel": "Restricted Common Stock",
        "verboseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Additional Disclosures [Abstract]",
        "terseLabel": "Weighted Average Remaining Contractual Life (Years) And Aggregate Intrinsic Value"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsAdditionalDisclosuresAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of accumulated difference between fair value of underlying shares on dates of exercise and exercise price on options exercised (or share units converted) into shares.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value",
        "terseLabel": "Aggregate intrinsic value of stock options exercised"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period",
        "negatedLabel": "Forfeitures (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Gross number of share options (or share units) granted during the period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross",
        "terseLabel": "Granted (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue": {
     "auth_ref": [
      "r291"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The weighted average grant-date fair value of options granted during the reporting period as calculated by applying the disclosed option pricing methodology.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value",
        "terseLabel": "Weighted average grant date fair value per share of stock options granted"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue": {
     "auth_ref": [
      "r75"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Intrinsic Value",
        "periodEndLabel": "Outstanding at the end (in dollars)",
        "periodStartLabel": "Outstanding at the beginning (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of options outstanding, including both vested and non-vested options.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Number",
        "periodEndLabel": "Outstanding at the end (in shares)",
        "periodStartLabel": "Outstanding at the beginning (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "A roll forward is a reconciliation of a concept from the beginning of a period to the end of a period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding [Roll Forward]",
        "terseLabel": "Number of Shares"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingRollForward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice": {
     "auth_ref": [
      "r277",
      "r278"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price",
        "periodEndLabel": "Outstanding at the end (in dollars per share)",
        "periodStartLabel": "Outstanding at the beginning (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price [Abstract]",
        "terseLabel": "Weighted Average Exercise Price"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePriceRollforward",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue": {
     "auth_ref": [
      "r294"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Aggregate Intrinsic Value",
        "periodEndLabel": "Exercisable at the end (in dollars)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of fully vested and expected to vest exercisable options that may be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Number",
        "periodEndLabel": "Exercisable at the end (in shares)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableNumber",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest exercisable or convertible options. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Exercise Price",
        "periodEndLabel": "Exercisable at the end (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod": {
     "auth_ref": [
      "r75"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued under share-based payment arrangement.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period",
        "terseLabel": "Number of shares issued"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationRestrictedCommonStockDetails",
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which option holders acquired shares when converting their stock options into shares.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Exercises in Period, Weighted Average Exercise Price",
        "terseLabel": "Exercised (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r283"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Forfeitures in Period, Weighted Average Exercise Price",
        "terseLabel": "Forfeited (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice": {
     "auth_ref": [
      "r281"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.",
        "label": "Share-based Compensation Arrangements by Share-based Payment Award, Options, Grants in Period, Weighted Average Exercise Price",
        "terseLabel": "Granted (in dollars per share)"
       }
      }
     },
     "localname": "ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_ShareBasedCompensationOptionAndIncentivePlansPolicy": {
     "auth_ref": [
      "r276",
      "r295",
      "r296",
      "r297",
      "r298",
      "r301",
      "r310",
      "r311"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for award under share-based payment arrangement. Includes, but is not limited to, methodology and assumption used in measuring cost.",
        "label": "Share-based Compensation, Option and Incentive Plans Policy [Policy Text Block]",
        "terseLabel": "Stock Based Compensation"
       }
      }
     },
     "localname": "ShareBasedCompensationOptionAndIncentivePlansPolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_SharePrice": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Price of a single share of a number of saleable stocks of a company.",
        "label": "Share Price",
        "verboseLabel": "Share price"
       }
      }
     },
     "localname": "SharePrice",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "perShareItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1": {
     "auth_ref": [
      "r297"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Expected term of award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term",
        "terseLabel": "Expected term"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2": {
     "auth_ref": [
      "r72"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Remaining Contractual Term",
        "terseLabel": "Outstanding (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1": {
     "auth_ref": [
      "r294"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Weighted average remaining contractual term for fully vested and expected to vest exercisable or convertible options, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Exercisable, Weighted Average Remaining Contractual Term",
        "terseLabel": "Exercisable at the end (in years)"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "durationItemType"
    },
    "us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1": {
     "auth_ref": [
      "r292"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Fair value of options vested. Excludes equity instruments other than options, for example, but not limited to, share units, stock appreciation rights, restricted stock.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period, Fair Value",
        "terseLabel": "Aggregate grant date fair value"
       }
      }
     },
     "localname": "SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_SignificantAccountingPoliciesTextBlock": {
     "auth_ref": [
      "r42",
      "r145"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The entire disclosure for all significant accounting policies of the reporting entity.",
        "label": "Significant Accounting Policies [Text Block]",
        "terseLabel": "Summary of Significant Accounting Policies"
       }
      }
     },
     "localname": "SignificantAccountingPoliciesTextBlock",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StatementEquityComponentsAxis": {
     "auth_ref": [
      "r20",
      "r65",
      "r116",
      "r135",
      "r136",
      "r137",
      "r149",
      "r150",
      "r151",
      "r153",
      "r159",
      "r161",
      "r174",
      "r194",
      "r240",
      "r307",
      "r308",
      "r309",
      "r328",
      "r329",
      "r344",
      "r353",
      "r354",
      "r355",
      "r356",
      "r357",
      "r358",
      "r376",
      "r419",
      "r420",
      "r421"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by component of equity.",
        "label": "Equity Components [Axis]"
       }
      }
     },
     "localname": "StatementEquityComponentsAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.",
        "label": "Statement [Line Items]"
       }
      }
     },
     "localname": "StatementLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfCashFlowsAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF CASH FLOWS"
       }
      }
     },
     "localname": "StatementOfCashFlowsAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfFinancialPositionAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "BALANCE SHEETS"
       }
      }
     },
     "localname": "StatementOfFinancialPositionAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementOfStockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "STATEMENTS OF STOCKHOLDERS EQUITY"
       }
      }
     },
     "localname": "StatementOfStockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "xbrltype": "stringItemType"
    },
    "us-gaap_StatementTable": {
     "auth_ref": [
      "r149",
      "r150",
      "r151",
      "r174",
      "r409"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Schedule reflecting a Statement of Income, Statement of Cash Flows, Statement of Financial Position, Statement of Shareholders' Equity and Other Comprehensive Income, or other statement as needed.",
        "label": "Statement [Table]"
       }
      }
     },
     "localname": "StatementTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationAssumptionsDetails",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans": {
     "auth_ref": [
      "r6",
      "r7",
      "r65",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of shares issued during the period as a result of an employee stock purchase plan.",
        "label": "Stock Issued During Period, Shares, Employee Stock Purchase Plans",
        "terseLabel": "Issuance of shares under ESPP (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesEmployeeStockPurchasePlans",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r65",
      "r66"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of new stock issued during the period.",
        "label": "Stock Issued During Period, Shares, New Issues",
        "terseLabel": "Issuance of common stock (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised": {
     "auth_ref": [
      "r6",
      "r7",
      "r65",
      "r66",
      "r282"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of share options (or share units) exercised during the current period.",
        "label": "Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period",
        "negatedLabel": "Exercised (in shares)",
        "verboseLabel": "Exercise of stock options (in shares)"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodSharesStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureStockBasedCompensationStockOptionsDetails",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueEmployeeStockPurchasePlan": {
     "auth_ref": [
      "r6",
      "r7",
      "r65",
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Aggregate change in value for stock issued during the period as a result of employee stock purchase plan.",
        "label": "Stock Issued During Period, Value, Employee Stock Purchase Plan",
        "terseLabel": "Issuance of shares under ESPP"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueEmployeeStockPurchasePlan",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueNewIssues": {
     "auth_ref": [
      "r6",
      "r7",
      "r65",
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.",
        "label": "Stock Issued During Period, Value, New Issues",
        "terseLabel": "Issuance of common stock"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueNewIssues",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockIssuedDuringPeriodValueStockOptionsExercised": {
     "auth_ref": [
      "r20",
      "r65",
      "r66"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Value of stock issued as a result of the exercise of stock options.",
        "label": "Stock Issued During Period, Value, Stock Options Exercised",
        "terseLabel": "Exercise of stock options"
       }
      }
     },
     "localname": "StockIssuedDuringPeriodValueStockOptionsExercised",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquity": {
     "auth_ref": [
      "r7",
      "r10",
      "r11",
      "r48",
      "r450",
      "r467",
      "r477",
      "r516"
     ],
     "calculation": {
      "http://www.nextcure.com/role/StatementBalanceSheets": {
       "order": 1.0,
       "parentTag": "us-gaap_LiabilitiesAndStockholdersEquity",
       "weight": 1.0
      }
     },
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.",
        "label": "Stockholders' Equity Attributable to Parent",
        "periodEndLabel": "Balance at the end",
        "periodStartLabel": "Balance at the beginning",
        "totalLabel": "Total stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquity",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets",
      "http://www.nextcure.com/role/StatementStatementsOfStockholdersEquity"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_StockholdersEquityAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Stockholders' Equity Attributable to Parent [Abstract]",
        "terseLabel": "Stockholders' equity"
       }
      }
     },
     "localname": "StockholdersEquityAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementBalanceSheets"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_StockholdersEquityNoteRedeemablePreferredStockIssuePolicy": {
     "auth_ref": [
      "r4",
      "r5",
      "r64"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for redeemable preferred stock issued. This disclosure may include the accounting treatment for the difference, if there is any, between the carrying value and redemption amount. For example, describe whether the issuer accretes changes in the redemption value.",
        "label": "Stockholders' Equity Note, Redeemable Preferred Stock, Issue, Policy [Policy Text Block]",
        "terseLabel": "Preferred Stock"
       }
      }
     },
     "localname": "StockholdersEquityNoteRedeemablePreferredStockIssuePolicy",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_StockholdersEquityNoteStockSplitConversionRatio1": {
     "auth_ref": [
      "r67"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Ratio applied to the conversion of stock split, for example but not limited to, one share converted to two or two shares converted to one.",
        "label": "Stockholders' Equity Note, Stock Split, Conversion Ratio",
        "terseLabel": "Reverse stock split ratio"
       }
      }
     },
     "localname": "StockholdersEquityNoteStockSplitConversionRatio1",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "pureItemType"
    },
    "us-gaap_SubsequentEventLineItems": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event.",
        "label": "Subsequent Event [Line Items]",
        "verboseLabel": "Nature of the Business"
       }
      }
     },
     "localname": "SubsequentEventLineItems",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsequentEventTable": {
     "auth_ref": [
      "r359",
      "r377"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Discloses pertinent information about one or more significant events or transactions that occurred after the balance sheet date through the date the financial statements were issued or the date the financial statements were available to be issued.",
        "label": "Subsequent Event [Table]"
       }
      }
     },
     "localname": "SubsequentEventTable",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SubsidiarySaleOfStockAxis": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Information by type of sale of the entity's stock.",
        "label": "Sale of Stock [Axis]"
       }
      }
     },
     "localname": "SubsidiarySaleOfStockAxis",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureNatureOfBusinessAndBasisOfPresentationPublicOfferingsAndCommonStockDetails"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_SupplementalCashFlowInformationAbstract": {
     "auth_ref": [],
     "lang": {
      "en-us": {
       "role": {
        "label": "Supplemental Cash Flow Information [Abstract]",
        "terseLabel": "Supplemental disclosures of cash flow information:"
       }
      }
     },
     "localname": "SupplementalCashFlowInformationAbstract",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfCashFlows"
     ],
     "xbrltype": "stringItemType"
    },
    "us-gaap_TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain": {
     "auth_ref": [
      "r188",
      "r189",
      "r235",
      "r239",
      "r343",
      "r378",
      "r379",
      "r380",
      "r381",
      "r382",
      "r383",
      "r384",
      "r385",
      "r386",
      "r387",
      "r388",
      "r389",
      "r390",
      "r391",
      "r392",
      "r393",
      "r394",
      "r395",
      "r396",
      "r397",
      "r398",
      "r399",
      "r400",
      "r401",
      "r402",
      "r403",
      "r404",
      "r405",
      "r406",
      "r407",
      "r474",
      "r475",
      "r476",
      "r533",
      "r534",
      "r535",
      "r536",
      "r537",
      "r538",
      "r539"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Instrument or contract that imposes a contractual obligation to deliver cash or another financial instrument or to exchange other financial instruments on potentially unfavorable terms and conveys a contractual right to receive cash or another financial instrument or to exchange other financial instruments on potentially favorable terms.",
        "label": "Financial Instruments [Domain]"
       }
      }
     },
     "localname": "TransfersAndServicingOfFinancialInstrumentsTypesOfFinancialInstrumentsDomain",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentAgenciesDebtSecuritiesMember": {
     "auth_ref": [
      "r434",
      "r442",
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Debentures, notes, and other debt securities issued by US government agencies, for example, but not limited to, Government National Mortgage Association (GNMA or Ginnie Mae). Excludes US treasury securities and debt issued by government-sponsored Enterprises (GSEs), for example, but is not limited to, Federal Home Loan Mortgage Corporation (FHLMC or Freddie Mac), Federal National Mortgage Association (FNMA or Fannie Mae), and the Federal Home Loan Bank (FHLB).",
        "label": "Agency bonds"
       }
      }
     },
     "localname": "USGovernmentAgenciesDebtSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_USGovernmentCorporationsAndAgenciesSecuritiesMember": {
     "auth_ref": [
      "r529"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "This category includes information about debt issued by US Government Corporations and Agencies. Investments in such US Government Corporations may include debt securities issued by the Government National Mortgage Association (Ginnie Mae) and by the Federal National Mortgage Association (Fannie Mae) and the Federal Home Loan Mortgage Corporation (Freddie Mac).",
        "label": "U.S. Government agencies"
       }
      }
     },
     "localname": "USGovernmentCorporationsAndAgenciesSecuritiesMember",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureFairValueMeasurementsDetails",
      "http://www.nextcure.com/role/DisclosureMarketableSecuritiesDetails"
     ],
     "xbrltype": "domainItemType"
    },
    "us-gaap_UnrecognizedTaxBenefits": {
     "auth_ref": [
      "r312",
      "r318"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of unrecognized tax benefits.",
        "label": "Unrecognized Tax Benefits",
        "terseLabel": "Unrecognized income tax benefits"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefits",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense": {
     "auth_ref": [
      "r317"
     ],
     "crdr": "debit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of expense for interest on an underpayment of income taxes and penalties related to a tax position claimed or expected to be claimed in the tax return.",
        "label": "Unrecognized Tax Benefits, Income Tax Penalties and Interest Expense",
        "terseLabel": "Uncertain income tax benefits, interest or penalties"
       }
      }
     },
     "localname": "UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestExpense",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesAdditionalInformationDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_UseOfEstimates": {
     "auth_ref": [
      "r45",
      "r46",
      "r47",
      "r175",
      "r176",
      "r178",
      "r179"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Disclosure of accounting policy for the use of estimates in the preparation of financial statements in conformity with generally accepted accounting principles.",
        "label": "Use of Estimates, Policy [Policy Text Block]",
        "terseLabel": "Use of Estimates"
       }
      }
     },
     "localname": "UseOfEstimates",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureSummaryOfSignificantAccountingPoliciesPolicies"
     ],
     "xbrltype": "textBlockItemType"
    },
    "us-gaap_ValuationAllowanceDeferredTaxAssetChangeInAmount": {
     "auth_ref": [
      "r324"
     ],
     "crdr": "credit",
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Amount of increase (decrease) in the valuation allowance for a specified deferred tax asset.",
        "label": "Valuation Allowance, Deferred Tax Asset, Increase (Decrease), Amount",
        "terseLabel": "Increase in valuation allowance"
       }
      }
     },
     "localname": "ValuationAllowanceDeferredTaxAssetChangeInAmount",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/DisclosureIncomeTaxesDeferredTaxAssetsDetails"
     ],
     "xbrltype": "monetaryItemType"
    },
    "us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding": {
     "auth_ref": [
      "r163",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.",
        "label": "Weighted Average Number of Shares Outstanding, Diluted",
        "verboseLabel": "Diluted (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfDilutedSharesOutstanding",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    },
    "us-gaap_WeightedAverageNumberOfSharesOutstandingBasic": {
     "auth_ref": [
      "r162",
      "r168"
     ],
     "lang": {
      "en-us": {
       "role": {
        "documentation": "Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.",
        "label": "Weighted Average Number of Shares Outstanding, Basic",
        "verboseLabel": "Basic (in shares)"
       }
      }
     },
     "localname": "WeightedAverageNumberOfSharesOutstandingBasic",
     "nsuri": "http://fasb.org/us-gaap/2022",
     "presentation": [
      "http://www.nextcure.com/role/StatementStatementsOfOperationsAndComprehensiveLoss"
     ],
     "xbrltype": "sharesItemType"
    }
   },
   "unitCount": 6
  }
 },
 "std_ref": {
  "r0": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "205",
   "URI": "https://asc.fasb.org/topic&trid=2122149",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r1": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(22))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r10": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r100": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(16))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r101": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(23))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r102": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(22))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r103": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62652-112803",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r104": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/subtopic&trid=2209399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r105": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "825",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126941378&loc=d3e61044-112788",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r106": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(15)(b)(2))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r107": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(12))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r108": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(16))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r109": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(4))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r11": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(31))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r110": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(25))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r111": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(8))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r112": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(18))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r113": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "946",
   "URI": "https://asc.fasb.org/subtopic&trid=2324412",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r114": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "985",
   "URI": "https://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r115": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "840",
   "URI": "https://asc.fasb.org/extlink&oid=123406913&loc=d3e41499-112717",
   "role": "http://fasb.org/us-gaap/role/ref/otherTransitionRef"
  },
  "r116": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "105",
   "URI": "https://asc.fasb.org/extlink&oid=126987489&loc=SL124442142-165695",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r117": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "205",
   "URI": "https://asc.fasb.org/extlink&oid=109222650&loc=SL51721683-107760",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r118": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r119": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6904-107765",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r12": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(32))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r120": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r121": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(13))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r122": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(14))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r123": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(17))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r124": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(18))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r125": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(4))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r126": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r127": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r128": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r129": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r13": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r130": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r131": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669619-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r132": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r133": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669625-108580",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r134": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL116659661-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r135": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r136": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r137": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r138": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(24))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r139": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(25))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r14": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19(a),20,24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r140": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3367-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r141": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3000-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r142": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r143": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r144": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4297-108586",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r145": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18726-107790",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r146": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(c))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r147": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r148": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(h)(2))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r149": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r15": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.19-26)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r150": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r151": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r152": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(2)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r153": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)(3)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22499-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r154": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r155": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22694-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r156": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22583-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r157": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22595-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r158": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r159": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22644-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r16": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.20)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r160": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22658-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r161": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124431687&loc=d3e22663-107794",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r162": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1448-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r163": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1505-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r164": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1252-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r165": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r166": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "60B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=SL5780133-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r167": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=126958026&loc=d3e1337-109256",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r168": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r169": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r17": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.21)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r170": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r171": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=109243012&loc=SL65017193-207537",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r172": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e3842-109258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r173": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "260",
   "URI": "https://asc.fasb.org/topic&trid=2144383",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r174": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "272",
   "URI": "https://asc.fasb.org/extlink&oid=125520817&loc=d3e70191-108054",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r175": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r176": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r177": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e5967-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r178": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6161-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r179": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6191-108592",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r18": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.24)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r180": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r181": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "22",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r182": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r183": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r184": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r185": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r186": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "32",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r187": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r188": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27232-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r189": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=SL120269820-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r19": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r190": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27337-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r191": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27357-111563",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r192": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r193": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r194": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=122640432&loc=SL121648383-210437",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r195": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919244-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r196": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919249-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r197": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919253-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r198": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "16",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919258-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r199": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124255953&loc=SL82919230-210447",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r2": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(a))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r20": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02.29-31)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r200": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r201": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922888-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r202": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922890-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r203": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922895-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r204": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124269663&loc=SL82922900-210455",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r205": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=109226691&loc=d3e2941-110230",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r206": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "420",
   "URI": "https://asc.fasb.org/extlink&oid=6394359&loc=d3e17939-110869",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r207": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r208": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "440",
   "URI": "https://asc.fasb.org/extlink&oid=123406679&loc=d3e25336-109308",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r209": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14435-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r21": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669646-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r210": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=121557415&loc=d3e14557-108349",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r211": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q2)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r212": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Subparagraph": "(SAB Topic 5.Y.Q4)",
   "Topic": "450",
   "URI": "https://asc.fasb.org/extlink&oid=27011672&loc=d3e149879-122751",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r213": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r214": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r215": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r216": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r217": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(i))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r218": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(A))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r219": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iii)(B))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r22": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e637-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r220": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(4)(iv))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r221": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-02(a)(5))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442552-122756",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r222": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r223": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r224": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(h)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r225": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(i)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r226": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r227": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r228": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r229": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1C",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495334-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r23": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e640-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r230": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r231": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495340-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r232": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1E",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495348-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r233": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r234": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r235": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r236": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1I",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495371-112611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r237": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466204&loc=SL6031897-161870",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r238": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r239": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496189-112644",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r24": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e681-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r240": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r241": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130561-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r242": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r243": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130563-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r244": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130564-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r245": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r246": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r247": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r248": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "606",
   "URI": "https://asc.fasb.org/extlink&oid=126920106&loc=SL49130566-203045",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r249": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "606",
   "URI": "https://asc.fasb.org/topic&trid=49130388",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r25": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14A",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=SL7669686-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r250": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(i)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r251": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r252": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r253": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r254": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(A)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r255": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(B)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r256": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(02)(C)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r257": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(03)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r258": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(l)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r259": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(o)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r26": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126968391&loc=d3e557-108580",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r260": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(p)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r261": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(q)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r262": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(1)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r263": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(r)(2)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r264": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=21916913&loc=d3e273930-122802",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r265": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "60",
   "Subparagraph": "(c)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=6414203&loc=d3e39689-114964",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r266": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "70",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=49170846&loc=d3e28014-114942",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r267": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(d)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=65877416&loc=SL14450657-114947",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r268": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "715",
   "URI": "https://asc.fasb.org/topic&trid=2235017",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r269": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1D",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=SL116886442-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r27": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(20))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r270": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4534-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r271": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126961718&loc=d3e4549-113899",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r272": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r273": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r274": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r275": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r276": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r277": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r278": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r279": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r28": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03(4))",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r280": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r281": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r282": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r283": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r284": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r285": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r286": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r287": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r288": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r289": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r29": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.4)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r290": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r291": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r292": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r293": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r294": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r295": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r296": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r297": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r298": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r299": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r3": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(26)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r30": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-03.9)",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=126953954&loc=SL114868664-224227",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r300": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r301": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r302": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r303": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r304": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r305": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r306": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(l)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r307": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r308": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r309": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128097895&loc=SL121327923-165333",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r31": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3213-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r310": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.D.2.Q6)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r311": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "718",
   "URI": "https://asc.fasb.org/topic&trid=2228938",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r312": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10B",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=SL37586934-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r313": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32247-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r314": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=123427490&loc=d3e32280-109318",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r315": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r316": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32705-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r317": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32718-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r318": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=SL6600010-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r319": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32809-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r32": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "14",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3255-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r320": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32840-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r321": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r322": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r323": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r324": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r325": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32847-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r326": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "21",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32857-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r327": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32639-109319",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r328": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r329": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(d)(3)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=126983759&loc=SL121830611-158277",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r33": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r330": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 6.I.5.Q1)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r331": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r332": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.C)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330215-122817",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r333": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "270",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424409&loc=d3e44925-109338",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r334": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=6424122&loc=d3e41874-109331",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r335": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "740",
   "URI": "https://asc.fasb.org/topic&trid=2144680",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r336": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "19",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=126929396&loc=SL4569616-111683",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r337": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r338": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=116870748&loc=SL6758485-165988",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r339": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r34": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3521-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r340": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r341": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(bb)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r342": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=123419778&loc=d3e5710-111685",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r343": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126731327&loc=d3e90205-114008",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r344": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r345": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(4)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r346": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r347": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r348": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(3)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r349": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r35": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "25",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3536-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r350": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594809&loc=d3e13220-108610",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r351": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13433-108611",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r352": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r353": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32136-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r354": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r355": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(b)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r356": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r357": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "20",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Subparagraph": "(d)",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=118261656&loc=d3e32211-110900",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r358": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32583-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r359": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=6450520&loc=d3e32618-110901",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r36": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r360": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124429444&loc=SL124452920-239629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r361": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r362": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(g)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r363": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(j)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128293352&loc=SL77916155-209984",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r364": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(a)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r365": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918627-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r366": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918631-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r367": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918643-209977",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r368": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r369": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(1)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r37": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r370": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(2)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r371": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r372": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(g)(4)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918686-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r373": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r374": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918707-209980",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r375": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/subtopic&trid=77888251",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r376": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)(iii)(03)",
   "Topic": "848",
   "URI": "https://asc.fasb.org/extlink&oid=125980421&loc=SL125981372-237846",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r377": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "855",
   "URI": "https://asc.fasb.org/extlink&oid=6842918&loc=SL6314017-165662",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r378": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r379": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)(ii)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r38": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3602-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r380": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r381": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r382": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r383": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(bb)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r384": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r385": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r386": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r387": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r388": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r389": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r39": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3044-108585",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r390": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r391": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=66007379&loc=d3e113888-111728",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r392": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(a)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=109249958&loc=SL34722452-111729",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r393": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r394": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r395": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r396": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)(i)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122625-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r397": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r398": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r399": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r4": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(b))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r40": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=d3e4273-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r400": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(4)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r401": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(5)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r402": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(6)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r403": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(a)(7)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r404": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(b)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r405": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r406": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r407": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "50",
   "Subparagraph": "(e)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=128311188&loc=d3e122739-111746",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r408": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "910",
   "URI": "https://asc.fasb.org/extlink&oid=126937589&loc=SL119991595-234733",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r409": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 11.L)",
   "Topic": "924",
   "URI": "https://asc.fasb.org/extlink&oid=6472922&loc=d3e499488-122856",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r41": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126999549&loc=SL98516268-108586",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r410": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(26))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r411": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.9-04(27))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399700&loc=SL114874048-224260",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r412": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "235",
   "Subparagraph": "(SX 210.9-05(b)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=120399901&loc=d3e537907-122884",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r413": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(a)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r414": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=124429447&loc=SL124453093-239630",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r415": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.7-03(a)(23)(a)(3))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126734703&loc=d3e572229-122910",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r416": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(22))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r417": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "220",
   "Subparagraph": "(SX 210.7-04(23))",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=120400993&loc=SL114874131-224263",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r418": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "40",
   "Subparagraph": "(d)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124506351&loc=SL117782755-158439",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r419": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r42": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "235",
   "URI": "https://asc.fasb.org/topic&trid=2122369",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r420": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(1)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r421": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(f)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r422": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(i)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r423": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(g)(2)(ii)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r424": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(h)(2)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124501264&loc=SL117420844-207641",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r425": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "440",
   "Subparagraph": "(a)",
   "Topic": "954",
   "URI": "https://asc.fasb.org/extlink&oid=6491277&loc=d3e6429-115629",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r426": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Subparagraph": "(d)",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99779-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r427": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=d3e99893-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r428": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "360",
   "Topic": "958",
   "URI": "https://asc.fasb.org/extlink&oid=126982197&loc=SL120174063-112916",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r429": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(c)",
   "Topic": "976",
   "URI": "https://asc.fasb.org/extlink&oid=6497875&loc=d3e22274-108663",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r43": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3550-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r430": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "310",
   "Subparagraph": "(b)",
   "Topic": "978",
   "URI": "https://asc.fasb.org/extlink&oid=126945304&loc=d3e27327-108691",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r431": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1403",
   "role": "http://www.xbrl.org/2003/role/disclosureRef"
  },
  "r432": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=124098289&loc=d3e6676-107765",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r433": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=126899994&loc=d3e18823-107790",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r434": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(m)(1)(ii)(A))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r435": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "52",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=128363288&loc=d3e4984-109258",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r436": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "30",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8906-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r437": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "31",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r438": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=121590138&loc=SL82922954-210456",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r439": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69B",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495735-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r44": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "260",
   "URI": "https://asc.fasb.org/extlink&oid=124432515&loc=d3e3630-109257",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r440": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "69C",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466577&loc=SL123495737-112612",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r441": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=SL123496158-112644",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r442": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r443": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(iv)(01)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r444": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "17",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123450688&loc=d3e4179-114921",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r445": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "80",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=35742348&loc=SL14450788-114948",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r446": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r447": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4J",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591551-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r448": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4K",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=120409616&loc=SL4591552-111686",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r449": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "53",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123414884&loc=SL77918982-209971",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r45": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6061-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r450": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "10",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=84165509&loc=d3e56426-112766",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r451": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "29F",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "40",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=126561865&loc=SL117819544-158441",
   "role": "http://www.xbrl.org/2003/role/exampleRef"
  },
  "r452": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r453": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "b-2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r454": {
   "Name": "Exchange Act",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "12",
   "Subsection": "d1-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r455": {
   "Name": "Form 10-K",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "310",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r456": {
   "Name": "Form 20-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "220",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r457": {
   "Name": "Form 40-F",
   "Number": "249",
   "Publisher": "SEC",
   "Section": "240",
   "Subsection": "f",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r458": {
   "Name": "Forms 10-K, 10-Q, 20-F",
   "Number": "240",
   "Publisher": "SEC",
   "Section": "13",
   "Subsection": "a-1",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r459": {
   "Name": "Regulation S-T",
   "Number": "232",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r46": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6132-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r460": {
   "Name": "Securities Act",
   "Number": "230",
   "Publisher": "SEC",
   "Section": "405",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r461": {
   "Name": "Securities Act",
   "Number": "7A",
   "Publisher": "SEC",
   "Section": "B",
   "Subsection": "2",
   "role": "http://www.xbrl.org/2003/role/presentationRef"
  },
  "r462": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(9))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r463": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442407-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r464": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124442411-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r465": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "220",
   "URI": "https://asc.fasb.org/extlink&oid=124431353&loc=SL124452729-227067",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r466": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "230",
   "URI": "https://asc.fasb.org/extlink&oid=126954810&loc=d3e3291-108585",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r467": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.4-08(g)(1)(ii))",
   "Topic": "235",
   "URI": "https://asc.fasb.org/extlink&oid=120395691&loc=d3e23780-122690",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r468": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "23",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21914-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r469": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "24",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21930-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r47": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "9",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "275",
   "URI": "https://asc.fasb.org/extlink&oid=99393423&loc=d3e6143-108592",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r470": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "5",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "250",
   "URI": "https://asc.fasb.org/extlink&oid=124436220&loc=d3e21711-107793",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r471": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "18",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "280",
   "URI": "https://asc.fasb.org/extlink&oid=126901519&loc=d3e8672-108599",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r472": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r473": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r474": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r475": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r476": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "321",
   "URI": "https://asc.fasb.org/extlink&oid=126980263&loc=SL75117539-209714",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r477": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "323",
   "URI": "https://asc.fasb.org/extlink&oid=114001798&loc=d3e33918-111571",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r478": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "326",
   "URI": "https://asc.fasb.org/extlink&oid=124258926&loc=SL82898722-210454",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r479": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "10",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Subparagraph": "(c)",
   "Topic": "410",
   "URI": "https://asc.fasb.org/extlink&oid=6393242&loc=d3e13237-110859",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r48": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 4.E)",
   "Topic": "310",
   "URI": "https://asc.fasb.org/extlink&oid=122038336&loc=d3e74512-122707",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r480": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "450",
   "URI": "https://asc.fasb.org/topic&trid=2127136",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r481": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(ii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r482": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.13-01(a)(4)(iii))",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=126975872&loc=SL124442526-122756",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r483": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1B",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)",
   "Topic": "470",
   "URI": "https://asc.fasb.org/extlink&oid=123466505&loc=SL123495323-112611",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r484": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(d)(ii)",
   "Topic": "715",
   "URI": "https://asc.fasb.org/extlink&oid=123447040&loc=d3e1928-114920",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r485": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r486": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r487": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)(3)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r488": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r489": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r49": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=124260329&loc=d3e26853-111562",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r490": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r491": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r492": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r493": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r494": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r495": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)(iv)(04)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r496": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r497": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r498": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r499": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(01)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r5": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(27)(c))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r50": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r500": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(02)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r501": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(2)(iii)(03)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r502": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r503": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r504": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r505": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r506": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(i)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r507": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(ii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r508": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iii)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r509": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(iv)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r51": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r510": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)(v)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r511": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r512": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r513": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32621-109319",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r514": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 6.I.Fact.4)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=122134291&loc=d3e330036-122817",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r515": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "65",
   "SubTopic": "40",
   "Subparagraph": "(e)(3)",
   "Topic": "815",
   "URI": "https://asc.fasb.org/extlink&oid=126732423&loc=SL123482106-238011",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r516": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "28",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123596393&loc=d3e14064-108612",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r517": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "20",
   "Subparagraph": "(b)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=123391704&loc=SL77918638-209977",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r518": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(a)(3)",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918673-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r519": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Topic": "842",
   "URI": "https://asc.fasb.org/extlink&oid=128292326&loc=SL77918701-209980",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r52": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27161-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r520": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r521": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "7",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "852",
   "URI": "https://asc.fasb.org/extlink&oid=124433192&loc=SL2890621-112765",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r522": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r523": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r524": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(c)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107207-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r525": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(1)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r526": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(2)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r527": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "20",
   "Subparagraph": "(b)(3)",
   "Topic": "860",
   "URI": "https://asc.fasb.org/extlink&oid=121570589&loc=d3e107314-111719",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r528": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "25",
   "SubTopic": "730",
   "Topic": "912",
   "URI": "https://asc.fasb.org/extlink&oid=6472174&loc=d3e58812-109433",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r529": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Subparagraph": "(b)",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62557-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r53": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "320",
   "URI": "https://asc.fasb.org/extlink&oid=126970911&loc=d3e27198-111563",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r530": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=d3e62586-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r531": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "320",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126980459&loc=SL120269850-112803",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r532": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "80",
   "Subparagraph": "(e)",
   "Topic": "944",
   "URI": "https://asc.fasb.org/extlink&oid=124508989&loc=d3e19393-158473",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r533": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(a)",
   "Publisher": "SEC",
   "Section": "1402",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r534": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(1)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r535": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r536": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(b)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(3)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r537": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(i)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r538": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(ii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r539": {
   "Name": "Regulation S-K (SK)",
   "Number": "229",
   "Paragraph": "(c)",
   "Publisher": "SEC",
   "Section": "1402",
   "Subparagraph": "(2)(iii)",
   "role": "http://www.xbrl.org/2009/role/commonPracticeRef"
  },
  "r54": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "320",
   "URI": "https://asc.fasb.org/topic&trid=2196928",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r55": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "30",
   "Topic": "350",
   "URI": "https://asc.fasb.org/extlink&oid=66006027&loc=d3e16265-109275",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r56": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "35",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905813&loc=d3e1205-110223",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r57": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "15",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=126905981&loc=d3e2611-110228",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r58": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(b)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r59": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r6": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(28))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r60": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "360",
   "URI": "https://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r61": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "360",
   "URI": "https://asc.fasb.org/topic&trid=2155823",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r62": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "440",
   "URI": "https://asc.fasb.org/topic&trid=2144648",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r63": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "470",
   "URI": "https://asc.fasb.org/topic&trid=2208564",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r64": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "05",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126960819&loc=d3e20905-112640",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r65": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=126973232&loc=d3e21463-112644",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r66": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.3-04)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187085-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r67": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "4",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB TOPIC 4.C)",
   "Topic": "505",
   "URI": "https://asc.fasb.org/extlink&oid=120397183&loc=d3e187143-122770",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r68": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "505",
   "URI": "https://asc.fasb.org/topic&trid=2208762",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r69": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r7": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(29))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r70": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(d)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r71": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r72": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(e)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r73": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(f)(2)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r74": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(h)(1)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r75": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=d3e5070-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r76": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=128089324&loc=SL79508275-113901",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r77": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SAB Topic 14.F)",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=122041274&loc=d3e301413-122809",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r78": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11149-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r79": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "13",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "20",
   "Topic": "718",
   "URI": "https://asc.fasb.org/extlink&oid=126964447&loc=d3e11178-113907",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r8": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(1))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r80": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "730",
   "URI": "https://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r81": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32687-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r82": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32537-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r83": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "3",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32559-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r84": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "740",
   "URI": "https://asc.fasb.org/extlink&oid=121826272&loc=d3e32632-109319",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r85": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(c),(3)",
   "Topic": "810",
   "URI": "https://asc.fasb.org/extlink&oid=109239629&loc=SL4573702-111684",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r86": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "Topic": "810",
   "URI": "https://asc.fasb.org/topic&trid=2197479",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r87": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=d3e19207-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r88": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "6A",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Subparagraph": "(a)",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=126976982&loc=SL6742756-110258",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r89": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "60",
   "SubTopic": "10",
   "Topic": "820",
   "URI": "https://asc.fasb.org/extlink&oid=7493716&loc=d3e21868-110260",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r9": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "10",
   "Subparagraph": "(SX 210.5-02(30)(a)(3))",
   "Topic": "210",
   "URI": "https://asc.fasb.org/extlink&oid=120391452&loc=d3e13212-122682",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r90": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13279-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r91": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "11",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13467-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r92": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "12",
   "Publisher": "FASB",
   "Section": "50",
   "SubTopic": "10",
   "Topic": "825",
   "URI": "https://asc.fasb.org/extlink&oid=123594938&loc=d3e13476-108611",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r93": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "230",
   "Topic": "830",
   "URI": "https://asc.fasb.org/extlink&oid=123444420&loc=d3e33268-110906",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r94": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "2",
   "Publisher": "FASB",
   "Section": "45",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=124435984&loc=d3e28551-108399",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r95": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "8",
   "Publisher": "FASB",
   "Section": "55",
   "SubTopic": "30",
   "Topic": "835",
   "URI": "https://asc.fasb.org/extlink&oid=114775985&loc=d3e28878-108400",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r96": {
   "Name": "Accounting Standards Codification",
   "Publisher": "FASB",
   "SubTopic": "320",
   "Topic": "940",
   "URI": "https://asc.fasb.org/subtopic&trid=2176304",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r97": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(1)(a))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r98": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(11))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  },
  "r99": {
   "Name": "Accounting Standards Codification",
   "Paragraph": "1",
   "Publisher": "FASB",
   "Section": "S99",
   "SubTopic": "210",
   "Subparagraph": "(SX 210.9-03(15)(2))",
   "Topic": "942",
   "URI": "https://asc.fasb.org/extlink&oid=126897435&loc=d3e534808-122878",
   "role": "http://fasb.org/us-gaap/role/ref/legacyRef"
  }
 },
 "version": "2.2"
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>81
<FILENAME>0001558370-23-002698-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001558370-23-002698-xbrl.zip
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M\L\ *('DARPD03ZC;WU<G@HU'*C]#VH )VZ>/Z$CU2/S,3]2'S(+=SLDV!G
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M8)QE-KS%0':" /T\0]N!;%GKJ<VG[>'E8"R\'M6 MDRPW/H T=AY+Z*7A[0
M_;QK2VX37B[;&4/[E30 Q\1XZ-R#&?D@#R#R#PI==$=))_V*,PXU.5%S75Q>
M?[X\.M\IQ":Z+Y&,M1 5KY&I>PJ>DML.F6/O^PXP EO=$]NPS2V2G00!^CF*
MMLF.K/74CI_82T]X%6(?'&?&3T!^L &/8?5FKQ8QNV 9OG] XK656E\_W]J2
MV?37E;HM=%_^'7D9\VW\/(&3RF96A4_,!S* :[CM,J9]UU/*Z<PQ,XFS7E"8
M1?=FO5-D7LH&NA]/](*G?FK5'?$CC85[ Z+%3H!O*<A2L_@E+!XNZ$:=,%."
M-<87M4:MCBIH_42^R'CY4$1'*/18M'XN"AX,A=?/1OSAZ ?_\3\>TI+D7:PP
M/O*[ 2X^09NY/N0.1U*8R&^'G GA[D)'ZKU54J&A&0\-:Z%H+16^WU>K3S^W
MWU^2PR=1'%=TB/\M'E&&6Y9%/W@7 *JV&1ZFSC?N_*D'<:E$+N.(A.D76TIR
MK>UOH<@=CLI>C[B!9P/M^OR_7QC89WUF K?6TI(I)VH6(?MO']RI)37L0><%
MRU<*[\HE([+_=LF=6E)J.F'//AG.WE[=];6&?3"LA8,9MCO 'S'^K>$0X6+N
M0A^AJ7U^(^Z8V%T;_Q<;+*+WEE81"]:OM>["F=*:9D$VV].9E))@6B.(8X!E
M,&9T]C8>?%".RDGSL<+EGXZKE6,ZW9<=Y+=NX>\ ;;%'@LSJ NPBH_U*:-2'
M/A]T\RLLKJ=;YR!CNLB+"I5]K,ZT>R-I<MC+>HATI>X3-OAG;\9);=3U(C[J
MRJ4B3RP*R\T_[BIH+$E#QO'1\*2F(%M3BRF1%4EK(RM-BR34UZ<)YR R>P)$
M%K'NJV*T&^@^8$\I$+[\R.#N(G>PT'WCAEBUV/TI'KL#N<BPAV@E^3\(9.]Q
MWJS@^X#W>0^7S*DLJGM"BA*O3V-7(5YP85?QECB$[2+)<+R19M6&XE4Z?)?(
M@4^[/-U_*T6ON]J\MT$M]G^.QW[_*2@DTWL-> ^*?%ML'K^CRW7*GPOI3*86
M76#\@KT()'U35V:]J)=>7EY?UO:9A4G9/MX2\\$L?FE NANVH20!DPX8,2P^
M "OAA<(ZATU<?HBE'1WG:]>?4MNA# ^# [;]\R2RJ<NH>3P$Y@&JX=EQ@ENH
MT@-L>J7#YG@+C#)7TQ;92F.'J&<W3U&5P^8L-T*9^V3W?)M:1DN4N2#PT.C,
M R[SQ+02!I&\2.&L)S7:(+*AUHVXK#4VNQ%+J=[JZT P^H&+1HT?]S:"](@=
M!V-!C PV>-\)IU]EJ^^ATY&JVG=[Z)_LR(_8,J%H:\(_Y8$IDJ5/V\W#5KP5
M%V<$#5<U"V"IY4W'QK@*3!T&_S?C]FY"]G%':KWB=$BQ9R!N\(&M=_Q$;7<L
M&K;-*R[JU%?@U/4#:;O*L5K5"AJ&:UE\?/')X(-NZ2N^E--TD33P&NX%48(%
MS]PV7J[DG+!W".%K.$ZF NR>SC9O4\DKYG2]0XB^^%&V<IV#O!<1.[B8$W8.
M$7H-!_1D<7E+8 ORD(BLTW23;!/H,&2XO-%R8,SY,2XFM4V X2^Q4>B#UA-6
M#2\E(T^T=U!+6/K>>J/+L_M6]ZF#=OQ$OS;E!\O,@$Z?5RH\K$Q%0-G+%1)5
MBQJ^Y=[C(;_!EE_K.0,=%I'"2J"5).L7!-1=(;+X84<FT7T-LPSNMG=4YH,=
M7 8!A9870/!%W$O+!+NOMW XA:><HO-M:Q[=MR3*V."9\K?5#(J]6AGW6><5
M=XJN)6T'W0\LE ';X_KQ/"Z4*FWA0TGBHK:[/@D?DK:#3'=;=Q_R[E!OV<-'
MT, JQH]$(D_1EY1L(=-#U]V?X,OEF35.L/AO"T^*"SM%'Y*T@DR?O=2M!"%W
MCV5ZJGWXV#SR1A\^> !RC3DRO$?L\>C%#;"A=5KB7629M4K?$;JACX+J4%2_
MABI)2W0GIR0PW;O&,2!IV[22"Q\ H2)V)(@50SPX:M?COP#).YYW1-F'P8;2
M?(LE'( 3B)F4< -%Y/LYN26F==N8$G=YLE^0(4#*>8??L463-O/FE'(DY!>)
MOK3-1RF>&I[E$5Q'+E_[J#E60ZWA2HL8HE77(!*K,GI>BE(BQOE4N[R^.DB7
M*!*][@,_21@WKK\.WYX+@>X6VW@$/<SDZW53S@;=Q:-.P.-V8J+B5WC(OHWB
MB'C[8>_>Z0'>%B?#6ATD(/6&4I)X) ZS*TOD'!G:7[B2GHQ5G4'4TS>VZ+=*
MXLW,4_=]GDP ;#5F*,YH9:H< .GRHT_2 '?-<O;;(')&S/I0I(VSD#)> ')"
M]*58FB]QY-_"! <T7A5"R7MD_$P\QOC2D$G*U6/2]8_*08I!O]V.PB_5)1_P
MSRODI#_]'U!+ P04    "  HA6)6CD/!)S8=  #;M@$ %0   &YX=&,M,C R
M,C$R,S%?9&5F+GAM;.T]VW+C.';OJ<H_,,Y+MBINV^KI9+IK>K?D6X\KMJ78
M[MF=IRZ:A"2D*4(+D+8U7Q\ E"B2 D" (@E(TR\V1>)RKL#!P<'!+W][FT?>
M"\ $HOCST=F[TR,/Q $*83S]?)228Y\$$![][:__^B^__-OQ\3_.'VZ]$ 7I
M',2)%V#@)R#T7F$R\Y[08N''WAW &$:1=XYA. 6>=W;Z;O#N]-U/WO'QJHUS
MG] Z*/9X8X-W9_F7BU5[*/[DO3\9G Q.!^^]GS^]__G38."-[_)R=Q2\":PK
M&,'X^R?VYYEVZ%$T8_+IC<#/1[,D67PZ.7E]?7WW^OX=PE-:__3LY!]WMX_!
M#,S]8QB3Q(\#<.31\I\(?WF+ C_A-"I4?WO&T;J!]R=Y7](2[-?QNM@Q>W5\
M-CA^?_;NC81'*Q#99XU.UL79US#)*Q0+?SC)/A:+0D73!;2S\EN@K,AU]O'C
MQQ/^]8@2VO-^P2@"#V#B\7>?DN4"?#XB<+Z(6%O\W0R#R>>C^"T)*-J#P=D@
M0_K?'Q/*<29,^0,931X3%'R?H2BD8GGUSQ0FRR./=?'UX:8$3@QH>RD&[P(T
M/V$%3K2;XQAJD?ED5Q0O(0DB1"B<]WY"_XXFYRF!,2!D&(=4&2 %<8P!H<!R
M"1NGSQ$,1I,)P%0)6:$+-)^CF*-Q"1(?1D27'MWT;85XC^E\[N,E92><QE3]
M S].AD& TCBAH(X1A1L",L9H 7"RI) S5B^8"-#G6T#!(8V)UV;?5HAWY^/O
M%(#G"#P"BB1,X [44#9F!;UK'^+?_"@%=Y36]#=7_,;XJ5NS@J!(M.Y!TAC%
MNO;L:#@;9+AU0 >=!8@)'Y+XV]&"/>Z@P/I-NX;ZUMNK-_8(NJ!%;5\.$6=(
M2#KO1"Q$+=NQ%T!RBP@9 _PX\S$8)@F&SRD?>9]086)>V39#.AM=PBA-X NX
MHE-XT'Q\:*]G8\)QVO@X6!-P]5B%'I"Y_PZD=!QC_[BE>T+MF,G)JOS)*Z20
M'<<^QN@5X*-:1H@@C##.VV,='J]^4(:=_7Q\=G8\R%A6[:N(RAH/<]GTX]#'
M(;/!4I*@^? -DDLT]V%\"29^&B7$1(6T&RM3R%":&6YDO0R9^.29DY$N(Z>^
MOV#+M,$)H'VQ-ZQ)PN'EL (0SK?E=*N)C!6T[,G56T(5%E*)O(KI<A1SU;V%
M).E(Z/(68)R<A'">"X8?1<VDJ[!$8VO!#YP.O+46H*+/C#PH/@XYFUL$<;OI
M-N#E31W/P?RYJ;:*@2VWVP*D,PH4#M)G<)P3HD5XA:VW*P^9PG<C$.NV5Q#3
MWS"&F6;&WU>M,WAVUO "[("5"T&8OX4)ZV!3W2O4][)1S[OC F$R5G",&!=0
M4.H^8IXAA!L/A.S-9AQ<O?AV"_UG&/&UU46*,5M*/I,$^T'.N,A_!A'WT=54
M^'96H8Q>E1,CA+=G'_;F&UTEXQ2P>6>4S #>[K&"C5ZE+8STJ^58;41SB,OX
M4959-S_!:&Y(8F0"34IH?XC;FGX^BZQ4MNF8F5%D@]XG'?"])^3I@XTPM7<^
M'PV.O 6&",-D^?GH-%?ZD[+6%\:N^N&@1:M(.3A\_/CQ]-0[]C8MTQ_KQCW:
MNI<U[['VUV-&WD.N&5QRC<<# H)W4_1"Z02SH8 ^;$8 ^N/;+9CZT16UJND2
MG0)041)!B2V-D)0YZ1STK+_+DM%1@+OX60ATM4 98@.M55,)B7O;42&ED^R6
M4@JA8UHH@FJE;RWPK\E4E/O2+R*?K/WI K&L+2^=B)0U;*!<A$,HRO*"4B3%
M11N+MPFU41T4O8F]!M1,"=30.J(.V5X2\QRAF+F(=51"5*=>+62U;*!?@46I
M'<*R4G2EI=O3D1KR(PU@[*F*&/BBNDB!MJLQUS#VXP#ZT4U,[4T>.Z#0%4EI
MJ=@HRMM ]@G[,9EPIVCX"/ +#& \'4T$4)(G"@81?U*J59M=2,G:=B<[*W&]
M7*#NH.]=ZZ78%O6];2SM#A,7/IFQ=1W]QP:R%S^JF57E%>1&F+**#:P? &4$
M#!(0BF$3O[TKK?DK=-FE22GE=FUT9_W7XC9J#^#>55Z%8%'K=T7,LC&PCJXX
M7Q;B*W@LDLHH4->2&P?U]6P088PPE_TDAR]_*,39J'3<H 4I<0S;V'T&UV8B
M:@QD_Q-U'5)%U35$QAE-S1]_A0!38LV6M^ %1'H*JZBLH[<UU:U2IA@AM@VG
MTH@W:J.>3KJMM*G$>HQ%.T!K4YN5V!65VA@KNVK-5@*CR1#3M<,4U*S%A67E
M2T99:1MH%L!@RZ-[Q,)SUF_XPLD/>(R7<IHU;$5*F@;M[*RI=<Q#.X'7NVI*
MT"EJ8@,T.M!%@I."@-)?&^&D/[Y=L+!Q@!<^3I;W_AP(U$]6;$N\5 7[PN<!
M+%(ZOOD$#*<89$[]"DC"B="HKA!SH]J-U4F#&:@!/+WICQQ^ICK&<-N=O%BD
M:;B*--V</KAZ"Z(T!.$U91CS?J?9:9;1Y,K',3O(L@YD/5^*&U!,@1WV*)\M
MNNW3'<9)!P?=:H8D;&E(Z%<VD!E6O4_,G5*A-+UK8&]W>!I'?BR9TT5%Y)Z9
M2B&;N"CULURH%I\6=4]"1Z3JM'?5* -9\@1M =>_)?K 3&.)^9E_$UM>Q:^]
M@BM<K56^RD%N874E(PX2=M.KE5< *S?MRN!8-MY>?1RR99S*W"J6D<_NU5)6
M H'X[+5U>JRP!CU?;LJ,_25?M#+(-^#'H=8PVT57\K"CCCK;W=R2R ;J'O;^
MC:HRKL6IHRL<[0X.-W& YB /=EKGVU ,%8H:4MFNJ>,0XLKQ0%G'%/D6-52/
M)<@ I-X53XE"40UK0>_?H-ND/PE [&.(),:=L)S0:I*6[ VE5;]?8[(  4_[
M(_4F2LN*45.5WLD\K",OT@"@5\-1 O#:B%0":CD8.WTFX)\IBXY]83Y^M7$I
M*2VWA.3E'4%6;37*RIL@W&88=BWYD28H_0=ART O&68JD.WK"0RACY>/?@0T
MSO#(RBM%1UK#"LH;,)B=.YH4-@#5:E-;44X$K:JM*%(==Y I5%9T2H)%2:NT
MH+?L]UWE4V*+JJ285.E\63,E:=24>U7UZCI%D-I)2Z.F.4%:GLC,F(:, >S?
M3ZV#4,E]K8>(7:W\C1JM+&71 [5N%2I8+285+U%!VW@I=6F[H!9N+6J*@K:H
MKO/>M6 ;V*+(BX&T*^$/(&(9<\<L3*,8WW2^+'Y1R+Y^ XJ#(29-V*:24E^V
M"VIAW:*^-.('J@.K=TTR0:-\M$4$ON5=J_#_4I)D0;T(WX/70N97C&+Z&*PB
M#A6[6B9MR'>]3%NQ&%X<9N*F#*X5%:T++MXJO/NN4D/>H'K8^M\U,L.E=)94
M@H.% -ETGM)A(,\E.088HG #FRQ@5J.:.(!6LZ(K^$O]WWH5&]&@K3A:,QXA
M4^#Z#:K50F;M1-='HJIQOYQ42'T+UUFUFB;4TL^37^"H))76Z>E[GDHK;XH]
M/PV?KNZN[I\>O=$U_36Z^)]?1[>75P^/WM7_?KUY^OW(U;Q[.19/S-:7>0@K
MA<Q2Y;F7@<8T+9ZV1@FS66[D6^C;%#*@Y,Y4HU(9 WKFS<[I<3KCQ7;:5DU&
MJ*2L-F6.;7X4DE4K;5%!N:[X4,[:J&:"4IQ*>;VVX;=+^&$8PJSKL0_#F_C"
M7\#$C]2G[=1U>F7(8$>&U.!BF3E!D)DC($OSR?#!8,;&AQ>0!;:H&:5?OU>F
MO=^5:?IXV67@ \NO'X-P?9BB)A^,N'"OK/EI1];(D+#+ATWX%X7MAC[6VE^%
M@AW1GZ>0UYS;M\ 6&EHK4ZRZNN)IP#\%*$[HTN JXD7IB@U,V</F>X0("#\?
M)3CMWU2F.HO9_4N7(/M_$V^O<AY0%%TCS&)C)<PS;L6%F4J/Q\:H;3(^;Z^W
M>U<^V8)U2_FV"[I@W364SK*.;J/F$(L*9BD/22>C-&&W#++[)>LM<4$5%S2K
M!;:ID72(@06/\A.2V+0<@^?J@80'0 E!8 *RS(0@<W@]@ !-,[[Q]"CU&R8=
M=>N"7=J"('5/*(>$D5/GAI 4A)<INZ$R@YD#6KS,[>H-X  2()O/&[3C@JW<
MUG1AAKG[_,]&T!8$0-F0"P9#8P70D $E\NX+ :?!/7CE7^2K,*VZO;+Z@Q5E
M+V#K/F\ST6S(W*W*KBOR%I[:RKM73.6X7LT7$5J";/ :K[(0L:#2!@JL:*M7
MEO^7%8568.^^+&3B*T6AD<:K6G-]"*A5"^TA046%]N1"<ON;S(?^-:8:$,$_
M0/@KE7X*\1=*-G;A["@NY/_!='423XLHW8-D-'GRW[)%SY9UUU.?O0K/?[<^
MF/1$)8<&'0I<AAU#1#*45,KTRN.?.YLP*EC5\T1\>=_N]_;=^PG].YJ<IU1R
M &'9.7F*[-%D3 <I$&?)P<;I<P2#T60"F&2Q0@4_V>9*Z0(3)#%)/YV>G9Y5
MK_?+8/#0Q*/"[ZTA\?PX]#@L[$L1&EHE \C+(>*%,Y@\#I3W'RNP_N)N1%/E
M5*HJKDE8M&\3H:VCJDY%-2F84#WU+$'&LN'6W6E:=R*>ZB3/[%"M;9;=C$?*
ML(#"=R?L86T)*^U?;I"PK"!E#:^-!Y 6MQ@54(."*CW#WD8(;-M4]RC)EDN/
MBP@F%RA^H9_8A@FS"LYD_#1NQH6=3"..&V/HT!+@\!R+DBU%8X[NF2^1P3;&
M,)":L(4"+NS9&?&C +M#-!]C%  0$I;)F8F$'P> K]OHH@B#,+.2XC![ >A'
M_D;"GZ:-N; E8\++IG@ZSO<;1GH_*B_4#5@MJ>^"?WY7[DI0Z]S)NDKP24:3
MKS'%[Y7YZ.(I\WRPDY]K)PHD;&:NSG!-&G#!_:G#JR:XN:1].>3Y-,VD[ *1
M1)I+2%G%!9>FD8XIL7&(4_L=X_AQ=T[M33!C>?K5959MK7Z])Z=M3%\U&#G$
MLRWA&J;)C +WAS2X2UFC7UZUX&A18N,FG\8^'F%^_"#;S5[?]%+/+WG-?OG6
M@KM$"RN'^"<:$VI5K:Y2OUQKP252AY"S##/4.=W*_3*P!1^*+F+VML(?T_G<
MQTMJUL)I#"<P8!D4-VEZ$%T]0D#6"1:+N17I\RT+!"!F6^%4<JI;X2L8V(YW
M 0IO X:WAH-M@J] X9O?.3#\5P;./FR"!S,0IA%WP<@R5ZHVQK6K]^^CZ2[Q
MK%,;Z(8,U,JZ6D35]F#>8;Y<9S;8#:35,&NN;?YE-QP"G(-6EVQ$7-J%?7@#
M4:S8NV*<[.?CJ6>(749(5AL-&>$8 ZY33.E'S0Z*P35\8T_J;!6J"B[LL#9D
MBPHM1^>>+4-;=^JY=2&:11^MTAZLMIVQA[$N4I2N2 +G;)7TE8!)&MW"%VDP
MA&$;3@^D=7M\)H@ZY!G@J[(Q9J%S@1]=O2U "-E.RM@/OOM3V1JGMI;3@Z^2
ME;6HN<\\*FNCR:\P#@F<SA(S%E;KNA 7TRHCJPC:<^[<^?@[2-@$L3DN8^:M
M>;]]<&'3J+=IE;YWW^UR"9Z3PKFA%PHM0^,:81;MJ_*X:-7LVY2%L1\'T(]N
M8D+G;^Z2DSM8I*7=<:H8L*=DRLHPLSMR\GCQ"< LJB/+:0+CZ6@B@)8P4YV(
M/RF=+>UVX8A7ID:L2XGN6\7?MLL&+Q!FE[F4M*#&<:.LXX+[I@LM*/MYE"2P
MR].OCU_0"\ QPV$-*(OLHK083D',-C0T.=VH)1<6.UWSOQ%A+ >-YVOZZA2W
M@;3.UV'8AL5#/$V0+3)8RRC80^>'&J_A'.&$[?&S^,*KMR!*6234, @HJ.$-
M10L#DIR#"<)@&$7HE84BTJH7F*Y $L6Y\LY[=6',Z5CF6J"20PO\*G85W#<9
MJ+]@"OHF(0/+Q) A^>2_2:2MI;9=\/3L+%,MT>( )(>I0%>24VG;!=>2-<FI
MT,(AR5&/K[(AM=&4)F_,B2-<W<Y4<N3W1A@N$ L 2U%:$>PQ(IQE9X,[6F)&
M1O@6Q5/I^JGM3IPX(=:M\)@396^$ZJ$PMS82F'(#3AQ!ZU88R@AW?HAP/5!E
MV:+N43Q: +:PWSH44UO:B6-F37E3BYU#&B='C4G6'4MVE4G6,TG8CIFFX5??
MC!/'T]JV\>K1WD/6_QTF,QB/8O [\'%I%;VC,*@:=L$)WE0WFDB(BA:=C]O:
MB$[HF$9A?)IAE$YG3Z^(04M4,M%!^R[XJG81C0Y(LH>CRB.="2.P^KV\I OA
M$DX\E^*.XXM>%RZXJ?H<:?2H<A@2U8[1HFK8C5/;?=DQ*DKLH<24)MUK'V+E
M94([-KI/%DV]*NULXQ0HX[I](Y.,EMO>)[M&3T!:)M >CC#;=&I]+MHO"Z:;
MD45$%7OAN[G(W@&?_<YB88SB=W_:CM]EK7J\6:_8[EY$\.84.5^>^Q';67^<
M 9!\H9J^H*Q3A?#J5>T[ZL\G,Y;UB_YC(><O5#0K5]I70_X4%=R)Y#5A4RF:
M3X&=[1NNZ> "@P2$8AC%;VONP=ZE24>B=>L%N'QK]BXHVY6 .Q2#97;VX3J-
M0S5O985=L-W;$.4B4V6XNA-[NXX$-0BMUJ_N@K7=-DOUL?\1--^!#=PV.YT.
MDB_8"@5SE'L/5<>9ZFI9,(8DRMG4&*I%T?(Y?>;KI41-<CCSA\(!1)4F&K7@
MB+VC*:VED]LF:%I.3[(Z2SZ:-&:J61,NV$,-!+F4X,0(86?&VOSQ5P@PI=ML
M>0M>0*0WY"HK6QAY)?-H"R.O$E-'F%GTXFS#JSQ!:MB&>X.PAA@+.:N'KR,,
MOHD7:4(X8F?J9$6J&BZ,M8UD5LA $8;NL6M@S*Z!2^O*3M@U<(1=>YL^07+0
MI/%L]R-_PH_\"1WF3_B1?<"^!_1']H$?V0>JLX1@CLBQYTG*.58^![0V(<'N
MS=K+4= 6221+2,5DO(=Y"T0*DK\;$@(2(D*X[MS'[LVZ,-YT(DD[4\:A<"?Q
MSH7 7V84_B"L[X+]T9:RU,=("$G@$./_?$>^94-$!R)A_Q2X)%Y6E']R6W9%
MT;"Z-5W8KFV3I4;(.Z3?(D\1"]/^&J-G0BUOADSF WH U+X)8 2YJ?S $&17
MDV9;:(Q8N=%.!15QC]'[.J.SHTY=2!_2Q7C1-=T.7"Y':3*:]"Z8I5Y=2%ZR
M+Y)9(ESG4UZ.00;%:H?B*=.-P<8A,6=76XEF/L,&7,A$TOH$:$@#.TP=K. Y
M:\I4>0,N9!3IAZER&M@[=B&Z[.X>)&8'+SYL'[P0WUSWGQYM>R\.7_RXM>['
MK74_;JVSO;_G[*UUDKGS 1# H@345Y^IB[K@RS.\:$N-D$,K)'Z)R0Q%X<U\
M@=%+%N.AW Y4UG#!Q];P3C0E7K8/.NS?A8[M7ECGZ(6.^WN?H.E-2&KVN'N?
MX 7BZY> =7\34_2F%+2Z(T*J*B[X7AHKD0HQ1ZVWNM"#'_<^[ED(@10ENA"N
M"1/0J^JT#:+DNQY^#EF/4H!Y,G)3+JXJ.6WN"X14BX,KW!SB72%U_"588!!D
MOG3Z' %.\SA<973C[Z682;C<7O-.ZW.-/+1'!8<D1T6,!B.WXPN3IAK/,7.(
M:SKR)XVXT:GJ]/JEAHMZ&-K;E'A,4/#]W"<LN>9\ 6+"(>)O1UD4H='^Q-E@
M>W^"-W;,^_"*G:P_>1FN9*^V*AYG/@9;=!MB[,?3S,-SOMR4&?M+?F#BU<>A
MWE[&SNWW/713O;CWY\I=C5(1%[<O6F)J:10O(6UY>EW!HMZSJ!1R97M"(%\B
M.G>YY3"D@]N'T3R&SRFYB0/*>_@"6,?RK8?:*DZL281RL4F068=#YW$2U<XI
M0!_5=*^KX83IKR9['0H]$?H#ZY,9//-%A)8@,QC&*0YF= QLQ BC%IVPX(T9
M981BY^K3D'7N\4=FFZOYHX6'Y;M[ZPP/F=U1Y\1NHV&+M_RV1A:Q$WQG>V\/
MO>2-:<K?DAM"^%F/,:"C5MBVU(G[<&&R[D@4VR640TZAQICQ/[\!PFXBR_ Z
M:UO*A%VX8&@X)F1".G5NK>P&[M7; F:GY84C5"<]N& #M2LZG9#)H=&)(C1?
M>3DO_ 5,_"@;4%E@'7X!X37"URD+-F$C+(M%ET=$F;;C0IA'-^-, V+8'TSH
MJ@VS^+R;. .6 KD&;TBHY+(UG3^EMN)]RB@[FA2P'*4)2?PXE-P?VE_?+AS6
ML3$ M49 ^W+X1*L3%B0J +6 UM>8\H"M6QL)G'DG+IP8LB%9YI1R:'9K3+#5
MCE]!-1Y0%%%\V<>VK?":SIRX8=DM>[R&8H<I@9D"=B]\ZWY<V)#I5H$[DL4U
M 0](#+_0@@E9^U=4H8>=]+37?J_>15%(0I>$D=D.F<?N,L6Y2R6S7(L!-U=O
MU'*%!$AGW 8-[;5WRUR4&E#()4G9D5"4,A/ 3\V0KASUJI[VVAW6^[ E).$!
M"2/S'X.0[86_+0"[>^@)L5<KS6/;:)U:>/K=[[5CKG>QU:?K <ER@;Q_!W Z
M8Q1X =B?@O5$,L8P (STD[X6S=J ]"K?'_=T0:U-S3^?5-L5Y8-;F!L.(!;D
M?;^$7!JJ(UP>=B'H;4)P8$O_+H6]3;(?DL"O4;,J\X9 ')B;PJ;8&U+^D"1?
ML*2V(?O&8!R8X\2F]!O3?I_D?^>EN04S?U>@#LP[8]'ZWY43!Z0IPS"$&>B;
M \MU-\ITW&>_J]S3?7+3U%#.-;E\KL?TV7B@> ",C_3]!8HYWJD?/0$\'ZBD
MM6](#L%3HS4T;$EWWY0^()DWGI9D9%$>%W$$P$-P[_2N(6TRP#7%:<>JO*%H
MPIC @.?#[]YA7^WO$-PWS<2Z&WH>D)36*^]P.L5@ZB>@%RG> 9Y#<-/T+N4[
MT/N M$"Y%\$_7E("Y#>:]!)LJ@'%(3A?>I=X8RH?D)QO;3X\H83=^-/#P*[7
M]5Z?F+,ET7JD=4V,=UYQK+'-5;7;%::HN[T^AF=WO2@BIT,BFB<G O@%LCO/
MA$1>FT;Z;NH6VMWK$WA-A:X%NNV;=-VC^"6SSAGA"!_4B]\O$$GN4?([2-CE
MF-,8_B$]FM)A?RXXE5M35F.):T:S/X,DKD9WA%>O6#G9!-TW$"ZX>?=+9B6$
M=#(_]M9;YMJ("3!-F#TP3IC-+1XO*'X"6=][E4-;3S0C#@9]&DVJ<L(DB.CE
MTVZUKY['SIN8LII*(M5/9M_<KF!4I-I6UG Q\W8'HE <KY3TL#LQ2D!3YNBN
MJ>-(RFX-L=7@42L)O7?FTOK&S6$<7K)[I1&_^V$UX"LO?=.JZ8)QJR6(189I
M86:7;5] #+ ?L?LVPCDE++-H6(IF'<9IUG7!QC-FG29N>[!DJ)T3MD+2&CE*
M#'JQERZY(X*)<R>W.F/O81[E%6H@%&.^TB2)T.E6=F%PZ4&J=,GAVC)P2$@Z
M;W9+TGN#15^AFWU8WZVG(>7"K%*H#>4E."G 1W]M8*,_OCTPE[%@S53YYM#J
M2$A(IC<5D#N8IG5H*;2>MKY:7HP(.5^B88?&3@T5[R@]YNE<2L?*=YN+! G3
MUX2L0&J!E/Z;FI3E[S;GU3I2EB&UG;-LO:2HNV=$4-#BO2%2L,M9PLKCZQX:
MH8VW1_/=\()M05>#=R"9H1!%:+KLZAB42<\NF+^:LM0'.1S:SFL<FR'"-P\)
M[>+TAD:'+GC?>M3D5F)L-,CJFKBV1=U**.=O***M1131!SI2]#%<U@#@Q*AI
M49Q[(O.ABO<#)-^O,6!A^  #DO0EU>)^]_I(D4/"+*:N/8?:/4AN$6&7=' <
MADF"X7.:,$O\"5UL+EM@=S  3*F6P$L8I7R38C*ATXR9P^W]]K7D% */@> M
M /8X$%X1"B]!7@:'5P2$N>,H+,?A"A@/<&CVP2^7N^X9 FOX'P'E$.4DH+-W
M$*64=M=4]IG 43)D_MPK'[-#E#FO] (NVNFD;Z?^;D"?+\4-*"(U.NW1(5]F
M)\)7VD/HDI!VIW<Q9+4WN==7<R10I >MJY>4UBZ/;V_?>Y.H7AFHH"COPLI6
M5WJ%\:7;*+FHBMJB6N=&;:]Y>\[7MDDD#C]H9QK90Y?OCH@/YRB-94[=EMIV
MP0'1I12V1*9&BZ]?3C+&K=80?_U_4$L#!!0    ( "B%8E8XT5*(=V$  "99
M!@ 5    ;GAT8RTR,#(R,3(S,5]L86(N>&UL[;U[<^2XE2_X_T;L=\#VWEA7
M1Z2ZNZK'X^D>>VYD2:JV8E25NI+*OMZ*#0=%(B5.,\DTR51)_O2+ _ !,@D2
M!!\XS)X_[%9E N>5Y_SP/N>/__-E%Y!G&B=^%/[IF[??_? -H:$;>7[X^*=O
M#LF9D[B^_\W__(__\__XX_]U=O:_W]]>$R]R#SL:IL2-J9-2CWSUTR=R'^WW
M3D@^TCCV@X"\CWWOD1+R]H?OWGWWPW?_0L[.,AKOG83UB4+"B;W[[FWQS7E&
M+PI_)C]^_^[[=S^\^Y'\V\\__MO/[]Z1FX]%NX],O*W?U3#PPU]_AO][8 P)
M4S-,?GY)_#]]\Y2F^Y^___[KUZ_???WQNRA^9/U_>/O]__YX?><^T9USYH=)
MZH0N_8:P]C\G_,/KR'52;B.I^\M#'.0$?OR^X*5L ?\ZRYN=P4=G;]^=_?CV
MNY?$^R83$;[68)(W?SEJG^GT]J>??OJ>?ULT982\M&@KT_W]]^++;YCA"/EC
M' 7TEFX)[_YS^KJG?_HF\7?[ -CRSYYBNFV6,HCC[Z'_]R%]A%\3U/P)U'S[
MKZ#F_YU]?.T\T. ; BT_WUXI%?ZI0BOKQ-71LM'WL^ES'Z5.8*24W+.W9L+)
MH?,U^ZNB('U):>A1+U<1>+:0YB)Q=^&4@7;D5@@&$ )1?&RR)/>FA+K?/4;/
MWWO4AYA\!W^<P1_<4NP??S^/&-:L'Y(T=MPTI\3E_],W3=_WM =(#<36<55T
M)W9S9NS/#DMD+;YW(X8!^_0LR'X;WGT;1[MF406[J.'+OP</!K]MKDM%D9@F
MT2%V::\?599?9>M"1M8"H)^&9Y_O>@C]'YP:R<G]47 U=Z6MDSQP-FP,>G2<
MO? G&J1)_DGI6-D'?[]+63S!R'3O/)2AG6FL;(34Q=J5 C]K;H'0V3H$-?6X
M@ASYP@G^?W:=C@$PO6)_)EW:RPV7XGQ'RC4Z8-%J"4YX+.P(C@A$":<ZW!N[
M1].+;"9^SR@V 'SM:Z2^IE(D'TKE[Q#ZE5)$4V_*B1&@-J,3K</PX 2W=!_%
M33,S1;,%.%638G7GDML@=[)&40<[FZ!*!-D9O>Z&QG[D78;>!</0%JWK[1;@
M=XVJU1VOT@BYYS7+.MCU!%G"Z!(@/.>X&3MAXL.V3B?L-31=@ NJ%#P:6VOM
MD#NB4MSA8VY!>3XHO Q3/WW]X ?TTV'W0.,&Q1N:(/8^E4*YU]6_1^IM2C%-
MO4P0)$"1")*S>=<M??1A9R9,/SF[IG%6T0R]ES4K5O6T:AO4WJ80=:#'E50)
MD)W-Z\X9I,9.<!5Z].4_Z:M2Z^-VZ/U.H5K5\6J-4'N>2M:!KI>1)9PN881G
M<[ZKT(UB-H3S8SN^17,>'9@PK^>1IT; KE[H'5-+[:J;MG9![;1ZD@]TX0J3
M%>%L2!23C!4!7K-Y];WS<N6QF/*WOCB0[I@SJMNC]^0.5:L^K&B,VGN[9![H
MMXP\J=*?>]:Y]CQFM23[#^R-OU4:H[DM>B=M4;'JH T-43MGF[P#'3.CN<K_
M($"=;,+Y4#1C?,[^W,3WT=>PRPR5EDMQRF/U&EVR;+8$AVR0=BQW!-(PL /Q
MN5V1SRHV\4T</?NAJYZ?*ILOQ2D5BC9Z9JWM$MQ3)?)8/EK,/G,.<SOJ392D
M3O#_^OO6992B\5*<M%')1A>MM%R"@S8+/)9["NJ$D9]K602@O8ZIHW#'VM>(
M';!)D>(ZH?0=4B=K%-'X,B%W*D9M+B^"Z]W!S5,4JL]@&IH@]B:50KE'U;]'
MZE5*,4T]BQ,DG.)\J^$[ZAYBYM)OWSW<^^G1U51%$\3>I5(H]Z[Z]TB]2RFF
MJ7=Q*B3:DK?OWCQ\2W+Z,[C8?>S FYV[U]U#U*1J_7O$SM6H2NY9E2^1NE6S
MC,8^):@106Y&M+I\<9^8R%1Q8JQHAMBQVA2K(Y?<!JF;M8IJ?)<Y(TIRJO.>
M&/^5!L%_AM'7\(XZ"1NCO:LD.;0<;ZC;(_9#+56KJTU%8Z2>J2?SP#4GD#_[
M%>B3G $1'&;SUK]$P2%,G9A?$HKK#S_:VJ'W3H5J5:^L-4+MC2I9!WIA098(
MNO/=K3G$,0U3<4L19ANIDQ[4+JALCMX3VQ6M7;AI;(O:+SM$'GK]1E G!7DB
MZ,]X"R>E\"#4?Z873NID\BBMH6R.WDW;%:U?N&EJB]I-.T0>?,6FH YO )S<
M;V>]?1V?.RE]C&+U/<5Z*_1.V:C6\37LH@EJ%VR6=(3+V#')J<[F;W<[)PC>
M'Q(_I(EZT*ZW0N]OC6I5_:W2!+6_-4LZT-\X49)3G<W?+G<T?F3#_R]Q]#5]
M.H]V>R=4XYRJ-7K_:U6SZH>-35'[8[O$ _TR)TX$=9*1G\]!7\JG5^)!H-H.
M34WQNZ92P9I?'K7#[91J<8=ZY(O\&D_0GL$=K]QMO#YX/J.S3E.:I/SF[(?
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MSH\B0^"\$B"&44N&&'*(L1)@+,FQ(J6(XDNX95'_K-(A*R/=\(Q/+O&4:T!
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M0]WJN9BR.>+0U9':_/F+1)L R141Y+-_8(OB^8P!MZ=+2]@M7B35];X*V>2
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M3@ 2_^+XH;#-O?.B,/]8M)$CZZ@FK-Q?'(,P8I0<5[\)YX@K(@E#N#2D%(>
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M*"!W= -SR$[?HSOB ##1PC08,EYP3"I?QY)"Y(O@9"<\\LQ]FZUQ?/0D@3Q
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M[F. 2EH'C7Z(/;R7^,:)'#(F*\+9\ MX!:,58:RFOK#[3..'J'U'?U9+-)@
M5]C_$D>)ZFE/9Z>EAGI%::T@YSV6&-Y5P2<*;,[$SOG<3(ISC6FI\6.3QO-D
M_W?9^O@00!;T"[J/J2O.&]G? >49>T(OJPG)/U?:1V'/$<DC1X>Q#5FI$S 2
M;<2(,[J*QIN(I2!$EF1%"EEX],K2,!RK(MJJ"FGC8ME/PIHA?00AV] ,C5&O
MV?KD9^)(IO4D>40Q'TD0*TBH8R&%G36[(D>P/@:0T4FG'V+DZ26^>642/22Q
M,^N9W01'$4_HRYZ&B9UL9)>[?1"]4GI+.39=^\Z#'_#7".>B5IC";#K]D,>\
MMNJ5A'M=G1!'N[[LIGZ><SB+!0LB\5B1C(N=.)]>^1OGE8D2\/C.]7^@(=WZ
M9EOLJ@JBKAL?J'?.6OJN$]S'OA- Q7I%P.KV01JLO50N*WEV=,!^,*LMO_FC
MWCA^A8LFXAZ)D^272QZR[  )SP[ ZT"R;Z*'P']T1$H//^15)+VBHF7ZY*1E
M;<R]\UI4R7(S^4D*"A 7-/B.?$Z@<\1B9!M0-^5L\\*4^RQ_;29-4$8I>>-E
M!3^AGF=(1>E,QB3[")J'4;QC?& FSX2%>IJO+A/%WY(@"A]I/'L!RZE_QHP!
MR3D0SH)P'I;P=B;_;?"L\3'V;L\</F*^7EPC$#.U;J3M[KD O-54OXZZ'=T6
M@KVZ6N!&X"370KJ*(_3X+0+QU+]I#L<%'U+<$\HX(0#EJ8UP=^1R5A:VF]SW
M^)V7?+K_VKZJ[>R$%+7[*2VO9]M[(%[,:@INZL4%><+IKXJ5[.NT(:QQZCZQ
MYIRJ#/BK^J" ,)Z+U(.;;9$S[":K9G_YDC)\@_NHUWYB%OF]R"\:(_H;4A]-
M]&DO%G<,5)P0H5922DXVD2MS >8BD2^E4.0R9!/CF,\QC7)UMJ^E"G&SZ8;&
M=E5+%Z0QUD?A^K))U7XAZZ5.\7$OE,JERF]X?339;Y@OC$K,RCD@6!!-IO7F
MR*?LS)P@A[KVP9ZZ-5+,U52S,DUI;HIYUM$AL;&+\OSZLYW2Z:QNIM34TB.M
M)*&T.F^\I2']Z@3W--XI[-#="WD\:JI=?;#5V@5Q?.I*/N02&65S_*-)?\:$
M !<[!^O3JP[[$52L4]B,BS'R(P]-)%^^L,4<9=&PV6YXT8/[B*^IO![F:J.Q
MP"CO-$E7S"L)+ P!NO48'0\*EK R$4QA"2/8DB\IF_"2K1,DU$XYCKI]^+18
M:Z>E;(L\(EI55&^690T1>WB[O*-M8UTVWX:<9S";6L<@&\SL7?BL:GCCO.X:
MTL=W-EY4#-:55 =AWG(Q47@D\&AAF%/&<<HU@9Z\9L,VB+XFY  ;?=5=0!ZH
MEO9K*IK_E?J/3RGUULQFSB.;64-9TOQ+F&"_U3*@%IE%1;6^8=3QWDUC,4C0
M0Y71,"+G23*FI. J6EA<E<YNG)S%GYS,%G%A"S'HIPVVL(\G4!@'$I#=.BF]
MH>Q7T+P;HT5FR7C28AAM/&F@L50\:5-E.CS)N1)@R^8D@C%"1)G"/(4U<D3Q
M<FO$<(+YQDF( [MAP,Q.'=RJ29);)DBV9/I$]6#DN,^B,$.ALAH@:AT6@P8J
MN4<*_81O9*?E+=F&Y"XVHGQLM;F2^6$PQM6&=/"6+[DN#K0CFU5/$HN*<#V#
M=-^!:^Z_F/C75&/T[6SI3EL:D0=*;AS?LUZJ=E;;?#BDAYB2'5M+[ Z[;#&Q
M5^S.6#L&*WXHR02?Z$MZ_Y4&S_1C%*9/JDW& >200\E00W6=D^G00@PQ@U6:
M!VY6Y&]P@V\36CJ3L&8F%OAVBI+I:@R_R_W7:*#=2BHG B<ULYB@2$;B!,"C
MKLFLF,$8X\:,L:S#0OA?\$,%XZFZ;&!"YY3@0C:-,6  D5.!C(HN\X(&L%X
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M<;6>']L86(>OG!#]/O*)\ZE ?FXAJZC?5XA3!WZC'V54[.\EP2G#OYDA4(P
MA>BG/PC,^ROEU$YK)&BX9F!C+.@OQJF/!H8_S*CC04\93GE$,#4%BC&A\6+4
MJ8X*<_]2&;^%C0N#KRU8.&H9+-32QXQ9?K1Y[V>=ZG@RCV$P'./HW^4ZV3,>
MR[]FR]6O$QF.UI[GPQ].<.$G;A E,+KGMS\F^E&[>)[X8*)E\C''BE:&)SP4
MZ.F- >E+28DDZN*O84W[ QP->K=TE]5@/(]"S@/2_US[6TK>_(TRL/Z6L)&$
MK!\?8_[*A%RQ5GZ8^"[YBQ,<+-[1>NBV\4/O0_O"')(U[FF\>]?V:\\NR1+
MWL[/<S0$S"L&]H'!DC4P#!?M][N:81"TL#B*+.S7DJ\HP6S_E0\?BQP@>B^A
M5%9MK0F&1< 3'T[&_S'''&7&D^Z$!Y\)C(1A3!JP675J Q:B7[AE \OVD#9@
M72F-SL42CJ_@IK\8?<1O"0/.E*:>Z+5)E1GVX6!2G3&@>V7%T;%MLIS3A>EL
MW_UFY%1>BDQON,:W(<L<N+IG!L7FY"P#VQ!Y3GS@&_Q3S7O:KQ#FA ?.X3;!
M,+#J+YNTCRV6,_[:^PF[#_:7.<"TOM[A7UXP8WYP_'C*8:6_%"<^F!C^+--E
MH^T4X80'#E-+8!@N-%XA\B8$5""@PX1CQ,QI;J?_I0I;.IDM'[DM/;#E%FSY
M#&S**U^\/)8H^"@$%AVHG8+60ZU]].CG/DJ=8)9UB";K$Q\E^OP 8PX-.GQ/
M>#SHI3Z&0:#Q(>(<BX+) 7^6GZ)<2/F%S02P'\$YS5\F+OCD/S=E,4Q.>X[?
MR&X)P#VAH<<_8S_FA1V@IU09 RAG&SD2(J.8?6,T>PG C?-K*UA[N=L'T2NE
M=S1^]EVJ&,ARP?7?2HQ!%SEZCF8Z&28'$T6,A^/I-@;P%8!6 H/B08+U]PA(
M#-=4P1EVL,.$DD]12FZI&SV&_C\M31NUK/0I"I_%[CL@?L+GV?+WYU&2,EW^
M1M-2FR&_BB&_4X"^(:;N#8DFS)8.E8-T-CY!RB0CF6A$-9E<D4(^,6EDD\4*
M=(!X'#=>:1MV(()8*P;_',8%,>+*!G09N]-"VFS*'<791]!.M6R?78C?*B:W
M_BBS '6C!+]%]&XW!%I(7V5[ V0;Q402_<2@?II?IV)@FDVWXY(#V3=6I9MG
MI]9]HMXAH)NMWA(EX&*POS;;NMG H,D]7$Q1;>M,Q LYK$]JXLH&[12,$(/T
MM/I.MD.1+;C%U;ES9^\S8!(8N]Y%!];Z"Q?D:*=B%CRX"MD$E=ZE3LJEO<XL
MMG[Q586\VWL@CTT-=>4(:VF..$YTI#;U=D&;%,1)3IU\ ?JHG/@B@L=J_8Q4
M]%FF(U=5UG!ET6%YSER3>P)W%ASL./0M32ASAJ=UZ%W09QI$>Q N&T@^TI::
MMGH]D3MW#_5E%]?HAMC1^TAOZNXY#SX5\4HN5IS\%QK2V F8OFMOYX<^''RD
M_C/5<7/=OL@=O9<)9%?7ZHC8V?O);URV0W#AWNY4^.#=A.U<M5S[(;UBHY5J
M?CX^%^1!-)%9^Y_Q:[- ')A3:6KQXM/Q?N<7D(]P 5'?#YC1S/PRJ3"?V[!]
M:04O,_VIUVR>;*Q06%B[,W)TZV<$&;3T>B+&HIX*&%_RR]DH3U'R+3P[6#&3
M&?B!B;A5?C8'$"1Q*H$ ^U<) .P??[\%=&_8AJQ_AS1\&U6 Z*Q\@3#XFN4S
M7G "I=&W!G5<IW'Y>/PM=O<Y7@+6OL+L0F/M6@@G&GU#KL.-/K+UXNZP4SI2
M_7O$KM2H2NY,E2^1NE.SC*8.E5&;SY.<EW9/JGV/V9.:5"D\2?X2JR<URFCL
M28+:LEY1%P]DUDERV&4)\$/O(TV?(B\*HL?7J<IJ].*,- HLF'^4)]3Z;!%&
MK@WM+6Y9E0_RB"0OW\>6)+;^RF4)O\:',AN&4S);UBOI)G,5B:BFR'>NPW )
M\#RIL4=Y*]W)#3L83ZLT.@Q>E<GO%ICV>WK#EZD!&ZRSO&EQ+9/37Z* 40O\
M]/7624=/,60BP!)0>-8?8[*Y<BMW["@]KQ$0HO91\KE2= *RG\ $>MK?I@#V
MYX+N\N']UD]^_1!3R-E*V0^<SH7J"KZ_)3!O,_UD&-[$]+<"W:VZ(T1LD)>
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MVHQA=F=C<5#5JL0,$[0I(04RGX]SF6*D+.P(4 %N7T0A3/$VVR.8A',#WWF
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MEA?:S$!\WDZ<-(W]AT,*B=O@L-4M12>Q\@H;U('];A+<:<)C6T9NVM>1N!8
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M"4#1!&*8\R$C6C$/1&F#WB-&CG.M9QBMKC7\1:;O4."QJO5 H_DP#6D'AJB
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M.!E&X0+UYN_-23MO%MFTR OLO/V$-ZHG$0ZK>NN[M J.L>6/?'*6/"5Y/](
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M&J]44XCC!L>6_<.:TRX^<%H9-Y*+8B[.TU5X4IM2KLTM X7[[P$8S7Z#[C2
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MU1F3-<.Z*GNU'LGFJ[RDG16T5!DM\B/BHOTC-17:W:KY(L5[]PW4#,>2UJE
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MI48"=><A#J#:VRBM3['I7DB1)KV'C3#3=3W2>:1,2BT@ XSAO%!%[>)\*^-
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M-G32;C4.VFY?=8C;SCT>WER0;N-TD'S4D_=C.>,?WDV^2:[1L_[]EOC&=OS
MQCCP'3S)MD+_'X!0NVFWE60[Q3]=UTVB/]PK)X/:G?YP=7/3]ZN_BM\DG6C&
M4#7I-5.@L]0AW0PG,GMEU;$H37<OB-. %1T8ID^IZ3?)T/_]=H1[:M=OM)OJ
M0>[A?) M$U+I7-0FY];DV\_D;K;PS_?XAM_W )38 2CM8LZ\L;3;@B_?'VNG
M#_JQ5;,?)Z\^@)-JY4H[.7/[K5+UM-FMJ9.TF;B$ \@H+SR !D4B775TL7WS
M_NAH4KR[S0^F8V=RU<YEC_W)9-W7+L_N^IH8O3[=9I$R0+5'SOUAASBU+M\\
M'H1;\SU >6#YL=/HR">-PZ+QD&R=N,/#DZ/*H?N@PFGD<NET4GXI2*SC1%X.
M!VL]$:>1.9%[;FLB3_6)YJ5*HY/<N <GDE4RA5SN=T\$T.2@?.A>F^-D:3#,
M'@RFC[(]-*9T^@?*Y0V3$D+')_'#*;KM6C<*'Z-4_71LIJ^S@^N,XN3]J[M\
M]:0X>P 7E-=1T8SNU;.UP95JPKB136J#2_]&/F^9<C9W;!XZI%>P 0D^='-*
M^UQ)M^\:QR.G/$S[MT?DOC@XNNR]='/%J_.I7#A0JRV__GCY4$F>'9^4BLLW
M1\&#.(:VCJ751@2 V>J=$BK!G1IJQS -;UKRZ7(MCQZ71T"8KG4KAD49L*&:
M%[9KP&+*#Y37N4;'I&^Y7FP_MPGM7K\[&TQEU3KL:N?I@_PC1:*?SXF$_REJ
M&CUSO6CI-:]/'+$<@[A\0>)$^ F\X$!6!<0W.9!FRY_>-%*-1IE4^_*M8C;.
MN_>7;W@@:Z1V*Y]C2-ZJYY798RW9PZ%M(?P_3<WD7\W1M=LY/BW?JZ0\25TU
MKH</$Z3ON70FE7T)3OPNZV)+IY+R7MGRX/+I03NJ6;5T\G!"IFR]YZKCM-UB
M:GB8R!>M5O+N\;R3GAX5]_.4]LI4?,UF%3E3> '$OGZY'"@JAJNIYBU1G;*E
M'U"(C:S8/B[=G5Y3:)4/"Y/&+Z^NIX[H%?Q,))0D57;>=;D'7%4/UUNAW[B1
MU3;UL][YH>$46G[C>#\CJV<EZQBX/9W@ Y=*Q37#UF<7>UBY&!WF][5AZY[<
M5Q\3C:+2'=#%5F[?=:E%NDX=UVJJO<CRG//I9:L\3M[(]VH]?7!32#M7<)9=
MBK/DW>G(<@;U)!V)L]*G2<G5D=6]5:_.TV6C>#FM'Q4<K7A/V:K\#C+B>JCF
M2W9;/4EY6OYFW)2OV\/JV;0^,=K>Y$-V^YMW.\<CJJ[KSRA#Y;N2UZZK%AD<
M-O<[V<?37]6LQH3=O%PHO(FP^\J=!L(^V,7V*JKAH 3H%EV7>.XI&1-3:=KX
M;[*)-@OBN,6A[5MQ(:)X6KF=9![367F:;=[8$S5Y<UJX?,4%_^:>5X'E=>WY
MX3%;J12S?E,>7F:[]7WU(%>T/V#/:[KG)-^S\M2>*Y7'VGDS6RNV2B='QPW#
M5EWW\?/>\TI[=BO*_6UQJHQ;]\4COZW_TN]*\L<0KQ=M^\7B[7[9M._/VX-J
MRVB4BZG2L7=^85X^+]X^M]\151W:V=-*RVP-+PME8N3OO*2_W_(HY"R6+S+M
M%-VN4@#Y(OB[V[TOZ/F+AB</=2V9WS]^.,U<7D:WGI[=.FZZ;YLZO=GRO4_%
MY7/;(^PH1E17*=D6]W/486(E=AR'9??TH/682<F'#X^902I;?3!TD)]WE60Z
M\]8 _P:&G  %SJCZ2.\$Y+!KP^NW++OC$F>L4O6P:HTH=-0)78I&M3E< OU$
M97<*+?NJ:S#T"?"E:GD,A5*QL_OEG)6O2ONUWN"^Z6755*.JU^NO$6]^]]C6
M8!%\QV,[JG<J1GY LK)ZU$[=N2?#7,7\B&/;4&BCE*O677!N)T>E?KXECX_*
MB>FM=:E-;*?1VH+;L^=V5#75>JML5>3[SKYR0X>S1\>;R]I6U$(6B.:CDGQR
MU3AP1JU2S<S>WZ;V[P9J;^%&O\==5C@^L33B_OP'7(-[+GK]Z!8D=!7N@4/M
MWV^N,1R9X +$[_KH.P6Y(R',9;L/K@Y6T_@8;+KH'/C1M7T'/Z%K=8\?&V[H
M.4SE!],.K(&,[U$A8&1;]*-;?##<X*F(;'!&P*[?=FIW]\2J_ZJ7I[IR/K5)
MQ>^<@+V7+86@T4E\,G3XW#6((^&6R$)'=JEZ$K<ZS;XLAG-)#U;,/NITL@?*
MI#7#8TN3=&,(1DS;BC+X)W;Y[><"$8B-]<_WA5/\%&L+5O)]T;9':&()5NVI
MC@>6++#\* D9_G\P3O!;<'YZ^"BW:L5_$9_%)-]C,/ T2%"8* 2"4^33@ JQ
MH[J[WY:O:[T2N;JWC&ZF]]:7^L*S4PH)A9Y)886SFWUT'6>WF("_%IV\BZ/S
M^]'1?7+@7U:.RU5EE#K^=;E%IQ71*;DZ.B77CDXOT4(V#I7D3$).K89*L4=_
M_]SF&/K+<*=./-6PB"["#C@"C8KIYL%=MM8<9-.IA)//%$Z;VF='H,5[72<6
ML: D;P%BB%_>_8*+NHZ^2-6\4 V]:I74D>&I)K_GZ[IJ5*N%D\' /^U.U0LK
M:^;+GUWN>'++?_IU:YH_]$V(0$7_,#SFD#Z<Y)@J,)H])/SJ'[*G?<T_MX=E
M__2@NO_8R PT<_+9KW[5[7\R,'BIAK&$K.NE7W>UH[&EE0]OK]*#\O&M?:9]
M=G1_5[*N;,@%/TW6BV>-<T/_U6@.C-:P==EKWF2O;SX[^_X(LKXQU[TR6<\H
M=^5*K3!,E-61F1V5Y<F%>O?94?RCR?I;@8&\'K*>NG6/[L_4?$O.-IJ7K:/)
MO5HE;VYH^)/(NKPA%_PT64^-)W7_NI1MM)+D[*'IY4_NG,9GO^>/(.L;<]TK
MD_7"66)02;>G;MF_*MT7>X7K"_]\*ZUO&A@DF;G*SM8JEVGYME>>/JK#>OHB
MWQUD-\%<%6X>C+G)A)Q<V^9#N_>O1^7R=DRN4H-[MWPX(),'W>N^N0CRXMU'
M3=FOW7VFK7!+94  _(YKZ(;J3!NJ26I=M-O&D+]Z4>/(?5:U6DZOV.P/",F<
M/1XVDFUG@Y%[V<Y"Q ZV]C:(RZRG2NKUM[>J(^+"5*US=4CP L'#V"X/1Z8]
M)2RLY<)WM+[J$E@:/,KOM9'J97/59DUI'28OU(O)5:=Y)&^L&A;=X[>?&+ZU
MPB;_3"<$!P<Y!@[R$^!0A&32VM R.KY+.1?L<DPBH# N-EHEDAK>E!O]BG:>
M<^R+6F5C47P!*#RSP3<# WEU,)#7!09+;; OO_=,NS!Y2-E:O3P\<8ZUBY.6
MF=A<1\K'WON[VE%??I55I5,:Z4.[*Q-[<%A//^0K5Z6-M:QLS%6^O>WDY5>9
M?KC)D=$TW1\<-CJ32;W=?_0WUPZ^,5>Y-GWI]\6NYVZV/.VKA[=VSR^3VUJG
MT<Z4=#+<6!/)!O'931"WED75O1P,VMI)>^!=G]^5#\];OZ[EHCOQ]2W;?1X,
M/C:2;C$U<!U,\.JQ^X=/9X9E#/TAO^R>7KNXOI[<5@<)I=T]2_[JW _[&T?-
MZ;KW@EU\^PD?8]OXHS%[A2M5'R)7JHQ3%.V[Y]F!GST\-RY+V8/4S<:1\457
M&MW&'WVEL\3Z.2R]W5>36;=P*+?(<'KQ>';9*)/.%DLWB?"N<*4Q+,TV$\.S
MFYM<<Y <W+1N&GJV7W(^Q96^"Y9^Q)4N-UTX-AW%FX(,X14M'3PS(]C7_K0Y
M'9&891H+G4 "7W4X<NPQ>G*$KSE1U(?>5?HV74X2,Y4:)>II.[>YDM7SNPZM
MUD]L^Y.9.7[OVBN^8QF>[Q#Z7,5X@+_$K1]7[IS43<)HR/>YZ?[5?BOAV\T_
MX]:7[_I+7'K)IO,[/J9A52WZ9H_N7UR[X;4*B8MAD0R,W*.2UNR\/.ALG!CV
M6]?^U+Z_R,4/1[Y'G. 9?N?)05ZG>'[@R0WU[J8^.4@>%4:;ZZEXV9TOW/(?
M?=UH+JD3EZB.UI^]:S=_67#LVWU7'AXGKB_=_$/.W-PXT97N&JTG2_;[R2Y:
M6;OP-F[<'KG$=BLM8M^0QXN3]L'DU\8)[)]$>'O[V. U"6^9R66QX98&RN#P
M+E\QBNGC_*#U9]SZNPMOFW7I3PIO=]?5F]:M\JBW3D[+V7:RKA<3XZWP]H=<
M_&+A;3]_8#YV*J735L,N7&:*3D,IWV^%M\]ZW4\*;]:17U$Z-Y?IUK5YECUM
MCRK]TL'G)NL?(+RM[:)7]FFOB:G7&[>ITJ_)4&XH5W<7UG[G,GG_N47W]V7J
M&^=060? S-((I?-0,1J7 S)0+Q^MQU+EL%F>_ADRP!N2AS\2-):)#(7>8?'V
M5W/:;B4JR<[^0<=N^4=_!HB\@\BP.:"2C_CP\H&T<=FZLS/I[N11;L@UV9[N
M.X5>:=-J$(&G++^RIPQ;,+T?CKTJ,[-T6=?WSWY=G)9/FL=V6?4[G;/QQLKC
M&Y.9N3E8M99Z;TN HU=-7!TDKO+ZX/K@SCG)D\O:17<+'"^E')OC8R^I;I_R
M)/@'#FFLFG.@T&H<VF/B6+#;8H]8FD'< ]+Q&E!'$MMX<. (5 !1F')_&OQY
M1"\2-*0I%I>,:PSB&5:LDM5;7CYDI-HE*V 9$R9=SQC2(ZIU@S>"/PX,5S-M
M>)</;AN#2C]U>C4=E'(G<M7JV]-&=V/UD>4W%4+RJE>U%+977LUJ=QQ1D)9?
M\EH7LP@Z(@+X"\#CDWE>7H32)=L9V91=D#\"CU/$?9RJHXPB'S95LV V&]W,
MYD9ZK(+'3][/%GF_-O*^AA^O#^GTZO3F(K,_Z@P..V7'F5;ES""UL9+@QC+/
M+<B_";]:'YQG$OM^@MP06<[N'Z?:D_V"LK^Y+HO-8BY?%KB5KRN,G1]?VF2J
M7G4&M;I>K=03_8M?FQNOLUGXLA7&7H*\;^_OWFS.5$IU#T;W/?F7?*_4'SL7
M0SEY5]A8+\AF8=J7 VX&VTJA/;PHCWS_H-Z"UN-6R5.OW$)MXRI=R<H:-Y]N
MIV38?+;=[>4NCY3CTEGKQ!S>R5[&S9?L37 M13:?3<CI1$I^0X'[=UM4-'M'
MH[16:I7E[%7+NTWV4Z:E;*S*MPDM*C:PS/;\M3YD"MVCDU0_VVIDTJ?$/3HY
M,Z^WU_JQ0LA+RW+.7^LOM77>K]8N'\L)7[V3F\?%A_W6QHH'&W:M:RZS&=9:
MK R]P6GEL)$MU]R"8^1+OGFN;!@'6ENIPA<4)9NM&P*U1. IB)=9H6SA03K;
MJ)1__3J7U>;UC7+C%#*_+C96ZUQ0/.5U^_]D/.NU12H]4\M,E*NBUSITG9;V
MJ]FUE='&DK:/+U+Y=E<:=+MZ$69'[W*<F=@7^XE#7R:'_5\=0[DS]C?7>;<:
MYK[Y-<[VXGJ':UP%+T_.ZLFKM.P\RM?E<>6LGVL<'B4_$Q7^,+Q<]X5&Y,C+
MWJ_#6G5?.RN3I']VX::KQ^G$9BG\;U;<_D5.IC,J<$[/5&= O(IOZ6]@@%?>
MPRQ8/TX\3/KMR96<\,].CYLMNWX]V5AU;A6SX.*+V0S+N_(5C9,;X1->'5W7
MAUOMZ>V1J5U?F8,2R8_)Y>C&KAULK."Y(;CU9<'Y18ZD/X3[Y(</_ME5>7Q5
M+AFIE'.8ZT_SFRO.;PB&;+G/2]!U(_R^'\%]]/2T>V8DKRX&UW>%1[E0RYS4
MDUONLP7G9X2IBF&IEF:H9A5+4&!\X[* 4N&"I\?ITML3<9!SD0W[9-Q0G+ML
M<U!R6JEVX>;*NDUO+)U?<@*+8S]7/()/)HRL#@Y/A[1<Z)G!T<F%?=A2)\>^
MGRM?7-V./N_%_U[(R69>L;*F*\Z3ASO'ZI^D6\E,S3G)Z/W>T?7&\IF-O.)W
M+]%1I.O2#=,'"W2XQ_*#9OHZT2N./629Y3A8K2M2'2^(T^BK#N63BP>("RM1
MZVAM!"-QB)%3G;%RG+VRRB<YXZ+VR[!O'_R-)0IO>%81R6+98:T3XCY-TO''
M@B<Y['8,[^3T<)"]\@:-6G-RWMC<F.0_%#PWH5K\,NK)&K<&,2BGMH:OS63$
MLQI/5"0\ -W;QO(<Y8<1O3^AH:7W-7G_I#0=#Z:3HG/Q>*@F_.[&<LXG=AU-
MCG]VVW\T17L-R!P2BSBJ"4J$/C0L@\HG*B!E'&@>_>Q#\EK./[3\ACT9WQ=[
MHYO$YP::E3;^1X/-,D:X+DIC*<?Y7/U^HI43![FT07)WM1[96):V\91F$YC3
M:T!F-4I3'152U]UAVBB3PX=:.9F_>\A:&^L:_@249A/ YG5%H(JZ;L!HJGFA
M&GK5*JDCPU--#C#=Q,E4:]XTO?)ABU ]6_9O>Y^^W,^36_Z23&D=H')PF3T;
M]B^G5W*V<.GFJGWEHI;=6"EFHT'E0ZE*$ I(0>7UT9WRY$%W:JUJIG5?L+(5
M^SQQ?M#>6,/0AT9W1D%@-ASP"1"8??3]06"5R-!&_<XH5-RC_N Z>?;P,#HO
M'VOUSP0'[QP9NCG \.)VQZ_,Y+BL'&9[9PG?'R2;IX=W>JYY^IC_3)"R.9D<
M&R1_)-O)@*2$'T;VR47957/UEF$=E.ZNFP-];&Y",M0,^M'CD).KH5_LT;70
M8B5*C)49:MSP.ZZA&ZHS;:@FJ741LF)26_6B)B0TY_JRX)[TSUI3TCGNVF?J
MM'V\N<+\LIV%TEFPM;>EO,KJE%=Y1\J[HM"N:?[0-^FC>LWK$P<><T@?3GM,
MF(8M".]=M7>9*AE$)L9^;=)(W=B/QQMK45I5@%]U^W\HW5V+WK<R"!V?&K\.
M_'Z^.3#*5>_8;"E%;;(%H<^H#RZ/'OHD=:A^[?<N#KR3MC\8)@\:?GY0Z:7.
M-A86MT6@-BR6:JT _RZ1]^<GGC-2E--<Z_[N_%CNE#H7T^K&&N"VT>^? >#7
M!YVW0WG_5#8*N99J#\OIE'^5Z-QNK%J_!8A8-.DG8?G7PV0QDS7W>X/2Q4AM
M#;/E]G1SVT!O6?Y'Q]:^)<"_"\N_Z(X;E_O#I".37C7?DB?N_G2P9?E;@'\%
MP*\/.KU2ZESI-YJ7<K9!QCWZ?VES<VLR?4F >,Y05,R9-Y9V6_#E^V/M]$$_
MMFKVXYMSU$]I'QFEZJ=C,WV='5QG%"?O7]WEJR<;5F;E[43%<R7=OFL<CYSR
M,.W?'I'[XN#H<A,\.6]'1K.LJBR]^JMB]6K<EX>U<B)Y9IRWU'/RZ&[8YI,)
M.;O&JK+)=C(-FT^UE6Z]T%>*G9[LYVN7[=O,>>^DOPDD(K+Y5$).)I+I]=/+
M6=_,==TD^L.]<C*HW>D/5S<W?;_Z]HDFF^J2\"V#'5N+_@'.!DM7';WM0I:*
MVS;OCXXFQ;O;_& Z=B97[5SVV(_4*1HR)OR3KQ'?$?.(W\1GF.B925N-@_9!
M^="]-L?)TF"8/1A,'V5[:$0Z"XM1#==.)Y7<'GWE%1->V1YIGS>GI6.O>M>2
MC<S=KX)F[5?NK^9GQ+@!>.$5\XWH\^WL::5EMH:7A3(Q\G=>TM]O>8^72\X4
MWGCYA ?&F,(>GB>_R-SCX<T%Z39.!\E'/7D_EC/^X5UXD3J^$!WLW!]2J=^S
MG=\\^;GWX<L#8M'KM!8-NRH(Q8;X'E_]ZA?!9;IV8]SR4N=CORD/[8O+DG&>
MO;-NBHOOGK_S]&U\-Q[VZ YLW]&(RS[VB:HC!:#+_/D/_1_)]:8F)21#]2$Q
M,72OOZ?(\O_\&*FZ;EB]A$FZWEYZ-YT+OW*,7C_XSG8QW)%.8V(4]8]O,Z,Z
M/<-*>/9H+[>;''D_Z&DE^@1'2,J[2H9^%9F5OCP2KW8I:4ATU:%A3O?^MTG%
M;U<Z)Q.I;@]5ZW]WV#?T7Y<2E.[__L"G7>.1T(%@&IQWC_XIP?]EV;\POBKU
M'=+]]]M_FK42_>B.5"LV(_Z]9]G.4#79J!.V7/[5MY]-M6,2R>Y*)2!>ED<A
M!$:A9ZK2_QLM.%O-)*JSU[&]_H_98YX[O\@!%?#$UG8FXO[H.CQ[N*=$OH+[
M@<] BQ.J:?2L/8A%(LZ/CNU0> G>V873=&W3T*7_R/B?> *&2"WX.;R)'PN/
M&Y='?XP>=<<V]1]CPS4ZADD9U%[?T"GSHN__]S_YI)SZ$1SX:%UG,[_Q5=:=
MIC^NN$P5\;Z=TK+YM)*3V]VTIK?3^4RJW<EVTVVB:%DEE4YUE6SZ&X.D]]E8
M9\%MI!9=Q[>?K?-JLWP@-9K%9KGQS_?.>Y[_"Y;9*)=:]6JS6FY(Q?,#J7Q3
M.BJ>'Y:E4NWLK-IH5&OGZUM[]IFE(_%)A\0GOHWXNJ]5MT]QT;.M'>E@M[0K
M)>5,NA"L-4).?G>UN=V0- J,CGP#&"S'2;2RJQ3(< &5BM/LR-HZJC;H.;9O
MZ0G--FUG3] !,>+H8<%P./5NED[%!DYF=NG(C+)0PFN1X$PEU?=LF),16?:_
M'TD#<JO3@-<O,[5&>*O4ZF?__8^2E7\@C%'9@!XT"DJ&)G&YO Z<\C=5&,E2
M04'1B;%W8&M89:,Y'9%O2 C/5<=IJST_Z]N_CNY;)%OUE6K%;Y0Q</>I92MR
MXH0A16S%6R1Y<R3)Q.2JY\#K+RC2)=4L\O>:6<4J2)EZ,6/.Z,FNG).5=D?6
M2#O=4?6V*E/NG-:S.555.WJRHW#&S-YH:FU9/;C4^S?'D\&PG"C+1O7"R]Y=
M IKP)SV4%,6E,SF)7KBICERR)_Z([@_X"8<!$!0U)F *V$-9'*^6?\$D<?PF
M)J]'I3WVC#PG9WN.6%@ ='B@GBZ^'Q/',S35Y,2&@A\?(KN;SOQ/]![X7.).
MOGOZ2N,44KN9]+,#??<<6.U:5K8>"#0-BX3(G\P^RSGBM+4+BH3W[S>#ON02
MC2*,;794T[2]COWP[8U(;]&R?-6LDY'M>-\$ -\,"^Z]KKMGK:G6FB1+Y?%Q
M.]VC4\ESR"W.JD%Z-I%:5:DQ'5),CU'.Q?+8?_]3R*6S/Y;2[+5!RZLO-S=_
MM[F5*1["@.>HE@OWN^>/1L315!<4XN+Y>:MX*K'#ERY\Q_55RY,\6VH0#:Z7
ML6$E)=F.I&3^TO\&[=+K$RFLQ2*5'[2^:O6(5-0\^%DII-(!90T1Y3O2G/>D
MM9GW%(!^4U=8 IH5>MYPS%W#I1 G3:F6+A%+)[JT0"2*H.V>#G' =+R^KD[A
M+6*]%=Y>H+VTS*RH$=G)_%6ZNS@>WS5;V<[%W4E?3AX6?TU>M/L#HC'?9DK9
MD6!92U'T(^7K%[#RM1" ET%7_$1MYYW5XG5)/WJ&*(1D\FTM3>1VFO[7[F2U
M-)6#4IEN+J]E"[G,K/23'MUZY,2W"ZUIRLZ=M!\/<P^EK?2SE7XV4/II E]&
M=6I& KI2#A\SCV/Y6*Y9M_5;X\;>[R;>1 )*?V4)*#S_K13T]E;'IZ]ITC<\
MDJ#+T<C>R"&)B:..(K*0%UX5\]5*7<<>2L%_]+[$?^S"=C\;S_LP*32[F#Q
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M--8BHE2%=!P*\5,IF4:T2NW,JZ.ZM"+@/]TJ>078EQ?!_K/-NR.P7SVO+(A
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MUW48X3!;F/Z :TR=DIYJTDO0"-8H<-N%9#[W6KA.?5ZX7N>!X%!29*PMB'_
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MDP@EX=!(#4I7&9 @ \HE@6@LA[X)4A2OGN(&/K\9V-;9.$M*_$0<Q5O _/*
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MA[X%IB6+@!T:@@IG Y=8\:DPQ8.OQ1Y! !^\;$2*32\N1AW(E<Q:O46@+X]
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M\B5@L9%@L2PB+ER[)FH%0GXXN)A +7LV#C]6^9&N"PJ\;/-'MNB" 6^+X3H
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M[YN&ABHK&F$<R;@1V+W%CRU^+,,/EY !YN^Z<.B&VX^7$HE#)W?)<R,Q0*0
MQ_!U"G)#"6O8"EP!PRY5AVTK6EJ00S4W8$NJ":G#@!'/XQRPN4_I] %[QSXW
MAFTENJ^%:X P??JM.9VO!@?.5JK;4 RQ".\\$\>RD!U@K1\/)2^ZGQUI:'O&
MF,6)LGY&P(I8U"C.Q6JE0ZN*R 2+.4I,W L*(,4MN*X'56U[TRW_V,(T-G\A
ML51>X;,#*HU>1B9S=0P[8B!%306<^/1MWQ,)573U!HGXZ,+X9Y%#C]5PP5U(
M'(X>(ON+32N2GPW*/[8 N@5044 9>@D#E/0"2S\*S5T>\!7&RS/@X\0Q6I@J
M6M#$X!W26-]!P\5AO?X6WKX\O"V*G@C%XL!\L1.I_DY53<\Q.JQ]#-7H6&!"
M-#-T/BDTZ$G'\V,7EV.(L_BX_# ;1\M:SKU(2=QH$;O$NHDTH)O(5LS^0AC8
M9 UHM("ZQ_K*]%5H]$A$+--49'5S(PU%D[$-R1 FZ_[0-7VP;GHDGM*T)?1?
M'LRNA6(V60Y*$1];V*!( N+>BX<AT*5'/6/<Y('A;A =Y,7ZL:8*/R!2' U\
M]K8.]Q84J<P1 2\5FY1Z@0,'.[VYX(MQB>I S!?48(("% L;\P8QG-/@3<-2
M-0U:NQ/F7^VJ8]OA*0]\S/F!=D0GL) 0,PHLPCC!#[4MX[>%W@8*PE"%*-;=
M)HQ8=ON4T+H+N3FGN*R9H?!]\+*40;-F]BB#1$J)NY@V0W@5FACL0Y,&]*-.
MR*N[W6R3DV>3DS/;Y.1M<O+KDI-5R=#__791K#>K[5PJG<U]8V-O0,=.6)14
M90U$V3*A[V-5>'K:J6P^5<B_[7H7K0Z)!Y41L GE;MSSQ-;9;MJ:DD\I>:60
MW9SSK%$B-C;(9&/:GG*!7PT":'AY[HYA+S1DLTP2P^,V"1%0()PTD21GBWY/
M65+7<%Q83$(S56!&4%[,QFIC<&,8ADP)'=IF-*B*+RJ3L2=)0J0!T)D@[AB;
MWE+&Z=D.FP20E#]+=10+,W&PV@<<,^L/P7YDE7FDODVE/]P1RRK=D:@(R*(G
M*&7PH("MA_W@(90?C/_B?>!!DC<=$;1 =6W-Q_KYF%L _!W()1R;:?=8+P Z
M+%#M'=ZD@@*&JC%G,T96F*8;9!8Z-J4PF+H0>0Z<P:PY!C2698N@.Q]!*5$H
M>L@Z)?$@(2H($ ^*M57X&8"E##+Q>@Y+93BG,%$"#2[L&P==7/$Z$C5+0P<&
M1DO^]S_Y9%+^4:F>'R2J-?RD_-B!U7A0% FW#Z%7V(S>L'TW>D)N%"IX[*,X
M('ZZ;-NNYX 1PN&014_<8HW*8H/Q S*<X&[QMD<L^%U"'AAI^S$+7D'9%[PN
M3!\+BW5/^K;0)MBQLEP3'N,2*2D6?<,E E*QB0)K"J33UPVP7P(D!][]\#4(
M&N-O 0"Q[+!(>Q7*:W$D: H=Z5L8+"'8QJJX]S32"04=1IS#1S#!@HP)[:U1
M+S+N?2@/J%'T,-PADVDUT7";X:X:*1]HL0B+=?;Q?1V%JRV*HI/.2VE%9FV>
MNY1YV!8+_V6Q3J?%:CV1W*&_62J"*$0L@K*(9^W:I@_7@PE.+$Z*';]F3X-1
MP,B-PRC,Y^WRACCLZCHFROF<,/FC$5P_C 7GB.2. @)[?5=BS<&KEG0,3R?E
MI(PH:&!W!GA6C50#C\=!PMKX3JT9>.3M1W06M>BIT"^<$CNZ.8,NT1]"O@96
M5A6UQ74*^PD"]3-XJ K5M?GVT5EDCXA%E<H.$7-/U/BFR5@U?6;FIYM6NX37
MT? H\7-$WF*P8':D+!F+;I8NF_,C06 !;UB3"/KH=VRM\F ,_2$?#WF&#922
MGEQ-\VS0N^CA)?'P5,NR?=P^(\YXE.(RQ98[\^<9W49PL'-%"4_*M\UZZZ!(
M;RZ7_B']-2+##B7QQJ,_5#M_[TAGQ-$&0%B5'!B]J&J8N#B@D,(0?HJ5#@49
M[!-M,*+J&Q"IKH-=N*?A5?Z%Z@31/"#WQ 6>W2/XMZ53K&:+QIJUT#,<6Q,3
ML%8@,7+_1KO(W$26^M__)%,%JG!%P6'AI(Q? Q]0K6#4M3:<?QODSV63#/FI
MUFUK)K(5N(>.3=D:TD!ZH[H;" $(;A"C3&_0DO9S5(P8 B!*:8'Q4=:YGTL<
MI0/&J09$@3R,.)T'5!?EQ]CI(F- 8#WVZ5P44I47HCGN:1;-31^Z?.'%[&!Z
MI.L%'^/WAI4X1( E$#PF%447]T'D #:V5G)P3MGF< D],'C3&RP'*=+)@UW/
M[I)OC?619(UJN!N3+WLTHJH@"D4=@@:8<#V[4H/MFH*%:B'Y#R+:H:0DCW[G
M28),A&3%45T"F2/(]\%5"CY/B@VB#422;73C<3"3S$A_<1XY+';^9@B):D/(
M.J,HR;<-,3"!*%G4?#K8V91*/I10G1)_0(:&&D7&XMEI@(H=$^$_$"U-]CQE
M>Z :X/?15T\;)9>_NRO%.H(!<+A]#+K NX:]# P8EDXW-PV, T "EM^1BD)$
MGPQ5SZ;TEGAB>IY"W",65 :87\U1XR*R' K&%=)Q?)#Y*1BGEM *#J$@CK!5
M/H%Y(VCP ;G/=$@"<2&JQC$07J2DA>YM!Z/O$E D41K"J>M3,-2YN(NII5.$
M(2S81*,*B@7V2W@*R>P4'N)'KDI_E<[.3O\6XLW&0.LSY('Q!I73<#A H3 $
M)\8*NDZ@&(UFZ!%9G7<4BG4(TN-ECQ>F?- +2"EYZ:^&DD%$$6?&HX#HE=@3
M:"FW$^M:!.$2T#9C-A\?Z8GN^+U@(@ .H*B"XAC6F"K8X,VSG40(4Q%6 \M9
M)/C$!!W,KPO93\"8-HLR85P):-Y0B #K:G2G&#G""0P<#NA"LXH2)58!&,"M
M<74Y4)-W@V_HF=B,JDLLVAQDC<BLL<0,.%]& M'>X/H.1B*BQDPTAZ#X1T4/
MHOFF4-=T!]A>3$&.&0N8_B@<!VPC&*XXL.R)2?0>V8G&A"'R1@-V&%>V*3$3
M95DXU()=P; TT]=%S;K94]@1U8\HWV0A\,%&*;Z MR[0;2>V,\"#C]@/V$F(
MJ\#-@E&$GB3$%:/5Q!!*$T(NVSBE2>(T^%M4/@!BC6H-)X$ZF;<.X6)$VH"
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M)-?1_OUF/7A: @1F)9E2'A1Y(,N9W;M1[QODO_W[[=!11Y3K?)LEZ(8%AY)
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MQ=K=["_EQ,N4Q-8?_@HW:],V?_FL_*MT=?42POJ:[Q 9*%/CX[E-V ?43(@
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MZHH^G+M[K_4J.R)@P";GB1=4R@3'RUS^"8/7*I>P^Z,<9VS)Q?Q+0=W-ROX
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MG ^?IN-^4J3II'A143C BP#]4@OJ[^3X@-*>."/VAK+L57%;%AQIG_FR,#-
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M,:9X7R7U9[CZ522)^H:U)L_0"(;S,AO\"OD S0'C#'H'L@P6^PWG56'0<ZJ
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M!^C*Q< &&94F0%I6OC%.$JP\P1?_]<L<1[$Y>#[0'5RC$WWP)O=G4?K0-PK
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M PXS!!AQ"4JGI!YQ_U62;Q:^R\VH50@*%XWDK&G5,+=1O)!HW!N[DO@0<E5
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M9 =L/;;BP>/IEX'BTL"3_'J63J(8F;!P*D(U:YF)0,O:56OU-F41VZ3M^ (
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M8I!QT.4GG8:ZK9E93-*CD!*-KO:@GT5H@J:0-&-NNO9!KDL'\D8*JQS9**&
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M5OS%,B_0,G>5D2)E3B=OKFY$-V. J)*?8\V+02X&>=(@ 0WRFJZ*,Y+3/TN
M:YR?TMZWHKG@G<8PHL7^%OL[:7^"II!\YP_??)?)(D0O[-<2;8N-&GA< 4@
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M%(&6:TR+H!5JPERAA\5XQ]!:\]B;WZ#,'T/16I,K4YI+CP=AW/S#F5Z>SY3
MF6 E%-Y(UXP%;[M":+1-:PMT:8P+%8A8>D"%PPF7]BU.)2L.OX2>H[";5M+L
MAA*=U3*%R!0Z@XK]!SVF$.1:2]JG'%KYE$Y1+,CWAV$36M\31= P3YDY,QW5
M5=+J3M*6PG^3@0.5#'(FP\D\E=,+;$ 6NS]<Q:^IS)OR ?Q4.<0/ED/@Q #E
M=@[CS(BVV)L7HFG63Q0ANTT;!/[D4J!\X-YNQY\:M,=;]\D[PA1.=\,364(O
MW ;040HT8K >?B7_[_&WVP,FEG0^M"<[@D!"Y_)'_T6VT])-7K1A1N.Z[&O%
M[S"WO49'IS: \CML*D<=+T0:$?0"Z!%_>T$TYQ'-+Q9$\X)HO@1$\Y/PRU&,
M4E&V?F"Z9&;G ,D*2,H$1S!&06D9*I0-4N1N%]$]8T'.5P9)MI&0K =:*RU0
M3_E>R<J.#%UF/H4S<,N7!KA-CYM-.&\$?ZCGJ8A*I_#6Z\HY[\L!B+U-S6=R
MCLX\5_9<#)/\Z1P_Q:T[#-CJ(%,,OC BK+E1H2.$F6;OB&J(S$0065H0D.FE
M3&NY8;+;GF= QY6&8@;IAP!%I94=8$Q71<*9V74Q'!L/8\[ Z^2$SZVW!J8G
M+F^+>UN5]XQ_E47&5"0>YE2,:V3-12!=(&M8D&Q+PAF0;$_-+B)D>II"I%.'
M;2.$,\I/\\\O)Y?BC?/MZX]?",OYMZ\_^U3PYC.,-O+Q3UY^LM3M%K-^%'44
M8.0GDN''44@/E?G9Q*W:L;18XF*))RU1!D=,_^A.9&#(A;[Y]JO>8WNF]K>8
MUF):IXO%;FS')7;&W;Y8U&)13T6/ET.SOLVA5F8&%9)6[7R;]OH8V76%6__#
M>\A<OX<.;%/*2&+A\TLFAI!6[Q1[LS1_E]UP7O.72QW2@]&I"L$E5O\S2*7$
M\^.2C3LZ6+"HU-WFBHWM*%HV28*42CA&BME"B)'*/D]@'H=8H9[(E+ 1S)93
M]BYF^SWU-@R&%TNLNVR87P*%EF#K&6X?^03S-0.A))A2PX[,<T1:L$0RBRF>
M-L5QTC_*OL[VAP$<T*_N:VGW!IKC%ES;BRTNMOA('"$LL0:34))31I,'!-DZ
M@-)AK%Y>83&OQ;Q.FE<0*".+VI;WK6BX,@5);P";I/%6K 3'F(#)R@Z0)"%%
MP?1O@L 5L1^ RJN.1XE#C=_IP@DUBH2O[G*+ 2\&?-;P JH!.K1@-8A(ABVM
M3IU7X#/\%-=,HFM2 OY1*"-S#\4L)3ZG!;NZ;1\6$UU,]*2);JJMZ64R^W=_
M2+)["/]N*U:N4:CXEC,@J0NL=V6]U_"R.2X@\,78'HT71>\"[I"L[)3R0A2Z
M^.U!O7/<>A%Y(XQW4(=P0%X5"^S[=ET#A:6XHK10G>WG!F#P:3;$MYX=2O%V
M!NF]KHZMG$ETZFC0([#D$@@>X)V#RAXKUH3XRL.4@D!<:]'4%&/1!0A&'?6I
M1%6P[:L,)V=<NF>KWT>\-.J'BE+.0[S YUP*5!*H85L>@WJ/0,\ )CLT<@2[
M*;6;= '<#,-660T]6]A?D17T X!^@.WK>TR$K?W3R!2Q$C8,7:_HR B;A' $
MJ]@9):!'C =9H;:QFD0(UP'I8L&F'0O7>#QX +S5'MQF\B\/M_2^>?VY @R3
MA2@]\[=";8Q\>2$,E(6)L4/?4TD*D])<,LD\/[<<#/NO\R*?/#3R-IVA5HVL
MIA_V*8%BT#WDV0MF\.W!Q,C_@VK."78[2&9GKY5\\(DT8*:V  ['  50>1*9
M1E#NR07+/X/E?[E@^1<L_V\.RS\SF97'HOE\%H#)0M&2AHC$(9T>7RYL<L?7
MV/]A:DDUF*3]/QVJEII.#C2=B&?*@3 T,139:, &@O"N[BDV^;*220"!=O--
M&@F&B.&&5M&N;!K5S4HN..X5=94)PP5.<RP&W2:?N4Z#AH4\]J7"RH4*/BQ'
M@A@_%XR>6:E\Z!D;"9>%_S? N,81?F)/4><<INSYH;:BSN(,<8&1+RFK.6@D
M$6L*P J)7B"G0+L-.:S)*LANZ<7YV$A2!KSF'5PA[BWRY,#'G':0!Q[UY#*V
MX.-JR/-U&/S,L6+J2,G6,TB?B85?ZH;+OGAT7\@V"+-+!RB6]6BS0#V*"PQG
MC&S/[0HXYSD,L3MY4(',G9[QM%O,>3'G1\TY>/ 4[?-^YBG8M//FCH2=C3]^
M5W91X/D,5B!\>#'NQ;C/-^YIY2O/SC'&,4LLXZ',N&3Q"[EPHSU)YVK+$:U)
M[;7N^NQ%41?VA7"^^V6++%OD-*HNG6%VI'!H BCC@*LV1":L!(+2/XY!8>^>
M@EG$KE$=7PQU,=0S?;D+LC5T@+/>UCN#F_10B1;*(P=$"<B38N6Z_]S^8V74
M=426Q Y_.!58EDA04=:Q-)EUJ7)9KPUUM?CAQ:P7LW[4_UK#*"738 ,S>L*@
M2]\K>50MDG(B119**<KD8;5,NG'RYQ161&O5S!4A"NJDR>=XJ$5^9=P IZ.!
MM<X+KQ[))>!K%OFN;VKM1VM?JPB::FUR\\MN6';#F<650FSI[C"R50G)N?)"
MEMBUQW('4CDT*X;QZ/6"T5IL[TFV1VZJNZETHL2A^BF6+>^LBB&AK0?T&V-6
MVW C^N:H.>3? 8+K3\V. 3"B+WRH=^SW ^BH'[:L ,JGC>6C0+5A5QXC?6.K
M"!N!I:!'Z?M2Z.U%@(;_;.AFT5<::(-:V1]3P-<,=N&SDN=_5"^T"^.4_!/,
MTV@*HASU71\BVJ<?,V*F\\HN=;%&Z#CCB;D093 UWW7OCFU<UEWE<8'5?WSQ
MR>=.WY6LBI]<A:GY<>[)^S4'&Q#E>Q?/!;%.=H3/5E^6?;4QUJY9ECCNQ:8+
M'W445<3NJ3\MO>JJP5\+3HEA8IYGCJZ:R$=:EQ)_21GF$$,.-[:PKS=7M$R?
ML()DW<>>+_WWM3ULV??#_D[E9?E1.#A!+43I6A^ZE@\5_E7N) -2Q4UKA$T!
MP17;IB:XVK<4%R'F:>)J/5N]ON77*FUP*(^C;"-\H8HIE*%;B*)HR(0?E5[Y
M8! CAC/-W(2J=^*[],A50B&KOU\WI@N #IVUVO.RJ$PZ3(LK8 E\]K1D'%Y1
M_"$%/#*DZF):W@JG E&BEZ?1)31O\7A-+ZU4=$_8\,Q$F]WO4LD#JAP$!7@#
M&C<#S8: F9)6?B>W*T4Z@'81=J :NR>T=4=$<ST/,NY[)Y$;U&W;*;DY_0,K
M>TN&@>J,#!B%[:/X1E>S8?WX &%[;,W/<<B(]_"KH;+I' K?A)A\1?=)7]ZH
MMX]-XTHQ^GK;Y8;BD[YB\*QD1KQRT'^^;7<4+1EWGJ[ML]770\=7*@2'R_L;
M^;^E.(\^I(?:>F5JP'WCD]!&1^ $S!/[6-E66%7XN%35^J@$V$(S+\,(Y/:"
MWN^FW@V':G/VJTC//0$6P1F!QQK@5CEY?V:0L.2 R1R8(8+3SS.' D.#>D&B
M:N6/[[2KUX&ZW%47#Y1",NAR+8I0:]M52H\0 >+N6?C>^:!^5T=Y:G]@P):9
MN11E(%H:EEMK-HI=7;"5$VSE1PNV<L%67BBV\@DG_ROC;,D"^;/X?)Q?CZ+T
MWX0IBZ&QKV4F(,)/3=L:'KU?N$J9KZ8]#N'/--&+C"Y '$>9"?4=]3Y_6)J,
M>XXL,\%B *K_TB,<)P8V/@WO]/NZ?]>OOF=+DU7BX_6KN@=9C[#??Y7"-1GR
M^)U&1J]#9'0I\R>O^.1,R'LTU;NOY,U7,GK4U:@Y"'C6LM&:0:K\G#CXQN]=
M$QG'8ZU8-S[!Z_OVX$0:]4L4[<3Q$Z,\VAWU9RFCQL<*E3QHNPZE99=8420\
M'!S,5X,V^YY2@X]#,$!S8PQ M\2C[97_9M50DK3CYDLMZ7:"T(VWI=LP0Q"-
M\)4^"^V%Y+X,JUAPA/% YS+_/[F[C=R,S(%M^.I#(]E=P#@K/ 5;E>V1#(7Y
MT7_%L9BQ@?T8WT5B,J$J,D;<\+"<KN[/O-D9)H8!F5_0)LWW)IAK#.;UAROI
M6(#=+7OGDSN6N%XIRL5=]7"BX8,4[=VQ2DS/[1"I1S%U7#)X-:(=ML%!ODW8
MA-Q*)5$N7K@D+E"/,9O5W,,(EMO)!J#-/K6L3<UW->PP5:RFKJU&M7;^3>ZN
MK.J#..;P%7?VY(S>6,JG\/3<=N!#Y!BW \-*3(:ES%S"S57:WIZ_R10R[^]I
M; 7A<3S3FHXMCMG5Z,V%$Y=?:3GS^J["ZUM;6D/[-!0G[;R3VA//7:&<0P^"
MH_.!LR?)A[ +KJNJ@?FH+0=G.!XX$"_!+SM8+_XZL36;&)0[,_,H5_TM,Q^P
M8@*MALY36O!![E/:>LX1;[B5QJD.6FI.2)?3QO4M!1 LI(25D9]JJANE482\
MA'IB0VZGEAL+2[6_ ?XMVX$X-ECGX4$K:F$G8Z?I#56=?:EM,31/IXQ,LX92
M'?_L;;G;7NWJ;67W4<J5Z YH:_-+@U."S$1^=*^KA#8_*:_HAV!WJ)GD#\+5
M/_55M>)2P,OG7TQB#OK/6@K0#1<<Z>K?R=7QA1=?_!_<6E>IC]$)'?PI<SNW
MU>XNN2>C4$?93B=BSL5+_A*(,]B8E%K2FU6IA'12INS(W^BI7VL]4^=L-H-4
MM. .5:#+.:FDCLL[L*H.JW# ;F@?X"R=TU^:9Q[E14C&O-GC?#@.;Z*5$EP)
M[W=>_QV7[;H]UUTHL>K-LGV$'S.&9!F!,8EG$RT# U0J0[5*J),_^'P3GI_\
MRS^^XA+,ONY[ PGP5'J,@[;9M3C%2AV4O&S.#,Z2HQV33QZX6ECQ,IC/8_]I
MLC#T?L I&<;&S8H$HA-A\%EACRQUVYBL[6(FRCG@$F\:7.CKM__YYJNK%Y^O
M&%Q4[0&,0Z'?>:ML7=)I^EU0.#E]G%L$S/"-KAN ?F<<SQ;T^)$537:'6Y"6
M;LLU1_UC\;LT$NMK6.!H7<--^$4D;TE>N4S&(/D(9!MK4O%N=^W"9)1:GB7D
M+ 9E+3+RALW616*KOMQ6+''3\R%G?RD!V]X&NJ5]@PA19!HG/ZMY ^5-1DVH
M9RY%,PVS&?55\HAT2E:HA*XZJ>I7J)#"W^@Z_ZE!6/[#03XPM2]WUCL#&RV'
MG#OD1![*;B/G*Z1E<!EE/WAHNW?TO1:V"I>>7,@$?O"(TL.@D)#K4]4=9,Z3
MH<MRPS9HW8M#NVZ-1]<R*3I$*LOS-4B9VU43&SFU][+[+?>:G 7SRT0EA2N7
MEBQ2SHQZ?<E.N@C:CI4;@!5U=WG'\&8QKD>;-]QL_/VJW >MGXJNW!XKNB*(
M. 38M953$B\@/*.5>A"OZDF#M)5#$&.OX,,\\*TX[A%@%/4%(Q4F#TR^3^0W
M1T]@OUA(YZ$;K+$J+TH)8&DMI-\Y4IGD70<3XN(\'C-D"DI^PJ& C.2)45QI
M2T 82M84RG:IST@N4&YNT3["X]H5Z!XV".#NN;VI5E:AD2V&,[44O$ ., ,9
M##_<KGY'IGG;MAL5R21#DJ:5U=D0+V[J?CWTO9QP_#T73:Z^EL%:C1>Y#Q23
M1<I:7HE,Y/<5<Y_YQ[RF.(L/3TO#.<S%KW5I14S#R3B8.1FWGJ3FD^MT+LH=
MM2@GGTV5XK3 R V82B_PKCI&WB()I;(7F2>4T<;.I1^%\.R,2U WY'UP!51R
M,K4Z1A3=D\.(I];4B]W7'3=87]$)BK[=?;E>PTVRHV[H4(JU;/Z;ZTHVA[:Q
M:6UO=NVUI,IQ7/Z.,RK-_C@<M:E>VF41:.KMG"X8MKPX!9P;G*)[7R0907#(
M#7K#7UKT["_"<>O0ZW=&60=<W,,M79O1%=#;'B]APEQ>A!QD3(KNRP?1)4&-
M#AZKQG_.A @6F7J$UXD;M81NE"RX3($O,\W 1_U0GQ>&2ZE#V7-J* 2=FC3'
M4_..B_W()#2#%!]GS6MC^LR?D"AIQ-L)OPNZ&NEJ\$DO-%9P$4AQ(WF )A(>
M &=%CAQU@X9-C29X:HZ1Z*O9UG DX]<.,Q5G8Y:J^R79CJYKKVF65"4:A<-$
M5O[8F8:]L >L*&HEUX\V<GSQVIB.91WQ6DKZFPE6[(;4]84]0P=ZT_*-ZBY9
M>M(S/>F/EY[TTI.^A)[T!Q4'WB9NO ]!TF$DHJH5@8B(S1*&34LB N:9D8:?
MFYIF5[271M^D2+^_G'A+LU%ZY9+VCAO3RE*'M-5:B%*PV]9=/VX;.1E*NM9_
M#$W%0-OGQ6-?8/XE?(%N@K[P(I8%3WR)ZVOTI:^KZV[@S)>^^-&\.*R]607M
MA:/S(8C5:L$;IZY@2S'-FQ6A+9+#V<G)2J)F-<@4$,#')/>U. N93D7/5!"?
M.M4<6!+1G,9SR**8M<\ 3L_]C90:*P&RQF*Z5R)):!!%7<=0!/:98L+SES(B
M>"AM9KOEJC4NK/@S7:3?A/B#(@;Z_T,,;=+0!=EMO8Y4L;Y?-E(7"ITN"+2D
M]ZS9.IL0^]+SF Q3N@5[$< O7 _U3MB[MXD45Q*.2T[A>!6C"KC\DROAQ84T
M)DH%/OM1 [8*VS$90>7+\6,_^D+/:!E-K_DD3^3$XM/@V]S E+Q+$CS*E=J'
MA<IKF6SRDTV<.!YU3X8C(84QS+4@,X7398ISL;?34LUV(*V#3%@L+,3S, [9
M"( D(KYB%V%A;5M,\A<AX,\K-9\,-A>C6HSJ$3\7#E/7);:*9W*\+OYJ,:WW
M-"WR1:6D/&DK7I#Z@I3A) ^I4YD,-W 3[NJ:<JAM?1"!AUU _6=2#<U?N>G;
M;# ))A"(N_9.!S\7PUT,]TE\8CSAS+!0-*M<5V[.!%O,(4B^HN#E;L1+%JEP
MXGQMONU7;W4(9[':Q6I/6JV1,)[6_>$CO90Y+RY0\>R"AS3&FISO[7J0PU02
M2#(ARVR4.4!HDPP<C# ULN4#6PIOGX ^\_MI,?S%\)^0%ZD1W;4";&)]^@CY
MD:&.>L]IN8W<\'@8A2GBCBLP%QPB)FIB[[.1A]MG%CN?M=$6^U[L^Z1]>Q(Q
M<$%6C1F[1AG3/HXV&") <C&^Q?@^+(DC.Q,E'B#@4X'"$WXQ4;!?S&TQMT<)
M['ABE8FZUJ< GG<M)V0"?]S8()\/1S$'@1$&NL\X#+R)$P&+K2ZV^B&V2O;7
M'8WZR'-L"6U<IP#<B3S7DN8LYO8^5:DP@^AI[1WA-Q(<)R8?1.MEY-\%@-7/
MZ]W0,PQ(0#6+12X6^<&)-[@:I$ZO9*O]V7%AP=ES'#K#[ !#[!7<-S1LJ9+
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MV5^G*7[.C,&EA:Y[K+]M'P(AXMW0:3,<):;U,71!Y"*PY5+2 (Z?:#L)LVR
MCWL9;3^[+TEZD=2^>]GC=JH5,Q(T#?_(X]D*VIWS/PU0P#4M 6W"Z8KX4HZJ
ME)W:;PLF;(()^VS!A"V8L-\8)FPYQ2[P%(.8<B@V&TET'"C:SE2JKKG/WMV
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MWYW43).&#TY*/MZ#[TN6!J="J,":D>=XOU58,GU2(_.!O>[LK#>('7!ZX!7
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MX7O\6M8;M/KJA*EM_L6?=7V)(T7VL]<0SFT65W%4+WVJ8#6N58U0EV#?2F\
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MD=4@:![&Q>ZKZEVJ*><5\PJ5RTLW[ND>..\C?9#T'3HHCLA];5JHV&R#7%P
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M((IEM[.2DOAAK?,)H[R#?!XR#M2(AYW=@*NVGM)YE,MS&^Z7#?D_E- CBM-
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M@. HJ_#J/J\>^Q+J*V\1S"!_WIT3;^<BG!"#GY!)!8:<_&(I1QLCE#I%*QG
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MN2RBO*F 7E1'Z#/VM5D[WZS]:&W6KLW:7U^S%J74:?4J,@O,:'Z,0@.K6U*
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M<0L*O9_R"*D@$FZXTU1B'\)3K@%=C';;:\@CQB:85%6WX:9#J@)-Y#,TMW,
M"3>92)V()V_+[5N*ZS)RQH/ 2*^'KI@_1 F6.V9 3'O6+"*H=!8M5%9"GIHS
M[(F HB$CJ*(<=Q2:'J "2F*/2%)4%))RA^">LO%N"6ECV-FBA%;B1[?<3]V7
MDA'(K@MA#'G."^IC_W668LV4CQ:IY!Y!6,=E$NKR12*\<,84^EE#QSHM1Q]
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M[CG\'CB+(I92<!(A36<E[=O\[WF[HUO5MR Q(HT6=XQ/<0&6)%>, 6:7&J^
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MT)\NJ-Z$^'A?DL2:\$G+P,ULAR0)W4F]L&[T8R34=BK(H74#54HB^YV_X/R
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M^I[TT9FL[Y&<VH[ DW0>&/9G@I=95'90+A'AI:=(1W3K_C;0X:DUJ."3,L9
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MS#<ZDWNRNZ$Q_K!,SOM)X=9]4>S)<>C-(<KF+]C(G="0V&<CW4;4^:GY6PB
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M[^6*D?1X6JY[.6NX/Z^0A/DJSL4$A2]U6-1&6M50&3)5_BS_ON#.&?CQT''
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M9"E'7/OZCI/7E>@C\+N'4SQ0K0O-N?(@W)P1TAN9-\*)U(AV^9".?"Z=8^F
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M99@"PLR3\RTE_EE2.%/7LSQ0T!;<%B1WI.3L>CR&NZ@[56.?X[Y-AB)8:D[
M/0<GTTI23^B=V'"-9G'LCR1N'EH&A] -IVI$LXI6^F@1>!_%H6WF*H03F6O'
MY&YEW<.YA<4R<?5<HA".WH'O8' 2TPT?!*+.9F'8*'?55(%9A!Z[ MA:@O]<
M-\)Y2U BK & _# 7AI@+=&C4C&K:>?M()6IM9@@\91-=]=BB2UX"IS&/:&,O
MB4 (9W8*.(R"8PK)>5\!ME^FC?C9!^_H&2"$^0KOT$.H\ 0N_3=_W*@?._-1
MZRBSG-Z#H8:=T]T82*<X.K;C!57YMB ),NTER:[O$D42IP_KM^I(.+PZ+0S3
MSK[%Q8705_F2KAE>W%^+$#S1H4DO,>RG)_(F?_/'JP<6DX^ S2^/%_C0J3@,
M=(I 9V0,7SH/!(L?72Y I!/"<?C9AZ1"S?'S&%+#N,-'-OT),_Y/A&L+431X
ME*-:]T+N.&;4D&@X8@,3%:-YE_8H.(Z.-O)PE6<H]^\SIQ?4A*M01/_N2(>+
M")5T F9^[!R#O<%=L86F=N.L10#_GDTAU7B"&$>B V6J3Q,LQ]@@SJR8/]VZ
M,12> T _?!:.S/"T=5,_61&1\XC(WZ^(R!41>0F(R!D7O7RTM:3$W&J1348J
M@@.ZD:D#QDZ3IZO#HSS!;Y&@QA,ZF]@O!L<E0PI$G*?:SH9AVY75()U.RR2Z
MOMF^)4*]HA6Y9AY\$)*B6.4FWZ=YPL5 T7Y$.I#"?6PFA_O&%"K8=#?$HXJ9
MH-].MKJX:?K2BD"4D]'H Z533JI8COAC5;RCL<T"+PM3:C2!EE/[NZQ%N<#B
MR;TU@D<1"@Y!SN;G=<,P[P/$/.6?G9[>7/>*P:QI;*4Z'AA[Z4N%U+'JN6B8
M\U'7N4X)SR:.<FH;"9CYL@("6GKTYYMZ.%P74)B73(V&,*B[J(D;MRUIBD:;
M/9"T3_5#)C. <GLW+"B\GYL1XE^JRK<A\[UM&HP@6[E;>,YI_)L"!R'K79@"
M;X:^*^7V_J/&S"74RO0^[# 7[*]"F%4B<:;CQ.NGLBMB/*6*(8>M,M#Z#.8
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MTJD-5X88^9FO4AKQV151'("K(>-2 _;=%"02S[K$@%S._,!YOP05VC#7]JS
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M"KN/J;PO#!!?2KOC.PM<-0NL\GN2W@R+>9,3]\1F4)HX9M_V C:^4:Y74$\
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M+!](B&?R=S0JLB,H<_+"Y+94S[@ZL>F3<7H5-5*R8+DU7I2ILFC8TYYR*,J
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M^9*?66F5.F8KSU)ZVUV;$X_25OSTB.N6F7$W0NCTT!)=##GW5_M9\(AH/P%
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MN()P<8[V)ND%"X6D(N^3BDH*-/IJ3Q@5NNVA8FXC (X05&)5CN%T\N5-+ U
MB;P7>->@!%3T?26E*X8C9"RH*--#W;D[$H0AUOF2S$/$>]'*9%T,,'PSI8U_
MNSZ^G%$&7M*I]C#3.;GJ^/-$V9BAG]R""TXS&[/R3""L3I:YG,<Z<NE4[^RN
M8/SJ0V'RU>8E"1ES6.W6@U^U:#.7=0)6@>G@$<3PT\+GC/$_WMQ%/"<8%TU^
M3%%UI)"-0*XJ<X-B=2&S"A=[L;G5'5XRDI7O5 : P7\8SJ-FR[.7"&]H)36:
MS05^2H>M_EF!K[AWMS[%._*HPMXEWV\P/.#&Q/*"5][R3KPN@LEUJ/ZVJ+#&
M=;3;XV.X.J6+<IV(FU\,3NQEN)TG5B])^N2\66[!2+79-=LA-I"YA?U%41'V
M!C&4/&5(?@&5<IS[BF?DQ9 5=;V%F8IYQL?AKJ0 AXQ7=Z7U6SB!!H';I-P.
MV;D08C#HOBT.!('&LTAC(YKY/^\4#$O_W62Q-2724(6I[ZB@LF<06EA*XEG@
M,$=/I-E/79\HL,6B3;M5,^^'A7!C%RMU!U>$1P@6GH?0K<@6,BSX4O1R5-T7
MK16@2H<C_?D9X!PC2,<140R==-+3(;\]<W4ZI/?ENP@MS823.9-+D)/%7T+T
MS4F6KHC',PCJQ'^E20M##S[$^>0G[AK&74O^/6-H?*=><WCQH1;>PTP)O ]>
MJ./OG':W'C[.5AC&/ SCHQ6&L<(P/@R&\0\[)98/9TVG@R_2&I1.ZI#C2[#U
M>OK) 3L.\(L=18GOX:UBV B<8</S2'(GYJV:&<*+RTDM?]#,6<_9O.H:10!"
M*CF$DEQYF"T8TD=ORVLY)FO3P0J'@1;^J*0)@IJ95Z&O3X/<Q=ID/">73B9?
M%U8HP6CFX[I@<+ZDDC%.X)*6!FN9_@+72"*&,2TZOF%8PK_]R[-/GKYX_O0C
M/3HMYON+#..^<M'(U_G]"%\S>OQD>9K[FGD($(BS?3TC?,D4]"%F)Q#QAOM^
M8#E'.Z_@/& (1_++BA;LYI:>\IKJ0G=%+*#H\U''CK$IU8G_?5>(0DE(@JE>
M.-2IK,E-</,4!M/ BR P_:-<:[Z.89U)8P@ON"YN&M;HQLTN5:F!5KGG)!W*
M*3I30?>&5E);_(0-K3$)7^4^!$"PQO L9#\NPB:68TI9TN!E/,&9+A&Y@'T[
ML%I6&CR>?K'PFSXO[;*R'\?\DT5V%WY$M9_-L.Q0_*9E4>AL6%42^E( SNA2
M_YC<X$/G#(,QZ[B3)<],V<&I)UP\5;.HDM;6R.^EFTAIG2<3QN0K 3-&R#<N
M_5.E368.X;W"4R5DQ*Y]8&DMC6]2I2ISQ(-D/ABW"O>Q#Q9)1XYD%3,W8YYR
M=MXM"7 YD+ZP(<8?;\,6O2_XB7E#Y/T @O*P:V4LH2"G10\G2J\*2-3)62$1
M+XX%OM,CQJ6G%%X-E?0@L5ZV!T.Q^5(A;<W.$/%F&+6;)WZTC5#SA,(%7$X.
MA,W'3S_6L^!-WE[GQ*S^^ET5G-;+;2_CR /-GO'YHML,KAQS.JB-':@[<4V[
MCS>Z\PGT$%V'^WVOF\U;Z;,5[R3Q8T6"I' J50S%B2A /OQZB/G81]"4^:Z4
MPMH/#5_S%"M-B6A:6(GK@MO]\4[DS;KY%=\DP0&,5U<7_,Y*NFFNV4Y([80P
MQ:V/+$27N6\43BA^$&H4[(96\M];6@,_?QJ-B'[,7X/WL]]?T(ZB08.:"OO!
M%JBL>6H&ZYFVNGX-VY#.D]^'5(P,74KA:<$\'(7!"PG3P/M9UJBN_/KG;52Y
MVZ2N+Z$'%62P;[7U0]^L$\X?N(=#P%LU]+([LCN:'0JOXOT\4ZS<V:P4-@*-
M__-N_D>_@9L&FZFW1.:$\Y ,PQ^)C[^@%JK#S^F *VN$^>,S4<]"M&/XG20'
MF%'-9(E8BK516#.TN]WLJ^8^;?34"CVF$CK2$:SD>QIF%ZTC$PJ!]S]&;)P)
M%B*,#9-7NOA"3^_].A\1*"!OP.IO3]+V)2?9)YM@?.GNYTS4<A_'9L1'J*1P
M?7N3?-/2/$#LR[0F_*UO_OPJP@V]=K(40T$=\F4T6APS)X33T[5^_Q5MVO0D
MP9DJVT*F92U(U*OIJ6$NB4H!;"/6RM+!=V3.6DOEU>=^4\ZJX^D(G@K77TP,
M'<X3X5N(O6;JJNY*<L#@[ZQGR%A(B;*FS4\< )T%7$Y1M1=.[I3HX+(.4B.Q
MB(HZ[&TT$ G/1W8B;[3($;9UAG9Q<CI9]&[:],KK3@<)_-0_6HN\Y.YK&;:A
M:'! Q+G)1UXRO@S]YO#?D)<6//8HQ^]+>R&,9W(9(AX& 0)]<.9-4>FDV)9^
MQ+;\![RR#S55^.!PU@ZH!,$_E565]*3QTY0-P$[GG78E8_O G4L<"^3I3I=V
M]FCZ92[!",9 G1'?2Z8LD2L<]^RGRYS=.$'IR./\$TN"U.*</JT==+K(=@HP
MRW3FN*A00J7:S[TB6A%0(?7>+(5.<K(OORY6@O[_V7OWWL2596_X_T=ZOH,U
M>YVC&0E8V.8ZL_:22$+N"4D(269>O4+&;L#!V,0V(<RG?[JJNWWADF0R$$S&
M1SIK3Z"Q^U)57==?92*7<7@KL@9_054N%]\BO"PXUS -+M!T+/%!=R5DM0FP
MJBFSQH25E@VL-'9A[3F&D=UW-7L@W4(DN^F[A%Z;5\ [0WSQ+IT!-9=<Z<(%
MS"YDFN#G%H?-F#6'(E!?;.*1MM61[ 5F(S([#>]*%@<=CA"C1<,$@IEGVPLN
MI["8"K1G!(()ZK;P_B.V<'>']Q\D<E.= V^OP 0RPVM6))HMR"8;N> #UN$N
M;\Q7BO&NL:*]I^ 5;0%,"$H?SC=^@#"V@',@88(1)1^W>.= %,;*OT)8@[%H
M.SZ[V.!]81(#:M,#POR%L-1'=ESHF\/YZD@4PGR$7UK3F?#P)#)C[?EI@_J'
M+YSW_^$1PD=AKA9<"V,OXI85_CZV^RP=<E%6B>!N'AR)RK,T8KHX8EI((Z9I
MQ'3K(J;\GIU+=(MZ";QQEYFN?I#LQ<#>F,.):HB&R1K3BU:33'?D<ML%.8@:
M; S7C;V'RQ@V#;3R(/A@A%(^>J7Q!!*.?MA=,")J?"T1DZ%,A(XL&D_"YAH]
M<_= ?)-=2NR> ' D8>\L"IV$GX,U!'%.YL_!5,G9ZG%<Q%+YKKD"B3.*2Z*Y
M4X% [HY@JJ(/N\U@5P%CQ).,L;@=J8YN:8!0TY5XKK@N,C S42TW(YHSA-W=
M$3"07]IX- 1J_C@N %YH]/>@N/;&IL$N7T_XY0P6UPM->;JXT*O=<0RTZ7E1
M=3S5,@;OP^M6$!U0)'5';M\HOD"?LBB4_B QV01,:U,D=-$CZSE,Y1)1.MZ+
M-Z+,+-15DF+:-);EN/%L-8. ABP8CI5<@'SJPWK< -04L]CACR 8S<W%EHW&
M'G[OO:9V(W@ SUPC3U2=%*K&>(B_$55'_G3$$?7T4#>/9.4+5RAJ&%R#"X.T
M\?3&:&(HFJAS8T3=0\0;R74>30J!0.^I[HO*7#A=T##&L'P>$A>XEDNZF1 .
MJI6@K(V7J$1XS6&_H=(%L7(G)$C%H'L$V1F\NA)\ZQ:ZT?S@7#._3E^8CBQD
M&.-8NONNZ1DFQV]XY+$>_B7#(&5D)7X'\@N2\7E.(?T6##X$-^9T9X55DL3
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MGX>KL>(_'K[-\&I%#@.!>.S@T&6HU@"5P%H<"&\=KRB:$QX>.+!-RPCZ(XP
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MH"GIPE[T*#Z.+AKH&PPT(8^:-U(Q4R[.]E>,2T4,KLTVMP^@TI%0\I#5P![
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MW7GQN8=I40NP$]FM*G!KQ<4J[DZ-]4CF)Q#V"N$3,&()7HEAE-N8J Y"U:\
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M^^1)R/122"^%;16(Z:40N124MUX*LIR3M_I.@&R#%5T +\4(5J_O/[NRY<9
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M1V+H)66/WV*/?*985E>MPJ7LD1AZ60][+/-0;7JU*^8..2.KJU(@W_6@3QV
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M=7NF6\QN7[AW\!LZ*]/C73L'L*3[D$L[SI@=CZZY[A2^A'639\@@!DY.)V>
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M]5'BF,X>0++N3H^=(8NK<77@F>/,B-ZFC&%][I>"A U;M&>=@MDL(N3DB8C
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MFX27>@33_+%DY(_ADE_O"HSM!S!KUGS*LN5_/<3_:>N#R_%=_KQEY4OE8^O
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M<4P:%(3SOR.^GQ%4 EB;">N8#W#N;133P-C^F=[_CF\1_(%A*4@R_C2!AAN
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M L?GZ+&3F7=G0PZ88X&9J]JZW4#/#!Z_G6_0\C;&Z%236E47]&,F=4]GT=+
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M>.1+YT/^.D.IZ0=[]W^[ +U24P9Y9Y+NJ0I7MBL:3V?%U=LKV/2U+7ZXHMX
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MB?X(#Y)BS35A@R@,_-+@;1>;$'S_QK;B[._OZ[W@H=X@ZR5E^<]_X3\[3M"
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M*E-K.T)\.J2M6A8)'92_$H]F$E^FW0IY1>Y9;0P'!.A?D1& 7]:1GPLU9,'
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M^V:XZ-*9FXE?&70NSD#7GQY_.;$20B7DH)"#0@[Z(+?^)0W7#G)4Q(QQS+%
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M*+%U&__:'!<\R=W=">[\+@.K!W=UKQFBZOIR1L.4D *K)%-94BSH3?.T49#
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MUTK=EM-*(VZAL%%ZVC#]C2M)L2?(2MW=9)]EF;X.S7*C\#YXM@2S:>+@E_2
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MA=WGV""!!(]("GMR(U#[5=P2?'@M8I/'$L; WA":0-\4!0=]$^@FO AG;K3
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MH6E#_@VB:B$#UNR(RS3?9?3DNAZO*?G<"52=7G=^5+WM+MK'GL_=G>K-8;9
M,\Z3"1I$_0:[^DW/,/9I @<JQSYSYG1])ZK+1 6>I/J7Y"BCYYH2ME2P6^1
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MW+_^__M7///++7A @LZ?OXPJ^QSB3)D#@)*4X;=0"B.22OY]DN80N!R#[,Q
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M" Q?3::C.Q;2S/W0VC6) =Z,./]?H71#102>HN@OF1P)NNJ61Q \3)2Y=61
M8-'JTU-=2X(<X4")1EAU"T7LS9S<$$'%$#="=5.&^;ONG<\0C)+R2F3H>0J[
M#Q&N2;!_8TPV!0GLSHIS4<FW<$V %:AU\%D3[D R'Y.A+6W<>A6\2],3H0[2
M,E&=FZ=;>G4OOA;?5O0T]9 W^6S=W>D@<%#<P=O^OM?XL\E>AP'L,-TKD.X5
M#].]PG2O,-TK3/?Z[8':PY*F,LDTDXG'XP?SL7OB,%[ANUQIF[-4YWY<:%2<
M!M#-+-)HCU?R#IB6YNF6S@'5VF[%@=5CLNTA,Z2.5W:+I6DR-V,UM?HX;U:2
M2571.MEA/+CR/K%9U1Q9JU!.=L(7M4EQ5!O)PT1PY6R<FDY!M]&FA-RH^)18
M#95T9C5,!E?&E-5]S+'N5WS?6#3GU7F[8HUEN-([T=MSX)@WY<#%G\^!>U%#
MOT0"5P&:4KCYO6\8^3YL=1Q J)3F@[K<S#)<KE!@M.HV69R4VM=H6J!S11X\
MLWNOP_O.=C461K:;B_2,.<0OY/]HY+_*B>O"A<#!P>JDSA<=!E+./[NYH^AY
M\$G[V:-H#LM(4ZP)TNS\KIZ=.YTX^GWVC5M#?!PG(!T:H:4";VJ'/' $[!4>
M2.7+Z-I9W:XO01)L(?*7,4)1.GRW*?K<L:V_GVW0@%Q*_@?^Y>C!;]]%FL>?
MN4Y1_*/;RP)O .NU* Z/?>XX1\KU=R,WC^=G(IX2E-ZR:U1Y\B2DDPJR>5#6
MEE>YAY!-.D<<=UA SN[ ]@-;]4_Q.H;'0;H<+F<DOOV/.RAV4>-Z2MQ+ 5DO
M?M?)"/F?_:62^^"!ZR\3%5-T9KB &[GW72+<N5H.$FF06Q#7Q*_%">H#1IQM
MN'@2K!7;^]4$;AK=;M_$_8@/O-JWVW*;U.Y<2/K^@"0E TTD%W0+)=H)OC,3
MMS!6:Y&/"BUQH]X>49^ JAM/W\].\[R7I"'9\?H#U*'687L@S/;\"PTK#V"'
MS(JSKV+0)@NR[ N\B-W/AJ89*_BWGU<CZ'"TCZAL-"9MYE?;,7S>2-?GBJ,\
MV,?IM1DXC$.ZR9T^^OW@FNH/.R;C'K-,.-5P(PN0ZORP.&!DQ(1 P0M):P-(
MFE@X[W_;B1+7XP^Y:7$"CM%]Y,C<)=YN%)2^(#KF\DI!%G=!=DID[H63@VNC
M]SG%)$]XQV@^*;8Y;,U&$OSVLI8X[?"(E1/,NY.@4(1;OD9L[GX4?6EHJ//$
M07,<U+B'N+(0"4\=2=YYCG!BK@30K@1?'-DM5,<GIW]%P)U\%]W%?$A?*)*3
M"!&+6U/@J*.7TRWLPHEN=(.PBZ9YK=H#SC$A(BNHGX[G:K\>0N@9[L5@DU)K
M$-E7X/O=^3-# II%&..0=W PQ4<Z*+1]2$J^*(>;1>Y">I]IOQ/2EB^1'L4S
M/&S>X8(-$WDLO%EY$D ]T-'7O46^03.'9$AZ >S1Z[L4X"'A8Q!-VP&E#+4*
MD-UI79#G_4P#]W,RB6*G06@XT\*-H1^%)_=WRG'$!-X@:"/DRV[[30SPG;_8
M3_ENY.WT%7>9\$K+1.%M>]/24"&\+J$$6=PHZKE<]&%*>!B,BSW -;/C0:/$
M5 J/UHGJZM/KKC?6X@$"BZ<=%*+P]?;5,/_!'H&W1]<9K3G$&L'!/I)_[LL$
MD9"JB$0<FI41R?M^.\I5P4-P<>L<"+08#O@250XYKXGLV07%H=Q''4$UW%QH
MUX&/O)#H('>0"2&_3'"T<8:;%>Y3;?8))*^_U)J@)!?3>\ONS6,LP'"JI_LG
M#;T07D=H_"U**"'<A?N.*-;<L% #MEW\FV3CN#M^!EQNELV,=)OT.I >9E[L
MZV&\SE R[CUD[O(B$(A-B6CA;JR8V!02DG&X&3"Z#7?U,J<F'N_R4@[34KQ6
M>KXD'_36.TB3*'P/_(,(B*J(@V. 3 )P$Y*@3")8<7> )2@>/&%>TU1C[C3Q
MC7';Z6>Y Q?5(W7?^GG6CA5D?M!S(G6W=QYOO89VCEW902G;M&.U5KF3?N V
MO5F\4DKU9;UPKDQ47TB NJ->]-3NOTG]OI/6S;5Q R_8G(SA5I%S"_ST?O!O
M"I& NR'DQ!6)E]^+8.&@")HW[7U (B+XDX/ "84#-_ZH";6+=J1)L,,VO7VY
M[Z/)F6W)^_RE(%>"OJ,R__:#RWV=!SJ?8]KW?"34T% 6#VC>[[&5"6]D$F5"
MV=RO1G=<ASE^L;=4&%F&YMC@S%&=YPF#?JOWWOW7EGX#[!.44 4?(*( $0*7
M>TSFCF)#1%P!(I+L73H18N+C,/$?VT1BZL-$TN>=.GTJ:/F[8#BK-/AC&*0#
M(!@=/-)_8G0^9((&__WO?T8?<5J7Y=R+U0NBSM<HQT^1(EYBPYG!\4HT^D4
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MXE9:.)GDWEM\:<K8IU10:MI#WX#S&Z*+E>]8]:XML(9Q;CP(7#=7\ *:YF'
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M>X+T2D[]PKGY&@*D*5+,*V:](,72\U?*<MV7#/=>$J38'_]XE^!PA2)-WGG
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MF1'QFP7 PX4@K PTR0>]$0H"^S"JTCC]DR5 7L#!)K0& @L"<(IG""%F"8R
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M8&JYB'EIUAM5YE%D'0@2T58%&>)T-O,WC@:@ZC@WA%$'E1B>=H9&6>&5/H%
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M%KN#0<W6]((C#.UL*_<Q"%GL9P]SAJJ0RLZJJ&9^M]&+_=RW'ZDS""%\7$"
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M+'GJ>DV1'(. /HD&72[<*&H!WPHL&Y/3+=IS/3\"ZM6%?"9!WV&=D/X'GL1
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M^L*/KK/(BP-'N$_UD6F)QX)BAMJ.</_@=ZHWW@XM4LJHHB_%LI7NM,SR@=:
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MU,2+9KC8CUO!+%00'337?#87 RC.<AF'^NGK>Q%B(\ZZW&;8/ISGI7(9A5=
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MQ+;? B_9!,"]1&X: 1P!7'NXTS8!G*XUG>((X>I!N-HRT^[$JZ/9W ]O.,\
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M2/I8G0U&6^FMD(VL,2?A%$! ;1'EM&R4&Q;_J +34@4FG2HP406F9U1@^JG
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MN(>(^#@Q\7$Z2@I*NG_[A?\$T) =.T/81DAP!CA&0T!(0X!O #A!GL0$WU[
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MZ;?GW&8^#>N@!E'0.+[=P9X7<?/[(38O[YJ0C?3(OW(S)W;[XM<OM]0SBT@
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M7XL9.@4ED:M-@RB4?HS>$Y-S<$A:C?Z0X+V3$TPT."I;1D!/32RCYDBW7W:
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MMB% :P9EH0IZJ[\3_+.C*/]F<8@0L'9 <53S8KP$I@Z/3I51=S%&7[1 ;.X
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MTFOTT+M(DQI1:2(@J(!4!6F)$.F='$1 Z1T%0J37@$!"%9".("!=>@?I"35
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MS9I)Y>U08N0-:B8<"..T/LRQ]3E++_)'$+IZ:^9Q1"[3C[C\02Y4\_)V;N&
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M095 *VB0#=;M8]<.;*>CSR28'AE#%)X7]CM%G_X_#OU_2_89=9O'8:BO2^@
M?Z//=[5JM UW793_@:7<G=G@_M>T)=KLS'J8VQ-.&]7>2*43Q%,AT:87G+ZI
M,O27)TNZ^4CEOYXUT6IJJ^TSW!_0LN L]+U U% RDZS$O (SYW^_XXV6LR0Y
M2[Q!H4"-]^GI]8$(1#J+#]'8<E("^44?_HT'JH"4:L^#U!HK82H\*[; ;_.
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M<'?[$$"RA2!<>'64,2(-FN0-VY_>*/CPIVF@22ANF."/U#T$'$\XJMKSC4C
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M:9UGO)L-&\+WHH*<ABN%[/Q:9BP+P"Y)#>L]XWL$E-1^V/,0.VCN(-R$R8N
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M2/!P_BT>'@5 %G"KFQ_S O#_#E6 R4LA13L<N\("80!,QR9N G=2Y;NB4A6
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M_M^W7]_9= S">17S\D&+V>_F3I02R[_?@A'W@,\^+#9HI:_45_< U>::P'M
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MG;(8Q0N]UYMQYU!V3-C-^WU_2)CT3H[;;=+.NFE19B\-Z8#:.AIF."[UD%-
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MM7;J6,24U&3'%SM-\B&/^,@?%_P!:XM&8#B/^Z?M4'O7'-4C*EY\M*>?W8[
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M%7_>D(6V9KGT7M[Q-Z3"S68^HK:_Z%C#&K^)C$!DCA"BI3(%G-4=U!B)$?6
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M+9Q_P",L3NTJKMM)-Z4"5,X^:6>3EF</8[*C?ZO&3ZV(6'_&GFX:?1'J81&
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M:N%/SVBY@_A8NDG=(15<=,>\.B,NF)_ 8;>V<L9.,)^,X5F>I]X&."T2U;L
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M[WJ-[;GE3X%KG3=''-?=O-.7'6D;+^ >DZN%V0(!-AR:V\#KBIW(["B:$%T
MV__DF/U?ZO84DYH,;HW$=86MRS6U@#Y,YCZ9DW]K8<S\N$]CG)5L]_[9.%#L
MN&K/'?-JOXKA'9]]PM__,2K7R:?$.*I+HAC9^XH2[;A Z;I3J\;5_IZO)NOS
MY6N<._0O/I?@_58UL5$L/>/8<TH3/J@QG_MF6QPO:355;EP^?H[E$DKY4</3
M__> _:\4A4(<O6YF#>@\TJ%;]_0HH1O"G-)@VLO[_CT17F;QH5-R#G?KL-Z$
MG'%((I/V6 5141%YE'1@[-3O8-I*&QLHS117C;=J?N?PFV,=$!^&TW+N:_DK
M,[-_+WU0KF239*8.SSMKOF&(PS(. \%CAW/7V(M/-T5'W6BC\E](=-&3^KL;
M)=&[B)%#< [=Q:BK4+L<6W95*.Z:GD3'X63J1>\Y\GZX[41;A)2$,^*N!$\$
M;!W^ '"15X0-.;0W4RN[&@?,S7)SK>]2O< _(-%Z]HL7\-5?B^4OX-'7[90W
M>38:0JQJ\4 5!=T"6K"4]DZ,_OTIA,%=T]IL^TY",[)?F?M$[8=K62:JC@]L
MY);M#YFJ1.#G*]%0\2!.1*<T!U>M5J9Z]9C(+2WGSJ38PF?B=P<18O\**>D(
MW=8_?\K!2YWVR".])$G8#^DF49$>=!(M:O:EXU=Y:2-<9%.@W;JAY9G<]U]E
MD$PY!@$HM?E6@M)H/&>:5W-53@1PR$<UYU1[3K[M#GR1Q=[2T/*7VY) "IIO
MQ_;--59!E.7T_Y,@I1O?G++: PSM,A6D4'P3+P<U/I&O7:O?7Y0ZFH=M!J\_
M;LQ8O\QCJ?8MP'K/9L-34N)C; ]O#?]F:*BFLFC!2'0K]P;5\S>91AOY?8AJ
MOB5266\(C9*D=JU$7[P^-(34H5S+OO_<:DH]"'DI8GQ/=M8=XOFTZ%:D_N0N
M[KI]=XEITNA5"OS=/^O7=X/;=<!SG]9(/!@5K1\D>2E/L*)4+S)&YP&P&>>]
MK+M3YA__.C5]F_:%"7Q1EA;QZ_Z-E#$CC*J6*AVY\&/]0^M!SO12DRJ8&(S?
M7?^).L!63,,Q7P6T;.1O]KV?"C4M6\<*3 Y1UF"?2/$^ZGB>(Q?(U]\PHUDX
M1ZW9H?#Z >#1]#5A_\U6B43O18%C-6N"!C;)&QKUB'F*=BGWBI1R]79/P@#;
M;J4@X5KL[KE/0]W[+]SRZ6#1*[V\ -0_!Z88%3-#+CO?7[(Z=2U7I=S25]X?
M@6/1)*$>T3ZP7DLVCFZR\=WD'RT_)#$N2/PMO=A!1^^79A^:W;].Y]>)#-6*
MB=%R N2!X47:I<6N98IF^**3[,QG1)S#HFK=\'2:RJD#@VX-E'*_UDXIR 14
M[$%U2DSN/7!M4X* DX>7*N<1N%A*?TZYJK@_<P+%GSMJA9P^AC!)["(<]W54
MQ3.+?8(TV^P+2O6#D_T.<I&>%XB5<CI74TS^\BS,62G3*\),>'TD/6Z_G&+)
M(KC!X&0K*_\'W]@\;]K+JYYRRZ:1;Y]79^XX\;XHHFY?1Z',L=#H?^JI=6B+
ML=2OCJ'BV8AP$#'Z3_(NC\W%*_PC"P:_(_HTVV9N;-XZ,?F<_\F=K^7E\^ \
M5.2=XY\' #EX?*R!/L2'&.5F4^HICWA6"0_V[G6/NBWL."V+W/YBZ4TPQCT"
MIEV79WR!I_/^JSO$^OGWK&,E[JK EQC"T_SH=NC2W,[]&XIZK9AI3H'B!X!1
MFK+ SP@:JB.&D_24D_W61$7K%U&+^D>UT1H)/X1 ZM>:Y818LR5#JMU^VO5A
M!*S<WG@QOH?&&ZVQ5AX4GEM=+3B;H=X2)_M:>5BCGV2'T\KY V33'VB1V?I=
MCU=D;Q#A2_>J]@'@9^HYPNA1%S[0&LEDM^)E9[#ZA,H:54*65C_?YLO\H9<[
M[%7RZ?*C_9.=&L(\A$=PCZ9+-X[% 2=<=VI#1Y_1NM0CUH#+U!ILEB?T+OM2
M7K$<&Z@X]OV;>-/ZGW*1<30*XUQFZV?$!@;K;EV0)5P?H,9B8_<AJ)(;"?:-
MT]_/%=KI=0,YD]M"0L[$FH24*G1,VP^B ]X36B_J267M.O^9'QC3ZU$T'9+F
M170U;BWMK;ZCP+'5V@&[+_OJW3@U_8YC>U_%\[$5E%16B'0QYABUJY*;DQ@<
MVZC 6<K_E$#)\CG C(9FRG+R?=WB3\6[LLWNVO?,J1 (AXC7_L*G"194')X(
M[;[W3+O72R<<8:32E5: +'/FXD7Q-3@HG3I/+\R18<J)W4$6%9[%$[9'%I'D
MUOCJEQ?<V'#4RM,Z6]E:E.FS,2.K,Y,QR71(6S.O&TS[NR&-495CF;LUSY>J
M&O?;:?&_$T7TEK)S=I,"MF;"S];9:A4-MG]AD[OT)35K:Z+B;\3BEPHX/@KW
MW)8([#6;\!)]A+QA#IL>66(\D0M=%Z3@#A4!+[G^^'>/WO#FQD*++"K[JH,O
M^[^?!><8?#C>-72)Q>3C468%=O;/3E4WSKV;2I9 +\TY2R:<&9!U;:)9V&22
M*<;F\W8WW)S.OQ3\OJ&A^95ICELL@R_VQSJZ)$MLYI00 <[:\U#==['X.Q^/
MAZ^B.W)/!W-O:FOCWI@Y?=3T9<4\HJGD +9%J6OKQ*K.SE,C'ZJ49C;QE=H[
M;,OQWZ8V<TVH0^ ZP'Y9Z=KP\CM6!#=G:U]W,"M9_&F0R%\SO*)N/?RRE?+9
MZK5A T7@\[4;+BY:?3?NPY#K%.F:FO$UA<SPMV&.7RGIX[TU,^P>#Z[\>?.U
M_,UL'VROWX,;[>4!*_6: L=JQ<M"R:BAIM</ (,"RZRV:DQVYAS@+\X?9/[8
ME\8-@-@T4\$B+QE])##8<?@1_$IK(SBG,BZ+-F)\T(M(,;&46W@\Y,#K]E")
M2)]DQ-5CS3S@5J54SU+7INSIY.V;9?QT5='U:;K)R4"<)D_^U?V&--)VI6F!
M/T1Y.7VLFL?,/J>3Q#?]R=?TNMBKK'FL[CBD)E4IT>XY8["(O<+0@GM$0(O"
MP&G=-PZVSD7)X0H,#6]'U!H':08OU]IET[F'Y.B_[.ZNEE"J1%\;@3+6C\K.
MD[PU/6,+C_M?PR=6G)@QVO>X=_D"AQ!P.O%+<5&#*HM[O5&;MA[1X%<S]_$K
MHY[2M=@T#)^78OH[='7EZ9K"O)TTE%FHR18D.5)^X4,I0Q2S3[:YH0X-E.C1
M8'AS(4;$.5L0IU&4>(:V+$.<S1^!W##O&!/)?,SZ#.MC-VHL[0M\H#M>[0C,
M>#OD%1>\:#Y! G=OUTK<)V\YBJDA^.QN"K=%PGBL4:9LQPY&4+FL]?5&9BX.
M?RRH]^F'A2B1[#/=*8%!/@EW:D7K[(5$"C7I@WRV!T 0L=))7B(*F3=V0X^L
M-S#?9:;J;%S?C :O:R4XVK7CW_X;;Q;8OWYZE,8$@]CN3L>L#];J[[\PM<\+
M=[DV/)0LF3&01;@F5 6;G3)^4*X9D AB#:-##XJ3:1\@90J8O>(HZ<[19\=^
M#P +[$6X%-=61?*;I('O+H^5B6H[/9P#R^1+H5P5 8#+[[YZL07"GDI=UL"Z
M(MG76D;_O_RP_X] ."?H!LLETG&2#;Y>3D7.GD6](P;S!0#>JOY68$G02P<]
MPH@RTX*<'?>TMID%J,+6G*6KHK%Q%/],V%3D?)DUA+M8I_@Z*1"X,IR25E-W
M[?1&VC''?.0<ZX2R!<'^ ,GL6LOYJR::Q_@M79XNB0:9O/#AJ*$(,J!HWR"9
MF3ASX9U%!N8P9]V,7T_3&J\![1_!%JLGU65I?#7M]709I\ZK4]VB[U;G&ML[
MWQD>IE$M?9FGPO 1HSU(%SC+O\"'0<S=5."\ODP$M >S/U4=#J&L31+>=Q@3
M)T8!YZ,('/'&ZA-B']<>/Z]BCEWW/]9_M4#CE$>1U:\E5#AS$_R'T&1Q$0 &
M @>[7J=."Q4:'EJ9)R<,%OV-A/Y$)@ZHZGA Q*=CY>.9,?JT\</)MJHPCS0Z
M@JRT6H0:5+TX)[>:P_$Z)SSFH%H1J'-$,*TFY"_>WO[M:\+2ZQ ^@M1I\YK<
ML#IFAVO51.Z+MABB9=U#YFBKLDD\ /YCF>_D+Q^%;*+O;!F^E>F1E8A&;*L(
M:P.]K-@9@ Y"HJ@8$8(8\'=-&Q[QF;RZVB3N,B/JW'2MML*+=XWK'3YD/&A"
MOBWZ1Q]K$K6_)?NM;QJ)'M#>H^-%-<IYM#FK8/'L(^%;PW(3-AJ?T? RU4M"
MP5FYK9C5MA4OT6F2DEO+$YOXG,%B&8DM-/R5%9].YRGY>6\Y:%3\ VOP>8D$
M?Y=H:LS>7$]TJ!Y(B61H=#<D0R%4\>3#2".GG0V0$QJ4_ZJ.YMC(UNY(U@-5
M&2R0!D&<B<.2<N:2!3WE,8D=0DNO*)I?GES-I)O^A\@@DT*_=?OR,D'>P/VU
ME#*<+PT36HJHE*"E2U8K5%B[,SAK\,.\[LBMHMGEI:F 6,D[?_X.5XU>.C_'
M0D<PT=[5/?_$QN@[JL9$NZZ#A(X#\)?M3 8[@R:N=]2X=04[Q__2]94N*L")
M#EFU".);/8RW;^%;AQ*=O5=2]J5N'^1[6">]..=0UC(46U(_'K7]G('$8,56
M/ST B$$L:7*63"'SZA$*ZS6$#;WVC3S>=<C[-W1]SEI/%23VMZI>2)=#D\7H
MI7YF'10!N8=U41.:ZQKIL.&Y=B+T5O4]@\7?C:GXEF <)]C9OXA$A4,JKT5"
M?I%2:GT[&N)DU&J3HMBHG?V,3<FC],D?>R)($Y@ZE)@[\'$#H+5;;\HL*ZO3
M69FW;VFRB2-$5"*L@,@X*>,KE^A:H;)30Y.-I%^>V3]HR->3H,@D,S7]O3*6
ML@$W79&=[QYUCPN!"[NZ'I;7WG>U:I/A:FK&N<A'9W1%AMADY=\=4I<=3:\A
MM+#[<=6 DP+N0<5REU2S K0*]EU=/[3L. ;^':A@'9M UN4(-#:25X @A4O3
M9* !S$P,J>>##O<,&.F.,+4&]^FD?3K^*#!59HP,_S\[OS<+L!C[T<<ANCT7
MU,>DG6&/.>.:IQ\ J'+UON6K*]ZKMY$Q7G>!4XVKS6R[5$+!'53HCH"N.2:N
M0@K+^!N&([=2G\-CLD5P,<R=)?<8E"NDFQ#Z+8+DEL%I5__\3W2,>HE [,V0
M[N]@6;2J4 VD8LY@?LY3IAE,I <F1&;DZW%O%8A7?7N)U^-+:P_':_-^/6J"
M 16XN""X1+U21.7ACOA<.?2<A\.<NX.V+E2(2$\P[82S 1V<N9[#AHYD$_=[
MESU<^JS=FV?D8"7B'P]B3&!6F+@V_OR)<Z>[8P6EN-#1]++Q<(E_QQH]RFH/
MU8-J>1*:09621-B0B+H1T.O:\PF7<^UT,'CY0V]0*!3Q>P$&V<Q!$UY]"Q1_
M2E<P5:&:86R7I:<S9ZAB_@Q/L)+TDW%M*S)[IBPC$-4.VQN=;VMXMF%G(/==
M*TV'?7R_[F SKD!%>!AJY3[NJBKYS )1N*Q"M;PPCQ<@_)N?=)%_U\#.$E&V
M1\A9S,_H.:2XP^$EJ9^B$<\0'1831;UE Y#LT7 B)I//(P^+KG71B(+WQ8*M
M([526:@7%ZLHH!2"T3': 4B!98/2+?T!NT&#Z48#FPT;^_RL<32ES?>9CZ +
M7W/[\.C]>G"H0).+PI^0=TFF$0PL6CB/&M;RDLG%R&>#ORCSDT3 !U"*JBGN
M8[S/X..>G$7R)?<K1<Y,V6?Z L6U2MLL2IP)/1$J:KY60P<OS'[/A;Z_6?:'
M+V%!FZL)< LZ4U5%@[8ZRS%'L<\>'T&ITPTJ&H7EY&X1N[,)6_5&_+&^(Q/D
ME:A$-HHB(!<YPN7QNV=O*[WVB\<;!6*:&C=?F,H/$*HH1>66]H>Q"&55T';/
M'*Q ).1U-SU5^#_/9VU$*NV*2VL<>,@ Y)6ZQH^^_=)>J$<%R0 6PD+^A: F
MKB3H]/&O!5M(Y]T<*L(KAF"E!DQUZ";'R('Z&LG%;;(:9'\>K(REO9W&A33&
MA,/V^?#WN:258Q)=2WXPG,;638,P0D=&4")XUQ 8VLMFY,WL-OFGHH3V>Y$9
MK7?[EP^=;OCS?RG@Q6S]7C!DW5IO(R=LFOR]Q%1JZNI'KE"L9A-<&3VY1%_)
MP=+^'O#*WW@>V+OO,^=-//ZT<[-.&TE9RF?RFH&&)%()D]5VSL1YNN,6R=IN
M"!=T27^%32&JL8GI9&"X>+-KD)@#-UHEJSHV9(%17>0'VYD6SMZO<<96*TQ\
MX[PJ5SM9[DA1]A">\_ S3&1R<"ZO[Z_L^\I8Q^CJ6DHQN;$6F7M^]^6;YT0S
MYZ1UN3AOL8XR!ULM.N9M76VO1N14LVL3=O?)R_Y+,G@LZ>:LZR>ZW$ND2X<W
MP[3X1PQ>@Z_:KS4<9O(IT@T*";+?/APWJ>^(2N<VM<1UQM7K38>?8(/5GZ5I
M*Q+P3.&DR^/^$==832ECA0KI6E%0N,O.&NW#9F,>M^-9L%(B.=MJ=(]]&R4+
M]W7]&[P"J(<9E<TBK8*ZZ9T\PK::))6Q/]E'#ISDQLP"/S?&]OW:C?)S.7\R
MO>^]3!A10.=R+&99U1)]6T)3(+&RT)?GR4Q=0#[G;,/#"U5:%%L:!-IEX-VR
ML/H)S(^S&=LYO;6J;<41QSD.@PAA8/<.Q9;5<SK1:,JC&(N!%SB_ZOXU_PS9
MWH./ L$DZ/@P2QHSZ'P8UY?,?\$23^VON]LL;( *AVA2&Z=I3L$L41$"6)K6
MK,*1>T5IA?K7E3^HJ4HMY<J]Y8(MX^BE:D&W+9#!)KM#[U6*BUIDBH\]UZW-
M)+> 1P;> ^#;'F&):T ?P_6O78MQ#J45&^I$SM8>)B!>!S%-=S[<G3E9I>EN
MZ/?EO59VK+9"M(BG#6'\CNCV7'U):#_]4\M=LDKF1W*XN!_T2ESG-3$LHZBQ
MS+J);6.4_&.*K8H M:=$[O%4^O.*WH9%%Z08W@]EAK/?3HK!E>J(8Q5OV1;:
MWGQ+]P4ZZOH;X'$ NDF0H4:PE+*;'1$='?C-EGBJV'6\]5I)OW,5W@TG-#TD
MAU('&B8(&;SWFL&!UM,?K*YA@=R2'7/YR;%N$'9G ?-82_74"'?"[L)+,O/N
M:^*@6T.,)!B#%X(2.7#$YDE#5 R!C6B1F>5(]W\P=%%7;M:;(IX;P^L=[^,?
MG5\[5BVGRHD4>]^M78.F.; N;5]DBSO-"7=K,&2ES^UL(CJ>X\EM3S=YI9Q<
M4H0J!YL:C<4_V;B0&/2L</3M6J9TO-,BY-F6&\]Q73]CE6Y8UYAPIYLI+Q=X
MXM\;LZCS_2]!=%BD[FE%_.L+49A8"DI-UDWNT?_Z6?C?"6\[,10=28@--R&T
M>U69^G(]VN!["=90IO:I433!-I,##?YEB7-5Z-_AO'?QEM]QUAW//K58Q*5[
M?SX%,%/5^*P>,@ZW75;/&<F6[15G*EQ]8?.CVR'68JPI^9EJ* "\;[C.D%?L
MM-@8/9O*6'DND$2XE52H8NV0UJ; PI1\B)(,B=6NU':MYNZ_TOCJ[T9_'+FO
M[Q(!>K-[Z>Y4-(Z,6=:+PDW@?.P]5"<\1^"$^*Y]SX]ULLQU-9I:!CNLI1GH
M?(),'S-V/DV2;'N%C2Q"&AY<HQ%.9C6B62$)M 5O]/D+%>.YQ_:F]CA+Y*D3
M+%+?,R(M[UEP15C"PT:E^9FZ^%YZ)*_Q@ ,%'@!XBUAX:W)X=7PQ5"$&QK]0
MHF0#QG#X.,FC11\ :_'^U4ENJR)6IF/G^\_4$35RFN1',E>A$64'G+*QO9X:
M#P#6L]TKVG*!+72FNW5!6.,BD9>NL)D7Z!5JJ!^MTT0A 1ZK0"!XQ%5*+,84
M26K03Q:M',[XRF4BR^Q<Z%^CRJ2G)$@EY%62>]_*P/'2*JR'D1X5VT!X>_TU
M,74IZ=YEHMJ2U,9\J7I1^Z.T'-P_G=]MSQD66%WVRV^%DO+P+^"*#IQ,2[<?
M[ -Z@R3YA8!E+'_58N"#YX.6I41CME*MN&6&KAW/A@<>E=,JRS2-V4!$"<VA
MRB;?:\UJ4X9?/F>1%'+OG+Q(XC'R""Z(F)KT/A\7UKS=CT+08G79%;Q,MR3X
M7Q#U_UNKLFZ*".IZKULU*7#G]N67;CU4PEY([0P?4T+_:H?B+[6U/0MK]@)[
MY+^IN]P:69GY7MHQ'_?G.,1C:7.X.=Q)>SD:89&-'&_0)E)7_FZC4\AL2D>[
M"[+7R0.G)SAF&>^;DL;W00R/M#DA%&6PRV2##,&2$O E_%D=\]TN\=57%R"T
M(_DNT@]5!-1W7I&R\67']7'C=]8D6YG+76+"%JU--J?-[ ;3<9W?:+(PX67:
MS#>I.(YD[BM#+"[,)=PQ[5W]6E",9,<&YBHX5F;"V(,;7ULQ9(K_ZO?=,C^M
M8F'BYZE&L5)7,WT>DH(=-:8</;%']/2N[\O53XY;Q<JDN04]0@GT07N3^"EQ
M3S>BTK?%32 Z>&T$M!]\W'7WD5HK1W@2KN5>1B<S"O8:$&]=.HJ*LI!$@<5(
MAOK1\V%*6K[+)6A_N-+8:F44DLFBM:?=(_GP0!RO"&8TNEF#0GF8NT1\2\EK
M=V:^UKI-!XQSF9P)]"<)6%ZO228S^BQ*<*3 #=A55&FI50.FM1M^'Y)"JY_(
MW!P12^EI\NN.(Q(76XR1(IYO,3#-E-7K)7W='>=Q%0_'6>'H7H77=UM,:(^6
M']YTLZXNX$"EL2P%2&G58:OSD?:DX1-7=D\QF#&?5[EZQE9= ].Q4.:YFD$D
M@F-6F\!BXD5JU15P6Z2OI'%Q,#='6C ?;9Z!W5[=H$I#157%<M"4!KEIT3XK
MYYZP]H3F?0BU1F:7M/7R?7\ T$!&SN*COIWI4.A^Y2=5"DG(_F2N!G?8YDPS
M[W(N\+"LYJ7<^ZFBF(\]&CMU0D\<+G]JM"%;V"*7-)@\UL"Z+\;]"AVT,^#!
MVID70WORR40.0P8['457M;Q4K9%(+AI$KT;/-_MGE\"2[VM\S_HA:;WD=2MX
M%CEA>W.J;JC?MSV2,S;+2A-CC;+9KKZA8JVF3J-EO."$E>O'KI+^IF81DVS]
M#A.E%YN>IB6J$KJ"M+)NL5[5K8%)U(]F+G-NO+6[1' COCD>5^PZ['_(SOCM
M[30,2V?Z\DP+*:AO[U:KWU5BN-"9KPW**C60S9MAY0:V6^/-N"?S++7VY)0
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MJKJ&-/(]4KDQ6?>OV\^/#H8@N$E)2+ABP6R_>/B/$%6V$]R$R_7#:2;1]*Q
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M+B>T=D35W+70>FV].G5T?.K:DSGFHFTZ9KF8LI/%QFSA29I9+_W#AWK=OO;
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ML$ V^?G2"W&SBI0S*9R!PFZP8R]M4=&!&+;'D.I79VXG=X.@>$@IUP1P[E:
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M]5'CBLC/_3YC1CSW )GGDS\DPE/V^*.#1FV^GO.5IKN_XSCZN+^[:73&0DG
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M5U/)&VD77Y8#):S1^[U41BGWY] HZR@*O]]RI6Y""I1WFE2>,H[-&1F:&_>
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MHZK$F9?[:7U^I@%UW:T1F^I50H($.Y(6B Q09@2#R]P;=9/#?BC.0*-(#$8
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MV%2,?ABG;/I6]YA0SE"F89PG\ P1%:IY5'[(ARR'@& 6/JZ&7USF, $@\SN
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M //K:-R*\B?E%A&=::O4JLAN&_P"GDDLNJ2]".3X.U$6XM;S2:\.Q[F/F;J
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M9#W(R!6K/NG/0CS;8=;ZU1GQ,/O'^=9$FZ2+$45LV&TG=WSM<KEW?.Q@5D&
MAAOVC"A/4M0S7O%9WH;M2V>.'5.V:S7L[TP*',]BJH+W*@>T:%9@"KYF GP
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M5V6,J[N=_ QV'M 7/DOUX?D/LJUV\7J)^*5>VU4@<3=EX]C\,'-0_AQD *I
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MX#1D$8^0P#.N')=>I?76>]ZO#;;-+V4]$S:B@O,W(H)(=R+.F.#W_KDCB2C
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MW2W2@O9H(UKC_Q<,_Y\FYO+W?P!02P,$%     @ *(5B5CGO>37Q^@  ?/\
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MP>'1\<DI]/KF]N[^X?'I[W]PP0#@8/Z'_&]Q8?_#!0L/#P</_ \N&%BO_RS
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M-7MMV9+4>M9R!R-/XV9T<;P^#U-,O'Z$3?G:(2CXL7G51)0#SH%-OWC" A)
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MHJ+%%W'*QASHF,>QQ%_Y0$B[]ZB=>R'B?:8NNES7:D+U/23LQFWN)T7CM*"
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MIK40-<;8'K^!"V87%_D,2NTI:,3(^/7(*>-$:-0()5JD77!T=->ABGLV\VM
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M("=S$.D]3TQDHF4>;D;%3Q42;U(W"CK^DJ4/L=-0W\AORX>IG)KRWR/C<&*
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MO&K\,(9.8MDXF Q+Z$Y@F&?CD7-1FSYXP-F5E+HU"5[_2\79%\60!:<EF,)
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MQIMC-+-? )"L\6+*F_*RI2-C7P?<B$PX;-3JZCZ5E)N"O-R1-,14/7-[(BR
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M/DIMQP7DL'5GJM8EGGSIRBX,4@V0D^Q)M/=K\Q'?]6U\%BQ<@E4[HWYC*E9
MGU2K\Y([T;0],]O:; T7LKM3^6QUKT@(G1TI6#5Q'W.VG^LO.[+Z$3<FS*N?
MI-P>B,;*E'FR)(TE;D$L%.T% /X7I>&R>A",Z<UY%7^CHWR9TS4*)SQ>3I>5
M'7S)!ZO^'/V V"TMQ+UIA^$N/?S,&E1TA,,WD+BD0RW?/U4#HEKAJ\9]:WFE
ML-F."X2DU1[%N%0>+;B.F[O@TNQ+6/"TH,)0( G%IL-U^J:AGJ=RE.4+: 0W
MK!8&E<IFEH(LX\0?Q:]XP)'KV%:[H8+"&M-V=<<\D7)_AG'Y?HX(Y9<CJGB
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MA@@RNC4,.^)_-$7G:LI%F]&7X<*3NR2\7Z/BQ+3+",.:YRAMA)_T$[[A7:+
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M"&8S0LSR1,GV=!3/B43APGYJ_VAI[&^RC.D&UB3&H?F[,'NM&(IU:!/+J27
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M9^YV?HD&E+@5Z!EO2+FY?'42&1 >Y*EE$0QLDQ]Y9@ZLZ_^E^O-7ZHL91#2
M<[J&LI'M/6 %JI>@_OX#8X\V,<!'L_3_X:D2Y]F!9+YAYPV@;/ &D*BALO8D
M?_HVZ$LU%';%VC XY/FIG^J<]'*H04023WR8]Z)UD<I&X^/(%2?[/.?F1W%;
M()S "3AW"7( <UYO&:9.C[=I#T:@]'[4'>L@F-):G6I@ ^/,H:!32CP+$,R]
M ;[6OP/ 2GA@L^/LG-$YI7PB*C:F#+F]TS[)#E,N1J1_!\SWH"0E?"FUQ;N"
M/FA+ G9F'FY]$]G=8Y4RI@I[5NEY8G'?K+]:-"AUJL<G6\Z?&%L@N)/=:X(S
M20L8!I6$/B\H%-JF'$X&74&.30;KP]\ P;C&5:S1'<F+_$Y2V)6:KOM_=&\$
MTWBF?+ $_UE;]D]Y<K3OO93 ^8ZO%H[?8#8$!N8L02B@@RW1QE6#SS$[7;+D
MVS?5A]Y.]1YVFB4INO6R_MGQJ.0!7YKMKWN3A<3ORG;"$.ED.1?C/OGZ+(X4
M2?9J9@NX03K;0#*4WZ69UH$-D!* %8C<LMI@C::W+\*QI%.:RTL-=9AX^*9B
MMFT Z0_EZJ'=0C@M>$6SML_/XURE^P)]QZ-YIP;SD _R];6(=*UCV3>D@?;U
M A[@48^!L7V1L 5,><D4LS3 #A;T7=\P+J[:9<J_)#WD9<+L^(PPC".<-<!D
M)9R5"P#TWCHU^/4:A"X'S^6F7%-.2 A3INUV$NN6H;&'&>7??'U"$2B/M?V!
MKUP;-"1!(OP&8*YA[?)&R^5X6IF^+G_JN(-WZ7WX)1O@=#6H'U3A\!4$(U-5
MDZ]D=2]$^07@.\YV6X-?6)@M1U K)Y#?UN3X9.B0T/:UY?UE-XBA=LIMDA.\
M4IK+A^4]>G"48VL1Y+C1D4S,T$*?1=N.4R;@F#:D4&IL#Y<0<ZGZ*1V@ (@/
MUR!"!@$?M%SY),/I(ISE#*.]72NG"D5W013=I.%CKOQ@[J"2[F:8>#.!!22-
M(4CP47>ZFT3TG8G7] !4=Y;=@;4XU0H2,!?3DPS251/,:M4\!.SIMO^1_L&Z
MGX9!@,P@"EU*>S_5"X;69Q6:)GW6+D*;W4MOXZZ0)2@853<B;^Y_ Z#%(7@9
M#\LK8/892 ,_I_E-^"0=C-)"ST^,9->E,2I&A1-B@I<J:7UWA;3K4(D/HM,W
M5V4ED^)763NCCI8:%>@LK!,51TJC(M:] <Z3!^FU^R\S',=8KN-3_K8C8:&7
MI?#"S7YO@.SKQ2A]*_^*3'/7',>?B*/ 5+CN("L2L;E,Q2#)O4Q7'QC!YQ5F
M9UWB$03/21YYJ7"27I)I%54S\2A+HRTF8<YAD9>N9*@8E;!LNGMG;,2,!OGF
M1+1S'OZ^\LJQ4?U)7:?WIC7;:AJJQ92",=PC=I%?XP7SK1/A47KR2^$:@6$#
MJR?&,!Q:&LMLNN:P>8N/K@<6FK9W49UHH& %LY>N"M7[A@?W9R0O KE8=PHA
ME40D^:\N& 7.#G]14W:BJ#9IRRC#[19?@7YX<8-S14M97NG*L-1]^2XUKQ*-
M<([QX7-.0_"Z>7",4U  !:?AIHDA^Y\&=>MZ*]K6AWV!5V!B4'.];F/+IZ08
MJLYV\G.O=PT#B\Y5MHY+ I>5M+8[ A45K4=K,OG/V%D.W18CU>:_;C[B;M1F
M%M]72C3'_A+=L:>8;  +$)QTX9P/4&*<OS1EX7LG]!(;_0-%W<(Y TL'5I;0
M,_A>( #[:C--B2>!:V2%G.#DIIHYV4K[Z10V,U.@BHVHDEC')KVK7,A$!G8F
MN[FK0&?7^NHL)R,&U0K9+EMK[G(+?=#,UN @T3M]FBAH[K1PU$LR+[,G$3)3
M<=$NC.<TV\]Z:GO4)#6J)F((P1YK/10"+]0A(YRH(8,0H,+?AGV076(YJ#XX
MR@CT&C^\ 01J@L3LW@#?ER^>999A#J^6>5R'2US=HO:^N!3('2II+*N?5:5,
M GG;SV0YG040W@#8E-G)4WXR]U^+_-3.*VQ\ZG@PXOY -OODLFS$)#[@'\M3
MG_>'&J>8_'C,<E>OXK.B9/Z^Q-1"Q?LL]M)VK:2*]ED*BOE1-VZ \&_M.F\,
M$RN_-(9W4(I1V+G\L(;\=?733O-)[+98E"C-#XFUP%Q;MZ:UKPMCWI[(8FX^
MF2R4H2(^EEU&]S_.,[3/=2-/&_PU5JD7S30Y+H-Q-J4R47>FG<X^:@N37FR1
MVQPA9= ^=43M/,Q)]&JP'.7]-*U-<"V$_%FK$R:!7H#\&:KBEJ,6%QS5ZWA&
M ,7R=^6>7&&8H?$J  I #<M+K)]GE9_\/7R^[>.#U8)9H@'0]6'+.>%DY5A5
M,S3F;NTH_7K2Y Y0=Q(;]? =1-_UH8A!MK),Z=NQ?PJ68H,Y[\+^LYUC>E.P
MO[4WGG1/Z/6@5U-H>=5I3K[1)W[6^ RA9.']^+1,JNJMI<Z46__#OSU[-23"
MR]-MJ-8GPDH.SWRDU__@;B)/TD-*1<C?@%])?=/)-S/73B&/!<-YAC9$6,I+
M22YT2; RE &F9UWDBQJMNO8^4\K0W+_^%;!NS,/N<_"SKC_,(36RLJ!-5D1T
MEA#XT]\9*';.?$NP@/!Q&=QIP^-JSI$Y9WW8F$'Q<0!"\2>Y B(56&PLU_0'
M\G5,T*7W69P:+ $ VVW7Q'776X6)4CT;WG_.M[DR&<V[[]9*G+L4R@B9=@S>
M1=_GZ!$[PF9%W7;_TP6),^B+)P. 7RK^3$,>G\>A)B'ZD=09'_%S1Z^M@G)>
MD#J%VZKTM;UM1@OGG^/")EU7!(WG"ITLNWG\Q<[G_WGZ[Z_O[Q67^P,H&YXH
M<[ ,SVBR=<6\U^\<D3\! ( O;1X=*GJU7V1%E)WKO-* N.U!*ES>Y9?W)4E7
MGB=+':U,*BH:GO8W!_O53(Q56%-'6FB%J62]V^;-1:9;=K9AL>NAAI-;D>-,
M9)&39IM'B)<2T-9)-$(1YL_^S8(VC9.GHHXBF%;&]S4CG&LT>-/.O1HTZX\O
M0LMI_[BW<LUWH#;K,E'=;S"ZEX1GPFB/MOHH[37!QPAHY_R/+3L,K$9G4:_D
M4+9"JT)3,#K5+O"OH)MALXB^@&OY<<*)C\BY_!PGC6NW]U7L\%*;T.>L!4XA
M\"G<B?'G7-LAFV0IMR/CI)VGN$9J$!UH;?I(G7'ERHT5KZ 6XB?0DZ0/>5<#
MT02X(I^F-#;\9_O6CSL'$Y#5HXR?;X!9)?W_I3+AT)T5K'[.A-LG_6\=DP[<
MSQ@<'UR5_,*OROQ*#7-L>$MC$!:#;U,K^6KE7*Y>!([1GT+%T67>!_T)(HQF
MS'WW?Y(.V"[_<\3V&Z#&_0TPD]Y)^K\ITNFENM@Q1PMBK/@QAY^16GI+3#%@
MV8T;SRK*=X)HCQOFUY6+\Z%6U6[+%"R#0W.P="L"+S=%&"C=4H5O[]NDGC+5
M2\Y<&TV)6?"A*DD9X88<\C))-?%.>P'=)]BRPAO LM@(**)E?F!$[O$C\T^Q
MDC0UE$3TH3IM1_=+YZ_)XK@@I-FX(A<3PIV4Z?ZFI82Q&0K%6S*&;R S,CP+
MP%/Y[V>[98QW' H]PS4/NQWMT$(D-G[)%K-(Z"+-6<]8RZL%VC7'BMZ3GI&[
M'#L[%K'WZ+=/ET[$]U/SG]J:Y^U/%N$LFNI_-Y/)T3(#1!2>E9T%SR([)"/1
M#_CYI$X^VLZLR^UQ">:D@>++UI83ABFOU^X+NBY>BX1&\TV$/78A%/@F657F
M"[AK=R=.(&3\ 6E:N%'L?^0(-:E_LL!K;5?E5P'O2:Z!>&_Z]<24^-#?Y]4@
M]E[P; , ;@0^YF5#<2K:%ETZ#IUIE..^7(DH)GEMU=X?_ERUSTKVO(&VY"?]
M1!^?>C)R_CFR!+BODY@!0>$G>B:T&GG^O K=B,G!/OD+RKMJ(M'NUS;3$/&_
MU5P&U+44/J87KUXUX+T_24F'_N6%;03Z3'3_/ 6\F"]MSH&&C&/=R5:_>:+X
M<SE$W"A80PU_!#DNL(I%*FN?@""(.G8% ;9\7O73WC$W?AO!G@QC;(-[!%F$
M\V@IF^Z*=FB)S"!I7NS%5J(9O>/]Q@CM-<\YP5@]I2P2=+.R$:^A3G T:)M3
MI!VZE&GZ,&YQNHVG@B1R.&>P'5\(4%$Y+<CN*]S18\<Z<\QB9 SAL0 0"$5M
MEXX,VWH9;3NROK<*<FE_%F&VTD#:21PF82AY ^B7;6S*6 ZN!^62[[GTY,J4
MHEZF8K>J(L=C!>1G7X9XP*5L9[I<3[KXU QB8Q_@/6AL2< X ?3G%K37<+)Z
M22MP2<9V4),X'W 15JK=MA)^V:%^$53?0)566J(5IZ&5K?D4LSUJQVVZR-#T
MSW$XPR@1?9/(WE0NGCQK:.8; ,M7BXWZ4P2H=WIR_I\QF+![^4+/8MBO]:IY
M4;Z5PMIGG?RD;,U_K4TU-ONGH0$>-MH Z]B_@IX:\_@'1"S_O'*RMPW-6LVM
M3F4X)"ZE<A)E2UM-^=7Q.5*(6IH-(8'#YNLEE,MK-:*N,U,_:T-T[3R1BZ0_
M ZC94;;Y$5YD7 +1;\AB#?J=,U9I4VYPP^K&QMRN\(J<10_(Y$4>EPU864.=
MA>K0\5[DB$'7E>GU]<Q+'D26!UV6_4DS& $D95"6$%0,HMA<[(SGZ_)N3LR[
MIGBD717YF]L*CGC<' ]7+E0*9)%RV7&=6=9LS=!,9SCZJK19H-Y%<RDQA6BR
M#HE>9L0Z8!HY]-B:7PJ&D(SFS(_UZZ^K-6V*I)0#YF6,%7RB;0?8D\,\7@]^
MRAG[LO"JF7X]48+$,>P-D*/H@6Y.3?#7=T^-)APWGMT9KF>DE_=#!1%U\3XP
M-$=E2S^16O2@%QHBJ#7;ATK[#&U2L<8=>E98INI_Q>O*%F;K_YB HADR)TH0
MJ)G3U^5AAEA5:DJ2;$!M5<GA7+#U;6(K1K(S$-JV->E9V.M@(SQSZDV0'Y6E
M[XK@PM0#)4N[.CHQ9 AK0&FL(?U\,$*HQ*+PKAX@G\AB#E9]<L/S[^4]W#E!
M\]L2:W<:>, 8S^YB6"V"L"P9="?*U3V+GE]GDYY/AE?$78<$_YE&GG3]?'7H
MB6\$9%_>: ;X%08_:O^,ZI+O8>;@4B6Y*^'A=%R7U;L8J>%2'FV:K@Q[_R&/
M(D%6>30;#8D\9(4Z4-&_,L3PN95J^J*D0?I=[BFSF"!?9&\/ _&V!\\/RL^_
MP.\1C8OB_&Y+YWH::E*?)MN=5(2BT^':E"L[9;U/)HUDU+R0J<W3Q37!$TR(
M.(ROW_;#^   :H%C!=%&:V;X\.U+$)3B(!J>$)K=7TIYC6%[@AEZ37NA"$"H
M,$<&"T7K:!*+#6 3']KR"[#$\$1-N:QU EP#\5^);:@(A?EX-N1''=SAO6\%
MDULH_7^V]+@SE (C-/NQL$' ?<\W0(B?;1?#!6KJ8 !_HS^IR(!,X>?D%//0
MQLC 9.]>ZE-R\T[_&M9PQ>T76>;V$0(P64W 4/OY_;$L(3M/D5WFHO//6DS!
M:-BPV+LNUOO06Z<+]^Z>-\"/.NFF7\"^+E848%-G6/?X^^^Y0AF ;&WPT&%E
M0/JRHR0+3N[O$9%8MT"*5[Q[3VA<R*FPR"XQW-ZHE5>D\)% ;3 S_@.!,,?V
M+1"F&B%&Z"=S/FSX!@@WNN"#3K;5#_B(15J8[V_T9]56M!ZB$.LR4#_'C2!<
MM\@1$>E0D6YX7IF4BV"@I1!6VBS>4TXW)[U@^[2U(&[-8%P9D^QX(^Y/Q_WR
M-CEIB?</F.)^'O2Q;*^FSS%S%XYM^( _>F#\^=R'L.W<[=#5RJ.S<L,67F1'
M\H/4]8</@:3[BL.']XR7*D _]1*C(U%B_(-RB^4&U#= 0V6!22<77-0.Y7%F
MW&V"7<=Y7)Q]A\W.D;+LG'N"A?@ZE>U^L7=#^]_3DY6* B1BX67LW4!46WW'
M6OKV[4Z5-?FYLU]%BSP'^8D2-A]UTM_'X(T,T\7[SR>"0!C7%RV>DR<?&@)_
MG7B2GO\02+JI07\IO+'H_M&K<898Q5N420YS7$06NS]1MMEVL!M08^N]+[$T
M<PR<Y4D5]B7\&<B\]\KX3-W:-&]/6W\A6KO[HRE;/ANI(9IQ5Q/]]1Q' 0$'
M,#K,NQR:&&O=Y-=E%UZFB<Q+S-^LRN-;M!QKAJ_P&I_K*#9XIA;89P.WMUXL
MXJF+C=U3@\J%+330Q=[R!<G@1*WD+["$*L@8APM)],.%G=0F=I,D?V!/1V7T
MGI/F*IBT*K5E*E7KOJC0AJ,AE?^"6GW*N!4D[+_K%)61=RX;1[>8?9)HQV_1
M;TY4QI5P166!X5^1/]M%X"<V4Q*M9()67.'UG<6E:N*N)L>HVB,0VGB LV)L
MRT1FFTK?-TF$ZH1#=O&W;%9N^;+09!%&X'UPW]VR+0P\OUWN\\0SZ81Z_1B8
MZ.Y:A"G7ZH<N.LR\]*ZYC#>7DFM7'-74-\VL"NQE%[=E61ZB5+U.V^$T-QE+
MPEB'GR9\TW?GD!=Y2]DT4Q+ZH$>Z1.9;O9(\VWN+";,V/J$&=$5U3>QG*^$4
M2W1#MR_BS_X5:\("C&#:& _ ERZW>]\*F=U DB/]#GO2H4W-DE4?XGPZS\">
M#-\ X%PGM/^N%9@^Y9-#E:ZTME&P%$!%L4RZ0X$Y%OBWJ$KD/P*NP_?V@^ Z
M?T>U-\ >;U7L?\Q<;1X_I^<W0*XL;]ZK:P"S[J/*M_X&("S?8+))V1(V<2L#
M@!X4:O$N6\130KM=7^XE+J;U?U]4IUJ5VNJ21B0%]*$7=[=PV7]!Q:_@7X>5
MQZ4B!W&:&+=%X50 )(BIEX?$&N[ZY /()^TJO5R)OJMT<K'HPUQE0&1-[#XL
MQ<\?Q75C,- N738AY(UEG< VX4S/QN]LMD[RIW'Z]PE/BM:_[X74*(FZ&0P\
MP&26V4BJ"=/<0^28A^6H%/7-PI3><:LEN_3M55ZW5_*M75T+WP[L2?=?-YSG
M&UP+\L\PUJM?8,RBAL%! C7I3ALWH-P6;1M" 6#\6$\<+8[SL @6=Y#/U8KN
MFEA]3K^=*M(]Y;AVX@?W3N--H1]EA51<3&2)=%1]Y607M$EKY'KZ-Q?N"]E1
MCF!67MO[MHN,6;;9(RT=Y!@_M[Q[]$]/ >V!%+'M%)'$A-YD3Z6AK,,K:!/G
M5(,UF'YRB7_8""\5V-D6A%/N<(2Y[!G@>DSYV;U&IK"1.M\ -HCL2H>^IX7O
M6S_6F-?E_P/A^J3H,O021?^_R%OF+++LCRTEA:%%1M<;0-%/)R8:[A_\,J$,
M@C1'!!_<;AWHLU'J,G-L%7UE9$)/.9["01"O2IF&CXYS]DHKL[3W&!:I?P,L
M5=0XQ#B.XSZ8'Z@CX#83DU]3_DRFY7TO1QK?[Z$ C"%-0!=,+ 3X9F^]V/YP
M,<F$;<&7=-(D:G_5EC9M1< //=$O_?!3J0S'E#_V7@V;G*JO13768\DG+N@&
MW7MC\9R2* YQR50BIO1FJ\&\R\7(9Y01WI/\'.7LS)CB8EP[3FWQVS36(7II
M5[+S\;+;@>VGWU^I1I.<= 9^M#M)XF?G4IA1>>MU?R4I(;&?1FM:+)IO0(HY
M/"F#K,'[5GCYW$E?W;!0*%F#;=BRQF+#4ZE-MS$<A/%5>T01+U)CG4XI*5@T
M$@746%.[:"ZA@'HGL]\8C&C /?BD3%-33"=BV^7-#WQ-S8)%;X#H3Y<DA=W-
MZ#;OSW/[O0LY6<?>7XZV>*Q+U!2]XOQ5SO62'2)HMMYG^=/FB7 I(;HZ_ 8P
M[ORU:R7+O-0N<"'@3MJ@3>1..9KE%,;3^BRVD\6BE+U30U_?K&>\'S7^FVK\
M*'OQ]VSD H& B.N$"C)4NQDA#LNO233H-2('QNR )Y@"M&&(>7IA&3YR*^=4
M5Z#!T\$%D,7^PH!1+E*;3J:H#4:0*.RF56=KE)_V0+LEE"5K*S@<QC,3O:CT
M90R;<;#@\6.AIS!JK?R/C.]04#<X@__M;'G"B&?R1C-+0K!F91H"D@"URW).
M$9SKIV1=4R53&+@[%K%%8.K<&TV< ;Y(O.YK:+P\N:.*2)O&0PC' T1>0 3,
M2%RK2!ME@!#!0')@>!;;X.7>^<&:018U.0"%6<]_SBTSYI8Z^@ W12(,-$R,
M'.3/C"G9L_EY'+>/1):+*$%\"3:<'ACI($SFMGU?V=/0,NM4<V8*]NH8[HB]
MK5 <]+HB4(Q7 4UQV&6&#O'I&T5$Q&?) .>LLO^,;MF*9";AMJ$2%10$7,$H
M@ZYI==M4G_A54IO;PGR:CAZ*KOH[*QT)6D&P9!V$$")'"1@MO*%H]W8&ND%.
MG5?ZV)I<3B;O[!I&Z)(  -+S2,Y?6N,:FJ?^N5,5F6NBU@LM6NN :=X.YC;*
M,^FKO;#X[05I:FG!YL+00&AUI#+]V\3G;#T& :.JI*??!O!.Y):=W+V!*,*J
M4"/2?K7N=E+;J1#W$.!^(=<)A!11_;),#6E].W1-V'CNFY$H.E+C[#&E+R&"
M4W-P1QG<T7=J)@K?Q2AW@_EW$.7R*6J)WQ(NY=PGPP#BG<VM+">3346>O6[-
MP5X8*,=&,-F&EZCN;Y?C</4]4;^^9]\+;T'[HGFDZ][$$0X\?#C"Q?6DP<(K
MAY?K!^%?6QH)*@3V7VSD_B!M32Q/%#NH' KXM7\25LE59!OBVT\&WYGV(]O
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MCTS<KZ"0]%NE1X-0C*:<41Z"_BJ;R ^APLZ/'K0T:'V-I!R B?Y,,>50+"(
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M'M"MWTJ>$72WAZT8_CVEX@\[)S@0\@; T!2>WLAJGX'1 (ZN)]]]+*SJ,,?
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M"WYP+[^,KR[JE]TK/X.O$1$IB]Q^_>#'7'L!-1C_=AGQ@T:Q[3DTYPS^4(X
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M&?%\[O!I: OGA/TF\D]]XN6QH8(G-2;M)1,7K1="6AT^6(6 [R)]B3A<D>?
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MA&+<OMN_I(V6I(N6?%N%PR05KKPEK>1FD,Y9_?1=1MZOC-!WP/_M*@7!(A
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MI+]/7B?-)V&92="[<]LEN-YS5V\;P>5PV",I--77*_]\ $JPM(E;F&'V.9V
M5!](/POQ4VT3$.,--WR2!]/KM'=UZ9SF=:K%M'X6_F*J6?*:CF[/4N[S2H\K
M_S-,*LIB.]7TJN2H"QY>2K7?)%ZUEWN?3:CC>:[RAK$^V%JY3PZP!?AV+]I'
M2OGU=XFL2>Q@&::[?QO\%!!G,HRIMO_@Q?"BK"$ZC\8#S7O;1HA:^>8W01F
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M<N]$4Z5 LV]VYU(^[)86NYUB?1,RJMV+ /HLDQI@/15D6C 7[:9K:4RA/((
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M\&.+ CR@W6@ :V^P=%H,!QY2^6!AJ.MI-^/.WPMCP -"3=$^N*AH..;Y]35
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MNDIR&NM48$-3=T9]X!O'.I3-+9SO#?"DZU4S?/EX-1XK=V4R98TF7.GY@&,
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MXU\O;<VA?6=6FNDC5'!9TR Z>A'T>Z=CJM-ZUI-[XJP.I+^<Q1X\F"F&8O,
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M+H# #+-2P<_G.@J7[5IG2G=J*-."BX1WK'@(&5D++O-YUIKS;"9_UK=RO=2
M],$#5?" 'Y0'N C'XX]7__H2RZ(:$@4T/,]\\;^'\,!>_G<8#S? XU<NA)5T
M]^-H/3P"1]^*?AMG#;99\_NQJ"9;_?L)*>%-.2H=><&\.,NQ=3B8N^G3//^
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M4NDTA?ENR-B?*02$,?!E:N'\?:&RWY+: ]B'&T34WG+4)?)E[9T#R5J#>^=
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M'\2),-?62(ATR.2I'W*:&Y%2?*C"\$CCM<HUO?4>+J#80CB#UQ[CS-+[UC.
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MS:>N4-'F/<<J-L943/H>9E?38  [675@<O/@*2!<FOL%.,S=.+^E6PO%\,
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M2E]J(%^##2CPSU:A Q$W!1BM<]0RZ:#+I[ZG;1!\H,-OU^QT82S.I?;U<?R
MI](50LQBT1@Z^5A;]:$S2P.NH/,V>,M_@JZW8850%Z\]>TR9J&G]ZAHF_=ZA
M@-)!(]*$5;O@Q<,K'6@3?:I[LHP[1NTN["-M[2EWZC;]2Q58V*V'$^4<E>#\
MJ'30(*(P;VS-.* G9OVNA[T'FZJ0.$UQ(?,M',*$U.N=R?$AEA96"66[-8H8
MV^\1\?^\S!R7U<JZ3]J]L6)N+B/2;$LER*BM.5:\V6"K?_=!7O7(NCN0+I##
MB'AI<#VO=0R1%R":X5=@.O<SXXB6DNJ3I^Y@S38V6G>L]JY>&+. YTAVI?K
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M^BH$M%:PX!ZM;@FMGFX)K8)(<Q!S4"4:Y2RD&I: %\#Z#;1.5E-8R[*"[;S
M 2[JAMH,67<A)GX#/UWJI!-X\##;V# ,T.W $ME[[+OCL6\MY?*LE.;.I&@*
M!.AZP4P#+\'&8#TK:"<!EDD.<J$% 8$L:@Z\.PD0'PR8S15UI<%K7J0B 'R
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MUYB6!SO_%K^4&SG*+EJ>)2A<2Q"N_M6P&ZSE>,DZS&7*Z!ZN),;PP352IB)
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MW&D?=QJOR>T5V7\WZKVRG<]O>J,/MWVWZ.V[W]]>]LA>M5Y_W^[5Z^>C<_<
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M_2QX+0D<)G$<EN B3D;M6.B?9L V?CCBN<A.*URTRL-GY8Y5X5;C&/:*T:1
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MSR2D2I^Y,%QW7]%LO_/Y]']02P,$%     @ *(5B5M;9",D3$   HG\  !D
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M4%)D70_T6C^&3B;5-Y4".3&CBB/N0@]=TR"4@/#4*Y +)K2Z!?\2NO.:RIE
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MUV)!5+3]^D%]8RL].= E")SK>@@:%'8?EH/%C'!*,M:<M_-HP+DQ]0K:GC%
MEGE&:7)8J_X_%=8L,L7*?-\FDRLY,8Z@U)]V!CLB4DEBD9'_VYKBZ&\'&QE\
M 3),9%ZH$_<?IYMBE9XUX@+V@='!YIV,]8V*EW'+ *?QS%WB1VG@_[%;%3_V
MR/KO#LHX_/(W7>YV^@9.$7,XEG!(.]=CPL%T$':R&%W3G%+S^\Z,P"$7M+4[
M5]J%O5/!&]9(OKYGN\=Z+<7!3)>4%%T^4^^.:%N*<6</D!P.B*2V\K][J_'&
MG1:OG!3:B,?"D=CKA1(B36,E^9==^:!FL(4SUG*L1BB^R7YB;7$NJB. )KWZ
M'>2)SB4_MCMDE-RV?H,J<K@7^I2M6(4IZZ[*&&W>WTD@@P_EI]UH;R-^3RY\
MU+/J+>Z]A4HVC#=6"28 S1W0^*ARR=-OV8 L\<(!8SU*'UG(QJFR!%T'SA.3
MDQ!@%/?\K'RAL1>;.:0-EG1<,86[GOMZE8X5DVG4]62:S;7Q@)A9TI7#K]:6
MXQ Y/F\LD8X4:@KX["?,?7NZ_FK4.\\I\ZZP>'C]U:Y77>M:K5I=CJ+GDYC0
M""P*> .F#%6S'&M0N9#?QX,U)PLOG?.&,HA7[5<LVRG$+<=92T9:[]G17@<4
M@Z4$4!H"D=H(JBPL3KL0UQQA$!=6(0WSP%B_Q'M=!!ZY<SAURFI 4?YNENH1
MZ'$OJAB+,7P ;@<Z(DA4ON9LTAH^/7[$ <\S+E"VL9+0Y^]>?#CKKC#GEYQV
MCS]P2;0YJ.,:+@CO*\T3+XOT#\#MTRZ]EOB3!*D"CUK;Z5-^L&C-0;'MXJHY
MFYAR>ZV5U7MVL;)%H.NC01+MPY3,NT^I)@&>V\T:\(X4>AOT7MB*N4!0G"-
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M9$+XAVVE4@21RGXSK'.'MK_87M7.DJ8["<%ZFWTV2M_*!5<UH">NI;[R\1!
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M<9U6>($()K@/"B*^FY8E]'30XE!C>8:UB=M[$G97;B@O=(ZH91Q13Q+T/2>
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M.;^!P%>3?&Q!1WRF1/6,\^2DTS]:)CK?UG7'&/Y[C>Z+DF?_ U!+ P04
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MLEEF,;HI,..@+$9)D;CS$E-$1B2":T$;$)[XN-R9T4R%(3+BPI]QS,5E%F4
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M].U3#Q95M;R+?^ U@?(,:/*=O^_\_?'^GCPW?S_WKG37)>G@LZS+W9VU?O\
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M_$&.<T$/89KX.ARH%0J_;?;'?(GI:EU\L_IO(>2B8+C&6 H4401P3GVZ]*B
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M,#(R,3(S,5]C86PN>&UL4$L! A0#%     @ *(5B5HY#P2<V'0  V[8! !4
M             ( !<!X  &YX=&,M,C R,C$R,S%?9&5F+GAM;%!+ 0(4 Q0
M   ( "B%8E8XT5*(=V$  "99!@ 5              "  =D[  !N>'1C+3(P
M,C(Q,C,Q7VQA8BYX;6Q02P$"% ,4    "  HA6)649O%>7$]  "^7P0 %0
M            @ &#G0  ;GAT8RTR,#(R,3(S,5]P<F4N>&UL4$L! A0#%
M  @ *(5B5J#J.:7+90, +28< !4              ( !)]L  &YX=&,M,C R
M,C$R,S%X,3!K+FAT;5!+ 0(4 Q0    ( "B%8E;3TC*.W:\  .GH   8
M          "  25!! !N>'1C+3(P,C(Q,C,Q>#$P:S P-2YJ<&=02P$"% ,4
M    "  HA6)6F&^D8;D3 0#,%@$ &               @ $X\00 ;GAT8RTR
M,#(R,3(S,7@Q,&LP,#8N:G!G4$L! A0#%     @ *(5B5CGO>37Q^@  ?/\
M !@              ( !)P4& &YX=&,M,C R,C$R,S%X,3!K,# W+FIP9U!+
M 0(4 Q0    ( "B%8E84(B?EP6T  /=[   8              "  4X !P!N
M>'1C+3(P,C(Q,C,Q>#$P:S P."YJ<&=02P$"% ,4    "  HA6)6%1)46MD4
M   RJP  &0              @ %%;@< ;GAT8RTR,#(R,3(S,7AE>#$P9#(W
M+FAT;5!+ 0(4 Q0    ( "B%8E9X2_BJ9@P  ,9:   9              "
M 56#!P!N>'1C+3(P,C(Q,C,Q>&5X,3!D,C@N:'1M4$L! A0#%     @ *(5B
M5M;9",D3$   HG\  !D              ( !\H\' &YX=&,M,C R,C$R,S%X
M97@Q,&0R.2YH=&U02P$"% ,4    "  HA6)6 SD,&24G   ])@$ &0
M        @ $\H < ;GAT8RTR,#(R,3(S,7AE>#$P9#,P+FAT;5!+ 0(4 Q0
M   ( "B%8E90RP1;5 4  ,DE   8              "  9C'!P!N>'1C+3(P
M,C(Q,C,Q>&5X,C-D,2YH=&U02P$"% ,4    "  HA6)69ZX@F84)  #[.0
M&               @ $BS0< ;GAT8RTR,#(R,3(S,7AE>#,Q9#$N:'1M4$L!
M A0#%     @ *(5B5E%B]UY9"0  \3<  !@              ( !W=8' &YX
M=&,M,C R,C$R,S%X97@S,60R+FAT;5!+ 0(4 Q0    ( "B%8E: FZR@SP4
M %0O   8              "  6S@!P!N>'1C+3(P,C(Q,C,Q>&5X,S)D,2YH
8=&U02P4&     !( $@#:!   <>8'

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
